<SEC-DOCUMENT>0000785161-20-000070.txt : 20201102
<SEC-HEADER>0000785161-20-000070.hdr.sgml : 20201102
<ACCEPTANCE-DATETIME>20201102164753
ACCESSION NUMBER:		0000785161-20-000070
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201102
DATE AS OF CHANGE:		20201102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Encompass Health Corp
		CENTRAL INDEX KEY:			0000785161
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				630860407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-10315
		FILM NUMBER:		201281044

	BUSINESS ADDRESS:	
		STREET 1:		9001 LIBERTY PARKWAY
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35242
		BUSINESS PHONE:		205-967-7116

	MAIL ADDRESS:	
		STREET 1:		9001 LIBERTY PARKWAY
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35242

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHSOUTH CORP
		DATE OF NAME CHANGE:	19950113

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHSOUTH REHABILITATION CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ehc-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:e0fc9ecd-686a-431a-a15f-a624ec9cb1a0,g:253d3480-dc2c-4d92-b5eb-51ca56c502e3,d:5ec2d1f903d340c19ee74983700dc28d--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ehc="http://www.encompasshealth.com/20200930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ehc-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80L2ZyYWc6NGRiMzEwZjk2MDEzNDdlM2ExNzdhN2YzODlhZTYyNDIvdGFibGU6NDQyODVlZTM4MjdjNDcxOTllZjc0ZDlmYWYwZDJkMzIvdGFibGVyYW5nZTo0NDI4NWVlMzgyN2M0NzE5OWVmNzRkOWZhZjBkMmQzMl8zLTEtMS0xLTA_252bf9c4-0e09-4923-ac11-20a7bcfb9802">0000785161</ix:nonNumeric><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80L2ZyYWc6NGRiMzEwZjk2MDEzNDdlM2ExNzdhN2YzODlhZTYyNDIvdGFibGU6NDQyODVlZTM4MjdjNDcxOTllZjc0ZDlmYWYwZDJkMzIvdGFibGVyYW5nZTo0NDI4NWVlMzgyN2M0NzE5OWVmNzRkOWZhZjBkMmQzMl80LTEtMS0xLTA_368bf6b7-9b9f-4e72-8e58-db8555ef80b3">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80L2ZyYWc6NGRiMzEwZjk2MDEzNDdlM2ExNzdhN2YzODlhZTYyNDIvdGFibGU6NDQyODVlZTM4MjdjNDcxOTllZjc0ZDlmYWYwZDJkMzIvdGFibGVyYW5nZTo0NDI4NWVlMzgyN2M0NzE5OWVmNzRkOWZhZjBkMmQzMl81LTEtMS0xLTA_b04d30f5-a9b8-462d-bd0d-5212e1d886ca">2020</ix:nonNumeric><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80L2ZyYWc6NGRiMzEwZjk2MDEzNDdlM2ExNzdhN2YzODlhZTYyNDIvdGFibGU6NDQyODVlZTM4MjdjNDcxOTllZjc0ZDlmYWYwZDJkMzIvdGFibGVyYW5nZTo0NDI4NWVlMzgyN2M0NzE5OWVmNzRkOWZhZjBkMmQzMl82LTEtMS0xLTA_17ee92a1-ee1b-40f3-ab43-1eb1cfd23724">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80L2ZyYWc6NGRiMzEwZjk2MDEzNDdlM2ExNzdhN2YzODlhZTYyNDIvdGFibGU6NDQyODVlZTM4MjdjNDcxOTllZjc0ZDlmYWYwZDJkMzIvdGFibGVyYW5nZTo0NDI4NWVlMzgyN2M0NzE5OWVmNzRkOWZhZjBkMmQzMl83LTEtMS0xLTA_172e7217-5d57-488d-9bfb-a62509b80822">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ehc-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic825b775519446e9be5f06a4c5e5d17b_I20201022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6cf41bad492345de99ed38cb8db55427_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if166fe2888ed4236b69cbd1304d9ed61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifee6c827439c4117821d833d1398c1e3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dc50352d6c046e996455f484c4b8d2b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16b97f17d8db408195ceeadc301ddfb1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie736b33e93524e6286ddda20f63fb392_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d86622446d240caa39846454393bef9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i709bd3432796446cb8af88e1449a8b8a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2dbc33472e04f73b22f6023e08ebc8e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b16ec5f39fd426987fd267959afaf04_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e461c575464b3faf3390da4ec357b2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0aa9d846293410c8246584aeefc69d8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f0ded8fb484018a4a1c01ca5701bcd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db578648abe46bf8900fa6e9eeff904_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77e27e7871034346bd94e7d93e7781a5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a5ea56a23aa4f73aca3bbb27f91c6e9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42639cc7412e46f29b28dfa5b1b7fedd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814c90a316b4443c999528ec80e7ee11_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f2714c865b0433b81dee771e5553136_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75303561f2ef48ad8ff4e6b1651fc33f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2656c38caa24df2bc08d8781a5e56b2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6671d6f397794090a985d9d5d859cb64_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e92833c9f1f4896aba1d31655bf9668_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba9d8fa1efdb4f6f928d5446c8898f66_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec188c294f984c1aa5e6a6cf0c9e7af3_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if20836f1c7e2469e9f0c2603fbd54843_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57b58b477c6b44f8aae21799d9a882d1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a276c6995d4d178488c77f6e17f1f0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3577cda3504a48d3bf46aed515f88491_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b92ed8623634131a7a34a47abf7dfb8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i111ab5fcfcc24b20b042f933187dcebf_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361753f0507443df95849a9f371e2888_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2023d91010c1475cbf531020218e9ace_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if66065e8c14946cd8962d13d307a0707_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1b6506fde8448a2b39adf066ab41b4d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica9a466d7fcb45179986a30bd2f10e97_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id973fd7c00f34ecdb68ed4e62bafd936_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2180fc581434643b14bf9f6f6ec6d6f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeecdaf0a74142089add642599699c41_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e111b0b8f72431eaf24841ce8608010_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b7aa9d337504c10b18e5c482efd7679_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa62b0932f148c892a41d1e76032b17_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia54e68786692437494a7725e493da451_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb56e8b6eccf4d0f952421ad0f6412f9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f7a8b690bbf4c35bee679ec147ea72d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i655f76689f4e487d80a6416983d67786_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eeff91751e644a28a060a7ad7988b9b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34acebad6a69473fad71f2a9f267509d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id46c52daa7f1470a96f7d883e6a8cfa5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4343fa926414dfb8314bc855f63f5b7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22de6a707d946778ca077c5a44462af_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8102226c2854289a3f93691bcd2de7c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2623f131c3949988d9bd1994b6eadcb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c6ede3de4b41f086db0871d013257f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i744c10f6ed7148d6b5050c2d1f9af046_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>ehc:state</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ehc:segment</xbrli:measure></xbrli:unit><xbrli:context id="i5873889771684c2cae78023b5cec4fc8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b66c244e6394649b16c65e6c1d17603_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eac552610d74721a0767d8c2e8f4b7d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cc0e8dca788458691540d426154ef62_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb9260dccfc4ad9a9987f170f8a116b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4591d2e05d1482594d3f6804849a4e2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88d947760b414ceface797d75918f6c3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77665009ef8c4684bcb85139cafb06dc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i322a014d46954ce696d8d8480f860d21_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4550c4ea110e4f929a058f20551c7afb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51235bf4750c4c599d6756b7879a4939_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5f0a3577bda4c609eb02fe086530d48_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c5802675ee44e99fb4499efcd6b2c8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345e73d6d939476ba32049426ba68d70_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc0c26b5364d4089bd5ce943f4309664_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5524ac2905524e6d812a13eb8e579d18_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992298aaa6ce4481ae6d6fa2fdebef80_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17489ebe48064383942c0df2df3d5443_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b6e3a1ee04d4f429b30592defb5a698_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6370fbb51164f019e9009265116e84e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib894026d74674e5f96d404bb4cfc3b09_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i732c02fb17ea40ad9e61516625f6ebc5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d4e1ad64bc4d1daff8885a47a9ffa4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d73a08c42ae41178ddeba3a203ab25f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ec8761fcd64c49b38ddf4391322512_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idabd0dd54725446c9f81802c9a397c00_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac15f62994f4ba29f3f686482654b89_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfd12a6455e04deeaa0f18ba31b44fad_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69c117f071984988883a0aca1685756b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97bbbbdd86244b42975499d324035936_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ef53d5ff22046d0bb56bf2117a9ff75_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4541f86f6464425ca691fe14b5d7e823_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd8e538bfc2e4ff8bd996ad27939cca6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaefd1a522f844a7aff1af78d82fd07e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2279c50c6c004924ab551e8bdb047c89_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b51433b8594e0fb5df286fd380aac0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a7ea8ec1664d5583fcb48015255e0e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ed726963d947acb35515778bbe3f2d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if015466e48914fd08001b347cd2dc00b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f354ef81c74b3e906182037853d5ec_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i694c2f12494e432eac4cc3d84cfad62c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46f9a922335944feb38605cd28479c87_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1805e49bad499d82a78e70a324756e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea5b28aef1345628308b8cd50db8b8e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i040e0067c9094904af97de3099bebb5f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b94005181d46348addb4f79179e077_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica170b9067d145f1a3adaa78a1913f4c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9274fa4448545fa95f5a18d72345a7e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i786f1ca5dc7149449a23ecb8c8d45527_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09b152c7501b43ae9e8f226b1846e828_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6303df3106440f089bd9b6a43b82d6f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i110e86db8c9843af98b966b2ffda9577_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i573b526d23014691a9fbcc99b22c39fd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i476f0404ddd94cadb700f8b16900ee5a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f9bdde56e16463b988f64934c46d7c7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac3ba654254a43e8aa2ac93fcdf11d2a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3c3d4ee236a4d4cb2625cc617ee83e3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4fa52ee1d974b97bae8afb7aa7d412e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb123f9a5b744a79f1bc96d6320a60f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf1c4c55ac84c38b5a62a045e25c279_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i413089dc6a054eca94c13747f4f64efc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91952fdfd623406fae39f30682f9061b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824f669848e64d61b82896e206f54278_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db501b105224f719473dd493715a2a6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab07423dc1c456ba919a6f038750cbc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b8e309cf85040a28f0109ed6a570c17_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3869c9910a4b0691c07e0cceb1ad09_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia66f0eef25f94b08b660e5e2ee7255f9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica29f20acf9c41c69b1152541cad96dd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ed9c2b17fe42f6a52a5c962bde16a7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35ad441b632046c092723ff744dbd45a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie258e26fd75b4ed780d94575a67a5b1a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a268959462c498a9cb35520cf233b92_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bbc1f21caa34ceb8709c3862095c706_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7f10e410cd6492ea62746dcbe08ed80_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaabb8c23a4b647edae1f42bce9eadd72_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa215d6614464fd0a8b6f316d94f43c2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2c160d712eb475cada54fe76f2c249a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if00c6bc809b1468f8c5e1fd14713e9de_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3594d867ccaa4a45baee188e9b52d0ef_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if75b0cdfb90148b7b50327f55b2b4c05_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c565f1d2caf41e5ad304df1e404ec13_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67c608503ce4f62b40fed8996b085cc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aceeeed5320482e9848586c21bfec7a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4f3d5a74c95403bb0c19dace55fa0e4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f3913477cf4583aabab55a753c76e7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fa310487b624ab3abfe31fac6c6eae8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e0c420dd3740c9b36010b9f1facfaa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4034d7e50f5c43f5960d10776b6b7bf4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1118ce1a69f43f0aa8ff017adb7d860_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d6897c3387c46f0b25a5ce68caf3780_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97911a33afcc4eb1b3bb2cf52223db83_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e799fccf1b749bdb9a2fe12fa808cee_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64dcfb692db141e38d22fc8b004d9924_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99a8ead0bbbc4ac8baa360ca8dd8f1d0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fbcb67b95b64900b8e58638b2420b02_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id221678cc7294df9b33d60a008d67b3d_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="bed"><xbrli:measure>ehc:bed</xbrli:measure></xbrli:unit><xbrli:context id="i33d295cd3f3b47759d61f44e07e56fc6_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164768e9d98945009ca4f1d1e36917a8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99a4b3491a24492fbd0635cfe176d18c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d63a47f4d3e460a94d90e53d7bcbef6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f877b7c9b844d33baa6901b87f3b8fb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i186e76d3e4134732aa2cae42033322a2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1560645449b747a1ba2a0753d5016fc6_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56f08b6a993948f2baf0abcbb8879961_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c76d4a587d74d698b634d1f495b2c74_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f63f58dc90642eea45a7aa1f02b8503_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e4e00603d8740a8bcf31cfc8d4f58e1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3b016833a9435ca260fd97a50d18c8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc22792722ba436c9181b2a61d9649df_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0584508681949b19044b898bcaac766_D20200301-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>ehc:entity</xbrli:measure></xbrli:unit><xbrli:context id="i1708048c2a42448693822a76f275381d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66fdf46a359740a785ea525eb38ea7fd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8546b47816c54ef381660703138b5caf_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ac9f48cbdbe488cb20eed7e2f9ca1ee_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i608f28a8c9c64873904629df071b372b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if83e06ff810244088cb996c03064f330_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8fb9a7dd06c4e609086c04b5dbfe4ca_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f1023a8574449fd9b9332edaf46f3bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i638ab89eae9440c5b0f1929587a02914_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0377bd53564ffdae03ff64e660194b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia523dc03179846ddaf98c887899b7679_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3892c4bc03204316bb6e77be3f27b240_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib40a6e6dd68b4a8da5d30d7aaa484c51_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41c4e44b7b64428b528add431c16513_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f1805d3ddcd4b188bc766e18298a2d5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i730f2a918b744a0e94177fd42ad004a4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62eb57fb87fc40e59f8f33f73b921693_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd067c2ff27b4ab8a68e5471e7c59ef9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dfc00f6eb92471998309b5c12c9388f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23cf331b54114349857c76ca9d89e4e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30dd8fb7ca9b4d95a01ed19cec48d797_D20191001-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02f7fbac1cd84620acf7f199e68c69d2_D20200401-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31cb706cd3d34a8f8c5550eb13fdc482_D20220331-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ba53aa991c7496c824228ff7f76db73_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaf492cdb0114d0caa049a3dc713ea52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide941e50cb94438c842272441f7f7a9d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54ca9b66117a446d97db8f7751e15718_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47e1840cf2284314b9ab50ccca85d8dc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd6a4fa2af14b42a85c77bc5fc6a804_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie70bf042dd674e718cc447fc2ec12ba6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff0d4dd7c88b4aecaeb023492578edbc_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a6a2cb269044ff8ba6e3aa662224738_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97fd8177ab534173b7dff83fda1b0e42_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d3d451adabf4a9e939a4aa764188f34_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ba9115048c4b0cb334ce276b07e19f_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e156b6c09f3459a802a8b8b9d61246b_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5048837d2a04accb50ef68638e25287_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5017d71cfec249b39dc7bf0b2f16e8a8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b1bdb6d04224fe9be09f756f95b5ab0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a8f469e2a84522ae2e22f5234508db_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e9516c1a9cb4fb3be4969e22995bee4_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9544a214c9f44991a2f78bb7573102e1_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib07fdb10b5d540cb9aedb3134847444d_D20180221-20180221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-21</xbrli:startDate><xbrli:endDate>2018-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c985034d924ca98f2216ba8ca4af2e_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c4dd0ed5ae24830b44a38ea9717cb05_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85c5fb8e5614004b32140f219b1306a_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c98c9ecdddb4aa885207bc289ebb66c_D20200218-20200218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-18</xbrli:startDate><xbrli:endDate>2020-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b8fa809e4a440c2bad66de860a5fd7d_I20200218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa6591e1e63436d87c66c1d9ccc6214_I20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib293675829044729970b8ad7871b3312_I20200306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3efb00ba5fd74b7fab554086f72556bc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ehc:HoldingsAndEHHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c3b00829fa4d4e999d2af5868388c4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f108164baf04c0891eeec5eedea407c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i109455a6fc6a45b8ac46c18c730e447c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia45c6446a6c14cb7a9ddd0a2cd90040c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aed46c41ce046eaad78b41f59a23787_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2768fdf72bc4ee4a44e6c72c3433df2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6bcf1050dcf44a2be092ce5a39ac1a3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7afd9afee71467ba27c4ef94b734857_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3782aabb4f6a4c8892fbf91aadc0bbf6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4130c6d73c9d4e2886d9e5ad5721507f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a29bb284f84291ac766be040a1b558_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i171f20bc121a4840b1b7a626e688e5c2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a6b0c4ea294ae9831e406beeaa1b02_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0646390aa047889e3811abde11c7d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98081f26b7b0413894e5100ec374ac7b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i104c1230c0b9400ea5b323e382d7bf2e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e31655e1c843588845e5d149d3d78f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cb6a7700bc94455b1a76981062358af_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8ae8d59fc12411b879d99d7434e8c7a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ca40e094ccf47d19b41a7336db5ee77_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a0e75c4e9e143ea8c9e88f3a1327641_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia509d100e6ab4e2a9c6a5b3bc3d344dc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie58dd346723c4144a958394c28b0c3d2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i186457b966e448f8b789ee4909b7ae8d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c5bfe222cb48208514b96445916886_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia715c07fe5d248e9b5940e457b3706eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0cb787bf3ff4d24aa0ab14e1e0c373c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0051b03acc3e4e2986db12da328b3bac_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic19a05f81373432ca6b36a5c0470017e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dc3ff3814494e65a5977ad5528ad3b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i934987b44af7446c8218601c95502de9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id68ab94595124a1e97f267729e976e5d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id58191662ff7460988e18540fde456ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e8394e3bcc5451cacdda373dfbbc0b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5999223d44049ab8c9ad683173bdc2d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief3957a1e65a4a2b85016faf016e95db_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42640997d4454f199cf25a948fc95738_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71f49077e01a45f097881493f89e0508_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d26a6364364e1a9b54ab393f994255_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib91ca67dc3504530b8450421abc7fb8a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf31d36bee454c13a050e3f343b6a3c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice01013cd7f94c859dbdc8f630c352a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cd83dbae36b43d7b4a6162c02698684_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id954ef15e93c4d14ae05f3cd3b278851_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90ef0119e13b4be5826ee406b88feacb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i728449144459420bb67f2d96b87cbb5e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib34fdd3cc9e945d8af9a195dca36f84b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i455ce14d267f4b87b426320cf9bbdc10_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a3de203d80490b878e5ccae2d26b36_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2152173f71549049764873566ae5676_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29cc50ab07e74bbe9b5f86334dca8053_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1c210278132437cbd3fe2285375e3cf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80e176382eb04cdab88c4972bf3f6d7a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecb21c9d51d840279240febc1301d0e7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb38ea719844f6cb5c7d56debf66f6e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fbf64e203144762b1d2ada6b0352efa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8958165af77d4177a1e12b5aa53be055_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49095c84bb0c46e1bb8ad5d5e2601b49_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbcfb44cf32548af90099a6a944afa74_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i130a002122d84a44a7f2a2f80eb06cb9_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c9a6e8916a642608c3dec74c2e5242b_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ehc:NicholsLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d74de04d0a49489fef3090ad053d4f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="hospital"><xbrli:measure>ehc:hospital</xbrli:measure></xbrli:unit><xbrli:context id="if254742956e843fdbdef4b70418d1d95_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e1097dbae78496f9253f83fa0d57473_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="location"><xbrli:measure>ehc:location</xbrli:measure></xbrli:unit><xbrli:context id="i8e7323c2241b4a16b1b13a4e1f206647_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4085dac83c04f60a84bda9c69ca0fd4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e018bd04e884537bdbb55709b14d86e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d7e9389f7bb49d1937b89476ce847a4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab84c70e34994c9dbed01b25069a83d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fb52c020c90481fb7260d98ee51f72b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica342deee7024b149e3a4aafeeb27c0e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce0d088460444de9f461fc5f954104e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac44cb5b0a604e55a2dd05a02d35a226_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b556ace711f4b07a26951c1b12a6868_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62367bba18c143edac791ed9c0e6b12d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5e3006bff47459eb04bfde259d0b285_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16bc1b11f6474259b5d2a6c7a7ed7d3f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i060b61eae5e141f5a0ecfd1970befba2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a8f9f90011a4999af002b1dd34ca597_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc6b9fc57a843aa950bd9f011875dea_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4eba057206a47f6ad35e724ea946fcc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b675f52d0454ca895e68f1f2ec026c3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia00b712980524ce3863212d497722fb9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic72bcc5ef89644cc8431b9901f34f714_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3f156c397a54a5e942b4169a6555c29_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e0deb3678448e38f17bc49a774bc9c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d7b86bab34f4844a928bf4006774a56_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief533155274145c69d708e96345ddceb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f70ec669814c3ab99525a8689c1d52_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc1cfae314f4bd3add26a155e7e540f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i542fad3dce5840d59dc96ad7e51d6df1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2819d470f954f05969b485651250dea_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMS0xLTEtMA_7fe2fe5d-8a17-4f0d-b904-5da3eff95fff id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMS0xLTEtMA_ebb6140b-8134-4576-8117-101988e3ab55 id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMy0xLTEtMA_4c2edf44-6da2-4948-b82c-510be11a7456 id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMy0xLTEtMA_96422c3d-18b4-4626-ad92-22d400d71628" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzUz_7165f141-3da2-4f42-969a-a86f3d941f6a" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i5ec2d1f903d340c19ee74983700dc28d_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">______________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTg4_94332bf5-6eda-4480-a592-085381085fac">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6NTk5NTI5Nzc5ZTE3NDViMmEzNWUwZmRhMzU5ZWRkNzAvdGFibGVyYW5nZTo1OTk1Mjk3NzllMTc0NWIyYTM1ZTBmZGEzNTllZGQ3MF8wLTAtMS0xLTA_bc442f69-c350-4c1e-8617-33c2bf6e8f82">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xNTE_080c4a3a-3217-44db-bd8a-807db94538ec">September&#160;30, 2020</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6M2VkYWQ1ZmRjYWQyNDU5ZjhjNTc0OWQxNGIxOGYwMjMvdGFibGVyYW5nZTozZWRhZDVmZGNhZDI0NTlmOGM1NzQ5ZDE0YjE4ZjAyM18wLTAtMS0xLTA_fe330ee2-2177-4bdf-b14a-145837fc517a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTgx_2b5620d9-66d8-47c4-a555-776a71df667c">001-10315</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">______________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTk0_a85c586e-c590-4290-80f5-4c2ba2fcd608">Encompass Health Corporation</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.625%"><tr><td style="width:1.0%"></td><td style="width:57.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6MjRkYWQ3NmIwMDdlNDI5MDllNGE0OWIwNjhmNThkMzkvdGFibGVyYW5nZToyNGRhZDc2YjAwN2U0MjkwOWU0YTQ5YjA2OGY1OGQzOV8wLTAtMS0xLTA_22276d43-db2c-4967-9f6c-bb2dd1e5e752">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6MjRkYWQ3NmIwMDdlNDI5MDllNGE0OWIwNjhmNThkMzkvdGFibGVyYW5nZToyNGRhZDc2YjAwN2U0MjkwOWU0YTQ5YjA2OGY1OGQzOV8wLTEtMS0xLTA_71ae9f76-a5aa-4dfc-8fb4-89a5ebf5bd67">63-0860407</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTk1_95c441ce-9299-42f6-8c22-badbfdf01745">9001 Liberty Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTgy_d56152b4-66ee-400c-906a-2b8ab1b00853">Birmingham</ix:nonNumeric>, <ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTk5_febbc9f2-0cad-4aed-b64c-f83f6049b07e">Alabama</ix:nonNumeric> <ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTk2_1c9fcb99-d07f-4990-84e7-3561f05f3183">35242</ix:nonNumeric> </span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTgz_577f6458-2928-4569-b0f7-6d8941e7b510">205</ix:nonNumeric>) <ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTg5_3cf7b3f0-5846-4db1-9ea8-682707046766">967-7116</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number)</span></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:17pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:37.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6ZjYyYmY1NmE1YTY2NGUxYThjZjEwYWM3YzJjZGExMjAvdGFibGVyYW5nZTpmNjJiZjU2YTVhNjY0ZTFhOGNmMTBhYzdjMmNkYTEyMF8xLTAtMS0xLTA_bd805ae6-7983-4b99-b695-ed88e8f6aa52">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6ZjYyYmY1NmE1YTY2NGUxYThjZjEwYWM3YzJjZGExMjAvdGFibGVyYW5nZTpmNjJiZjU2YTVhNjY0ZTFhOGNmMTBhYzdjMmNkYTEyMF8xLTEtMS0xLTA_0e3fb15f-ffc4-4c82-819b-56bdeccb7950">EHC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6ZjYyYmY1NmE1YTY2NGUxYThjZjEwYWM3YzJjZGExMjAvdGFibGVyYW5nZTpmNjJiZjU2YTVhNjY0ZTFhOGNmMTBhYzdjMmNkYTEyMF8xLTItMS0xLTA_7d339095-a1f8-472e-8341-6678d071c542">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8yMDAw_244366b2-b452-4b08-88d1-946108794ba1">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTkw_df9c0846-9f08-4f0a-b2a1-44d856136d63">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:26.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6NWEwNzI3M2E0MzIwNDU1N2I1YzQ4NmQ2OGJkNDdiN2UvdGFibGVyYW5nZTo1YTA3MjczYTQzMjA0NTU3YjVjNDg2ZDY4YmQ0N2I3ZV8wLTAtMS0xLTA_6b130e59-0d25-4d0e-8d47-ff5a410cd5af">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6NWEwNzI3M2E0MzIwNDU1N2I1YzQ4NmQ2OGJkNDdiN2UvdGFibGVyYW5nZTo1YTA3MjczYTQzMjA0NTU3YjVjNDg2ZDY4YmQ0N2I3ZV8xLTEtMS0xLTA_e5c4bdfa-7a3a-4110-becf-968a9e1461e7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6NWEwNzI3M2E0MzIwNDU1N2I1YzQ4NmQ2OGJkNDdiN2UvdGFibGVyYW5nZTo1YTA3MjczYTQzMjA0NTU3YjVjNDg2ZDY4YmQ0N2I3ZV8xLTMtMS0xLTA_22381474-ba6c-4377-ae8a-993fe4d8967e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes&#160;<ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTg0_5a74d4b6-9f25-4ae9-a41c-b7b003f19cc9">&#9744;</ix:nonNumeric>&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant had <ix:nonFraction unitRef="shares" contextRef="ic825b775519446e9be5f06a4c5e5d17b_I20201022" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTEw_020e78b7-137c-4ede-9927-33329e6304e7">99,432,464</ix:nonFraction> shares of common stock outstanding, net of treasury shares, as of October 22, 2020.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:35pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_13">PART&#160;I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_13">Financial Information</a></span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_148">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_148">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_148">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_163">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_163">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_163">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_166">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_166">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_166">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_169">PART&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_169">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_172">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_172">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_172">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_175">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_175">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_175">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_178">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_178">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_178">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_181">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_181">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5ec2d1f903d340c19ee74983700dc28d_181">50</a></span></div></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE TO READERS</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this report, the terms &#8220;Encompass Health,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Encompass Health Corporation and its consolidated subsidiaries, unless otherwise stated or indicated by context. This drafting style is suggested by the Securities and Exchange Commission and is not meant to imply that Encompass Health Corporation, the publicly traded parent company, owns or operates any specific asset, business, or property. The hospitals, operations, and businesses described in this filing are primarily owned and operated by subsidiaries of the parent company. In addition, we use the term &#8220;Encompass Health Corporation&#8221; to refer to Encompass Health Corporation alone wherever a distinction between Encompass Health Corporation and its subsidiaries is required or aids in the understanding of this filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report contains historical information, as well as forward-looking statements that involve known and unknown risks and relate to, among other things, future events, the spread and impact of the COVID-19 pandemic, changes to Medicare reimbursement and other healthcare laws and regulations from time to time, our business strategy, our dividend and stock repurchase strategies, our financial plans, our growth plans, our future financial performance, our projected business results, or our projected capital expenditures. In some cases, the reader can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;targets,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Any forward-looking statement is based on information current as of the date of this report and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors that could cause, and in the case of the COVID-19 pandemic has already caused, actual results to differ, such as decreases in revenues or increases in costs or charges, materially from those estimated by us include, but are not limited to, the following:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of the factors discussed in Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of our Annual Report on Form 10-K for the year ended December&#160;31, 2019 and Part II, Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as well as uncertainties and factors, if any, discussed elsewhere in this Form 10-Q, including in the &#8220;Executive Overview&#8212;Key Challenges&#8221; section of Part I, Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our other filings from time to time with the SEC, or in materials incorporated therein by reference;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a pandemic, epidemic, or other widespread outbreak of an infectious disease or other public health crisis, such as the COVID-19 pandemic, which could decrease our patient volumes, pricing, and revenues, lead to staffing and supply shortages and associated cost increases, or otherwise interrupt operations;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governmental actions in response to the COVID-19 pandemic, such as shelter-in-place orders, facility closures and quarantines, which could impair our ability to operate and provide care;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infectious disease prevention and control efforts that are required and effectively minimize the spread of COVID-19 among patients and employees; </span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the rules and regulations of the healthcare industry at either or both of the federal and state levels, including those contemplated now and in the future as part of national healthcare reform and deficit reduction (such as the re-basing of payment systems, the introduction of site neutral payments or case-mix weightings across post-acute settings, the Patient-Driven Groupings Model for home health, the new patient assessment measures, which we refer to as &#8220;Section GG functional measures,&#8221; for inpatient rehabilitation, and other payment system reforms), which may decrease revenues and increase the costs of complying with the rules and regulations;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our ability to obtain and retain favorable arrangements with third-party payors;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictive interpretations of the regulations governing the claims that are reimbursable by Medicare;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with extensive and changing healthcare regulations as well as the increased costs of regulatory compliance and compliance monitoring in the healthcare industry, including the costs of investigating and defending asserted claims, whether meritorious or not;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings, including disclosed and undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the use by governmental agencies and contractors of statistical sampling and extrapolation to expand claims of overpayment or noncompliance;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays and other substantive and procedural deficiencies in the administrative appeals process associated with denied Medicare reimbursement claims, including from various Medicare audit programs, and our exposure to any related delay or reduction in the receipt of the reimbursement amounts for services previously provided, including through recoupment of ongoing claims reimbursement by CMS;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, which may decrease our reimbursement rate or increase costs associated with our operations;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, including as a result of the COVID-19 pandemic, and the impact on our labor expenses from potential union activity and staffing recruitment and retention;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive pressures in the healthcare industry, including from other providers that may be participating in integrated delivery payment arrangements in which we do not participate, and our response to those pressures;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with our growth strategy, including realization of anticipated revenues, cost savings, productivity improvements arising from the related operations and avoidance of unanticipated difficulties, costs or liabilities that could arise from acquisitions or integrations;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased costs of defending and insuring against alleged professional liability and other claims, including claims relating to actions or omissions in connection with the COVID-19 pandemic, and the ability to predict the costs related to claims;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential incidents affecting the proper operation, availability, or security of our or our vendors&#8217; or partners&#8217; information systems, including the patient information stored there;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new or changing quality reporting requirements impacting operational costs or our Medicare reimbursement;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price of our common stock as it affects our willingness and ability to repurchase shares and the financial and accounting effects of any repurchases;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and willingness to continue to declare and pay dividends on our common stock, which could be affected by reduced cash flow resulting from the COVID-19 pandemic;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain proper local, state and federal licensing, including compliance with the Medicare conditions of participation and provider enrollment requirements, which is required to participate in the Medicare program;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key management personnel;</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our payor mix or the acuity of our patients affecting reimbursement rates; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general conditions in the economy and capital markets, including any disruption, instability, or uncertainty related to armed conflict or an act of terrorism, a governmental impasse over approval of the United States federal budget, an increase to the debt ceiling, an international trade war, a sovereign debt crisis, or a widespread outbreak of an infectious disease such as COVID-19.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements referred to in this section also should be considered in connection with any subsequent written or oral forward-looking statements that may be issued by us or persons acting on our behalf. We undertake no duty to update these forward-looking statements, even though our situation may change in the future. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I. FINANCIAL INFORMATION</span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_16"></div><div style="margin-bottom:7pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Financial Statements (Unaudited)</span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Per Share Data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMy0xLTEtMS0w_dc8147fb-89db-416f-9112-866ccfc41675">1,173.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMy0zLTEtMS0w_0b77741f-7af0-47ce-a0be-9fdc8205d36b">1,161.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMy01LTEtMS0w_68804db1-093d-424d-b0ec-38395e40778b">3,430.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMy03LTEtMS0w_732558ed-adb5-44b5-a620-e2ae0d410c35">3,420.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNS0xLTEtMS0w_07ca9ba0-a327-4d2a-b37a-156915fef851">664.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNS0zLTEtMS0w_35e77557-ad33-4005-a9d8-94cb86deae9b">660.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNS01LTEtMS0w_71b94e6c-3b2c-4129-8944-aa2b05cb39dc">1,995.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNS03LTEtMS0w_1e0fbd13-89d0-48af-bcd1-27e3c6f0ccb1">1,904.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNi0xLTEtMS0w_6d9d774e-0c73-4bce-9d41-06cf8518f3dd">163.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNi0zLTEtMS0w_6b1bfeed-b50c-4598-90bb-a8141915de2a">156.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNi01LTEtMS0w_2cce331c-2623-4519-b358-93962e4361a5">471.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNi03LTEtMS0w_37671576-b25c-4a72-a807-df3b536106e2">456.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNy0xLTEtMS0w_6b0b70c5-bc3d-4ec5-9e60-69efca014e35">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNy0zLTEtMS0w_b4631814-c59d-4349-9729-283ecbc8ccdb">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNy01LTEtMS0w_ee6512dd-36a3-474b-b514-ec2c7fbf4671">60.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNy03LTEtMS0w_c5029c10-92e7-44d6-9a28-b9ad944f90e6">61.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOC0xLTEtMS0w_c33c968f-8bff-4c58-a97a-62bd48743ab2">52.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOC0zLTEtMS0w_7fe47cda-3cfc-4193-bd85-58e4b54f3f70">42.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOC01LTEtMS0w_b1fdd5d1-0a05-4e64-9635-c8ceaad29927">148.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOC03LTEtMS0w_1ee6f2b6-7915-460a-ad59-265de5fb09a0">124.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOS0xLTEtMS0w_08ad314d-f4b3-4de9-bf9f-b144c27b9562">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOS0zLTEtMS0w_1b475738-58ff-494a-b714-6cb9f48669e8">52.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOS01LTEtMS0w_e27bd639-b5b0-4898-ab0d-b7f0d0b41c57">117.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOS03LTEtMS0w_287ce8cb-539f-4b89-9085-07150a2e8cb7">183.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTAtMS0xLTEtMA_cc31b030-fbe8-4827-b7da-3c462bace905">61.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTAtMy0xLTEtMA_e972b9b8-9d87-4898-9c89-170d376cd6f9">55.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTAtNS0xLTEtMA_ad89a574-3d4d-41f5-ade6-9dfba0d28ff4">180.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTAtNy0xLTEtMA_fc7abc65-9534-46bb-8c5c-0f70b45f0dd3">160.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTEtMS0xLTEtMA_3678628a-0e5b-4280-a2de-c576afe91d81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTEtMy0xLTEtMA_dda60c68-3076-4264-80c2-11dafe112651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTEtNS0xLTEtMA_c0689499-a515-421b-a090-e17b5cff2190">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTEtNy0xLTEtMA_7fd05a33-0451-45d9-a28a-86acb6700d1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTMtMS0xLTEtMA_b586637e-74fb-4b88-8321-94f493dc8e50">1,001.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTMtMy0xLTEtMA_f7aaa038-04fd-4525-ae54-b4bac15305d4">989.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTMtNS0xLTEtMA_76c2b8d6-0bfc-457d-afa6-317edd8e4e2d">2,978.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTMtNy0xLTEtMA_d8334a19-7759-4831-b5c1-704e71fb0099">2,890.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTQtMS0xLTEtMA_9b2259f7-8cb8-4226-8bfd-6547ff381371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTQtMy0xLTEtMA_ee780a10-bb5b-479c-8b51-647b435bd9e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTQtNS0xLTEtMA_fc22641e-9f98-4ea5-9a90-960ec8840913">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTQtNy0xLTEtMA_e4348f53-1516-4bb0-8207-d7a44c21c7b4">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTUtMS0xLTEtMA_27aeb2ad-12d2-4e7b-a63d-4e55d65b2be7">49.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTUtMy0xLTEtMA_3117e5b8-8906-4b55-9b90-7a3da634354c">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTUtNS0xLTEtMA_e1707c12-f47e-4531-9f70-320b37969b1c">138.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTUtNy0xLTEtMA_f506e2f8-d0ca-42bf-82a2-cf9888195288">115.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTYtMS0xLTEtMA_47f2016c-35b1-4d80-ba0f-7d921411c797">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTYtMy0xLTEtMA_c85de7b5-a5ae-4e70-b86f-6600daf8bded">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTYtNS0xLTEtMA_da24edf1-dae4-4dad-a20a-17361fb6b48e">6.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTYtNy0xLTEtMA_d69d95c1-93e0-4bdd-9f87-ba33af15aade">26.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTctMS0xLTEtMA_e83215b8-d538-4179-aa1d-0ad3bdd3325f">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTctMy0xLTEtMA_502a6bb9-14f4-4103-93e2-ec9c734fa3f3">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTctNS0xLTEtMA_67ad95f0-1f45-49c6-bb14-9f6280a2f31f">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTctNy0xLTEtMA_10b56a6a-555d-42db-b680-7adc35e9b6b0">5.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTgtMS0xLTEtMA_000a3f0c-d058-4971-a572-8ad33ed5ee99">127.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTgtMy0xLTEtMA_aa39a579-807f-4742-bfcd-415fd3aea9a2">153.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTgtNS0xLTEtMA_575937ce-1a3a-4d30-8d89-8ec13a9a7a74">322.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTgtNy0xLTEtMA_268f6716-5810-469c-af68-027de924a85a">444.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTktMS0xLTEtMA_196f1051-d7bd-4d3f-9819-be0a5d232e3d">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTktMy0xLTEtMA_933def5f-c4f8-404b-85fe-da66a166dc8d">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTktNS0xLTEtMA_2118f0ea-acf6-4999-8764-7d7502440021">65.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTktNy0xLTEtMA_f2c23a6a-b06f-45d2-9568-8ce1c705c752">88.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjAtMS0xLTEtMA_97f1a968-b381-4c6c-ab80-3722dd382c64">100.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjAtMy0xLTEtMA_7c09ae60-a92d-4862-a10d-4270229ebb9b">119.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjAtNS0xLTEtMA_0018f62a-e16b-479b-bc20-9d6957fdf82b">257.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjAtNy0xLTEtMA_9b97e47c-9390-4ba6-a397-d19514e0afe7">356.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjEtMS0xLTEtMA_61aec65e-01e3-450b-a715-cab1e168b800">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjEtMy0xLTEtMA_e72ee539-7b0e-4254-9047-070d1a494144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjEtNS0xLTEtMA_f8845c17-28dd-41ce-8a84-abe7b7369b45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjEtNy0xLTEtMA_50bd1f97-1c00-41ad-b643-0ff84a121408">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net and comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItMS0xLTEtMA_384e526c-55e9-456c-9af1-ab25928c8250"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItMS0xLTEtMA_7f066a1e-0b11-4f9f-9e06-d3d1f0717bec">100.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItMy0xLTEtMA_1e0e01a0-bdbf-4915-b21e-90b7b874d814"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItMy0xLTEtMA_a9a02509-2da7-44bc-8335-df956b226754">119.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItNS0xLTEtMA_453ab30b-5c08-489a-afa1-c22de810a246"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItNS0xLTEtMA_aa2c4d48-044a-4e1d-af65-c9e1f8ace91c">257.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItNy0xLTEtMA_03006664-d2ad-460f-894a-2a0445720a05"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItNy0xLTEtMA_23f85370-cd49-4c05-8b48-66b9421a95bb">355.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net and comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtMS0xLTEtMA_3296b99e-6b83-4c8f-aea7-99f9a7d22747"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtMS0xLTEtMA_f6b62a1b-2aec-4d54-8c5b-2a5155eb7efd">22.4</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtMy0xLTEtMA_c6fa8b6a-5468-4632-ab67-b78de4a99a34"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtMy0xLTEtMA_f1d0688b-cbe9-4731-9a6f-eb4a07115592">21.9</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtNS0xLTEtMA_1422b4ed-f7ac-41f2-bd1b-9409408fce71"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtNS0xLTEtMA_809a3bff-e15e-43c9-8125-03f1c660c1c2">58.9</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtNy0xLTEtMA_1d546123-3005-4962-9593-a00feeb63906"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtNy0xLTEtMA_ded5825c-bfb4-4f04-b4b7-541446ead672">64.5</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net and comprehensive income attributable to Encompass Health</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtMS0xLTEtMA_7726f083-59de-450c-93e6-9aec09726271"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtMS0xLTEtMA_97df1cb2-75dd-43c0-afff-2b5b1c9b2e45">77.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtMy0xLTEtMA_2bb8c8b9-bb04-4d4d-b1c9-5a4a461b291d"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtMy0xLTEtMA_b716344e-e3c4-4937-b190-cf49fb1b82b4">97.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtNS0xLTEtMA_526ab746-ade9-4421-bbc4-ee2704145353"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtNS0xLTEtMA_edf18735-93f5-477a-b900-a06a57fe7bb9">198.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtNy0xLTEtMA_6ced7785-38c4-4efb-a384-b94774faddcb"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtNy0xLTEtMA_72b1c3eb-2756-46f5-8bbd-39f838871fcd">291.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjktMS0xLTEtMA_75269bea-7387-4be9-ba7c-8374684db1c5">98.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjktMy0xLTEtMA_0cb287e6-0c9c-405c-8b6b-ab463bec4d7d">97.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjktNS0xLTEtMA_3bdf9500-f06e-491f-a129-fb824d54b338">98.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjktNy0xLTEtMA_3f2bbfe8-0774-4f04-896e-c4c346d53987">98.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzAtMS0xLTEtMA_77535d64-66b0-4794-a494-c9f09e954615">99.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzAtMy0xLTEtMA_e1ee1b6e-3fdb-4309-8a7d-c851aba1e1d5">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzAtNS0xLTEtMA_06ca4ff6-65ec-4ccb-a9d1-ca2cb216c16b">99.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzAtNy0xLTEtMA_7ab77045-9514-4a3b-8897-04c252c68253">99.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per common share:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzMtMS0xLTEtMA_94bdaa4d-9288-4559-9a5e-7d169ca766ed">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzMtMy0xLTEtMA_b3a016bc-364f-4964-bb03-b6495921cc38">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzMtNS0xLTEtMA_639a597d-00ef-494c-a052-f48698bb696c">2.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzMtNy0xLTEtMA_9defde56-2454-4e72-abb1-87232d9e1a88">2.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzQtMS0xLTEtMA_0ce995c1-e344-4070-a2ca-c4cecd3b1a9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzQtMy0xLTEtMA_533bbbb8-c9bc-448e-b378-e9e730ea5bb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzQtNS0xLTEtMA_93104b06-41ac-4724-9a38-78834535111e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzQtNy0xLTEtMA_ab8c6984-de1c-440a-8e42-822aab66285e">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzUtMS0xLTEtMA_42f6491e-52a0-4158-a3a4-688ad6360ecb">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzUtMy0xLTEtMA_51f354a5-7c5f-4650-9347-6edc7ddeffb0">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzUtNS0xLTEtMA_013e5db3-1649-4bd2-acc2-f44fce51df61">2.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzUtNy0xLTEtMA_b8a29392-a378-4acc-b3ed-88376cdcf5bb">2.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzctMS0xLTEtMA_f1cccac5-f369-4ad8-aada-24394b227a1d">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzctMy0xLTEtMA_e9052588-68a1-4b06-ac2d-b94d66518016">0.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzctNS0xLTEtMA_c630441e-ff7e-42f7-8dca-35c32db51502">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzctNy0xLTEtMA_79b34c25-f07b-4399-9349-96c0197a7803">2.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzgtMS0xLTEtMA_ab3d25c5-d0d9-4db5-beda-8c955c0f7f25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzgtMy0xLTEtMA_a6c65e02-2661-4809-876d-d3dde9bf3cac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzgtNS0xLTEtMA_25fe47f0-85ea-4144-92b2-ce49f89435da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzgtNy0xLTEtMA_569149e6-fe92-4529-ac89-877b1b0b8057">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzktMS0xLTEtMA_9dd9a89b-5d50-4b40-a4cc-8a229bc9cab4">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzktMy0xLTEtMA_8ef0823a-623a-41b0-82e5-a0734fdfec06">0.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzktNS0xLTEtMA_8c1dd15b-d94f-4716-82e6-69ed6c09992f">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzktNy0xLTEtMA_f5c68be6-79e9-47aa-8083-f00f5275a6c3">2.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDItMS0xLTEtMA_fe8328ef-0c85-4897-891c-fe5e0ee3fc10">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDItMy0xLTEtMA_54854104-07f1-4204-ba02-db4c565fec76">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDItNS0xLTEtMA_27407e11-b0ea-47e0-a3d2-89d745ee1a06">198.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDItNy0xLTEtMA_136477f4-cef2-44ca-8bcc-680ebc98c2a7">291.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDMtMS0xLTEtMA_1149eda8-9b3a-4513-962c-96c2b7d76e85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDMtMy0xLTEtMA_dc9503fa-8e4a-40ec-b8a6-90ade4995ce7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDMtNS0xLTEtMA_aa1c1da6-a8bd-4704-ab2f-4f78399b73e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDMtNy0xLTEtMA_2cb10cf9-1a87-4798-bb00-f7b806bdd01d">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDQtMS0xLTEtMA_45386b85-6a8f-4116-9558-f53e20d08583">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDQtMy0xLTEtMA_e9c623f8-2741-41e7-a469-9627f9f0636c">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDQtNS0xLTEtMA_6a52d9d4-4fc1-41fc-92d3-e0b3949f2684">198.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDQtNy0xLTEtMA_86ec85f8-57e1-47d4-9b7f-e8aa014ea5e1">291.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNC0xLTEtMS0w_1adfa618-4e91-4f91-93be-4708df5b36f5">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNC0zLTEtMS0w_5cd47fc4-d1b8-4639-b44a-0d53c5ab0650">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNS0xLTEtMS0w_15d337ec-a445-40d5-bb5e-80ce0522bfa8">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNS0zLTEtMS0w_fde08422-4b5d-4959-a0f5-b39f77b1581e">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNi0xLTEtMS0w_6c174978-44eb-4cec-9224-6be54196b65e">593.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNi0zLTEtMS0w_79b8a881-6ea3-4bee-b110-2c2e5c543f1c">506.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNy0xLTEtMS0w_51e9403d-56bf-4575-9398-a26bd380c7fb">73.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNy0zLTEtMS0w_29301840-cb77-414b-9115-3dbf105a31b3">97.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfOC0xLTEtMS0w_8b7ac621-9e20-44c9-a52b-31f63cca3a72">1,174.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfOC0zLTEtMS0w_39b4598b-f195-4bd7-8ee2-cef3f8ef63f1">755.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfOS0xLTEtMS0w_0e0ef16b-b9b9-4a4a-9674-bde92bcda219">2,094.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfOS0zLTEtMS0w_ac8d7caa-edeb-4b8f-a70b-699c4c1691a6">1,959.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTAtMS0xLTEtMA_b4fcf783-531c-469a-8524-481fce61809d">267.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTAtMy0xLTEtMA_45a374d7-ea86-4d44-a14b-7533f57b23ff">276.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTEtMS0xLTEtMA_d30e5ed6-87ab-4c9b-b18a-cbcce20a1362">2,318.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTEtMy0xLTEtMA_b1d6126d-8733-4700-8b1c-fdbd6ee226fc">2,305.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTItMS0xLTEtMA_cb715739-a975-4bfc-880e-34bebe8224a4">441.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTItMy0xLTEtMA_60279774-a296-472e-8005-f8b306433f92">476.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTMtMS0xLTEtMA_f9f305d7-6169-4125-9f68-b2e1ce58364e">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTMtMy0xLTEtMA_3ff9c461-1148-4d82-a432-7c8c64e73911">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTQtMS0xLTEtMA_e5a8873c-48fe-44e9-a9f0-4c2d32a60350">305.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTQtMy0xLTEtMA_4fc27f2c-c98e-4ecd-9f2a-2ae3f709853f">304.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMS0xLTEtMA_ebb6140b-8134-4576-8117-101988e3ab55">6,610.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMy0xLTEtMA_4c2edf44-6da2-4948-b82c-510be11a7456">6,080.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTgtMS0xLTEtMA_54df403f-2ebc-4de4-8ce6-415c33b296c0">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTgtMy0xLTEtMA_2281e3e8-a17f-4aad-9625-12d633f4b2e3">39.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTktMS0xLTEtMA_ae5fc12c-b14d-4690-8e90-9f01fd542e31">47.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTktMy0xLTEtMA_c48b527d-77cc-409b-8d9d-acd47d078889">40.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjAtMS0xLTEtMA_ac65daea-8947-45d9-9a4a-e8929b166b3b">119.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjAtMy0xLTEtMA_20616852-5e1c-4630-8a1a-bc2261533882">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjEtMS0xLTEtMA_3b9c7143-d208-43ef-b6f0-3eebde2602c1">478.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjEtMy0xLTEtMA_9e445b69-abe7-489c-b5f5-4751f7d20b6b">546.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjItMS0xLTEtMA_07234169-996c-4697-95db-637c91302b30">682.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjItMy0xLTEtMA_ac682c06-c4ce-4e2f-9b45-bcf1c8bdff20">721.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjMtMS0xLTEtMA_5430e1aa-ec9a-457b-96b4-0ea201307799">3,539.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjMtMy0xLTEtMA_154e089b-7dcd-406a-b202-4bc6cf7056ee">3,023.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjQtMS0xLTEtMA_e7ba1d0c-254f-4198-ae06-88e414973fc9">228.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjQtMy0xLTEtMA_2cf7ffc3-cc42-4b32-b5d2-252e560f3f4b">243.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjUtMS0xLTEtMA_9b0f245a-b99a-4760-9ee3-911ce9f1cea1">230.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjUtMy0xLTEtMA_b5c4a49d-960a-4529-9b58-4e237c728165">159.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjYtMS0xLTEtMA_acffcfd8-1d08-4da9-82a4-9bee70f126c1">4,680.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjYtMy0xLTEtMA_652d1f4b-3273-406c-8694-e570be63978d">4,148.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjctMS0xLTEtMA_e17ba41d-7124-44d9-9b7e-8e17b0d0bfc7"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjctMy0xLTEtMA_098b521e-5c9b-49e3-9013-75b7c02eb208"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjktMS0xLTEtMA_c76a7694-93fa-4549-a9e4-731f550d110c">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjktMy0xLTEtMA_50abcbd5-53d4-4818-9466-06517875ea7d">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzEtMS0xLTEtMA_e8a9912b-3f93-473d-8de4-022cfcb7b789">1,520.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzEtMy0xLTEtMA_4ac481be-257d-4479-b7e4-7e4652763352">1,352.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzItMS0xLTEtMA_376598f8-1e1c-44b3-b8fe-1912524aa72f">374.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzItMy0xLTEtMA_630bfafb-9ef9-451c-99c9-24bb59781d05">340.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzMtMS0xLTEtMA_844d362e-e45c-4633-8051-b3eea0a9feaa">1,895.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzMtMy0xLTEtMA_6b27c476-7fcc-4676-aedf-73ea0c323e1b">1,693.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">and shareholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMS0xLTEtMA_7fe2fe5d-8a17-4f0d-b904-5da3eff95fff">6,610.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMy0xLTEtMA_96422c3d-18b4-4626-ad92-22d400d71628">6,080.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzUz_7165f141-3da2-4f42-969a-a86f3d941f6a" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of September&#160;30, 2020 and December&#160;31, 2019 include total assets of variable interest entities of $<ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMTAz_e343074b-febe-4345-abc1-5fb6600a1180">222.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMTEw_e476c36c-635b-40e3-831a-9a790b504d0f">215.0</ix:nonFraction> million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September&#160;30, 2020 and December&#160;31, 2019 include total liabilities of the variable interest entities of $<ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzA4_f545c332-fd6e-4270-a763-c8b5cf5530ed">44.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzE1_83653dd3-c3b1-4c5b-956d-4b176764a4b3">41.1</ix:nonFraction> million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></ix:footnote></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div><span><br/></span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_40"></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encompass Health Common Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Common <br/>Shares Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in Excess of <br/>Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling <br/>Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16b97f17d8db408195ceeadc301ddfb1_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC0xLTEtMS0w_998e690d-9b9f-444c-a63b-aa30dc4a255d">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b97f17d8db408195ceeadc301ddfb1_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC0zLTEtMS0w_67e70642-aa8a-41a3-a9e5-12d317ce209c">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736b33e93524e6286ddda20f63fb392_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC01LTEtMS0w_5ba32c73-b656-4f67-b583-ddaee34a1824">2,362.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d86622446d240caa39846454393bef9_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC03LTEtMS0w_9eb38af1-b6e1-4aac-b72a-08b418456b55">406.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i709bd3432796446cb8af88e1449a8b8a_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC0xMS0xLTEtMA_2e622945-c408-4041-880d-0d11f6c91305">494.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2dbc33472e04f73b22f6023e08ebc8e_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC0xMy0xLTEtMA_2ff5dff0-409b-4e22-ad35-4d000780c36e">368.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b16ec5f39fd426987fd267959afaf04_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC0xNS0xLTEtMA_d0e668f3-9396-464a-9757-7d3aeaa25019">1,831.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e461c575464b3faf3390da4ec357b2_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNS03LTEtMS0w_628e53a1-97fc-48f5-8ce6-7e92d30eb823">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0aa9d846293410c8246584aeefc69d8_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNS0xMy0xLTEtMA_9986ad45-0a35-4f7b-bad2-a5c74ed44b99">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNS0xNS0xLTEtMA_d065686b-0cc0-4e08-812c-2b329fee197f">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfOC0wLTEtMS0wL3RleHRyZWdpb246Y2NhNmQ1NGIxOTY3NDY4ZDllN2RmMzg4MjdjZDE0NTJfMTA5OTUxMTYyNzgxNQ_180f785a-8420-4208-ab8e-7fddcba55ddc">0.28</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19f0ded8fb484018a4a1c01ca5701bcd_D20200701-20200930" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfOC01LTEtMS0w_a85ddbf8-cc27-4c3b-a6c9-4e361320c5dd">28.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfOC0xNS0xLTEtMA_a3314b42-b660-4144-90ad-caaaa61be534">28.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f0ded8fb484018a4a1c01ca5701bcd_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTAtNS0xLTEtMA_14230624-43f2-49a0-991c-2b79d25b1eec">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTAtMTUtMS0xLTA_44b40188-11e8-4ab7-819b-f3c06585ab9e">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0aa9d846293410c8246584aeefc69d8_D20200701-20200930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTMtMTMtMS0xLTA_6b7d3556-01e1-4057-a713-387da797398b">21.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTMtMTUtMS0xLTA_31df272a-11f4-484b-b13b-6be16c4cc5d3">21.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0aa9d846293410c8246584aeefc69d8_D20200701-20200930" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTQtMTMtMS0xLTA_9fa50fec-87a1-4320-9bf2-15c2b3d47892">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTQtMTUtMS0xLTA_2f2623d4-b29a-442f-b176-2277e424e383">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f0ded8fb484018a4a1c01ca5701bcd_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTktNS0xLTEtMA_2b77f250-94b3-4d61-a946-93bfb7b66259">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9db578648abe46bf8900fa6e9eeff904_D20200701-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTktMTEtMS0xLTA_209e017c-99e0-4c46-9503-71646b2385dd">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0aa9d846293410c8246584aeefc69d8_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTktMTMtMS0xLTA_41adfb48-f136-4463-aba1-71bcc73ee17a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTktMTUtMS0xLTA_e6d1211e-5517-42e0-a5f5-356a33eb44d1">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77e27e7871034346bd94e7d93e7781a5_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtMS0xLTEtMA_870207ae-fc29-43f2-aa29-9e1646d91e45">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e27e7871034346bd94e7d93e7781a5_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtMy0xLTEtMA_3fd09a4e-5ce8-4781-82d6-28a8e6a5f5a8">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5ea56a23aa4f73aca3bbb27f91c6e9_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtNS0xLTEtMA_666a0614-68f3-4faa-8e9a-b2ba4a5cd39c">2,343.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42639cc7412e46f29b28dfa5b1b7fedd_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtNy0xLTEtMA_e041573f-16da-4bdc-870b-b0bafc317a06">328.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814c90a316b4443c999528ec80e7ee11_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtMTEtMS0xLTA_15e394d5-3f4e-48dc-9498-4319ad908edb">495.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2714c865b0433b81dee771e5553136_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtMTMtMS0xLTA_d3e1d3d1-1dd0-4d80-9ea5-0fe227d07bd0">374.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtMTUtMS0xLTA_2e93009b-fc4e-4565-bf8f-8bb10239c1ab">1,895.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encompass Health Common Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Common Shares Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75303561f2ef48ad8ff4e6b1651fc33f_I20190630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC0xLTEtMS0w_7a6b2caf-719f-49fb-be2e-a9f7e66e21d0">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75303561f2ef48ad8ff4e6b1651fc33f_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC0zLTEtMS0w_4d4aea73-108a-4296-a468-1e1d6e648823">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2656c38caa24df2bc08d8781a5e56b2_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC01LTEtMS0w_2edd72d2-8b37-45ac-b26d-6f9fe3b77bb6">2,455.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6671d6f397794090a985d9d5d859cb64_I20190630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC03LTEtMS0w_32233972-4622-400d-a1b6-d656dd0a6ff2">691.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e92833c9f1f4896aba1d31655bf9668_I20190630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC0xMS0xLTEtMA_47684dc8-ccb7-4e97-a06f-b173ecec6a16">489.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9d8fa1efdb4f6f928d5446c8898f66_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC0xMy0xLTEtMA_2933ab84-a70b-4e5e-8fb3-caa089b229ee">307.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec188c294f984c1aa5e6a6cf0c9e7af3_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC0xNS0xLTEtMA_59bd6259-433e-4683-b8a1-ac363613eaa2">1,583.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20836f1c7e2469e9f0c2603fbd54843_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNS03LTEtMS0w_f93b4b34-39ba-413c-aae7-039994c442c9">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNS0xMy0xLTEtMA_34d0f157-a9db-481b-9646-cd82f98c259e">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNS0xNS0xLTEtMA_9a018273-2327-4f13-bfc2-2c05ec1a988e">115.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57b58b477c6b44f8aae21799d9a882d1_D20190701-20190930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNy0xMS0xLTEtMA_6816e66e-1c19-4db2-bcd1-4c7e6f27491e">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNy0xNS0xLTEtMA_ce875f90-30a5-48e8-b6fa-4b8ff092bbe3">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfOC0wLTEtMS01ODgvdGV4dHJlZ2lvbjo5ODdiZWQ0YjAyYjA0NmFkYTM4M2E4MDc1NWVhZjY4Ml8xMDk5NTExNjI3ODIx_4697d6ae-e822-44cf-98e1-dba1cf228f8f">0.28</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59a276c6995d4d178488c77f6e17f1f0_D20190701-20190930" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfOC01LTEtMS0w_4e00c5a1-fb36-4634-b291-857e3cccc3ea">27.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfOC0xNS0xLTEtMA_2a1b0d79-7463-4c19-8ab3-f0be4340db6f">27.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a276c6995d4d178488c77f6e17f1f0_D20190701-20190930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTAtNS0xLTEtMA_4c0d424e-e8e7-483c-98d4-735f58f18157">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTAtMTUtMS0xLTA_5c59b912-22d7-4ba8-aace-c43c8292f698">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTMtMTMtMS0xLTA_183eeb86-b232-41c4-b745-d120a955dab2">20.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTMtMTUtMS0xLTA_3154e6e5-8c5a-4f5d-b768-dda03bdaea5e">20.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTQtMTMtMS0xLTA_72ace4bc-6805-40bb-bc21-ba6294bab4d5">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTQtMTUtMS0xLTA_fd0ece87-daab-4e58-9af3-ac7873343b4a">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value adjustments to redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59a276c6995d4d178488c77f6e17f1f0_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTUtNS0xLTEtMA_24947dc4-3383-42be-bedc-1e415cfc83f9">18.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTUtMTUtMS0xLTA_86fc1f3e-fe32-430f-bfbb-d524ea5544cd">18.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidation of Yuma Rehabilitation Hospital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930" decimals="-5" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTYtMTMtMS0xLTA_18ec146c-d552-4702-ad8d-ab6adec59a71">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTYtMTUtMS0xLTg0NA_1c79f10d-c48d-448f-9103-19fc84a8e1f7">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock in open market</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3577cda3504a48d3bf46aed515f88491_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTctMS0xLTEtMA_4830d90d-7d5a-4f08-99e5-001c7dba2ca0">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57b58b477c6b44f8aae21799d9a882d1_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTctMTEtMS0xLTA_ce20153a-92d2-449b-bc63-f509464fff1e">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTctMTUtMS0xLTA_0557327e-1878-4fdd-ba39-4d1b29db2ced">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3577cda3504a48d3bf46aed515f88491_D20190701-20190930" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTktMS0xLTEtMA_d98712b7-d6a4-4fc9-a243-d8cefd7f4e7a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a276c6995d4d178488c77f6e17f1f0_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTktNS0xLTEtMA_1066dd3e-edfe-411a-ad93-636e82785461">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57b58b477c6b44f8aae21799d9a882d1_D20190701-20190930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTktMTEtMS0xLTA_3280bf4e-1b40-4cb6-9996-d5d8258e6f31">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTktMTMtMS0xLTA_5f6b581a-e7c5-40ec-bb7b-6668cf929a89">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTktMTUtMS0xLTA_ac59fede-3791-403b-9d3d-2ec109b84863">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b92ed8623634131a7a34a47abf7dfb8_I20190930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtMS0xLTEtMA_95c69d9a-1de0-4fe3-9098-3b3286d53478">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b92ed8623634131a7a34a47abf7dfb8_I20190930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtMy0xLTEtMA_31885931-ef80-4a79-8f2b-f7073bd5c905">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ab5fcfcc24b20b042f933187dcebf_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtNS0xLTEtMA_7e0969ae-c107-4d09-b1bf-9b648f004a45">2,417.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361753f0507443df95849a9f371e2888_I20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtNy0xLTEtMA_00bcfde6-f63c-4dff-a1ee-304736346898">594.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2023d91010c1475cbf531020218e9ace_I20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtMTEtMS0xLTA_e07ba68f-ab4a-481f-9947-f89e09aed21f">491.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66065e8c14946cd8962d13d307a0707_I20190930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtMTMtMS0xLTA_6179ead4-4f28-419d-94f2-8bafbf10e254">338.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtMTUtMS0xLTA_2d3b4a7a-2329-4ab0-b413-525e089ea2a3">1,671.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div><span><br/></span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encompass Health Common Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Common <br/>Shares Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in Excess of <br/>Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling <br/>Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica9a466d7fcb45179986a30bd2f10e97_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC0xLTEtMS0w_45c18746-50d8-4de5-9436-ca31dbf562bb">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9a466d7fcb45179986a30bd2f10e97_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC0zLTEtMS0w_ac5a2234-977a-4e51-bd99-18e4cc693e46">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id973fd7c00f34ecdb68ed4e62bafd936_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC01LTEtMS0w_54ae5c89-e60d-4fdb-b116-c2bc7a83e9e1">2,369.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2180fc581434643b14bf9f6f6ec6d6f_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC03LTEtMS0w_591978e6-1ce3-4bda-a026-10642ad81856">526.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeecdaf0a74142089add642599699c41_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC0xMS0xLTEtMA_25ebc9f4-98c1-4ef1-88bc-39eafa7416c4">492.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e111b0b8f72431eaf24841ce8608010_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC0xMy0xLTEtMA_73a3568a-5228-4f21-89b8-727b0a1d6e81">340.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC0xNS0xLTEtMA_c3f75a06-5986-477c-aa82-b799ab4ecfa9">1,693.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7aa9d337504c10b18e5c482efd7679_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNS03LTEtMS0w_687b72e3-5e11-4e13-b99c-02d56cac20bd">198.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa62b0932f148c892a41d1e76032b17_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNS0xMy0xLTEtMA_3ad684e8-f606-406b-956a-a4b2ab019dd4">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNS0xNS0xLTEtMA_6e329818-13c8-441a-93ed-bf5705948938">251.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia54e68786692437494a7725e493da451_D20200101-20200930" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNi0xLTEtMS0w_97efdf1f-3382-4dff-b682-c84444e57965">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb56e8b6eccf4d0f952421ad0f6412f9_D20200101-20200930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNi0xMS0xLTEtMA_c322387d-8730-483a-9ad0-d11fc0df916d">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNi0xNS0xLTEtMA_4481d57c-7c3b-4598-9a45-4a853857e388">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNy0wLTEtMS02MTAvdGV4dHJlZ2lvbjo3NmRkZGNhOGIxZDI0OGU2OGQwYzExYmUyZTY0NjkyZl8xMDk5NTExNjI3ODE1_0d254fc6-14c7-45d9-b43f-b7c9c974efc1">0.84</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f7a8b690bbf4c35bee679ec147ea72d_D20200101-20200930" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNy01LTEtMS0w_6290df9d-0504-45a5-9afb-ed39f1c560a6">83.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNy0xNS0xLTEtMA_2e555138-4744-4696-8ced-89d43e5634fb">83.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange of Holdings shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia54e68786692437494a7725e493da451_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOC0xLTEtMS0w_38b4140e-40fc-4e35-8284-fbbdf986c3e8">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f7a8b690bbf4c35bee679ec147ea72d_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOC01LTEtMS0w_f48b5750-69ca-478d-a84b-9ff497d20e67">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb56e8b6eccf4d0f952421ad0f6412f9_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOC0xMS0xLTEtMA_fed121c8-3485-4f9f-96a7-522992d23c15">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOC0xNS0xLTEtMA_657d9c73-268e-445a-a4e5-aba0a000413a">46.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f7a8b690bbf4c35bee679ec147ea72d_D20200101-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOS01LTEtMS0w_19c64e2b-f6af-4b79-9b69-a3cb9f689ec8">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOS0xNS0xLTEtMA_d0788865-3d4f-43d2-b6b1-e2eea4572e2f">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfa62b0932f148c892a41d1e76032b17_D20200101-20200930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTItMTMtMS0xLTA_73f90320-c291-433a-8bab-648fdd7bbfc0">50.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTItMTUtMS0xLTA_08751c9d-81df-4007-8908-260da4d73b50">50.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa62b0932f148c892a41d1e76032b17_D20200101-20200930" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTMtMTMtMS0xLTA_5e8a197f-3735-4525-9e9c-d8ea1e8d45c6">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTMtMTUtMS0xLTA_4b3079c6-276b-462b-af76-3b2f5df0c802">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock in open market</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia54e68786692437494a7725e493da451_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTYtMS0xLTEtMA_021dc325-3772-42ac-b42a-3f5edf90be1f">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb56e8b6eccf4d0f952421ad0f6412f9_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTYtMTEtMS0xLTA_419caad7-f4b8-4d53-9155-4efb682f81cc">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTYtMTUtMS0xLTA_161bea8c-ef7a-454f-b577-7aae0438aa96">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia54e68786692437494a7725e493da451_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTgtMS0xLTEtMA_ab3dce4b-f9d3-4aa3-8e2a-ce1f0d649347">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f7a8b690bbf4c35bee679ec147ea72d_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTgtNS0xLTEtMA_57277e66-709b-4e29-b804-72858dd6324b">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb56e8b6eccf4d0f952421ad0f6412f9_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTgtMTEtMS0xLTA_30941e25-efef-4c00-8d0a-5248bd16ee6c">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfa62b0932f148c892a41d1e76032b17_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTgtMTMtMS0xLTA_698af4b4-9597-44c5-8230-0859d78ddc0a">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTgtMTUtMS0xLTA_49ec5853-0737-4d46-b5a1-c17b00cbab56">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77e27e7871034346bd94e7d93e7781a5_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktMS0xLTEtMA_a027a8a2-8319-4fce-8540-0c7ee7a466d9">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e27e7871034346bd94e7d93e7781a5_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktMy0xLTEtMA_70acb1e1-80e6-4b5d-a15d-7b867ca2473f">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5ea56a23aa4f73aca3bbb27f91c6e9_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktNS0xLTEtMA_90080e58-f73a-49de-bf6d-792454079467">2,343.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42639cc7412e46f29b28dfa5b1b7fedd_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktNy0xLTEtMA_286e19da-1304-4b35-81ab-a0395422358e">328.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814c90a316b4443c999528ec80e7ee11_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktMTEtMS0xLTA_c2a676dc-6e17-4522-a859-2f46bde0e17e">495.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2714c865b0433b81dee771e5553136_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktMTMtMS0xLTA_fecb96a7-5489-4630-a330-05a495e9c3ba">374.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktMTUtMS0xLTA_46be5b91-24ba-4651-aeaa-09919e78b06b">1,895.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encompass Health Common Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Common Shares Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i655f76689f4e487d80a6416983d67786_I20181231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC0xLTEtMS0w_4deedacc-0e6c-4fac-8187-01b596afcf84">98.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i655f76689f4e487d80a6416983d67786_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC0zLTEtMS0w_97a72690-478a-42fa-a7ce-cd053251b1b5">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eeff91751e644a28a060a7ad7988b9b_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC01LTEtMS0w_1ace3232-6c64-4e41-8cd9-31c17228bf23">2,588.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34acebad6a69473fad71f2a9f267509d_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC03LTEtMS0w_86f96fcd-84b5-453a-a7f3-2f4a5699ce1b">885.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id46c52daa7f1470a96f7d883e6a8cfa5_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC0xMS0xLTEtMA_2fc5f230-2982-4753-8fda-54a154affbb9">427.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4343fa926414dfb8314bc855f63f5b7_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC0xMy0xLTEtMA_856d31be-5670-4959-a454-a934fe3146a7">280.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22de6a707d946778ca077c5a44462af_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC0xNS0xLTEtMA_9f6536a4-9ab1-47a6-8317-d3d56df5c64c">1,557.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8102226c2854289a3f93691bcd2de7c_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNS03LTEtMS0w_f92206e8-68e6-438f-bee4-8ddd097e87be">291.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNS0xMy0xLTEtMA_5ee03d80-1303-4b49-89b6-6c5152dfb01c">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNS0xNS0xLTEtMA_377e36af-b7d3-441e-b356-505e7c0502de">345.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic2623f131c3949988d9bd1994b6eadcb_D20190101-20190930" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNy0xLTEtMS0w_eb126328-c247-4e26-bfb2-c8ce1a4aeafe">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c6ede3de4b41f086db0871d013257f_D20190101-20190930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNy0xMS0xLTEtMA_15e228f1-28c8-4d70-b2bc-9bb963efbd50">16.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNy0xNS0xLTEtMA_5ef1506d-634c-4df0-a683-10b041c7dbdf">16.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfOC0wLTEtMS02MzEvdGV4dHJlZ2lvbjo4MDk2NGRmYWNmNGY0OTIzYjVkNzY1M2MwZDJiNGUyYl8xMDk5NTExNjI3ODIx_64e6c624-3097-48ca-8436-ac17908528ba">0.82</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744c10f6ed7148d6b5050c2d1f9af046_D20190101-20190930" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfOC01LTEtMS0w_cb8f3070-0069-4c5c-8a57-f99cc9274ba5">81.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfOC0xNS0xLTEtMA_44a9c442-e4ad-4362-aa8f-b3014cbcafe3">81.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744c10f6ed7148d6b5050c2d1f9af046_D20190101-20190930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTAtNS0xLTEtMA_157fb2cd-2afa-4290-9f3d-5ebd3407c0d7">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTAtMTUtMS0xLTA_52b9b290-7d45-4793-989f-e58ef4e18d8a">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTMtMTMtMS0xLTA_7552b8f6-35bc-4566-b12d-72a8841a7940">52.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTMtMTUtMS0xLTA_51f1702c-2e36-443e-bb22-276cb88ab387">52.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTQtMTMtMS0xLTA_73929832-d372-48c0-bfcb-f2e4ea055662">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTQtMTUtMS0xLTA_b82e3202-3e8f-4aab-80c1-09d877ed4434">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value adjustments to redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i744c10f6ed7148d6b5050c2d1f9af046_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTUtNS0xLTEtMA_ab83b6c5-f152-4471-b1c0-a3af64b86ee0">118.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTUtMTUtMS0xLTA_ddbd3156-7a79-4069-8b38-3a5127ac9045">118.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidation of Yuma Rehabilitation Hospital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930" decimals="-5" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTYtMTMtMS0xLTE3Mg_c58139c9-524d-4dc1-b69b-11e2e4c68f47">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTYtMTUtMS0xLTI2MA_1b1b9a11-3960-4598-b55d-ee392ad23091">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock through the open market</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic2623f131c3949988d9bd1994b6eadcb_D20190101-20190930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTYtMS0xLTEtMA_c1b5469e-28b8-4d8f-ab0d-6f3d71d7fb75">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c6ede3de4b41f086db0871d013257f_D20190101-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTYtMTEtMS0xLTA_c3024a14-6355-4d36-bd35-a184b34872fb">45.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTYtMTUtMS0xLTA_f6016412-cca1-48f0-8aa9-54a9b9383332">45.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2623f131c3949988d9bd1994b6eadcb_D20190101-20190930" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTgtMS0xLTEtMA_a5c6cc11-01fa-4f61-92cf-8989cf3fff5c">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744c10f6ed7148d6b5050c2d1f9af046_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTgtNS0xLTEtMA_610d8f62-cfe5-4ceb-939b-96e3b7471e62">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3c6ede3de4b41f086db0871d013257f_D20190101-20190930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTgtMTEtMS0xLTA_c00ea004-5068-4df0-8942-b6c90c2fd54a">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTgtMTMtMS0xLTA_16a50749-0ddf-46d2-8e93-5cb2528ab8d4">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTgtMTUtMS0xLTA_3d0ec777-87be-4ffb-be91-03757d6a1214">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b92ed8623634131a7a34a47abf7dfb8_I20190930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktMS0xLTEtMA_ea3dbb55-b70e-491b-8e60-e6f98eb0542d">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b92ed8623634131a7a34a47abf7dfb8_I20190930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktMy0xLTEtMA_4e06d4e3-d176-4d85-9a85-5163cc6d6bc9">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ab5fcfcc24b20b042f933187dcebf_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktNS0xLTEtMA_8bc6c625-7be5-4f8e-8d3f-22395bc901fe">2,417.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361753f0507443df95849a9f371e2888_I20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktNy0xLTEtMA_7efcf5ff-71cd-4931-ba91-58abbf015a02">594.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2023d91010c1475cbf531020218e9ace_I20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktMTEtMS0xLTA_570d19e0-058e-4927-b026-f89da45dcd7d">491.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66065e8c14946cd8962d13d307a0707_I20190930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktMTMtMS0xLTA_9858882f-7403-4a8f-b123-bc3c2cf2ea0f">338.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktMTUtMS0xLTA_d48a0d81-447a-44de-a1a2-6ccfd30f2499">1,671.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div><span><br/></span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNC0xLTEtMS0w_8218df13-c603-4b72-8c4d-1cfa14875b75">257.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNC0zLTEtMS0w_3cdd8b2c-7621-4035-a3cf-7f35ab31813a">355.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNS0xLTEtMS0w_191d0e03-1374-441d-9a8b-808a4f55e631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNS0zLTEtMS0w_f4b5def5-4f8f-458a-bed9-34bb9f1054c8">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfOC0xLTEtMS0w_d1f531ea-a547-4231-b101-02314f71eea7">180.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfOC0zLTEtMS0w_bff7aacc-9f0f-4839-8a5a-e443ba6073e7">160.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfOS0xLTEtMS0w_b38d9fb7-a519-4a75-a071-6e4dd4a2f43d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfOS0zLTEtMS0w_0a060d88-43f1-4c0f-b0e3-0e06c1401a18">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTItMS0xLTEtMA_46d41d11-67e3-48bd-9b6c-1d554a57d644">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTItMy0xLTEtMA_e61df81f-d941-412f-bd5e-36a3a66f34eb">87.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTMtMS0xLTEtMA_5c4357ec-1cbf-4884-944f-f3e7a73454b8">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTMtMy0xLTEtMA_9a4e67a8-0137-4019-a6b2-c966cd0fd12f">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of Yuma Rehabilitation Hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTQtMS0xLTEtMA_4125abf9-5402-4e0d-ab96-94887e78cf3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTQtMy0xLTEtMA_ef331605-b79c-40d2-9e79-537dbe78b851">19.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTUtMS0xLTEtMA_34e7a63d-8eda-4a79-b51d-eb616929faff">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTUtMy0xLTEtMA_5655f61e-1556-420b-a389-f1ac36bd7d02">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in assets and liabilities, net of acquisitions&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTctMS0xLTEtMA_57230ff7-d8fc-4e84-8f95-e429e217b1e7">71.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTctMy0xLTEtMA_b964f3a5-ccf5-49a9-9a19-d3eeaf7c2c7f">37.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTgtMS0xLTEtMA_4a4c3c03-17b5-42b2-9afb-b56caa017cb6">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTgtMy0xLTEtMA_9da06a48-258f-4f15-9a88-1f2773274fd2">11.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTktMS0xLTEtMA_66358c2f-4aa3-42c6-ab72-52a69d999c8e">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTktMy0xLTEtMA_2841b0d0-348f-48c9-96e6-6ece02d79caa">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjAtMS0xLTEtMA_328b8b49-5b5e-4f8e-97dd-74e0be2163d5">86.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjAtMy0xLTEtMA_e8b10877-16b7-4ca4-ba51-6b1e48817aa2">21.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjEtMS0xLTEtMA_f49e4eb4-3484-40fe-adbd-ac63ee746118">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjEtMy0xLTEtMA_17f9dd7d-22da-43f7-b283-e7c012449ff7">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjItMS0xLTEtMA_20f8d714-49d6-41d5-9f14-2813b10eaa83">90.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjItMy0xLTEtMA_0d4dee5b-c459-4fc1-88a8-9b08619054cc">118.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjMtMS0xLTEtMA_ce2830a4-c7d2-41ba-902a-b500f9d87acd">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjMtMy0xLTEtMA_c52fa26f-afb5-473f-be78-0a3fa22fcb74">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjQtMS0xLTEtMA_856f61b2-a6fc-4d2d-987e-2a32b301c9c6">167.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjQtMy0xLTEtMA_815d1a5b-884b-4b25-87df-be0f8d55b565">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjUtMS0xLTEtMA_b75d631e-7bd6-44ce-a2e2-339695e00afd">425.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjUtMy0xLTEtMA_ba17f5e8-d761-4b0f-9865-df8a287176e5">419.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjctMS0xLTEtNzUw_e050a843-c0f5-465b-b2cc-43d8636623fd">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjctMy0xLTEtNzUw_6b3d63e1-f636-40a5-80b1-0ab2d7df6836">231.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjctMS0xLTEtMA_54ff4188-0dae-4ef5-a379-f89f6b790559">256.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjctMy0xLTEtMA_c25fa59d-5663-4b75-9936-13073aa7146f">259.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to capitalized software costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsForSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjgtMS0xLTEtMA_5ffcceac-0d77-44b9-843c-db837246a784">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsForSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjgtMy0xLTEtMA_54db3741-924b-4fa5-8386-759328894aad">9.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMzItMS0xLTEtMA_bc40ef27-1909-443c-93ca-c71f705ff7a7">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMzItMy0xLTEtMA_c6770933-a778-46bd-9c7d-2f3f5abfb66e">11.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMzMtMS0xLTEtMA_4aac6577-997a-4c86-86f9-b075975e8ad0">264.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMzMtMy0xLTEtMA_5ca958bc-5c26-44d0-a5be-34eca938b702">511.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from bond issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDAtMS0xLTEtMA_64654c65-814f-4873-9154-8491bfda0d5b">592.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDAtMy0xLTEtMA_088603f4-e15e-4494-b7e2-0cb8fbe581d1">1,000.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on debt, including pre-payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDEtMS0xLTEtMA_5ae14f00-9d35-45ed-8fc9-f95cea753a27">14.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDEtMy0xLTEtMA_59ed9b8d-36ff-4cd1-b867-895ebd004ed0">115.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDItMS0xLTEtMA_5befcb7e-3e7a-485d-a9f1-73a2fe84a9de">330.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDItMy0xLTEtMA_eff71a82-d5e0-4502-bd65-7b136d29443e">525.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDMtMS0xLTEtMA_c8bdf97a-9109-4e39-96dc-2a57f60874ab">375.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDMtMy0xLTEtMA_658f2f43-4c7c-49d9-8348-508720cc5d20">555.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments under finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDQtMS0xLTEtMA_043ee06b-1533-4604-8163-f176caf40fbd">16.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDQtMy0xLTEtMA_35f78269-8a6e-4e1d-b6d2-37e32d48a5b6">14.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDUtMS0xLTEtMA_c3a98e7d-87c6-4106-b894-d4829fcae76c">13.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDUtMy0xLTEtMA_d4af1592-bdfa-48f5-a919-851fce84fe41">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid on behalf of employees for shares withheld</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDYtMS0xLTEtODMz_c79b7ef2-a860-4300-a606-a0fcf665e70b">15.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDYtMy0xLTEtODMz_460161cf-7807-4898-ad5e-214edbaddd29">16.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid on common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDctMS0xLTEtOTE1_98c57dbf-ee24-4b76-9c64-5df500709968">84.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDctMy0xLTEtOTE1_47c84b89-4206-4468-919c-1ca07f99efbc">81.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests of consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDgtMS0xLTEtOTIx_bed56001-72de-4dfe-8155-0fa29163ed7f">52.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDgtMy0xLTEtOTIx_2b35a74f-82de-4925-864e-15205b9a643a">57.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock, including fees and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDYtMS0xLTEtMA_609f7b2b-6573-4374-976a-e842c8eca231">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDYtMy0xLTEtMA_0f791a2b-8bb9-4606-9001-17adae5d3093">45.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of equity interests in consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsOfDistributionsToAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDgtMS0xLTEtMA_6d58592e-7923-4eef-b7b1-5d5214788a30">162.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsOfDistributionsToAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDgtMy0xLTEtMA_a22230b0-30af-4a3b-8cf6-9ccad2def94c">162.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTItMS0xLTEtMA_46f13e86-59dd-4e28-97ba-c77ee96eee02">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTItMy0xLTEtMA_b1804bde-1666-470d-940b-a8132deca87d">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTMtMS0xLTEtMA_51dd8cb3-b734-4f49-a3db-1522087fd97e">208.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTMtMy0xLTEtMA_6f10125d-3712-4770-8afe-28d83b935d97">472.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTQtMS0xLTEtMA_913883f8-3abd-45ed-8463-028772356866">368.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTQtMy0xLTEtMA_17a6d01c-c706-4555-a6ff-97bb4fb952f4">380.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTUtMS0xLTEtMA_d3e5ee73-e798-4561-a67f-e2f5889486f9">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22de6a707d946778ca077c5a44462af_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTUtMy0xLTEtMA_68affd75-1e54-4634-8aa5-67d6c0e6a8e3">133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTYtMS0xLTEtMA_34ef2ec9-88fc-45ee-8c45-4e6eaa2e88c9">528.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTYtMy0xLTEtMA_df0fd174-7719-4db0-8238-3dd19c2c65ac">513.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTktMS0xLTEtMA_72d9cb1e-ed47-4d53-89ee-7720a49c47b2">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22de6a707d946778ca077c5a44462af_I20181231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTktMy0xLTEtMA_51fe780e-7bd2-4017-970a-8ee79036df3a">69.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash at beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjAtMS0xLTEtMA_653fa73d-fe97-40c8-b47b-36113f209180">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22de6a707d946778ca077c5a44462af_I20181231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjAtMy0xLTEtMA_622da362-0de3-4f98-a870-854e19e334f8">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other long-term assets at beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjEtMS0xLTEtMA_e45176fb-8c9b-458d-8e50-89f7a266f5ab">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22de6a707d946778ca077c5a44462af_I20181231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjEtMy0xLTEtMA_8af4c402-1733-4acc-a836-3b5985389ea2">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjItMS0xLTEtMA_681f1bc0-ee33-4198-b1c1-623d4f81a60d">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22de6a707d946778ca077c5a44462af_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjItMy0xLTEtMA_304b1166-5f27-4ae1-a10f-07b33ccca497">133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjQtMS0xLTEtMA_e137c47d-a289-4455-bc6e-b885803888ff">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjQtMy0xLTEtMA_0e86d5e5-8dc2-4c95-afca-cc05450505b2">422.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash at end of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjUtMS0xLTEtMA_1d3558a4-fe75-4b78-99cd-6215626de507">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjUtMy0xLTEtMA_768e9623-7fce-47e4-90c6-a38ba290ae34">66.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other long-term assets at end of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjYtMS0xLTEtMA_03954c82-31aa-4db4-8142-44339fa370d3">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjYtMy0xLTEtMA_87f8e1dc-aa07-40f1-9c2e-eac6e5137485">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjctMS0xLTEtMA_a351d568-a9d3-4275-a9e5-6253b5f80e62">528.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjctMy0xLTEtMA_5bd0e676-0388-45ec-95bb-62182d1ded58">513.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental schedule of noncash financing activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of ASC 842</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="ehc:NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNzAtMS0xLTEtMA_1a18e0e8-aa53-4cb4-8ba9-566f48269062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="ehc:NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNzAtMy0xLTEtMA_faa88752-b8d1-4714-9687-531581c974a1">349.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div><span><br/></span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_52"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81Mi9mcmFnOjc1YzFhYWY4YjI5ZTRhMjVhMTgxOGJmMDMwNDQyMDg0L3RleHRyZWdpb246NzVjMWFhZjhiMjllNGEyNWExODE4YmYwMzA0NDIwODRfMjA4NQ_ec9ccbff-937d-498b-a5c8-eb80309f37a2" continuedAt="ia730fb838a264b5fa197f9156889291e" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ia730fb838a264b5fa197f9156889291e" continuedAt="ie6d1b0d74fab4355beddaacacda7389e"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is one of the nation&#8217;s largest providers of post-acute healthcare services, offering both facility-based and home-based patient services in <ix:nonFraction unitRef="state" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81Mi9mcmFnOjc1YzFhYWY4YjI5ZTRhMjVhMTgxOGJmMDMwNDQyMDg0L3RleHRyZWdpb246NzVjMWFhZjhiMjllNGEyNWExODE4YmYwMzA0NDIwODRfMjYw_8810ac3b-14a8-4ef6-b3b9-e7cf6f1eb02d">39</ix:nonFraction> states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using <ix:nonFraction unitRef="segment" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81Mi9mcmFnOjc1YzFhYWY4YjI5ZTRhMjVhMTgxOGJmMDMwNDQyMDg0L3RleHRyZWdpb246NzVjMWFhZjhiMjllNGEyNWExODE4YmYwMzA0NDIwODRfNDU1_5a541ede-859a-4799-a6aa-ca6f33bcfb0c">two</ix:nonFraction> reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. See also Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Encompass Health Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes contained in Encompass Health&#8217;s Annual Report on Form&#160;10-K filed with the United States Securities and Exchange Commission on February&#160;27, 2020 (the &#8220;2019 Form 10&#8209;K&#8221;). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December&#160;31, 2019 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented.</span></div></ix:continuation><div id="i5ec2d1f903d340c19ee74983700dc28d_1869"></div><ix:continuation id="ie6d1b0d74fab4355beddaacacda7389e" continuedAt="ia16301d1253c4bd68c20321f4974b883"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of an amendment to the joint venture agreement related to Yuma Rehabilitation Hospital, the accounting for this hospital changed from the equity method of accounting to a consolidated entity effective July 1, 2019. The amendment revised certain participatory rights held by our joint venture partner resulting in Encompass Health gaining control of this entity from an accounting perspective. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. The consolidation of Yuma Rehabilitation Hospital did not have a material impact on our financial position, results of operations, or cash flows. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased by $<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xODY5L2ZyYWc6YzYwYWY4OWRmZTMyNGMxYmE0ZTkxOWQ3YzM0ODFhN2EvdGV4dHJlZ2lvbjpjNjBhZjg5ZGZlMzI0YzFiYTRlOTE5ZDdjMzQ4MWE3YV8xNDg0MzQwNjk3NzA5Mw_4497d6ed-be6a-41dd-92d2-fb81c6ce9c82"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xODY5L2ZyYWc6YzYwYWY4OWRmZTMyNGMxYmE0ZTkxOWQ3YzM0ODFhN2EvdGV4dHJlZ2lvbjpjNjBhZjg5ZGZlMzI0YzFiYTRlOTE5ZDdjMzQ4MWE3YV8xNDg0MzQwNjk3NzA5Mw_d837081a-f9d2-444f-919c-a36b4151f941">24.9</ix:nonFraction></ix:nonFraction>&#160;million and we recorded a $<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xODY5L2ZyYWc6YzYwYWY4OWRmZTMyNGMxYmE0ZTkxOWQ3YzM0ODFhN2EvdGV4dHJlZ2lvbjpjNjBhZjg5ZGZlMzI0YzFiYTRlOTE5ZDdjMzQ4MWE3YV8xNDg0MzQwNjk3NzEwOA_2ff56e7e-61e7-4156-a253-c151f2da6586"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xODY5L2ZyYWc6YzYwYWY4OWRmZTMyNGMxYmE0ZTkxOWQ3YzM0ODFhN2EvdGV4dHJlZ2lvbjpjNjBhZjg5ZGZlMzI0YzFiYTRlOTE5ZDdjMzQ4MWE3YV8xNDg0MzQwNjk3NzEwOA_b7215e26-6515-4020-881b-47b06c26c34f">19.2</ix:nonFraction></ix:nonFraction>&#160;million gain as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three and nine months ended September 30, 2019.</span></div></ix:continuation><div id="i5ec2d1f903d340c19ee74983700dc28d_55"></div><ix:continuation id="ia16301d1253c4bd68c20321f4974b883" continuedAt="i4b1dcd367ab44a52ae1367a776d60ba0"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RleHRyZWdpb246NTFkMWQ4ZDEzMTVhNGFiOGJiMmY2MjdjZDllNzFlZmFfMjY4_2c75484c-a78d-4a3a-8ca4-c324451d8871" continuedAt="i780e1dd07cc14457a9d725c54000ce9f" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source and segment are as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:35.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5873889771684c2cae78023b5cec4fc8_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy0xLTEtMS0w_40c0b7a6-3197-4a0e-b56a-18f1e6f886aa">592.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b66c244e6394649b16c65e6c1d17603_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy0zLTEtMS0w_60007d2e-2214-4374-bb9c-89d98c10e00e">624.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eac552610d74721a0767d8c2e8f4b7d_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy01LTEtMS0w_61733802-3871-48ae-9ac4-b5bb2e6ff81a">228.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc0e8dca788458691540d426154ef62_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy03LTEtMS0w_04f0228c-d576-4fa9-a9c5-6c98eb4494ee">248.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb9260dccfc4ad9a9987f170f8a116b_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy05LTEtMS0w_33dccd16-f8ec-4003-9b0a-eb2b33520944">821.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4591d2e05d1482594d3f6804849a4e2_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy0xMS0xLTEtMA_6207999e-2e7a-442d-994f-ad76282ce8b2">872.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d947760b414ceface797d75918f6c3_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC0xLTEtMS0w_fef55798-4857-46b4-a92b-734873a45f03">141.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77665009ef8c4684bcb85139cafb06dc_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC0zLTEtMS0w_af0bcda8-acda-4d37-979c-32e69e834f58">94.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i322a014d46954ce696d8d8480f860d21_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC01LTEtMS0w_69598ab5-28f0-444c-a2e9-98bca49e978f">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4550c4ea110e4f929a058f20551c7afb_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC03LTEtMS0w_ce376e7f-e685-490a-8162-c61bbeacbea6">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51235bf4750c4c599d6756b7879a4939_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC05LTEtMS0w_8deea67a-f5a8-4b1a-bdb8-db58df6fd2cc">170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5f0a3577bda4c609eb02fe086530d48_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC0xMS0xLTEtMA_1f816cc3-4e8b-4ef5-bcdb-bf9a6fb3af9a">119.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c5802675ee44e99fb4499efcd6b2c8_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS0xLTEtMS0w_88a6f377-eca6-4c72-ad43-6aa18c8540dd">95.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345e73d6d939476ba32049426ba68d70_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS0zLTEtMS0w_bbb7bd0b-8d77-47df-ac90-f0194cf30390">87.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c26b5364d4089bd5ce943f4309664_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS01LTEtMS0w_dcaa4849-9f02-45ec-8790-db81a956f2bc">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5524ac2905524e6d812a13eb8e579d18_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS03LTEtMS0w_706144d4-a393-4652-9916-3f78befb956b">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992298aaa6ce4481ae6d6fa2fdebef80_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS05LTEtMS0w_6bcee4f1-d995-442b-b7d3-0fcaacbdf600">108.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17489ebe48064383942c0df2df3d5443_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS0xMS0xLTEtMA_d1c5230a-7303-4747-a41a-09295fe12e6f">97.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6e3a1ee04d4f429b30592defb5a698_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi0xLTEtMS0w_6469da22-cc5c-46c9-a6be-9b37b997d4a3">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6370fbb51164f019e9009265116e84e_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi0zLTEtMS0w_c3a99d61-5bc9-4d28-a01a-f0349e5f7c0e">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib894026d74674e5f96d404bb4cfc3b09_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi01LTEtMS0w_1f3651bb-3a27-4644-9189-86dec72c6bbe">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i732c02fb17ea40ad9e61516625f6ebc5_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi03LTEtMS0w_ee937224-5f3d-4696-b09e-1bd30374855c">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2d4e1ad64bc4d1daff8885a47a9ffa4_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi05LTEtMS0w_200d7cfe-2f92-47f8-9142-5a107f0f716c">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d73a08c42ae41178ddeba3a203ab25f_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi0xMS0xLTEtMA_8acef972-20ab-4079-97b0-c244e016939b">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ec8761fcd64c49b38ddf4391322512_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy0xLTEtMS0w_8caa09ac-045c-40c3-a107-8d365a833292">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabd0dd54725446c9f81802c9a397c00_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy0zLTEtMS0w_3e233753-3618-41d3-9d45-6e6cf0b78d11">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac15f62994f4ba29f3f686482654b89_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy01LTEtMS0w_77e71bb8-6d48-43cd-a92d-f56be5f7af4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd12a6455e04deeaa0f18ba31b44fad_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy03LTEtMS0w_40bdc72b-f561-49ca-9531-6309c1e571c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c117f071984988883a0aca1685756b_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy05LTEtMS0w_4c98f6d0-e660-4a4a-b73c-2b85dd9bc063">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97bbbbdd86244b42975499d324035936_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy0xMS0xLTEtMA_912914c4-0559-4ffa-a1c6-4af43dff9617">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef53d5ff22046d0bb56bf2117a9ff75_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC0xLTEtMS0w_ccbdc7fc-d8c1-4bd7-9d0c-a6dbe33fd429">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4541f86f6464425ca691fe14b5d7e823_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC0zLTEtMS0w_e568c969-692f-49d2-987d-4cacbb265afe">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd8e538bfc2e4ff8bd996ad27939cca6_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC01LTEtMS0w_04f3344d-6101-41e1-be9d-9826ec28ad47">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaefd1a522f844a7aff1af78d82fd07e_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC03LTEtMS0w_bd86fc7d-f35a-4407-93d3-a1794c5a4ba8">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2279c50c6c004924ab551e8bdb047c89_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC05LTEtMS0w_432d9cc3-9257-471a-b58d-7c544482933a">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b51433b8594e0fb5df286fd380aac0_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC0xMS0xLTEtMA_6dc97ce0-6ec4-4cbe-a98e-8bc2f362e58e">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a7ea8ec1664d5583fcb48015255e0e_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS0xLTEtMS0w_f17b2966-2d15-4576-ac52-dc36b3af958d">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ed726963d947acb35515778bbe3f2d_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS0zLTEtMS0w_dec510e4-8f07-485d-a6f6-2725383dbf0d">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if015466e48914fd08001b347cd2dc00b_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS01LTEtMS0w_a7bffaa4-8975-4b1d-bc1b-04c650f54011">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f354ef81c74b3e906182037853d5ec_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS03LTEtMS0w_20c7b98e-12a3-4e24-b9ed-983573e1b1c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i694c2f12494e432eac4cc3d84cfad62c_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS05LTEtMS0w_2d810446-0310-455f-be31-b147195d8dc2">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f9a922335944feb38605cd28479c87_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS0xMS0xLTEtMA_92d55125-2f89-413c-bbfb-33e84f601b0d">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d1805e49bad499d82a78e70a324756e_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtMS0xLTEtMA_371b7d98-b746-4bba-bfc3-5644f83e1557">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ea5b28aef1345628308b8cd50db8b8e_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtMy0xLTEtMA_4293853c-a7ba-4f17-8d29-1edc15a7d7e0">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040e0067c9094904af97de3099bebb5f_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtNS0xLTEtMA_30002dd5-8289-4651-a1f3-c4e2b5f7a615">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b94005181d46348addb4f79179e077_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtNy0xLTEtMA_b41cbfbd-aafd-4397-a997-9e31d00022d1">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica170b9067d145f1a3adaa78a1913f4c_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtOS0xLTEtMA_6073b293-ac40-4d11-9233-c280858371b6">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9274fa4448545fa95f5a18d72345a7e_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtMTEtMS0xLTA_935e34e6-4260-4296-afcf-818d7360a854">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtMS0xLTEtMA_318253b1-e883-406f-b75b-d548bcf8ac26">899.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtMy0xLTEtMA_9e1c1dea-29a3-4624-a70c-5a98fd569d90">872.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtNS0xLTEtMA_1f70d1e2-deb8-420b-bbd3-dabe9f0f1de8">274.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtNy0xLTEtMA_031b4219-3e2b-4dff-9d22-ffaa0ee88d14">289.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtOS0xLTEtMA_64eb21cc-947d-4bf0-a0c2-6d7bbfdf34e0">1,173.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtMTEtMS0xLTA_6fdaa2fe-a8f2-4918-acd2-90ef2f5fd36a">1,161.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i4b1dcd367ab44a52ae1367a776d60ba0" continuedAt="i8badad58d1b74a39b81acada747c3eb9"><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><ix:continuation id="i780e1dd07cc14457a9d725c54000ce9f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:35.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i786f1ca5dc7149449a23ecb8c8d45527_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy0xLTEtMS0w_59061b40-f150-430a-a9c2-d688a6471414">1,738.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b152c7501b43ae9e8f226b1846e828_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy0zLTEtMS0w_35f7492b-e5d9-4fbf-99cb-176466306ea6">1,892.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6303df3106440f089bd9b6a43b82d6f_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy01LTEtMS0w_fa8b87f8-f0e7-4bb3-a5c5-480584ef45f6">658.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110e86db8c9843af98b966b2ffda9577_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy03LTEtMS0w_c3d8e96d-9fdb-4438-8074-46de2703ee81">684.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573b526d23014691a9fbcc99b22c39fd_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy05LTEtMS0w_0e949620-0e53-49f3-8059-7a9ee7f2f501">2,396.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476f0404ddd94cadb700f8b16900ee5a_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy0xMS0xLTEtMA_f4c4fba6-a83b-4b9b-b760-8e7debfbd0c9">2,577.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9bdde56e16463b988f64934c46d7c7_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC0xLTEtMS0w_e2c7d696-355b-4c82-8307-36c02d987d9b">418.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac3ba654254a43e8aa2ac93fcdf11d2a_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC0zLTEtMS0w_d85c1864-6682-4e0b-9688-6edf6bf7990b">276.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c3d4ee236a4d4cb2625cc617ee83e3_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC01LTEtMS0w_5c122c6d-68a0-4f77-a9b3-8523eefe80d5">88.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4fa52ee1d974b97bae8afb7aa7d412e_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC03LTEtMS0w_4bc36e6b-ab8d-4e12-8596-f7971157eddd">77.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb123f9a5b744a79f1bc96d6320a60f_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC05LTEtMS0w_38370f4c-f2cc-4eda-ae9c-1f346b5421d8">506.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf1c4c55ac84c38b5a62a045e25c279_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC0xMS0xLTEtMA_f52c4915-e4fd-493c-bafb-11f60620918c">353.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i413089dc6a054eca94c13747f4f64efc_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS0xLTEtMS0w_0aa168eb-c8b3-4300-8010-d12059ecf631">274.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91952fdfd623406fae39f30682f9061b_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS0zLTEtMS0w_c5d7a9de-1e60-43f1-81de-a549d3888f87">257.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824f669848e64d61b82896e206f54278_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS01LTEtMS0w_b5870039-4016-47c5-871f-054f92d42ca6">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db501b105224f719473dd493715a2a6_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS03LTEtMS0w_91a25c27-7bdd-4c5c-87a5-e5a14666b0fc">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab07423dc1c456ba919a6f038750cbc_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS05LTEtMS0w_942c7e7b-8c83-4bee-9abe-10997799e391">310.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8e309cf85040a28f0109ed6a570c17_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS0xMS0xLTEtMA_0a030e9b-4f6f-467a-8aae-f57a41a0a3e1">284.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3869c9910a4b0691c07e0cceb1ad09_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi0xLTEtMS0w_d6329d24-c594-4176-ab1a-e9a0140343d9">103.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66f0eef25f94b08b660e5e2ee7255f9_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi0zLTEtMS0w_70cea430-b87a-4823-8753-7ca09945e604">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica29f20acf9c41c69b1152541cad96dd_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi01LTEtMS0w_ea8f2848-8ba1-4ddc-86a6-fcf718480570">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ed9c2b17fe42f6a52a5c962bde16a7_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi03LTEtMS0w_8f823911-3201-4f31-8a07-9adefc5e1c82">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ad441b632046c092723ff744dbd45a_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi05LTEtMS0w_2e0d4f93-c0ac-400b-9238-38d8b3c03618">115.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie258e26fd75b4ed780d94575a67a5b1a_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi0xMS0xLTEtMA_4c1121dd-04e5-48ba-9e1a-92c4f19b293b">95.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a268959462c498a9cb35520cf233b92_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy0xLTEtMS0w_c222d83e-1db8-4925-87a1-e48fe8c8a040">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbc1f21caa34ceb8709c3862095c706_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy0zLTEtMS0w_1db66a69-0ae0-475f-b4e3-9d6346d5c42d">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f10e410cd6492ea62746dcbe08ed80_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy01LTEtMS0w_d91a4d49-3922-47f5-90ca-7b2acceec982">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabb8c23a4b647edae1f42bce9eadd72_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy03LTEtMS0w_6d5abb4b-0068-4b26-a1da-063db208c002">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa215d6614464fd0a8b6f316d94f43c2_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy05LTEtMS0w_bb6302e7-8838-4482-8474-704b61d6a46a">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2c160d712eb475cada54fe76f2c249a_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy0xMS0xLTEtMA_9cfc0b9c-bfa0-40e2-9dab-79ede366592f">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if00c6bc809b1468f8c5e1fd14713e9de_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC0xLTEtMS0w_8f471cb3-8ecd-4a50-b4c5-891115625e65">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3594d867ccaa4a45baee188e9b52d0ef_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC0zLTEtMS0w_57d23f8d-f268-4abb-abcf-c774673168e2">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75b0cdfb90148b7b50327f55b2b4c05_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC01LTEtMS0w_96e3bd4a-85c9-462a-810c-9d8ff21c5e63">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c565f1d2caf41e5ad304df1e404ec13_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC03LTEtMS0w_eab59852-d423-408d-9f05-d25f199d904f">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67c608503ce4f62b40fed8996b085cc_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC05LTEtMS0w_4cd8c6cb-7ed8-4c5f-b09a-2af9531891a0">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aceeeed5320482e9848586c21bfec7a_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC0xMS0xLTEtMA_1685f40b-c7ef-4137-88db-f1ed8bae102f">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f3d5a74c95403bb0c19dace55fa0e4_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS0xLTEtMS0w_f4600ee4-34f8-408c-8c8e-adc9ebe95aa7">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f3913477cf4583aabab55a753c76e7_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS0zLTEtMS0w_cd3b75c9-5dae-44bd-870e-2e6381f64a4d">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fa310487b624ab3abfe31fac6c6eae8_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS01LTEtMS0w_f8d35ab0-b241-4cd5-8924-c7f69dd25c8b">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e0c420dd3740c9b36010b9f1facfaa_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS03LTEtMS0w_ebe1f89b-a8e7-4259-81b0-e1af92fb125b">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4034d7e50f5c43f5960d10776b6b7bf4_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS05LTEtMS0w_848d68fd-d6ac-47e6-98c5-44f466d1e67b">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1118ce1a69f43f0aa8ff017adb7d860_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS0xMS0xLTEtMA_8f3628bc-91b4-4426-8c36-804838dffac9">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6897c3387c46f0b25a5ce68caf3780_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtMS0xLTEtMA_1f3952fb-efb5-4989-9738-f5a7efdc602e">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97911a33afcc4eb1b3bb2cf52223db83_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtMy0xLTEtMA_3d182abe-5b41-4d5a-b1cc-d6c0a27510ab">36.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e799fccf1b749bdb9a2fe12fa808cee_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtNS0xLTEtMA_3c3f3782-e4f6-48a4-8f3f-4ff6a949a7b1">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64dcfb692db141e38d22fc8b004d9924_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtNy0xLTEtMA_42605935-cefa-41e3-9a18-a23027dc7ed5">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a8ead0bbbc4ac8baa360ca8dd8f1d0_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtOS0xLTEtMA_3e6977f6-a3d6-4ed3-a667-49fd6958a1f3">37.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbcb67b95b64900b8e58638b2420b02_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtMTEtMS0xLTA_04569171-f33a-4d27-9d7e-59fe89451fa8">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtMS0xLTEtMA_e327f1bd-9b4d-4165-973a-2392e9051b89">2,633.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtMy0xLTEtMA_02f1b632-3266-4f9a-a154-9fdb336d64b9">2,616.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtNS0xLTEtMA_59e550e0-367b-4947-8abc-cf48760276d2">796.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtNy0xLTEtMA_b4642c8f-8c65-4a3d-b53b-2e6b950a66bc">804.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtOS0xLTEtMA_fb4135e2-32dd-40e5-96e6-40c9575f5114">3,430.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtMTEtMS0xLTA_dfe93935-7dfc-4ce8-b255-f0b4865c4bb0">3,420.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare Administrative Contractors, under programs known as &#8220;widespread probes&#8221;, have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute or &#8220;appeal&#8221; most of these denials, and for claims we choose to take to administrative law judge (&#8220;ALJ&#8221;) hearings, we have historically experienced a success rate of <ix:nonFraction unitRef="number" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="2" name="ehc:MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RleHRyZWdpb246NTFkMWQ4ZDEzMTVhNGFiOGJiMmY2MjdjZDllNzFlZmFfMTQ4NDM0MDY5NzgwNDM_d30b782f-e751-4e3d-9402-f0250a321569">70</ix:nonFraction>%. This historical success rate is a component of our estimate of transaction price utilized in determining </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. If current OHMA practices continue, an increased number of unfavorable ALJ decisions could have a negative effect on our long-term ALJ success rate. We are exploring various remedies to counter such negative effects. We believe it is too early to determine what impact, if any, these recent changes in the appeals process will have on our historical success rate or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 Form 10-K for our policy related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i5ec2d1f903d340c19ee74983700dc28d_61"></div><ix:continuation id="i8badad58d1b74a39b81acada747c3eb9" continuedAt="i59326ccc066648ac966278609ac265b3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) pandemic</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has caused a disruption to our nation&#8217;s healthcare system. Such disruption includes reductions in the availability of personal protective equipment (&#8220;PPE&#8221;) to prevent spread of the disease during patient treatment and increases in the cost of PPE. Elective procedures were postponed by physicians and acute-care hospitals and limited by governmental order to preserve capacity for the expected volume of COVID-19 patients and reduce the risk of the spread of COVID-19. Initially, these postponements and limitations were widespread. Now, they are more market or state specific and driven by the extent of the pandemic in those areas. Beginning in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mid-March and continuing into the second and third quarters, we experienced decreased volumes in both segments which we believe resulted from a number of conditions related to the COVID-19 pandemic including: lower acute-care hospital censuses due to the deferral of elective surgeries and shelter-in-place orders, restrictive visitation policies in place at acute-care hospitals that severely limit access to patients and caregivers by our clinical rehabilitation liaisons and care transition coordinators, lock downs of assisted living facilities that prevent our home care and hospice clinicians and other care providers from visiting patients, and heightened anxiety among patients and their family members regarding the risk of exposure to COVID-19 during acute-care and post-acute care treatment. In the home health and hospice segment, we also experienced decreases in visits per episode and institutional referrals because of the COVID-19 pandemic, both of which negatively impacted pricing for home health.</span></div><div style="text-indent:36pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2020, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">federal government began to undertake numerous legislative and regulatory initiatives designed to provide relief to the healthcare industry during the COVID-19 pandemic</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. A specific initiative impacting us is the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;) which</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> temporaril</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">y suspends the automatic 2% reduction of Medicare program payments known as &#8220;sequestration&#8221; for the period of May 1 through December 31, 2020 and authorizes the cash distribution of relief funds from the United States Department of Health and Human Services (&#8220;HHS&#8221;) to healthcare providers in response to the COVID-19 pandemic. On April 10, 2020, HHS began distributing CARES Act relief funds, for which we did not apply, to various of our bank accounts. We refused the CARES Act relief funds, and our banks returned all the funds to HHS. We intend to refuse any additional CARES Act relief funds distributed in the future.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i59326ccc066648ac966278609ac265b3" continuedAt="i17570d998d2841bb9b0660eb80752edf"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the CARES Act and a series of waivers and guidance issued by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) suspend various Medicare patient coverage criteria and documentation and care requirements in an effort to provide regulatory relief until the public health emergency for the COVID-19 pandemic has ended. For inpatient rehabilitation, the regulatory relief includes the temporary suspension of the requirement that patients must be able to tolerate a minimum of three hours of therapy per day for five days per week, waiver of certain of the requirements that at least 60% of a facility&#8217;s patients must have a diagnosis from at least 1 of 13 specified medical conditions, and waiver of the requirement for a physician to conduct and document a post-admission evaluation (as part of the Notice of Final Rulemaking for Fiscal Year 2021 for inpatient rehabilitation facilities under the inpatient rehabilitation facility prospective payment system, CMS removed the post-admission evaluation requirement from the inpatient rehabilitation coverage criteria effective October 1, 2020). In addition, the requirement of physician face-to-face visits at least three days a week may be fulfilled using telehealth. For home health, the relief includes the allowance of nurse practitioners and physician assistants under certain conditions to certify, establish and periodically review the plan of care, as well as supervise the provision of items and services for beneficiaries under the Medicare home health benefit and expands the use of telehealth. Additionally, CMS expanded the definition of &#8220;homebound&#8221; to include patients needing skilled services who are homebound due solely to their COVID-19 diagnosis or patients susceptible to contract COVID-19. For hospice, the relief includes the temporary waiver of the requirement to use volunteers and to conduct a nurse visit every two weeks to evaluate aides, as well as the expanded use of telehealth for routine services and patient recertification.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in April 2020, we amended our credit agreement primarily to provide covenant relief due to business disruptions from the COVID-19 pandemic. The amendment included, among other things, the carve-out of the COVID-19 pandemic from the definition of material adverse effect for 364 days and modifications to the interest coverage and leverage ratios under the agreement. </span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i17570d998d2841bb9b0660eb80752edf" continuedAt="i195b86c25f204332b2cb8e13e700b693">The foregoing and other disruptions to our business as a result of the COVID-19 pandemic have had and are likely to continue to have an adverse effect on our business and could have a material adverse effect on our business, results of operations, financial condition and cash flows.</ix:continuation> </span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_64"></div><ix:continuation id="i195b86c25f204332b2cb8e13e700b693" continuedAt="i849fb3a83e1a488b8305e0b8e924e387"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82NC9mcmFnOjlhZjQ1ZWEwYzdiNzRlYzRhNjNkMmZmODgyYjk4MmYxL3RleHRyZWdpb246OWFmNDVlYTBjN2I3NGVjNGE2M2QyZmY4ODJiOTgyZjFfMzMyMQ_f06b5d81-c47d-4e1e-a99a-04d46aa4a5a7" continuedAt="icbf7360e1e544437b1af3eab40241a85" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326),&#8221; which provides guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new guidance was effective for us beginning January 1, 2020. The adoption of this guidance resulted in an immaterial change to our condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, &#8220;Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&#8221; The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The new guidance was effective for us beginning January 1, 2020. The adoption of this guidance did not have a material impact to our condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Securities and Exchange Commission adopted final rules that amend the financial disclosure requirements in Rule 3-10 of Regulation S-X for guarantors of registered debt securities and subsidiary issuers. The new rules are effective January 4, 2021, but early adoption is permitted. The new rules permit alternative disclosures of summarized financial information, rather than our previous footnote presentation of condensed consolidating financial statements. The new rules also permit the summarized financial information and related disclosures to be presented outside of the condensed consolidated financial statements and accompanying notes. We elected to early adopt the new rules effective July 1, 2020. The summarized financial information and related disclosures are presented in Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In December 2019, the FASB issued ASU 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. Either prospective or retrospective transition of this standard is dependent upon the specific amendments. The new guidance is effective for us beginning January&#160;1, 2021, including interim periods within that reporting period. Early adoption is permitted. We continue to review the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i849fb3a83e1a488b8305e0b8e924e387"><ix:continuation id="icbf7360e1e544437b1af3eab40241a85">We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.</ix:continuation></ix:continuation></span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_67"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNTIyOQ_8a43704f-685a-4c43-a8b6-523fbad22472" continuedAt="i951bba9c4e874ec7a020e02e089948f7" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="i951bba9c4e874ec7a020e02e089948f7" continuedAt="i5b38015f8cdb4dd391346515ea2a984f"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the nine months ended September&#160;30, 2020, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2020, we acquired <ix:nonFraction unitRef="number" contextRef="id221678cc7294df9b33d60a008d67b3d_I20200131" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNDQz_a6461425-9bf1-452c-99ff-d32323c634c0">68</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="id221678cc7294df9b33d60a008d67b3d_I20200131" decimals="INF" name="ehc:NumberofBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNDY5_c32c1daf-cc8a-45ec-b9f7-bb643955d897">13</ix:nonFraction>-bed inpatient rehabilitation unit in Denver, Colorado through a joint venture with Portercare Adventist Health System. The acquisition was funded through a contribution of our existing <ix:nonFraction unitRef="bed" contextRef="id221678cc7294df9b33d60a008d67b3d_I20200131" decimals="INF" name="ehc:NumberofBedsContributed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNjU3_937245de-3375-45a1-8e3e-b6175974620b">40</ix:nonFraction>-bed inpatient rehabilitation hospital in Littleton, Colorado and through contributions of funds which were utilized by the consolidated joint venture to build a <ix:nonFraction unitRef="bed" contextRef="id221678cc7294df9b33d60a008d67b3d_I20200131" decimals="INF" name="ehc:NumberofBedsExpanded" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfODEx_307481b8-905a-4bdd-81b0-1cb2f83437af">20</ix:nonFraction>-bed expansion to the Littleton hospital.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2020, we acquired <ix:nonFraction unitRef="number" contextRef="i33d295cd3f3b47759d61f44e07e56fc6_I20200531" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfODgw_d1a030e3-0d2e-4a68-b129-3efd9b222b94">51</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="i33d295cd3f3b47759d61f44e07e56fc6_I20200531" decimals="INF" name="ehc:NumberofBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfOTA2_2bac5804-fd06-4908-839a-4577a2ae98dc">45</ix:nonFraction>-bed inpatient rehabilitation unit in Dayton, Ohio through a joint venture with Premier Health Partners. The acquisition was funded through contributions of funds which were utilized by the consolidated joint venture to build a <ix:nonFraction unitRef="bed" contextRef="i33d295cd3f3b47759d61f44e07e56fc6_I20200531" decimals="INF" name="ehc:NumberofDeNovoBeds" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfMTEzNg_291c1133-ea79-47c3-8ac1-9c20478f0a40">60</ix:nonFraction>-bed de novo inpatient rehabilitation hospital.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#8217;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. <ix:nonFraction unitRef="usd" contextRef="i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfMjM3MA_03278cab-635b-40d8-a8d0-b45fafffe6a7">None</ix:nonFraction> of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.</span></div><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNTE4OQ_b7170c6f-ffbf-41ca-9178-bee5c4c3588b" continuedAt="i8409dd4b843e41ddab76eda7c87ec514" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:87.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.665%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNC0xLTEtMS0w_7840ba62-dd90-4cb7-bdf9-a60a80400da5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of <ix:nonNumeric contextRef="i164768e9d98945009ca4f1d1e36917a8_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNi0wLTEtMS0wL3RleHRyZWdpb246ZjY3Y2IyNDNiMGIxNDZjMGEzNWVhNzZhYmEwZTYyYjBfMTY0OTI2NzQ0MTcyMQ_bfce9496-ba9f-48d0-a457-6339ef28d4dd">2</ix:nonNumeric> to <ix:nonNumeric contextRef="i99a4b3491a24492fbd0635cfe176d18c_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNi0wLTEtMS0wL3RleHRyZWdpb246ZjY3Y2IyNDNiMGIxNDZjMGEzNWVhNzZhYmEwZTYyYjBfMTY0OTI2NzQ0MTczMQ_09b9bd82-82f0-47db-9736-b8c45b98fd1d">3</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d63a47f4d3e460a94d90e53d7bcbef6_I20200930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNi0xLTEtMS0w_9bdf6d62-0839-43c1-b319-1e5a27a298d5">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of <ix:nonNumeric contextRef="i5f877b7c9b844d33baa6901b87f3b8fb_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNy0wLTEtMS0wL3RleHRyZWdpb246ODYzMTM5MmE1OTZiNGZjMTk3ZGE5MGQ0MmQwNDM2M2VfMTY0OTI2NzQ0MTcxMg_3b4bde82-5788-463a-ac20-d6aa5708ac85">20</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186e76d3e4134732aa2cae42033322a2_I20200930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNy0xLTEtMS0w_8c05ed52-f15d-4186-905c-f9fb7872c8f6">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfMTAtMS0xLTEtMA_ab60c06a-ec19-465c-80c1-2aff9d33203c">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfMTItMS0xLTEtMA_dcb968bf-4003-492a-8153-ead890516986">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNTE5Nw_ea6ea9a5-2469-4d21-8e80-3257ef4216d8" continuedAt="ieca5a332e4f644a192b874d90ce5b6a5" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the inpatient rehabilitation acquisitions during each period presented is as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:56.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMi0xLTEtMS0w_b4390b79-a752-438e-81f7-f2ab4ac1558b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMi0zLTEtMS0w_dda146b6-2e83-41de-a3d3-cfa9b2fa58ec">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMi01LTEtMS0w_ecf6cb87-28f3-4074-8e24-55593208af17">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMi03LTEtMS0w_c47df116-b213-4184-8423-134d97445e01">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMy0xLTEtMS0w_167c7f0b-6464-41ec-bc2e-103d23d5f7b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMy0zLTEtMS0w_d801164d-a366-4860-a085-a6d0951babae">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMy01LTEtMS0w_ed539a73-4e26-437b-8dcb-a635fc6e6651">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMy03LTEtMS0w_023976b3-6a6f-436d-b9e7-8d4e6a0132ff">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNC0xLTEtMS0w_87e6c885-a716-4b23-8bbd-596cde97ea2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNC0zLTEtMS0w_accc51de-bb29-4e34-866c-45ed99c79f1e">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNC01LTEtMS0w_781e9745-b9b6-4bfc-8aeb-cd63a287b192">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNC03LTEtMS0w_b716c17c-f11e-47cc-8d43-ee26f56f87c3">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNS0xLTEtMS0w_a46ea15c-1560-4ddd-8236-1670d544eb3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930" decimals="-5" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNS0zLTEtMS0w_2862a599-e3d9-401a-a9bb-6f79b9c5e590">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930" decimals="-5" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNS01LTEtMS0w_c48a1536-bde0-438e-abc1-db412a6b73d3">10.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930" decimals="-5" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNS03LTEtMS0w_517b965e-3c5f-46f5-b07f-d655fc419a2d">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNy0xLTEtMS0w_99ed6e0b-66a9-4ce5-8227-adb8038c7a76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNy0zLTEtMS0w_d7357c6b-4090-4db8-b2ac-52edb7cdb8d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNy01LTEtMS0w_c3f0b690-dd02-489a-8fa8-4b278672455e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNy03LTEtMS0w_30946cd1-bad6-4c52-8d2d-a1b7d8c627ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i5b38015f8cdb4dd391346515ea2a984f" continuedAt="ie1215a2da4b64b32ab6679eb7bc913f9"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we acquired the assets of Generation Solutions of Lynchburg, LLC in Lynchburg, Virginia. This acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in Central Virginia. The acquisition was funded using cash on hand and was immaterial to our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired location from the date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. The fair values of identifiable intangible assets were based on valuations using an income approach. The income approach is based on management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired location&#8217;s mobile workforce and established relationships within the community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. All of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.</span></div><ix:continuation id="i8409dd4b843e41ddab76eda7c87ec514"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of <ix:nonNumeric contextRef="i1560645449b747a1ba2a0753d5016fc6_D20200301-20200331" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZkODc3YjIyYTRjNTQxN2RiYTQzMjk3ZmY5MDllZDIwL3RhYmxlcmFuZ2U6NmQ4NzdiMjJhNGM1NDE3ZGJhNDMyOTdmZjkwOWVkMjBfNi0wLTEtMS0wL3RleHRyZWdpb246OGYzMDUwYTMxNDcxNDViMTlkYzk4MzQwMDA2MDMxMzNfMTY0OTI2NzQ0MTcxMQ_aca572ba-3eb1-490b-8783-ecc1ba5bd153">10</ix:nonNumeric> years)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56f08b6a993948f2baf0abcbb8879961_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZkODc3YjIyYTRjNTQxN2RiYTQzMjk3ZmY5MDllZDIwL3RhYmxlcmFuZ2U6NmQ4NzdiMjJhNGM1NDE3ZGJhNDMyOTdmZjkwOWVkMjBfNi0xLTEtMS0w_3d535a3f-5a66-453b-8527-8035371fcc93">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c76d4a587d74d698b634d1f495b2c74_I20200331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZkODc3YjIyYTRjNTQxN2RiYTQzMjk3ZmY5MDllZDIwL3RhYmxlcmFuZ2U6NmQ4NzdiMjJhNGM1NDE3ZGJhNDMyOTdmZjkwOWVkMjBfNy0xLTEtMS0w_c4ee2b8f-fbb0-408d-8f76-4decc39d0c35">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c76d4a587d74d698b634d1f495b2c74_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZkODc3YjIyYTRjNTQxN2RiYTQzMjk3ZmY5MDllZDIwL3RhYmxlcmFuZ2U6NmQ4NzdiMjJhNGM1NDE3ZGJhNDMyOTdmZjkwOWVkMjBfOS0xLTEtMS0w_67a687fc-9c81-44b8-b1d8-9c4ec8edf7c1">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><ix:continuation id="ieca5a332e4f644a192b874d90ce5b6a5"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the home health and hospice acquisitions during each period presented is as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f63f58dc90642eea45a7aa1f02b8503_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMi0xLTEtMS0w_055da522-9775-4237-9e74-ea44ed7c06f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4e00603d8740a8bcf31cfc8d4f58e1_D20190701-20190930" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMi0zLTEtMS0w_7d943434-e2f1-47e3-a611-929902b8d4bc">68.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3b016833a9435ca260fd97a50d18c8_D20200101-20200930" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMi01LTEtMS0w_4cff7aae-1c9c-4acb-b420-b2d030935264">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc22792722ba436c9181b2a61d9649df_D20190101-20190930" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMi03LTEtMS0w_da4e48bf-15a4-4183-8156-bd9433113408">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f63f58dc90642eea45a7aa1f02b8503_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMy0xLTEtMS0w_6335ffec-ef43-4646-88c9-926941281e40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4e00603d8740a8bcf31cfc8d4f58e1_D20190701-20190930" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMy0zLTEtMS0w_5b634419-8046-4d87-bb39-e923d19f8270">163.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3b016833a9435ca260fd97a50d18c8_D20200101-20200930" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMy01LTEtMS0w_aa817e9a-ca6d-4181-ad98-ff2befe969e8">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc22792722ba436c9181b2a61d9649df_D20190101-20190930" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMy03LTEtMS0w_fa832b85-5e91-4188-a935-d7734c920875">174.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f63f58dc90642eea45a7aa1f02b8503_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNC0xLTEtMS0w_82d99fd0-b6a7-4f1b-b9d1-561ecc5d7eac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e4e00603d8740a8bcf31cfc8d4f58e1_D20190701-20190930" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNC0zLTEtMS0w_c0ce9bbc-0d01-455c-b654-fec8f06e2216">15.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3b016833a9435ca260fd97a50d18c8_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNC01LTEtMS0w_d00d1852-6e3a-40df-b9a2-e801aa8403b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc22792722ba436c9181b2a61d9649df_D20190101-20190930" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNC03LTEtMS0w_71d92b15-8e49-4917-9a5f-2aca6301c3e1">15.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f63f58dc90642eea45a7aa1f02b8503_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNy0xLTEtMS0w_5680d561-273b-44e6-a5c7-4a37bfd58f0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4e00603d8740a8bcf31cfc8d4f58e1_D20190701-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNy0zLTEtMS0w_db6d6919-f7bc-4ebc-92f9-08a29b0686d1">217.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3b016833a9435ca260fd97a50d18c8_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNy01LTEtMS0w_d3f78794-c4e7-4307-8ae8-2b42a5c743cd">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc22792722ba436c9181b2a61d9649df_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNy03LTEtMS0w_35176b48-7950-4074-9732-0d0c5b79fad1">231.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Results of Operations</span></div><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNTIwOA_3a3bc067-ffa0-4509-abf4-6ab27daa677c" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions): </span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfMi0xLTEtMS0w_e54a84a4-a558-4168-9730-75e7d0c18129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfMi0zLTEtMS0w_ffc65b77-69f5-433e-b673-32f3a22737e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0584508681949b19044b898bcaac766_D20200301-20200930" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNC0xLTEtMS0w_ce054291-feaa-4e8f-b931-46537b06e711">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0584508681949b19044b898bcaac766_D20200301-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNC0zLTEtMS0w_95496efb-8938-4778-9909-aa305d9f20c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 07/01/2020-09/30/2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNS0xLTEtMS0w_74f2bdd0-757b-4843-b667-788fe950241a">1,173.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNS0zLTEtMS0w_a742e80b-baa2-4f78-9df5-461857433702">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 07/01/2019-09/30/2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNi0xLTEtMS0w_f06dde3b-46ef-4b13-929e-6c08f8837c2d">1,166.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNi0zLTEtMS0w_32378001-afc6-41ae-8dda-fd9cbfebacfb">98.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-09/30/2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNy0xLTEtMS0w_262ef348-510a-4d1c-b523-892325aa7711">3,435.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNy0zLTEtMS0w_3ab1f3db-9d7d-4e9e-89e6-666ec2f44bdc">198.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2019-09/30/2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfOC0xLTEtMS0w_3a019b75-d837-448e-aba9-6a6641ee30d0">3,436.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfOC0zLTEtMS0w_40fe021f-515a-4589-afd4-070b3f6afac3">292.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been achieved if the acquisitions had occurred as of the beginning of our 2019 reporting period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><ix:continuation id="ie1215a2da4b64b32ab6679eb7bc913f9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K for information regarding acquisitions completed in 2019.</span></ix:continuation></div><div id="i5ec2d1f903d340c19ee74983700dc28d_73"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfMTMyNw_9b5e352e-0aaf-4c7f-b7d5-6c0a3083e039" continuedAt="i50a505683b704407ba0996e1621d0b9a" escape="true">Variable Interest Entities</ix:nonNumeric></span></div><ix:continuation id="i50a505683b704407ba0996e1621d0b9a"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, we consolidated <ix:nonFraction unitRef="entity" contextRef="i1708048c2a42448693822a76f275381d_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="ehc:VariableInterestEntityNumberofEntitiesConsolidated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfNjY_716d820a-e18d-4b03-9ffb-23e344e832e4">nine</ix:nonFraction> and <ix:nonFraction unitRef="entity" contextRef="i66fdf46a359740a785ea525eb38ea7fd_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="ehc:VariableInterestEntityNumberofEntitiesConsolidated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfNzM_fdf16e0e-205a-4d73-a75e-9ec5aacd24bb">eight</ix:nonFraction>, respectively, limited partnership-like entities that are variable interest entities (&#8220;VIEs&#8221;) and of which we are the primary beneficiary. Our ownership percentages in these entities range from <ix:nonFraction unitRef="number" contextRef="i8546b47816c54ef381660703138b5caf_D20200101-20200930" decimals="3" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfMjcw_59a8b077-2c34-4343-9042-61c71b548bd7">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i5ac9f48cbdbe488cb20eed7e2f9ca1ee_D20200101-20200930" decimals="3" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfMjc2_67b97989-57ab-4e04-a4ab-eb010484f461">75.0</ix:nonFraction>% as of September&#160;30, 2020. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfMTMzMw_ca1bf5c3-317a-4e9c-a5e3-2450ee104a9d" continuedAt="i71f3a462d1d4487d93dabeec432ab71d" escape="true">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:15pt;margin-top:5pt"><ix:continuation id="i71f3a462d1d4487d93dabeec432ab71d"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMy0xLTEtMS0w_bd481e57-f2c6-459e-933e-648e31f7a146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMy0zLTEtMS0w_546c6b83-586b-44a5-971e-c23cc87e3df5">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNC0xLTEtMS0w_c42b20f9-3e1d-4143-a414-60f405d9a99b">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNC0zLTEtMS0w_bcf3f15d-3a5b-4a52-b2c6-6e3d03bacdfc">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNS0xLTEtMS0w_3d497fea-97a8-4240-8c77-36d23c74d2f2">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNS0zLTEtMS0w_a60fb9c4-419e-444e-86d1-99d2e91a9dbf">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNi0xLTEtMS0w_3cb7dba5-c041-4bce-a3cc-8ab5380d6152">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNi0zLTEtMS0w_1aef8ea1-0cf2-4905-8188-e95f2a4938c8">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNy0xLTEtMS0w_5eb3c36b-8ff9-4620-9d77-3f38baf1c2e1">121.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNy0zLTEtMS0w_0601d09a-f64f-4710-9290-b485b0dbd8ad">122.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfOC0xLTEtMS0w_985df4eb-6fb3-4d1e-b84b-ce576a38e5ee">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfOC0zLTEtMS0w_cf32b95c-3906-49e0-b563-c1251566768f">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfOS0xLTEtMS0w_b629424c-c15e-4483-a385-d86576475b2f">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfOS0zLTEtMS0w_2c9747fd-ee40-4749-97e8-049824fcac0e">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTAtMS0xLTEtMA_30c7694f-487b-4695-a710-fa2244099713">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTAtMy0xLTEtMA_0ace90d6-8e91-42c2-ad4d-edb951c01bc0">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTEtMS0xLTEtMA_eff01161-1c77-4ca4-b577-769f08596f05">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTEtMy0xLTEtMA_2351a53d-eaba-4618-b5c1-388a1fc504d5">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTItMS0xLTEtMA_a93bbf1d-47f4-4495-80ed-fd8ed5de0f3a">222.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTItMy0xLTEtMA_514afc40-4194-4d53-bdf0-cae6ed5c5527">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTUtMS0xLTEtMA_55334a9f-cb80-4f44-a424-45949f172938">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTUtMy0xLTEtMA_99b3daba-b370-4567-b95a-1d97b245f79b">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTYtMS0xLTEtMA_8e03c326-48a8-4198-a3bc-385025f812a4">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTYtMy0xLTEtMA_18a65e65-a344-4df0-91a3-7036c7a7d22e">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTctMS0xLTEtMA_d2a306ff-cefb-4afd-8b40-d378ae29004b">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTctMy0xLTEtMA_3ad1f515-ef81-4f06-bdcf-de72d7f7d264">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTgtMS0xLTEtMA_6a54f846-04d0-435a-8c52-958a534c639e">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTgtMy0xLTEtMA_1f860b84-2923-4f6b-9174-2b3faba6e0a9">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTktMS0xLTEtMA_dde1e35d-cb85-4628-8a87-0fc4ae2c8cab">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTktMy0xLTEtMA_9385ed17-88f3-4f95-960f-24f73926ec04">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjAtMS0xLTEtMA_d633bed5-872a-4ff1-96eb-cbe1fdf30220">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjAtMy0xLTEtMA_7aa7287a-8192-4c17-890d-a0d424c78950">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjEtMS0xLTEtMA_e69bc623-1642-4047-9efd-5f782a0896da">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjEtMy0xLTEtMA_073ab3a5-2f4b-41a2-8b01-c1e5ff4c358f">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjItMS0xLTEtMA_26c2062e-1460-4377-96d4-70955a93af86">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjItMy0xLTEtMA_4ce87b10-5085-40d4-976c-5f149bb91e17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjMtMS0xLTEtMA_eeadee49-b0b9-404c-aafb-9e5a957a8971">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjMtMy0xLTEtMA_b5647966-0370-4b0a-9613-475ee76e6e60">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="margin-bottom:10pt;padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfODI0NjMzNzIxODM0Mg_da2040a4-0f0a-4352-9be6-016f542df4d9" continuedAt="icfa2d0263f114cbdb1af16791840e37c" escape="true">Long-term Debt</ix:nonNumeric></span></div><ix:continuation id="icfa2d0263f114cbdb1af16791840e37c" continuedAt="i426fc833dc65406ea991569a156ecc41"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY5Mw_320c4375-9cab-4986-b1b1-c8d0b08b3106" continuedAt="i53261b596eea469a93c7685148f8e566" escape="true">Our long-term debt outstanding consists of the following (in&#160;millions):</ix:nonNumeric></span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><ix:continuation id="i53261b596eea469a93c7685148f8e566"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:59.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608f28a8c9c64873904629df071b372b_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMi0xLTEtMS0w_6296f1f5-9d5f-4c1d-9ff0-4dbcad6d89ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83e06ff810244088cb996c03064f330_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMi0zLTEtMS0w_790b8ae6-7cfa-43e2-97a4-2d5093a2c2a3">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8fb9a7dd06c4e609086c04b5dbfe4ca_I20200930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMy0xLTEtMS0w_c6777b1a-f136-4238-847a-58ebcce43191">254.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1023a8574449fd9b9332edaf46f3bd_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMy0zLTEtMS0w_1c86ba08-8de0-4604-9fe3-31a2002cfa1c">265.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i638ab89eae9440c5b0f1929587a02914_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNS0wLTEtMS0wL3RleHRyZWdpb246OTg0YTUyOWM3ZjdhNDQ1Mzk1NDkzZjBiZmZkMmYyOTJfMTY0OTI2NzQ0MTcwMg_85682d3d-20a6-41ff-a115-8a75c924d67d">5.125</ix:nonFraction>% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638ab89eae9440c5b0f1929587a02914_I20200930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNS0xLTEtMS0w_8f830b2f-9838-4e0c-9a60-8fb1c5dfedb1">297.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0377bd53564ffdae03ff64e660194b_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNS0zLTEtMS0w_9eff51ea-476f-486e-8c90-3042111d4f56">297.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia523dc03179846ddaf98c887899b7679_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNi0wLTEtMS0wL3RleHRyZWdpb246NTY1ZjQyNzE5MTkxNDIyMThhYzcxZWJjYTA2YTJjMDdfMTY0OTI2NzQ0MTcwMA_ca119628-1082-43d1-9b39-627aad83471f">5.75</ix:nonFraction>% Senior Notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia523dc03179846ddaf98c887899b7679_I20200930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNi0xLTEtMS0w_e22986d2-23f3-4fb4-864e-3cbbfb4fb396">697.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3892c4bc03204316bb6e77be3f27b240_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNi0zLTEtMS0w_96451a09-a4a9-4bdd-9e30-404961c881eb">697.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib40a6e6dd68b4a8da5d30d7aaa484c51_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNy0wLTEtMS0wL3RleHRyZWdpb246MTI0NzM1NjVhMWVlNGJkMWIyMzFlZmFiNzA2NmZlNmNfMTY0OTI2NzQ0MTcwMA_7e99b7db-9307-443d-81f2-30ac03666728">5.75</ix:nonFraction>% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib40a6e6dd68b4a8da5d30d7aaa484c51_I20200930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNy0xLTEtMS0w_592e96a3-e635-4e76-87a8-a65a761b316c">346.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41c4e44b7b64428b528add431c16513_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNy0zLTEtMS0w_5fc192da-a7d9-45a4-a04f-91bfe747df49">345.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f1805d3ddcd4b188bc766e18298a2d5_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOC0wLTEtMS0wL3RleHRyZWdpb246MjMxZDZiNGMyNTdkNDA3MGFlYTlmOGI2YjAwNjg0ZWVfMTY0OTI2NzQ0MTcwMA_2d864912-4c58-4bda-b961-5efbfd0c017f">4.50</ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1805d3ddcd4b188bc766e18298a2d5_I20200930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOC0xLTEtMS0w_3abaed51-80e7-447d-bbf7-e91631d61bc6">784.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730f2a918b744a0e94177fd42ad004a4_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOC0zLTEtMS0w_d8948248-5171-4d2e-abff-09df2c4171e1">491.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62eb57fb87fc40e59f8f33f73b921693_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOS0wLTEtMS0wL3RleHRyZWdpb246M2I3OTI0ZTg2MTZiNDk1MmJkZTY2OGU4ZTc3ZDY3OWRfMTY0OTI2NzQ0MTcwMA_dc2250a5-81b6-49e7-8f41-7cf55d8d768b">4.75</ix:nonFraction>% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62eb57fb87fc40e59f8f33f73b921693_I20200930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOS0xLTEtMS0w_f218e1fb-cc39-42b0-9ce1-89ce2d4ef5d6">782.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd067c2ff27b4ab8a68e5471e7c59ef9_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOS0zLTEtMS0w_9c59e92e-376b-40da-9c79-4177727fcdc0">491.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dfc00f6eb92471998309b5c12c9388f_I20200930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTAtMS0xLTEtMA_e80a0a8c-b5ab-4deb-92b6-25b933d679d2">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23cf331b54114349857c76ca9d89e4e9_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTAtMy0xLTEtMA_9943fe01-de60-4b3d-8f6d-6c3ed0b7c129">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTEtMS0xLTEtMA_a589c550-5737-49b7-9b4d-d5cfcf2754be">372.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTEtMy0xLTEtMA_91411da4-d00b-41cb-a29b-e3e6c0fbef82">384.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTItMS0xLTEtMA_f2f07e48-09b7-4bf7-9a23-4543bec8da63">3,576.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTItMy0xLTEtMA_2fde1667-b87b-458b-8813-97301770abba">3,062.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTMtMS0xLTEtMA_01d854c9-8e09-48e8-9a0f-9684ec0d1697">37.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTMtMy0xLTEtMA_b3c23bbe-0095-4438-9d3d-4a02f90b7a6d">39.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTQtMS0xLTEtMA_1def6491-e7bc-4c68-8b61-ede6d97cfedf">3,539.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTQtMy0xLTEtMA_1481b6bb-7a7b-490f-9f7a-9f24f8fa8227">3,023.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we amended our existing credit agreement. The following are the changes made to the material</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provisions of the credit agreement:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the financial covenants to update the applicable interest coverage ratio and leverage ratio included in that covenant. The revised applicable ratios are set forth below. </span></div><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="ehc:ScheduleOfFinancialCovenantsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY4NA_d3e9c4a5-aaa9-49a4-969c-56c614537867" escape="true"><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:67.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Coverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30dd8fb7ca9b4d95a01ed19cec48d797_D20191001-20200331" decimals="INF" name="ehc:DebtInstrumentCovenantInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOmJmMzU5MDAxMmI0ZDQxNTRhMTg5Mjg5MWUxMmEyYWE5L3RhYmxlcmFuZ2U6YmYzNTkwMDEyYjRkNDE1NGExODkyODkxZTEyYTJhYTlfMS0xLTEtMS05OTMvdGV4dHJlZ2lvbjpkNmY3YjQ4MWQyNWQ0MGYxOTk1ZjFmYmVjNjM1YTkxYV8xNjQ5MjY3NDQxNjg0_3a02f842-ddfe-4672-b97c-6014da4d0e5a">3.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02f7fbac1cd84620acf7f199e68c69d2_D20200401-20211231" decimals="INF" name="ehc:DebtInstrumentCovenantInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOmJmMzU5MDAxMmI0ZDQxNTRhMTg5Mjg5MWUxMmEyYWE5L3RhYmxlcmFuZ2U6YmYzNTkwMDEyYjRkNDE1NGExODkyODkxZTEyYTJhYTlfMi0xLTEtMS0xMDIzL3RleHRyZWdpb246YTJmOWZhMzFiYTc4NDg5ZWJhZTdhZTNiNWJhZjljOTdfMTY0OTI2NzQ0MTY4NA_2e5ce464-5669-4b9b-940f-3248db5e8724">2.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31cb706cd3d34a8f8c5550eb13fdc482_D20220331-20221231" decimals="INF" name="ehc:DebtInstrumentCovenantInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOmJmMzU5MDAxMmI0ZDQxNTRhMTg5Mjg5MWUxMmEyYWE5L3RhYmxlcmFuZ2U6YmYzNTkwMDEyYjRkNDE1NGExODkyODkxZTEyYTJhYTlfMy0xLTEtMS0xMDI2L3RleHRyZWdpb246NTIzNDExYzExMGQ0NDRmNzgxNmRjY2Y5NjFkZGRhZjNfMTY0OTI2NzQ0MTY4NA_a897a1c6-4c81-4e7a-8358-de02f1015f1d">3.00</ix:nonFraction> to 1.00</span></div></td></tr></table></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:67.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ba53aa991c7496c824228ff7f76db73_I20200331" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfMS0xLTEtMS0xMDI5L3RleHRyZWdpb246ZjdhNTA2MGRmZmNkNGU1ZGJhMzAwOGZhZDBiN2M1NTdfMTY0OTI2NzQ0MTY4NA_a944ec5d-8bf5-469a-b0cd-5ccbd34ab437">4.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b16ec5f39fd426987fd267959afaf04_I20200630" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfMi0xLTEtMS0xMDMyL3RleHRyZWdpb246NDBiMDY2YjFkMzIxNGFiOWI1MGE4ODgyYjlmYmRiOTdfMTY0OTI2NzQ0MTY4NA_49d89b9b-037b-4a39-83e0-10fd1fc78331">4.75</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfMy0xLTEtMS0xMDM1L3RleHRyZWdpb246OGI1OGJlMjdlZWMwNDM2ODkxYmI4NGE0NTQwY2UxOTBfMTY0OTI2NzQ0MTY4NA_f9bd5b41-10fc-4663-bada-a066d40d4362">5.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieaf492cdb0114d0caa049a3dc713ea52_I20201231" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfNC0xLTEtMS0xMDQ1L3RleHRyZWdpb246ZmNhMGM5Y2MxNmFhNDczNDllMmQ0YmE4MTk0ZjRlZDhfMTY0OTI2NzQ0MTY4NA_927cbc38-e479-4246-8610-637a8784c2a6">6.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide941e50cb94438c842272441f7f7a9d_I20210331" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfNS0xLTEtMS0xMDM4L3RleHRyZWdpb246YWMyYjY2NWNiOWE1NDlhMTlmNjk0NWI3ZTRiM2JkNTlfMTY0OTI2NzQ0MTY4OA_ca01e727-5f3a-4558-a556-f22ec8ffa5f4">6.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54ca9b66117a446d97db8f7751e15718_I20210630" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfNi0xLTEtMS0xMDQ3L3RleHRyZWdpb246OWRjYWZhMjRjMDNjNGZiZWJhMDdiODgwMmRhNjliZTlfMTY0OTI2NzQ0MTY4NA_4a2d588d-db60-4653-a44a-e2b172cb9980">6.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i47e1840cf2284314b9ab50ccca85d8dc_I20210930" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfNy0xLTEtMS0xMDUwL3RleHRyZWdpb246MDhmNmU3YjgwZDRjNGFmY2I2ZDUyNWJkZTQ4ZTI3NDJfMTY0OTI2NzQ0MTY4NA_bacfd5bf-02d2-4614-9572-2ac46ce13439">5.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dd6a4fa2af14b42a85c77bc5fc6a804_I20211231" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfOC0xLTEtMS0xMDUzL3RleHRyZWdpb246YzlkNmQ0NTA5OTQyNDE2MjhjMjIxNWQyYTMzMzdjMmZfMTY0OTI2NzQ0MTY4NA_d1976703-2040-4b9c-9d15-2f51abcc5496">5.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie70bf042dd674e718cc447fc2ec12ba6_I20220331" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfOS0xLTEtMS0xMDU2L3RleHRyZWdpb246ZDEzMzQyMTdkNmFkNDgzYjg1MzIxZmNlYWY0NmM2OTZfMTY0OTI2NzQ0MTY4NA_3019bff1-6f59-49b0-b419-c139071185ee">4.25</ix:nonFraction> to 1.00</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the definition of &#8220;Material Adverse Effect&#8221; to carve out the direct and indirect impacts of COVID-19 and the related legislative, regulatory and executive actions on us from that definition for a period of 364 days; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the investment limitation covenant and the restricted payment limitation covenant, to add to each a leverage ratio condition (not in excess of 4.50x) to the provisions allowing unlimited investments and restricted payments in the event certain conditions are met including a senior secured leverage ratio (not in excess of 2:00x) and the existence of no events of default in addition to the new leverage ratio condition.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i426fc833dc65406ea991569a156ecc41"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other material terms of the existing credit agreement remain the same and are described in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued an additional $<ix:nonFraction unitRef="usd" contextRef="iff0d4dd7c88b4aecaeb023492578edbc_I20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTI5OA_922fb778-4a13-4622-845a-73cefde53f26">300</ix:nonFraction> million of our existing <ix:nonFraction unitRef="number" contextRef="iff0d4dd7c88b4aecaeb023492578edbc_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTMxNw_414a1d81-1d8e-46f5-b840-b3d356a63f7d">4.50</ix:nonFraction>% Senior Notes due 2028 at a price of <ix:nonFraction unitRef="number" contextRef="iff0d4dd7c88b4aecaeb023492578edbc_I20200531" decimals="3" name="ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTM1Ng_ea3ad133-7ff2-414f-bd81-44ce6c6b46b8">99.0</ix:nonFraction>% of the principal amount and an additional $<ix:nonFraction unitRef="usd" contextRef="i8a6a2cb269044ff8ba6e3aa662224738_I20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTQwMQ_797aa8ae-3c94-4b26-b20f-b15ef603bccd">300</ix:nonFraction> million of our existing <ix:nonFraction unitRef="number" contextRef="i8a6a2cb269044ff8ba6e3aa662224738_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTQyMA_ba3f5947-672d-48a1-9e5e-bf971e80dc56">4.75</ix:nonFraction>% Senior Notes due 2030 at a price of <ix:nonFraction unitRef="number" contextRef="i8a6a2cb269044ff8ba6e3aa662224738_I20200531" decimals="3" name="ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTQ1OQ_b55f26dd-918c-4d79-b862-4a1d4e6614a6">98.5</ix:nonFraction>% of the principal amount, which resulted in approximately $<ix:nonFraction unitRef="usd" contextRef="i97fd8177ab534173b7dff83fda1b0e42_D20200501-20200531" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTUxOQ_c81bc745-520b-42f3-8967-e87983b72792">583</ix:nonFraction> million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In October 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i2d3d451adabf4a9e939a4aa764188f34_I20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY0OTI2NzQ1MDA5NA_fd303415-4b18-4720-87cf-25c5364243fe">400</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i2d3d451adabf4a9e939a4aa764188f34_I20201031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY0OTI2NzQ1MDEwOA_7d247c24-885a-450f-be03-b4f24fe2bc4f">4.625</ix:nonFraction>% Senior Notes due 2031 (the &#8220;2031 Notes&#8221;) at par. The 2031 Notes mature on April 1, 2031 and bear interest at a per annum rate of <ix:nonFraction unitRef="number" contextRef="i2d3d451adabf4a9e939a4aa764188f34_I20201031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTQ4NDM0MDY5ODM0NTQ_ba9e2e95-4fa2-4aaf-8857-9abf95bd7e4a">4.625</ix:nonFraction>%. Interest is payable semiannually in arrears on April 1 and October 1 of each year. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In October 2020, we issued notice for redemption of all $<ix:nonFraction unitRef="usd" contextRef="i15ba9115048c4b0cb334ce276b07e19f_I20201031" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY0OTI2NzQ1MDExNg_7e6e88c7-255b-46e2-862b-a11375d3ebd2">700</ix:nonFraction>&#160;million in outstanding principal amount of the <ix:nonFraction unitRef="number" contextRef="i15ba9115048c4b0cb334ce276b07e19f_I20201031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTQ4NDM0MDY5ODM0NjI_96ac6552-fce2-4666-bdde-05d83a530043">5.75</ix:nonFraction>% Senior Notes due 2024 (the &#8220;2024 Notes&#8221;). Pursuant to the terms of the 2024 Notes, this full redemption will settle on November 1, 2020 and will be made at a price of par. We plan to use the net proceeds from the 2031 Notes offering together with cash on hand to fund the redemption. We expect to record an approximate $<ix:nonFraction unitRef="usd" contextRef="i4e156b6c09f3459a802a8b8b9d61246b_D20201001-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY0OTI2NzQ1MDEzMA_09319407-4466-441f-9b72-a4919e01d3ba">2</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> in the fourth quarter of 2020.</span></div></ix:continuation><div id="i5ec2d1f903d340c19ee74983700dc28d_94"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNDI3NQ_e27553c5-2c99-4eae-9f15-98df0f8a4f19" continuedAt="if6d068872f2c48c0a9fe486fdc4ce2e7" escape="true">Redeemable Noncontrolling Interests</ix:nonNumeric></span></div><ix:continuation id="if6d068872f2c48c0a9fe486fdc4ce2e7" continuedAt="i1b01f835ca224bcd80e034297e95fbbc"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:RedeemableNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNDI5MQ_aa3095f4-3d44-4aeb-970f-dade0d230674" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the nine months ended September&#160;30, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5048837d2a04accb50ef68638e25287_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMi0xLTEtMS0w_bdf40cc1-e6b1-45e6-a8f3-9fb4a471dadf">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5017d71cfec249b39dc7bf0b2f16e8a8_I20181231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMi0zLTEtMS0w_002b3827-db4e-451a-aa6b-148a1b07b9a4">261.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMy0xLTEtMS0w_742027a3-4ccc-4011-b3fd-0c71bda614d2">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMy0zLTEtMS0w_6e5b0e3f-ed29-4ead-b4ef-6ec4c4844c05">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNC0xLTEtMS0w_e61d5e9c-78f7-4184-a44b-e34f8fd106b4">5.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNC0zLTEtMS0w_779ba211-764a-4458-ac9f-16619457a362">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930" decimals="-5" name="ehc:Contributiontojointventure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNS0xLTEtMS0w_30e9c83c-5752-49e1-95e0-afe92827ff25">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930" decimals="-5" name="ehc:Contributiontojointventure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNS0zLTEtMS0w_2d680508-461b-4fad-86ce-c8aef2cc9682">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="ehc:Reclassificationtononcontrollinginterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNi0xLTEtMS0w_a6c5cf02-3334-497c-bbd4-900077b4fbe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930" decimals="-5" name="ehc:Reclassificationtononcontrollinginterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNi0zLTEtMS0w_a545c0c2-dad8-4da3-ba94-81038a1068f4">11.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNy0xLTEtMS0w_d01554a5-3e89-411e-a461-f35bedef5a4a">162.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNy0zLTEtMS0w_395084e9-1d7d-44c5-8964-59f9cee7769c">162.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange transaction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930" decimals="-5" name="ehc:NoncontrollingInterestExchangeTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfOC0xLTEtMS0w_e6c4406f-6e11-4cc4-b5af-7b7413d4cadb">46.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="ehc:NoncontrollingInterestExchangeTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfOC0zLTEtMS0w_626c982d-a365-4396-a0ce-ea2eed5525df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfOS0xLTEtMS0w_c5057548-96ee-4aab-88c6-8ed276137847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930" decimals="-5" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfOS0zLTEtMS0w_2da476ea-a190-443e-a1c9-1fe6c7870601">118.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1bdb6d04224fe9be09f756f95b5ab0_I20200930" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMTEtMS0xLTEtMA_aff62918-4975-492b-962c-5166add1e313">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a8f469e2a84522ae2e22f5234508db_I20190930" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMTEtMy0xLTEtMA_c277bc81-8c0f-4283-b67d-834b7f2de75f">210.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="ehc:ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNDI4MA_d599b509-3b33-4cfd-becf-a8d1517f0a61" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the condensed consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net and comprehensive income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the condensed consolidated statements of comprehensive income for the three and nine months ended September&#160;30, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMi0xLTEtMS0w_13950f00-a595-456b-88bf-f399ab202fc7">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMi0zLTEtMS0w_d0c23df7-6492-424e-9e31-7ae4eb9c9517">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMi01LTEtMS0w_d6f25e1d-0577-4306-9f4b-b4e66a256b16">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMi03LTEtMS0w_ed49fa9d-48c7-40ba-8119-87186fbcc554">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMy0xLTEtMS0w_7f62c514-42b4-421c-ac6d-3afe1f145909">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMy0zLTEtMS0w_2f20b06a-fe74-4af4-bd5d-23b5c8ce21bd">3.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMy01LTEtMS0w_4ae2060a-49c4-41ca-91db-e66043dbb2ca">5.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMy03LTEtMS0w_7e2bf512-6fb7-4854-a750-a7faa49669d3">10.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfNC0xLTEtMS0w_b6252baa-64bd-4811-bd9a-54936a0ada9a">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfNC0zLTEtMS0w_b6718266-b012-447f-90aa-805bf7f5fe8f">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfNC01LTEtMS0w_60024e93-03d2-49d1-8542-f67d01466b25">58.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfNC03LTEtMS0w_a6365069-146b-4f85-a80b-4d52a9ce339c">64.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2014, we acquired <ix:nonFraction unitRef="number" contextRef="i9e9516c1a9cb4fb3be4969e22995bee4_I20141231" decimals="3" name="ehc:RedeemableNoncontrollingInterestEquityAcquiredPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNzc4_24a37ec4-e215-4fb7-b778-5299cf605cbe">83.3</ix:nonFraction>% of our home health and hospice business when we purchased EHHI Holdings, Inc. (&#8220;EHHI&#8221;). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#8220;Holdings&#8221;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $<ix:nonFraction unitRef="usd" contextRef="i9e9516c1a9cb4fb3be4969e22995bee4_I20141231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMTM0MQ_29b80ec1-5d00-4820-a26a-207d664221e7">64</ix:nonFraction> million on the acquisition date, in exchange for approximately <ix:nonFraction unitRef="number" contextRef="i9e9516c1a9cb4fb3be4969e22995bee4_I20141231" decimals="3" name="ehc:SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMTM5OQ_f54f02e8-6052-41a7-8119-d4e54eb4f540">16.7</ix:nonFraction>% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i1b01f835ca224bcd80e034297e95fbbc"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately <ix:nonFraction unitRef="number" contextRef="i9544a214c9f44991a2f78bb7573102e1_D20180201-20180228" decimals="3" name="ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMTg2Mw_5712d272-d650-4923-bf47-258c64e29520">5.6</ix:nonFraction>% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="ib07fdb10b5d540cb9aedb3134847444d_D20180221-20180221" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjAzNA_d894e7f1-1bfa-4bbd-ad4f-9814c797a013">65</ix:nonFraction> million in cash. In July 2019, we received additional exercise notices, representing approximately <ix:nonFraction unitRef="number" contextRef="i37c985034d924ca98f2216ba8ca4af2e_D20190701-20190731" decimals="3" name="ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjEyOA_e744cb09-1e56-4707-99a6-1e9d7b96bad0">5.6</ix:nonFraction>% of the outstanding shares of the common stock of Holdings. In September 2019, Encompass Health settled the acquisition of those shares upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i7c4dd0ed5ae24830b44a38ea9717cb05_D20190901-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjI5Ng_25c421db-c130-4429-aacc-503493ce2c0b">163</ix:nonFraction> million in cash. In January 2020, we received additional exercise notices, representing approximately <ix:nonFraction unitRef="number" contextRef="if85c5fb8e5614004b32140f219b1306a_D20200101-20200131" decimals="3" name="ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjM5Mw_55e12e20-88c7-4ba2-85b8-b901e089c381">4.3</ix:nonFraction>% of the outstanding shares of the common stock of Holdings. On February 18, 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i4c98c9ecdddb4aa885207bc289ebb66c_D20200218-20200218" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjU2NA_80b3c73e-e7a6-4e99-84ff-986e29b20b39">162</ix:nonFraction> million in cash. Upon settlement of these exercises, approximately $<ix:nonFraction unitRef="usd" contextRef="i5b8fa809e4a440c2bad66de860a5fd7d_I20200218" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjYyNg_bbf32301-4ff7-40f5-9ccf-8a35c93381d1">46</ix:nonFraction> million of the shares of Holdings held by two management investors remained outstanding. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#8220;Exchange Agreement&#8221;) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#8220;EHC Shares&#8221;). Each of the Exchange Agreements provided that the management investor must deliver a written exchange notice (an &#8220;Exchange Notice&#8221;) to Encompass Health in order to exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#8217;s common stock on the New York Stock Exchange (the &#8220;NYSE&#8221;) on the date of delivery of the Exchange Notice.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors. Based on the last sales price of Encompass Health&#8217;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate <ix:nonFraction unitRef="shares" contextRef="i7fa6591e1e63436d87c66c1d9ccc6214_I20200220" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMzkxMw_37873ca6-3698-4f02-bec9-7a8e474f872f">560,957</ix:nonFraction> EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than <ix:nonFraction unitRef="number" contextRef="ib293675829044729970b8ad7871b3312_I20200306" decimals="3" name="ehc:TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNDA2OQ_af0eebfb-e858-4bc1-af54-5269cee626f9">0.6</ix:nonFraction>% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares. Encompass Health now owns <ix:nonFraction unitRef="number" contextRef="i3efb00ba5fd74b7fab554086f72556bc_I20200930" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNDIyMw_6cfec342-f062-4398-88d2-c11ee1fa701c">100</ix:nonFraction>% of Holdings and EHHI.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i5ec2d1f903d340c19ee74983700dc28d_97"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RleHRyZWdpb246OWNjY2Q2ODNlMDUwNGMwNGJjMjc1NzNkNjVmMzBhZjJfMjk3MQ_bd76225b-bcd3-4b6f-aa1e-f86f9a848976" continuedAt="i19226c7a9e59421cb799a55279515611" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i19226c7a9e59421cb799a55279515611" continuedAt="i3aaf61b950854fd78de494e5ebb27a58"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RleHRyZWdpb246OWNjY2Q2ODNlMDUwNGMwNGJjMjc1NzNkNjVmMzBhZjJfMjk3Ng_f3d0cb39-60ea-478b-a623-f21761f83980" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): </span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c3b00829fa4d4e999d2af5868388c4_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMy0xLTEtMS0w_550bd729-e4d8-485d-bb71-e2f309e72fa4">70.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f108164baf04c0891eeec5eedea407c_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMy0zLTEtMS0w_3f6c21b6-c584-43d5-87f1-ce8ab4d7b44c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109455a6fc6a45b8ac46c18c730e447c_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMy01LTEtMS0w_eef42eb3-ade4-4a35-9bf0-fe4c432c5c8a">70.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45c6446a6c14cb7a9ddd0a2cd90040c_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMy03LTEtMS0w_7434fe73-4f7f-4d4c-ada3-e22f41522ff6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c3b00829fa4d4e999d2af5868388c4_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNC0xLTEtMS0w_ed6dae1d-94ba-459e-be6c-ed5aca612ca9">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f108164baf04c0891eeec5eedea407c_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNC0zLTEtMS0w_1fd0c9d7-69a0-455f-a74e-a549e547b410">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109455a6fc6a45b8ac46c18c730e447c_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNC01LTEtMS0w_7fe65b44-46b7-4feb-b464-70d2bf4dde09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45c6446a6c14cb7a9ddd0a2cd90040c_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNC03LTEtMS0w_bd4c24b2-fe1e-49fa-8b5c-6cc53785d890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aed46c41ce046eaad78b41f59a23787_I20200930" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNS0xLTEtMS0w_f8679b92-5e78-4eb9-bc87-508be729bbc5">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2768fdf72bc4ee4a44e6c72c3433df2_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNS0zLTEtMS0w_77a7c856-f325-462e-9707-54c17b219000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6bcf1050dcf44a2be092ce5a39ac1a3_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNS01LTEtMS0w_4b3394ed-3bed-4961-9dc6-3c7368a6eac9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7afd9afee71467ba27c4ef94b734857_I20200930" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNS03LTEtMS0w_8eba3233-b36a-4def-bbd1-aca58bb4f9b9">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3782aabb4f6a4c8892fbf91aadc0bbf6_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOC0xLTEtMS0w_ab5478a8-83bb-46fb-b627-5eb571f22f2d">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4130c6d73c9d4e2886d9e5ad5721507f_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOC0zLTEtMS0w_878fbb8d-5357-4162-9c1c-b76c6818dc53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a29bb284f84291ac766be040a1b558_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOC01LTEtMS0w_faea23ec-596e-48b3-8bbd-e24f40c924a8">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i171f20bc121a4840b1b7a626e688e5c2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOC03LTEtMS0w_23108c77-8e74-4a0d-80ff-5a2f6dde1ea4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3782aabb4f6a4c8892fbf91aadc0bbf6_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOS0xLTEtMS0w_05e44bf3-9f64-429b-9a50-a38b5d5d6d98">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4130c6d73c9d4e2886d9e5ad5721507f_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOS0zLTEtMS0w_63f95bfe-0585-4236-8e91-25ec196b7698">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a29bb284f84291ac766be040a1b558_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOS01LTEtMS0w_424c0aad-79ed-4f86-8c44-5be7c264ee3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i171f20bc121a4840b1b7a626e688e5c2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOS03LTEtMS0w_058ad2bc-1e5a-45fc-8c38-98a09f03a00f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a6b0c4ea294ae9831e406beeaa1b02_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMTAtMS0xLTEtMA_54021a48-cfcf-44f0-abcd-bec1c7adb6e5">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0646390aa047889e3811abde11c7d7_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMTAtMy0xLTEtMA_3a0d1013-996f-4cdc-93e8-89fa699db689">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98081f26b7b0413894e5100ec374ac7b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMTAtNS0xLTEtMA_31584090-fa3c-48a1-bc03-d5f5ab859493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i104c1230c0b9400ea5b323e382d7bf2e_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMTAtNy0xLTEtMA_4ece07ea-8c2e-4e85-9072-d1be32fcae08">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from December 31, 2019 to September 30, 2020 primarily resulted from the final purchase of equity interests in Holdings from management investors discussed in Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i3aaf61b950854fd78de494e5ebb27a58"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our financial assets and liabilities are determined as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity and Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The fair values of our equity and debt securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active. </span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to our home health segment was determined using the product of a twelve-month adjusted EBITDA measure and a specified median market price multiple based on a basket of public home health companies and transactions, after adding cash and deducting indebtedness that included the outstanding principal balance under any intercompany notes. To determine the fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our joint venture hospitals, we use the applicable hospitals&#8217; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable facilities. The projected operating results use management&#8217;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the three and nine months ended September 30, 2020, we did not record any material gains or losses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to these assets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our consolidation of Yuma Rehabilitation Hospital and the remeasurement of our previously held equity interest at fair value, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i90e31655e1c843588845e5d149d3d78f_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RleHRyZWdpb246OWNjY2Q2ODNlMDUwNGMwNGJjMjc1NzNkNjVmMzBhZjJfODI0NjMzNzIxMjQ0Mw_2705d942-b1c6-4deb-96bc-0721ebc019b6"><ix:nonFraction unitRef="usd" contextRef="i2cb6a7700bc94455b1a76981062358af_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RleHRyZWdpb246OWNjY2Q2ODNlMDUwNGMwNGJjMjc1NzNkNjVmMzBhZjJfODI0NjMzNzIxMjQ0Mw_68a0eb00-f4a3-4411-a92c-92f6efea0552">19.2</ix:nonFraction></ix:nonFraction>&#160;million gain as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three and nine months ended September&#160;30, 2019. We determined the fair value of our previously held equity interest using the income approach valuation technique. The income approach included the use of the hospital's projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the hospital. The projected operating results use management's best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; to the consolidated financial statements accompanying the 2019 Form 10&#8209;K, the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. <ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RleHRyZWdpb246OWNjY2Q2ODNlMDUwNGMwNGJjMjc1NzNkNjVmMzBhZjJfMjk3OQ_28726565-8f8f-44a2-8019-7ae2ebfbe056" continuedAt="ib14bab1405a8419faec5a2abd873ef05" escape="true">The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:15pt;margin-top:5pt"><ix:continuation id="ib14bab1405a8419faec5a2abd873ef05"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ae8d59fc12411b879d99d7434e8c7a_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMy0xLTEtMS0w_a0a2bbe0-ddee-4310-ab65-9944f6198d72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca40e094ccf47d19b41a7336db5ee77_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMy0zLTEtMS0w_80a7e16e-3282-4a8d-863a-cf09424cf43c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0e75c4e9e143ea8c9e88f3a1327641_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMy01LTEtMS0w_12ad4d1d-f4d1-4102-8dde-06c2b2a0b95e">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia509d100e6ab4e2a9c6a5b3bc3d344dc_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMy03LTEtMS0w_c9fc4fbc-2ee6-49ed-a2ae-0507a13aa979">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58dd346723c4144a958394c28b0c3d2_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNC0xLTEtMS0w_8dcf3078-936c-4dc0-bb37-116a7d77661d">254.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186457b966e448f8b789ee4909b7ae8d_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNC0zLTEtMS0w_812af1f0-daf9-437e-b5c1-ba43ab071afc">256.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c5bfe222cb48208514b96445916886_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNC01LTEtMS0w_53c4fe71-0310-4434-a275-54871f0395b9">265.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia715c07fe5d248e9b5940e457b3706eb_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNC03LTEtMS0w_09188599-386a-4f29-95e8-fcd9ff4e7aa0">266.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f0377bd53564ffdae03ff64e660194b_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS0wLTEtMS0wL3RleHRyZWdpb246ZWZlYzY3ODU1NzkwNDBlYzljMmQxN2VlNTRlYmM1ZDVfMTA5OTUxMTYyNzgxNA_1812e13c-49d0-4d37-a050-d37f8593cec9"><ix:nonFraction unitRef="number" contextRef="i638ab89eae9440c5b0f1929587a02914_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS0wLTEtMS0wL3RleHRyZWdpb246ZWZlYzY3ODU1NzkwNDBlYzljMmQxN2VlNTRlYmM1ZDVfMTA5OTUxMTYyNzgxNA_2780cf40-90b2-4af1-afd8-2bc66c96e519">5.125</ix:nonFraction></ix:nonFraction>% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0cb787bf3ff4d24aa0ab14e1e0c373c_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS0xLTEtMS0w_37cd65a9-b186-4585-a857-95eb98defbf5">297.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0051b03acc3e4e2986db12da328b3bac_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS0zLTEtMS0w_df812a17-bb9c-4feb-a6f0-f1275f1799a6">302.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19a05f81373432ca6b36a5c0470017e_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS01LTEtMS0w_3c133b45-d7ec-442d-bf98-8700fe11e3e5">297.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc3ff3814494e65a5977ad5528ad3b0_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS03LTEtMS0w_e5166d26-7a59-4cce-a30d-aadb288f2a72">306.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia523dc03179846ddaf98c887899b7679_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi0wLTEtMS0wL3RleHRyZWdpb246ODM4ZDBmZDliMDhmNGRmMWI5OTU1OGJjNjJmZmRkOGNfMTA5OTUxMTYyNzgxMg_1f0ecb5f-54e1-49c8-a3d7-e8ef7c8f27d7"><ix:nonFraction unitRef="number" contextRef="i3892c4bc03204316bb6e77be3f27b240_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi0wLTEtMS0wL3RleHRyZWdpb246ODM4ZDBmZDliMDhmNGRmMWI5OTU1OGJjNjJmZmRkOGNfMTA5OTUxMTYyNzgxMg_8617eaa9-dd12-42bd-9e91-a7f317c226f6">5.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934987b44af7446c8218601c95502de9_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi0xLTEtMS0w_d8f658d6-3a6a-47fe-bcfe-74002a03d92f">697.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id68ab94595124a1e97f267729e976e5d_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi0zLTEtMS0w_5218b252-e8a8-4eea-962e-b3f5bcff453a">701.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id58191662ff7460988e18540fde456ef_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi01LTEtMS0w_0b01c51b-8459-4655-994c-8624328dd040">697.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8394e3bcc5451cacdda373dfbbc0b3_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi03LTEtMS0w_960b4416-1131-4d24-9f03-e8635dffc708">708.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib40a6e6dd68b4a8da5d30d7aaa484c51_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy0wLTEtMS0wL3RleHRyZWdpb246YmZkMWEyYTkxNTYzNDFiZWFmZTA3Yzg3ODRlZTk1Y2ZfMTA5OTUxMTYyNzgxMg_1e1ce535-b4a4-4809-a01f-25ff69117894"><ix:nonFraction unitRef="number" contextRef="ic41c4e44b7b64428b528add431c16513_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy0wLTEtMS0wL3RleHRyZWdpb246YmZkMWEyYTkxNTYzNDFiZWFmZTA3Yzg3ODRlZTk1Y2ZfMTA5OTUxMTYyNzgxMg_206fb410-c746-439a-a015-f52e7b1cce05">5.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5999223d44049ab8c9ad683173bdc2d_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy0xLTEtMS0w_b97bd8f3-13a5-425d-b6da-14d8add38247">346.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief3957a1e65a4a2b85016faf016e95db_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy0zLTEtMS0w_1148cf5b-fca3-496f-964f-becb9ef5f23b">361.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42640997d4454f199cf25a948fc95738_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy01LTEtMS0w_87feb3b2-1d62-45bd-a87b-65707ca26181">345.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f49077e01a45f097881493f89e0508_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy03LTEtMS0w_449dcfdf-7bb5-48d9-8d21-ab45e1526ac0">369.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i730f2a918b744a0e94177fd42ad004a4_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC0wLTEtMS0wL3RleHRyZWdpb246NDk1OTBmYzk5OTdkNDM5MDhjNTZlYTIwMDRkNzc1YTlfMTA5OTUxMTYyNzgxMg_3e4a53b0-f392-4aac-a93f-d3668352d54c"><ix:nonFraction unitRef="number" contextRef="i6f1805d3ddcd4b188bc766e18298a2d5_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC0wLTEtMS0wL3RleHRyZWdpb246NDk1OTBmYzk5OTdkNDM5MDhjNTZlYTIwMDRkNzc1YTlfMTA5OTUxMTYyNzgxMg_b4f3d06d-eb07-4c4f-8159-a5f676b8a009">4.50</ix:nonFraction></ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d26a6364364e1a9b54ab393f994255_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC0xLTEtMS0w_1b7cbb5c-cb6f-41b3-aaa7-b9ea9a4aaec2">784.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib91ca67dc3504530b8450421abc7fb8a_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC0zLTEtMS0w_675efaa2-5a9d-49c2-a4c2-c37607571fd1">804.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf31d36bee454c13a050e3f343b6a3c8_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC01LTEtMS0w_a896d479-02f6-4c23-a0a1-53b9892bc95c">491.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice01013cd7f94c859dbdc8f630c352a2_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC03LTEtMS0w_3d20e155-344b-4463-b4a9-8a5726b892f0">519.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62eb57fb87fc40e59f8f33f73b921693_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS0wLTEtMS0wL3RleHRyZWdpb246M2MyM2I3M2FjODhmNDk2Yzk5MDY5NTM3Y2VjMGUxNWFfMTA5OTUxMTYyNzgxMg_1836756b-4f35-4a06-be96-796d8c8dfe82"><ix:nonFraction unitRef="number" contextRef="idd067c2ff27b4ab8a68e5471e7c59ef9_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS0wLTEtMS0wL3RleHRyZWdpb246M2MyM2I3M2FjODhmNDk2Yzk5MDY5NTM3Y2VjMGUxNWFfMTA5OTUxMTYyNzgxMg_b5df9640-78e5-46fe-957d-da9a96f7c979">4.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd83dbae36b43d7b4a6162c02698684_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS0xLTEtMS0w_e55979f4-429b-4375-869c-5fbc1a4b9c1c">782.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id954ef15e93c4d14ae05f3cd3b278851_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS0zLTEtMS0w_69650335-e3e9-4437-a822-7015e3de5211">814.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90ef0119e13b4be5826ee406b88feacb_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS01LTEtMS0w_fe7b57d9-8aef-44ad-9233-ee534491259a">491.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728449144459420bb67f2d96b87cbb5e_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS03LTEtMS0w_8f9a82e7-9a90-4806-b240-58204231fcc1">520.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib34fdd3cc9e945d8af9a195dca36f84b_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTAtMS0xLTEtMA_a2afb8db-5613-4089-ba3d-8e6546f16257">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i455ce14d267f4b87b426320cf9bbdc10_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTAtMy0xLTEtMA_dbf9bb42-6e2a-42c4-bc68-30b8cc3f4543">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a3de203d80490b878e5ccae2d26b36_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTAtNS0xLTEtMA_4e07dd74-fcc0-45eb-9b8f-4868622b3cde">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2152173f71549049764873566ae5676_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTAtNy0xLTEtMA_7ba46e3d-1d25-45a4-9575-672f9f4a33c1">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29cc50ab07e74bbe9b5f86334dca8053_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTItMS0xLTEtMA_81f4ea23-f9e8-4012-afbc-acfabf2c21ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c210278132437cbd3fe2285375e3cf_I20200930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTItMy0xLTEtMA_00b17b52-cd86-43df-bf35-cfe3d730abf2">36.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e176382eb04cdab88c4972bf3f6d7a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTItNS0xLTEtMA_6992d7cb-b676-4c06-8ef3-ee9e548f646c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb21c9d51d840279240febc1301d0e7_I20191231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTItNy0xLTEtMA_ec21b373-5fa3-4c13-96e1-1d1c199527d4">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs within the fair value hierarchy. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzE3MzM_b4b67271-dbaf-4096-900e-f8e23b280b34" continuedAt="i550eae926a4549148f9b93967e64097f" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="i550eae926a4549148f9b93967e64097f" continuedAt="ib959d9d68e4e4070864e605e5b5c5c31"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we issued a total of <ix:nonFraction unitRef="shares" contextRef="i4cb38ea719844f6cb5c7d56debf66f6e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzcz_171a6280-80c0-4ea6-a3ca-94ecf598f093">0.4</ix:nonFraction> million restricted stock awards to members of our management team and our board of directors. Approximately <ix:nonFraction unitRef="shares" contextRef="i6fbf64e203144762b1d2ada6b0352efa_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzE3Ng_d9fdbe50-1ef6-40bf-9235-3ab7ce19da16">0.2</ix:nonFraction> million of these awards contain only a service condition, while the remainder contain both a service and a performance condition. For the awards that include a performance condition, the number of shares that will ultimately be granted to employees may vary based on the Company&#8217;s performance during the applicable <ix:nonNumeric contextRef="i8958165af77d4177a1e12b5aa53be055_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzE0ODQzNDA2OTc2NzUx_66df67cd-9ced-4df5-96cd-337260292c9c">two year</ix:nonNumeric> performance measurement period. Additionally, we granted <ix:nonFraction unitRef="shares" contextRef="i49095c84bb0c46e1bb8ad5d5e2601b49_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzU0Ng_8c8ed690-41cf-435c-8bed-d6b68a923fc4">0.1</ix:nonFraction> million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the EHHI acquisition discussed in Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we granted stock appreciation rights (&#8220;SARs&#8221;) based on Holdings common stock to certain members of EHHI management at closing. Half of the SARs vested on December&#160;31, 2018 and the remainder vested on December 31, 2019. Upon exercise, each SAR must be settled for cash in the amount by which the per share fair value of Holdings&#8217; common stock on the exercise date exceeds the per share fair value on the grant date. As of December 31, 2019, the fair value of the remaining <ix:nonFraction unitRef="shares" contextRef="ifbcfb44cf32548af90099a6a944afa74_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzEzMDg_230fa3ed-016b-46db-9a12-65ee1bfc3c88">115,545</ix:nonFraction> SARs was approximately $<ix:nonFraction unitRef="usd" contextRef="ifbcfb44cf32548af90099a6a944afa74_I20191231" decimals="-6" format="ixt:numdotdecimal" name="ehc:AllocatedSharebasedCompensationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzEzMzQ_f12bb5a3-c62d-44cf-a2db-e17272389a87">101</ix:nonFraction> million, all of which was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated balance sheet. In January 2020, members of the management team exercised the remaining SARs, and in February 2020, we settled those awards upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i130a002122d84a44a7f2a2f80eb06cb9_D20200201-20200229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzE2MTM_e226093b-9135-4ca8-a393-2b20a46770c8">101</ix:nonFraction> million in cash.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><ix:continuation id="ib959d9d68e4e4070864e605e5b5c5c31" continuedAt="ia0e5af82717a4f75a0ec3e6e7b734c75"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Note&#160;14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia0e5af82717a4f75a0ec3e6e7b734c75">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</ix:continuation> </span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_109"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDkvZnJhZzo4YTc4MTQ5ODkwYzE0M2E5OGY4OWE4NzhkMWFjMzFjYi90ZXh0cmVnaW9uOjhhNzgxNDk4OTBjMTQzYTk4Zjg5YTg3OGQxYWMzMWNiXzc0Nw_e2f76399-e9bb-4dd1-9443-b3f32b615292" continuedAt="i32662feb0aa64eac9439af3f8f9359a8" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><ix:continuation id="i32662feb0aa64eac9439af3f8f9359a8"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDkvZnJhZzo4YTc4MTQ5ODkwYzE0M2E5OGY4OWE4NzhkMWFjMzFjYi90ZXh0cmVnaW9uOjhhNzgxNDk4OTBjMTQzYTk4Zjg5YTg3OGQxYWMzMWNiXzU5_196f1051-d7bd-4d3f-9819-be0a5d232e3d">26.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDkvZnJhZzo4YTc4MTQ5ODkwYzE0M2E5OGY4OWE4NzhkMWFjMzFjYi90ZXh0cmVnaW9uOjhhNzgxNDk4OTBjMTQzYTk4Zjg5YTg3OGQxYWMzMWNiXzIxOTkwMjMyNTYzNDM_933def5f-c4f8-404b-85fe-da66a166dc8d">34.3</ix:nonFraction> million for the three months ended September&#160;30, 2020 and 2019, respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rate. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDkvZnJhZzo4YTc4MTQ5ODkwYzE0M2E5OGY4OWE4NzhkMWFjMzFjYi90ZXh0cmVnaW9uOjhhNzgxNDk4OTBjMTQzYTk4Zjg5YTg3OGQxYWMzMWNiXzIxOTkwMjMyNTY2MDk_2118f0ea-acf6-4999-8764-7d7502440021">65.8</ix:nonFraction> million for the nine months ended September&#160;30, 2020 primarily resulted from the application of our estimated effective blended federal and state income tax rate offset by tax benefits resulting from share-based compensation windfalls. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDkvZnJhZzo4YTc4MTQ5ODkwYzE0M2E5OGY4OWE4NzhkMWFjMzFjYi90ZXh0cmVnaW9uOjhhNzgxNDk4OTBjMTQzYTk4Zjg5YTg3OGQxYWMzMWNiXzM0MQ_f2c23a6a-b06f-45d2-9568-8ce1c705c752">88.6</ix:nonFraction> million for the nine months ended September 30, 2019 primarily resulted from the application of our estimated effective blended federal and state income tax rate, tax benefits resulting from share-based compensation windfalls and the deductibility of the June 2019 settlement discussed in Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90ZXh0cmVnaW9uOjY3ZGUyNzMwNTQ5ODQ1MGVhZWI1NDlmOTExNzk5ZmU1XzQ3Ng_9ac99d67-cb02-481d-88f4-dfc5e762f0fe" continuedAt="ibc8c6410df0c413eacb3ac346eca4d75" escape="true">Earnings per Common Share</ix:nonNumeric></span></div><ix:continuation id="ibc8c6410df0c413eacb3ac346eca4d75" continuedAt="i235f34d06a484c40a647b7e8494c785f"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90ZXh0cmVnaW9uOjY3ZGUyNzMwNTQ5ODQ1MGVhZWI1NDlmOTExNzk5ZmU1XzQ5Ng_9a2f0d73-923b-4b75-817f-77910bb8c043" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzQtMS0xLTEtMA_5e300d85-b1be-4728-a1e5-e4544ab15748">100.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzQtMy0xLTEtMA_5371794d-43c6-4f3c-aacf-62758c0612f8">119.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzQtNS0xLTEtMA_70943f3f-d240-445b-aae7-1431a00fc868">257.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzQtNy0xLTEtMA_a13921ee-ec25-4af3-bbad-039969ca3d26">356.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzUtMS0xLTEtMA_b893fe7c-c6f6-4942-b513-31dd29a579dc">22.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzUtMy0xLTEtMA_06da9724-684d-4b80-ac85-c519ed431088">21.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzUtNS0xLTEtMA_1e36c8d3-e66d-42de-a57a-aeea35fef6ea">58.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzUtNy0xLTEtMA_cff75778-915c-4143-8b94-b9dcf42dcb7d">64.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income allocated to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzYtMS0xLTEtMA_a408fbd7-57dc-4cfc-8821-fd4315b682e2">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzYtMy0xLTEtMA_988b5e63-c10d-4bf3-9fee-ae5fc6d9da60">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzYtNS0xLTEtMA_424f5038-4f39-4eef-af83-35e2b4008484">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzYtNy0xLTEtMA_a632ebee-fc17-4ade-9ae8-5b3c2c3cbdeb">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzgtMS0xLTEtMA_3c66e069-f2f6-468e-a015-53c335769956">77.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzgtMy0xLTEtMA_bd57bfd5-e84f-450b-a542-da35968f9caa">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzgtNS0xLTEtMA_de88c586-5c6c-47ee-813b-3ab22d51f194">197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzgtNy0xLTEtMA_171a2160-a3df-4bcd-8949-de674cb58f8b">290.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzktMS0xLTEtMA_1149eda8-9b3a-4513-962c-96c2b7d76e85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzktMy0xLTEtMA_dc9503fa-8e4a-40ec-b8a6-90ade4995ce7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzktNS0xLTEtMA_aa1c1da6-a8bd-4704-ab2f-4f78399b73e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzktNy0xLTEtMA_2cb10cf9-1a87-4798-bb00-f7b806bdd01d">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="ehc:NetIncomeLossAvailabletoCommonStockholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzExLTEtMS0xLTA_d0b2c501-28fb-403a-b07e-a22a92a4fc2c">77.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="ehc:NetIncomeLossAvailabletoCommonStockholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzExLTMtMS0xLTA_90c74420-9e04-4421-93c9-1450566b0467">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="ehc:NetIncomeLossAvailabletoCommonStockholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzExLTUtMS0xLTA_dec8459e-ccf2-4cef-b079-709b43fada89">197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="ehc:NetIncomeLossAvailabletoCommonStockholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzExLTctMS0xLTA_b1b99990-3c99-4d87-9873-1df99cfeec6c">290.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzEzLTEtMS0xLTA_75269bea-7387-4be9-ba7c-8374684db1c5">98.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzEzLTMtMS0xLTA_0cb287e6-0c9c-405c-8b6b-ab463bec4d7d">97.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzEzLTUtMS0xLTA_3bdf9500-f06e-491f-a129-fb824d54b338">98.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzEzLTctMS0xLTA_3f2bbfe8-0774-4f04-896e-c4c346d53987">98.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE1LTEtMS0xLTA_94bdaa4d-9288-4559-9a5e-7d169ca766ed">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE1LTMtMS0xLTA_b3a016bc-364f-4964-bb03-b6495921cc38">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE1LTUtMS0xLTA_639a597d-00ef-494c-a052-f48698bb696c">2.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE1LTctMS0xLTA_9defde56-2454-4e72-abb1-87232d9e1a88">2.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE2LTEtMS0xLTA_0ce995c1-e344-4070-a2ca-c4cecd3b1a9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE2LTMtMS0xLTA_533bbbb8-c9bc-448e-b378-e9e730ea5bb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE2LTUtMS0xLTA_93104b06-41ac-4724-9a38-78834535111e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE2LTctMS0xLTA_ab8c6984-de1c-440a-8e42-822aab66285e">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE3LTEtMS0xLTA_e30cceec-a234-4bf6-9dc3-0c08d2a1dcbf">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE3LTMtMS0xLTA_31616761-ccfe-4af9-bdbb-536e9f4a3625">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE3LTUtMS0xLTA_3f7c0000-b0cd-46b2-bca6-5da246667bc9">2.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE3LTctMS0xLTA_9153188f-e30b-4a05-b965-b33abe6a6960">2.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIxLTEtMS0xLTA_5e300d85-b1be-4728-a1e5-e4544ab15748">100.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIxLTMtMS0xLTA_5371794d-43c6-4f3c-aacf-62758c0612f8">119.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIxLTUtMS0xLTA_70943f3f-d240-445b-aae7-1431a00fc868">257.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIxLTctMS0xLTA_a13921ee-ec25-4af3-bbad-039969ca3d26">356.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIyLTEtMS0xLTA_b893fe7c-c6f6-4942-b513-31dd29a579dc">22.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIyLTMtMS0xLTA_06da9724-684d-4b80-ac85-c519ed431088">21.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIyLTUtMS0xLTA_1e36c8d3-e66d-42de-a57a-aeea35fef6ea">58.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIyLTctMS0xLTA_bfe29c85-4e10-4b25-a309-63523d3aa5d7">64.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI1LTEtMS0xLTA_a008ae4d-7304-4ac8-a7aa-92903542b833">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI1LTMtMS0xLTA_2033c223-ddcb-487f-9b96-a81ff24eca0d">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI1LTUtMS0xLTA_5b8c0c85-194a-4148-87ca-4c57cf81bf87">198.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI1LTctMS0xLTA_496cf6b0-3c97-4d32-afba-54560e93114b">291.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI2LTEtMS0xLTA_1149eda8-9b3a-4513-962c-96c2b7d76e85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI2LTMtMS0xLTA_dc9503fa-8e4a-40ec-b8a6-90ade4995ce7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI2LTUtMS0xLTA_aa1c1da6-a8bd-4704-ab2f-4f78399b73e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI2LTctMS0xLTA_2cb10cf9-1a87-4798-bb00-f7b806bdd01d">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI3LTEtMS0xLTA_a9a63d86-8b1f-4d06-af31-5b391817f38f">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI3LTMtMS0xLTA_57ebe882-a61f-44df-a4be-34ec5c4633b8">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI3LTUtMS0xLTA_baadb65e-fa79-4330-a42c-3a9355ef2c9a">198.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI3LTctMS0xLTA_c4daa7bb-179c-43a0-8c24-1315c024a39f">291.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI5LTEtMS0xLTA_77535d64-66b0-4794-a494-c9f09e954615">99.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI5LTMtMS0xLTA_e1ee1b6e-3fdb-4309-8a7d-c851aba1e1d5">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI5LTUtMS0xLTA_06ca4ff6-65ec-4ccb-a9d1-ca2cb216c16b">99.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI5LTctMS0xLTA_7ab77045-9514-4a3b-8897-04c252c68253">99.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMxLTEtMS0xLTA_f1cccac5-f369-4ad8-aada-24394b227a1d">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMxLTMtMS0xLTA_e9052588-68a1-4b06-ac2d-b94d66518016">0.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMxLTUtMS0xLTA_c630441e-ff7e-42f7-8dca-35c32db51502">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMxLTctMS0xLTA_79b34c25-f07b-4399-9349-96c0197a7803">2.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMyLTEtMS0xLTA_ab3d25c5-d0d9-4db5-beda-8c955c0f7f25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMyLTMtMS0xLTA_a6c65e02-2661-4809-876d-d3dde9bf3cac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMyLTUtMS0xLTA_25fe47f0-85ea-4144-92b2-ce49f89435da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMyLTctMS0xLTA_569149e6-fe92-4529-ac89-877b1b0b8057">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMzLTEtMS0xLTA_b7bc1feb-c705-462e-81f9-04f8032b3eef">0.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMzLTMtMS0xLTA_08c67e3e-d633-4a64-88f1-ee95725337be">0.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMzLTUtMS0xLTA_161f2f1b-c290-45e7-9891-b350bb7da665">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMzLTctMS0xLTA_c6390220-3968-4e73-9766-c80173ad88b1">2.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i235f34d06a484c40a647b7e8494c785f" continuedAt="iadd97394f0d8450fb2b8ca05458b2d35"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90ZXh0cmVnaW9uOjY3ZGUyNzMwNTQ5ODQ1MGVhZWI1NDlmOTExNzk5ZmU1XzQ3Nw_d5dc68fe-28c3-4037-88a5-b6686636bec8" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzItMS0xLTEtMA_75269bea-7387-4be9-ba7c-8374684db1c5">98.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzItMy0xLTEtMA_0cb287e6-0c9c-405c-8b6b-ab463bec4d7d">97.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzItNS0xLTEtMA_3bdf9500-f06e-491f-a129-fb824d54b338">98.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzItNy0xLTEtMA_3f2bbfe8-0774-4f04-896e-c4c346d53987">98.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzUtMS0xLTEtMA_b8cf1bd0-a236-4688-a2a8-ef746c862ed9">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzUtMy0xLTEtMA_6fc09b4b-5c59-42cf-9798-9ec0273cde29">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzUtNS0xLTEtMA_71c92a0d-4123-40bc-b5fa-002882d19542">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzUtNy0xLTEtMA_c5bc39ab-a5c1-4ec5-97ca-6a708c20502e">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzYtMS0xLTEtMA_bd749b64-6585-4a4f-a027-ba21923095a8">99.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzYtMy0xLTEtMA_87ab2cb6-d9dd-411e-bcff-1e2774ae3867">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzYtNS0xLTEtMA_2936b8e5-b8c1-4389-a881-6c5778008652">99.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzYtNy0xLTEtMA_3b0da5f0-7d45-4c27-8522-8abca6996ca1">99.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><ix:continuation id="iadd97394f0d8450fb2b8ca05458b2d35" continuedAt="i57f550f2f820467cbcd047bbaa62be67"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Common Share</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i57f550f2f820467cbcd047bbaa62be67">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K for additional information related to our common stock.</ix:continuation> </span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_118"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:LossContingencyDisclosures" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTgvZnJhZzoyZDI1ZTYyNzA3ZDQ0NDVlYjVlODUwOTlmMjkxMmFlYi90ZXh0cmVnaW9uOjJkMjVlNjI3MDdkNDQ0NWViNWU4NTA5OWYyOTEyYWViXzUwNzM_7641af86-f27e-441c-bdbd-c928679d0769" continuedAt="ie4bd4107ecb44ea69931488f297ba0ca" escape="true">Contingencies and Other Commitments</ix:nonNumeric></span></div><ix:continuation id="ie4bd4107ecb44ea69931488f297ba0ca" continuedAt="i293aa6b0db2e4e3b8858bf092435e9d3"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nichols Litigation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nichols v. HealthSouth Corp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In July 2019, we entered into settlement agreements with all but one plaintiff and paid those settling plaintiffs an aggregate amount of cash less than $<ix:nonFraction unitRef="usd" contextRef="i2c9a6e8916a642608c3dec74c2e5242b_D20190701-20190731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTgvZnJhZzoyZDI1ZTYyNzA3ZDQ0NDVlYjVlODUwOTlmMjkxMmFlYi90ZXh0cmVnaW9uOjJkMjVlNjI3MDdkNDQ0NWViNWU4NTA5OWYyOTEyYWViXzg1OQ_581de864-9eaa-453f-a48b-628ab8dc8a40">0.1</ix:nonFraction> million. The remaining plaintiff alleges that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiff is seeking compensatory and punitive damages. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This case was stayed in the circuit court on August&#160;8, 2005. However, the complaint has been amended from time to time, including to request certification as a class action. Additionally, one of the former officers named as a defendant has repeatedly attempted to remove the case to federal district court. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. On December&#160;10, 2014, we filed a motion to dismiss on the grounds the plaintiffs lacked standing because their claims were derivative in nature, and the claims were time-barred by the statute of limitations. On May&#160;26, 2016, the trial court granted our motion to dismiss. On appeal, the Supreme Court of Alabama reversed the trial court&#8217;s dismissal on March 23, 2018. On April 6, 2018, we filed an application for rehearing with the Alabama Supreme Court. On March 22, 2019, the Alabama Supreme Court denied our application for rehearing and remanded the case to the trial court for further proceedings. The court has not yet set a date for the trial to begin. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in this case against the sole remaining plaintiff. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate an amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i293aa6b0db2e4e3b8858bf092435e9d3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the False Claims Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the United States Department of Health and Human Services Office of Inspector General and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.</span></div></ix:continuation><div id="i5ec2d1f903d340c19ee74983700dc28d_121"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzMyODQ_68b0790c-543e-4308-b1a5-54d295942139" continuedAt="ia5a4b93ada1e41ad9cbe0ce78cf0f1e7" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="ia5a4b93ada1e41ad9cbe0ce78cf0f1e7" continuedAt="ic182c10702a64f25a1cb234da6f3b243"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using <ix:nonFraction unitRef="segment" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE4NQ_0d63303b-ad5c-43bd-83e4-4b32eef6652a">two</ix:nonFraction> operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inpatient Rehabilitation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our national network of inpatient rehabilitation hospitals stretches across <ix:nonFraction unitRef="state" contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzY3Mg_9fd604c5-2095-4608-b639-4fc706e084e0">36</ix:nonFraction> states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of September&#160;30, 2020, we operate <ix:nonFraction unitRef="hospital" contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930" decimals="INF" name="ehc:NumberOfInpatientRehabilitationHospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzgwNg_c0d10855-6ead-452b-97c6-55e8390ca2cd">136</ix:nonFraction> inpatient rehabilitation hospitals. We are the sole owner of <ix:nonFraction unitRef="hospital" contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930" decimals="INF" name="ehc:Numberofsolelyownedinpatientrehabilitationhospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzg3MA_3cd5b793-61a6-434c-86c9-8461238c4204">87</ix:nonFraction> of these hospitals. We retain <ix:nonFraction unitRef="number" contextRef="if254742956e843fdbdef4b70418d1d95_I20200930" decimals="3" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzkwMw_2b309e6a-0277-4a64-b933-90f2b9665d3e">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4e1097dbae78496f9253f83fa0d57473_I20200930" decimals="3" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzkwOQ_990a83b7-be37-41b9-bada-2c2f718fc26d">97.5</ix:nonFraction>% ownership in the remaining <ix:nonFraction unitRef="hospital" contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930" decimals="INF" name="ehc:Numberofjointlyownedinpatientrehabilitationhospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzkzOQ_9273c42e-df23-44ca-9deb-fc9c1a744166">49</ix:nonFraction> jointly owned hospitals. In addition, we manage <ix:nonFraction unitRef="hospital" contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="ehc:NumberOfInpatientRehabilitationUnitsUnderManagementContracts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzk5MA_2287dab9-84a8-466d-8458-b5e6d97ae846">three</ix:nonFraction> inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Home Health and Hospice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- As of September&#160;30, 2020, we provide home health services in <ix:nonFraction unitRef="location" contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930" decimals="INF" name="ehc:Numberofhomehealthlocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE1MTE_55250826-aac7-41c1-9e0a-a9391e131ca5">242</ix:nonFraction> locations and hospice services in <ix:nonFraction unitRef="location" contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930" decimals="INF" name="ehc:Numberofhospicelocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE1NDg_2c2bf4a9-f594-44fd-bda2-459aa1797f11">83</ix:nonFraction> locations across <ix:nonFraction unitRef="state" contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE1Njg_50b3efa6-bfff-4137-a8cf-13be2bc2976a">31</ix:nonFraction> states with concentrations in the Southeast and Texas. In addition, <ix:nonFraction unitRef="hospital" contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="ehc:NumberofJointVenturesAccountedforUsingtheEquityMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE2Mzk_079603e3-90c9-4d56-9f49-ef2588cad1fe">one</ix:nonFraction> of these home health agencies operates as a joint venture which we account for using the equity method of accounting. We are the sole owner of <ix:nonFraction unitRef="location" contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930" decimals="INF" name="ehc:Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE3ODU_38562a40-3e79-474f-8a70-2a61905a3eff">317</ix:nonFraction> of these locations. We retain <ix:nonFraction unitRef="number" contextRef="ia4085dac83c04f60a84bda9c69ca0fd4_I20200930" decimals="3" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE4MTg_d587d329-3db9-47d1-bba0-7929e9e67510">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4e018bd04e884537bdbb55709b14d86e_I20200930" decimals="3" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE4MjQ_c144f378-1863-4543-be8f-6985f1c906f5">81.0</ix:nonFraction>% ownership in the remaining <ix:nonFraction unitRef="location" contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="ehc:Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE4NTQ_531c2edc-937a-4312-9dab-83d6fdbb771d">eight</ix:nonFraction> jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Our hospice services include in-home services to terminally ill patients and their families to address patients&#8217; physical needs, including pain control and symptom management, and to provide emotional and spiritual support. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The accounting policies of our reportable segments are the same as those described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K. All revenues for our services are generated through external customers. See Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (&#8220;Segment Adjusted EBITDA&#8221;).</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="ic182c10702a64f25a1cb234da6f3b243" continuedAt="i1bf078f7df3d4547ab7e7ee37453822b"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzMyNzA_56756a27-896e-410e-a350-63e12605da8f" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information for our reportable segments is as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtMS0xLTEtMA_9e30fce8-030a-4106-b116-a53b18b258ac">899.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtMy0xLTEtMA_d27c7943-feed-44ff-bb54-289be277f8ac">872.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtNS0xLTEtMA_9ad1a8b2-ccd0-4042-8fee-e7bbfb70c4ef">2,633.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtNy0xLTEtMA_e4c2e7e6-355b-491e-b91a-a2fe49b35dcf">2,616.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtOS0xLTEtMA_c8695f2b-a50b-4a59-bc50-7d4a4ec1903d">274.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtMTEtMS0xLTA_a12750b7-bf8d-4396-b119-e4b450470cae">289.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtMTMtMS0xLTA_243efc96-744a-43c3-baef-68fb1af0646e">796.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtMTUtMS0xLTA_e8d97153-dfe5-4a9d-b9cd-8fc7f8b81602">804.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzYtMS0xLTEtMA_08c966e1-3f8f-4a37-891b-114b269d5ad5">475.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzYtMy0xLTEtMA_d600e354-7656-4efa-8df1-b7333e91f7cf">459.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzYtNS0xLTEtMA_990f7111-8cb1-48a1-921d-9118ead39245">1,408.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzYtNy0xLTEtMA_237fd61a-711f-4182-9e2a-6ccca11a4348">1,347.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzctMS0xLTEtMA_9f78f334-e101-4144-bbd5-1921498ff5f7">135.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzctMy0xLTEtMA_b48251d9-43ae-4351-88f7-e234fc177473">131.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzctNS0xLTEtMA_1569c84a-504e-4918-83a2-a410e9c7884e">394.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzctNy0xLTEtMA_bf6aaf77-2581-4d64-9548-a4d7cca93f54">386.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzgtMS0xLTEtMA_b841100c-ed77-491c-9b52-0c5193291d27">45.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzgtMy0xLTEtMA_ba062b39-1862-4d42-a05b-9b0aaddff92e">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzgtNS0xLTEtMA_0d25e7cd-b328-4736-b200-6b5bb6599e05">126.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzgtNy0xLTEtMA_d50ce9dd-82cc-4317-9f44-1663e83c0851">109.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzktMS0xLTEtMA_d78c2536-3168-4a79-b831-617929cb60ce">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzktMy0xLTEtMA_de65e5ab-550b-47fc-ae80-fa97695e744a">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzktNS0xLTEtMA_526d6679-6839-41dc-b675-b81533cf13ee">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzktNy0xLTEtMA_656ca6a4-f342-4f95-b9db-a6fce0f3b1d3">49.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services sold (excluding depreciation and amortization)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzExLTktMS0xLTA_81cc3d5f-15fa-411f-856c-84c2f5d0729d">121.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzExLTExLTEtMS0w_624e61a7-56e2-447b-bf98-a80523daf7bc">136.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzExLTEzLTEtMS0w_522bc100-7491-4262-91a6-d55ee9884c5d">389.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzExLTE1LTEtMS0w_0868700f-51cd-466f-87ae-7d3ca1e552aa">372.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEyLTktMS0xLTA_a3cc21f9-4ad5-4eb4-99ff-08909a7605f2">100.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEyLTExLTEtMS0w_4ae8aef9-ed6e-42e1-a381-0166892808e9">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEyLTEzLTEtMS0w_129763da-4ddf-4552-bc5b-bf4f2ae337e1">299.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEyLTE1LTEtMS0w_ab1095de-59d5-4588-aedb-73a2307ab367">278.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTEtMS0xLTA_9ccb6038-41ba-4b69-bd9c-dde24321158b">671.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTMtMS0xLTA_d993ddcf-833f-469a-b2a7-419d474b7e2f">644.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTUtMS0xLTA_d7de8c88-3f52-493e-80b0-75bf90de9c68">1,976.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTctMS0xLTA_af964d06-d77c-403a-a75a-2fca256107cc">1,892.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTktMS0xLTA_89096b6f-a880-4e2a-8305-ab82773f7cf7">222.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTExLTEtMS0w_87acccc6-9027-42f6-823c-cdf1651a4b3e">236.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTEzLTEtMS0w_1aa4cc1f-66a4-4815-8196-a989c6e33512">688.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTE1LTEtMS0w_a0dcbea0-f1ac-41e1-86b0-e9fb5ef397c5">650.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTEtMS0xLTA_fd4db32c-1989-4ba5-aa34-edcd5f558461">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTMtMS0xLTA_e81772b9-7d81-4e11-a2c7-175bc8883f62">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTUtMS0xLTA_2c5ac9eb-087f-4dc0-8ac7-e4429174c365">3.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTctMS0xLTA_e31d09ea-bdf1-4254-8239-f496ceb640cb">6.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTktMS0xLTA_c9068d97-086e-4284-8891-5ab8f7ee276e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTExLTEtMS0w_aa155a93-f171-44e6-a149-2ba75092f772">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTEzLTEtMS0w_bbbc968f-b83d-4e98-b5ed-234b3f81f60d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTE1LTEtMS0w_72fccbb4-087e-4a98-8c4d-b140d679f074">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTEtMS0xLTA_930a7e50-4018-4d65-b7b7-b46daaa4a35e">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTMtMS0xLTA_dcc2d5aa-033a-4809-9c32-58729cd49504">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTUtMS0xLTA_ff58567a-21ee-438c-8c2f-d7a88df14ae1">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTctMS0xLTA_f8a5d37e-edea-4edf-858c-d4551cf4ae98">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTktMS0xLTA_160bc2b1-9192-4315-852d-95b17fbe7eb2">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTExLTEtMS0w_7f103a7f-43a7-4c23-b04d-81f838513522">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTEzLTEtMS0w_46e398ed-4707-463c-828b-544b38932e7e">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTE1LTEtMS0w_a6a11505-caa9-45ea-ae63-9609673ea348">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTEtMS0xLTA_dfbe7551-569d-40d7-8e48-87a2bf015733">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTMtMS0xLTA_eabd59ad-2154-4269-9b2f-1fbfe38a7725">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTUtMS0xLTA_805f797d-ff8a-490f-9359-1f2530b1518d">58.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTctMS0xLTA_d33208f6-14ba-4cc4-9cab-aa97aa20a9a9">60.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTktMS0xLTA_44765c66-b037-4081-9f06-25581aefd478">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTExLTEtMS0w_cad28427-73f8-44ed-8337-77bff95551b5">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTEzLTEtMS0w_a3f3bde1-1d82-48b1-af1c-d37e2d9e32f3">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTE1LTEtMS0w_64469014-1b78-458f-afd1-5c7b1640cf19">8.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTEtMS0xLTA_481ad2e0-ea67-4e75-b5eb-c6c46bcff1e6">209.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTMtMS0xLTA_eb901b4c-48c8-41a7-bb2d-3bd5e4cb980d">210.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTUtMS0xLTA_44cfbea1-73d4-40db-9fb1-23d9f9462f74">605.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTctMS0xLTA_2c705315-7bc7-497c-b656-8439f6627408">674.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTktMS0xLTA_2d1faa15-e117-464b-a69c-eb12fa974962">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTExLTEtMS0w_a38ab46d-2320-4a6e-a809-3297cdb712cb">50.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTEzLTEtMS0w_875f4ce8-901d-45ff-9705-95389d2f2638">107.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTE1LTEtMS0w_5f71ef41-e3ea-4d97-9a96-2e3f82c51f47">146.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTEtMS0xLTA_ece6c86b-93c0-4cb4-bc83-8d9efa5f0ddd">90.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTMtMS0xLTA_14a2615c-284b-4a1e-9db9-bc0542bec1c0">103.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTUtMS0xLTA_49f4a773-ceb3-4b0e-8840-b741b591ef9d">262.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTctMS0xLTA_d25afe5c-51f0-481a-a0ab-758a4920127f">266.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTktMS0xLTA_1540a906-ebc9-4162-ae21-f4c317ce2a7f">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTExLTEtMS0w_45311005-0f60-4062-88d2-16dec6dcff0c">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTEzLTEtMS0w_15d7fa69-6534-440a-8403-0f4301d071af">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTE1LTEtMS0w_ab3183f5-6f9d-4109-827f-5f5b57d192b5">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzMyNDY_1b527b2a-bad2-44d9-848e-585b5badca24" continuedAt="i539bb8c2b72b4bc29209ca1a7cc40745" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzItMS0xLTEtMA_d8105eab-68f6-42c4-b5c3-d55b17bc5710">5,058.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzItMy0xLTEtMA_b2f3c111-e367-4180-953a-5a5d3f9572b4">1,611.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzItNS0xLTEtMA_b5a0dfb1-0417-4030-a122-5cbabe8135d0">6,610.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzMtMS0xLTEtMA_4bbac530-e284-42d6-98af-043eea679959">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzMtMy0xLTEtMA_48299d52-9766-4fea-97ea-39264d96fcd3">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzMtNS0xLTEtMA_f07e2d82-7e46-4757-8d11-0f77cb38dc48">5.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7e9389f7bb49d1937b89476ce847a4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzUtMS0xLTEtMA_c5122fdd-0f37-48e5-96a1-6d46c1aa20cf">4,501.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab84c70e34994c9dbed01b25069a83d2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzUtMy0xLTEtMA_24f884a0-638a-4102-9417-aecbb76d5a95">1,612.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzUtNS0xLTEtMA_7557ac5a-d4ec-441a-b921-7f31519b8342">6,080.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7e9389f7bb49d1937b89476ce847a4_I20191231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzYtMS0xLTEtMA_08fdc672-4ec5-42ab-bd87-e677511c1268">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab84c70e34994c9dbed01b25069a83d2_I20191231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzYtMy0xLTEtMA_324f77c4-82d7-4d3e-b2ed-d7f505754818">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzYtNS0xLTEtMA_0ff9e665-2ad0-4fe4-aa1d-f6bd1090de54">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i1bf078f7df3d4547ab7e7ee37453822b"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="ehc:ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzMyNDg_df3d91aa-afb6-4057-9f8b-2f1b60343ae4" continuedAt="i982f4457a5c64cda88f494f188c33efc" escape="true">Segment reconciliations (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:15pt;margin-top:5pt"><ix:continuation id="i982f4457a5c64cda88f494f188c33efc"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb52c020c90481fb7260d98ee51f72b_D20200701-20200930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzItMS0xLTEtMA_cc87c286-59a0-49cc-b898-041053e23603">261.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica342deee7024b149e3a4aafeeb27c0e_D20190701-20190930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzItMy0xLTEtMA_09c1486b-63bc-49b1-a512-d75448b98370">261.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce0d088460444de9f461fc5f954104e_D20200101-20200930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzItNS0xLTEtMA_b60a3f7e-da4c-48a9-9f62-13ec11f5d3fa">712.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac44cb5b0a604e55a2dd05a02d35a226_D20190101-20190930" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzItNy0xLTEtMA_e2bdf565-f97c-43b9-8151-addece857526">820.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzMtMS0xLTEtMA_c224acc3-20bc-47d7-be31-1b75ddaa1cae">39.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzMtMy0xLTEtMA_16720e50-e755-4c5f-84ad-40e9a3ea8919">52.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzMtNS0xLTEtMA_ad1de6cb-238e-447e-92e9-4f5ed5e506ff">117.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzMtNy0xLTEtMA_e8172337-b57a-4198-8add-21e05efeb3b7">183.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzQtMS0xLTEtMA_66ed8564-3dda-4226-a69c-e059e286fd44">61.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzQtMy0xLTEtMA_47a05297-d8ea-43a9-9c02-9720bca89f16">55.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzQtNS0xLTEtMA_2c813fc9-ac18-4af7-9ea1-88120c57221c">180.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzQtNy0xLTEtMA_6bab88d2-9c84-412c-a95f-ab13f4161964">160.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzUtMS0xLTEtMA_5f4ad9ef-5fbd-40f8-8699-5c6edadbacb1">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzUtMy0xLTEtMA_06907429-156f-492d-9433-f04630e0308f">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzUtNS0xLTEtMA_6eec2226-6a57-40b8-b719-b1dda9c2c0d4">10.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzUtNy0xLTEtMA_4f0c0898-1f8c-48d5-b672-66fb8ddaa428">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzYtMS0xLTEtMA_22784cd8-497e-47e1-8734-a0490b5632d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzYtMy0xLTEtMA_8f199c22-7c4c-4980-bd6b-5bd0731ebcde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzYtNS0xLTEtMA_1fca3d26-bf03-4f1c-9495-a01e01005d40">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzYtNy0xLTEtMA_43810cb2-fce9-4672-b83d-011f2b8c5be4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzgtMS0xLTEtMA_feedbaf2-07fe-433c-9f85-c4ebe4d0fd6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzgtMy0xLTEtMA_3f07ed5f-93eb-49d0-84c3-dbbc75f068a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzgtNS0xLTEtMA_21f08d91-ddfe-4a2e-8b60-cc7e8816550d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzgtNy0xLTEtMA_08974bac-b0db-42de-afa2-8fe4af62b060">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzktMS0xLTEtMA_6e8d5a9c-b5f9-40ca-a511-b80c5d28ab33">49.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzktMy0xLTEtMA_7fef5756-a4c9-4656-9cc0-1d350eecc3a0">40.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzktNS0xLTEtMA_73142257-ca9d-4136-994a-c63436cda9cc">138.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzktNy0xLTEtMA_4dc1ed7f-2632-4d0f-9afa-e6f783416e9e">115.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzExLTEtMS0xLTA_c818d7f0-7f5b-493a-9d85-f27895c1272e">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzExLTMtMS0xLTA_25e5aab8-fcd1-4a26-9a5a-bd50848a39f3">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzExLTUtMS0xLTA_b49e4394-9b58-46a8-9b76-c2753c48fd8d">58.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzExLTctMS0xLTA_f5e81721-0820-4088-94a8-05830737e82e">64.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARs mark-to-market impact on noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="ehc:SARsmarktomarketimpactonnoncontrollinginterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEyLTEtMS0xLTA_75a64a1b-1a2c-4962-a7c2-4989347fb117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" name="ehc:SARsmarktomarketimpactonnoncontrollinginterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEyLTMtMS0xLTA_09a59f43-eb9a-452e-b186-df4097095e7f">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="ehc:SARsmarktomarketimpactonnoncontrollinginterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEyLTUtMS0xLTA_3b339b0a-c0cf-45a3-9c4f-57334bdf072a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" name="ehc:SARsmarktomarketimpactonnoncontrollinginterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEyLTctMS0xLTA_a4357a3a-21f7-42e7-8669-644d1a7632b0">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEzLTEtMS0xLTA_e285d342-be77-4cd0-8181-d9fc9708177c">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEzLTMtMS0xLTA_b948e103-6683-4745-930a-b7410e3ba432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEzLTUtMS0xLTA_aa1964a8-122a-4323-b079-79eda1e0acdb">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEzLTctMS0xLTA_a7952046-bc87-423d-a746-f473c0fd4d30">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE0LTEtMS0xLTA_0e38a666-13b8-4312-86be-bd18d4989e93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE0LTMtMS0xLTA_b1dcded5-483c-42dd-ade3-4aa28559ba07">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE0LTUtMS0xLTA_e525e728-827e-481b-88d9-2ca8351dfbf4">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE0LTctMS0xLTA_02b26a3e-e999-4e3d-905c-95759ffd8131">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll taxes on SARs exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="ehc:PayrolltaxesonSARsexercise" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE1LTEtMS0xLTA_a9991747-3006-4539-8996-777c987434f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930" decimals="-5" name="ehc:PayrolltaxesonSARsexercise" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE1LTMtMS0xLTA_47ef0688-c400-4b76-97b9-814f983a2006">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" name="ehc:PayrolltaxesonSARsexercise" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE1LTUtMS0xLTA_7d76f7b0-77d0-4eb8-8799-eff2b737f0fb">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930" decimals="-5" name="ehc:PayrolltaxesonSARsexercise" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE1LTctMS0xLTA_d07ecb16-fd5b-4531-a76d-eb299b66a8f3">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE3LTEtMS0xLTA_8e3339e5-04e3-4a19-abf8-19748fb2757d">127.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE3LTMtMS0xLTA_dee456db-8db3-400b-bb41-6feabd6a43f7">153.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE3LTUtMS0xLTA_d5d633eb-783c-4845-ab6a-1698dd10da87">322.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE3LTctMS0xLTA_d36105f7-cf1a-47cc-b7f9-07861a4b5c11">444.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:15pt;margin-top:5pt"><ix:continuation id="i539bb8c2b72b4bc29209ca1a7cc40745"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets for reportable segments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b556ace711f4b07a26951c1b12a6868_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzEtMS0xLTEtMA_1efdc3f8-bd26-4660-bd97-178a6b9fbe6e">6,670.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62367bba18c143edac791ed9c0e6b12d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzEtMy0xLTEtMA_0a641613-4ff2-46da-957f-15bd03d4674c">6,114.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of deferred income tax liabilities to net deferred income tax assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:PriorPeriodReclassificationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzItMS0xLTEtMA_826b6a09-c153-4e5e-8dc8-c0be21a04d66">60.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5e3006bff47459eb04bfde259d0b285_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:PriorPeriodReclassificationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzItMy0xLTEtMA_87b33a92-a686-41c6-955c-50b1cb423731">33.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consolidated assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzMtMS0xLTEtMA_6dcccf62-516b-4e12-a850-5d5d60aa112c">6,610.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzMtMy0xLTEtMA_39b677d3-285d-40a3-ad7b-c552dfd0bff0">6,080.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzMyNTM_ded251c3-635c-4752-b267-31d7ed8e12c7" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional detail regarding the revenues of our operating segments by service line follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bc1b11f6474259b5d2a6c7a7ed7d3f_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzMtMS0xLTEtMA_c2fb8849-3b7f-4f4e-aea3-92f4cf69a995">883.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i060b61eae5e141f5a0ecfd1970befba2_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzMtMy0xLTEtMA_63d1a9cb-3e04-4b91-b4da-3f7891c42b78">850.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a8f9f90011a4999af002b1dd34ca597_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzMtNS0xLTEtMA_e1d72946-7356-41a7-a76c-c0c69ea20b96">2,581.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc6b9fc57a843aa950bd9f011875dea_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzMtNy0xLTEtMA_50dccc94-498f-465c-9dde-01f5537429d9">2,550.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4eba057206a47f6ad35e724ea946fcc_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzQtMS0xLTEtMA_25918e99-ea3d-4942-aad5-cc58ddad78c7">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b675f52d0454ca895e68f1f2ec026c3_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzQtMy0xLTEtMA_68e4fbec-29c4-4361-ac67-8d5d47be5705">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00b712980524ce3863212d497722fb9_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzQtNS0xLTEtMA_37784ee0-b959-4933-9d2d-896c67b22e93">51.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72bcc5ef89644cc8431b9901f34f714_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzQtNy0xLTEtMA_4f439520-3fc5-44f6-b9ad-8223136465e5">66.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inpatient rehabilitation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzUtMS0xLTEtMA_30e87871-704f-4be8-ba53-a808ce6af283">899.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzUtMy0xLTEtMA_47dd3233-fea6-49f7-b2c1-db9a6faeb71b">872.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzUtNS0xLTEtMA_75b3cf05-34fd-42c4-b783-d517e11d08be">2,633.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzUtNy0xLTEtMA_0e8b77ad-6c69-4433-9c54-4b54efad6503">2,616.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3f156c397a54a5e942b4169a6555c29_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzctMS0xLTEtMA_2cec2806-0068-430a-8bb2-dd45c61dcf63">223.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7e0deb3678448e38f17bc49a774bc9c_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzctMy0xLTEtMA_db7c3407-eec0-4f41-b7cb-2c8ce6be70a8">238.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7b86bab34f4844a928bf4006774a56_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzctNS0xLTEtMA_ecf4f5fc-ceaf-4b89-b18c-8cec7f652d55">649.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief533155274145c69d708e96345ddceb_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzctNy0xLTEtMA_f737688e-cf5c-444e-b8e7-9ec566e90a1d">681.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f70ec669814c3ab99525a8689c1d52_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzgtMS0xLTEtMA_97bf2ca2-c207-4bf4-9dd8-77b08a236f69">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc1cfae314f4bd3add26a155e7e540f_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzgtMy0xLTEtMA_08edc223-f922-4ac8-a8c0-f5d6dc9d5706">50.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i542fad3dce5840d59dc96ad7e51d6df1_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzgtNS0xLTEtMA_660f719d-31fe-4fb9-a771-46e41798061c">147.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2819d470f954f05969b485651250dea_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzgtNy0xLTEtMA_b0e88b4c-85da-429f-b8de-ccea18b2c0d0">123.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total home health and hospice</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzktMS0xLTEtMA_2dacb7bb-a322-49bf-9afc-e24f6ee07d86">274.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzktMy0xLTEtMA_eedba53f-b0a2-4e52-99ad-ff0617329424">289.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzktNS0xLTEtMA_3ae8c3d5-a11d-468f-a87f-31442c6ac087">796.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzktNy0xLTEtMA_e996fa01-f92c-4800-9d2d-671a10e841aa">804.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net operating revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzEwLTEtMS0xLTA_b137b368-286c-488c-8249-77ce550c6b45">1,173.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzEwLTMtMS0xLTA_87d5e1ec-bbd6-4979-9580-ed662c39d021">1,161.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzEwLTUtMS0xLTA_06cf4528-5d76-4718-87b3-3ed1b1748c4d">3,430.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzEwLTctMS0xLTA_f39725d4-f6fd-43e3-bea2-b6a55ef17c13">3,420.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) relates to Encompass Health Corporation and its subsidiaries and should be read in conjunction with our condensed consolidated financial statements included under Part&#160;I, Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report. In addition, the following MD&amp;A should be read in conjunction with our audited consolidated financial statements for the year ended December&#160;31, 2019, Part II, Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed on February&#160;27, 2020 (collectively, the &#8220;2019 Form 10&#8209;K&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This MD&amp;A is designed to provide the reader with information that will assist in understanding our condensed consolidated financial statements, the changes in certain key items in those financial statements from period to period, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our condensed consolidated financial statements. See &#8220;Cautionary Statements Regarding Forward-Looking Statements&#8221; on page ii of this report for a description of important factors that could cause actual results to differ from expected results. See also Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report and to the 2019 Form 10&#8209;K.</span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_151"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Business</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a national leader in integrated healthcare services, offering both facility-based and home-based patient care through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. As of September&#160;30, 2020, our national footprint includes 39 states and Puerto Rico. As discussed in this Item, &#8220;Segment Results of Operations,&#8221; we manage our operations in two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. For additional information about our business, see Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated and discharged, revenues, and number of hospitals. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. We operate hospitals in 36 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. As of September&#160;30, 2020, we operate 136 inpatient rehabilitation hospitals and manage three inpatient rehabilitation units through management contracts. Our inpatient rehabilitation segment represents approximately 77% of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three and nine months ended September&#160;30, 2020.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health business is the nation&#8217;s fourth largest provider of Medicare-certified skilled home health services in terms of revenues. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Our hospice business is the nation&#8217;s eleventh largest provider of Medicare-certified hospice services in terms of revenues. We provide hospice services to terminally ill patients and their families that address patients&#8217; physical needs, including pain control and symptom management, and to provide emotional and spiritual support. As of September&#160;30, 2020, we provide home health services in 242 locations and provide hospice services in 83 locations across 31 states, with concentrations in the Southeast and Texas. In addition, one of these home health agencies operates as a joint venture that we account for using the equity method of accounting. Our home health and hospice segment represents approximately 23% of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three and nine months ended September&#160;30, 2020.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Overview</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the three and nine months ended September&#160;30, 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased 1.1% and 0.3%, respectively, over the same periods of 2019 due primarily to favorable pricing in the inpatient rehabilitation segment partially offset by decreased volumes in both segments and a pricing decrease in the home health and hospice segment. See &#8220;Results of Operations&#8221; and the &#8220;Segment Results of Operations&#8221; sections of this Item for additional volume and pricing information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our growth efforts thus far in 2020 related to our inpatient rehabilitation segment have included the following:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 50-bed inpatient rehabilitation hospital in Murrieta, California in February 2020;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating a 40-bed inpatient rehabilitation hospital in Coralville, Iowa with our joint venture partner, University of Iowa&#160;Health Care, in June 2020;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in Sioux Falls, South Dakota in June 2020;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued our capacity expansions by adding 89 new beds to existing hospitals; and</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announced or continued the development of the following hospitals:</span></div><div style="margin-bottom:15pt;margin-top:5pt;padding-left:22.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:35.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of New Beds  </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">De novos:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toledo, Ohio</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumming, Georgia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Tampa, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockbridge, Georgia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greenville, South Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pensacola, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shreveport, Louisiana</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waco, Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libertyville, Illinois</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St. Augustine, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lakeland, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clermont, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Naples, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cape Coral, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacksonville, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint ventures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Angelo, Texas</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Knoxville, Tennessee</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain development projects may be delayed due to the COVID-19 pandemic.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continued our growth efforts in our home health and hospice segment. We acquired one home health location in Lynchburg, Virginia and began accepting patients at our home health location in Sebring, Florida and our new hospice location in Allen, Texas.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We continued our shareholder distributions during the nine months ended September&#160;30, 2020 by paying a quarterly cash dividend of $0.28 per share on our common stock in January, April, July, and October. On October 20, 2020, our board of directors declared a cash dividend of $0.28 per share, payable on January 15, 2021 to stockholders of record on January 4, 2021. In addition, prior to mid-March 2020, we repurchased 0.1 million shares of our common stock in the open market for approximately $4.9 million. For additional information see the &#8220;Liquidity and Capital Resources&#8221; section of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The rapid onset of the COVID-19 outbreak in the United States has resulted in significant changes to our operating environment. The willingness and ability of patients to seek healthcare services has been negatively affected by restrictive measures, such as travel bans, social distancing, quarantines, and shelter-in-place orders. Elective procedures have been postponed by physicians and acute-care hospitals and limited by governmental order to preserve capacity for the expected volume of COVID-19 patients and reduce the risk of the spread of COVID-19. Patients recovering from elective surgeries have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">historically represented approximately 15% of our home health admissions.&#160;While not a significant percentage of our inpatient rehabilitation population, we treat patients recovering from elective surgery with multiple comorbidities that qualify for inpatient rehabilitation care. It is also believed that many in need of treatment for more severe medical conditions chose not to seek care because of fear of infection. These changes to the healthcare environment, along with the factors noted in the &#8220;Results of Operations&#8221; section of this Item, caused decreased patient volumes in both our inpatient rehabilitation and home health and hospice segments beginning in mid-March and continuing into the second and third quarters. We are also experiencing supply chain disruptions as a result of the COVID-19 pandemic, including increased procurement timelines. We have experienced and are likely to continue to experience significant price increases in medical supplies, particularly personal protective equipment (&#8220;PPE&#8221;). Beginning in March 2020, we experienced increased supply expenses due to higher utilization of PPE and increased purchasing of other medical supplies and cleaning and sanitization materials. The federal government began to undertake numerous legislative and regulatory initiatives designed to provide relief to the healthcare industry during the COVID-19 pandemic as described below in the &#8220;Key Challenges&#8221; section. These initiatives have given our hospitals and agencies the types of enhanced flexibilities they need to care for our patients and assist acute-care hospitals in maintaining hospital capacity in the current environment. The COVID-19 pandemic is still rapidly evolving and much of its impact remains unknown and difficult to predict, with the impact on our operations and financial performance being dependent on numerous factors, including the ongoing nature of the COVID-19 pandemic, such as its rate of spread, duration, and geographic coverage; the status of testing capabilities, and the development of vaccines and other therapeutic remedies; the legal, regulatory, and administrative developments related to the pandemic at federal, state, and local levels, such as shelter-in-place orders, facility closures and quarantines; and our infectious disease prevention and control efforts.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the operating environment for healthcare providers is continuously changing during this pandemic, we have taken the following steps to ensure the safety and well-being of our patients and employees:</span></div><div style="margin-bottom:15pt;margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:476.25pt"><tr><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:460.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Staying current with the Centers for Disease Control and Prevention&#8217;s (the &#8220;CDC&#8221;) guidance on testing and the use of PPE, which is frequently updated</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limiting visitors in our hospitals</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Screening everyone entering our hospitals and self-screening all home health and hospice employees</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performing pre-visit telephone calls to assess risk factors within the home, including patient and caregiver health status</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Following social distancing recommendations in our therapy gyms and performing therapy in patient rooms, if needed</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suspended most of the hospital-based outpatient services (we have resumed these services at some locations)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implemented work-at-home policies for home office and certain field personnel</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Halted all non-essential travel</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also continue to take actions to enhance our operational and financial flexibility and ensure our long-term sustainability. Our executive team voluntarily reduced their base compensation for six months. In addition, we have: </span></div><div style="margin-bottom:15pt;margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:476.25pt"><tr><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:460.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">secured secondary sources of PPE and other medical supplies, at times paying premium prices;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">aligned staffing with patient demand;</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">amended our senior credit facility in April 2020 (primarily provided covenant relief due to disruptions from the COVID-19 pandemic);</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">issued an additional $300 million of our 4.50% Senior Notes due 2028 (the &#8220;2028 Notes&#8221;) and an additional $300 million of our 4.75% Senior Notes due 2030 (the &#8220;2030 Notes&#8221;) in May 2020;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">issued $400 million of 4.625% Senior Notes due 2031 (the &#8220;2031 Notes&#8221;) in October 2020;</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">issued notice for redemption of all $700&#160;million in outstanding principal amount of the 5.75% Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) that will settle on November 1, 2020;</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">developed plans for reducing capital expenditures; and</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">not purchased any shares under our authorized share repurchase program since mid-March.</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After lengthy consideration, we developed plans to manage labor costs in response to lower patient volumes via furloughs, changes to compensation structures and workforce reductions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Outlook</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding the current impacts from the COVID-19 pandemic, we remain optimistic regarding the intermediate and long-term prospects for both of our business segments. Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide. While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future. Even more specifically, the average age of our patients is approximately 76, and the population group ranging in ages from 75 to 79 is expected to grow at approximately 5% per year through 2026. We believe the demand for the services we provide will continue to increase as the U.S. population ages. We believe these factors align with our strengths in, and focus on, post-acute services. In addition, we believe we can address the demand for facility-based and home-based post-acute care services in markets where we currently do not have a presence by constructing or acquiring new hospitals and by acquiring or opening home health and hospice agencies in those extremely fragmented industries.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading provider of integrated healthcare services, offering both facility-based and home-based patient care through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We are committed to delivering high-quality, cost-effective, integrated patient care across the healthcare continuum with a primary focus on the post-acute sector. As the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated and discharged, revenues, and number of hospitals, we believe we differentiate ourselves from our competitors based on the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology. As the fourth largest provider of Medicare-certified skilled home health services in terms of revenues, we believe we differentiate ourselves from our competitors by the application of a highly integrated technology platform, our ability to manage a variety of care pathways, and a proven track record of consummating and integrating acquisitions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Although the healthcare industry is currently engaged in addressing the healthcare crisis caused by the COVID-19 pandemic, the industry also faces the prospect of ongoing efforts to transform the healthcare system to coordinated care delivery and payment models. The nature, timing and extent of that transformation remains uncertain, as the development and implementation of new care delivery and payment systems will require significant time and resources. Our short-term goal is to serve our communities and provide the best care possible during the COVID-19 pandemic. Our long-term goal is to position the Company in a prudent manner to be responsive to industry shifts. We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis. We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2023. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate and significant availability under our revolving credit facility. For these and other reasons, we believe we will be able to adapt to changes in reimbursement, sustain our business model, and grow through acquisition and consolidation opportunities as they arise. See also Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Competitive Strengths&#8221; and &#8220;Strategy and 2020 Strategic Priorities&#8221; in the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key Challenges</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare is a highly-regulated industry facing many well-publicized regulatory and reimbursement challenges. The industry also is facing uncertainty associated with the efforts to identify and implement workable coordinated care and integrated delivery payment models as well as post-acute site neutrality in Medicare reimbursement. The Medicare reimbursement systems for both inpatient rehabilitation and home health are undergoing significant changes. The future of many aspects of healthcare regulation remains uncertain. Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care. We believe we have the necessary capabilities &#8212; change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities &#8212; to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so. For a detailed discussion of the challenges we face, see Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview-Key Challenges&#8221; to the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to execute our business plan, the following are some of the challenges we face.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Operating in a Highly Regulated Industry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. More specifically, because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters could materially and adversely affect us. These rules and regulations have affected, or could in the future affect, our business activities by having an impact on the reimbursement we receive for services provided or the costs of compliance, mandating new documentation standards, requiring additional licensure or certification, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and limiting our ability to enter new markets or add new capacity to existing hospitals and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agencies. Ensuring continuous compliance with extensive laws and regulations is an operating requirement for all healthcare providers. See Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulation,&#8221; Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges,&#8221; to the 2019 Form 10&#8209;K for detailed discussions of the most important regulations we face and our programs intended to ensure we comply with those regulations.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare Administrative Contractors (&#8220;MACs&#8221;), under programs known as &#8220;widespread probes&#8221;, have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute or &#8220;appeal&#8221; most of these denials, and for claims we choose to take to administrative law judge (&#8220;ALJ&#8221;) hearings, we have historically  experienced a success rate of 70%. This historical success rate is a component of our estimate of transaction price utilized in determining </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. If current OHMA practices continue, an increased number of unfavorable ALJ decisions could have a negative effect on our long-term ALJ success rate. We are exploring various remedies to counter such negative effects. We believe it is too early to determine what impact, if any, these recent changes in the appeals process will have on our historical success rate or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. For additional details, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, &#8220;Sources of Revenues,&#8221; Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, &#8220;Net Operating Revenues&#8221; and &#8220;Accounts Receivable,&#8221; to the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Changes to Our Operating Environment Resulting from the COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As discussed above, the COVID-19 pandemic has resulted in significant changes to our operating environment. In March 2020, the federal government began to undertake numerous legislative and regulatory initiatives designed to provide relief to the healthcare industry during the COVID-19 pandemic. </span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Temporary suspension of the automatic 2% reduction of Medicare program payments, known as &#8220;sequestration&#8221;</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2011, President Obama signed into law the Budget Control Act of 2011, which provided for an automatic 2% reduction of Medicare program payments for all healthcare providers. This automatic reduction, known as &#8220;sequestration,&#8221; began affecting payments received after April 1, 2013 and, as a result of subsequent legislation, will continue through fiscal year 2030. On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;), which temporarily suspends the automatic 2% reduction of Medicare claim reimbursements for the period of May 1 through December 31, 2020. At this time, we cannot reasonably estimate the total impact of the suspension of sequestration on our revenues due to the ongoing volume volatility in both segments (see &#8220;Results of Operations&#8221; section of this Item). Through September 30, 2020, the impact of the suspension of sequestration on our inpatient rehabilitation and home health and hospice revenues was $21.9 million and $8.6 million, respectively. </span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution of relief funds directly to healthcare providers</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also authorized the cash distribution of relief funds from the Department of Health and Human Services (&#8220;HHS&#8221;) to healthcare providers. On April 10, 2020, HHS began distributing CARES Act relief funds, for which we did not apply, to various of our bank accounts. We refused the CARES Act relief funds, and our banks returned all the funds to HHS. We intend to refuse any additional CARES Act relief funds distributed in the future.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Temporary suspension of certain patient coverage criteria and documentation and care requirements</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act and a series of waivers and guidance issued by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) suspend various Medicare patient coverage criteria and documentation and care requirements until the public health emergency for the COVID-19 pandemic has ended. These efforts to provide regulatory relief help to ensure patients continue to have adequate access to care notwithstanding the burdens being placed on healthcare providers by the COVID-19 pandemic.</span></div><div style="margin-bottom:10pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Medicare pays our inpatient rehabilitation hospitals a fixed payment reimbursement amount per discharge under the inpatient rehabilitation facility prospective payment system (the &#8220;IRF-PPS&#8221;) based on the patient&#8217;s rehabilitation impairment category established by CMS and other characteristics and conditions identified by the attending clinicians. In order to qualify for reimbursement under the IRF-PPS, our hospitals must comply with various Medicare rules and regulations, including documentation and coverage </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, or specifications as to what conditions must be met to qualify for reimbursement. These requirements relate to, among other things, pre-admission screening, and individual treatment planning that all delineate the role of physicians in ordering and overseeing patient care. The CARES Act regulatory relief includes the temporary suspension of the requirement that patients must be able to tolerate a minimum of three hours of therapy per day for five days per week. Additionally, CMS has waived certain of the requirements that at least 60% of a facility&#8217;s patients must have a diagnosis from at least 1 of 13 specified medical conditions and the requirement for a physician to conduct and document a post-admission evaluation (as defined and discussed below, the 2021 Final IRF Rule removed the post-admission evaluation requirement from the inpatient rehabilitation coverage criteria effective October&#160;1, 2020). CMS has also issued a waiver to permit the rehabilitation physician to conduct face-to-face visits using telehealth.</span></div><div style="margin-bottom:10pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Medicare pays home health benefits for patients discharged from a hospital or patients otherwise suffering from chronic conditions that require ongoing but intermittent skilled care. As a condition of participation under Medicare, patients must be homebound (meaning unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, or have a continuing need for occupational therapy, and receive treatment under a plan of care established and periodically reviewed by a physician. A physician must document that he or she or a qualifying nurse practitioner has had a face-to-face encounter with the patient and then certify to CMS that a patient meets the eligibility requirements for the home health benefit. The CARES Act includes a provision allowing nurse practitioners and physician assistants under certain conditions to certify, establish and periodically review the plan of care, as well as supervise the provision of items and services for beneficiaries under the Medicare home health benefit and expands the use of telehealth. Additionally, CMS expanded the definition of &#8220;homebound&#8221; to include patients needing skilled services who are homebound due solely to their COVID-19 diagnosis or patients susceptible to contract COVID-19.</span></div><div style="margin-bottom:10pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare pays hospice benefits for patients with life expectancies of six months or less, as documented by the patient&#8217;s physician(s). Medicare hospice reimbursements to each provider are subject to a number of conditions of participation. These conditions require, among others, the use of volunteers and onsite visits to evaluate aids. Volunteers provide day-to-day administrative and/or direct patient care services in an amount that, at a minimum, equals five percent of the total patient care hours of all paid hospice employees and contract staff. A nurse or other professional conducts an onsite visit every two weeks to evaluate if aides are providing care consistent with the care plan. The CARES Act includes the temporary waiver of the requirement to use volunteers and to conduct a nurse visit every two weeks to evaluate aides, as well as the expanded use of telehealth.</span></div><div style="margin-bottom:10pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 30, 2020, CMS announced a pause of certain claims processing requirements for the Home Health Review Choice Demonstration (&#8220;RCD&#8221;) in Illinois, Ohio, and Texas until the Public Health Emergency&#160;for the COVID-19 pandemic has ended.&#160;CMS offered home health agencies the option of continuing their participation in the RCD, which we elected to do. On August 31, 2020, CMS resumed the demonstration in  Illinois, Ohio, and Texas and began phasing in participation in North Carolina and Florida. We operate agencies (representing approximately 44% of our home health Medicare claims) in these five states.</span></div><div style="margin-bottom:10pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 30, 2020, CMS also suspended most medical reviews, including pre-payment medical reviews by MACs under the Targeted Probe and Educate (&#8220;TPE&#8221;) initiative and post-payment reviews conducted by MACs, Supplemental Medical Review Contractors and Recovery Audit Contractors (&#8220;RACs&#8221;) until the Public Health Emergency&#160;for the COVID-19 pandemic has ended. On July 7, 2020, CMS announced it will discontinue exercising enforcement discretion and will allow medical reviews to resume on or after August 3, 2020. Through September 30, 2020, our MACs have not resumed reviews under TPE. Certain of our RACs have resumed post-payment reviews.</span></div><div style="margin-bottom:10pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory actions provide flexibility to our hospitals and agencies to care for patients and assist acute-care hospitals in maintaining hospital capacity during the COVID-19 pandemic when the otherwise applicable rules would likely have constrained our ability to do so.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Changes to Our Operating Environment Resulting from Healthcare Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. On August 4, 2020, CMS released its Notice of Final Rulemaking for Fiscal Year 2021 for inpatient rehabilitation facilities under the inpatient rehabilitation facility prospective payment system (the &#8220;2021 Final IRF Rule&#8221;). The 2021 Final IRF Rule implements a net 2.4% market basket increase effective for discharges between October 1, 2020 and September&#160;30, 2021. The 2021 Final IRF Rule also includes changes that impact our hospital-by-hospital base rate for Medicare reimbursement. Such changes include, but are not limited to, revisions to the wage index and labor-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related share values. The 2021 Final IRF Rule updates case-mix group relative weights and average lengths of stay values. The 2021 Final IRF Rule also removes the post-admission physician evaluation requirement for all IRF discharges beginning on or after October 1, 2020, codifies certain inpatient rehabilitation coverage documentation requirements, and, under certain conditions, allows the use of non-physician practitioners to perform the IRF services and documentation requirements for one of the three required face-to-face physician visits in a patient&#8217;s second and subsequent weeks in an IRF stay. As discussed above and in the &#8220;Results of Operations&#8221; section of the Item, the COVID-19 pandemic has significantly impacted our patient mix, and we expect this to continue for the remainder of 2020. As such, the ability to accurately estimate the impact of the 2021 Final IRF Rule is limited. Based on our analysis that utilizes, among other things, the acuity of our patients over the twelve-month period ended September 30, 2020, our experience with outlier payments over this same time frame, and other factors, we believe the 2021 Final IRF Rule will result in a net increase to our Medicare payment rates of approximately 2.3% effective October 1, 2020.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 29, 2020, CMS released its Notice of Final Rulemaking for Calendar Year 2021 for home health agencies under the home health prospective payment system (the &#8220;2021 Final HH Rule&#8221;). The 2021 Final HH Rule will implement a net 2.0% market basket increase (market basket update of 2.3% reduced by a productivity adjustment of 0.3%) and make changes to the underlying wage index system. The 2021 Final HH Rule does not implement any additional payment changes as behavioral adjustments for 2021 due to lack of data and the COVID-19 pandemic, nor does it update the case-mix weights, low-utilization payment adjustment thresholds or outlier fixed-dollar loss ratio for 2021. Making the previously temporary COVID-19 pandemic-related relief permanent, the 2021 Final HH Rule authorizes the use of telecommunications technologies in providing care to beneficiaries under the Medicare home health benefit, as long as the telecommunications technology meets certain criteria and does not replace in-person visits. We are in the process of evaluating the details of the 2021 Final HH Rule and cannot yet estimate its impact on our business, including our Medicare home health payment rates effective for 30-day payment periods ending on or after January 1, 2021.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Maintaining Strong Volume Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to the factors described in our 2019 Form 10&#8209;K and as discussed above, beginning in March, we experienced significant volume decreases in both segments which we believe resulted from a number of conditions related to the COVID-19 pandemic as discussed in the &#8220;Results of Operations&#8221; section of this Item. While most of our markets have substantially recovered, a current or future resurgence of COVID-19 infections could cause disruptions to our volume growth.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Recruiting and Retaining High-Quality Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the 2019 Form 10&#8209;K for a discussion of competition for staffing, shortages of qualified personnel, and other factors that may increase our labor costs. Additionally, our operations have been affected and may in the future be affected by staffing shortages where employees must self-quarantine due to exposure to COVID-19 or where employees are unavailable due to a lack of childcare or care for elderly family.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain confident in the prospects of both of our business segments based on the increasing demands for the services we provide to an aging population. This confidence is further supported by our strong financial foundation and the substantial investments we have made in our businesses. We have a proven track record of working through difficult situations, and we believe in our ability to overcome current and future challenges.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor Mix</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derived consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the following payor sources:</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Medicare as a percentage of revenue decreased during the three and nine months ended September 30, 2020 as compared to the same periods of 2019 primarily due to the COVID-19 pandemic, as discussed below. Within the inpatient rehabilitation segment, Medicare Advantage as a percentage of revenue increased during the three and nine months ended September 30, 2020 as compared to the same periods of 2019 due in part from suspension of prior authorization requirements. For additional discussion by segment, see the &#8220;Segment Results of Operations&#8221; section of this Item.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our payors, see the &#8220;Sources of Revenues&#8221; section of Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the 2019 Form 10&#8209;K. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Results</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020 and 2019, our consolidated results of operations were as follows:</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Percentage Change)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,890.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income tax expense </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Encompass Health</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses as a % of Net Operating Revenues</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the discussion that follows, we use &#8220;same-store&#8221; comparisons to explain the changes in certain performance metrics and line items within our financial statements. We calculate same-store comparisons based on hospitals and home health and hospice locations open throughout both the full current periods and prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on our results of operations. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Operating Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased in the three and nine months ended September&#160;30, 2020 over the same periods of 2019 primarily due to favorable pricing in our inpatient rehabilitation segment partially offset by decreased volumes in both segments and a pricing decrease in the home health and hospice segment. See additional discussion in the &#8220;Segment Results of Operations&#8221; section of this Item. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January and February 2020, both segments were exhibiting strong year-over-year volume growth. Beginning in mid-March, we experienced decreased volumes in both segments which we believe resulted from a number of conditions related to the COVID-19 pandemic including: lower acute-care hospital censuses due to the deferral of elective surgeries and shelter-in-place orders, restrictive visitation policies in place at acute-care hospitals that severely limit access to patients and caregivers by our clinical rehabilitation liaisons and care transition coordinators, lock down of assisted living facilities, and heightened anxiety among patients and their family members regarding the risk of exposure to COVID-19 during acute-care and post-acute care treatment. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inpatient rehabilitation patient census and home health starts of episodes reached a low point the week ended April 12 (Easter weekend). By the end of the third quarter of 2020, volumes in both of our segments had substantially recovered although we continue to experience COVID-related challenges in certain geographic markets. The states of Florida and Texas are current examples of this where we have concentrations in both segments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Salaries and Benefits</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we initiated a program for eligible frontline employees to earn additional paid time off in recognition of their outstanding efforts responding to the COVID-19 pandemic. With more than 21,000 employees potentially benefiting from this additional paid time off, we accrued approximately $43 million in salary and benefits expense in the second quarter of 2020 in connection with this award (approximately $29 million in the inpatient rehabilitation segment; approximately $14 million in the home health and hospice segment).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in terms of dollars and as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased during the nine months ended September&#160;30, 2020 compared to the same period of 2019 primarily due to salary increases for our employees, the award of additional PTO to employees in response to the COVID-19 pandemic as discussed above, the ramp up of new stores, and declining employee productivity during the second quarter of 2020 due to the impact of the COVID-19 pandemic. See additional discussion in the &#8220;Segment Results of Operations&#8221; section of this Item.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries and benefits are expected to increase in the fourth quarter of 2020 due to an approximate 2.75% merit increase provided to our nonmanagement hospital employees effective in October 2020.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 primarily due to the COVID-19 pandemic related impact on patient volumes and increased lab costs, offset by lower travel and entertainment costs. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supplies</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in terms of dollars and as a percent of revenue during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 primarily due to increased utilization and cost of medical supplies, including PPE, due to the COVID-19 pandemic. We expect to continue to see increased utilization and cost of medical supplies in 2020 as a result of the COVID-19 pandemic.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased in terms of dollars and as a percent of revenue during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily due to decreased expenses associated with stock appreciation rights. For additional information on stock appreciation rights, see Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the accompanying condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, and Note&#160;14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the consolidated financial statements accompanying the 2019 Form 10&#8209;K. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Depreciation and Amortization</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 due to our capital investments.</span></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Expense and Amortization of Debt Discounts and Fees</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 primarily resulted from the issuances of our 2028 Notes and 2030 Notes in September 2019 and May 2020 partially offset by the November 2019 redemption of our 5.75% Senior Notes due 2024. For additional information, see Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Income</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 primarily due to the $19.2 million gain resulting from our consolidation of Yuma Rehabilitation Hospital and the remeasurement of our previously held equity interest at fair value in July 2019. See Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Consolidation,&#8221; to the condensed consolidated financial statements included in Part I, Item 1,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income from Continuing Operations Before Income Tax Expense</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pre-tax income from continuing operations decreased during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 primarily due to the decrease in earnings, as discussed in the &#8220;Segment Results of Operations&#8221; section of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provision for Income Tax Expense</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 primarily due to lower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income from continuing operations before income tax expense.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently estimate our cash payments for income taxes to be approximately $45 million to $65 million, net of refunds, for 2020. These payments are expected to primarily result from federal and state income tax expenses based on estimates of taxable income for 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain jurisdictions, we do not expect to generate sufficient income to use all of the available state net operating losses and other credits prior to their expiration. This determination is based on our evaluation of all available evidence in these jurisdictions including results of operations during the preceding three years, our forecast of future earnings, and prudent tax planning strategies. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable tax jurisdiction, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the financial statement effects of uncertain tax positions when it is more likely than not, based on the technical merits, a position will be sustained upon examination by and resolution with the taxing authorities. Total remaining unrecognized tax benefits were $0.2 million and $0.4 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report and Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_157"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. For additional information regarding our business segments, including a detailed description of the services we provide, financial data for each segment, and a reconciliation of total </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segment Adjusted EBITDA to income from continuing operations before income tax expense, see Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inpatient rehabilitation segment derived its</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the following payor sources:</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed above, Medicare Advantage as a percentage of revenue increased during the three and nine months ended September&#160;30, 2020 as compared to the same periods of 2019 due in part from suspension of prior authorization requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding our inpatient rehabilitation segment&#8217;s operating results for the three and nine months ended September&#160;30, 2020 and 2019 is as follows:</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Percentage Change)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,581.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient rehabilitation segment revenues</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Actual Amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discharges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient revenue per discharge</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient visits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average length of stay (days)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy %</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"># of licensed beds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full-time equivalents*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees per occupied bed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Full-time equivalents included in the above table represent our employees who participate in or support the operations of our hospitals and exclude an estimate of full-time equivalents related to contract labor.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage the productive portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing certain metrics, including employees per occupied bed, or &#8220;EPOB.&#8221; This metric is determined by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by our occupancy percentage.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:45pt;text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses as a % of Net Operating Revenues</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Operating Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inpatient revenue increased during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 primarily due to favorable pricing partially offset by decreased volumes.</span><span style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Same-store discharges declined 2.8% and 4.5% during the three and nine months ended September&#160;30, 2020, respectively, compared to the same periods of 2019 primarily due to the COVID-19 pandemic. Discharge growth from new stores during the three months ended September&#160;30, 2020 resulted from our joint ventures in Boise, Idaho (July 2019) and Coralville, Iowa (June 2020) and wholly owned hospitals in Katy, Texas (September 2019), Murrieta, California (February 2020) and Sioux Falls, South Dakota (June 2020). Discharge growth from new stores during the nine months ended September&#160;30, 2020 also resulted from our joint venture in Lubbock, Texas (May 2019) and a joint venture hospital in Yuma, Arizona changing from the equity method of accounting to a consolidated entity effective July 1, 2019. Growth in net patient revenue per discharge during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 primarily resulted from a higher acuity patient mix and the temporary suspension of sequestration starting in May 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in outpatient and other revenue during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 resulted from the COVID-19 pandemic related suspension of hospital-based outpatient services in mid-March 2020 and the closure of certain hospital-based outpatient programs in 2019. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in and Advances to Nonconsolidated Affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K for information regarding the joint ventures discussed above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjusted EBITDA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Adjusted EBITDA during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 primarily resulted from COVID-19 pandemic related impacts on patient volumes and medical supplies as discussed above. The decrease in Adjusted EBITDA during the nine months ended September&#160;30, 2020 compared to the same period of 2019 was also impacted by the award of additional paid time off to employees in response to the COVID-19 pandemic, as discussed above, plus the ramp up of new stores. Higher expense trends resulting from the COVID-19 pandemic, as discussed above, have continued into October and could lead to a reduction in inpatient rehabilitation segment Adjusted EBITDA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health and hospice segment derived its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the following payor sources:</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding our home health and hospice segment&#8217;s operating results for the three and nine months ended September&#160;30, 2020 and 2019 is as follows:</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:35.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Percentage Change)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home health and hospice segment revenues</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services sold (excluding depreciation and amortization)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="33" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Actual Amounts)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home health:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recertifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Episodes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per episode</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Episodic visits per episode</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total visits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,857,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,059,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost per visit</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient days</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:45pt;text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses as a % of Net Operating Revenues</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services sold (excluding depreciation and amortization)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Operating Revenues</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The decline in home health revenue during the three months and nine months ended September&#160;30, 2020 compared to the same periods of 2019 was primarily driven by decreased volumes and pricing. Same-store admissions declined 4.6% and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.9% during the three and nine months ended September&#160;30, 2020, respectively, compared to the same periods of 2019 primarily due to the COVID-19 pandemic. New-store admissions growth for the three months ended September&#160;30, 2020 primarily resulted from one acquired location in Virginia (Q1 2020) and one de novo location in Florida (Q2 2020). New-store admissions growth for the nine months ended September&#160;30, 2020 primarily resulted from the acquisition of Alacare on July 1, 2019. Revenue per episode during the three and nine months ended September&#160;30, 2020 compared to the same periods of 2019 was negatively impacted by the implementation of the Patient Driven Groupings Model (the &#8220;PDGM&#8221;) on January 1, 2020, the effects of which were exacerbated by the COVID-19 pandemic, offset by the temporary suspension of sequestration starting in May 2020.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Hospice same-store admissions growth of 15.8% yielded a 1.6% increase in hospice revenue during the three months ended September&#160;30, 2020 compared to the same period of 2019. Hospice revenue growth was impacted by a decrease in length of stay resulting from a change in patient mix. The percentage of our referrals from institutional settings increased while the percentage of referrals from senior living facilities decreased. Hospice revenue increased during the nine months ended September 30, 2020 compared to the same period of 2019 primarily due to the acquisition of Alacare on July 1, 2019.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K for information regarding the acquisition discussed above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjusted EBITDA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Adjusted EBITDA during the three months ended September&#160;30, 2020 compared to the same period of 2019 resulted from a decrease in cost of services as a percent of revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased as percent of revenues for the three months ended September&#160;30, 2020 compared to the same period of 2019 primarily due to changes in the clinician compensation structure implemented in May 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Support and overhead costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percent of revenues for the three months ended September&#160;30, 2020 compared to the same period of 2019 increased primarily due to an increase in sales force full-time equivalents and increased administrative costs associated with the implementation of PDGM and the RCD program, as well as a decline in the revenue base.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Adjusted EBITDA during the nine months ended September&#160;30, 2020 compared to the same period of 2019 resulted from COVID-19 pandemic related impacts on patient volume as discussed above, a decrease in Medicare reimbursement rates primarily related to the implementation of PDGM, and an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Support and overhead costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a percent of revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percent of revenues for the nine months ended September&#160;30, 2020 compared to the same period of 2019 increased primarily due to COVID-19 pandemic related impacts on patient volumes, staff productivity and medical supplies, as well as the award of additional paid-time-off to employees in response to the COVID-19 pandemic. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Support and overhead costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percent of revenues for the nine months ended September&#160;30, 2020 compared to the same period of 2019 increased due to the same factors as discussed above for the third quarter of 2020.  Higher expense trends resulting from the COVID-19 pandemic, as discussed above, have continued into October and could lead to a reduction in home health and hospice segment Adjusted EBITDA.</span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_160"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash on hand, cash flows from operations, and borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objectives of our capital structure strategy are to ensure we maintain adequate liquidity and flexibility. Pursuing and achieving those objectives allow us to support the execution of our operating and strategic plans and weather temporary disruptions in the capital markets and general business environment. Maintaining adequate liquidity is a function of our unrestricted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our available borrowing capacity. Maintaining flexibility in our capital structure is a function of, among other things, the amount of debt maturities in any given year, the options for debt prepayments without onerous penalties, and limiting restrictive terms and maintenance covenants in our debt agreements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further enhance our liquidity and ensure availability under our credit agreement, in April 2020, we amended our credit agreement primarily to provide covenant relief due to business disruptions from the COVID-19 pandemic. The amendment included, among other things, the carve-out of the COVID-19 pandemic from the definition of material adverse effect for 364 days and modifications to the interest coverage and leverage ratios under the agreement. In May 2020, we issued an additional $300 million of our existing 2028 Notes at a price of 99.0% of the principal amount and an additional $300 million of our existing 2030 Notes at a price of 98.5% of the principal amount, which resulted in approximately $583 million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In October 2020, we issued $400&#160;million aggregate principal amount of 2031 Notes. Also in October 2020, we issued notice for redemption of all $700&#160;million in outstanding principal amount of the 2024 Notes. Pursuant to the terms of the 2024 Notes, this full redemption will settle on November 1, 2020 and will be made at a price of par. We plan to use the net proceeds from the 2031 Notes offering together with cash on hand to fund the redemption. We expect to record an approximate $2&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> in the fourth quarter of 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2023. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and we have significant availability under our revolving credit facility. We continue to generate cash flows from operations and we have significant flexibility with how we choose to invest our cash and return capital to shareholders.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current Liquidity</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had $450.0 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;This amount excludes $78.1&#160;million in restricted cash ($57.2 million included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $20.9 million included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our condensed consolidated balance sheet) and $73.9 million of restricted marketable securities (included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our condensed consolidated balance sheet). Our restricted assets pertain primarily to obligations associated with our captive insurance company, as well as obligations we have under agreements with joint venture partners. See Note&#160;4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Marketable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as of September&#160;30, 2020, we had approximately $964 m</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">illion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> available to us under our revolving credit facility. Our credit agreement governs the substantial majority of our senior secured borrowing capacity and contains a leverage ratio and an interest coverage ratio as financial covenants. Our leverage ratio is defined in our credit agreement as the ratio of consolidated total debt (less up to $300 million of cash on hand) to Adjusted EBITDA for the trailing four quarters. In calculating the leverage ratio under our credit agreement, we are permitted to use pro forma Adjusted EBITDA, the calculation of which includes historical income statement items and pro forma adjustments resulting from (1) the dispositions and repayments or incurrence of debt and (2) the investments, acquisitions, mergers, amalgamations, consolidations and operational changes from acquisitions to the extent such items or effects are not yet reflected in our trailing four-quarter financial statements. Our interest coverage ratio is defined in our credit agreement as the ratio of Adjusted EBITDA to consolidated interest expense, excluding the amortization of financing fees, for the trailing four quarters. As of September&#160;30, 2020, the maximum leverage ratio requirement per our credit agreement was 5.50x and the minimum interest coverage ratio requirement was 2.0x, and we were in compliance with these covenants. Based on Adjusted EBITDA for the trailing four quarters and the interest rate in effect under our credit agreement during the three-month period ended September&#160;30, 2020, if we had drawn on the first day and maintained the maximum amount of outstanding draws under our revolving credit facility for that entire period, we would still be in compliance with the maximum leverage ratio and minimum interest coverage ratio requirements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not face near-term refinancing risk, as the amounts outstanding under our credit agreement do not mature </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our bonds all mature in 2023 and beyond. See the &#8220;Contractual Obligations&#8221; section below for information related to our contractual obligations as of September&#160;30, 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired a significant portion of our home health and hospice business when we purchased EHHI Holdings, Inc (&#8220;EHHI&#8221;) on December 31, 2014. In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#8220;Holdings&#8221;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $64 million on the acquisition date, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair value. The fair value was determined using the product of the trailing twelve-month adjusted EBITDA measure for Holdings and a specified median market price multiple based on a basket of public home health companies and transactions, after adding cash and deducting indebtedness that included the outstanding principal balance under any intercompany notes. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $65 million in cash. In July 2019, we received additional exercise notices, representing approximately 5.6% of the outstanding shares of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock of Holdings. In September 2019, Encompass Health settled the acquisition of those shares upon payment of approximately $163 million in cash. As of December&#160;31, 2019, the fair value of those outstanding shares of Holdings owned by management investors was approximately $208 million. In January 2020, we received additional exercise notices, representing approximately 4.3% of the outstanding shares of the common stock of Holdings. In February 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $162 million in cash. Upon settlement of these exercises, approximately $46 million of the shares of Holdings held by two management investors remained outstanding. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#8220;Exchange Agreement&#8221;) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#8220;EHC Shares&#8221;). Each of the Exchange Agreements provided that the management investor must deliver a written exchange notice (an &#8220;Exchange Notice&#8221;) to Encompass Health in order to exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#8217;s common stock on the New York Stock Exchange (the &#8220;NYSE&#8221;) on the date of delivery of the Exchange Notice.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors. Based on the last sales price of Encompass Health&#8217;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate 560,957 EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than 0.6% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares. Encompass Health now owns 100% of Holdings and EHHI. See also Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the EHHI acquisition, we granted stock appreciation rights (&#8220;SARs&#8221;) based on Holdings common stock to certain members of EHHI management at closing. Half of the SARs vested on December&#160;31, 2018 and the remainder vested on December 31, 2019. Upon exercise, each SAR must be settled for cash in the amount by which the per share fair value of Holdings&#8217; common stock on the exercise date exceeds the per share fair value on the grant date. As of December 31, 2019, the fair value of the remaining 115,545 SARs was approximately $101 million, all of which was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated balance sheet. In January 2020, members of the management team exercised the remaining SARs and in February 2020, we settled those awards upon payment of approximately $101 million in cash. See also Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of risks and uncertainties facing us see Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under Part II, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report and Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources and Uses of Cash </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cash flows provided by or used in operating, investing, and financing activities for the nine months ended September&#160;30, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the nine months ended September&#160;30, 2020 compared to the same period of 2019 primarily resulted from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timing of and increase in payroll accruals offset by a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to the impact of the COVID-19 pandemic on our operations (see the &#8220;Results of Operations&#8221; section of this Item). The increase in payroll accruals was attributable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the award of additional PTO to employees during the second quarter of 2020 in response to the COVID-19 pandemic and the deferral of payroll taxes resulting from government relief efforts during the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The de</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">crease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the nine months ended September&#160;30, 2020 compared to the same period of 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily resulted from the acquisition of Alacare during the third quarter of 2019. See Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by financing activities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the nine months ended September&#160;30, 2020 compared to the same period of 2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily resulted from the public offering of $1.0 billion of senior notes in September 2019 offset by higher cash used for principal payments on net debt and repurchases of common stock during 2019. For additional information, see Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated contractual obligations as of September&#160;30, 2020 are as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">October 1 through December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 - 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 - 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 and thereafter </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, excluding revolving credit facility and finance lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,204.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)(g)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,155.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Included in long-term debt are amounts owed on our bonds payable and other notes payable. These borrowings are further explained in Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, accompanying the condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Interest on our fixed rate debt is presented using the stated interest rate. Interest expense on our variable rate debt is estimated using the rate in effect as of September&#160;30, 2020. Interest pertaining to our credit agreement and bonds is included to their respective ultimate maturity dates. Interest related to finance lease obligations is excluded from this line. Amounts exclude amortization of debt discounts, amortization of loan fees, or fees for lines of credit that would be included in interest expense in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Amounts include interest portion of future minimum finance lease payments.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our inpatient rehabilitation segment leases approximately 13% of its hospitals as well as other property and equipment under operating leases in the normal course of business. Our home health and hospice segment leases relatively small office spaces in the localities it serves, space for its corporate office, and other equipment under operating leases in the normal course of business. Amounts include interest portion of future minimum operating lease payments. For more information, see Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on Encompass Health and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty. Our purchase obligations primarily relate to software licensing and support and medical equipment. Purchase obligations are not recognized in our condensed consolidated balance sheet.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Because their future cash outflows are uncertain, the following noncurrent liabilities are excluded from the table above: general liability, professional liability, and workers' compensation risks, noncurrent amounts related to third-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">party billing audits, and deferred income taxes. For more information, see Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2019 Form 10&#8209;K and Note&#160;8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements included in Part&#160;I, Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above does not include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $34.0 million because of the uncertainty surrounding the timing and amounts of any related cash outflows. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital expenditures include costs associated with our hospital refresh program, de novo projects, capacity expansions, technology initiatives, and building and equipment upgrades and purchases. During the nine months ended September&#160;30, 2020, we made capital expenditures of approximately $265 million for property and equipment, capitalized software, and other intangible assets. These expenditures are exclusive of approximately $1 million in net cash related to our acquisition activity. During 2020, we expect to spend approximately $410 million to $450 million for capital expenditures. Approximately $155 million to $165 million of this budgeted amount is considered nondiscretionary expenditures, which we may refer to in other filings as &#8220;maintenance&#8221; expenditures. Actual amounts spent will be dependent upon the timing of development projects and acquisition opportunities for our home health and hospice business.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Authorizations for Returning Capital to Stakeholders</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, February 2020, May 2020 and July 2020, our board of directors declared cash dividends of $0.28 per share that were paid in January 2020, April 2020, July 2020, and October 2020, respectively.</span><span style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2020, our board of directors declared a cash dividend of $0.28 per share, payable on January 15, 2021 to stockholders of record on January 4, 2021. We expect quarterly dividends to be paid in January, April, July, and October. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our board of directors after consideration of various factors, including our capital position and alternative uses of funds. Cash dividends are expected to be funded using cash flows from operations, cash on hand, and availability under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2014, our board of directors approved an increase in our existing common stock repurchase authorization from $200 million to $250 million. On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million. As of September&#160;30, 2020, approximately $199 million remained under this authorization. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule&#160;10b5-1 under the Securities Exchange Act of 1934, as amended. In the first quarter of 2020 prior to mid-March, we repurchased 0.1 million shares of our common stock in the open market for approximately $4.9 million under this repurchase authorization using cash on hand. From mid-March through the end of the third quarter, in response to the uncertainty resulting from the COVID-19 pandemic, we have not purchased any shares under this repurchase authorization.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental Guarantor Financial Information</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:6.75pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness under our credit agreement and the 5.125% Senior Notes due 2023, 5.75% Senior Notes due 2024, 5.75% Senior Notes due 2025, 4.50% Senior Notes due 2028, and 4.75% Senior Notes due 2030 (collectively, the &#8220;Senior Notes&#8221;) are guaranteed by certain consolidated subsidiaries. These guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. The Senior Notes are guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our credit agreement and other capital markets debt. The other subsidiaries of Encompass Health do not guarantee the Senior Notes (such subsidiaries are referred to as the &#8220;non-guarantor subsidiaries&#8221;).</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:6.75pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1) we are not in default under our credit agreement, and (2) either (a) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 2x and our leverage ratio (as defined in our credit agreement) remains less than or equal to 4.50x or (b) there is capacity under the Available Amount as defined in the credit agreement. The terms of our Senior Notes indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture&#8217;s restricted payments covenant to declare and pay dividends. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, and Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10-K.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying condensed consolidated financial statements, Holdings had 5.5% noncontrolling interest as of December 31, 2019, and accordingly, Holdings and its wholly-owned subsidiaries were not guarantors of our debt. In February 2020, we acquired for cash all but 1.2% of the remaining noncontrolling interest in Holdings following the most recent exercise of the put option by the management investors. On February 20, 2020, Encompass Health Corporation and each of the two remaining management investors agreed to exchange the remaining shares representing the noncontrolling interest for an equal value of shares of common stock of Encompass Health Corporation. We settled the exchanges on March 6, 2020 and now own 100% of Holdings. Pursuant to the terms of our credit agreement and our Senior Notes indentures, we executed joinders for Holdings and its wholly-owned subsidiaries on April 23, 2020 at which time they became guarantors of the indebtedness under the credit agreement and our Senior Notes indentures.</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information is presented below for Encompass Health, the parent company, and the subsidiary guarantors on a combined basis after elimination of intercompany transactions and balances among Encompass Health and the subsidiary guarantors and does not include investments in and equity in the earnings of non-guarantor subsidiaries. Amounts for prior periods have been revised to reflect the status of guarantors and non-guarantors as of September&#160;30, 2020.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.029%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany revenues generated from non-guarantor subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,237.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany expenses incurred in transactions with non-guarantor subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:15pt;margin-top:5pt;padding-left:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of<br/>September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,973.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany receivable due from non-guarantor subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,370.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,267.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,981.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,788.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted EBITDA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes Adjusted EBITDA as defined in our credit agreement is a measure of our ability to service our debt and our ability to make capital expenditures. We reconcile Adjusted EBITDA to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use Adjusted EBITDA on a consolidated basis as a liquidity measure. We believe this financial measure on a consolidated basis is important in analyzing our liquidity because it is the key component of certain material covenants contained within our credit agreement, which is discussed in more detail in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K. These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under our credit agreement&#8212;our interest coverage ratio and our leverage ratio&#8212;could result in our lenders requiring us to immediately repay all amounts borrowed. If we anticipated a potential covenant violation, we would seek relief from our lenders, which would have some cost to us, and such relief might be on terms less favorable to us than those in our existing credit agreement. In addition, if we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to our assessment of our liquidity.</span></div><div style="padding-left:2.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as &#8220;Adjusted Consolidated</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EBITDA,&#8221; allows us to add back to consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> interest expense, income taxes, and depreciation and amortization and then add back to consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1) all unusual or nonrecurring items reducing consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3)&#160;non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4)&#160;share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment debt and acquisitions, and (7) any restructuring charges not in excess of 20% of Adjusted Consolidated EBITDA. We also subtract from consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> all unusual or nonrecurring items to the extent they increase consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the credit agreement, the Adjusted EBITDA calculation does not require us to deduct net income attributable to noncontrolling interests or&#160;gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or&#160;unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement&#8217;s &#8220;unusual or nonrecurring&#8221; classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, our ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Adjusted EBITDA for the three and nine months ended September&#160;30, 2020 and 2019 was as follows (in millions):</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Net Income to Adjusted EBITDA</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARs mark-to-market impact on noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll taxes on SARs exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests in continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt-related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions from nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARs mark-to-market impact on noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll taxes on SARs exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information see the &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; sections of this Item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For information regarding recent accounting pronouncements, see Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included under Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_163"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary exposure to market risk is to changes in interest rates on our variable rate long-term debt. We use sensitivity analysis models to evaluate the impact of interest rate changes on our variable rate debt. As of September&#160;30, 2020, our primary variable rate debt outstanding related to $254.8 million under our term loan facilities. Assuming outstanding balances were to remain the same, a 1% increase in interest rates would result in an incremental negative cash flow of approximately $2.1 million over the next 12 months, while a 1% decrease in interest rates would result in an incremental positive cash flow of approximately $0.4 million over the next 12 months.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, for additional information regarding our long-term debt. </span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_166"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Controls and Procedures</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, an evaluation was carried out by our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended. Based on our evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our Internal Control over Financial Reporting during the quarter ended September&#160;30, 2020 that have a material effect on our Internal Control over Financial Reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_172"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Legal Proceedings </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide services in the highly regulated healthcare industry. In the ordinary course of our business, we are a party to various legal actions, proceedings, and claims as well as regulatory and other governmental audits and investigations. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These matters could potentially subject us to sanctions, damages, recoupments, fines, and other penalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these matters have been material to us in the past, and others in the future </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may, either individually or in the aggregate, be material and adverse to our business, financial position, results of operations, and liquidity. We do not believe any of our pending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legal proceedings are material to us, but there can be no assurance our assessment will not change based on future developments. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the False Claims Act (the &#8220;FCA&#8221;) allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the FCA. These lawsuits, also known as &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, are common in the healthcare industry and can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or prevented by existing law or court order from discussing or disclosing the filing of such suits. Therefore, from time to time, we may be party to one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the FCA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to certain legal proceedings in which we are involved is included in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements contained in Part&#160;I, Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report and should be read in conjunction with the related disclosure previously reported in our Annual Report on Form&#160;10&#8209;K for the year ended December&#160;31, 2019 (the &#8220;2019 Form 10&#8209;K&#8221;) and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020.</span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_175"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:34.8pt">Risk Factors</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors disclosed in Part I, Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the 2019 Form&#160;10-K and Part II, Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. However, the risk factor related to the ongoing COVID-19 pandemic has been updated below to include more recent developments. Certain other information in those risk factors has been updated by the discussion in the &#8220;Executive Overview&#8212;Key Challenges&#8221; section of Part I, Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, which section is incorporated by reference herein.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) pandemic has significantly affected and will continue to significantly affect our operations, business, and financial condition, and our liquidity could be negatively impacted, particularly if the operations of a significant number of acute-care hospitals and physician practices are disrupted for a lengthy period of time.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic has significantly affected and will continue to significantly affect our facilities, employees, business operations, and financial performance, as well as the United States economy and financial markets. The COVID-19 pandemic is still rapidly evolving and much of its impact remains unknown and difficult to predict, with the impact on our operations and financial performance being dependent on numerous factors, including the rate of spread, duration and geographic coverage of the COVID-19 pandemic, the status of testing capabilities, and the development of vaccines and therapeutic remedies; the legal, regulatory and administrative developments related to the pandemic at federal, state, and local levels, such as shelter-in-place orders, facility closures and quarantines; and the infectious disease prevention and control efforts of the Company, governments and third parties. We began experiencing a negative impact on our operations and financial results in March 2020, which has continued into the second and third quarters. It is likely the COVID-19 pandemic will continue to significantly affect our financial performance, such as supply expenses, for at least the third and fourth quarters of 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Specifically, beginning in mid-March and continuing into the second and third quarters, we experienced decreased patient volumes in both of our operating segments which we believe resulted from a number of conditions related to the COVID-19 pandemic negatively affecting willingness and ability of patients to seek healthcare services including: reduction in elective procedures by acute-care hospitals and physician practices, restrictive governmental measures, such as travel bans, social distancing requirements, quarantines and shelter-in-place orders, and patient and caregiver fear of infection. In the home health and hospice segment, we also experienced decreases in visits per episode and institutional referrals because of the COVID-19 pandemic, both of which negatively affected pricing for home health.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe one of the primary drivers of our reduced volumes is the significant reduction in volumes of elective procedures by acute-care hospitals and physician practices. There is also reason to believe patients, because of fear of infection, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">have delayed or foregone treatment for conditions, such as stroke and heart attack, that are non-elective in nature. As a reminder, a large number of patients are referred to us following procedures or treatment at acute-care hospitals. Other factors related to the COVID-19 pandemic that have led to decreasing patient volumes include: lower acute-care hospital censuses due to shelter-in-place orders, restrictive visitation policies in place at acute-care hospitals that severely limit access to patients and caregivers by our clinical rehabilitation liaisons and care transition coordinators, lock downs of assisted living facilities that prevent our home care and hospice clinicians and other care providers from visiting patients, and heightened anxiety among patients and their family members regarding the risk of exposure to COVID-19 during acute-care and post-acute care treatment. Significant outbreaks of COVID-19 in our markets, hospitals or large acute-care referral sources could further increase patient anxiety and unwillingness to seek treatment from us or otherwise limit referrals. These factors have contributed, and could in the future contribute, to a decline in new patients for both of our operating segments as well as decreases in visits per episode and institutional referrals in our home health segment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we are experiencing supply chain disruptions as a result of the COVID-19 pandemic, including shortages and delays, and we have experienced, and are likely to continue to experience, significant price increases in equipment, pharmaceuticals and medical supplies, particularly personal protective equipment, or &#8220;PPE.&#8221; Beginning in March 2020, we experienced increased supply expenses due to higher utilization of PPE and increased purchasing of other medical supplies and cleaning and sanitization materials as well as higher prices for supplies in shortage. Shortages of essential PPE and pharmaceutical and medical supplies may also limit our ability to admit and treat patients.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations and financial results have been and may in the future be adversely affected by staffing shortages where employees must self-quarantine due to exposure to COVID-19 or where employees are unavailable due to a lack of childcare or care for elderly family members (social distancing, quarantines and shelter-in-place orders). Staffing shortages have limited, and may in the future limit, our ability to admit additional patients at a given facility or agency. Delays in obtaining COVID-19 test results may also adversely affect employee availability. In addition to staffing shortages, significant outbreaks or PPE shortages in our markets or hospitals may reduce employee morale or create labor unrest or other workforce disruptions. Staffing shortages or employee relations issues related to COVID-19 may lead to increased compensation expenses and limitations on the ability to admit new patients. In April, we initiated a program for eligible frontline employees to earn additional paid time off in recognition of their outstanding efforts responding to the COVID-19 pandemic. With more than 21,000 employees potentially benefiting from this additional paid time off, we accrued approximately $43 million in salary and benefits expense during the second quarter in connection with this award. We may also experience additional benefit costs related to increased workers&#8217; compensation claims and group health insurance expenses as a result of the COVID-19 pandemic.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations and financial results may be further adversely affected by future federal or state laws, regulations, orders, or other governmental or regulatory actions addressing the current COVID-19 pandemic or the United States healthcare system, which, if adopted, could result in direct or indirect restrictions on our business, potentially adversely affecting our financial condition, results of operations and cash flow. State and local executive actions in response to the COVID-19 pandemic, such as shelter-in-place orders, facility closures and quarantines, have in the past, and could in the future, impair our ability to operate or prevent people from seeking care from us. For example, local health departments have restricted our ability to take patients in certain markets for periods of time in reaction to perceived COVID-19 outbreaks.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also be subject to lawsuits from patients, employees and others exposed to COVID-19 at our facilities. For example, suits on behalf of two former patients alleging COVID-19 exposure have been brought against one of our hospitals. Such actions may involve large damage claims as well as substantial defense costs. Our professional and general liability insurance may not cover all claims against us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;), signed into law on March 27, 2020, authorized the cash distribution of relief funds to healthcare providers in response to the COVID-19 pandemic. On April 10, 2020, HHS began distributing CARES Act relief funds, for which we did not apply, to various of our bank accounts. We refused the CARES Act relief funds, and our banks returned all the funds to HHS. We intend to refuse any additional CARES Act relief funds distributed in the future.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing and other disruptions to our business as a result of the COVID-19 pandemic have had and are likely to continue to have an adverse effect on our business and could have a material adverse effect on our business, results of operations, financial condition and cash flows. Furthermore, assessing the CARES Act and numerous regulatory changes and formulating our response to the COVID-19 pandemic have required our management to devote extensive resources and are likely to continue to do so in the near future, which may negatively affect our ability to implement our business plan and respond to opportunities. To the extent the COVID-19 pandemic adversely affects our business, results of operations, financial condition and cash flows, it may also have the effect of heightening many of the other risks described in this report and the risk factors disclosed in Part I, Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our repurchases of equity securities during the three months ended September&#160;30, 2020:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:18.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares (or Units) Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share (or Unit) ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1 through<br/>July 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,253,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 1 through     August 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,253,887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1 through<br/>September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,253,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Except as noted in the following sentence, the number of shares reported in this column includes the shares purchased under the plan or program, if any, as reported in the third column of this table and the shares tendered by employees as payments of the tax liabilities incident to the vesting of previously awarded shares of restricted stock and the exercise price and tax liability incident to the net settlement of an option exercise. In July, 799 shares were purchased pursuant to our Directors&#8217; Deferred Stock Investment Plan. This plan is a nonqualified deferral plan allowing non-employee directors to make advance elections to defer a fixed percentage of their director fees. The plan administrator acquires the shares in the open market which are then held in a rabbi trust. The plan also provides that dividends paid on the shares held for the accounts of the directors will be reinvested in shares of our common stock which will also be held in the trust. The directors&#8217; rights to all shares in the trust are nonforfeitable, but the shares are only released to the directors after departure from our board.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2013, we announced our board of directors authorized the repurchase of up to $200 million of our common stock. On February 14, 2014, our board approved an increase in this common stock repurchase authorization from $200 million to $250 million. On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule&#160;10b5-1 under the Securities Exchange Act of 1934, as amended.</span></div><div id="i5ec2d1f903d340c19ee74983700dc28d_181"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Exhibits</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Exhibit Index immediately following the signature page of this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ENCOMPASS HEALTH CORPORATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Douglas E. Coltharp</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Douglas E. Coltharp</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2020</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i5ec2d1f903d340c19ee74983700dc28d_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits required by Regulation S-K are set forth in the following list and are filed by attachment to this report unless otherwise noted.</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:5.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex31.htm">3.1.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex31.htm">Amended and Restated Certificate of Incorporation of Encompass Health Corporation, effective as of January 1, 2018 (incorporated by reference to Exhibit 3.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 25, 2017).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000134100406000665/healthsouthexhibit.txt">3.1.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000134100406000665/healthsouthexhibit.txt">Certificate of Designations of 6.50% Series A Convertible Perpetual Preferred Stock, as filed with the Secretary of State of the State of Delaware on March&#160;7, 2006 (incorporated by reference to Exhibit&#160;3.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on March&#160;9, 2006).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex32.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex32.htm">Amended and Restated Bylaws of Encompass Health Corporation, effective as of January 1, 2018 (incorporated by reference to Exhibit 3.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 25, 2017).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000119312520263689/d12659dex42.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000119312520263689/d12659dex42.htm">Tenth Supplemental Indenture, dated as of October 5, 2020, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 4.625% Notes due 2031 (incorporated by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000119312520263689/d12659dex42.htm"> to Exhibit 4.2 to the Encompass Health&#8217;s Current Report on Form 8-K filed on October 5, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex101.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex101.htm">Encompass Health Corporation Fifth Amended and Restated Change in Control Benefits Plan.+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex22.htm">22</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex22.htm">List of Subsidiary Guarantors.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex311.htm">Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex312.htm">Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex322.htm">32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q93020ex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sections of the Encompass Health Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in XBRL (eXtensible Business Reporting Language), submitted in the following files:</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+  Management contract or compensatory plan or arrangement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ehc10q93020ex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i4f1d86af0c894ea0a8611dd64da5745b_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ENCOMPASS HEALTH CORPORATION</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FIFTH AMENDED AND RESTATED</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CHANGE IN CONTROL</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BENEFITS PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Encompass Health Corporation, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), has adopted the Encompass Health Corporation Fifth Amended and Restated Change in Control Benefits Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the benefit of certain Participant employees of the Company and its subsidiaries, on the terms and conditions hereinafter stated. The Plan is intended to help retain qualified employees, maintain a stable work environment and provide financial security to certain Participant employees of the Company in the event of a Change in Control. The Plan is intended to be a plan that &#8220;is unfunded and is maintained by an employer primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees&#8221; within the meaning of Sections 201(2), 301(a)(3) and 401(a)(1) of ERISA. Conversely, to the maximum extent permitted by law, the Plan is not intended to provide for any &#8220;deferral of compensation,&#8221; as defined in Section 409A of the Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and authoritative Department of Treasury regulations and other interpretive guidance issued thereunder (including the Proposed Treasury Regulations issued June 22, 2016, to the extent the application of such proposed regulations facilitates the administration of this Plan in accordance with the intentions set forth in this paragraph). Instead, payments and benefits under the Plan are intended to fall within the exceptions for &#8220;short-term deferrals,&#8221; as set forth in Treasury Regulations Section 1.409A-1(b)(4), and &#8220;separation pay due to involuntary separation from service or participation in a window program,&#8221; as set forth in Treasury Regulations Section 1.409A-1(b)(9)(iii) and it is further intended that each Participant&#8217;s benefits shall be payable only upon a Participant&#8217;s &#8220;separation from service&#8221; under Treasury Regulations Section 1.409A-1(h). For purposes of Treasury Regulations Section 1.409A-2(b)(2)(iii), the right to each payment under the Plan shall be treated as the right to a separate payment. The Plan shall be administered and interpreted to the extent possible in a manner consistent with these intentions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE I</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DEFINITIONS AND INTERPRETATIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Capitalized terms used in the Plan shall have the following respective meanings, except as otherwise provided or as the context shall otherwise require&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Annual Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the base salary paid to a Participant immediately prior to his or her Termination Date on an annual basis exclusive of any bonus payments or additional payments under any Benefit Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any grant or award of Options, Stock Appreciation Rights or any other right or interest relating to Common Stock or cash, granted to a Participant pursuant to an equity compensation plan of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any &#8220;employee benefit plan&#8221; (including any employee benefit plan within the meaning of Section 3(3) of ERISA), program, arrangement or practice maintained, sponsored or provided by the Company, including those relating to compensation, bonuses, profit sharing, stock option, or other stock-related rights or other forms of incentive or deferred compensation, paid time-off benefits, insurance coverage (including any self-insured arrangements) health or medical benefits, Disability benefits, workers&#8217; compensation, supplemental unemployment benefits, severance benefits and post employment or retirement benefits (including&#58;  compensation, pension, health, medical or life insurance, or other benefits).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in any individual employment, severance or similar agreement between the Company and a Participant, or in the event that a Participant is not a party to such an agreement, Cause shall mean&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Company&#8217;s procurement of evidence of the Participant&#8217;s act of fraud, misappropriation, or embezzlement with respect to the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Participant&#8217;s indictment for, conviction of, or plea of guilty or no contest to, any felony (other than a minor traffic violation)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the suspension or debarment of the Participant or of the Company or any of its affiliated companies or entities as a direct result of any willful or grossly negligent act or omission of the Participant in connection with his or her employment with the Company from participation in any Federal or state health care program. For purposes of this clause (iii), the Participant shall not have acted in a &#8220;willful&#8221; manner if the Participant acted, or failed to act, in a manner that he or she believed in good faith to be in, or not opposed to the best interests of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;the Participant&#8217;s admission of liability of, or finding by a court or the SEC (or a similar agency of any applicable state) of liability for, the violation of any &#8220;Securities Laws&#8221; (as hereinafter defined) (excluding any technical violations of the securities laws which are not criminal in nature). As used herein, the term &#8220;securities laws&#8221; means any federal or state law, rule or regulation governing the issuance or exchange of securities, including, without limitation, the Securities Act and the Exchange Act&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;a formal indication from any agency or instrumentality of any state or the United States of America, including, but not limited to, the United States Department of Justice, the SEC or any committee of the United States Congress that the Participant is a target or the subject of any investigation or proceeding into the actions or inactions of the Participant for a violation of any Securities Laws in connection with his or her employment by the Company (excluding any technical violations of the securities law which are not criminal in nature)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;the Participant&#8217;s failure after reasonable prior written notice from the Company to comply with any valid and legal directive of the Chief Executive Officer or the Board that is not remedied within thirty (30) days of the Participant being provided written notice thereof from the Company&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;other than as provided in clauses (i) through (vi) above, the Participant&#8217;s breach of any material provision of any employment agreement, if applicable, or the Participant&#8217;s breach of the material duties of the Participant&#8217;s job that is not remedied within thirty (30) days or repeated breaches of a similar nature, such as the failure to report to work, perform duties, or follow directions, all as provided herein, which shall not require additional notices as provided in clauses (i) through (vi) above.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cause shall be determined by the affirmative vote of at least fifty percent (50%) of the members of the Board (excluding the Participant, if a Board member, and excluding any member of the Board involved in events leading to the Board&#8217;s consideration of terminating the Participant for Cause).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the acquisition (other than from the Company) by any person, entity or &#8220;group&#8221; (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act, but excluding, for this purpose, the Company or its subsidiaries, or any employee benefit plan of the Company or its subsidiaries which acquires beneficial ownership of voting securities of the Company) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of thirty percent (30%) or more of either the then-outstanding shares of Common Stock or the combined voting power of the Company&#8217;s then-outstanding voting securities entitled to vote generally in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;during any period of up to twenty-four (24) consecutive months, individuals who at the beginning of such period constituted the Board (together with any new directors whose election by the Board or whose nomination for election by the stockholders of the Company was approved by a vote of a majority of the directors of the Company then still in office who were either directors at the beginning of such period or whose election or nomination for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">election was previously so approved) cease to constitute at least a majority of the Board&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the Company is liquidated or dissolved or adopts a plan of liquidation or dissolution&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;the merger or consolidation of the Company with or into another person or the merger of another person with or into the Company, or the sale of all or substantially all the assets of the Company (determined on a consolidated basis) to another person, other than a transaction following which (A) in the case of a merger or consolidation transaction, holders of securities that represented one hundred percent (100%) of the combined voting power entitled to vote generally in the election of directors of the Company immediately prior to such transaction (or other securities into which such securities are converted as part of such merger or consolidation transaction) own directly or indirectly at least a majority of the combined voting power entitled to vote generally in the election of directors of the surviving person in such transaction immediately after such transaction and (B) in the case of a sale of assets, each transferee is owned by holders of securities that represented at least a majority of the combined voting power entitled to vote generally in the election of directors of the Company immediately prior to such sale.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Internal Revenue Code of 1986, as amended. Reference in the Plan to any Section of the Code shall be deemed to include any amendments or successor provisions to such Section and any regulations under such Section.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean $.01 par value common stock of the Company, and such other securities of the Company as may be substituted for Common Stock.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Compensation Committee of the Board.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a physical or mental condition which is expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months and which renders the Participant incapable of performing the work for which he or she is employed or similar work, as evidenced by eligibility for and actual receipt of benefits payable under a group Disability plan or policy maintained by the Company or any of its subsidiaries that is by its terms applicable to the Participant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Employee Retirement Income Security Act of 1974, as amended and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) as of any given date, the closing price at which the shares of Common Stock were traded (or if no transactions were reported on such date on the next preceding date on which transactions were reported) on the New York Stock Exchange on such date, or, if different, the principal exchange or automated quotation system on which such stock is traded, or (ii) should the Compensation Committee elect, the average closing price over a pre-established series of such trading days preceding or following such given date. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, when used with reference to any Participant, any of the following actions or failures to act, but in each case only if it occurs while such Participant is employed by the Company and then only if it is not consented to by such Participant in writing&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;assignment of a position that is of a lesser rank than held by the Participant prior to the assignment and that results in a material adverse change in such Participant&#8217;s reporting position, duties or responsibilities or title or elected or appointed offices as in effect immediately prior to the effective date of such change, or in the case of a Tier 1 or Tier 2 Participant who was immediately prior to the Change in Control an executive officer of the Company, such Participant ceasing to be an executive officer of a company with securities registered under the Exchange Act&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;a material reduction in such Participant&#8217;s total compensation from that in effect immediately prior to the Change in Control. For purposes of this clause (ii), &#8220;total compensation&#8221; shall mean the sum of base salary, target bonus opportunity and the opportunity to receive compensation in the form of equity in the Company. Notwithstanding the foregoing, a reduction will not be deemed to have occurred hereunder on account of (A)&#160;any change to a plan term other than ultimate target bonus opportunity or equity opportunity, (B)&#160;the actual payout of any bonus amount or equity amount, (C)&#160;any reduction resulting from changes in the market value of securities or other instruments paid or payable to the Participant, or (D)&#160;any reduction in the total compensation of a group of similarly situated Participants that includes such Participant&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any change in a Participant&#8217;s status as a Tier 1 Participant, Tier 2 Participant or Tier 3 Participant to a status that provides a lower benefit hereunder in the event of a Change in Control if such change in status occurs during the period beginning six (6) months prior to a Change in Control and ending twenty-four (24) months after a Change in Control&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;any change of more than fifty (50) miles in the location of the principal place of employment of such Participant immediately prior to the effective date of such change.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this definition, none of the actions described in clauses (i) through (iv) above shall constitute &#8220;Good Reason&#8221; if taken for Cause. Additionally, none of the actions described in clauses (i) through (iv) above shall constitute &#8220;Good Reason&#8221; with respect to any Participant if remedied by the Company within thirty (30) days after receipt of written notice thereof given by such Participant (or, if the matter is not capable of remedy within thirty (30) days, then within a reasonable period of time following such thirty (30) day period, provided that the Company has commenced such remedy within said thirty (30) day period)&#59; provided that &#8220;Good Reason&#8221; shall cease to exist for any action described in clauses (i) through (iv) above on the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) day following the later of the occurrence of such action or the Participant&#8217;s knowledge thereof, unless such Participant has given the Company written notice thereof prior to such date. Furthermore, any benefits under the Plan resulting from the occurrence described in clause (iii) above shall be based on the status of the Participant as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto as of the date of such occurrence.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a right granted pursuant to an equity compensation plan of the Company to purchase Common Stock at a specified price during specified time periods.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an employee of the Company who is included on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto, as that schedule may be amended in accordance with Section 2.01.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean this Encompass Health Corporation Change in Control Benefits Plan, as amended, restated, supplemented or modified from time to time in accordance with its terms.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Potential Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be deemed to have occurred if the event set forth in any one of the following paragraphs shall have occurred&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Company enters into an agreement, the consummation of which would result in the occurrence of a Change in Control&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Company or any person, entity or &#8220;group&#8221; (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Exchange Act, but excluding, for this purpose, the Company or its subsidiaries, or any employee benefit plan of the Company or its subsidiaries which acquires beneficial ownership of voting securities of the Company) publicly announces an intention to take or to consider taking actions which, if consummated, would constitute a Change in Control&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the acquisition (other than from the Company) by any person, entity or &#8220;group&#8221; (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Exchange Act, but excluding, for this purpose, the Company or its subsidiaries, or any employee benefit plan of the Company or its subsidiaries which acquires beneficial ownership of voting securities of the Company) of beneficial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifteen (15%) or more of either the then-outstanding shares of Common Stock or the combined voting power of the Company&#8217;s then-outstanding voting securities entitled to vote generally in the election of Directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;the Board adopts a resolution to the effect that a Potential Change in Control has occurred&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided, however, that no Potential Change in Control shall be deemed pending for purposes of the Plan if such event or condition is no longer in effect or existence or is otherwise rescinded or terminated (by means of a public filing or announcement in the case of clause (ii) above).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pro-rated Portion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a fraction (i) whose numerator is the number of months elapsed from the beginning of any not yet completed performance period applicable to any cash incentive award or plan through the effective date of termination of a Participant&#8217;s employment in the circumstances described in Section 3.01 below, and (ii) whose denominator is the total number of months in such performance period under the applicable cash incentive award or plan. For purposes of this definition, the months elapsed will include the month in which the effective date of termination occurs if such date is the 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, or a subsequent, day of that month.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Appreciation Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">SAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a right granted to a Participant pursuant to an equity compensation plan of the Company to receive a payment equal to the difference between the Fair Market Value of a share of Common Stock as of the date of exercise of the SAR over the grant price of the SAR. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the United States Securities Exchange Commission.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Successor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a successor to all or substantially all of the business, operations or assets of the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Participant, the termination date specified in the Termination Notice delivered by such Participant to the Company in accordance with Section 2.02 or as set forth in any Termination Notice delivered by the Company, or as applicable, the Participant&#8217;s date of death.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Termination Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as appropriate, written notice from (a) a Participant to the Company purporting to terminate such Participant&#8217;s employment for Good Reason in accordance with Section 2.02 or (b) the Company to any Participant purporting to terminate such Participant&#8217;s employment for Cause or Disability in accordance with Section 2.03.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tier 1 Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each Participant designated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto as a Tier 1 Participant, as that schedule may be amended in accordance with Section 2.01.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tier 2 Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each Participant designated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto as a Tier 2 Participant, as that schedule may be amended in accordance with Section 2.01.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tier 3 Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each Participant designated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto as a Tier 3 Participant, as that schedule may be amended in accordance with Section 2.01.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the Plan, unless a clear contrary intention appears, (a) the words &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder&#8221; refer to the Plan as a whole and not to any particular Article, Section or other subdivision, (b) reference to any Article or Section, means such Article or Section hereof and (c) the words &#8220;including&#8221; (and with correlative meaning &#8220;include&#8221;) means including, without limiting the generality of any description preceding such term. The Article and Section headings herein are for convenience only and shall not affect the construction hereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE II</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ELIGIBILITY AND BENEFITS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An employee of the Company shall be a &#8220;Participant&#8221; in the Plan during each calendar year (or partial calendar year) for which he or she has been designated as a Participant (and in the Tier so designated) by the Chief Executive Officer of the Company and for each succeeding calendar year he or she is employed in such position, unless the Participant is given written notice by December 31 of the preceding year of the determination of the Chief Executive Officer or the Board that such Participant shall cease to be a Participant or shall participate in a different Tier for such succeeding calendar year. Notwithstanding the foregoing, any Participant may not be removed from the Plan, nor placed in a lower tier (with Tier 1 being the highest Tier and Tier 3 being the lowest Tier), during the pendency of a Potential Change in Control or within two years following a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan is only for the benefit of Participants, and no other employees, personnel, consultants or independent contractors shall be eligible to participate in the Plan or to receive any rights or benefits hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Notices from Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of the Plan, in order for any Participant to terminate his or her employment for Good Reason, such Participant must give a Termination Notice to the Company in accordance with the requirements specified under the definition of Good Reason in Section 1.01, which notice shall be signed by such Participant, shall be dated the date it is given to the Company, shall specify the Termination </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date and shall state that the termination is for Good Reason and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for such Good Reason. Any Termination Notice given by a Participant that does not comply in all material respects with the foregoing requirements as well as the &#8220;Good Reason&#8221; definition provisions set forth in Section 1.01 shall be invalid and ineffective for purposes of the Plan. If the Company receives from any Participant a Termination Notice that states the termination is for Good Reason and which the Company believes is invalid and ineffective as aforesaid, it shall promptly notify such Participant of such belief and the reasons therefor. Any termination of employment by the Participant that either does not constitute Good Reason or fails to meet the Termination Notice requirements set forth above shall be deemed a termination by the Participant without Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Notices from Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of the Plan, in order for the Company to terminate any Participant&#8217;s employment for Cause, the Company must give a Termination Notice to such Participant, which notice shall be dated the date it is given to such Participant, shall specify the Termination Date and shall state that the termination is for Cause and shall set forth in reasonable detail the particulars thereof. For purposes of the Plan, in order for the Company to terminate any Participant&#8217;s employment for Disability, the Company must give a Termination Notice to such Participant, which notice shall be dated the date it is given to such Participant, shall specify the Termination Date and shall state that the termination is for Disability and shall set forth in reasonable detail the particulars thereof. Any Termination Notice given by the Company that does not comply, in all material respects, with the foregoing requirements shall be invalid and ineffective for purposes of the Plan. Any Termination Notice purported to be given by the Company to any Participant after the death or retirement of such Participant shall be invalid and ineffective.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accelerated Vesting of Pre-2015 Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With respect to Awards granted prior to January 1, 2015, upon the occurrence of a Change in Control, notwithstanding the provisions of any Benefit Plan or agreement (except as provided in this Section 2.04)&#58;</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">each outstanding option to purchase Company Common Stock (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall become automatically vested and exercisable and</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the case of those Stock Options outstanding as of the Effective Date, such Stock Options shall remain exercisable by such Participant until the later of the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of the third month following the date at which, or December 31 of the calendar year in which, the Stock Option would have otherwise expired, but in no event beyond the original term of such Stock Option&#59; and</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the case of all Stock Options granted to a Participant after the Effective Date, such Stock Options shall remain exercisable by such Participant for a period of (x) three years in the case of a Tier 1 Participant, (y) two years in the case of a Tier 2 Participant or (z) one year in the case of a Tier 3 Participant, beyond the date at which the Stock Option would have otherwise expired, but in no event beyond the original term of such Stock Option&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the vesting restrictions based upon continued employment on all other awards relating to Common Stock (including but not limited to restricted stock, restricted stock units and SARs) held by a Participant shall immediately lapse and in the case of restricted stock units and SARs shall become immediately payable, to the extent permitted by Section 409A&#59;</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the vesting restrictions based upon achievement of performance criteria on any awards related to Common Stock (including but not limited to performance shares or performance share units) held by a Participant shall deemed to have been met to the extent determined by the Compensation Committee as constituted immediately prior to the Change of Control&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in the event that the terms of any award under a Benefit Plan shall provide for vesting treatment of equity awards to such Participant that are more favorable than the provisions of paragraphs (a) through (c) above, the provisions of such award shall control the vesting treatment with respect to any equity awards to which such provisions are applicable. Also notwithstanding the foregoing, payments described in this Section generally shall be made immediately following the accelerated vesting date described in this Section, and in no event later than the last day of the &#8220;applicable 2&#189; month period,&#8221; as defined in Treasury Regulations Section 1.409A-1(b)(4)&#59; provided, however, that payments of amounts described in this Section that are &#8220;deferrals of compensation&#8221; subject to Section 409A may be accelerated only to the extent such acceleration does not trigger a &#8220;plan failure&#8221; pursuant to Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accelerated Vesting of Post-2014 Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With respect to Awards granted on or after January 1, 2015, upon the occurrence of a Change in Control, notwithstanding the provisions of any Benefit Plan or agreement (except as provided in this Section 2.05)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with respect to outstanding Options and SARs&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If (x) the Company is the surviving entity and the Common Stock remains listed, quoted, or traded on a national securities exchange or automated quotation system or (y) the surviving entity assumes such Awards or substitutes in lieu thereof stock options or stock appreciation right relating to the stock of such surviving entity having an equivalent then-current value and remaining term, provided that such stock must be listed, quoted, or traded on a national securities exchange or automated quotation system (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Substitute Options&#47;SARs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), such Awards or the Substitute Options&#47;SARs, as applicable, shall be governed by their respective terms&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If (x)(i) the Company is the surviving entity and the Common Stock remains listed, quoted, or traded on a national securities exchange or automated quotation system or (ii) the surviving entity assumes such Awards or issues Substitute Options&#47;SARs and (y) the Participant is terminated without Cause or for Good Reason within twenty-four&#160;(24) months following the date of the Change in Control, such Awards or Substitute Options&#47;SARs, as applicable, held by the Participant that were not previously vested and exercisable shall become fully vested and exercisable effective as of the date of such termination and remain exercisable until the date that is two (2)&#160;years following the date of such termination, or the original expiration date, whichever first occurs&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If (x)(i) the Company is not the surviving entity or (ii)&#160;the Common Stock does not remain listed, quoted, or traded on a national securities exchange or automated quotation system and (y)&#160;the surviving entity does not assume such Awards or issue Substitute Options&#47;SARs, each such Award shall become fully vested effective as of the date of the Change in Control and promptly cancelled in exchange for a cash payment in an amount equal to (A)&#160;the excess of Market Value per share of the Common Stock subject to the Award over the exercise or base price (if any) per share of Common Stock subject to such Award multiplied by (B)&#160;the number of shares of Common Stock subject to such Award&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with respect to other outstanding Awards not subject to performance-based objectives (other than Options or SARs)(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Time-based Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if (x) the Company is the surviving entity and the Common Stock remains listed, quoted, or traded on a national securities exchange or automated quotation system or (y) the surviving entity assumes such Awards or substitutes in lieu thereof time-based awards relating to the stock of such surviving entity having an equivalent then-current value and vesting date, provided that such stock must be listed, quoted, or traded on a national securities exchange or automated quotation system (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Substitute Time-based Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), such Awards or the Substitute Time-based Awards, as applicable, shall be governed by their respective terms&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if (x)(i) the Company is the surviving entity and the Common Stock remains listed, quoted, or traded on a national securities exchange or automated quotation system or (ii) the surviving entity assumes the such Awards or issues Substitute Time-based Awards and the Participant is terminated without Cause or for Good Reason within twenty-four&#160;(24) months following the Change in Control, such Awards or Substitute Time-based Awards, as applicable, held by the Participant that were not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">previously vested shall become fully vested immediately upon such termination&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If (x)(i) the Company is not the surviving entity or (ii)&#160;the Common Stock does not remain listed, quoted, or traded on a national securities exchange or automated quotation system and (y) the surviving entity does not assume the such Awards or issue Substitute Time-based Awards, such Awards shall become fully vested effective as of the date of the Change in Control and promptly cancelled in exchange for a cash payment of an amount equal to the Fair Market Value per share of the Common Stock subject to the Award immediately prior to the Change in Control multiplied by the number of shares of Common Stock subject to the Award&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;with respect to Awards subject to performance-based objectives (including but not limited to performance shares or performance share units), the vesting restrictions based upon achievement of the performance-based objectives shall deemed to have been met to the extent determined by the Compensation Committee as constituted immediately prior to the Change of Control and such achievement shall result in the deemed issuance of Time-based Awards or Substitute Time-based Awards, as applicable, with the same vesting date as provided in the original Award granted by the Company and such Awards will be subject to paragraphs (ii)(2) and (3) above, if applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compensation Committee may, in its sole discretion, provide that&#58; (x) an Award shall, upon the occurrence of a Change in Control, be cancelled in exchange for a payment in an amount equal to (i) the Fair Market Value per share of the Common Stock subject to the Award immediately prior to the Change in Control over the exercise or base price (if any) per share of Common Stock subject to such Award multiplied by (ii) the number of shares granted under such Award&#59; and (y) each Award shall, upon the occurrence of a Change in Control, be cancelled without payment therefore if the Fair Market Value per share of the Common Stock subject to such Award immediately prior to the Change in Control is less than the exercise or purchase price (if any) per share of Common Stock subject to such Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in the event that the terms of any award under a Benefit Plan shall provide for vesting treatment of equity awards to such Participant that are more favorable than the provisions of paragraphs (a) and (b) above, the provisions of such award shall control the vesting treatment with respect to any equity awards to which such provisions are applicable.  Also notwithstanding the foregoing, payments described in this Section generally shall be made immediately following the accelerated vesting date described in this Section, and in no event later than the last day of the &#8220;applicable 2&#189; month period,&#8221; as defined in Treasury Regulations Section 1.409A-1(b)(4)&#59; provided, however, that payments of amounts described in this Section that are &#8220;deferrals of compensation&#8221; subject to Section 409A may be accelerated only to the extent such acceleration does not trigger a &#8220;plan failure&#8221; pursuant to Section 409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEVERANCE AND RELATED TERMINATION BENEFITS</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that a Participant&#8217;s employment is terminated within twenty-four (24) months following a Change in Control or during the pendency of a Potential Change in Control provided that a related Change in Control occurs, (x) by the Participant for Good Reason (while such Good Reason exists) or (y) by the Company without Cause (other than for Disability), then in each case, such Participant (or his or her beneficiary) shall be entitled to receive, and the Company shall be obligated to pay to the Participant, subject to Sections 3.02 through 3.04 hereof&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the case of a Tier 1 Participant&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to 2.99 times the sum of (A) the Participant&#8217;s highest Annual Salary in the three years preceding the Termination Date plus (B) the average of the actual bonuses received by such Participant for the three (3) years preceding the Termination Date&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to (A) the Pro-rated Portion of the Participant&#8217;s target cash incentive opportunity for any not yet completed incentive performance period in which the termination occurs, plus (B) in the event of termination after a completed incentive performance period but before payment of the award earned, the amount of such cash incentive award based on actual performance&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a lump sum payment as soon as practicable following the Termination Date in an amount equal to (A) all unused paid time off accrued by such Participant as of the Termination Date under the Company&#8217;s paid time off policy, plus (B) all accrued but unpaid compensation, excluding any nonqualified deferred compensation, earned by such Participant as of the Termination Date to be paid by the Company ((A) and (B) together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, for a period of thirty-six months following the Termination Date, such Participant and his or her dependents shall continue to be covered by all medical, dental and vision insurance plans and programs (excluding disability) maintained by the Company under which the Participant was covered immediately prior to the Termination Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Continued Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the same cost sharing between the Company and Participant as a similarly situated active employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the case of a Tier 2 Participant</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to two times the sum of (A) the Participant&#8217;s highest Annual Salary in the three years preceding the Termination Date plus (B) the average of the actual bonuses received by such Participant for the three (3) years preceding the Termination Date&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to (A) the Pro-rated Portion of the Participant&#8217;s target cash incentive opportunity for any not yet completed incentive performance period in which the termination occurs, plus (B) in the event of termination after a completed incentive performance period but before payment of the award earned, the amount of such cash incentive award based on actual performance&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a lump sum payment as soon as practicable following the Termination Date in an amount equal to all Accrued Obligations as soon as practicable following the Termination Date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, for a period of twenty-four months following the Termination Date, such Participant and his or her dependents shall receive Continued Benefits at the same cost sharing between the Company and Participant as a similarly situated active employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the case of a Tier 3 Participant</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to the sum of (A) the Participant&#8217;s highest Annual Salary in the three years preceding the Termination Date plus (B) the average of the actual bonuses received by such Participant for the three (3) years preceding the Termination Date&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to (A) the Pro-rated Portion of the Participant&#8217;s target cash incentive opportunity for any not yet completed incentive performance period in which the termination occurs, plus (B) in the event of termination after a completed incentive performance period but before payment of the award earned, the amount of such cash incentive award based on actual performance&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a lump sum payment as soon as practicable following the Termination Date in an amount equal to all Accrued Obligations as soon as practicable following the Termination Date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, for a period of twelve months following the Termination Date, such Participant and his or her dependents shall receive Continued </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Benefits at the same cost sharing between the Company and Participant as a similarly situated active employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything herein to the contrary, in the event that a Participant is deemed to be a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i) of the Code, the lump sum severance payment, together with interest at an annual rate (compounded monthly) equal to the federal short-term rate (as in effect under Section 1274(d) of the Code on the Termination Date) shall be paid, to the extent required by Section 409A, to such Participant immediately following the six-month anniversary of the Termination Date and no later than thirty (30) days following such anniversary. In any event, all Accrued Obligations shall be paid to the Participant no later than sixty (60) days following the Termination Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The cost of the Continued Benefits paid by the Company will be imputed as wage income to the Participant to the extent required to comply with Sections 409A and 105(h) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Golden Parachute Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Anything in the Plan to the contrary notwithstanding, in the event it shall be determined that any payment or distribution to or for the benefit of any Participant or the acceleration thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Triggering Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) would be subject to the excise tax imposed by Section 4999 of the Code or any interest or penalties with respect to such excise tax (collectively, such excise tax, together with any such interest or penalties, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (all such payments and benefits, including any cash severance payments payable pursuant to any other plan, arrangement or agreement, hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Total Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then, after taking into account any reduction in the Total Payments provided by reason of Section 280G of the Code in such other plan, arrangement or agreement, the cash severance payments shall first be reduced, and the noncash severance payments shall thereafter be reduced, to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax but only if (A) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (B) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which the Participant would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments). For purposes of determining whether a portion of the Total Payments would be subject to the Excise Tax, the value of the Participant&#8217;s non-competition covenant contained in the Release Agreement (defined below in Section 3.03) shall be determined through independent appraisal by the independent accounting firm described in subsection (b), and a corresponding portion of the amount payable pursuant to Section 3.01 shall be allocated as reasonable compensation for the Participant&#8217;s non-competition covenant and therefore exempt from the definition of the term &#8220;parachute payment&#8221; within the meaning of Sections 280G and 4999 of the Code.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All determinations required to be made under this Section 3.02 with respect to a particular Participant shall be made in writing within ten (10) business days of the receipt of notice from the Participant that there has been a Triggering Payment (or at such earlier time as is requested by the Company and the Participant) by the independent accounting firm then retained by the Company in the ordinary course of business (which firm shall provide detailed supporting calculations to the Company and such Participant) and such determinations shall be final and binding on the Company (including the Compensation Committee) and all Participants. Any fees incurred as a result of work performed by any independent accounting firm pursuant to this Section 3.02 shall be paid by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Condition to Receipt of Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As a condition to receipt of any payment or benefits under this Article III, such Participant must enter into a restrictive covenant (non-solicitation, non-compete, non-disclosure, non-disparagement) and release agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) with the Company and its affiliates substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Participant must execute and deliver a Release Agreement, and such Release Agreement must become effective and irrevocable in accordance with its terms, no later than sixty (60) days following such Participant&#8217;s Termination Date. If this requirement is not satisfied, the Participant shall forfeit the right to all benefits, except for the Accrued Obligations and the Continued Benefits as provided, described in this Article III. In the event such Participant&#8217;s receipt of any or all of the payment or benefits under this Article III is subject to Section 409A and such 60-day period extends into a new calendar year, the Company shall deliver such portion of the payments and benefits to the Participant on the later of the first business day of that new year or the effective date of such Release Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Anything in the Plan to the contrary notwithstanding, the Company&#8217;s obligation to provide the Continued Benefits shall cease if and when the Participant becomes employed by a third party that provides such Participant with substantially comparable health and welfare benefits.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any amounts payable under the Plan shall be in lieu of and not in addition to any other severance or termination payment under any other plan or agreement with the Company. Without limiting the generality of the foregoing, in the event that a Participant becomes entitled to any payment under the Plan, such Participant shall not be entitled to receive any payment under the Company&#8217;s Executive Severance Plan. As a condition to receipt of any payment under the Plan, the Participant shall waive any entitlement to any other severance or termination payment by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan Unfunded&#59; Participant&#8217;s Rights Unsecured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall not be required to establish any special or separate fund or make any other segregation of funds or assets to assure the payment of any benefit hereunder. The right of any Participant to receive the benefits provided for herein shall be an unsecured obligation against the general assets of the Company.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:center;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE IV</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DISPUTE RESOLUTION</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Claims Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It shall not be necessary for a Participant who has become entitled to receive a benefit hereunder to file a claim for such benefit with any person as a condition precedent to receiving a distribution of such benefit. However, any Participant or beneficiary who believes that he or she has become entitled to a benefit hereunder and who has not received, or commenced receiving, a distribution of such benefit, or who believes that he or she is entitled to a benefit hereunder in excess of the benefit which he or she has received, or commenced receiving, may file a written claim for such benefit with the Compensation Committee no later than ninety (90) days following the date on which he or she allegedly became entitled to receive a distribution of such benefit. Such written claim shall set forth the Participant&#8217;s or beneficiary&#8217;s name and address and a statement of the facts and a reference to the pertinent provisions of the Plan upon which such claim is based. The Compensation Committee shall, within ninety (90) days after such written claim is filed, provide the claimant with written notice of its decision with respect to such claim. If such claim is denied in whole or in part, the Compensation Committee shall, in such written notice to the claimant, set forth in a manner calculated to be understood by the claimant the specific reason or reasons for denial&#59; specific references to pertinent provisions of the Plan upon which the denial is based&#59; a description of any additional material or information necessary for the claimant to perfect his or her claim and an explanation of why such material or information is necessary&#59; and an explanation of the provisions for review of claims set forth in Section 4.01(b) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Participant or beneficiary who has filed a written claim for benefits with the Compensation Committee which has been denied may appeal such denial to the Compensation Committee and receive a full and fair review of his or her claim by filing with the Compensation Committee a written application for review at any time within sixty (60) days after receipt from the Compensation Committee of the written notice of denial of his or her claim provided for in Section&#160;4.01(a) above. A Participant or beneficiary who submits a timely written application for review shall be entitled to review any and all documents pertinent to his or her claim and may submit issues and comments to the Compensation Committee in writing. Not later than sixty (60) days after receipt of a written application for review, the Compensation Committee shall give the claimant written notice of its decision on review, which written notice shall set forth in a manner calculated to be understood by the claimant specific reasons for its decision and specific references to the pertinent provisions of the Plan upon which the decision is based. In the event the claimant disputes the decision of the Compensation Committee, the claimant may not bring suit in court with respect to such dispute under the Plan later than one hundred eighty (180) days after receiving the Compensation Committee&#8217;s written notice of its decision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any act permitted or required to be taken by a Participant or beneficiary under this Section 4.01 may be taken for and on behalf of such Participant or beneficiary by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such Participant&#8217;s or beneficiary&#8217;s duly authorized representative. Any claim, notice, application or other writing permitted or required to be filed with or given to a party by this Article shall be deemed to have been filed or given when deposited in the U.S. mail, postage prepaid, and properly addressed to the party to whom it is to be given or with whom it is to be filed. Any such claim, notice, application, or other writing deemed filed or given pursuant to the next foregoing sentence shall in the absence of clear and convincing evidence to the contrary, be deemed to have been received on the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) business day following the date upon which it was filed or given. Any such notice, application, or other writing directed to a Participant or beneficiary shall be deemed properly addressed if directed to the address set forth in the written claim filed by such Participant or beneficiary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE V</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Miscellaneous Provisions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cumulative Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as provided in Section 3.04, the rights and benefits provided to any Participant under the Plan are in addition to and shall not be a replacement of, all of the other rights and benefits provided to such Participant under any Benefit Plan or any agreement between such Participant and the Company except for any severance or termination benefits.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Mitigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No Participant shall be required to mitigate the amount of any payment provided for in the Plan by seeking or accepting other employment following a termination of his or her employment with the Company or otherwise. Except as otherwise provided in Section 3.04, the amount of any payment provided for in the Plan shall not be reduced by any compensation or benefit earned by a Participant as the result of employment by another employer or by retirement benefits. The Company&#8217;s obligations to make payments to any Participant required under the Plan shall not be affected by any set off, counterclaim, recoupment, defense or other claim, right or action that the Company may have against such Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Board may amend or terminate the Plan at any time&#59; provided, however, that the Plan may not be amended or terminated during the pendency of a Potential Change in Control or within two (2) years following a Change in Control. Notwithstanding the foregoing, nothing herein shall abridge the authority of the Compensation Committee to designate a new Participant or a new participation Tier for a current Participant or to determine that a Participant shall no longer be entitled to participate in the Plan in accordance with Section 2.01(a) hereof. The Plan shall terminate when all of the obligations to Participants hereunder have been satisfied in full.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent payments and benefits under the Plan remain subject to Section 409A, payments and benefits under the Plan are intended to comply with Section 409A, and all provisions of the Plan and Notice of Participation shall be interpreted in accordance with Section 409A and Department of Treasury regulations and other interpretive guidance issued </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">thereunder, including without limitation any such regulations or other guidance that may be issued after the adoption or amendment of the Plan (and including the Proposed Treasury Regulations issued June 22, 2016, to the extent the application of such proposed regulations facilitates the administration of this Plan in accordance with the intentions set forth in this paragraph). The Plan shall be interpreted and administered, to the extent possible, in accordance with these intentions. Notwithstanding any provision of the Plan to the contrary, in the event that the Board determines that any payments or benefits may or do not comply with Section 409A, the Board may adopt such amendments to the Plan (without Participant consent) or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Board determines are necessary or appropriate to (i) exempt the Plan and any payments or benefits thereunder from the application of Section 409A, or (ii) comply with the requirements of Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The failure of Participants or the Company to insist upon strict adherence to any term of the Plan on any occasion shall not be considered a waiver of such party&#8217;s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compensation Committee shall have full and final authority, subject to the express provisions of the Plan, with respect to designation of Participants and administration of the Plan, including but not limited to, the authority to construe and interpret any provisions of the Plan and to take all other actions deemed necessary or advisable for the proper administration of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall indemnify and hold harmless each member of the Compensation Committee and any other employee of the Company that acts at the direction of the Compensation Committee against any and all expenses and liabilities arising out of his or her administrative functions or fiduciary responsibilities, including any expenses and liabilities that are caused by or result from an act or omission constituting the negligence of such member in the performance of such functions or responsibilities, but excluding expenses and liabilities that are caused by or result from such member&#8217;s or employee&#8217;s own gross negligence or willful cause. Expenses against which such member or employee shall be indemnified hereunder shall include, without limitation, the amounts of any settlement or judgment, costs, counsel fees, and related charges reasonably incurred in connection with a claim asserted or a proceeding brought or settlement thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidations, Mergers, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event of a merger, consolidation or other transaction, nothing herein shall relieve the Company from any of the obligations set forth in the Plan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that nothing in this Section 5.06 shall prevent an acquirer of or Successor to the Company from assuming the obligations, or any portion thereof, of the Company hereunder pursuant to the terms of the Plan provided that such acquirer or Successor provides adequate assurances of its ability to meet this obligation. In the event that an acquirer of or Successor to the Company agrees to perform the Company&#8217;s obligations, or any portion thereof, hereunder, the Company shall require any person, firm or entity which becomes its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Successor to expressly assume and agree to perform such obligations in writing, in the same manner and to the same extent that the Company would be required to perform hereunder if no such succession had taken place.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Plan shall be binding upon and inure to the benefit of the Company and its Successors and assigns. The Plan and all rights of each Participant shall inure to the benefit of and be enforceable by such Participant and his or her personal or legal representatives, executors, administrators, heirs and permitted assigns. If any Participant should die while any amounts are due and payable to such Participant hereunder, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of the Plan to such Participant&#8217;s devisees, legatees or other designees or, if there be no such devisees, legatees or other designees, to such Participant&#8217;s estate. In the event of the death of any Participant during the applicable period of eligibility for the Continued Benefits set forth in Section 3.01, dependents of such Participant shall be eligible during such period to continue participation in any Continued Benefits in which the Participant was enrolled at the time of death. No payments, benefits or rights arising under the Plan may be assigned or pledged by any Participant, except under the laws of descent and distribution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All notices and other communications provided for in the Plan shall be in writing and shall be sent, delivered or mailed, addressed as follows&#58; (a) if to the Company, at the Company&#8217;s principal office address or such other address as the Company may have designated by written notice to all Participants for purposes hereof, directed to the attention of the General Counsel, and (b) if to any Participant, at his or her residence address on the records of the Company or to such other address as he or she may have designated to the Company in writing for purposes hereof. Each such notice or other communication shall be deemed to have been duly given or mailed by United States certified or registered mail, return receipt requested, postage prepaid, except that any change of notice address shall be effective only upon receipt.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall have the right to deduct from any payment hereunder all taxes (federal, state or other) which it is required to be withhold therefrom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Employment Rights Conferred</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Plan shall not be deemed to create a contract of employment between any Participant and the Company and&#47;or its affiliates. Nothing contained in the Plan shall (i) confer upon any Participant any right with respect to continuation of employment with the Company or (ii) subject to the rights and benefits of any Participant hereunder, interfere in any way with the right of the Company to terminate such Participant&#8217;s employment at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Plan contains the entire understanding of the Participants and the Company with respect to Change in Control severance arrangements maintained on behalf of the Participants by the Company. There are no restrictions, agreements, promises, warranties, covenants or undertakings between the Participants and the Company with respect to the subject matter herein other than those expressly set forth herein. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prior Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Plan supersedes all prior agreements, programs and understandings (including verbal agreements and understandings) between the Participants and the Company regarding the terms and conditions of Participant&#8217;s severance arrangements in the event of a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any provision of the Plan is, becomes or is deemed to be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of the Plan shall not be affected thereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Plan shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to its conflict of laws rules, and applicable federal law.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Remainder of the Page Intentionally Left Blank&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the secretary of the Company does hereby certify the adoption of the Plan on July 24, 2018 by the Encompass Health Corporation Board of Directors.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ENCOMPASS HEALTH CORPORATION</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#1042;&#1091;&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Patrick Darby</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  Executive Vice President, General Counsel and Secretary</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE I</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Tier 1 Participants</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Douglas E. Cotharp, Executive Vice President and Chief Financial Officer &#91;grandfathered&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Barbara Jacobsmeyer, President, Inpatient Hospitals &#91;grandfathered&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Patrick Darby, Executive Vice President, General Counsel and Secretary &#91;grandfathered&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Tier 2 Participants</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive Vice Presidents and equivalent offices, including Chief Financial Officer, President, Inpatient Hospitals and General Counsel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regional Presidents</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Accounting Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Human Resources Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Information Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Medical Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Treasurer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Tier 3 Participants</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Strategy &#38; Development Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Compliance Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Investor Relations Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deputy General Counsel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SVP, Financial Operations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SVP, Public Policy, Legislation &#38; Regulations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SVP, Reimbursement</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RESTRICTED COVENANT AND RELEASE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Release Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into between __________________________ (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Encompass Health Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to the terms and conditions of the Encompass Health Corporation Fifth Amended and Restated Change in Control Benefits Plan, which is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WITNESSETH</font></div><div style="margin-top:12pt;text-align:justify;text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Executive is employed by the Company as ____________________ and is a &#8220;Participant&#8221; in the Plan (as such term is defined in the Plan)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Executive&#8217;s last day of employment with the Company will be ______________ ___, _____, and such date shall be the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; for purposes of this Agreement and the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Executive is eligible to receive benefits under Section 3.01 of the Plan, subject to the terms and conditions of the Plan, including, but not limited to, Executive&#8217;s execution and delivery to the Company of this Agreement and it becoming effective&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Executive has agreed to comply with, among other things, certain confidentiality, noncompetition and nonsolicitation provisions, which are provided below, and such provisions shall be fully enforceable by the Company&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Executive and the Company wish to settle, fully and finally, all matters between them under the terms and conditions exclusively set forth in this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is mutually acknowledged, the Company and Executive agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Benefits under the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Provided that this Agreement becomes effective pursuant to Paragraph 4 of this Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.95pt">The Company shall pay the amount listed on Line&#160;1 of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> attached hereto, subject to all applicable federal, state and local withholdings, in accordance with the terms and conditions of the Plan, paid out in a lump sum within sixty (60) days of the Termination Date. In the event any of such payment is subject to Section 409A and such 60-day period extends into a new calendar year, the Company shall deliver such payment to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant on the later of the first business day of that new year or the effective date of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.27pt">Executive will continue to be eligible to participate in the Company sponsored group healthcare benefits, (excluding disability insurance but specifically including medical, dental and vision plans), under which the Executive was covered immediately prior to the Termination Date, for the number of months listed on Line 2 of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> attached hereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:1.69pt;vertical-align:baseline">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> after the Termination Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), provided that Executive continues to contribute toward the premiums at the level of an active employee of the Company. Thereafter, Executive&#8217;s right to continue coverage under the Company sponsored group healthcare plan at Executive&#8217;s own expense, pursuant to the statutory scheme commonly known as &#8220;COBRA,&#8221; shall be governed by applicable law and the terms of the plans and programs, and will be explained to Executive in a packet to be sent to Executive under separate cover.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.95pt">Executive acknowledges and agrees that the severance payments and benefits provided in subsection (a) and (b) of Section 1 are subject to forfeiture and repayment and any awards relating to Common Stock shall be cancellable and&#47;or forfeitable in the event of a material violation by Executive of Sections 6, 7, and&#47;or 8 of this Agreement</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Executive, on behalf of Executive, Executive&#8217;s heirs, executors, administrators, successors and assigns, hereby irrevocably and unconditionally releases the Company and its subsidiaries, divisions and affiliates, together with their respective owners, assigns, agents, directors, partners, officers, trustees, members, managers, employees, insurers, employee benefit programs (including, but not limited to, trustees, administrators, fiduciaries, and insurers of such programs), attorneys and representatives and any of their predecessors and successors and each of their estates, heirs and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, causes of action, rights, costs, losses, debts and expenses of any nature whatsoever, known or unknown, which Executive or Executive&#8217;s heirs, executors, administrators, successors or assigns ever had, now have or hereafter can, will or may have (either directly, indirectly, derivatively or in any other representative capacity) by reason of any matter, fact or cause whatsoever against the Company or any of the other Company Releases from the beginning of time to the date upon which Executive signs this Agreement, including, but not limited to, any claims arising out of or relating to Executive&#8217;s employment with the Company and&#47;or termination of employment from the Company. This release includes, without limitation, all claims arising out of, or relating to, Executive&#8217;s employment with the Company and the termination of Executive&#8217;s employment with the Company, including all claims for severance or termination benefits under Executive&#8217;s employment agreement with the Company, if any, and under any plan, policy or agreement (other than those benefits expressly payable hereunder) and all claims arising under any foreign, federal, state and local labor, laws including, without limitation, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Employee Retirement Income Security Act of 1974, the Americans </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with Disabilities Act, Title VII of the Civil Rights Act of 1964, the Family and Medical Leave Act, the Civil Rights Act of 1991, the Fair Labor Standards Act, the Equal Pay Act, the Immigration and Reform Control Act, the Uniform Services Employment and Re-Employment Act, the Rehabilitation Act of 1973, Sarbanes-Oxley Act, Executive Order 11246, the Lilly Ledbetter Fair Pay Act, the False Claims Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Alabama Age Discrimination Statute and the Workers&#8217; Adjustment and Retraining Notification Act (and any similar state or local law), each as amended.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.27pt">Nothing in this Paragraph 2 shall be deemed to release (i)&#160;Executive&#8217;s right to enforce the terms of this Agreement&#59; (ii) Executive&#8217;s rights, if any, to any vested benefits or options under any incentive, bonus, or other benefit plan maintained by the Company&#59; (iii) any right to indemnification under the Company&#8217;s Restated Certificate of Incorporation or its Amended and Restated By Laws&#59; or (iv) any claim that cannot be waived under applicable law. Nothing in this Agreement prevents Executive from initiating a complaint with or participating in any legally authorized investigation or proceeding conducted by the Equal Employment Opportunity Commission or any federal, state, or local law enforcement agency. Notwithstanding the foregoing, Executive agrees that Executive is waiving all rights to damages and all other forms of recovery arising out of any charge, complaint or lawsuit filed on behalf of Executive or any third party as to all claims waived in this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.95pt">Executive acknowledges and agrees that the Company has fully satisfied any and all obligations owed to Executive arising out of Executive&#8217;s employment with the Company, and no further sums are owed to Executive by the Company or by any of the other Company Releases at any time. Executive further acknowledges and agrees that the Company has paid Executive for all earned wages and accrued but unused paid time off through the Termination Date. By entering into this Agreement, Executive explicitly waives any rights to severance or other post-termination benefits under any oral or written plan, policy, employment agreement, contract or arrangement with the Company, other than as provided in this Agreement. Executive acknowledges and agrees that, in the absence of this Agreement, the Company has no obligation to provide any of the consideration set forth in Paragraph 1 of this Agreement. Executive further acknowledges and agrees that Executive has no rights to any unvested benefits or options under any incentive, bonus or other benefit plan, except as otherwise provided in the Plan&#59; and that all such vesting shall cease as of the Termination Date. Executive further acknowledges and agrees that any right to continue to contribute to the Company&#8217;s 401(k) plan for employees ended on the Termination Date. Furthermore, Executive acknowledges and agrees that the payments and benefits provided under Paragraph 1 of this Agreement shall not be included in any computation of earnings under the Company&#8217;s 401(k) plan or any other plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive represents that Executive has no lawsuits pending against the Company or any of the other Company Releases. Executive further covenants and agrees that neither Executive nor Executive&#8217;s heirs, executors, administrators, successors or assigns will be entitled to any personal recovery in any  proceeding of any nature whatsoever against the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company or any of the other Company Releases arising out of any of the matters released in Paragraph 2.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Consultation with Attorney&#47;Voluntary Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive acknowledges that (a) the Company is hereby advising Executive of Executive&#8217;s right to consult with an attorney of Executive&#8217;s own choosing prior to executing this Agreement, (b) Executive has carefully read and fully understands all of the provisions of this Agreement, and (c) Executive is entering into this Agreement, including the releases set forth in Paragraph 2 above, knowingly, freely and voluntarily in exchange for good and valuable consideration, including the obligations of the Company under this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Consideration &#38; Revocation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.95pt">Executive acknowledges that Executive has been given at least twenty-one (21) calendar days following receipt of this Agreement to consider the terms of this Agreement, although Executive may execute it sooner.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.27pt">Executive will have seven (7) calendar days from the date on which Executive signs this Agreement to revoke Executive&#8217;s consent to the terms of this Agreement. Such revocation must be in writing and must be addressed and sent via facsimile as follows&#58; Encompass Health Corporation, Attention&#58; General Counsel, facsimile&#58; (205) 262-8692. Notice of such revocation must be received within the seven (7) calendar days referenced above. In the event of such revocation by Executive, this Agreement shall not become effective and Executive shall not have any rights under this Agreement or the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.95pt">Provided that Executive does not revoke this Agreement, this Agreement shall become effective on the eighth calendar day after the date on which Executive signs this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Executive acknowledges and agrees that&#58; (i) the &#8220;Company Business&#8221; (as defined in Paragraph 9(a) below) is intensely competitive and that Executive&#8217;s employment by the Company required Executive to have access to, and knowledge of, &#8220;Confidential Information&#8221; (as defined in Paragraph 9(b) below)&#59; (ii) the use or disclosure of any Confidential Information could place the Company at a serious competitive disadvantage and could do serious damage, financial and otherwise, to the Company&#59; (iii) Executive was given access to, and developed relationships with, employees, clients, patients, physicians and partners of the Company at the time and expense of the Company&#59; and (iv) by Executive&#8217;s training, experience and expertise, Executive&#8217;s services to the Company were extraordinary, special and unique, and the Company invested in training and enhancing Executive&#8217;s skill and experience in the Company Business.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.27pt">Executive further acknowledges and agrees that (i) Executive&#8217;s experience and capabilities are such that the provisions contained in Paragraphs 6, 7, and 8 will not prevent Executive from earning a livelihood&#59; (ii) the Company would be seriously and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">irreparably injured if Executive were to engage in &#8220;Competitive Activities&#8221; (as defined below), or to otherwise breach the obligations contained in Paragraphs 6, 7 and 8, no adequate remedy at-law would exist and damages would be difficult to determine&#59; (iii) the provisions contained in Paragraphs 6, 7 and 8 are justified by and reasonably necessary to protect the legitimate business interests of the Company, including the Confidential Information and good will of the Company&#59; and (iv) the provisions in Paragraphs 6, 7 and 8 are fair and reasonable in scope, duration and geographical limitations. Accordingly, Executive agrees to be bound fully by the restrictive covenants in this Agreement to the maximum extent permitted by law, it being the intent and spirit of the parties that the restrictive covenants and the other agreements contained herein shall be valid and enforceable in all respects.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.95pt">Executive acknowledges and agrees that, from and after the Termination Date, and at all times thereafter, Executive will not communicate, divulge or disclose to any &#8220;Person&#8221; (as defined in Paragraph 9(c) below) or use for Executive&#8217;s own benefit or purpose any Confidential Information of the Company, except as required by law or court order or expressly authorized in writing by the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Executive shall promptly notify the Company prior to making any disclosure required by law or court order so that the Company may seek a protective order or other appropriate remedy.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">From the Termination Date through the end of the Severance Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Noncompetition Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Executive shall not, directly or indirectly, participate in the management, operation or control of, or have any financial or ownership interest in, or aid or knowingly assist anyone else in the conduct of, any business or entity that (i) engages in the Company Business in any Restricted Territory (as defined in Paragraph 9(d) below), or (ii) is, to Executive&#8217;s knowledge, making preparations for engaging in the Company Business in any Restricted Territory (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Competitive Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, however, that (x) the &#8220;beneficial ownership&#8221; by Executive, either individually or as a member of a &#8220;group&#8221; (as such terms are used in Rule 13d of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended), of not more than one percent (1%) of the voting stock of any publicly held corporation shall not alone constitute a breach of this Paragraph 7 and (y) Executive may enter into, at arm&#8217;s length, any bona fide joint venture (or partnership or other business arrangement) with any Person who is not directly engaged in the Company Business but which is an affiliate of another Person engaged in the Company Business.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:12pt;padding-left:65.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Nonsolicitation&#59; Nondisparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.95pt">Executive shall not, directly or indirectly, within the Noncompetition Period, without the prior written consent of the Company, solicit or direct any other Person to solicit any officer or other employee of the Company to&#58; (i) terminate such officer&#8217;s or employee&#8217;s employment with the Company&#59; or (ii) seek or accept employment or other affiliation with Executive or any Person engaged in any Competitive Activity in which Executive is directly or indirectly involved (other than, in each case, any solicitation directed at the public in general in publications available to the public in general or any contact which Executive can demonstrate was initiated by such officer, director or employee or any contact after such officer&#8217;s or employee&#8217;s employment with the Company is terminated). Executive&#8217;s obligations. under this Paragraph 8(a) with respect to new Company employees hired after the Termination Date shall be subject to the condition that Executive shall have been notified of such new employees.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.27pt">Executive shall not, directly or indirectly, within the Noncompetition Period, without the prior written consent of the Company, solicit or direct any other Person to solicit any Person or entity in a business relationship with the Company (whether an independent contractor, joint venture partner or otherwise) to terminated such Person or entity&#8217;s business relationship with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.95pt">Executive shall not, directly or indirectly, within the Noncompetition Period, make any statements or comments of a defamatory or disparaging nature to third parties regarding the Company or any of their members, principals, officers, managers, directors, personnel, employees, agents, services or products&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that nothing contained in this Paragraph 8(b) shall preclude Executive from providing truthful testimony in response to a valid subpoena, court order, regulatory request or as may be required by law.</font></div><div style="margin-top:12pt;padding-left:65.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.95pt">For the purposes of this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the business of owning, operating or managing inpatient rehabilitation facilities offering a range of rehabilitative health care services, and services directly ancillary thereto for which the Company receives compensation.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.27pt">For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; includes, but is not limited to, certain or all of the Company&#8217;s and its patients&#8217;, physicians&#8217; and third-party managed care providers&#8217; supply agreement arrangements, regulatory packages, registration packages, data compensation packages, methods, information, systems, plans for acquisition or disposition of products, expansion plans, financial status and plans, customer lists, client data, personnel information, consulting reports, investigative reports, Personal Health Information (PHI), strategic plans and trade secrets.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.95pt">For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an individual, corporation, joint venture, partnership, limited liability company, association, joint stock or other company, business trust, trust or other entity or organization, including any national, federal, state, territorial agency, local or foreign judicial, legislative, executive, regulatory or administrative authority, commission, court, tribunal, any political or other subdivision, department or branch of any of the foregoing, and any self regulatory organization or arbitrator.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:33.27pt">For the purposes of this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the area within seventy-five (75) miles of any location where an inpatient rehabilitation facility, which is owned or operated by the Company, is located as of the Termination Date.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">Notice to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that Executive accepts employment with another party at any time during the Severance Period, Executive shall inform the Company in writing on or before the commencement date of such employment and provide the Company with such other information relating to available health and welfare benefits as a result of said employment as required by Section 3.03(a) of the Plan. </font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">Duty to Inform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive shall inform in writing any Person, who seeks to employ or engage Executive in any capacity, of Executive&#8217;s obligations under Paragraphs 6, 7 and 8 of this Agreement, prior to accepting such employment or engagement. </font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">Company Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive represents that Executive has returned to the Company all property of the Company. Such property includes, but is not limited to, laptop computers, BlackBerry, printers, other computer equipment (including computers, printers and equipment paid-for by the Company for use at Executive&#8217;s residence), cellular phones and pagers, keys, security passes, passwords, work files, records, credit cards, building ID&#8217;s and all other Company property in Executive&#8217;s possession on the last day of Executive&#8217;s employment with the Company. Following the Termination Date, the Company shall also have no obligation to continue to make payments under any car loan or corporate membership provided to Executive as an employee of the Company.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">No Admission of Wrongdoing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing herein is to be deemed to constitute an admission of wrongdoing by the Company or any of the other Company Releases.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement is binding on, and will inure to the benefit of, the Company and the other Company Releases. All rights of Executive under this Agreement shall inure to the benefit of, and be enforceable by, Executive&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributes, devisees and legatees.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive agrees that the Company would suffer irreparable harm if Executive were to breach, or threaten to breach, any provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement and that the Company would by reason of such breach, or threatened breach, be entitled to injunctive relief in a court of appropriate jurisdiction, without the need to post any bond, and Executive further consents and stipulates to the entry of such injunctive relief in such a court prohibiting Executive from breaching this Agreement. This Paragraph 15 shall not, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">however, diminish the right of the Company to claim and recover damages and other appropriate relief, including but not limited to repayment of any severance payments or benefits provided to Executive, in addition to injunctive relief.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that any one or more</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:1.69pt;vertical-align:baseline">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. Moreover, if any one or more of the provisions contained in this Agreement shall be held to be excessively broad as to duration, activity or subject, such provisions shall be construed by limiting and reducing them so as to be enforceable to the maximum extent allowed by applicable law. Furthermore, a determination in any jurisdiction that this Agreement, in whole or in part, is invalid, illegal or unenforceable shall not in any way affect or impair the validity, legality or enforceability of this Agreement in any other jurisdiction.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The failure of either party to this Agreement to enforce any of its terms, provisions or covenants shall not be construed as a waiver of the same or of the right of such party to enforce the same. Waiver by either party hereto of any breach or default by the other party of any term or provision of this Agreement shall not operate as a waiver of any other breach or default.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">No Oral Modifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may not be changed orally, but may be changed only in a writing signed by Executive and a duly authorized representative of the Company.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">Governing Law&#59; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to the application of any choice-of-law rules that would result in the application of another state&#8217;s laws. With respect to any action, suit or proceeding, each party irrevocably (i) submits to the jurisdiction of the courts of the State of Delaware and the United States District Court of the District of Delaware, and (ii) waives any objection which it may have at any time to the laying of venue of any proceeding brought in any such court, waives any claim that such proceedings have been brought in an inconvenient forum and further waives the right to object, with respect to such proceedings, that such court does not have jurisdiction over such party.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> This Agreement sets forth the entire understanding between Executive and the Company, and supersedes all prior agreements, representations, discussions, and understandings concerning their subject matter. Executive represents that, in executing this Agreement, Executive has not relied upon any representation or statement made by the Company or any other Company Releases, other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">than those set forth herein, with regard to the subject matter, basis or effect of this Agreement or otherwise.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">Descriptive Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The paragraph headings contained herein are for reference purposes only and will not in any way affect the meaning or interpretation of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed simultaneously in counterparts, each of which shall be an original, but all of which shall constitute but one and the same agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Executive and the Company have executed this Agreement on the date indicated below.</font></div><div style="text-align:justify;text-indent:76.5pt"><font><br></font></div><div style="text-align:justify;text-indent:243pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:70.588%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ENCOMPASS HEALTH CORPORATION</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  _____________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;  ___________________________________</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXECUTIVE</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;  ________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;  ___________________________________</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;EXHIBIT A to the Form of Restricted Covenant and Release Agreement&#93;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;INSERT PLAN&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:70.588%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;  _______________________________</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Amount Payable&#58;  ____________________</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.    Months&#58;  ___________________________</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-22
<SEQUENCE>3
<FILENAME>ehc10q93020ex22.htm
<DESCRIPTION>EX-22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6fae03098a1140a298e7ee55f84dec42_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 22</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">List of Subsidiary Guarantors</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following direct and indirect subsidiaries of Encompass Health Corporation guarantee each series of its senior unsecured notes.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.105%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A&#38;B Home Health Solutions, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Abba Home Health, L.P.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advanced Homecare Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advanced Homecare Management, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AHM Action Home Health, LP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AHM Texas GP, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AHM Texas LP, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Apex Hospice LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Best Home Care LP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Home Health of Alabama, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Home Health of East Tennessee, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Home Health of the Gulf Coast, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Central Mississippi, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of East Louisiana, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Louisiana, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of North Mississippi, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Northeast Alabama LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Northeast Mississippi, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of South Alabama, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Southwest Mississippi, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of the Gulf Coast, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Medical Systems, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareServices of the Treasure Coast, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth Health System, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Columbus, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Dothan, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Gainesville, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Greensboro, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Lexington, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of North Florida, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Panama City, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Richmond, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of South Carolina, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Tallahassee, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of the Bay Area, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Valley, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Virginia, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Washington, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Western Carolina, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Winchester, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth Hospice, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continental Home Care, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continental Medical Systems, LLC</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.105%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continental Rehabilitation Hospital of Arizona, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CS Health&#160;&#38; Wellness, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Day-By-Day&#160;Staff Relief, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DOSIK, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DRC Health Systems, L.P.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EHHI Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Acquisition Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Acquisition Holdings Subsidiary, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Alabama Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Arizona Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Arkansas Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Boise Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Bryan Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health C Corp Sub Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health California Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Central Arkansas Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Colorado Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Deaconess Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Fairlawn Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health GKBJH Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Gulfport Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health of Alabama, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health of Birmingham, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health of Central Virginia, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health of Florida, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health of Kentucky, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health of New England, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health of Ohio, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Hospice of Alabama, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Hospice of Pennsylvania, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Hospice of the Midwest, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Hospice of the Southwest, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Iowa Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Johnson City Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Joint Ventures Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Jonesboro Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Kansas Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Kentucky Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Littleton Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Lubbock Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Martin County Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Maryland Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Massachusetts Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Midland Odessa Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Myrtle Beach Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Nevada Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health New Mexico Real Estate, LLC</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.105%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Ohio Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Owned Hospitals Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Pennsylvania Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Properties, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Abilene, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Albuquerque, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Altamonte Springs, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Arlington, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Austin, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Bakersfield, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Bluffton, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Braintree, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cardinal Hill, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Charleston, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cincinnati, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of City View, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Colorado Springs, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Columbia, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Concord, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cypress, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dallas, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Desert Canyon, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dothan, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of East Valley, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Erie, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Florence, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Fort Smith, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Franklin, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Fredericksburg, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Gadsden, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Harmarville, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Henderson, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Humble, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Katy, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Kingsport, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Lakeview, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Largo, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Las Vegas, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Littleton, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Manati, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Mechanicsburg, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Miami, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Middletown, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Modesto, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Montgomery, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Murrieta, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of New England, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Newnan, LLC</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.105%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Nittany Valley, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northern Kentucky, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northern Virginia, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northwest Tucson, L.P.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Ocala, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Panama City, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Pearland, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Petersburg, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Plano, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Reading, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Richardson, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Round Rock, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of San Antonio, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of San Juan, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sarasota, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Scottsdale, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Shelby County, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Spring Hill, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sugar Land, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sunrise, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tallahassee, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Texarkana, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of the&#160;Mid-Cities,&#160;LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of The Woodlands, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Toms River, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Treasure Coast, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tustin, L.P.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Utah, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Vineland, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Western Massachusetts, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of York, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital The Vintage, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital Vision Park, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Institute of Tucson, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Savannah Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Sea Pines Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Sewickley Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health South Carolina Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health South Dakota Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Support Companies, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Texas Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Tucson Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Tulsa Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Tyler Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Utah Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health ValleyofTheSun Rehabilitation Hospital, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Virginia Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Walton Rehabilitation Hospital, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health West Tennessee Holdings, LLC</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:67.105%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health West Virginia Real Estate, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Westerville Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Winston-Salem Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Yuma Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Home Health of Austin, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Home Health of Colorado, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Home Health of DFW, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Home Health of East Texas, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Home Health of New England, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Home Health of the Mid Atlantic, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Home Health of the Midwest, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Home Health of the Southeast, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Home Health of the West, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Hospice of the West, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass of Fort Worth, LP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass of West Texas, LP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA ASSOCIATES, L.L.C.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA HEALTHCARE, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA HOME HEALTH AGENCY, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA HOMECARE, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Guardian Home Care, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Hallmark Homecare, L.P.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthCare Innovations of Oklahoma, L.L.C.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HEALTHCARE INNOVATIONS OF WESTERN OKLAHOMA, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthCare Innovations-Travertine Health Services, L.L.C.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthSouth Rehabilitation Hospital of Austin, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthSouth Rehabilitation Hospital of Fort Worth, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Home Health Care of Bogalusa, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Home Health Care Systems, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Hospice Care of Mississippi, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Idaho Homecare Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Orion Homecare, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preferred Home Health, L.P.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print Promotions Group, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rebound, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rehabilitation Hospital Corporation of America, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rehabilitation Hospital of North Alabama, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rehabilitation Hospital of Plano, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reliant Blocker Corp.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Saad Healthcare of St. Clair County LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Texas Senior Care, L.P.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TH of San Antonio LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WellCare, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wellmark Healthcare Services of El Paso, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">West Mississippi Home Health Services, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Western Neuro Care, Inc.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ehc10q93020ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i334b2618202c46d5b4a05d58a433cec5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark J. Tarr, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Encompass Health Corporation&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Tarr</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ehc10q93020ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2b51f2ebcc8445b3aaa91da837cbc98b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Douglas E. Coltharp, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Encompass Health Corporation&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OUGLAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OLTHARP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas E. Coltharp</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ehc10q93020ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i257d7f2effae47b488789cfd3b0e39f9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Encompass Health Corporation on Form 10-Q for the period ended September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Mark J. Tarr, President and Chief Executive Officer of Encompass Health Corporation, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Encompass Health Corporation.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Tarr</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement has been provided to Encompass Health Corporation and will be retained by Encompass Health Corporation and furnished to the Securities and Exchange Commission or its staff upon request.&#160;&#160;This written statement shall not, except to the extent required by the 2002 Act, be deemed filed by Encompass Health Corporation for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Encompass Health Corporation specifically incorporates it by reference.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ehc10q93020ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iaf3e860f97ca4691a21c743476711428_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Encompass Health Corporation on Form 10-Q for the period ended September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Douglas E. Coltharp, Executive Vice President and Chief Financial Officer of Encompass Health Corporation, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Encompass Health Corporation.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OUGLAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OLTHARP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas E. Coltharp</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement has been provided to Encompass Health Corporation and will be retained by Encompass Health Corporation and furnished to the Securities and Exchange Commission or its staff upon request.&#160;&#160;This written statement shall not, except to the extent required by the 2002 Act, be deemed filed by Encompass Health Corporation for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Encompass Health Corporation specifically incorporates it by reference.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ehc-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e0fc9ecd-686a-431a-a15f-a624ec9cb1a0,g:253d3480-dc2c-4d92-b5eb-51ca56c502e3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ehc="http://www.encompasshealth.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.encompasshealth.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.encompasshealth.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquityUnaudited" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.encompasshealth.com/role/BasisofPresentation">
        <link:definition>2101101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.encompasshealth.com/role/BasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationTables" roleURI="http://www.encompasshealth.com/role/BasisofPresentationTables">
        <link:definition>2303301 - Disclosure - Basis of Presentation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationTextualDetails" roleURI="http://www.encompasshealth.com/role/BasisofPresentationTextualDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationNetOperatingRevenuesDetails" roleURI="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation - Net Operating Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.encompasshealth.com/role/BusinessCombinations">
        <link:definition>2106102 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTables">
        <link:definition>2307302 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTextualDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails">
        <link:definition>2408403 - Disclosure - Business Combinations - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails">
        <link:definition>2409404 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNetCashPaidforAcquisitionsDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails">
        <link:definition>2410405 - Disclosure - Business Combinations - Net Cash Paid for Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsProFormaResultsofOperationDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails">
        <link:definition>2411406 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntities" roleURI="http://www.encompasshealth.com/role/VariableInterestEntities">
        <link:definition>2112103 - Disclosure - Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesTables" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTables">
        <link:definition>2313303 - Disclosure - Variable Interest Entities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesTextualDetails" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails">
        <link:definition>2414407 - Disclosure - Variable Interest Entities - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails">
        <link:definition>2415408 - Disclosure - Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.encompasshealth.com/role/LongtermDebt">
        <link:definition>2116104 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.encompasshealth.com/role/LongtermDebtTables">
        <link:definition>2317304 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtLongtermDebtOutstandingDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails">
        <link:definition>2418409 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtFinancialCovenantsDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails">
        <link:definition>2419410 - Disclosure - Long-term Debt - Financial Covenants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTextualDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails">
        <link:definition>2420411 - Disclosure - Long-term Debt - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterests" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests">
        <link:definition>2121105 - Disclosure - Redeemable Noncontrolling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsTables" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables">
        <link:definition>2322305 - Disclosure - Redeemable Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails">
        <link:definition>2423412 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails">
        <link:definition>2424413 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsTextualDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails">
        <link:definition>2425414 - Disclosure - Redeemable Noncontrolling Interests - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.encompasshealth.com/role/FairValueMeasurements">
        <link:definition>2126106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTables">
        <link:definition>2327306 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2428415 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTextualDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails">
        <link:definition>2429416 - Disclosure - Fair Value Measurements - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails">
        <link:definition>2430417 - Disclosure - Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.encompasshealth.com/role/ShareBasedPayments">
        <link:definition>2131107 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails">
        <link:definition>2432418 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.encompasshealth.com/role/IncomeTaxes">
        <link:definition>2133108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.encompasshealth.com/role/IncomeTaxesDetails">
        <link:definition>2434419 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShare" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShare">
        <link:definition>2135109 - Disclosure - Earnings per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShareTables" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareTables">
        <link:definition>2336307 - Disclosure - Earnings per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails">
        <link:definition>2437420 - Disclosure - Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails">
        <link:definition>2438421 - Disclosure - Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherCommitments" roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments">
        <link:definition>2139110 - Disclosure - Contingencies and Other Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherCommitmentsDetails" roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails">
        <link:definition>2440422 - Disclosure - Contingencies and Other Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.encompasshealth.com/role/SegmentReporting">
        <link:definition>2141111 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.encompasshealth.com/role/SegmentReportingTables">
        <link:definition>2342308 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTextualDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingTextualDetails">
        <link:definition>2443423 - Disclosure - Segment Reporting - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails">
        <link:definition>2444424 - Disclosure - Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails">
        <link:definition>2445425 - Disclosure - Segment Reporting - Segment Reporting Information, Total Assets and Investments In and Advances to Nonconsolidated Affiliates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails">
        <link:definition>2446426 - Disclosure - Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails">
        <link:definition>2447427 - Disclosure - Segment Reporting - Reconciliation of Assets from Segment to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails">
        <link:definition>2448428 - Disclosure - Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ehc_Numberofhomehealthlocations" abstract="false" name="Numberofhomehealthlocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_NumberofBedsExpanded" abstract="false" name="NumberofBedsExpanded" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_AdjustedEBITDA" abstract="false" name="AdjustedEBITDA" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_PortercareAdventistMember" abstract="true" name="PortercareAdventistMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_AllocatedSharebasedCompensationLiability" abstract="false" name="AllocatedSharebasedCompensationLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" abstract="false" name="IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Jointventureownershippercentage" abstract="false" name="Jointventureownershippercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" abstract="false" name="RedeemableNoncontrollingInterestEquityAcquiredPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ehc_Numberofsolelyownedinpatientrehabilitationhospitals" abstract="false" name="Numberofsolelyownedinpatientrehabilitationhospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_InpatientRehabilitationSegmentMember" abstract="true" name="InpatientRehabilitationSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestMember" abstract="true" name="RedeemableNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_GenerationSolutionsofLynchburgMember" abstract="true" name="GenerationSolutionsofLynchburgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" abstract="false" name="Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" abstract="true" name="StatementOfComprehensiveIncomeAndIncomeStatementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_CostofServicesExcludingDepreciationandAmortization" abstract="false" name="CostofServicesExcludingDepreciationandAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_NumberofBedsAcquired" abstract="false" name="NumberofBedsAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_HomehealthMember" abstract="true" name="HomehealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_PatientsMember" abstract="true" name="PatientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" abstract="false" name="ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ehc_PortercareAdventistandPremierHealthPartnersMember" abstract="true" name="PortercareAdventistandPremierHealthPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_SARsmarktomarketimpactonnoncontrollinginterests" abstract="false" name="SARsmarktomarketimpactonnoncontrollinginterests" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_TermLoanFacilitiesMember" abstract="true" name="TermLoanFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_NoncontrollingInterestExchangeTransaction" abstract="false" name="NoncontrollingInterestExchangeTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NumberOfInpatientRehabilitationHospitals" abstract="false" name="NumberOfInpatientRehabilitationHospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantLeverageRatio" abstract="false" name="DebtInstrumentCovenantLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_NumberofDeNovoBeds" abstract="false" name="NumberofDeNovoBeds" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_PremierHealthPartnersMember" abstract="true" name="PremierHealthPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_OccupancyCost" abstract="false" name="OccupancyCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ScheduleOfFinancialCovenantsTableTextBlock" abstract="false" name="ScheduleOfFinancialCovenantsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ehc_NumberofBedsContributed" abstract="false" name="NumberofBedsContributed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" abstract="true" name="RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_SeniorNotes4.50Due2028Member" abstract="true" name="SeniorNotes4.50Due2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_HomeHealthandHospiceSegmentMember" abstract="true" name="HomeHealthandHospiceSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_SeniorNotes04.750Due2030Member" abstract="true" name="SeniorNotes04.750Due2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" abstract="false" name="DebtInstrumentDiscountRateAtIssuanceOfFaceValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ehc_WorkersCompensationMember" abstract="true" name="WorkersCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_Numberofhospicelocations" abstract="false" name="Numberofhospicelocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_InpatientMember" abstract="true" name="InpatientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_SeniorNotes04625Due2031Member" abstract="true" name="SeniorNotes04625Due2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_HoldingsAndEHHIMember" abstract="true" name="HoldingsAndEHHIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod" abstract="false" name="NumberofJointVenturesAccountedforUsingtheEquityMethod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_PayrolltaxesonSARsexercise" abstract="false" name="PayrolltaxesonSARsexercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_SeniorNotes05.75Due2025Member" abstract="true" name="SeniorNotes05.75Due2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_Reclassificationtononcontrollinginterests" abstract="false" name="Reclassificationtononcontrollinginterests" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" abstract="false" name="TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings" abstract="false" name="MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ehc_ManagedCareMember" abstract="true" name="ManagedCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" abstract="false" name="NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_OtherIncomeSourceMember" abstract="true" name="OtherIncomeSourceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" abstract="false" name="Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" abstract="false" name="ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ehc_OtherThirdpartyPayorsMember" abstract="true" name="OtherThirdpartyPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" abstract="false" name="IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_VariableInterestEntityNumberofEntitiesConsolidated" abstract="false" name="VariableInterestEntityNumberofEntitiesConsolidated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" abstract="false" name="SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ehc_BusinessCombinationNoncontrollingInterestFairValue" abstract="false" name="BusinessCombinationNoncontrollingInterestFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_OutpatientandotherMember" abstract="true" name="OutpatientandotherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_SeniorNotes0575Due2024Member" abstract="true" name="SeniorNotes0575Due2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_HospiceMember" abstract="true" name="HospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_SeniorNotes05.125Due2023Member" abstract="true" name="SeniorNotes05.125Due2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantInterestCoverageRatio" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_Contributiontojointventure" abstract="false" name="Contributiontojointventure" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NetIncomeLossAvailabletoCommonStockholders" abstract="false" name="NetIncomeLossAvailabletoCommonStockholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_EHHIMember" abstract="true" name="EHHIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_Numberofjointlyownedinpatientrehabilitationhospitals" abstract="false" name="Numberofjointlyownedinpatientrehabilitationhospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" abstract="false" name="NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ehc_NicholsLitigationMember" abstract="true" name="NicholsLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" abstract="false" name="NumberOfInpatientRehabilitationUnitsUnderManagementContracts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ehc-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e0fc9ecd-686a-431a-a15f-a624ec9cb1a0,g:253d3480-dc2c-4d92-b5eb-51ca56c502e3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CoverPage" xlink:type="simple" xlink:href="ehc-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d4c2fc98-e5db-4ddd-8b74-c7eedf03e3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_434312ae-9983-4666-aab5-e428bb15297f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d4c2fc98-e5db-4ddd-8b74-c7eedf03e3c1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_434312ae-9983-4666-aab5-e428bb15297f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_5911cc4a-87ac-4d8d-a223-ab5285afc4f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d4c2fc98-e5db-4ddd-8b74-c7eedf03e3c1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_5911cc4a-87ac-4d8d-a223-ab5285afc4f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be93848a-40c0-4aa0-8f04-411923da2a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_021ead68-c7e3-42a0-9327-f9ccce261f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_be93848a-40c0-4aa0-8f04-411923da2a56" xlink:to="loc_us-gaap_ProfitLoss_021ead68-c7e3-42a0-9327-f9ccce261f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fd5e09ce-88e9-4b70-bbfe-b679ff6cd9df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_be93848a-40c0-4aa0-8f04-411923da2a56" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fd5e09ce-88e9-4b70-bbfe-b679ff6cd9df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d9c518e2-b2d7-4f9b-be38-5fa9a13ce3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ebb998e9-597c-4f8a-9539-8567530b264b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_d9c518e2-b2d7-4f9b-be38-5fa9a13ce3a7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ebb998e9-597c-4f8a-9539-8567530b264b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_26059f3e-b8ea-4930-ac13-e81d120a41d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_d9c518e2-b2d7-4f9b-be38-5fa9a13ce3a7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_26059f3e-b8ea-4930-ac13-e81d120a41d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2239a282-0f94-4ba7-a433-d0af7e03d039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_6a5cda5f-c32d-4c95-8568-4f155f2dbdfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_2239a282-0f94-4ba7-a433-d0af7e03d039" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_6a5cda5f-c32d-4c95-8568-4f155f2dbdfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_36f0613f-84e5-4b6d-afda-7a712a187fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_2239a282-0f94-4ba7-a433-d0af7e03d039" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_36f0613f-84e5-4b6d-afda-7a712a187fed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ba31fe41-d5b6-4f24-b826-e66ca08386ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_6f6b715a-d5aa-490d-a23a-9e53d1d4a7c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba31fe41-d5b6-4f24-b826-e66ca08386ad" xlink:to="loc_us-gaap_LaborAndRelatedExpense_6f6b715a-d5aa-490d-a23a-9e53d1d4a7c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_b2a7f3bc-ebcd-4230-b63b-7501035be194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba31fe41-d5b6-4f24-b826-e66ca08386ad" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_b2a7f3bc-ebcd-4230-b63b-7501035be194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_2798d53b-b9d0-4cb7-bcf2-f77e9ebf17bf" xlink:href="ehc-20200930.xsd#ehc_OccupancyCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba31fe41-d5b6-4f24-b826-e66ca08386ad" xlink:to="loc_ehc_OccupancyCost_2798d53b-b9d0-4cb7-bcf2-f77e9ebf17bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_90bc1e33-b2c4-4047-88a6-0e081b518042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba31fe41-d5b6-4f24-b826-e66ca08386ad" xlink:to="loc_us-gaap_SuppliesExpense_90bc1e33-b2c4-4047-88a6-0e081b518042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8b930706-ca37-47f5-835a-51c34e50f659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba31fe41-d5b6-4f24-b826-e66ca08386ad" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8b930706-ca37-47f5-835a-51c34e50f659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3f251329-3086-427c-96d1-1f82cc85817c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba31fe41-d5b6-4f24-b826-e66ca08386ad" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3f251329-3086-427c-96d1-1f82cc85817c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_ea5dcd57-6fe2-4ec3-a844-389b6551cd00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba31fe41-d5b6-4f24-b826-e66ca08386ad" xlink:to="loc_us-gaap_LitigationSettlementExpense_ea5dcd57-6fe2-4ec3-a844-389b6551cd00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d902117d-ec56-4ae7-8da5-417f13206d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8a05b5b4-b2db-4a30-9128-bc6e1a73d375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d902117d-ec56-4ae7-8da5-417f13206d92" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8a05b5b4-b2db-4a30-9128-bc6e1a73d375" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_0463f1e2-1727-4397-ae32-815ec2d6bcaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d902117d-ec56-4ae7-8da5-417f13206d92" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_0463f1e2-1727-4397-ae32-815ec2d6bcaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_be30d2b9-2550-49af-b239-5d836b24cef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_49a9a319-b421-48ab-9f49-b8b663ecc75d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_be30d2b9-2550-49af-b239-5d836b24cef3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_49a9a319-b421-48ab-9f49-b8b663ecc75d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_26317e08-93fb-4c79-a91e-e96fb0d4e3cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_be30d2b9-2550-49af-b239-5d836b24cef3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_26317e08-93fb-4c79-a91e-e96fb0d4e3cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d17da60-4c21-43e8-8167-cd0774d0ea61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1d0c1683-1885-4d3e-a4a5-af91d1de4d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d17da60-4c21-43e8-8167-cd0774d0ea61" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1d0c1683-1885-4d3e-a4a5-af91d1de4d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3ac3ef5c-e741-4de7-a737-b332a5559722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d17da60-4c21-43e8-8167-cd0774d0ea61" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3ac3ef5c-e741-4de7-a737-b332a5559722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4096722-90e1-4fd3-bd6a-ff370d54bfb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d17da60-4c21-43e8-8167-cd0774d0ea61" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4096722-90e1-4fd3-bd6a-ff370d54bfb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_442d928b-1f86-45b7-8f29-e2d7f95e93d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d17da60-4c21-43e8-8167-cd0774d0ea61" xlink:to="loc_us-gaap_CostsAndExpenses_442d928b-1f86-45b7-8f29-e2d7f95e93d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2ad8eec9-e170-4969-93e9-b4da3cfa6cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d17da60-4c21-43e8-8167-cd0774d0ea61" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2ad8eec9-e170-4969-93e9-b4da3cfa6cd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_00e0bc7f-63ea-4151-a844-7eabb48b5917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3d17da60-4c21-43e8-8167-cd0774d0ea61" xlink:to="loc_us-gaap_InterestExpense_00e0bc7f-63ea-4151-a844-7eabb48b5917" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_919a7672-36da-426e-a196-47b14f394119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a99b27aa-96a6-4167-9e8f-bbce496069f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_919a7672-36da-426e-a196-47b14f394119" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a99b27aa-96a6-4167-9e8f-bbce496069f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_e56fa427-4087-4f73-b448-6d326abf67e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_919a7672-36da-426e-a196-47b14f394119" xlink:to="loc_us-gaap_RestrictedCashCurrent_e56fa427-4087-4f73-b448-6d326abf67e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d24c83ad-6b59-4b6a-9f5e-11891eb00d39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_919a7672-36da-426e-a196-47b14f394119" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d24c83ad-6b59-4b6a-9f5e-11891eb00d39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_974f49be-3d01-4937-8ed7-25c59a56bc9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_919a7672-36da-426e-a196-47b14f394119" xlink:to="loc_us-gaap_OtherAssetsCurrent_974f49be-3d01-4937-8ed7-25c59a56bc9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_56eddeca-2688-415d-b620-91ef5c34dbc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_77b076a6-44eb-4b8d-bab6-294f0ff235b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_56eddeca-2688-415d-b620-91ef5c34dbc5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_77b076a6-44eb-4b8d-bab6-294f0ff235b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_76332e55-e9de-4f77-87ec-45750520c1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_56eddeca-2688-415d-b620-91ef5c34dbc5" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_76332e55-e9de-4f77-87ec-45750520c1b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dcfeea51-74a0-4cd2-b4bb-c116568baa9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_56eddeca-2688-415d-b620-91ef5c34dbc5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dcfeea51-74a0-4cd2-b4bb-c116568baa9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a257116a-8897-46f3-a2d6-fc1b29f98e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_56eddeca-2688-415d-b620-91ef5c34dbc5" xlink:to="loc_us-gaap_Liabilities_a257116a-8897-46f3-a2d6-fc1b29f98e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6b070476-11aa-46b4-b224-95e4486a3502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b999d81d-d087-41b5-9c38-98dae94d7d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6b070476-11aa-46b4-b224-95e4486a3502" xlink:to="loc_us-gaap_LiabilitiesCurrent_b999d81d-d087-41b5-9c38-98dae94d7d1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_dd01b979-f19a-4602-8c3e-2ebf9f163f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6b070476-11aa-46b4-b224-95e4486a3502" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_dd01b979-f19a-4602-8c3e-2ebf9f163f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_866cc5cf-9b5b-4aa9-a095-c18248917fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6b070476-11aa-46b4-b224-95e4486a3502" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_866cc5cf-9b5b-4aa9-a095-c18248917fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9b840431-11ea-4673-b571-76a8cd70475d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6b070476-11aa-46b4-b224-95e4486a3502" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9b840431-11ea-4673-b571-76a8cd70475d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_be7a16a0-31d2-44e4-bce2-c884bbe69e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ba02245f-1e39-4653-8a51-2d88bd95fd3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be7a16a0-31d2-44e4-bce2-c884bbe69e7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ba02245f-1e39-4653-8a51-2d88bd95fd3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ad511272-0401-4263-ab82-4ee5c8b3848d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be7a16a0-31d2-44e4-bce2-c884bbe69e7d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ad511272-0401-4263-ab82-4ee5c8b3848d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c4dd6330-b5ed-4f45-b554-0ad795ee6616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be7a16a0-31d2-44e4-bce2-c884bbe69e7d" xlink:to="loc_us-gaap_Goodwill_c4dd6330-b5ed-4f45-b554-0ad795ee6616" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_064ef9f6-dd18-419a-9e0f-bff01504ca26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be7a16a0-31d2-44e4-bce2-c884bbe69e7d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_064ef9f6-dd18-419a-9e0f-bff01504ca26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_9fd445b4-1ef3-453e-b461-f9bcb5263e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be7a16a0-31d2-44e4-bce2-c884bbe69e7d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_9fd445b4-1ef3-453e-b461-f9bcb5263e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_301e5acc-8805-4013-9aae-4b8bf5c5cb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be7a16a0-31d2-44e4-bce2-c884bbe69e7d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_301e5acc-8805-4013-9aae-4b8bf5c5cb65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_896e3b90-b449-4733-881e-306b10b482e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_be7a16a0-31d2-44e4-bce2-c884bbe69e7d" xlink:to="loc_us-gaap_AssetsCurrent_896e3b90-b449-4733-881e-306b10b482e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_00b54751-4c51-456c-a19c-63e0c4d75e63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a715bb29-dbbd-4877-b48b-022370ea848a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00b54751-4c51-456c-a19c-63e0c4d75e63" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a715bb29-dbbd-4877-b48b-022370ea848a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_83db8bd3-0f8b-4729-9305-551896bb60ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00b54751-4c51-456c-a19c-63e0c4d75e63" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_83db8bd3-0f8b-4729-9305-551896bb60ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_00471a47-40e9-4655-a9cb-18f169f7b749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00b54751-4c51-456c-a19c-63e0c4d75e63" xlink:to="loc_us-gaap_AccountsPayableCurrent_00471a47-40e9-4655-a9cb-18f169f7b749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a4eada0a-ef29-489c-a69f-a36bee6364aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00b54751-4c51-456c-a19c-63e0c4d75e63" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a4eada0a-ef29-489c-a69f-a36bee6364aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f774f9fe-0bc7-4d26-9fb9-f9fa9e3f4fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_308fca68-7992-4dee-9c37-9f3d77d9b1a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f774f9fe-0bc7-4d26-9fb9-f9fa9e3f4fe5" xlink:to="loc_us-gaap_StockholdersEquity_308fca68-7992-4dee-9c37-9f3d77d9b1a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c5176add-7419-413d-a91f-d912a365a470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f774f9fe-0bc7-4d26-9fb9-f9fa9e3f4fe5" xlink:to="loc_us-gaap_MinorityInterest_c5176add-7419-413d-a91f-d912a365a470" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnaudited"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2bbb8e3-431a-4761-a970-00f0752ba1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59487d26-0654-45b9-a843-e50bd24e03a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2bbb8e3-431a-4761-a970-00f0752ba1e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59487d26-0654-45b9-a843-e50bd24e03a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c437296-040f-42b7-9d5b-8051ed6b393d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2bbb8e3-431a-4761-a970-00f0752ba1e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c437296-040f-42b7-9d5b-8051ed6b393d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_622ada25-f3a1-4b18-b91e-5d9214314a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2bbb8e3-431a-4761-a970-00f0752ba1e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_622ada25-f3a1-4b18-b91e-5d9214314a69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fb5fc111-26a2-49b9-93f0-709e8efc168d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fb5fc111-26a2-49b9-93f0-709e8efc168d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ad25f542-f60e-4d0b-9056-e921595da200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_ShareBasedCompensation_ad25f542-f60e-4d0b-9056-e921595da200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e55a2b07-6028-4150-b75c-71c8d6ed9cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e55a2b07-6028-4150-b75c-71c8d6ed9cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6adf23de-886f-4d8b-842c-b3ba838aae49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6adf23de-886f-4d8b-842c-b3ba838aae49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_27d75e0c-b27e-4260-82c7-a3f2fc9917d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_27d75e0c-b27e-4260-82c7-a3f2fc9917d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5dad1ca5-01b7-4ec9-ae7c-a584cb4bfe3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5dad1ca5-01b7-4ec9-ae7c-a584cb4bfe3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8eeff9cb-05d6-46ab-98c7-f29f797a4239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8eeff9cb-05d6-46ab-98c7-f29f797a4239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_6a8a6fed-7aa6-4c4e-9a0f-12eba7ac6aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_6a8a6fed-7aa6-4c4e-9a0f-12eba7ac6aa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9a151869-adc8-47a0-a2bb-cd143f369449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9a151869-adc8-47a0-a2bb-cd143f369449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_cdf8a589-a46c-43b7-a6ca-b40a9f590155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_cdf8a589-a46c-43b7-a6ca-b40a9f590155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_eaad1627-e21c-4d47-a380-4dc7e7d1478c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_eaad1627-e21c-4d47-a380-4dc7e7d1478c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_1d52ba55-a54a-4038-be8b-ead515dc12f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_1d52ba55-a54a-4038-be8b-ead515dc12f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_6fc3857e-d2f4-4188-b79b-3a7f1513cefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_cda3fc9a-27dc-4bc8-83d7-eb692c5be146" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_6fc3857e-d2f4-4188-b79b-3a7f1513cefe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d8bd1fa-d957-494b-ba26-e703843c97e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca51cd80-d97b-4e09-ba85-02ac7271596a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d8bd1fa-d957-494b-ba26-e703843c97e4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca51cd80-d97b-4e09-ba85-02ac7271596a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_3c356801-7f51-4a93-a4ba-6b05a77b2a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d8bd1fa-d957-494b-ba26-e703843c97e4" xlink:to="loc_us-gaap_PaymentsForSoftware_3c356801-7f51-4a93-a4ba-6b05a77b2a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b39565f2-1cc2-4344-bcc1-12c9ca37e2af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d8bd1fa-d957-494b-ba26-e703843c97e4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b39565f2-1cc2-4344-bcc1-12c9ca37e2af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5eb57fa-5881-4896-b5d2-dc38955e827e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d8bd1fa-d957-494b-ba26-e703843c97e4" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5eb57fa-5881-4896-b5d2-dc38955e827e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_48ace626-2282-410c-bf3b-93f976183308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_48ace626-2282-410c-bf3b-93f976183308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_d95a9c03-2d0b-4e3e-902d-b09672fa0e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_d95a9c03-2d0b-4e3e-902d-b09672fa0e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_6aaf813f-20b8-4402-979a-15388a3dbaf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_6aaf813f-20b8-4402-979a-15388a3dbaf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_d34bdd23-6431-4d01-b334-a9e079bf8054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_d34bdd23-6431-4d01-b334-a9e079bf8054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_8d1fe49a-ac0e-4045-a338-5adb932f9d07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_8d1fe49a-ac0e-4045-a338-5adb932f9d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9aca8d19-058f-4f95-ab87-3529d0f7f5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9aca8d19-058f-4f95-ab87-3529d0f7f5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_09ff0ef5-29b2-490b-8cb9-8638ff4bf01e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_09ff0ef5-29b2-490b-8cb9-8638ff4bf01e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_fd3f8710-b3cc-46ef-a76c-0614934aea13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_fd3f8710-b3cc-46ef-a76c-0614934aea13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_b6fed34e-4b02-4074-98f9-880aba24183a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_b6fed34e-4b02-4074-98f9-880aba24183a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b6a3ffd5-2d15-4fed-8f15-956c15adf16b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b6a3ffd5-2d15-4fed-8f15-956c15adf16b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0d981828-44cd-40e7-be0e-bf4d6feaeae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0d981828-44cd-40e7-be0e-bf4d6feaeae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_bbc078ef-bca6-474f-93e5-f459a9c76891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e42b90e-3b9d-4aad-9b56-45f44b063f5c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_bbc078ef-bca6-474f-93e5-f459a9c76891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2188c687-9d1c-4ce8-b6fe-a4699e16f24d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_58f38642-d5b5-4c69-a314-831bc1eddf09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2188c687-9d1c-4ce8-b6fe-a4699e16f24d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_58f38642-d5b5-4c69-a314-831bc1eddf09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_e1ee694a-253e-4e77-b32e-851a3b7b0edb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2188c687-9d1c-4ce8-b6fe-a4699e16f24d" xlink:to="loc_us-gaap_RestrictedCashCurrent_e1ee694a-253e-4e77-b32e-851a3b7b0edb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_013891c4-c3a8-4e6d-adb1-e291e77c11ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2188c687-9d1c-4ce8-b6fe-a4699e16f24d" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_013891c4-c3a8-4e6d-adb1-e291e77c11ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_236e239b-5d73-4fc3-8fa5-e79182bd227a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_33965859-7e3e-476f-98cc-48e3d8a26693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_236e239b-5d73-4fc3-8fa5-e79182bd227a" xlink:to="loc_us-gaap_ProfitLoss_33965859-7e3e-476f-98cc-48e3d8a26693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_919a5936-d195-4086-b820-d2301673c4c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_236e239b-5d73-4fc3-8fa5-e79182bd227a" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_919a5936-d195-4086-b820-d2301673c4c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_3bc8ec98-bb32-48ec-9ae5-08448127ef4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_236e239b-5d73-4fc3-8fa5-e79182bd227a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_3bc8ec98-bb32-48ec-9ae5-08448127ef4f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentation" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationTables"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationTextualDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationNetOperatingRevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinations"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsTables"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsTextualDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_058e6752-2b64-4a3f-bd85-54b9799d108f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4c57953b-35b4-46be-87c3-eccc54f11727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_058e6752-2b64-4a3f-bd85-54b9799d108f" xlink:to="loc_us-gaap_Goodwill_4c57953b-35b4-46be-87c3-eccc54f11727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_62627cd7-a1c4-4d4b-bf87-90dadee4bf94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_058e6752-2b64-4a3f-bd85-54b9799d108f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_62627cd7-a1c4-4d4b-bf87-90dadee4bf94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ac2a2d66-4bde-4895-9587-f31c75bf89f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_058e6752-2b64-4a3f-bd85-54b9799d108f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ac2a2d66-4bde-4895-9587-f31c75bf89f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsNetCashPaidforAcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsProFormaResultsofOperationDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntities"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntitiesTables"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntitiesTextualDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebt"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtTables"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_5c4db326-eb89-4e34-94cb-76881b86fa43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_61d7ddf1-caf1-4f4e-8402-3bacdbf9eee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_5c4db326-eb89-4e34-94cb-76881b86fa43" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_61d7ddf1-caf1-4f4e-8402-3bacdbf9eee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a8b3b594-13b3-49f9-91c0-b2babd546299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_5c4db326-eb89-4e34-94cb-76881b86fa43" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a8b3b594-13b3-49f9-91c0-b2babd546299" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtFinancialCovenantsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtTextualDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterests"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsTables"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_944e8cf9-6d2b-4cfb-876b-c7e1fd7de977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_d50397eb-9082-4844-938f-52b7478701bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_944e8cf9-6d2b-4cfb-876b-c7e1fd7de977" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_d50397eb-9082-4844-938f-52b7478701bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_d76cd775-8aff-4c9d-92c8-3f62393d4e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_944e8cf9-6d2b-4cfb-876b-c7e1fd7de977" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_d76cd775-8aff-4c9d-92c8-3f62393d4e3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsTextualDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsTextualDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="ehc-20200930.xsd#ShareBasedPayments"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#ShareBasedPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ehc-20200930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShare"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShareTables"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_ffc7f798-6bc1-4983-948b-ebde8a391016" xlink:href="ehc-20200930.xsd#ehc_NetIncomeLossAvailabletoCommonStockholders"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_f18f0698-e414-41ac-a4b5-b91b69f441b6" xlink:href="ehc-20200930.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_ffc7f798-6bc1-4983-948b-ebde8a391016" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_f18f0698-e414-41ac-a4b5-b91b69f441b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_96e1f1df-aef5-466e-948a-04438d4edd89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_ffc7f798-6bc1-4983-948b-ebde8a391016" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_96e1f1df-aef5-466e-948a-04438d4edd89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_440fc366-2e04-487e-9a33-86e684aec9b3" xlink:href="ehc-20200930.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d486ba94-84ae-4dab-ac6c-f8bf0a2b5066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_440fc366-2e04-487e-9a33-86e684aec9b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d486ba94-84ae-4dab-ac6c-f8bf0a2b5066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_a88a27b8-55e8-46f2-a0ba-e03888edcaed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_440fc366-2e04-487e-9a33-86e684aec9b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_a88a27b8-55e8-46f2-a0ba-e03888edcaed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_cdf1242c-4e12-4c2d-a6e3-8d6c6c4a2be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_440fc366-2e04-487e-9a33-86e684aec9b3" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_cdf1242c-4e12-4c2d-a6e3-8d6c6c4a2be3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a39a6f7d-8635-4f57-b080-6a91d2803efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_8d22cb58-f084-4ee9-ab54-7eae9661fc57" xlink:href="ehc-20200930.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a39a6f7d-8635-4f57-b080-6a91d2803efd" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_8d22cb58-f084-4ee9-ab54-7eae9661fc57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0b9047a2-7a13-4e63-b212-2167ca9914d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a39a6f7d-8635-4f57-b080-6a91d2803efd" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_0b9047a2-7a13-4e63-b212-2167ca9914d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_992825a5-c763-4a8d-b930-b3a21572f4f9" xlink:href="ehc-20200930.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_bcd77b94-db6c-4335-b2e4-e6c2886e4e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_992825a5-c763-4a8d-b930-b3a21572f4f9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_bcd77b94-db6c-4335-b2e4-e6c2886e4e21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_d5dd29f7-c9ed-4d24-bd2e-b9e2f2f75240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_992825a5-c763-4a8d-b930-b3a21572f4f9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_d5dd29f7-c9ed-4d24-bd2e-b9e2f2f75240" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_45c923d4-10a0-464a-aa02-10e138f9d241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfba5d0b-6f1f-46a7-b8b4-5398454f32a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_45c923d4-10a0-464a-aa02-10e138f9d241" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfba5d0b-6f1f-46a7-b8b4-5398454f32a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_74fb44a6-0d3a-4db3-8af9-39f6b7b6118c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_45c923d4-10a0-464a-aa02-10e138f9d241" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_74fb44a6-0d3a-4db3-8af9-39f6b7b6118c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="simple" xlink:href="ehc-20200930.xsd#ContingenciesandOtherCommitments"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#ContingenciesandOtherCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReporting"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReporting" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingTables"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingTextualDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_4612a39f-150c-405f-975d-b3774dccb3a1" xlink:href="ehc-20200930.xsd#ehc_AdjustedEBITDA"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21f50d11-a9e2-4ddc-ad01-c5f870cd763a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_AdjustedEBITDA_4612a39f-150c-405f-975d-b3774dccb3a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21f50d11-a9e2-4ddc-ad01-c5f870cd763a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b553656d-60a7-4294-8d59-36f8db4b80f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_AdjustedEBITDA_4612a39f-150c-405f-975d-b3774dccb3a1" xlink:to="loc_us-gaap_CostsAndExpenses_b553656d-60a7-4294-8d59-36f8db4b80f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2756329b-6eba-45dd-8518-c2cd8d8a369f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_AdjustedEBITDA_4612a39f-150c-405f-975d-b3774dccb3a1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2756329b-6eba-45dd-8518-c2cd8d8a369f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ecd7346e-e2f1-49c0-b8ce-089ee62fd1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_AdjustedEBITDA_4612a39f-150c-405f-975d-b3774dccb3a1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ecd7346e-e2f1-49c0-b8ce-089ee62fd1c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a291145c-acff-42b1-9b85-0084586940f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_AdjustedEBITDA_4612a39f-150c-405f-975d-b3774dccb3a1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a291145c-acff-42b1-9b85-0084586940f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3ddba494-dbb2-4576-9b1a-4ee3aca8182d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization_49298cf7-d529-48cd-8f7f-a889c0b973ea" xlink:href="ehc-20200930.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ddba494-dbb2-4576-9b1a-4ee3aca8182d" xlink:to="loc_ehc_CostofServicesExcludingDepreciationandAmortization_49298cf7-d529-48cd-8f7f-a889c0b973ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_dbb68f00-f825-4748-a87a-ed2d7f5590e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ddba494-dbb2-4576-9b1a-4ee3aca8182d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_dbb68f00-f825-4748-a87a-ed2d7f5590e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_35600143-708c-465a-b324-11e2fb3b1d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ddba494-dbb2-4576-9b1a-4ee3aca8182d" xlink:to="loc_us-gaap_LaborAndRelatedExpense_35600143-708c-465a-b324-11e2fb3b1d58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_28394058-7724-452b-bd47-ec42e7af80b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ddba494-dbb2-4576-9b1a-4ee3aca8182d" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_28394058-7724-452b-bd47-ec42e7af80b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_666da51b-9bbf-4116-b22b-a149eb1b9a4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ddba494-dbb2-4576-9b1a-4ee3aca8182d" xlink:to="loc_us-gaap_SuppliesExpense_666da51b-9bbf-4116-b22b-a149eb1b9a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_401540eb-4394-4e38-8fa1-334ae8b9fdd7" xlink:href="ehc-20200930.xsd#ehc_OccupancyCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ddba494-dbb2-4576-9b1a-4ee3aca8182d" xlink:to="loc_ehc_OccupancyCost_401540eb-4394-4e38-8fa1-334ae8b9fdd7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_dd8544fe-da1c-4955-bbd3-5b78713c9193" xlink:href="ehc-20200930.xsd#ehc_AdjustedEBITDA"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_ehc_AdjustedEBITDA_dd8544fe-da1c-4955-bbd3-5b78713c9193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_19e79b42-a8e3-4c40-ae5e-f978b8389753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_19e79b42-a8e3-4c40-ae5e-f978b8389753" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4c0e69d4-c280-4b74-9221-2828ca6537ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4c0e69d4-c280-4b74-9221-2828ca6537ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b170b9f1-c69a-4716-9397-21591d80f195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b170b9f1-c69a-4716-9397-21591d80f195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_6fd26b76-28eb-44f1-b71e-22d751694d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_us-gaap_LitigationSettlementExpense_6fd26b76-28eb-44f1-b71e-22d751694d34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_de634bd0-f864-4c2e-a08c-de066cfdce23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_us-gaap_InterestExpenseDebt_de634bd0-f864-4c2e-a08c-de066cfdce23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e21357cd-064d-4ebb-82e6-c10c35352113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e21357cd-064d-4ebb-82e6-c10c35352113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests_ab5c3eaa-21e7-481d-aa62-014d592df545" xlink:href="ehc-20200930.xsd#ehc_SARsmarktomarketimpactonnoncontrollinginterests"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests_ab5c3eaa-21e7-481d-aa62-014d592df545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss_9f851e95-2977-4958-b48d-c12557592b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_us-gaap_MarketableSecuritiesGainLoss_9f851e95-2977-4958-b48d-c12557592b2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_6a0a17a0-6a96-499e-a9b9-8e75502702f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_6a0a17a0-6a96-499e-a9b9-8e75502702f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayrolltaxesonSARsexercise_8fdc20f8-8a92-417d-b502-b0a17843304f" xlink:href="ehc-20200930.xsd#ehc_PayrolltaxesonSARsexercise"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_ehc_PayrolltaxesonSARsexercise_8fdc20f8-8a92-417d-b502-b0a17843304f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b9a22fcd-fbb1-483a-89a4-352983e5e78a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d0aa47a1-1f08-41a2-9eb9-1d0200a6ef61" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b9a22fcd-fbb1-483a-89a4-352983e5e78a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ehc-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e0fc9ecd-686a-431a-a15f-a624ec9cb1a0,g:253d3480-dc2c-4d92-b5eb-51ca56c502e3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CoverPage" xlink:type="simple" xlink:href="ehc-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CoverPage" xlink:type="extended" id="i29a566a30b3949919329be1364c5a979_CoverPage"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended" id="ia75fd51007dc424aad03d5c060b7f9d7_CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="i19fd0698483c4501b3981a338b9addd8_CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" id="ia86114397f604d698e523cd677af4e72_CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_262299cb-3894-40df-8b7e-f270e11bf7d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_099c43ac-43fa-4ec1-94c0-5d032568c631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262299cb-3894-40df-8b7e-f270e11bf7d0" xlink:to="loc_us-gaap_Assets_099c43ac-43fa-4ec1-94c0-5d032568c631" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d2b0e41b-ed03-4724-88fd-2a80d24235ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_262299cb-3894-40df-8b7e-f270e11bf7d0" xlink:to="loc_us-gaap_Liabilities_d2b0e41b-ed03-4724-88fd-2a80d24235ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aa9f5fdf-2945-4516-95fb-e8221369760e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_262299cb-3894-40df-8b7e-f270e11bf7d0" xlink:to="loc_us-gaap_StatementTable_aa9f5fdf-2945-4516-95fb-e8221369760e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_149b6637-c875-4136-92db-5143ded0171b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_aa9f5fdf-2945-4516-95fb-e8221369760e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_149b6637-c875-4136-92db-5143ded0171b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_149b6637-c875-4136-92db-5143ded0171b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_149b6637-c875-4136-92db-5143ded0171b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_149b6637-c875-4136-92db-5143ded0171b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3d7bfc08-3721-4be4-964b-51400c1b3eab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_149b6637-c875-4136-92db-5143ded0171b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3d7bfc08-3721-4be4-964b-51400c1b3eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4dcf892e-afda-4335-82a3-b3e17fe7217f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3d7bfc08-3721-4be4-964b-51400c1b3eab" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4dcf892e-afda-4335-82a3-b3e17fe7217f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="extended" id="i3c0ab0d7b18c4f2698f9896dab903e3c_CondensedConsolidatedStatementsofShareholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_18171275-cf2b-4515-98bc-1ded30e311b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18171275-cf2b-4515-98bc-1ded30e311b1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f561b18-faaf-477c-bf0b-45fd34990aff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f561b18-faaf-477c-bf0b-45fd34990aff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_43388e37-12b4-4d44-b5bd-2a8fa27c4fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_43388e37-12b4-4d44-b5bd-2a8fa27c4fe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_13d7c076-4ea6-432c-9951-c7610eafba22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_13d7c076-4ea6-432c-9951-c7610eafba22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_188bdec7-7eff-49c1-b129-82233575dd9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_188bdec7-7eff-49c1-b129-82233575dd9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_50efee61-b5f0-4a46-bec0-54ec786f63fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_50efee61-b5f0-4a46-bec0-54ec786f63fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_a1eb63c7-74bf-4bed-80c0-fd934acd127b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_DividendsCommonStockCash_a1eb63c7-74bf-4bed-80c0-fd934acd127b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_faf4253c-5582-482d-8738-ed30020378a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_faf4253c-5582-482d-8738-ed30020378a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1b3e477d-e09c-4ffe-8c05-edbed682c852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1b3e477d-e09c-4ffe-8c05-edbed682c852" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96416370-7885-45f2-9139-a3e09508f7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96416370-7885-45f2-9139-a3e09508f7e1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_bd6c29fc-5665-49e9-a5d1-7f4684acd335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_bd6c29fc-5665-49e9-a5d1-7f4684acd335" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions_f76f9e1e-4f16-444f-8fe1-5bee95c577e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_PartnersCapitalAccountContributions_f76f9e1e-4f16-444f-8fe1-5bee95c577e2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_6b058357-1cf2-4167-887b-80862677b4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_6b058357-1cf2-4167-887b-80862677b4c8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_b37ef4f3-08d4-4176-ac3d-c14bc7dc5fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_b37ef4f3-08d4-4176-ac3d-c14bc7dc5fa8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_21f926f2-3b72-4d08-9181-7a22447037ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_21f926f2-3b72-4d08-9181-7a22447037ae" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_c0267848-48eb-4338-86ef-8ab18201c93b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_c0267848-48eb-4338-86ef-8ab18201c93b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_9391b389-a4cc-42d8-9e98-d3049c7632ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockholdersEquityOther_9391b389-a4cc-42d8-9e98-d3049c7632ab" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_2740f5d6-443a-43b5-b7fd-15d6af55cd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_2740f5d6-443a-43b5-b7fd-15d6af55cd1b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f1d3dd2-710c-4371-a73e-8fdc95ae1c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7e65c0fd-8264-48c3-bd3f-2568c8d5bb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_04a58509-4a1d-4780-96aa-dfa2fa57d3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_18171275-cf2b-4515-98bc-1ded30e311b1" xlink:to="loc_us-gaap_StatementTable_04a58509-4a1d-4780-96aa-dfa2fa57d3a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b4b62133-9bbb-42b6-b575-d737255749c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_04a58509-4a1d-4780-96aa-dfa2fa57d3a6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b4b62133-9bbb-42b6-b575-d737255749c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b4b62133-9bbb-42b6-b575-d737255749c0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b4b62133-9bbb-42b6-b575-d737255749c0" xlink:to="loc_us-gaap_EquityComponentDomain_b4b62133-9bbb-42b6-b575-d737255749c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b4b62133-9bbb-42b6-b575-d737255749c0" xlink:to="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f375e4fc-ed0a-40e9-b6ee-f0f3b3cd4826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:to="loc_us-gaap_CommonStockMember_f375e4fc-ed0a-40e9-b6ee-f0f3b3cd4826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_49ac9e21-a1eb-4375-b890-4c6220a692eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_49ac9e21-a1eb-4375-b890-4c6220a692eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5ec61244-96eb-4965-85b6-97f1c8b5ffbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:to="loc_us-gaap_RetainedEarningsMember_5ec61244-96eb-4965-85b6-97f1c8b5ffbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_68eb5276-927f-4fab-89fb-a59d40b3c6fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:to="loc_us-gaap_TreasuryStockMember_68eb5276-927f-4fab-89fb-a59d40b3c6fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_af522481-b530-4403-b880-b136534d9c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:to="loc_us-gaap_NoncontrollingInterestMember_af522481-b530-4403-b880-b136534d9c84" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical" xlink:type="extended" id="i660c063f6f544dbbb7b4d2fcda21d387_CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="ib633cd84c0e74afb8f353f6b15341cbc_CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentation" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentation" xlink:type="extended" id="ifd284fd3a484439fa009868800d58c7c_BasisofPresentation"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationPolicies"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationPolicies" xlink:type="extended" id="i816f8782199b40e19f679e0f37741cbe_BasisofPresentationPolicies"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationTables"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationTables" xlink:type="extended" id="i3ba6dfe72e3049c3a33d9f1ae5ce3905_BasisofPresentationTables"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationTextualDetails" xlink:type="extended" id="if722c9a21d2243f094b0e7ff163d619d_BasisofPresentationTextualDetails"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationNetOperatingRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails" xlink:type="extended" id="i20dc8b4aa8b243cd92b0032fe1f55935_BasisofPresentationNetOperatingRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ddd0ffbc-fbed-48b2-869a-6466b371a8fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07b24ced-9c5b-400a-8210-faffe4acaf46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ddd0ffbc-fbed-48b2-869a-6466b371a8fb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07b24ced-9c5b-400a-8210-faffe4acaf46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_be1575bb-d6fc-4bc9-b7e9-4ef02945c710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ddd0ffbc-fbed-48b2-869a-6466b371a8fb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_be1575bb-d6fc-4bc9-b7e9-4ef02945c710" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41c7f8e4-8d66-4c71-ad5f-30aa96ded7cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_be1575bb-d6fc-4bc9-b7e9-4ef02945c710" xlink:to="loc_srt_ProductOrServiceAxis_41c7f8e4-8d66-4c71-ad5f-30aa96ded7cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_41c7f8e4-8d66-4c71-ad5f-30aa96ded7cb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_41c7f8e4-8d66-4c71-ad5f-30aa96ded7cb" xlink:to="loc_srt_ProductsAndServicesDomain_41c7f8e4-8d66-4c71-ad5f-30aa96ded7cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_41c7f8e4-8d66-4c71-ad5f-30aa96ded7cb" xlink:to="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_e0250a88-2b9f-4f91-baba-68695c5f2612" xlink:href="ehc-20200930.xsd#ehc_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_MedicareMember_e0250a88-2b9f-4f91-baba-68695c5f2612" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember_b0084a86-5c03-48d8-acca-98399f180f1b" xlink:href="ehc-20200930.xsd#ehc_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_MedicareAdvantageMember_b0084a86-5c03-48d8-acca-98399f180f1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember_6e13e6c0-97cb-4c35-9f0d-a13b4cffe3b7" xlink:href="ehc-20200930.xsd#ehc_ManagedCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_ManagedCareMember_6e13e6c0-97cb-4c35-9f0d-a13b4cffe3b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember_d9ba4ef6-6d48-4f28-9bd3-039441415e05" xlink:href="ehc-20200930.xsd#ehc_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_MedicaidMember_d9ba4ef6-6d48-4f28-9bd3-039441415e05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember_6fa2f6ac-95db-4ca8-b30f-62c7fb266235" xlink:href="ehc-20200930.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_OtherThirdpartyPayorsMember_6fa2f6ac-95db-4ca8-b30f-62c7fb266235" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember_2cd71378-d32a-46dc-835f-f0b79693a13c" xlink:href="ehc-20200930.xsd#ehc_WorkersCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_WorkersCompensationMember_2cd71378-d32a-46dc-835f-f0b79693a13c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember_f53a0741-55b0-456d-8463-cad633f7e4ca" xlink:href="ehc-20200930.xsd#ehc_PatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_PatientsMember_f53a0741-55b0-456d-8463-cad633f7e4ca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember_ad5b0efb-d3f8-4960-8422-f5156e52c93f" xlink:href="ehc-20200930.xsd#ehc_OtherIncomeSourceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_OtherIncomeSourceMember_ad5b0efb-d3f8-4960-8422-f5156e52c93f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_38e5a243-ff73-4d39-92af-4e14c906d32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_be1575bb-d6fc-4bc9-b7e9-4ef02945c710" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_38e5a243-ff73-4d39-92af-4e14c906d32c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_38e5a243-ff73-4d39-92af-4e14c906d32c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_38e5a243-ff73-4d39-92af-4e14c906d32c" xlink:to="loc_us-gaap_SegmentDomain_38e5a243-ff73-4d39-92af-4e14c906d32c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_75304931-c9ce-49ab-8bec-2d180466abd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_38e5a243-ff73-4d39-92af-4e14c906d32c" xlink:to="loc_us-gaap_SegmentDomain_75304931-c9ce-49ab-8bec-2d180466abd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_9eebb710-f488-4363-af55-02cccf9b70af" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_75304931-c9ce-49ab-8bec-2d180466abd7" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_9eebb710-f488-4363-af55-02cccf9b70af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_b158a808-0dbc-44dd-8bb5-d16b50c1f893" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_75304931-c9ce-49ab-8bec-2d180466abd7" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_b158a808-0dbc-44dd-8bb5-d16b50c1f893" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinations"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="extended" id="i653a22f22c494e1b855cd7de0e2c9c89_BusinessCombinations"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsTables"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="extended" id="id5e997fcaf61465a887aa0fcfeb434da_BusinessCombinationsTables"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="extended" id="i072b2039506340078aa0dfb28e81ae69_BusinessCombinationsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c89212ee-5bbf-4d06-aa4b-be438a7c2c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c89212ee-5bbf-4d06-aa4b-be438a7c2c38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsAcquired_ddd26e8a-c426-4d13-b95b-672f167ecc1f" xlink:href="ehc-20200930.xsd#ehc_NumberofBedsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_ehc_NumberofBedsAcquired_ddd26e8a-c426-4d13-b95b-672f167ecc1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsContributed_3ecff0b9-aaff-4584-b0c0-16c704aecf70" xlink:href="ehc-20200930.xsd#ehc_NumberofBedsContributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_ehc_NumberofBedsContributed_3ecff0b9-aaff-4584-b0c0-16c704aecf70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsExpanded_5d355b7f-5346-47c9-9009-a66da2f8bfc0" xlink:href="ehc-20200930.xsd#ehc_NumberofBedsExpanded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_ehc_NumberofBedsExpanded_5d355b7f-5346-47c9-9009-a66da2f8bfc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofDeNovoBeds_3c1010f6-2d84-4ac1-a95e-f12c04c0a4e9" xlink:href="ehc-20200930.xsd#ehc_NumberofDeNovoBeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_ehc_NumberofDeNovoBeds_3c1010f6-2d84-4ac1-a95e-f12c04c0a4e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d1b32cc9-9b16-4f0a-ba15-b2964ca219e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d1b32cc9-9b16-4f0a-ba15-b2964ca219e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ce1f4fd-cb5f-4862-9d71-98e5dada8c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ce1f4fd-cb5f-4862-9d71-98e5dada8c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3ce1f4fd-cb5f-4862-9d71-98e5dada8c6b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ce1f4fd-cb5f-4862-9d71-98e5dada8c6b" xlink:to="loc_us-gaap_RelatedPartyDomain_3ce1f4fd-cb5f-4862-9d71-98e5dada8c6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_12eae7ed-64e8-4e09-b71f-15f02ae29e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ce1f4fd-cb5f-4862-9d71-98e5dada8c6b" xlink:to="loc_us-gaap_RelatedPartyDomain_12eae7ed-64e8-4e09-b71f-15f02ae29e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_1acd7a16-d00f-4961-aa9c-94208a39774b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_12eae7ed-64e8-4e09-b71f-15f02ae29e5c" xlink:to="loc_us-gaap_CorporateJointVentureMember_1acd7a16-d00f-4961-aa9c-94208a39774b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6bd0cfc2-8772-4888-8001-981c5787e3c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6bd0cfc2-8772-4888-8001-981c5787e3c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6bd0cfc2-8772-4888-8001-981c5787e3c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6bd0cfc2-8772-4888-8001-981c5787e3c5" xlink:to="loc_us-gaap_SegmentDomain_6bd0cfc2-8772-4888-8001-981c5787e3c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb602bf8-7e37-4ba1-a998-0f038cb1dcf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6bd0cfc2-8772-4888-8001-981c5787e3c5" xlink:to="loc_us-gaap_SegmentDomain_bb602bf8-7e37-4ba1-a998-0f038cb1dcf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_c944baa4-0427-4928-9185-b67e13cd3e9a" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bb602bf8-7e37-4ba1-a998-0f038cb1dcf1" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_c944baa4-0427-4928-9185-b67e13cd3e9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7c69516b-1979-487e-8784-03f59840b7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7c69516b-1979-487e-8784-03f59840b7d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c69516b-1979-487e-8784-03f59840b7d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7c69516b-1979-487e-8784-03f59840b7d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c69516b-1979-487e-8784-03f59840b7d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b20fa820-2d47-4000-905a-2bc1ab2ca8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7c69516b-1979-487e-8784-03f59840b7d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b20fa820-2d47-4000-905a-2bc1ab2ca8eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistMember_5f5c1f36-7e87-4486-ba70-807400d2233a" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b20fa820-2d47-4000-905a-2bc1ab2ca8eb" xlink:to="loc_ehc_PortercareAdventistMember_5f5c1f36-7e87-4486-ba70-807400d2233a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PremierHealthPartnersMember_6ccaabf7-b915-4d7c-9520-fd9086745ec7" xlink:href="ehc-20200930.xsd#ehc_PremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b20fa820-2d47-4000-905a-2bc1ab2ca8eb" xlink:to="loc_ehc_PremierHealthPartnersMember_6ccaabf7-b915-4d7c-9520-fd9086745ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_65c9f67e-56a3-4dcd-9372-093b24941915" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistandPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b20fa820-2d47-4000-905a-2bc1ab2ca8eb" xlink:to="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_65c9f67e-56a3-4dcd-9372-093b24941915" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended" id="i7495beed8dfe4cec9d8692959fb36819_BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ded8ef4f-d36b-4ff7-8680-cd25710e232f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ded8ef4f-d36b-4ff7-8680-cd25710e232f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8819833a-52d8-48a7-bb54-fc84e351bd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8819833a-52d8-48a7-bb54-fc84e351bd55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a4ed5c23-6981-45f1-bdb0-9cbc1b4e02fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a4ed5c23-6981-45f1-bdb0-9cbc1b4e02fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_19b6633b-23c4-4dde-91ae-f41c15de9112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_Goodwill_19b6633b-23c4-4dde-91ae-f41c15de9112" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f7a83d2c-5d02-486f-9855-22b0a4ca2165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f7a83d2c-5d02-486f-9855-22b0a4ca2165" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ea507f48-9506-4246-b8e9-51388e3ddbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ea507f48-9506-4246-b8e9-51388e3ddbd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ea507f48-9506-4246-b8e9-51388e3ddbd6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ea507f48-9506-4246-b8e9-51388e3ddbd6" xlink:to="loc_us-gaap_SegmentDomain_ea507f48-9506-4246-b8e9-51388e3ddbd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1b362c48-9854-4220-aa41-b34730987ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ea507f48-9506-4246-b8e9-51388e3ddbd6" xlink:to="loc_us-gaap_SegmentDomain_1b362c48-9854-4220-aa41-b34730987ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_6810fa4e-62ac-46c8-a934-b3a5310af22a" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1b362c48-9854-4220-aa41-b34730987ead" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_6810fa4e-62ac-46c8-a934-b3a5310af22a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_9f64b009-bc99-4d90-98dc-9131b987ea28" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1b362c48-9854-4220-aa41-b34730987ead" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_9f64b009-bc99-4d90-98dc-9131b987ea28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5b5d6453-a48a-4ba7-b039-a6076537ac66" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:to="loc_srt_RangeAxis_5b5d6453-a48a-4ba7-b039-a6076537ac66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b5d6453-a48a-4ba7-b039-a6076537ac66_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5b5d6453-a48a-4ba7-b039-a6076537ac66" xlink:to="loc_srt_RangeMember_5b5d6453-a48a-4ba7-b039-a6076537ac66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_59c7367c-bb29-41e5-a983-99cdb26dbe82" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5b5d6453-a48a-4ba7-b039-a6076537ac66" xlink:to="loc_srt_RangeMember_59c7367c-bb29-41e5-a983-99cdb26dbe82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d10f35eb-106c-4004-a4de-98bd9f1f6e33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_59c7367c-bb29-41e5-a983-99cdb26dbe82" xlink:to="loc_srt_MaximumMember_d10f35eb-106c-4004-a4de-98bd9f1f6e33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d045acaa-5aff-4f73-ba5b-f46407c6c770" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_59c7367c-bb29-41e5-a983-99cdb26dbe82" xlink:to="loc_srt_MinimumMember_d045acaa-5aff-4f73-ba5b-f46407c6c770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_847c6dfb-66c8-4f0a-a246-3c4b3d3de20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_847c6dfb-66c8-4f0a-a246-3c4b3d3de20b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_847c6dfb-66c8-4f0a-a246-3c4b3d3de20b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_847c6dfb-66c8-4f0a-a246-3c4b3d3de20b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_847c6dfb-66c8-4f0a-a246-3c4b3d3de20b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4fb9ca-f96c-4acd-ab63-6f2e760c2d74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_847c6dfb-66c8-4f0a-a246-3c4b3d3de20b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4fb9ca-f96c-4acd-ab63-6f2e760c2d74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_013d8faf-6e6e-4a49-85b0-8ae5c8c85348" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistandPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4fb9ca-f96c-4acd-ab63-6f2e760c2d74" xlink:to="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_013d8faf-6e6e-4a49-85b0-8ae5c8c85348" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsofLynchburgMember_0f61377d-56f4-4c7d-8ce0-69cd3a15fc15" xlink:href="ehc-20200930.xsd#ehc_GenerationSolutionsofLynchburgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4fb9ca-f96c-4acd-ab63-6f2e760c2d74" xlink:to="loc_ehc_GenerationSolutionsofLynchburgMember_0f61377d-56f4-4c7d-8ce0-69cd3a15fc15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1ee2e870-2c9a-4b03-a713-db04ed307aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1ee2e870-2c9a-4b03-a713-db04ed307aca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ee2e870-2c9a-4b03-a713-db04ed307aca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1ee2e870-2c9a-4b03-a713-db04ed307aca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ee2e870-2c9a-4b03-a713-db04ed307aca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7387cf8-6e60-4a29-8755-60d0eb7319d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1ee2e870-2c9a-4b03-a713-db04ed307aca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7387cf8-6e60-4a29-8755-60d0eb7319d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_ca6fa22b-aebb-484d-8b8c-0ebcb792a021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7387cf8-6e60-4a29-8755-60d0eb7319d2" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_ca6fa22b-aebb-484d-8b8c-0ebcb792a021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_35a6eebc-4062-48a5-8a3b-857dc9dac123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7387cf8-6e60-4a29-8755-60d0eb7319d2" xlink:to="loc_us-gaap_TradeNamesMember_35a6eebc-4062-48a5-8a3b-857dc9dac123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3a05595b-37d5-409f-bf26-b9b60943ca46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7387cf8-6e60-4a29-8755-60d0eb7319d2" xlink:to="loc_us-gaap_LicensingAgreementsMember_3a05595b-37d5-409f-bf26-b9b60943ca46" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsNetCashPaidforAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails" xlink:type="extended" id="i71620faf4cbe469ea994483c650e89d4_BusinessCombinationsNetCashPaidforAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_0441e5bd-7efd-454f-bf07-ab21df643f19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_0441e5bd-7efd-454f-bf07-ab21df643f19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8c38e1e4-52fc-40f5-9d62-e9716e4827d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8c38e1e4-52fc-40f5-9d62-e9716e4827d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_5606c6cb-85ca-40a4-80a2-08cddc740e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_5606c6cb-85ca-40a4-80a2-08cddc740e86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_694e2c04-ddf2-4cbe-a9ec-8a657b427bc1" xlink:href="ehc-20200930.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_694e2c04-ddf2-4cbe-a9ec-8a657b427bc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0d9e85d2-4b8a-43e9-bfd7-e6a4b6090c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0d9e85d2-4b8a-43e9-bfd7-e6a4b6090c43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ac242be-e309-4d3c-9f38-7ddace4c42ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ac242be-e309-4d3c-9f38-7ddace4c42ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d045f562-e04c-4a0b-bbec-2305ab4d5ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ac242be-e309-4d3c-9f38-7ddace4c42ec" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d045f562-e04c-4a0b-bbec-2305ab4d5ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d045f562-e04c-4a0b-bbec-2305ab4d5ff1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d045f562-e04c-4a0b-bbec-2305ab4d5ff1" xlink:to="loc_us-gaap_SegmentDomain_d045f562-e04c-4a0b-bbec-2305ab4d5ff1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f697900b-ceda-4daf-aaed-905ee8a11ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d045f562-e04c-4a0b-bbec-2305ab4d5ff1" xlink:to="loc_us-gaap_SegmentDomain_f697900b-ceda-4daf-aaed-905ee8a11ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_437ec991-5fd5-4e42-a35f-53418e9152a2" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f697900b-ceda-4daf-aaed-905ee8a11ca7" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_437ec991-5fd5-4e42-a35f-53418e9152a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_24ec47b5-e1b4-4fcb-b9a2-d068ce9838c4" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f697900b-ceda-4daf-aaed-905ee8a11ca7" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_24ec47b5-e1b4-4fcb-b9a2-d068ce9838c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_98edc427-f5dd-4324-b86e-e1b98993ae09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ac242be-e309-4d3c-9f38-7ddace4c42ec" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_98edc427-f5dd-4324-b86e-e1b98993ae09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_98edc427-f5dd-4324-b86e-e1b98993ae09_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_98edc427-f5dd-4324-b86e-e1b98993ae09" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_98edc427-f5dd-4324-b86e-e1b98993ae09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62e1eef4-d1b2-478e-9a09-f25d6cca129f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_98edc427-f5dd-4324-b86e-e1b98993ae09" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62e1eef4-d1b2-478e-9a09-f25d6cca129f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_438d8318-9839-42c3-87f6-000c4a3306d5" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistandPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62e1eef4-d1b2-478e-9a09-f25d6cca129f" xlink:to="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_438d8318-9839-42c3-87f6-000c4a3306d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsofLynchburgMember_36aa4e6f-67ab-4947-a17a-b469c1334da3" xlink:href="ehc-20200930.xsd#ehc_GenerationSolutionsofLynchburgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62e1eef4-d1b2-478e-9a09-f25d6cca129f" xlink:to="loc_ehc_GenerationSolutionsofLynchburgMember_36aa4e6f-67ab-4947-a17a-b469c1334da3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsProFormaResultsofOperationDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="extended" id="i4249e9b219054abcb7dc8ad70171aea6_BusinessCombinationsProFormaResultsofOperationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_2847b179-6c71-461f-a77e-1fdf767485d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_2847b179-6c71-461f-a77e-1fdf767485d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f7477ef0-4b96-4317-93eb-540620f4a9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f7477ef0-4b96-4317-93eb-540620f4a9ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_59c9e609-c00f-4a5d-ba8e-4ce4e0f9923c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_59c9e609-c00f-4a5d-ba8e-4ce4e0f9923c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4836b27e-b72b-46e5-b592-3c4530da21d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4836b27e-b72b-46e5-b592-3c4530da21d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89aed0aa-13a2-4887-8207-4d9a78ad568f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89aed0aa-13a2-4887-8207-4d9a78ad568f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_84da6771-b5d3-485c-9e59-4673799fc80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89aed0aa-13a2-4887-8207-4d9a78ad568f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_84da6771-b5d3-485c-9e59-4673799fc80b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84da6771-b5d3-485c-9e59-4673799fc80b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84da6771-b5d3-485c-9e59-4673799fc80b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84da6771-b5d3-485c-9e59-4673799fc80b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edc35ee9-cbd0-4e44-9d61-b5d58689ee85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84da6771-b5d3-485c-9e59-4673799fc80b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edc35ee9-cbd0-4e44-9d61-b5d58689ee85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_393b7a87-943e-4ca0-8aa6-76eaf29f8d5e" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistandPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edc35ee9-cbd0-4e44-9d61-b5d58689ee85" xlink:to="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_393b7a87-943e-4ca0-8aa6-76eaf29f8d5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsofLynchburgMember_d0d3966e-512b-4282-995d-cae87f3dc65b" xlink:href="ehc-20200930.xsd#ehc_GenerationSolutionsofLynchburgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edc35ee9-cbd0-4e44-9d61-b5d58689ee85" xlink:to="loc_ehc_GenerationSolutionsofLynchburgMember_d0d3966e-512b-4282-995d-cae87f3dc65b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a69274e8-9674-495b-8769-d6f8026ef960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89aed0aa-13a2-4887-8207-4d9a78ad568f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a69274e8-9674-495b-8769-d6f8026ef960" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a69274e8-9674-495b-8769-d6f8026ef960_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a69274e8-9674-495b-8769-d6f8026ef960" xlink:to="loc_us-gaap_SegmentDomain_a69274e8-9674-495b-8769-d6f8026ef960_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0f7d768a-3238-4a30-9ff0-5c0fbdc470f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a69274e8-9674-495b-8769-d6f8026ef960" xlink:to="loc_us-gaap_SegmentDomain_0f7d768a-3238-4a30-9ff0-5c0fbdc470f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_65e548bb-2876-47d3-9403-bf4b33e45795" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0f7d768a-3238-4a30-9ff0-5c0fbdc470f5" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_65e548bb-2876-47d3-9403-bf4b33e45795" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_5f611f07-63c8-47d2-845a-c2c8fefb13ec" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0f7d768a-3238-4a30-9ff0-5c0fbdc470f5" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_5f611f07-63c8-47d2-845a-c2c8fefb13ec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntities"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="extended" id="i7df5808a493a410ea992672a39aab41a_VariableInterestEntities"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntitiesTables"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="extended" id="i952708b8dc1d45b1887d59af0f07ae42_VariableInterestEntitiesTables"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntitiesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails" xlink:type="extended" id="ib8817df8f684438db85fe1b5b82d3542_VariableInterestEntitiesTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_b765abac-20a3-4cab-9d45-2be06bbde656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_76e340fb-912f-4eeb-9426-11cc2c7ddfcb" xlink:href="ehc-20200930.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b765abac-20a3-4cab-9d45-2be06bbde656" xlink:to="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_76e340fb-912f-4eeb-9426-11cc2c7ddfcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_38d26ed7-9f31-4a11-96ef-17f2a36af01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b765abac-20a3-4cab-9d45-2be06bbde656" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_38d26ed7-9f31-4a11-96ef-17f2a36af01b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a2e28881-523a-48bf-9efd-bb1e4371dafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b765abac-20a3-4cab-9d45-2be06bbde656" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a2e28881-523a-48bf-9efd-bb1e4371dafc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_da091fea-4a4c-4385-9180-b7cdbb1f50d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a2e28881-523a-48bf-9efd-bb1e4371dafc" xlink:to="loc_srt_ConsolidatedEntitiesAxis_da091fea-4a4c-4385-9180-b7cdbb1f50d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_da091fea-4a4c-4385-9180-b7cdbb1f50d3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_da091fea-4a4c-4385-9180-b7cdbb1f50d3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_da091fea-4a4c-4385-9180-b7cdbb1f50d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f242f677-356e-466b-83db-0122acb40fe9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_da091fea-4a4c-4385-9180-b7cdbb1f50d3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f242f677-356e-466b-83db-0122acb40fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_bf3bb01a-ce7e-4930-b4d6-cb8c8932b1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f242f677-356e-466b-83db-0122acb40fe9" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_bf3bb01a-ce7e-4930-b4d6-cb8c8932b1a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2fa2ff92-9d57-42cc-9177-7586f53907bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a2e28881-523a-48bf-9efd-bb1e4371dafc" xlink:to="loc_srt_RangeAxis_2fa2ff92-9d57-42cc-9177-7586f53907bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2fa2ff92-9d57-42cc-9177-7586f53907bd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2fa2ff92-9d57-42cc-9177-7586f53907bd" xlink:to="loc_srt_RangeMember_2fa2ff92-9d57-42cc-9177-7586f53907bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c74bc3cf-0b24-4285-87ca-582e5115a8b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2fa2ff92-9d57-42cc-9177-7586f53907bd" xlink:to="loc_srt_RangeMember_c74bc3cf-0b24-4285-87ca-582e5115a8b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3846984d-ecd1-4c67-9c99-2d189da93ecb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c74bc3cf-0b24-4285-87ca-582e5115a8b6" xlink:to="loc_srt_MinimumMember_3846984d-ecd1-4c67-9c99-2d189da93ecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_81c7b608-5083-4e8b-8ce0-e2637e009671" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c74bc3cf-0b24-4285-87ca-582e5115a8b6" xlink:to="loc_srt_MaximumMember_81c7b608-5083-4e8b-8ce0-e2637e009671" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" xlink:type="extended" id="ic5df1093a5634ff6aac802423c9281e5_VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_bb16f702-3b02-49b7-915a-e29f1cf96d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb16f702-3b02-49b7-915a-e29f1cf96d30" xlink:to="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_174dd466-43d1-4ec3-9da6-d97a08106cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_174dd466-43d1-4ec3-9da6-d97a08106cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d90be11f-c46a-4945-b711-af0747dadb33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d90be11f-c46a-4945-b711-af0747dadb33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_50a836ea-d6ff-40af-a6d5-28ecc1a8a142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:to="loc_us-gaap_OtherAssetsCurrent_50a836ea-d6ff-40af-a6d5-28ecc1a8a142" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f7c40c6b-a84d-42ad-8ee8-ea282c145379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:to="loc_us-gaap_AssetsCurrent_f7c40c6b-a84d-42ad-8ee8-ea282c145379" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e952f3a5-2008-4947-8d37-c46c4edd361c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e952f3a5-2008-4947-8d37-c46c4edd361c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_73b1483c-6e31-41a5-b44f-5177df38257d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_73b1483c-6e31-41a5-b44f-5177df38257d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_91b9422c-68b8-4dfa-9d0a-aee7379c41f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_Goodwill_91b9422c-68b8-4dfa-9d0a-aee7379c41f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_eb66b8b7-6d66-47f5-8f9e-28a37d0ff1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_eb66b8b7-6d66-47f5-8f9e-28a37d0ff1b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b0c28be2-2a3e-4a96-ab72-2646c5497bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b0c28be2-2a3e-4a96-ab72-2646c5497bb6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8079f8ed-5696-4209-b546-53a816b2741d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_Assets_8079f8ed-5696-4209-b546-53a816b2741d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb16f702-3b02-49b7-915a-e29f1cf96d30" xlink:to="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ccbabf80-eb83-4bb6-9d3f-c5b281e90919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ccbabf80-eb83-4bb6-9d3f-c5b281e90919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_be230a79-c848-4d73-8d6b-27dab73d5c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_be230a79-c848-4d73-8d6b-27dab73d5c1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ac201b89-5caf-4989-a567-2af6a8bc4e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:to="loc_us-gaap_AccountsPayableCurrent_ac201b89-5caf-4989-a567-2af6a8bc4e26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ea0cb60c-acb3-4e74-8543-bca8a3e31fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ea0cb60c-acb3-4e74-8543-bca8a3e31fb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3589251a-55e3-4f66-9e2f-7dee02b2cc76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:to="loc_us-gaap_LiabilitiesCurrent_3589251a-55e3-4f66-9e2f-7dee02b2cc76" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6c38f6c3-e9b7-4762-83ff-31790069f262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6c38f6c3-e9b7-4762-83ff-31790069f262" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_610b03a5-4699-4857-aa15-23e7446775cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_610b03a5-4699-4857-aa15-23e7446775cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_54b9b1b9-4a86-498e-8c51-dcb2374d8005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_54b9b1b9-4a86-498e-8c51-dcb2374d8005" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_25c57880-1799-490a-bb04-8a35b0c74281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:to="loc_us-gaap_Liabilities_25c57880-1799-490a-bb04-8a35b0c74281" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ee67286d-b83b-4312-9825-f89e2047839a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb16f702-3b02-49b7-915a-e29f1cf96d30" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ee67286d-b83b-4312-9825-f89e2047839a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_ce6cbd7e-d67f-4e54-9bf3-d32d70e39fef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ee67286d-b83b-4312-9825-f89e2047839a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_ce6cbd7e-d67f-4e54-9bf3-d32d70e39fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ce6cbd7e-d67f-4e54-9bf3-d32d70e39fef_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ce6cbd7e-d67f-4e54-9bf3-d32d70e39fef" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ce6cbd7e-d67f-4e54-9bf3-d32d70e39fef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6cd7d31b-f36b-4a7a-a501-57b913e705b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ce6cbd7e-d67f-4e54-9bf3-d32d70e39fef" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6cd7d31b-f36b-4a7a-a501-57b913e705b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_aa5c18b0-1dd8-4d55-b6fd-8918536c1f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_6cd7d31b-f36b-4a7a-a501-57b913e705b3" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_aa5c18b0-1dd8-4d55-b6fd-8918536c1f9b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebt"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="extended" id="ifa88ed1d99a8404982be41b7cf6dc1d4_LongtermDebt"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtTables"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="extended" id="i0867736b95a94d4d94ba657325f50425_LongtermDebtTables"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended" id="i6197f7d48fa24e65a8df307f4d75f2c4_LongtermDebtLongtermDebtOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0c506724-b645-47c7-afdd-d438befd5f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0c506724-b645-47c7-afdd-d438befd5f22" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee222a91-44b5-437e-a5b8-fd5cf35d1d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee222a91-44b5-437e-a5b8-fd5cf35d1d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f4713d8a-5ebd-4955-a059-3031b7efd6fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_LongTermDebt_f4713d8a-5ebd-4955-a059-3031b7efd6fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_fc4d83bb-9cc9-433c-b20e-cc26346ea54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_FinanceLeaseLiability_fc4d83bb-9cc9-433c-b20e-cc26346ea54f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_f67e6928-f4fe-484f-a13a-07453daae0fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_f67e6928-f4fe-484f-a13a-07453daae0fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_12df17ed-ec8e-43c6-b02d-71ce7e440b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_12df17ed-ec8e-43c6-b02d-71ce7e440b81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_da969eb0-ad58-4157-90a3-73db4172b6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_da969eb0-ad58-4157-90a3-73db4172b6f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0c506724-b645-47c7-afdd-d438befd5f22" xlink:to="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_89453f0a-3039-4006-87d5-f725edfa497d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:to="loc_us-gaap_CreditFacilityAxis_89453f0a-3039-4006-87d5-f725edfa497d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_89453f0a-3039-4006-87d5-f725edfa497d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_89453f0a-3039-4006-87d5-f725edfa497d" xlink:to="loc_us-gaap_CreditFacilityDomain_89453f0a-3039-4006-87d5-f725edfa497d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3b39e3d3-dbfc-4cc3-9251-26f0c960be26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_89453f0a-3039-4006-87d5-f725edfa497d" xlink:to="loc_us-gaap_CreditFacilityDomain_3b39e3d3-dbfc-4cc3-9251-26f0c960be26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_788d7b02-69c3-47c1-be82-0de633211a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3b39e3d3-dbfc-4cc3-9251-26f0c960be26" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_788d7b02-69c3-47c1-be82-0de633211a5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_03c59cf0-d7d2-4585-8c8a-121053acbe7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_03c59cf0-d7d2-4585-8c8a-121053acbe7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_03c59cf0-d7d2-4585-8c8a-121053acbe7f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_03c59cf0-d7d2-4585-8c8a-121053acbe7f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_03c59cf0-d7d2-4585-8c8a-121053acbe7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2f194eeb-8c7d-4c7a-bdb5-f8325cc3cf07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_03c59cf0-d7d2-4585-8c8a-121053acbe7f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2f194eeb-8c7d-4c7a-bdb5-f8325cc3cf07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_5665741c-30ce-4eb1-a0d6-54437edcec23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2f194eeb-8c7d-4c7a-bdb5-f8325cc3cf07" xlink:to="loc_us-gaap_LoansPayableMember_5665741c-30ce-4eb1-a0d6-54437edcec23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_6e941262-4eb4-475c-939d-23b962f67cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2f194eeb-8c7d-4c7a-bdb5-f8325cc3cf07" xlink:to="loc_us-gaap_SeniorNotesMember_6e941262-4eb4-475c-939d-23b962f67cfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_a7fb0186-9cbd-4acd-b6d7-7c4e09942afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2f194eeb-8c7d-4c7a-bdb5-f8325cc3cf07" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_a7fb0186-9cbd-4acd-b6d7-7c4e09942afa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9d25a63f-09db-4564-a6c3-864d70f91a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:to="loc_us-gaap_DebtInstrumentAxis_9d25a63f-09db-4564-a6c3-864d70f91a6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9d25a63f-09db-4564-a6c3-864d70f91a6c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d25a63f-09db-4564-a6c3-864d70f91a6c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9d25a63f-09db-4564-a6c3-864d70f91a6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d25a63f-09db-4564-a6c3-864d70f91a6c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_8bac15b8-f1cb-4b60-911d-b478aa25935a" xlink:href="ehc-20200930.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_TermLoanFacilitiesMember_8bac15b8-f1cb-4b60-911d-b478aa25935a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_c3b47591-47b6-4cea-95b4-105ed27d61e1" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_c3b47591-47b6-4cea-95b4-105ed27d61e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_2aa6a4de-88c3-42ea-9e37-3397c27fe955" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_SeniorNotes0575Due2024Member_2aa6a4de-88c3-42ea-9e37-3397c27fe955" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_daf8e6bb-b381-480a-bb23-d409a06c8abd" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_daf8e6bb-b381-480a-bb23-d409a06c8abd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_07c67e95-dc6e-48cc-bdfc-607f1010015c" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_07c67e95-dc6e-48cc-bdfc-607f1010015c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_d4e42c3a-790e-497f-bb5c-ffad387aab64" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_d4e42c3a-790e-497f-bb5c-ffad387aab64" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtFinancialCovenantsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="extended" id="ib4220bbbbb134cf7aea574c448c637c2_LongtermDebtFinancialCovenantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bbc3f52a-08d4-47cf-8d59-2fc8d7add09f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_ac2c2f44-c402-4a43-af9f-55d5f792a31d" xlink:href="ehc-20200930.xsd#ehc_DebtInstrumentCovenantInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbc3f52a-08d4-47cf-8d59-2fc8d7add09f" xlink:to="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_ac2c2f44-c402-4a43-af9f-55d5f792a31d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_4b5e9b6e-2288-4c49-9c6e-5a77265cb334" xlink:href="ehc-20200930.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbc3f52a-08d4-47cf-8d59-2fc8d7add09f" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_4b5e9b6e-2288-4c49-9c6e-5a77265cb334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dee6e5c6-c7d6-4b13-a58a-06bfce43e446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbc3f52a-08d4-47cf-8d59-2fc8d7add09f" xlink:to="loc_us-gaap_DebtInstrumentTable_dee6e5c6-c7d6-4b13-a58a-06bfce43e446" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b6913ee2-424e-4f6e-954d-9095dedf3518" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dee6e5c6-c7d6-4b13-a58a-06bfce43e446" xlink:to="loc_srt_StatementScenarioAxis_b6913ee2-424e-4f6e-954d-9095dedf3518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b6913ee2-424e-4f6e-954d-9095dedf3518_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_b6913ee2-424e-4f6e-954d-9095dedf3518" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b6913ee2-424e-4f6e-954d-9095dedf3518_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_73c78227-ba22-4327-81a7-dc131e1212e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_b6913ee2-424e-4f6e-954d-9095dedf3518" xlink:to="loc_srt_ScenarioUnspecifiedDomain_73c78227-ba22-4327-81a7-dc131e1212e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_fb79dd8b-db46-483d-890e-df4f7a749bc7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_73c78227-ba22-4327-81a7-dc131e1212e6" xlink:to="loc_srt_ScenarioForecastMember_fb79dd8b-db46-483d-890e-df4f7a749bc7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="extended" id="ib36676ea81d945b480300bf9df71b6a6_LongtermDebtTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_753dbef4-fddf-4a92-a148-29df25825bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_753dbef4-fddf-4a92-a148-29df25825bf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7d4606dd-f416-4339-b470-4eb05550858e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7d4606dd-f416-4339-b470-4eb05550858e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_ca98d399-2756-4ce8-b50f-7683bd639002" xlink:href="ehc-20200930.xsd#ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_ca98d399-2756-4ce8-b50f-7683bd639002" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_f1a19a1c-34c8-4af4-8b70-36d757526b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_f1a19a1c-34c8-4af4-8b70-36d757526b0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_489b615f-2e72-4bbc-aa06-234c2a2a2584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_LongTermDebt_489b615f-2e72-4bbc-aa06-234c2a2a2584" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6bb3dec1-47d4-4733-b12e-e790621fcb66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6bb3dec1-47d4-4733-b12e-e790621fcb66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f3fab0fe-3962-40cc-866b-2561b380b30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f3fab0fe-3962-40cc-866b-2561b380b30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f3fab0fe-3962-40cc-866b-2561b380b30d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f3fab0fe-3962-40cc-866b-2561b380b30d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f3fab0fe-3962-40cc-866b-2561b380b30d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2d8ebeff-af94-4254-bd20-9bc9bf9627bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f3fab0fe-3962-40cc-866b-2561b380b30d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2d8ebeff-af94-4254-bd20-9bc9bf9627bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_b25a71f8-e609-4289-94c0-be910079c20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d8ebeff-af94-4254-bd20-9bc9bf9627bf" xlink:to="loc_us-gaap_SeniorNotesMember_b25a71f8-e609-4289-94c0-be910079c20b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1d92dd89-6c62-47bb-afa6-95555cf48e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:to="loc_us-gaap_DebtInstrumentAxis_1d92dd89-6c62-47bb-afa6-95555cf48e81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1d92dd89-6c62-47bb-afa6-95555cf48e81_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d92dd89-6c62-47bb-afa6-95555cf48e81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1d92dd89-6c62-47bb-afa6-95555cf48e81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d92dd89-6c62-47bb-afa6-95555cf48e81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_4de14439-8e18-478f-989c-7888b2164ee3" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_4de14439-8e18-478f-989c-7888b2164ee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_298093c0-a799-4f30-bd24-b6dabf74e569" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_298093c0-a799-4f30-bd24-b6dabf74e569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_89e9abb5-c7ea-4545-9b51-7648e4443d63" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_89e9abb5-c7ea-4545-9b51-7648e4443d63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_c87c8f35-39d1-466a-a822-f2f61b3a237c" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:to="loc_ehc_SeniorNotes0575Due2024Member_c87c8f35-39d1-466a-a822-f2f61b3a237c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_80d7e159-b0e1-4736-a275-d07d8135fb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_80d7e159-b0e1-4736-a275-d07d8135fb4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80d7e159-b0e1-4736-a275-d07d8135fb4b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_80d7e159-b0e1-4736-a275-d07d8135fb4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80d7e159-b0e1-4736-a275-d07d8135fb4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8560e88a-236e-4847-927f-8032a2e5d192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_80d7e159-b0e1-4736-a275-d07d8135fb4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8560e88a-236e-4847-927f-8032a2e5d192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4906da64-54e4-40a1-9b3f-ab92a687d846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8560e88a-236e-4847-927f-8032a2e5d192" xlink:to="loc_us-gaap_SubsequentEventMember_4906da64-54e4-40a1-9b3f-ab92a687d846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_db06079b-2c40-436b-9fc0-5107a0154c9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:to="loc_srt_StatementScenarioAxis_db06079b-2c40-436b-9fc0-5107a0154c9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_db06079b-2c40-436b-9fc0-5107a0154c9b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_db06079b-2c40-436b-9fc0-5107a0154c9b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_db06079b-2c40-436b-9fc0-5107a0154c9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7d62e3b4-d81a-47ac-a652-02f363b57710" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_db06079b-2c40-436b-9fc0-5107a0154c9b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7d62e3b4-d81a-47ac-a652-02f363b57710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_66d99988-5c33-4c9a-a985-b14447613230" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7d62e3b4-d81a-47ac-a652-02f363b57710" xlink:to="loc_srt_ScenarioForecastMember_66d99988-5c33-4c9a-a985-b14447613230" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterests"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="extended" id="id4dc08dfde004747a4ed9b1261567c72_RedeemableNoncontrollingInterests"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsTables"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="extended" id="ib9ec8369cbdf41df9aa4566632de22d8_RedeemableNoncontrollingInterestsTables"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="extended" id="ifb3dd0772fe140b3922d536ade3806b4_RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_10bd0be3-709c-4091-a9f4-c06a5d7acd77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:href="ehc-20200930.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_10bd0be3-709c-4091-a9f4-c06a5d7acd77" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_4dcb0617-724b-4f21-80c0-e964e1462be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_4dcb0617-724b-4f21-80c0-e964e1462be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_6a35389f-d00c-4484-96ab-6593e195d261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_6a35389f-d00c-4484-96ab-6593e195d261" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c5ec2873-d924-44b1-b14a-6dc80ae47bf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c5ec2873-d924-44b1-b14a-6dc80ae47bf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Contributiontojointventure_8b55f7a6-79a3-4ed4-bf9c-edeba45ecf13" xlink:href="ehc-20200930.xsd#ehc_Contributiontojointventure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_ehc_Contributiontojointventure_8b55f7a6-79a3-4ed4-bf9c-edeba45ecf13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Reclassificationtononcontrollinginterests_523b4304-d001-436c-9eb5-bf003ee6528e" xlink:href="ehc-20200930.xsd#ehc_Reclassificationtononcontrollinginterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_ehc_Reclassificationtononcontrollinginterests_523b4304-d001-436c-9eb5-bf003ee6528e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_f999468b-633a-42c7-92ec-98921a96d423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_f999468b-633a-42c7-92ec-98921a96d423" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExchangeTransaction_3717ffb1-6964-4808-828b-f96b221253d0" xlink:href="ehc-20200930.xsd#ehc_NoncontrollingInterestExchangeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_ehc_NoncontrollingInterestExchangeTransaction_3717ffb1-6964-4808-828b-f96b221253d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_328b0b0e-1876-4cff-8b82-188edf1524c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_328b0b0e-1876-4cff-8b82-188edf1524c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_f213b8fa-78b9-468a-aac0-204bba0a4214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_72775f99-dca3-4f3a-b7cc-ac85f1f22d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_10bd0be3-709c-4091-a9f4-c06a5d7acd77" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_72775f99-dca3-4f3a-b7cc-ac85f1f22d4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_59b72316-8f78-45e1-84db-beb5dd7546d3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_72775f99-dca3-4f3a-b7cc-ac85f1f22d4f" xlink:to="loc_dei_LegalEntityAxis_59b72316-8f78-45e1-84db-beb5dd7546d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_59b72316-8f78-45e1-84db-beb5dd7546d3_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_59b72316-8f78-45e1-84db-beb5dd7546d3" xlink:to="loc_dei_EntityDomain_59b72316-8f78-45e1-84db-beb5dd7546d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_76cdb3f6-1bf4-499f-8f1c-88506f17645a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_59b72316-8f78-45e1-84db-beb5dd7546d3" xlink:to="loc_dei_EntityDomain_76cdb3f6-1bf4-499f-8f1c-88506f17645a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember_4e504b42-1753-473b-865c-297b750f31bc" xlink:href="ehc-20200930.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_76cdb3f6-1bf4-499f-8f1c-88506f17645a" xlink:to="loc_ehc_RedeemableNoncontrollingInterestMember_4e504b42-1753-473b-865c-297b750f31bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="extended" id="i743111778bef4552b6057df958362bc3_RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="extended" id="i547ef4e74240454282f751fd6e047178_RedeemableNoncontrollingInterestsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_8ed4990d-fa72-46c7-b1e4-1b3aeedcc623" xlink:href="ehc-20200930.xsd#ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_8ed4990d-fa72-46c7-b1e4-1b3aeedcc623" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_4a3d5c83-04ed-4a0f-9f4e-3114d27a2e12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_4a3d5c83-04ed-4a0f-9f4e-3114d27a2e12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_28b0f066-0897-427b-9111-1cdcf1a56d0b" xlink:href="ehc-20200930.xsd#ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_28b0f066-0897-427b-9111-1cdcf1a56d0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_1f54fd93-5522-40a2-8060-271d366228d7" xlink:href="ehc-20200930.xsd#ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_1f54fd93-5522-40a2-8060-271d366228d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4a6011a9-9ef9-4af0-a9f5-2dc88ff3af9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4a6011a9-9ef9-4af0-a9f5-2dc88ff3af9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_a7babdde-f874-4e11-ae73-9336a379967a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_a7babdde-f874-4e11-ae73-9336a379967a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_26b33714-adfb-4892-ada4-639d04cb29ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_26b33714-adfb-4892-ada4-639d04cb29ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_d6d59734-af3b-4dda-acab-92a82fd7b0b5" xlink:href="ehc-20200930.xsd#ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_d6d59734-af3b-4dda-acab-92a82fd7b0b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_eb07514a-a128-489e-9120-9eb7af2e545e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_eb07514a-a128-489e-9120-9eb7af2e545e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_86d8ce68-7691-45f4-8b75-2e4accd41cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_86d8ce68-7691-45f4-8b75-2e4accd41cfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86d8ce68-7691-45f4-8b75-2e4accd41cfe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_86d8ce68-7691-45f4-8b75-2e4accd41cfe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86d8ce68-7691-45f4-8b75-2e4accd41cfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3600f5a4-ec62-4766-a661-d72a08faa2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_86d8ce68-7691-45f4-8b75-2e4accd41cfe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3600f5a4-ec62-4766-a661-d72a08faa2f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EHHIMember_3559e8bd-e412-459a-b3e9-e1ef5f90ff4b" xlink:href="ehc-20200930.xsd#ehc_EHHIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3600f5a4-ec62-4766-a661-d72a08faa2f5" xlink:to="loc_ehc_EHHIMember_3559e8bd-e412-459a-b3e9-e1ef5f90ff4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cb097b5d-12cb-4a33-8a00-28b832b656c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cb097b5d-12cb-4a33-8a00-28b832b656c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cb097b5d-12cb-4a33-8a00-28b832b656c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cb097b5d-12cb-4a33-8a00-28b832b656c5" xlink:to="loc_us-gaap_SegmentDomain_cb097b5d-12cb-4a33-8a00-28b832b656c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_17621247-878c-4250-b205-fc89a1bd27df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cb097b5d-12cb-4a33-8a00-28b832b656c5" xlink:to="loc_us-gaap_SegmentDomain_17621247-878c-4250-b205-fc89a1bd27df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_58ff2680-5446-4d49-a438-c02f2065492a" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_17621247-878c-4250-b205-fc89a1bd27df" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_58ff2680-5446-4d49-a438-c02f2065492a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4a7f531a-757c-4a62-b54a-fe03928d64e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:to="loc_srt_OwnershipAxis_4a7f531a-757c-4a62-b54a-fe03928d64e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4a7f531a-757c-4a62-b54a-fe03928d64e4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_4a7f531a-757c-4a62-b54a-fe03928d64e4" xlink:to="loc_srt_OwnershipDomain_4a7f531a-757c-4a62-b54a-fe03928d64e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_78316e48-b62c-4ccf-a816-a726c18b647e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_4a7f531a-757c-4a62-b54a-fe03928d64e4" xlink:to="loc_srt_OwnershipDomain_78316e48-b62c-4ccf-a816-a726c18b647e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HoldingsAndEHHIMember_ce6e24b2-c0b4-4c6f-bb69-5e04c910d713" xlink:href="ehc-20200930.xsd#ehc_HoldingsAndEHHIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_78316e48-b62c-4ccf-a816-a726c18b647e" xlink:to="loc_ehc_HoldingsAndEHHIMember_ce6e24b2-c0b4-4c6f-bb69-5e04c910d713" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="extended" id="i993c337a869f4d7089f42f54b029e4bf_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i24f88eded6d740388080d32cf04ee253_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i5ad6c384a01344ce9fb633766358a408_FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266b8ed2-d066-43bf-a891-ece088802ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5792408e-7181-4c8c-b079-1ff021c67148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266b8ed2-d066-43bf-a891-ece088802ab5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5792408e-7181-4c8c-b079-1ff021c67148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_07d60dc0-0458-4fa9-af05-7b6e3a047184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5792408e-7181-4c8c-b079-1ff021c67148" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_07d60dc0-0458-4fa9-af05-7b6e3a047184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aa87cfd1-b137-48ad-9cd6-5b2025d2df8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5792408e-7181-4c8c-b079-1ff021c67148" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aa87cfd1-b137-48ad-9cd6-5b2025d2df8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_14c7afff-5eeb-4130-9606-cfb0380dbef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5792408e-7181-4c8c-b079-1ff021c67148" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_14c7afff-5eeb-4130-9606-cfb0380dbef7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266b8ed2-d066-43bf-a891-ece088802ab5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_eae54555-7076-4299-a1d7-70a433bddcdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:to="loc_us-gaap_ValuationTechniqueAxis_eae54555-7076-4299-a1d7-70a433bddcdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_eae54555-7076-4299-a1d7-70a433bddcdf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_eae54555-7076-4299-a1d7-70a433bddcdf" xlink:to="loc_us-gaap_ValuationTechniqueDomain_eae54555-7076-4299-a1d7-70a433bddcdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_475b77b2-354b-49f3-8c16-cf7b870a2766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_eae54555-7076-4299-a1d7-70a433bddcdf" xlink:to="loc_us-gaap_ValuationTechniqueDomain_475b77b2-354b-49f3-8c16-cf7b870a2766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketApproachValuationTechniqueMember_9c09a11f-4c9a-4c35-bba3-602df5d14c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketApproachValuationTechniqueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_475b77b2-354b-49f3-8c16-cf7b870a2766" xlink:to="loc_us-gaap_MarketApproachValuationTechniqueMember_9c09a11f-4c9a-4c35-bba3-602df5d14c3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_faa1ac11-766e-447a-8f59-5508e311d255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_475b77b2-354b-49f3-8c16-cf7b870a2766" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_faa1ac11-766e-447a-8f59-5508e311d255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3de8d7e-a0d2-419f-a238-399c3a5e935d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3de8d7e-a0d2-419f-a238-399c3a5e935d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3de8d7e-a0d2-419f-a238-399c3a5e935d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3de8d7e-a0d2-419f-a238-399c3a5e935d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3de8d7e-a0d2-419f-a238-399c3a5e935d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_842dc390-1a30-464c-a4ac-8a2760e605c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3de8d7e-a0d2-419f-a238-399c3a5e935d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_842dc390-1a30-464c-a4ac-8a2760e605c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_94637d39-90d5-450e-b8c8-d3cef289e755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_842dc390-1a30-464c-a4ac-8a2760e605c3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_94637d39-90d5-450e-b8c8-d3cef289e755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bd12fa3-644f-49d4-951a-9412c50c9fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bd12fa3-644f-49d4-951a-9412c50c9fd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bd12fa3-644f-49d4-951a-9412c50c9fd0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bd12fa3-644f-49d4-951a-9412c50c9fd0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bd12fa3-644f-49d4-951a-9412c50c9fd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_81f7fde3-0482-4291-9baf-55a8ae17c369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bd12fa3-644f-49d4-951a-9412c50c9fd0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_81f7fde3-0482-4291-9baf-55a8ae17c369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_247185f5-e26f-4a03-a3c4-6b1204766d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_81f7fde3-0482-4291-9baf-55a8ae17c369" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_247185f5-e26f-4a03-a3c4-6b1204766d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b2b5392a-c14a-4988-9d2c-983d88cdf208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_81f7fde3-0482-4291-9baf-55a8ae17c369" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b2b5392a-c14a-4988-9d2c-983d88cdf208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_91efa496-5c58-4e6e-95cf-1903db14ed30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_81f7fde3-0482-4291-9baf-55a8ae17c369" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_91efa496-5c58-4e6e-95cf-1903db14ed30" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="extended" id="idf2bfb2383cf4f8f866a0ad5ef15c50b_FairValueMeasurementsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4223aa65-63f5-4f22-9f95-1acf2542d607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_716bbfdc-1789-4700-91d1-0fec0bf8afe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4223aa65-63f5-4f22-9f95-1acf2542d607" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_716bbfdc-1789-4700-91d1-0fec0bf8afe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44cadcec-18fb-44eb-824d-c8718e0d677a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4223aa65-63f5-4f22-9f95-1acf2542d607" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44cadcec-18fb-44eb-824d-c8718e0d677a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a18a97e4-521b-4039-8091-f5e873e2bd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44cadcec-18fb-44eb-824d-c8718e0d677a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a18a97e4-521b-4039-8091-f5e873e2bd8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a18a97e4-521b-4039-8091-f5e873e2bd8f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a18a97e4-521b-4039-8091-f5e873e2bd8f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a18a97e4-521b-4039-8091-f5e873e2bd8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6f944d1-5017-430e-9e36-6044e4d90d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a18a97e4-521b-4039-8091-f5e873e2bd8f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6f944d1-5017-430e-9e36-6044e4d90d76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_5ff16a10-97b3-4141-a9e3-36602acdd3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6f944d1-5017-430e-9e36-6044e4d90d76" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_5ff16a10-97b3-4141-a9e3-36602acdd3cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" xlink:type="extended" id="ia9c16d7a300b44ce95498eee41e2d86d_FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8c183487-8d54-43da-8443-d4d45a1a8596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_5019a17a-707e-4486-b0d8-dcefc26ff1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8c183487-8d54-43da-8443-d4d45a1a8596" xlink:to="loc_us-gaap_LongTermDebtFairValue_5019a17a-707e-4486-b0d8-dcefc26ff1c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be94b395-4247-4fca-b7d0-e6a42e36cf91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8c183487-8d54-43da-8443-d4d45a1a8596" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be94b395-4247-4fca-b7d0-e6a42e36cf91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8c183487-8d54-43da-8443-d4d45a1a8596" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_59298166-1b76-4b95-88a2-ed1db3f229fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:to="loc_us-gaap_CreditFacilityAxis_59298166-1b76-4b95-88a2-ed1db3f229fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_59298166-1b76-4b95-88a2-ed1db3f229fc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_59298166-1b76-4b95-88a2-ed1db3f229fc" xlink:to="loc_us-gaap_CreditFacilityDomain_59298166-1b76-4b95-88a2-ed1db3f229fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d0d59d57-6984-4a46-b26e-fe8be056077e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_59298166-1b76-4b95-88a2-ed1db3f229fc" xlink:to="loc_us-gaap_CreditFacilityDomain_d0d59d57-6984-4a46-b26e-fe8be056077e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_96f10b40-34cf-4350-9b09-8be2e3eea7d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d0d59d57-6984-4a46-b26e-fe8be056077e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_96f10b40-34cf-4350-9b09-8be2e3eea7d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_af50418e-b78a-496f-b236-99078f7b9522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d0d59d57-6984-4a46-b26e-fe8be056077e" xlink:to="loc_us-gaap_LetterOfCreditMember_af50418e-b78a-496f-b236-99078f7b9522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe86f1b4-d541-48ee-ab5d-9334a201ddc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe86f1b4-d541-48ee-ab5d-9334a201ddc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fe86f1b4-d541-48ee-ab5d-9334a201ddc0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe86f1b4-d541-48ee-ab5d-9334a201ddc0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fe86f1b4-d541-48ee-ab5d-9334a201ddc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fca978d6-bd39-47a0-8714-78e5bab8b6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe86f1b4-d541-48ee-ab5d-9334a201ddc0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fca978d6-bd39-47a0-8714-78e5bab8b6a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_8e5555c5-49e9-4a52-9f9f-cb0cad5a0f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fca978d6-bd39-47a0-8714-78e5bab8b6a9" xlink:to="loc_us-gaap_LoansPayableMember_8e5555c5-49e9-4a52-9f9f-cb0cad5a0f2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_28b9c7d4-3552-478d-bf1e-c20f8a869eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fca978d6-bd39-47a0-8714-78e5bab8b6a9" xlink:to="loc_us-gaap_SeniorNotesMember_28b9c7d4-3552-478d-bf1e-c20f8a869eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f3775fc2-ec66-42d7-99dc-08f61c776d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fca978d6-bd39-47a0-8714-78e5bab8b6a9" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f3775fc2-ec66-42d7-99dc-08f61c776d5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea0b260a-b755-4f2d-8377-f462a786a80d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea0b260a-b755-4f2d-8377-f462a786a80d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ea0b260a-b755-4f2d-8377-f462a786a80d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea0b260a-b755-4f2d-8377-f462a786a80d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ea0b260a-b755-4f2d-8377-f462a786a80d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea0b260a-b755-4f2d-8377-f462a786a80d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_6e7b5047-1756-46ab-979a-37d792d950ea" xlink:href="ehc-20200930.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_TermLoanFacilitiesMember_6e7b5047-1756-46ab-979a-37d792d950ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_2fb7b1e9-578c-49b8-b7ac-33c1c335b2a5" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_2fb7b1e9-578c-49b8-b7ac-33c1c335b2a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_7bb6de3a-beae-4e15-bc34-d559036e30a2" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_SeniorNotes0575Due2024Member_7bb6de3a-beae-4e15-bc34-d559036e30a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_3c825887-96d7-49f0-a7a5-e901dc26bbd7" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_3c825887-96d7-49f0-a7a5-e901dc26bbd7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_bbe2def3-c939-45c0-a244-225c254cddab" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_bbe2def3-c939-45c0-a244-225c254cddab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_e575f5e2-dab1-4432-8aea-9bc9f74b4bf0" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_e575f5e2-dab1-4432-8aea-9bc9f74b4bf0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_8ad2a728-a6d5-432c-83c5-5d7ff28813fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_8ad2a728-a6d5-432c-83c5-5d7ff28813fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8ad2a728-a6d5-432c-83c5-5d7ff28813fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8ad2a728-a6d5-432c-83c5-5d7ff28813fe" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8ad2a728-a6d5-432c-83c5-5d7ff28813fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_20862fab-0f15-459e-8103-33ff0137d0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8ad2a728-a6d5-432c-83c5-5d7ff28813fe" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_20862fab-0f15-459e-8103-33ff0137d0ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_be2dbbe9-1420-4c36-af96-de72d75bbb50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_20862fab-0f15-459e-8103-33ff0137d0ab" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_be2dbbe9-1420-4c36-af96-de72d75bbb50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5481d560-cb37-467e-bc31-dae955b853dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_be2dbbe9-1420-4c36-af96-de72d75bbb50" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5481d560-cb37-467e-bc31-dae955b853dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0df9e0cc-ab17-45ca-b7ae-e0de37e30b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_be2dbbe9-1420-4c36-af96-de72d75bbb50" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0df9e0cc-ab17-45ca-b7ae-e0de37e30b05" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="ehc-20200930.xsd#ShareBasedPayments"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="extended" id="i2cc443f3f01d4d35b6a5ddf5a851c5c4_ShareBasedPayments"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#ShareBasedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails" xlink:type="extended" id="i1df5a4f767354321830fe08f52527e41_ShareBasedPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c0715fe-7e9f-44e5-b2d8-660cfeecc4e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c0715fe-7e9f-44e5-b2d8-660cfeecc4e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_39e9fa96-9e85-4a11-aaf3-37b3f115e47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_39e9fa96-9e85-4a11-aaf3-37b3f115e47a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7ba8552a-1279-4826-844f-7e92943b6a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7ba8552a-1279-4826-844f-7e92943b6a7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_480a7701-efd8-417e-aa44-5794f45f613f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_480a7701-efd8-417e-aa44-5794f45f613f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AllocatedSharebasedCompensationLiability_27181ece-4775-4b78-b0d1-421c265b3592" xlink:href="ehc-20200930.xsd#ehc_AllocatedSharebasedCompensationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_ehc_AllocatedSharebasedCompensationLiability_27181ece-4775-4b78-b0d1-421c265b3592" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_8713da1c-aff9-4d1b-aecc-aafffb9b82f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_8713da1c-aff9-4d1b-aecc-aafffb9b82f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2172db05-5671-4655-9181-cf977cfc0ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2172db05-5671-4655-9181-cf977cfc0ef8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2fdb4727-a1ee-4e54-87b0-5c665493ae16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2172db05-5671-4655-9181-cf977cfc0ef8" xlink:to="loc_us-gaap_AwardTypeAxis_2fdb4727-a1ee-4e54-87b0-5c665493ae16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fdb4727-a1ee-4e54-87b0-5c665493ae16_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2fdb4727-a1ee-4e54-87b0-5c665493ae16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fdb4727-a1ee-4e54-87b0-5c665493ae16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b6fa4c-8770-435f-9ea5-e67532716e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2fdb4727-a1ee-4e54-87b0-5c665493ae16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b6fa4c-8770-435f-9ea5-e67532716e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_879a7d66-f3e8-4c4f-b6fa-12300b3962a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b6fa4c-8770-435f-9ea5-e67532716e1b" xlink:to="loc_us-gaap_RestrictedStockMember_879a7d66-f3e8-4c4f-b6fa-12300b3962a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3a0c5ad6-b89f-48f0-b3d1-a03813f8ecc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b6fa4c-8770-435f-9ea5-e67532716e1b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3a0c5ad6-b89f-48f0-b3d1-a03813f8ecc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_345d23cd-1006-4d6b-a15d-873b7c57fdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b6fa4c-8770-435f-9ea5-e67532716e1b" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_345d23cd-1006-4d6b-a15d-873b7c57fdc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_2fe26a12-bf99-4db3-bf37-a6b91a20c1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2172db05-5671-4655-9181-cf977cfc0ef8" xlink:to="loc_us-gaap_VestingAxis_2fe26a12-bf99-4db3-bf37-a6b91a20c1bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2fe26a12-bf99-4db3-bf37-a6b91a20c1bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_2fe26a12-bf99-4db3-bf37-a6b91a20c1bf" xlink:to="loc_us-gaap_VestingDomain_2fe26a12-bf99-4db3-bf37-a6b91a20c1bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a6f8437c-7d76-4f65-8151-d57e98237f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_2fe26a12-bf99-4db3-bf37-a6b91a20c1bf" xlink:to="loc_us-gaap_VestingDomain_a6f8437c-7d76-4f65-8151-d57e98237f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b038703b-c11c-4b38-abab-d0862e186027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a6f8437c-7d76-4f65-8151-d57e98237f43" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b038703b-c11c-4b38-abab-d0862e186027" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_dc4f343c-6fac-4835-a5cf-ceffa480391b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a6f8437c-7d76-4f65-8151-d57e98237f43" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_dc4f343c-6fac-4835-a5cf-ceffa480391b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ehc-20200930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="extended" id="if34d1c18716f4709a33d6b5ba079b55b_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesDetails" xlink:type="extended" id="i673251a9b675478c949dcdc68b9979c6_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShare"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="extended" id="ife7a3069fc9f47d7a266c67bbe168fac_EarningsperCommonShare"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShareTables"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareTables" xlink:type="extended" id="i97952e8ecca643cabb31acbe3eb764aa_EarningsperCommonShareTables"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" xlink:type="extended" id="i44169bb06d1646eb92e27476cb03c2ec_EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" xlink:type="extended" id="ib6d02b8937a74647a1b066cb3421b1cc_EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="simple" xlink:href="ehc-20200930.xsd#ContingenciesandOtherCommitments"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="extended" id="if54519cff8a448c496b533d0233ea856_ContingenciesandOtherCommitments"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#ContingenciesandOtherCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails" xlink:type="extended" id="i732192dd0bce4ea6908bfd806ea07af9_ContingenciesandOtherCommitmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_85142746-e7a2-4be1-b7da-a7c3a3863e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_f03255cc-3d94-430a-a251-856e8995b1cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_85142746-e7a2-4be1-b7da-a7c3a3863e91" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_f03255cc-3d94-430a-a251-856e8995b1cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_85142746-e7a2-4be1-b7da-a7c3a3863e91" xlink:to="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fbd5543d-3983-4119-b5b0-3a3b3a923f3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:to="loc_srt_RangeAxis_fbd5543d-3983-4119-b5b0-3a3b3a923f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fbd5543d-3983-4119-b5b0-3a3b3a923f3a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fbd5543d-3983-4119-b5b0-3a3b3a923f3a" xlink:to="loc_srt_RangeMember_fbd5543d-3983-4119-b5b0-3a3b3a923f3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8dee720-6e84-49f7-94ab-6c0fa3ac2990" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fbd5543d-3983-4119-b5b0-3a3b3a923f3a" xlink:to="loc_srt_RangeMember_c8dee720-6e84-49f7-94ab-6c0fa3ac2990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_52b6002f-9379-4051-9747-85f06f24545f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c8dee720-6e84-49f7-94ab-6c0fa3ac2990" xlink:to="loc_srt_MaximumMember_52b6002f-9379-4051-9747-85f06f24545f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_71c7095a-3159-4797-8b66-b7f8b1a9a5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:to="loc_us-gaap_LitigationStatusAxis_71c7095a-3159-4797-8b66-b7f8b1a9a5e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_71c7095a-3159-4797-8b66-b7f8b1a9a5e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_71c7095a-3159-4797-8b66-b7f8b1a9a5e7" xlink:to="loc_us-gaap_LitigationStatusDomain_71c7095a-3159-4797-8b66-b7f8b1a9a5e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_cd754d73-dce0-4514-b400-9896d662c0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_71c7095a-3159-4797-8b66-b7f8b1a9a5e7" xlink:to="loc_us-gaap_LitigationStatusDomain_cd754d73-dce0-4514-b400-9896d662c0b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_5d2d8da0-4110-47a7-905f-3740637f81cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_cd754d73-dce0-4514-b400-9896d662c0b7" xlink:to="loc_us-gaap_SettledLitigationMember_5d2d8da0-4110-47a7-905f-3740637f81cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d323d2ca-dc1b-48b0-91e6-8e19acc0bd06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:to="loc_srt_LitigationCaseAxis_d323d2ca-dc1b-48b0-91e6-8e19acc0bd06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d323d2ca-dc1b-48b0-91e6-8e19acc0bd06_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d323d2ca-dc1b-48b0-91e6-8e19acc0bd06" xlink:to="loc_srt_LitigationCaseTypeDomain_d323d2ca-dc1b-48b0-91e6-8e19acc0bd06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8274e9fc-6049-44e5-b8e8-ab4b72dd6d3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d323d2ca-dc1b-48b0-91e6-8e19acc0bd06" xlink:to="loc_srt_LitigationCaseTypeDomain_8274e9fc-6049-44e5-b8e8-ab4b72dd6d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NicholsLitigationMember_03f6adb1-3406-4056-9d91-8ff6d17ce3df" xlink:href="ehc-20200930.xsd#ehc_NicholsLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8274e9fc-6049-44e5-b8e8-ab4b72dd6d3a" xlink:to="loc_ehc_NicholsLitigationMember_03f6adb1-3406-4056-9d91-8ff6d17ce3df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReporting"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReporting" xlink:type="extended" id="i630d3b18f911400eb78be13c132f07fc_SegmentReporting"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingTables"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTables" xlink:type="extended" id="i6fe6ee84f7a342a18aad04cb9a4ce199_SegmentReportingTables"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTextualDetails" xlink:type="extended" id="i330a461ff6fc447ea7f08b457ec81012_SegmentReportingTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ad89a3fb-cfda-4ef1-bc11-a434be8d54ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ad89a3fb-cfda-4ef1-bc11-a434be8d54ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_e439583e-1fb7-4d47-9945-e96c42e8da66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_e439583e-1fb7-4d47-9945-e96c42e8da66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals_df02533e-6cf6-492b-8e02-6dd97c943de2" xlink:href="ehc-20200930.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_NumberOfInpatientRehabilitationHospitals_df02533e-6cf6-492b-8e02-6dd97c943de2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_c6e95405-86f1-4d8f-93ff-2204b6d5bb44" xlink:href="ehc-20200930.xsd#ehc_Numberofsolelyownedinpatientrehabilitationhospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_c6e95405-86f1-4d8f-93ff-2204b6d5bb44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage_c83a53ad-b2af-42d3-9b96-e269a9289bfe" xlink:href="ehc-20200930.xsd#ehc_Jointventureownershippercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Jointventureownershippercentage_c83a53ad-b2af-42d3-9b96-e269a9289bfe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_3c8603c8-dcc8-476c-8921-0b5b2b4f83d8" xlink:href="ehc-20200930.xsd#ehc_Numberofjointlyownedinpatientrehabilitationhospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_3c8603c8-dcc8-476c-8921-0b5b2b4f83d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_0aee8e23-98fb-4cf2-9bd4-eeecd7e01821" xlink:href="ehc-20200930.xsd#ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_0aee8e23-98fb-4cf2-9bd4-eeecd7e01821" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhomehealthlocations_489f492b-78df-49ea-a356-af96d8f4c192" xlink:href="ehc-20200930.xsd#ehc_Numberofhomehealthlocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofhomehealthlocations_489f492b-78df-49ea-a356-af96d8f4c192" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhospicelocations_e6374747-44f5-4594-9ec5-b1e307dc57d9" xlink:href="ehc-20200930.xsd#ehc_Numberofhospicelocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofhospicelocations_e6374747-44f5-4594-9ec5-b1e307dc57d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod_a296a9bc-bd16-48b7-a2c7-61d597a7876a" xlink:href="ehc-20200930.xsd#ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod_a296a9bc-bd16-48b7-a2c7-61d597a7876a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_a57028f5-ecde-4ab7-ac92-1cf40e5956ca" xlink:href="ehc-20200930.xsd#ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_a57028f5-ecde-4ab7-ac92-1cf40e5956ca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_376870af-8c21-4481-9746-6d1d4c74beb9" xlink:href="ehc-20200930.xsd#ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_376870af-8c21-4481-9746-6d1d4c74beb9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_616cfcfd-d392-4844-ac0b-ac75ea981b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_616cfcfd-d392-4844-ac0b-ac75ea981b00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_488401f1-88c3-4e05-bf4b-53245d4073fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_616cfcfd-d392-4844-ac0b-ac75ea981b00" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_488401f1-88c3-4e05-bf4b-53245d4073fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_488401f1-88c3-4e05-bf4b-53245d4073fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_488401f1-88c3-4e05-bf4b-53245d4073fb" xlink:to="loc_us-gaap_SegmentDomain_488401f1-88c3-4e05-bf4b-53245d4073fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9d5a7d54-702f-4c74-96a9-5dbf2d30818b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_488401f1-88c3-4e05-bf4b-53245d4073fb" xlink:to="loc_us-gaap_SegmentDomain_9d5a7d54-702f-4c74-96a9-5dbf2d30818b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_5899fee0-7a88-4a4b-a373-ac02a7bdea24" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9d5a7d54-702f-4c74-96a9-5dbf2d30818b" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_5899fee0-7a88-4a4b-a373-ac02a7bdea24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_24381002-5070-4243-a30d-3ee1182f0e09" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9d5a7d54-702f-4c74-96a9-5dbf2d30818b" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_24381002-5070-4243-a30d-3ee1182f0e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c409514c-6c89-4c9f-88a8-986e5b223f73" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_616cfcfd-d392-4844-ac0b-ac75ea981b00" xlink:to="loc_srt_RangeAxis_c409514c-6c89-4c9f-88a8-986e5b223f73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c409514c-6c89-4c9f-88a8-986e5b223f73_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c409514c-6c89-4c9f-88a8-986e5b223f73" xlink:to="loc_srt_RangeMember_c409514c-6c89-4c9f-88a8-986e5b223f73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c3cd29ef-172f-43a0-99f9-4d66eb138d6c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c409514c-6c89-4c9f-88a8-986e5b223f73" xlink:to="loc_srt_RangeMember_c3cd29ef-172f-43a0-99f9-4d66eb138d6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a8f1bb0d-6604-4dfd-bb08-5252b5a075fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c3cd29ef-172f-43a0-99f9-4d66eb138d6c" xlink:to="loc_srt_MinimumMember_a8f1bb0d-6604-4dfd-bb08-5252b5a075fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_618f35a9-3112-4f16-ab10-e2b61d5a2ed0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c3cd29ef-172f-43a0-99f9-4d66eb138d6c" xlink:to="loc_srt_MaximumMember_618f35a9-3112-4f16-ab10-e2b61d5a2ed0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="extended" id="i99055d8aef4e4fe68b146ee730deae32_SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6ed6bdc-e02a-481d-bbec-a8aed37c1fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6ed6bdc-e02a-481d-bbec-a8aed37c1fd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_874bcee4-45b7-4912-8328-362ba64e1a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_us-gaap_LaborAndRelatedExpense_874bcee4-45b7-4912-8328-362ba64e1a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_73e7bbee-520a-46db-8962-ee3cbbf5e54a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_73e7bbee-520a-46db-8962-ee3cbbf5e54a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_a8c5c93a-0995-4290-b926-d82ba985e7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_us-gaap_SuppliesExpense_a8c5c93a-0995-4290-b926-d82ba985e7bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_e32471c9-3776-4df9-9f40-b16122de1af1" xlink:href="ehc-20200930.xsd#ehc_OccupancyCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_ehc_OccupancyCost_e32471c9-3776-4df9-9f40-b16122de1af1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization_d62dfedd-d495-4965-b02d-a632e74a7241" xlink:href="ehc-20200930.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_ehc_CostofServicesExcludingDepreciationandAmortization_d62dfedd-d495-4965-b02d-a632e74a7241" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_1b5cc2c8-e66b-4cc2-8b81-f40ce50ab007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_1b5cc2c8-e66b-4cc2-8b81-f40ce50ab007" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fb180a3c-46a6-4c94-9a0d-67a04b06b6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_us-gaap_CostsAndExpenses_fb180a3c-46a6-4c94-9a0d-67a04b06b6c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9a8e7e4a-8dcc-4970-97d0-cb076c3e8f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9a8e7e4a-8dcc-4970-97d0-cb076c3e8f0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7f0a5592-80db-4428-b82c-12d5e17adc40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7f0a5592-80db-4428-b82c-12d5e17adc40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_24d5c1d7-6822-443e-bf88-aaf9162f68b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_24d5c1d7-6822-443e-bf88-aaf9162f68b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_ffc22dd8-fc2e-4ddd-a459-dbd3eace1edb" xlink:href="ehc-20200930.xsd#ehc_AdjustedEBITDA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_ehc_AdjustedEBITDA_ffc22dd8-fc2e-4ddd-a459-dbd3eace1edb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_de83be24-42dc-418d-8cdc-d270727dafd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_de83be24-42dc-418d-8cdc-d270727dafd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b40f3784-184a-4a81-b17d-45f86233b73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b40f3784-184a-4a81-b17d-45f86233b73a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c76a7938-5c48-4dcf-a669-edfe7c5c1585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b40f3784-184a-4a81-b17d-45f86233b73a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c76a7938-5c48-4dcf-a669-edfe7c5c1585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c76a7938-5c48-4dcf-a669-edfe7c5c1585_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c76a7938-5c48-4dcf-a669-edfe7c5c1585" xlink:to="loc_us-gaap_SegmentDomain_c76a7938-5c48-4dcf-a669-edfe7c5c1585_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b74d870d-96ea-4b40-a9bb-d74590365791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c76a7938-5c48-4dcf-a669-edfe7c5c1585" xlink:to="loc_us-gaap_SegmentDomain_b74d870d-96ea-4b40-a9bb-d74590365791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_a3d724bb-6b7b-406b-abcf-0b8d095387c0" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b74d870d-96ea-4b40-a9bb-d74590365791" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_a3d724bb-6b7b-406b-abcf-0b8d095387c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_d775c655-e079-4750-a239-82b29f537751" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b74d870d-96ea-4b40-a9bb-d74590365791" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_d775c655-e079-4750-a239-82b29f537751" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails" xlink:type="extended" id="iabc52610e1f0407ea5f664dd179f70ee_SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_ae1bdd4c-e245-4b96-9486-9b27bc014896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1a8c5826-e68e-4da2-bde9-cbe9f522160f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_ae1bdd4c-e245-4b96-9486-9b27bc014896" xlink:to="loc_us-gaap_Assets_1a8c5826-e68e-4da2-bde9-cbe9f522160f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_09597be4-9cab-43e0-86d7-1cbb3058e12b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_ae1bdd4c-e245-4b96-9486-9b27bc014896" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_09597be4-9cab-43e0-86d7-1cbb3058e12b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_1d6df45e-09d5-4cca-a5d1-dc350bb0510a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_ae1bdd4c-e245-4b96-9486-9b27bc014896" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_1d6df45e-09d5-4cca-a5d1-dc350bb0510a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1932b8d0-ae89-4cad-9759-260171022bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_1d6df45e-09d5-4cca-a5d1-dc350bb0510a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1932b8d0-ae89-4cad-9759-260171022bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1932b8d0-ae89-4cad-9759-260171022bf2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1932b8d0-ae89-4cad-9759-260171022bf2" xlink:to="loc_us-gaap_SegmentDomain_1932b8d0-ae89-4cad-9759-260171022bf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1f9936da-d239-4646-a56b-df14813f9f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1932b8d0-ae89-4cad-9759-260171022bf2" xlink:to="loc_us-gaap_SegmentDomain_1f9936da-d239-4646-a56b-df14813f9f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_5c0f5a53-cfc2-4770-846d-b56f5729ae5e" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1f9936da-d239-4646-a56b-df14813f9f26" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_5c0f5a53-cfc2-4770-846d-b56f5729ae5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_ffdd6597-9793-4240-923d-924c4237817c" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1f9936da-d239-4646-a56b-df14813f9f26" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_ffdd6597-9793-4240-923d-924c4237817c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="extended" id="i68719bd7508b41959f709bf10712d346_SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_8b6fc9c6-0b21-4074-b9d8-28c6ac48860e" xlink:href="ehc-20200930.xsd#ehc_AdjustedEBITDA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_ehc_AdjustedEBITDA_8b6fc9c6-0b21-4074-b9d8-28c6ac48860e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cdfc3575-d9c0-4dd1-8230-c7d0438d0ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cdfc3575-d9c0-4dd1-8230-c7d0438d0ec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ce5fa81b-c098-4611-af78-48ee9cfe5529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ce5fa81b-c098-4611-af78-48ee9cfe5529" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a540099c-b63c-4162-bf7b-2640ade73495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a540099c-b63c-4162-bf7b-2640ade73495" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_8c705a2d-05ce-43b1-97ca-c75c66bd6d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_LitigationSettlementExpense_8c705a2d-05ce-43b1-97ca-c75c66bd6d7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_212ab53e-6841-47dd-8599-408a381af97a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_212ab53e-6841-47dd-8599-408a381af97a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3415e998-94c7-48b2-b083-12403326fac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_InterestExpenseDebt_3415e998-94c7-48b2-b083-12403326fac5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f8cedf1a-0f82-4b90-a3e6-b37f8acb04e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f8cedf1a-0f82-4b90-a3e6-b37f8acb04e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests_52218c9d-582b-4407-95d9-234a07b73184" xlink:href="ehc-20200930.xsd#ehc_SARsmarktomarketimpactonnoncontrollinginterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests_52218c9d-582b-4407-95d9-234a07b73184" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss_d1168e1e-b40b-4ad3-98c0-75ce6b492853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_MarketableSecuritiesGainLoss_d1168e1e-b40b-4ad3-98c0-75ce6b492853" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_8d4ea449-bf3d-454d-86af-8653546e56ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_8d4ea449-bf3d-454d-86af-8653546e56ff" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayrolltaxesonSARsexercise_dfb03baf-2d6b-443d-99f5-1654cb979268" xlink:href="ehc-20200930.xsd#ehc_PayrolltaxesonSARsexercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_ehc_PayrolltaxesonSARsexercise_dfb03baf-2d6b-443d-99f5-1654cb979268" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c73d88db-b769-462a-a519-866fd4a8a686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c73d88db-b769-462a-a519-866fd4a8a686" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f3536776-05ef-49d8-8430-28650825c5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f3536776-05ef-49d8-8430-28650825c5ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f4720c68-5500-4755-93f2-64f71a41a867" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f3536776-05ef-49d8-8430-28650825c5ca" xlink:to="loc_srt_ConsolidationItemsAxis_f4720c68-5500-4755-93f2-64f71a41a867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f4720c68-5500-4755-93f2-64f71a41a867_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_f4720c68-5500-4755-93f2-64f71a41a867" xlink:to="loc_srt_ConsolidationItemsDomain_f4720c68-5500-4755-93f2-64f71a41a867_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8096495e-6c93-4224-a9e5-01e53b358a47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_f4720c68-5500-4755-93f2-64f71a41a867" xlink:to="loc_srt_ConsolidationItemsDomain_8096495e-6c93-4224-a9e5-01e53b358a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2bd69e51-3a20-4502-a7c7-9c818c9f0bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8096495e-6c93-4224-a9e5-01e53b358a47" xlink:to="loc_us-gaap_OperatingSegmentsMember_2bd69e51-3a20-4502-a7c7-9c818c9f0bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_2ad2d9dd-dbad-43ae-9af9-16b75bb2782d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8096495e-6c93-4224-a9e5-01e53b358a47" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_2ad2d9dd-dbad-43ae-9af9-16b75bb2782d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails" xlink:type="extended" id="i1f584fc6d43f4cd789d497fd90dcc7e9_SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_3f954e66-f934-4094-92b7-df44a952e3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_33f38f79-bb1c-4355-bb19-2fdf2165ba1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_3f954e66-f934-4094-92b7-df44a952e3c4" xlink:to="loc_us-gaap_Assets_33f38f79-bb1c-4355-bb19-2fdf2165ba1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_aac9a080-6fb4-4e44-b640-d0a94b6c1156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_3f954e66-f934-4094-92b7-df44a952e3c4" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_aac9a080-6fb4-4e44-b640-d0a94b6c1156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_e38260ee-4da7-4cc9-96e5-d24e206a023a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_3f954e66-f934-4094-92b7-df44a952e3c4" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_e38260ee-4da7-4cc9-96e5-d24e206a023a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a34c40df-f845-4bad-a881-a2e52635794b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_e38260ee-4da7-4cc9-96e5-d24e206a023a" xlink:to="loc_srt_ConsolidationItemsAxis_a34c40df-f845-4bad-a881-a2e52635794b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a34c40df-f845-4bad-a881-a2e52635794b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_a34c40df-f845-4bad-a881-a2e52635794b" xlink:to="loc_srt_ConsolidationItemsDomain_a34c40df-f845-4bad-a881-a2e52635794b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8d7f846a-06c8-42d4-9ce0-bdd7e8896c1e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_a34c40df-f845-4bad-a881-a2e52635794b" xlink:to="loc_srt_ConsolidationItemsDomain_8d7f846a-06c8-42d4-9ce0-bdd7e8896c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_96ac3ee9-2e0f-40ca-86ac-4b32fe65b1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8d7f846a-06c8-42d4-9ce0-bdd7e8896c1e" xlink:to="loc_us-gaap_OperatingSegmentsMember_96ac3ee9-2e0f-40ca-86ac-4b32fe65b1cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_63c6e740-50c5-4479-b229-ef246f6c9ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8d7f846a-06c8-42d4-9ce0-bdd7e8896c1e" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_63c6e740-50c5-4479-b229-ef246f6c9ec9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended" id="iaa47522e6672408d819bee390dae8988_SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ea114d79-f17d-48cc-b938-8b06d08ee61e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8eb27782-5673-4211-b1fa-b3e6a1db0991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ea114d79-f17d-48cc-b938-8b06d08ee61e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8eb27782-5673-4211-b1fa-b3e6a1db0991" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a4cd56cc-9317-45b4-b2f7-613a70027952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ea114d79-f17d-48cc-b938-8b06d08ee61e" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a4cd56cc-9317-45b4-b2f7-613a70027952" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f25d1c92-ca5a-4af7-aa70-b42f612adb97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a4cd56cc-9317-45b4-b2f7-613a70027952" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f25d1c92-ca5a-4af7-aa70-b42f612adb97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f25d1c92-ca5a-4af7-aa70-b42f612adb97_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f25d1c92-ca5a-4af7-aa70-b42f612adb97" xlink:to="loc_us-gaap_SegmentDomain_f25d1c92-ca5a-4af7-aa70-b42f612adb97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1d1162ab-de78-4240-94b8-a692ff71235e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f25d1c92-ca5a-4af7-aa70-b42f612adb97" xlink:to="loc_us-gaap_SegmentDomain_1d1162ab-de78-4240-94b8-a692ff71235e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_2f36d3fb-e4c4-46ee-82e1-d2f11206d3e4" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1d1162ab-de78-4240-94b8-a692ff71235e" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_2f36d3fb-e4c4-46ee-82e1-d2f11206d3e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_2f54abae-ece4-42e3-aae3-cbc8051bbd98" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1d1162ab-de78-4240-94b8-a692ff71235e" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_2f54abae-ece4-42e3-aae3-cbc8051bbd98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_d5a98a47-ba84-4f1a-b4d3-ab7862428c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a4cd56cc-9317-45b4-b2f7-613a70027952" xlink:to="loc_us-gaap_SubsegmentsAxis_d5a98a47-ba84-4f1a-b4d3-ab7862428c24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_d5a98a47-ba84-4f1a-b4d3-ab7862428c24_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_d5a98a47-ba84-4f1a-b4d3-ab7862428c24" xlink:to="loc_us-gaap_SubsegmentsDomain_d5a98a47-ba84-4f1a-b4d3-ab7862428c24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_d5a98a47-ba84-4f1a-b4d3-ab7862428c24" xlink:to="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientMember_ca15149f-51fe-4b01-bd24-8186bfe07962" xlink:href="ehc-20200930.xsd#ehc_InpatientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:to="loc_ehc_InpatientMember_ca15149f-51fe-4b01-bd24-8186bfe07962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OutpatientandotherMember_d5d0ff2d-c799-417b-aa7e-737e73b63ace" xlink:href="ehc-20200930.xsd#ehc_OutpatientandotherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:to="loc_ehc_OutpatientandotherMember_d5d0ff2d-c799-417b-aa7e-737e73b63ace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember_cd6b023d-0554-4eb7-aeee-98be4acf8abb" xlink:href="ehc-20200930.xsd#ehc_HomehealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:to="loc_ehc_HomehealthMember_cd6b023d-0554-4eb7-aeee-98be4acf8abb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember_fd75360c-f5c2-4dc7-8690-b783d897daf8" xlink:href="ehc-20200930.xsd#ehc_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:to="loc_ehc_HospiceMember_fd75360c-f5c2-4dc7-8690-b783d897daf8" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ehc-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e0fc9ecd-686a-431a-a15f-a624ec9cb1a0,g:253d3480-dc2c-4d92-b5eb-51ca56c502e3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f16f7799-3764-4cc7-ae70-7fc35d597292_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards issued (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_748fbbe8-7255-451e-9bef-c0321735a8c0_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_ee622444-17c1-45ef-aba7-847cf372c295_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8d686b84-17d1-4a58-87b6-a5c055f81cae_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_ad6b20fb-d3c9-4292-9246-8262f3a5aa72_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_025efb7b-4003-4d7f-be14-d02d48415190_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.125% Senior Notes due 2023</link:label>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_label_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 05.125%, Due 2023 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 05.125%, Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes05.125Due2023Member" xlink:to="lab_ehc_SeniorNotes05.125Due2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_4b400be1-6b64-4df7-9596-068c623d5bf0_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_ee4bc85d-c238-4c6f-9462-3ce1c48dde03_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_5c4076d1-d3cf-4113-aee4-4181d1aa01c3_terseLabel_en-US" xlink:label="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_label_en-US" xlink:label="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_documentation_en-US" xlink:label="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:href="ehc-20200930.xsd#ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:to="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_b03abd74-5949-4f5b-9a67-fe389dc8445a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_681ed0d3-ca4d-45b0-bba2-afa026c69627_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_d05753fe-981d-45d1-90b5-a0becc2f357a_terseLabel_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consolidated limited partnership-like entities</link:label>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_label_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number of Entities Consolidated</link:label>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_documentation_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities consolidated as variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:href="ehc-20200930.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:to="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AllocatedSharebasedCompensationLiability_ac82e544-d29f-42b6-94dd-50a3aa9fb0f9_terseLabel_en-US" xlink:label="lab_ehc_AllocatedSharebasedCompensationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of SARs</link:label>
    <link:label id="lab_ehc_AllocatedSharebasedCompensationLiability_label_en-US" xlink:label="lab_ehc_AllocatedSharebasedCompensationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Liability</link:label>
    <link:label id="lab_ehc_AllocatedSharebasedCompensationLiability_documentation_en-US" xlink:label="lab_ehc_AllocatedSharebasedCompensationLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AllocatedSharebasedCompensationLiability" xlink:href="ehc-20200930.xsd#ehc_AllocatedSharebasedCompensationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AllocatedSharebasedCompensationLiability" xlink:to="lab_ehc_AllocatedSharebasedCompensationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_5926cb71-0c6d-45c8-99c2-1d2ac7fd8072_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of face value (percent)</link:label>
    <link:label id="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_label_en-US" xlink:label="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Discount Rate At Issuance Of Face Value</link:label>
    <link:label id="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Discount Rate at Issuance of Face Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:href="ehc-20200930.xsd#ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:to="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_8f71663a-1c2c-4ff9-a8b3-dfef6ba320ed_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_180fcef3-de31-48ed-b3d5-d5274b6ab007_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bc7645e-32b9-4867-8810-d9017a9b0b0a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_699ff74a-40f5-4fc1-a374-1ff2125ad07e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_4a4631bf-7516-4e19-b7f0-5914279eaea9_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions declared</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_5ed49fdf-de36-4e2a-88ef-fa94d00fa1b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions declared</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock_0d87ca33-7d60-4e07-8879-0edf93a692f9_terseLabel_en-US" xlink:label="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense</link:label>
    <link:label id="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock_label_en-US" xlink:label="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table Text Block]</link:label>
    <link:label id="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of all significant reconciling items in the reconciliation segment adjusted EBITDA to income from continuing operations before income tax expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:href="ehc-20200930.xsd#ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:to="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_f057a61e-bfc9-4e59-b62c-a70574d514e0_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock_53a19d2e-7ba3-4ecd-a282-816a19158cce_terseLabel_en-US" xlink:label="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Covenants</link:label>
    <link:label id="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock_label_en-US" xlink:label="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Financial Covenants [Table Text Block]</link:label>
    <link:label id="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Financial Covenants [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:href="ehc-20200930.xsd#ehc_ScheduleOfFinancialCovenantsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:to="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_06617102-e8fb-4a99-b500-273eb93a4b81_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_67145db2-8b85-4c2b-b1e7-e7b4c6f55980_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_d8eb6274-e112-41bd-abe6-c3e104af92e0_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3cd4070c-dd3c-405c-a6e1-74de8aa28b42_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6b813a6b-26f4-408a-a937-ba4878860235_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f3a0e2a1-ea66-4d6d-aa5e-8f2cd24989c5_totalLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_c9bb396f-93f6-419a-a5aa-e2ac2651bd27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bf566a9f-1a7b-4268-b780-0215001e72a7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1ea5f03a-9dc6-48ba-8e8b-008c22e696d7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnersCapitalAccountContributions_bd1ea7fd-77c6-4298-8f59-0a0c9f3f0cce_terseLabel_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contributions from consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PartnersCapitalAccountContributions_label_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partners' Capital Account, Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountContributions" xlink:to="lab_us-gaap_PartnersCapitalAccountContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_a55ed8f5-6c49-4281-a5c5-de3598ecd5e8_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OccupancyCost_ba3c89ad-2a1d-48d1-80b6-624718c2ed87_terseLabel_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Occupancy costs</link:label>
    <link:label id="lab_ehc_OccupancyCost_label_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Occupancy Cost</link:label>
    <link:label id="lab_ehc_OccupancyCost_documentation_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost" xlink:href="ehc-20200930.xsd#ehc_OccupancyCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OccupancyCost" xlink:to="lab_ehc_OccupancyCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89c6701c-000a-4315-a3c0-6cf4d819632e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_44697d28-55c7-4903-b574-984034b8e8f0_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on consolidation of Yuma Rehabilitation Hospital</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_64f2a747-96af-4bc3-9c67-98f594cc2f1a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8d08a71d-6057-478d-a052-e83b5477c468_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_07acde43-ee1c-4354-916d-56413f00364e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation of Yuma Rehabilitation Hospital</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_bd7fe96f-ff31-43b1-a379-5a7fb86a79ed_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of treasury stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_935ecddf-ee97-4ab3-9d47-ddaa3fd2035d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and Performance Condition</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofDeNovoBeds_d8c3a50a-92a3-42cc-b181-4300d1907322_terseLabel_en-US" xlink:label="lab_ehc_NumberofDeNovoBeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of de novo beds</link:label>
    <link:label id="lab_ehc_NumberofDeNovoBeds_label_en-US" xlink:label="lab_ehc_NumberofDeNovoBeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of DeNovo Beds</link:label>
    <link:label id="lab_ehc_NumberofDeNovoBeds_documentation_en-US" xlink:label="lab_ehc_NumberofDeNovoBeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of DeNovo Beds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofDeNovoBeds" xlink:href="ehc-20200930.xsd#ehc_NumberofDeNovoBeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofDeNovoBeds" xlink:to="lab_ehc_NumberofDeNovoBeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_65594cef-c32c-44d5-a4f2-fb1b7c8d0a1e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock, including fees and expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6e4db345-94f8-4e48-87ca-66d7b311b155_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_e21f07ff-6a10-405c-9b4b-a2bbbe760d15_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6c601c56-9bd3-4d3a-b284-30d6123dafba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance measurement period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_26e5a82e-e506-4905-992b-77b8e3e1e6aa_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e4006576-265e-4db3-ba44-f8251f11006d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e545c5ad-b883-4f2a-9c00-5eb9ce018b34_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_da35398d-8143-4092-a81e-2fe87b27512b_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARs</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a7a44e4d-7cf4-4294-b429-a0a9dc68d8fa_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests_a893be0e-94c2-4736-8832-7f47782dffcf_terseLabel_en-US" xlink:label="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARs mark-to-market impact on noncontrolling interests</link:label>
    <link:label id="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests_label_en-US" xlink:label="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARs mark-to-market impact on noncontrolling interests</link:label>
    <link:label id="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests_documentation_en-US" xlink:label="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in noncontrolling interest during the period as a result of SARs mark-to-market adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:href="ehc-20200930.xsd#ehc_SARsmarktomarketimpactonnoncontrollinginterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:to="lab_ehc_SARsmarktomarketimpactonnoncontrollinginterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_922e4acd-131a-4d68-91af-be192dcd0acd_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_90e923f3-8588-4db1-b1e8-61ea6bf505c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6a953d3c-317c-45ad-8677-f9b3183125a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cd377470-33d8-4959-b109-5862d77a9fc6_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_eb77946c-016c-49e3-b88a-7722d1d77f96_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_96334e50-cb3e-47d5-bd01-54cb1c40b3b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_a26a48b0-de9c-48b9-924d-939f22ca71a4_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ebf5e91f-0691-44fa-97be-189e28cf06e7_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_6942601b-77e3-4be6-a894-4896649656dc_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock in open market (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_19744aa4-0c1f-4d34-94c9-fd0e16acc274_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_da8c1325-3961-48a0-832b-ba115f355428_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_2df0660e-6766-4bbc-a805-c1ecb02e6cc7_terseLabel_en-US" xlink:label="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_label_en-US" xlink:label="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_documentation_en-US" xlink:label="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of solely owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:href="ehc-20200930.xsd#ehc_Numberofsolelyownedinpatientrehabilitationhospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:to="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_414c42f7-34f2-4870-a4b8-9ed477988630_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HoldingsAndEHHIMember_72e94cd2-8ee9-4fe2-9778-15015be4c69a_terseLabel_en-US" xlink:label="lab_ehc_HoldingsAndEHHIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdings And EHHI</link:label>
    <link:label id="lab_ehc_HoldingsAndEHHIMember_label_en-US" xlink:label="lab_ehc_HoldingsAndEHHIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdings And EHHI [Member]</link:label>
    <link:label id="lab_ehc_HoldingsAndEHHIMember_documentation_en-US" xlink:label="lab_ehc_HoldingsAndEHHIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdings And EHHI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HoldingsAndEHHIMember" xlink:href="ehc-20200930.xsd#ehc_HoldingsAndEHHIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HoldingsAndEHHIMember" xlink:to="lab_ehc_HoldingsAndEHHIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_dcb6a9c2-e0bc-4ffc-aea0-15fbc1165d57_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_5c3cfbaa-d9b9-4bee-8620-facbabf74608_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_9236f19a-7beb-4d1e-96b4-0ecd5960956e_terseLabel_en-US" xlink:label="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement Of Comprehensive Income And Income Statement [Abstract]</link:label>
    <link:label id="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_label_en-US" xlink:label="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement Of Comprehensive Income And Income Statement [Abstract]</link:label>
    <link:label id="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_documentation_en-US" xlink:label="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement Of Comprehensive Income And Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:href="ehc-20200930.xsd#ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:to="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_683ca56d-02d7-4c81-afe0-b2c32b61fc49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_472a87cf-57ab-4f85-90e4-2c2d116c2a3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_3734c322-ffb1-4330-8ae5-239c52731f4e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_GenerationSolutionsofLynchburgMember_5614d720-c723-4a60-a3ad-77db2a1e4421_terseLabel_en-US" xlink:label="lab_ehc_GenerationSolutionsofLynchburgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generation Solutions of Lynchburg</link:label>
    <link:label id="lab_ehc_GenerationSolutionsofLynchburgMember_label_en-US" xlink:label="lab_ehc_GenerationSolutionsofLynchburgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generation Solutions of Lynchburg [Member]</link:label>
    <link:label id="lab_ehc_GenerationSolutionsofLynchburgMember_documentation_en-US" xlink:label="lab_ehc_GenerationSolutionsofLynchburgMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generation Solutions of Lynchburg [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsofLynchburgMember" xlink:href="ehc-20200930.xsd#ehc_GenerationSolutionsofLynchburgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_GenerationSolutionsofLynchburgMember" xlink:to="lab_ehc_GenerationSolutionsofLynchburgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_eff2e3e1-0f1d-4e95-b9ba-8ce2930e955d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f37b1b76-fa2a-494a-98c1-3d38fb1f80dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_a92ecfc0-cedc-4893-b1db-3ba6b3d0a267_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_d32ccca2-8d39-45be-ab74-62f45ce3c460_terseLabel_en-US" xlink:label="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_label_en-US" xlink:label="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_documentation_en-US" xlink:label="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:href="ehc-20200930.xsd#ehc_Numberofjointlyownedinpatientrehabilitationhospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:to="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f3d47639-b63f-4100-afba-2cc1dca08f49_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_badd0c76-4644-466e-b37c-9dc0b2cc1417_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments under finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6fdc47fd-06fb-42c4-9371-d644bb4fb47c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NicholsLitigationMember_f4e6befb-4908-4db3-9b06-947b7a8da191_terseLabel_en-US" xlink:label="lab_ehc_NicholsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nichols Litigation</link:label>
    <link:label id="lab_ehc_NicholsLitigationMember_label_en-US" xlink:label="lab_ehc_NicholsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nichols Litigation [Member]</link:label>
    <link:label id="lab_ehc_NicholsLitigationMember_documentation_en-US" xlink:label="lab_ehc_NicholsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nichols Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NicholsLitigationMember" xlink:href="ehc-20200930.xsd#ehc_NicholsLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NicholsLitigationMember" xlink:to="lab_ehc_NicholsLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_9f3e31b2-cad7-4605-ba66-2a0afd0eb1e6_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a265f734-31c5-4f42-a6fc-5450b6aa2b2c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_a790a0d2-9167-4f40-92af-da4e15a9d8ca_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9d2e85f7-065a-46e1-80de-29a7835ecf36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d6736f7f-0dee-4c55-88d8-1e0709488c0a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_82548fd4-fdb5-4e78-a44b-45b1947bd362_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a691f821-9934-4459-8849-a9a780286ca6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e957837d-2b0b-442c-80c8-426c44b421a0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_47ff9aad-4c86-4b6c-adec-8d48898e1bc2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_af551572-cbfa-41a1-af87-603033dc20fb_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofhospicelocations_dd710e4c-0cbb-4a7d-8016-7cbcd1da4420_terseLabel_en-US" xlink:label="lab_ehc_Numberofhospicelocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospice locations</link:label>
    <link:label id="lab_ehc_Numberofhospicelocations_label_en-US" xlink:label="lab_ehc_Numberofhospicelocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospice locations</link:label>
    <link:label id="lab_ehc_Numberofhospicelocations_documentation_en-US" xlink:label="lab_ehc_Numberofhospicelocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospice locations the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhospicelocations" xlink:href="ehc-20200930.xsd#ehc_Numberofhospicelocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofhospicelocations" xlink:to="lab_ehc_Numberofhospicelocations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_3f8e870b-e8a3-4ed2-a034-df7abbdeb2fe_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_453ba292-bca9-42c9-a241-541c61208ab8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate_17b84baf-4efc-4834-aa55-39c5c3e7a1ef_terseLabel_en-US" xlink:label="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of ASC 842</link:label>
    <link:label id="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate_label_en-US" xlink:label="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Financing Activities, Adoption Of Accounting Standard Update</link:label>
    <link:label id="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate_documentation_en-US" xlink:label="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Financing Activities, Adoption Of Accounting Standard Update</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:href="ehc-20200930.xsd#ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:to="lab_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_1126c953-c9e1-4e9f-b871-82b9677be397_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e9b8a783-a1e9-44c2-9668-65bef77bba9c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f8670e36-94bf-48ee-ae66-4e6e64bf9d25_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7cb833bb-e3b6-4e85-8e5b-3589c83a9295_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_1c7b66c6-0305-4614-948e-4cac7b00b495_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_374fc515-09de-4ef3-bab7-c6cbbae4c63f_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_d7cd3c07-88fa-4c92-89e3-ce9fe7e5ba14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Weighted Average Number of Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_4f78380f-f2e6-405b-99db-f25a1bbaea22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PremierHealthPartnersMember_b497af94-ce20-4419-b27a-30a3c62e8444_terseLabel_en-US" xlink:label="lab_ehc_PremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premier Health Partners</link:label>
    <link:label id="lab_ehc_PremierHealthPartnersMember_label_en-US" xlink:label="lab_ehc_PremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premier Health Partners [Member]</link:label>
    <link:label id="lab_ehc_PremierHealthPartnersMember_documentation_en-US" xlink:label="lab_ehc_PremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premier Health Partners [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PremierHealthPartnersMember" xlink:href="ehc-20200930.xsd#ehc_PremierHealthPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PremierHealthPartnersMember" xlink:to="lab_ehc_PremierHealthPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_448dc9bb-f2c8-488e-80cc-215da4b36517_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofhomehealthlocations_059d239e-b3a0-4cac-90a7-fe2f0957b409_terseLabel_en-US" xlink:label="lab_ehc_Numberofhomehealthlocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of home health locations</link:label>
    <link:label id="lab_ehc_Numberofhomehealthlocations_label_en-US" xlink:label="lab_ehc_Numberofhomehealthlocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of home health locations</link:label>
    <link:label id="lab_ehc_Numberofhomehealthlocations_documentation_en-US" xlink:label="lab_ehc_Numberofhomehealthlocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of home health locations the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhomehealthlocations" xlink:href="ehc-20200930.xsd#ehc_Numberofhomehealthlocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofhomehealthlocations" xlink:to="lab_ehc_Numberofhomehealthlocations" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_2546c3a9-54e1-43bf-a3fe-ffa78bf269e6_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes due 2025</link:label>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_label_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2025 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes05.75Due2025Member" xlink:to="lab_ehc_SeniorNotes05.75Due2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_2ca7610a-1ac8-441c-89a1-2fc67d81ccdd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, pro forma information, earnings of acquiree since acquisition date, actual</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_476eb7be-ae69-4774-97c4-6d0bbfbedc36_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicaidMember_23b06235-2651-4552-9550-566291ebc93e_terseLabel_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ehc_MedicaidMember_label_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ehc_MedicaidMember_documentation_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember" xlink:href="ehc-20200930.xsd#ehc_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicaidMember" xlink:to="lab_ehc_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4529ccd1-2be3-4b84-9fff-2386b1e43eaf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_77acfc70-7cbf-4916-b4c2-d203e6339f21_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_7dc4c0c5-6876-465d-ad2f-b04d1caa4df7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill increase</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ebf2c211-9255-42ed-a281-013976cb14bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Earnings Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_686dde02-828e-4f7e-aa5d-a635b8166e35_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2ed74077-c1d9-47ee-a2f8-47dda40bfa4a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_69c5fe2f-54a0-429b-9848-5a9227232dcc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment for litigation settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b5321645-f5b4-40e6-a25c-468cb66d3bc6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1ea74336-c066-490d-8c92-a4259c8950c4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_27a1c8ce-caf9-40d3-b0d7-306a6f39005d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_4049f4a3-23bb-4528-a961-27f660fa96e9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_24077726-3e49-41e1-876a-9cde71420a9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_3b98a0e1-5b78-4095-856a-09ed24d7373a_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government, class action, and related settlements</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_d58a17b3-6e95-4bdb-9f50-083fa4db2d0b_negatedLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government, class action, and related settlements</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_bfa2b874-004c-4271-8bf4-9dc0de0aa73d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_450c36c5-45aa-48cb-b7f0-6c043df37d33_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_da244072-e97e-47c2-8606-e8e1dfe3609c_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Notes due 2028</link:label>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_label_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, Due 2028 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes4.50Due2028Member" xlink:to="lab_ehc_SeniorNotes4.50Due2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_4aeb4590-386e-4c43-8104-b68119c1408b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_4942300c-29d6-4a45-899a-60e71ab00275_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_12b6542f-66e9-456c-be41-473fc8a880c1_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Notes due 2030</link:label>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_label_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.750%, Due 2030 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.750%, Due 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes04.750Due2030Member" xlink:to="lab_ehc_SeniorNotes04.750Due2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c9db418a-5354-48d5-87d7-4d0c1a31c483_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_b85da601-e970-4850-bded-34ed69917328_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_6f73444a-068a-40a0-9e12-32e7e03a582d_terseLabel_en-US" xlink:label="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares exercised by investor</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_label_en-US" xlink:label="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests, Decrease from Redemptions or Purchase of Interests, Percent</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_documentation_en-US" xlink:label="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests), percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:href="ehc-20200930.xsd#ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:to="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ed806177-bd08-4f28-a6b6-3bce4ee8eacc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_db978b6e-68c1-4384-a857-5a74593d2e08_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, pro forma net income</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_273856fb-9f29-4771-940c-1f189d09dabc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c42758a8-95d6-4ec8-9856-c80fe3a48329_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_22c16d79-a647-422c-b727-db5299fd8b36_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_78513eae-cf12-49ec-be95-0dd5c3d095a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_fd408147-d05d-4de2-9d0c-89dd066c2c1b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ManagedCareMember_14477b08-264b-44da-b975-d74e1cb56107_terseLabel_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care</link:label>
    <link:label id="lab_ehc_ManagedCareMember_label_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care [Member]</link:label>
    <link:label id="lab_ehc_ManagedCareMember_documentation_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember" xlink:href="ehc-20200930.xsd#ehc_ManagedCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ManagedCareMember" xlink:to="lab_ehc_ManagedCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_50a4b4f6-0843-4cda-b706-1420173161e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_21e0b6ce-4e80-4225-aaa3-6160f4b62d94_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_b04bcde7-1112-4819-9765-718d1f268d94_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_17a83e20-c9ea-4f93-b26d-5b4f8b1f930d_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HospiceMember_5d507723-037f-4a37-bbd8-70c07235c056_terseLabel_en-US" xlink:label="lab_ehc_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice</link:label>
    <link:label id="lab_ehc_HospiceMember_label_en-US" xlink:label="lab_ehc_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_ehc_HospiceMember_documentation_en-US" xlink:label="lab_ehc_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember" xlink:href="ehc-20200930.xsd#ehc_HospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HospiceMember" xlink:to="lab_ehc_HospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_3a96dead-a684-430e-9f7b-d6e3e2a8e03d_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_56dc9f71-a723-47f3-bbe1-1ee96c0d64de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense and amortization of debt discounts and fees</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_e0a29a8d-a840-4dbe-90ed-13b45e412c82_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest, equity, acquired percent</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Acquired Percent</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Acquired Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:href="ehc-20200930.xsd#ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:to="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_1f1e725e-5376-4b7a-9f8e-7d1c62ec4a09_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_506b8ece-0bd1-4830-afad-86f2ce481d83_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_15550c74-0e78-41b2-9d9f-742d0d6c3faa_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_d1552bd9-62f7-49a2-804b-123fafe4b243_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d858725f-ac7d-482c-a1e3-d443e20ad8a6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense and amortization of debt discounts and fees</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_b15bd142-9d30-48e3-aba8-51aac5bfe39d_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicareAdvantageMember_696f1782-ba60-4cb1-87b8-c52a74573140_terseLabel_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_ehc_MedicareAdvantageMember_label_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_ehc_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember" xlink:href="ehc-20200930.xsd#ehc_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicareAdvantageMember" xlink:to="lab_ehc_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_fa3c86b3-5b32-4714-b3cd-4781f9c6e467_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b40e539f-1424-41fe-bb9b-618107152bc4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c4e970dd-4d99-4740-af9c-12b175876b0a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings_10814dbb-4ced-4eab-8284-340a187052eb_terseLabel_en-US" xlink:label="lab_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collection success rate of denied payments (percent)</link:label>
    <link:label id="lab_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings_label_en-US" xlink:label="lab_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Denials, Percentage Collected After Appeal, Including Administrative Law Judge Hearings</link:label>
    <link:label id="lab_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings_documentation_en-US" xlink:label="lab_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Denials, Percentage Collected After Appeal, Including Administrative Law Judge Hearings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings" xlink:href="ehc-20200930.xsd#ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings" xlink:to="lab_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_InpatientMember_b6eedc62-acad-4579-8997-3d3b6a914cb1_terseLabel_en-US" xlink:label="lab_ehc_InpatientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient</link:label>
    <link:label id="lab_ehc_InpatientMember_label_en-US" xlink:label="lab_ehc_InpatientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient [Member]</link:label>
    <link:label id="lab_ehc_InpatientMember_documentation_en-US" xlink:label="lab_ehc_InpatientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientMember" xlink:href="ehc-20200930.xsd#ehc_InpatientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_InpatientMember" xlink:to="lab_ehc_InpatientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_89a39662-88b1-43c4-8449-0ccb61b9a88d_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a70284b4-f9de-4c54-abd8-0545226b8daf_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_3e8eea09-56f0-46aa-9494-3ec4ca6e4fbd_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e0fdee68-2e73-43e1-87b0-52dc69d9c9f9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_1c4191cd-988b-42cd-b73d-388a7aae0448_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_c166f22c-8aa4-426b-a09f-c54410c704c6_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio" xlink:href="ehc-20200930.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantLeverageRatio" xlink:to="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_d11a9175-92d5-4e4f-9aaa-db310d9aaff6_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests Activity</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b70f90ce-2e6b-4b04-9a84-1dcfeeadbbb5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_74f53d6e-0396-4071-b119-d8110d322ed2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23069531-b7bd-4573-9b0d-c15388231406_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_bb959291-74f0-4e29-856d-6df824c0e205_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_cc86dd5b-dc24-468c-9e36-755214a3d7f6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ae2514d4-4000-4ffa-813e-7563ab08c66f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cdb587a2-d304-4146-958b-74c2757e5f82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4a222a8c-e768-4636-a2dc-990ad9c66dc3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_92a07039-064c-4b0d-80aa-6109f71b4ae6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_56dded3b-48ca-4026-9a94-447eacf5889c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_508d6311-37e2-4094-84ab-35f33ce126ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock in open market</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5cc0fc82-cf92-4504-a4ed-e271e0cbcc5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_b0ac3e79-4be9-4843-9f3b-78ddb4794148_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_9b728537-c83e-4b8b-9c7c-f60fe4a6d142_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_61b89b6e-7f9d-4614-8895-a23554d7ec2d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_20f65f84-dbe0-4f60-8de9-e874edeafcc9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8ef5845f-185d-42a0-a152-65a9b608445d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HomehealthMember_c6b72117-66a7-4658-889a-21517a9bb4a1_terseLabel_en-US" xlink:label="lab_ehc_HomehealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health</link:label>
    <link:label id="lab_ehc_HomehealthMember_label_en-US" xlink:label="lab_ehc_HomehealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health [Member]</link:label>
    <link:label id="lab_ehc_HomehealthMember_documentation_en-US" xlink:label="lab_ehc_HomehealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember" xlink:href="ehc-20200930.xsd#ehc_HomehealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HomehealthMember" xlink:to="lab_ehc_HomehealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketApproachValuationTechniqueMember_3985a7a2-a2c6-413f-8601-824e74e02695_terseLabel_en-US" xlink:label="lab_us-gaap_MarketApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Approach</link:label>
    <link:label id="lab_us-gaap_MarketApproachValuationTechniqueMember_label_en-US" xlink:label="lab_us-gaap_MarketApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Market Approach [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketApproachValuationTechniqueMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketApproachValuationTechniqueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketApproachValuationTechniqueMember" xlink:to="lab_us-gaap_MarketApproachValuationTechniqueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_1a23b700-9003-4a4a-8e1a-6af47ee63158_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_79e2cab4-7566-45af-bb8d-d205ab9135d5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_95a2613c-98ca-448e-9107-b63be0a0b945_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f3b5332e-545d-4e12-8884-559180b62ca8_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities&#8212;</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d4474b32-3b6a-4af9-a0cf-303f78183245_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_aa90f9c9-ef44-4682-b4c3-48a71e0efecd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ebbdb301-69ff-458c-bf17-4045915f38a2_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_13cfa3aa-afff-400c-9d6c-ab6b9e1f6b74_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90082a9c-5c75-49b4-836d-05a475f41e05_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, dilutive stock options, and restricted stock units (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_60c72023-bf02-474e-b21b-6ae26870ef82_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_26df29d8-9a44-49dd-a814-313dc0538913_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1457b00c-ffb7-4d4c-b0c7-cf2db45362c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Reclassificationtononcontrollinginterests_39c5412f-a304-4d41-a351-e2aeb62d3076_negatedTerseLabel_en-US" xlink:label="lab_ehc_Reclassificationtononcontrollinginterests" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to noncontrolling interests</link:label>
    <link:label id="lab_ehc_Reclassificationtononcontrollinginterests_label_en-US" xlink:label="lab_ehc_Reclassificationtononcontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to noncontrolling interests</link:label>
    <link:label id="lab_ehc_Reclassificationtononcontrollinginterests_documentation_en-US" xlink:label="lab_ehc_Reclassificationtononcontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of redeemable noncontrolling interests reclassified to noncontrolling interests during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Reclassificationtononcontrollinginterests" xlink:href="ehc-20200930.xsd#ehc_Reclassificationtononcontrollinginterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Reclassificationtononcontrollinginterests" xlink:to="lab_ehc_Reclassificationtononcontrollinginterests" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_75559f6d-3cc7-4feb-9b6b-07c90c0290f5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2eec8684-8d1c-4409-8da9-fc81270b62aa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3c79f5af-c5e5-4f38-91ac-69465c2cd2a8_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_0ef62571-1145-4b1e-9770-6aa60cccc260_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on debt, including pre-payments</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_132917bd-3b22-47de-9669-017d56d4b722_terseLabel_en-US" xlink:label="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary's common stock held by subsidiary 's management, percent</link:label>
    <link:label id="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_label_en-US" xlink:label="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary's common stock held by subsidiary 's management, Percent</link:label>
    <link:label id="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_documentation_en-US" xlink:label="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of subsidiary's common stock held by subsidiary 's management, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:href="ehc-20200930.xsd#ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:to="lab_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_078ddde8-e137-425e-bbc2-7d890b64c03f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_72d38c66-47b3-443d-8aab-6c0e2dc79797_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_405b8c1d-d0d4-4d13-8c94-806ba88b6b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_2546bbb1-ca2e-4d60-8703-3f18459b2d19_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Approach</link:label>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_label_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Income Approach [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:to="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_07a8fb8b-b0b5-460c-974b-b988b4101e29_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_43636c45-d907-4e13-824e-d025acec19fe_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIE</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OtherIncomeSourceMember_2ed0a419-aa6d-408b-b392-2c3a29e8b602_terseLabel_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_ehc_OtherIncomeSourceMember_label_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Source [Member]</link:label>
    <link:label id="lab_ehc_OtherIncomeSourceMember_documentation_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Source [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember" xlink:href="ehc-20200930.xsd#ehc_OtherIncomeSourceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OtherIncomeSourceMember" xlink:to="lab_ehc_OtherIncomeSourceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d92bf864-0c68-472f-9b30-9c4d0f9bc5e7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_efae81dc-f52d-46d6-a7c3-52e4dc7c9d17_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_f02378f9-02f4-4644-bdde-62e5e8e58f7a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill expected to be tax-deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_7240f7d9-0117-4d79-b4a7-b37d2013da70_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_a0effea6-2f73-4479-b6d5-c67b5d87026b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c195c967-1bec-468c-8e65-d4ecd7f7d753_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Encompass Health</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_bc3549f6-0de8-46d4-b9f9-bbab4c485879_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_cbed4a5c-e9ab-46b9-a533-465e089714ac_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_8c19a246-00cd-4e56-9f4a-03d10d18a6db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Noncash or Part Noncash Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Noncash or Part Noncash Acquisitions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:to="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_CostofServicesExcludingDepreciationandAmortization_7439136a-d8df-4f10-9c09-6cc282ce36f1_terseLabel_en-US" xlink:label="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services sold (excluding depreciation and amortization)</link:label>
    <link:label id="lab_ehc_CostofServicesExcludingDepreciationandAmortization_label_en-US" xlink:label="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Services, Excluding Depreciation and Amortization</link:label>
    <link:label id="lab_ehc_CostofServicesExcludingDepreciationandAmortization_documentation_en-US" xlink:label="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate cost of services rendered during the reporting period, excluding depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:href="ehc-20200930.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:to="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_bca52a15-263d-4f23-8269-f2bd62c0a17d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to capitalized software costs</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6eac2f99-f1ec-41b0-9277-cecb5c3da92a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_fcd9519b-e4bc-4489-a475-8aee95c9b74b_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_095b8fb7-ce18-40af-a468-50912731b281_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestLineItems_ac6e2d0f-73a0-4a0c-8ffe-39ddfeb3bc0a_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestLineItems_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8ea70224-9743-4960-a1c2-6559d974145c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net income of nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_32a79900-454b-448c-8441-293ef1243d10_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember" xlink:href="ehc-20200930.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestMember" xlink:to="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_158a59f1-1eb3-48d8-a811-bfcc2e6e18f6_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_a790fa27-1c6c-4a70-bf0a-a7571670db74_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_7d54e498-b73b-419e-994e-00dbaf606035_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Net Operating Revenues by Payor</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8a35111e-178b-47bd-8ba2-7b31d3b422c3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_90dc3e5f-82c0-4023-b8b4-2fc92e849ef6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_6254efc6-08b1-44dc-8806-3400477febcf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from bond issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Senior Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_6097df88-ae08-4a1e-9c7e-10dc506f8b6e_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e7432d4d-0825-4fbe-913c-a708b2586efd_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e05bbcd7-8b87-4a04-8926-6a97a17fe14a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_64b67297-a554-4328-938e-556d1007a321_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_7f5a937b-f5c0-4ded-aa4c-5a8ac82b5b31_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_09520924-f441-4bf8-a8d2-fdb53d00c60c_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock_209dc223-b018-4d9d-b736-19b62a294ab6_terseLabel_en-US" xlink:label="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Noncontrolling Interests</link:label>
    <link:label id="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock_label_en-US" xlink:label="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Income Attributable to Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Income Attributable to Noncontrolling Interests [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:href="ehc-20200930.xsd#ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:to="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_36c1e798-107c-4131-ad35-5cdc2ffc5433_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_06c81f50-a4d5-4b51-b704-64f5dd05fe30_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ead1a70d-d9e1-4a5b-bb21-dfc962cf2c6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid on behalf of employees for shares withheld</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_c5a2cb6f-95c1-4184-a8f4-808e4583eda4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_7756967c-5ded-4ac6-ab5a-5fda6110a6f2_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_14ef714c-1e87-4f48-9e41-ed86b6945bf2_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Contributiontojointventure_7b891dd5-3018-44ff-9be3-04cc020ab351_terseLabel_en-US" xlink:label="lab_ehc_Contributiontojointventure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to joint venture</link:label>
    <link:label id="lab_ehc_Contributiontojointventure_label_en-US" xlink:label="lab_ehc_Contributiontojointventure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to joint venture</link:label>
    <link:label id="lab_ehc_Contributiontojointventure_documentation_en-US" xlink:label="lab_ehc_Contributiontojointventure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of primarily intangible assets relating to a joint venture agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Contributiontojointventure" xlink:href="ehc-20200930.xsd#ehc_Contributiontojointventure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Contributiontojointventure" xlink:to="lab_ehc_Contributiontojointventure" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EHHIMember_8ce362fe-115e-4d8f-b3f9-6346010ebebe_terseLabel_en-US" xlink:label="lab_ehc_EHHIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EHHI</link:label>
    <link:label id="lab_ehc_EHHIMember_label_en-US" xlink:label="lab_ehc_EHHIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EHHI [Member]</link:label>
    <link:label id="lab_ehc_EHHIMember_documentation_en-US" xlink:label="lab_ehc_EHHIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EHHI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EHHIMember" xlink:href="ehc-20200930.xsd#ehc_EHHIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EHHIMember" xlink:to="lab_ehc_EHHIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_eeaa2c0c-fafd-4527-bb8c-27aee729ff7c_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d1ffea00-2a1b-4e7b-8ffa-c185140bd687_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_3df2ccee-b3ec-4a5b-85ac-343563ed67e5_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7692b2a3-430f-43b6-a253-82b1bd7cf89a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes04625Due2031Member_152249d6-70a2-4149-bae0-d1af622883dc_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes04625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.625% Senior Notes due 2031</link:label>
    <link:label id="lab_ehc_SeniorNotes04625Due2031Member_label_en-US" xlink:label="lab_ehc_SeniorNotes04625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.625%, Due 2031 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes04625Due2031Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes04625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.625%, Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes04625Due2031Member" xlink:to="lab_ehc_SeniorNotes04625Due2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_09d4f0ba-7a77-4d2e-b713-8aeaff9df6bb_totalLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and finance lease obligations</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e613f66a-32c3-49e0-8338-bd922c333b77_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_abfd7c65-b954-463f-9233-09c9f6e2b99f_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_359b7a9b-1248-4d0c-bc84-45b6319d4118_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c5d4c198-b746-48fa-bde9-40fa56a0a32b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9671346f-6c65-4d29-9817-838153ab4311_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_0f353e15-5ed5-4155-bbc0-773fbf315531_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bdfbf7eb-0cef-477c-b9b0-7e6e99a23bc7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_477bc6cc-5799-411b-a404-659e08a0d232_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_71d29e6c-c9db-4978-bb97-7d61053e4056_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_72938c51-bb42-4862-8155-2dee2bde0fa2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_8ab4748c-4552-4acc-a7fa-8066b4168cdd_terseLabel_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third-party payors</link:label>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_label_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third-party Payors [Member]</link:label>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_documentation_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third-party Payors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember" xlink:href="ehc-20200930.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OtherThirdpartyPayorsMember" xlink:to="lab_ehc_OtherThirdpartyPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_23f6995a-59e3-42f5-a7f6-fce943413f62_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_411a18cb-2dc6-4a2f-90b2-8efffead9a8e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_fb3ab5ec-cdf8-4e1a-ada4-0962500a93e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_bd199311-87b8-4ca1-878f-d6bdf4e19e4a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7d10654a-50eb-44d5-9ac4-a5df801096be_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_afa9c28c-b135-4c10-9e7f-b657adb84b94_terseLabel_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice</link:label>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_label_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice Segment [Member]</link:label>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_documentation_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HomeHealthandHospiceSegmentMember" xlink:to="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_e46b7f4e-c3e1-42c9-98bd-20005130e20b_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_bbb94a95-f16e-4a6c-9bd5-9ce87f36e330_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_89f9f84f-9f38-4987-b4f5-07478abcafbe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARs outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d197d527-d01a-4fe5-b29d-fcb23e58ff98_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_dc9b2ac8-25e6-4ad0-b507-bd8eebc6839b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e8e05170-5ffb-473d-b202-c4a8fb43765a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_172e9139-762d-4265-ac80-67856e957d7c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_05d29c35-929d-486e-bf13-12a0168a7588_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c9e7058-6549-4d69-a8be-82f7cb71b5ee_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_66c85865-7654-424b-9ab0-ddb076794275_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_0e6a7f38-74b3-45ef-b1fa-60de5c09d388_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (shares)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OutpatientandotherMember_dcb3045c-15b2-4a63-b670-388eaa074a06_terseLabel_en-US" xlink:label="lab_ehc_OutpatientandotherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outpatient and other</link:label>
    <link:label id="lab_ehc_OutpatientandotherMember_label_en-US" xlink:label="lab_ehc_OutpatientandotherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outpatient and other [Member]</link:label>
    <link:label id="lab_ehc_OutpatientandotherMember_documentation_en-US" xlink:label="lab_ehc_OutpatientandotherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outpatient and other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OutpatientandotherMember" xlink:href="ehc-20200930.xsd#ehc_OutpatientandotherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OutpatientandotherMember" xlink:to="lab_ehc_OutpatientandotherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_cb7882e4-517e-43d6-a854-4f741215cc2d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in consolidated entities (percent)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_42e9c481-0adc-495c-95b1-7d1b83ee7e8f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7abb0d6b-cbbb-4327-8598-d543e9703859_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_440745a0-6a8e-4268-bb14-c226d9fd5f54_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fff800c7-62be-4d3b-8755-dd43257345a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_4a262682-876e-4ec0-b184-b52dd61d05e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_a64637cd-2487-4d82-88c1-c20e71d1092f_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, by Legal Entity [Table]</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, by Legal Entity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_f697a01d-cfd2-4985-aa17-662716190ef2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_b71d9cd9-7991-4515-a332-24e80c96870e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid on common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_6fc8149b-696b-46b4-a561-4137d9ced28a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_cc60cacf-0da9-4718-b504-31f2777526e8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of Holdings shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_58ae5d52-8701-412b-a359-4b42f5cd21b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_49cbab4c-e0b7-4c98-8674-27a69266fcd3_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_9effac2e-a956-474f-9b0b-397c7e743860_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_074acaee-d8a3-410d-a470-c88396b4db1a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_8f6cfe12-2515-4478-960f-7360f2eb66e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other long-term assets at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_0b12ef50-a0d0-447e-a420-70aff8e5da56_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other long-term assets at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PayrolltaxesonSARsexercise_f18eda7d-877e-4dc8-87cf-5a8dd32bb81d_negatedLabel_en-US" xlink:label="lab_ehc_PayrolltaxesonSARsexercise" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll taxes on SARs exercise</link:label>
    <link:label id="lab_ehc_PayrolltaxesonSARsexercise_label_en-US" xlink:label="lab_ehc_PayrolltaxesonSARsexercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll taxes on SARs exercise</link:label>
    <link:label id="lab_ehc_PayrolltaxesonSARsexercise_documentation_en-US" xlink:label="lab_ehc_PayrolltaxesonSARsexercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll taxes on SARs exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayrolltaxesonSARsexercise" xlink:href="ehc-20200930.xsd#ehc_PayrolltaxesonSARsexercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PayrolltaxesonSARsexercise" xlink:to="lab_ehc_PayrolltaxesonSARsexercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_a0c3d218-4769-4abd-8c80-283effcfea95_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofBedsExpanded_ce365176-577d-406f-b850-141b7961ecc9_terseLabel_en-US" xlink:label="lab_ehc_NumberofBedsExpanded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beds expanded</link:label>
    <link:label id="lab_ehc_NumberofBedsExpanded_label_en-US" xlink:label="lab_ehc_NumberofBedsExpanded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Expanded</link:label>
    <link:label id="lab_ehc_NumberofBedsExpanded_documentation_en-US" xlink:label="lab_ehc_NumberofBedsExpanded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Expanded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsExpanded" xlink:href="ehc-20200930.xsd#ehc_NumberofBedsExpanded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofBedsExpanded" xlink:to="lab_ehc_NumberofBedsExpanded" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes0575Due2024Member_ed634f36-5491-4687-8108-8e77771aadb2_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes0575Due2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes due 2024</link:label>
    <link:label id="lab_ehc_SeniorNotes0575Due2024Member_label_en-US" xlink:label="lab_ehc_SeniorNotes0575Due2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2024 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes0575Due2024Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes0575Due2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes0575Due2024Member" xlink:to="lab_ehc_SeniorNotes0575Due2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_fc50c662-e0cf-434c-a2a6-9707d9087aa0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_1f954d7e-a2b0-4fc1-8ed1-ab9aa81fcb01_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_255b93d1-f4a4-4db9-8fd6-2866b2a105c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared on common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_956a852c-90b7-4999-96d4-c5b8c0c7df88_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1f1b781c-cd7c-4035-91cd-1a11e544cb55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_0959c21e-485d-4b44-9422-0d9a82c8d7bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_4fd38935-feb8-44de-9d2b-a0852f5805bc_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_3f11afb2-ba5e-41d5-bb57-b8b9e3974bcf_terseLabel_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation units under management contracts</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_label_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inpatient Rehabilitation Units Under Management Contracts</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_documentation_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation units under management contracts with the Company as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:href="ehc-20200930.xsd#ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:to="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_67cf2f46-0b9f-45f0-a4d4-04f7610bd4e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_46f4f03a-aeef-4fb3-ada3-a8b9a5c75fa8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_28a13eb4-4d1f-4d0b-bc0f-d5aa67ed1202_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead_7af5227a-8859-4d72-8ef0-ef07c8ecd920_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Support and overhead costs</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Overhead</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_22b48935-f03e-488d-89b1-eb749728888b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d342886c-8dc6-4328-a490-9ac5bfadd344_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6d67690a-3c03-4f82-9983-40eaddbdf665_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c37c7a61-3fdc-4219-a1c7-31ca1ca26ba8_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_a596289c-47ac-4b50-b8ff-66545aee225f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_fc9e4411-074f-43de-867c-3ccee0b3ce76_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d85ca566-ce65-429c-956a-1f721ff4a1a6_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_9b552416-f369-4fda-8247-8dd97ea83c9e_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Other Commitments</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f4d8e092-a36b-4839-b28c-d4889830a128_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_77393f3c-2190-4f19-9bdd-71f74f079be9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NetIncomeLossAvailabletoCommonStockholders_68ad7ad7-cd7b-420f-b4ce-605deb093c2f_totalLabel_en-US" xlink:label="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_ehc_NetIncomeLossAvailabletoCommonStockholders_label_en-US" xlink:label="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders</link:label>
    <link:label id="lab_ehc_NetIncomeLossAvailabletoCommonStockholders_documentation_en-US" xlink:label="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income after adjustments for dividends on preferred stock (declared in the period), cumulative preferred stock (accumulated for the period), and/or income allocated to participating securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:href="ehc-20200930.xsd#ehc_NetIncomeLossAvailabletoCommonStockholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:to="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofBedsContributed_3dd8fcf6-be8c-462a-ad21-3acf9073ccf9_terseLabel_en-US" xlink:label="lab_ehc_NumberofBedsContributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beds contributed</link:label>
    <link:label id="lab_ehc_NumberofBedsContributed_label_en-US" xlink:label="lab_ehc_NumberofBedsContributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Contributed</link:label>
    <link:label id="lab_ehc_NumberofBedsContributed_documentation_en-US" xlink:label="lab_ehc_NumberofBedsContributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Contributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsContributed" xlink:href="ehc-20200930.xsd#ehc_NumberofBedsContributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofBedsContributed" xlink:to="lab_ehc_NumberofBedsContributed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f36aef5b-dab8-4aa5-b1be-c6a47526f570_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ac1af454-4406-4831-9614-d1683da3bef9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio_6f016076-9693-48e5-a69f-197a0c423fc7_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Coverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:href="ehc-20200930.xsd#ehc_DebtInstrumentCovenantInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:to="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_249afabc-0b23-4427-a9c6-acd9fe1ee9d2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_9962919d-03bc-411e-b59f-4b79ae85c345_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding common stock of Holdings, fair value</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Other, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_5270c3a8-52e7-40ae-bcf4-c910e3639a10_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests included in continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_c0a3f9b8-d6be-4382-95b6-661bccb1bf41_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to nonredeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_97338e87-7f41-4dd8-9017-786e5b238f61_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_bbcf8965-7859-4254-adf5-3fdb810e46d2_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_ab0ec9d1-efce-42dc-9cd4-164339af140d_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_5e9bce7f-28b5-4e00-8cb2-909b4bd62e4b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c37375ed-2e72-462c-917a-102509716856_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_954c0749-237c-4885-ab07-cf5c316f2091_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_85b0a88e-2a4d-4f57-820f-acf0884e206c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AdjustedEBITDA_f772eff9-56d3-464b-bb24-a53e4ba847a8_totalLabel_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Adjusted EBITDA</link:label>
    <link:label id="lab_ehc_AdjustedEBITDA_658b4bc8-27a0-4731-a949-62e7ffc97c36_verboseLabel_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Segment Adjusted EBITDA</link:label>
    <link:label id="lab_ehc_AdjustedEBITDA_label_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_ehc_AdjustedEBITDA_documentation_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA" xlink:href="ehc-20200930.xsd#ehc_AdjustedEBITDA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AdjustedEBITDA" xlink:to="lab_ehc_AdjustedEBITDA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ec0050f3-7df8-4d61-a071-1dd331cfdac3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5006af80-b994-4284-bb1f-6cecf8e1fd97_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_50532f51-b398-419b-b7e9-f24e76d9be6b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3bc4004c-acdf-4d68-b810-60f4756767c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_a09a5bb4-9efe-4b6f-9424-332278986608_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_a882c491-89e3-4ece-bfc2-f98f703e29fc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ed2dff65-63c7-4e18-8ff2-23ee253e18a7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_b2f14868-d1d9-4ca3-83ed-c5e71f6b0307_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_66ba689a-0798-4658-97fc-56aa9bea5396_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_bcc3537d-9062-45c9-acd0-1b3222d0edce_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_88e9cd85-47c4-4c0b-bda5-0bdfafc92a98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains or losses related to non-financial assets and liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_label_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_c6d55714-ee5d-4ed5-89cf-bea608fda219_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5f049479-5502-4ba9-bca1-9899700d77eb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_ea27aaf3-fd4e-44b5-8359-e500f0efa872_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_e1587796-d75f-4e3d-aff0-be2baad9e4ba_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbae8c5d-eebc-458c-a00a-768b8eb85d61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_54473bcc-1776-4f04-9cf4-f9128b5d0757_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9efbbd64-2aca-4142-8a3a-d95538533be0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_00a13ba6-c262-4cc4-a7ea-13708fb8ee9d_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_InpatientRehabilitationSegmentMember_5743aedc-7174-432f-90c1-8034e40ec525_verboseLabel_en-US" xlink:label="lab_ehc_InpatientRehabilitationSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation</link:label>
    <link:label id="lab_ehc_InpatientRehabilitationSegmentMember_label_en-US" xlink:label="lab_ehc_InpatientRehabilitationSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation Segment [Member]</link:label>
    <link:label id="lab_ehc_InpatientRehabilitationSegmentMember_documentation_en-US" xlink:label="lab_ehc_InpatientRehabilitationSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_InpatientRehabilitationSegmentMember" xlink:to="lab_ehc_InpatientRehabilitationSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d5f21bcc-f16e-406c-9d54-ad5e9915ec81_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_9b9c3920-b477-4cc5-bef8-eab0a23989a8_terseLabel_en-US" xlink:label="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_label_en-US" xlink:label="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_documentation_en-US" xlink:label="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:href="ehc-20200930.xsd#ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:to="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_713b8fcb-0ffe-460f-8147-b9eabf3ac9c9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2c0d80ea-15e6-48dd-9d1b-12dc78923b81_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5d265ce1-c61f-464a-9d19-38f6b3481b67_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PortercareAdventistandPremierHealthPartnersMember_848c2959-1066-4ddd-b5a4-9a29ad0c4d32_terseLabel_en-US" xlink:label="lab_ehc_PortercareAdventistandPremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist and Premier Health Partners</link:label>
    <link:label id="lab_ehc_PortercareAdventistandPremierHealthPartnersMember_label_en-US" xlink:label="lab_ehc_PortercareAdventistandPremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist and Premier Health Partners [Member]</link:label>
    <link:label id="lab_ehc_PortercareAdventistandPremierHealthPartnersMember_documentation_en-US" xlink:label="lab_ehc_PortercareAdventistandPremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist and Premier Health Partners [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistandPremierHealthPartnersMember" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistandPremierHealthPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PortercareAdventistandPremierHealthPartnersMember" xlink:to="lab_ehc_PortercareAdventistandPremierHealthPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4c076599-0367-490e-9609-fbd80ebff820_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_898ef028-e88a-439d-b4d6-3841f35ac03d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_83fb84d7-8032-47ad-91ae-10dd13f90e6f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_008f37fa-9137-4721-902b-12a8e7c1e444_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_68821284-4c55-4905-816c-49ac5a612518_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_aa0f5a69-8cf0-4b25-af8e-a8a1e9e09e28_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions paid to noncontrolling interests of consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_4c2fce1c-2388-4615-aa92-d19a46193735_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in assets and liabilities, net of acquisitions&#8212;</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_dd7c4158-43af-4b0f-be3a-b0296b81caf2_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c40ae3ff-04e6-4c97-a62a-ced170326507_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e33cec5d-8848-4537-a2e8-e249f28f2232_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2052ad97-b570-4c1f-a2a8-9e00d64463fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d93bfdca-2521-495d-b4da-be5e657670df_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_5f34cb5a-9b10-49ec-929f-5bf913a4c079_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_c4a49469-7b9f-453f-94a8-456a74ffb8f9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_e9ec3b14-1b9c-4886-b4ea-3072ca34d53e_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of deferred income tax liabilities to net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e1d810a0-8695-4c16-981d-0f9cdcade5c5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3981a090-d49b-459a-95e5-c4c1e0591373_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c2bb2dae-cc66-48d9-898a-b47c01fd880c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_082882f3-ee1f-4401-8bee-c7f5e11ef963_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9732bdea-8437-4b65-896a-e31fea22fe70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_13efc450-ce19-44ae-9dd1-7cea65123577_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:href="ehc-20200930.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:to="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_11b25314-8e27-4125-8559-d9fb754649a6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_855b3bd1-fa6b-4b83-904e-7ff6c0c21521_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_db63ecdb-425b-414e-88c3-02d8da7f5d23_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_af8490f6-42e7-45de-a2cf-3b3ea5fb0725_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_f3779c5f-af06-45de-bf68-c06fc8766fa3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e9ea4a33-5318-4374-bdc1-f302077a6cc0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PatientsMember_d953eed1-a1f7-4f6b-ab4d-139c207c28ce_terseLabel_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients</link:label>
    <link:label id="lab_ehc_PatientsMember_label_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:label id="lab_ehc_PatientsMember_documentation_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember" xlink:href="ehc-20200930.xsd#ehc_PatientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PatientsMember" xlink:to="lab_ehc_PatientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_f3ea820f-f0f4-42a4-96a3-371d08c6d01c_terseLabel_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_label_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities [Member]</link:label>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_documentation_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember" xlink:href="ehc-20200930.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TermLoanFacilitiesMember" xlink:to="lab_ehc_TermLoanFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofBedsAcquired_3db877e9-8548-458f-af6b-834655354213_terseLabel_en-US" xlink:label="lab_ehc_NumberofBedsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beds acquired</link:label>
    <link:label id="lab_ehc_NumberofBedsAcquired_label_en-US" xlink:label="lab_ehc_NumberofBedsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Acquired</link:label>
    <link:label id="lab_ehc_NumberofBedsAcquired_documentation_en-US" xlink:label="lab_ehc_NumberofBedsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsAcquired" xlink:href="ehc-20200930.xsd#ehc_NumberofBedsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofBedsAcquired" xlink:to="lab_ehc_NumberofBedsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5796d04e-40e0-4fdd-88af-7fc059a2f666_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_af98fb4a-38c6-414f-8002-127a00a1fb85_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of Holdings shares (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c057776f-724f-485b-9540-16b194991a45_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of noncash financing activity:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_ecd655e3-eec7-412c-abee-5792279c611b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62c136dd-3e70-4822-94ba-45f1877314aa_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5d99dc0a-062f-4102-9a1c-7d7825c8e671_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_51873733-aee4-49c5-b52c-3d6036982d8f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_26a0752a-3139-4b1a-b4ec-35425165a8da_terseLabel_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation hospitals operated</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_label_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inpatient Rehabilitation Hospitals</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_documentation_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals" xlink:href="ehc-20200930.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfInpatientRehabilitationHospitals" xlink:to="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_87f166cd-2ad5-4313-b3e3-cc49f92a8684_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_59dbd0ec-b438-4d74-a03d-a45f9327288b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_174e2deb-1223-464c-852f-144aa33b07fb_totalLabel_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_label_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss from Continuing Operations Attributable to Common Shareholders Diluted</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_documentation_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income loss from continuing operations attributable to common shareholders diluted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:href="ehc-20200930.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:to="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2c051422-d59b-4f64-ad89-a4721a746048_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_84e94d3d-6e13-4f17-a9d1-639a8468c304_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7eeeb6f6-db90-4378-b83b-ca915d39b186_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and advances to nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1c6f2508-4bfc-434e-bb47-34201a69de67_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used to settle award</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cash Used to Settle Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_55506f53-8af6-4180-95ff-a6becb99fabd_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6e008c37-2c48-4a6e-8cb8-411e1d6f1121_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_4fe57560-4a5f-4eba-bf17-64e4d2e7aff8_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_cbef27b8-3bd7-4a53-8356-38bb22581e64_verboseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_WorkersCompensationMember_649bac6b-2985-4899-bce4-3e9d7b38ad8e_terseLabel_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation</link:label>
    <link:label id="lab_ehc_WorkersCompensationMember_label_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation [Member]</link:label>
    <link:label id="lab_ehc_WorkersCompensationMember_documentation_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember" xlink:href="ehc-20200930.xsd#ehc_WorkersCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_WorkersCompensationMember" xlink:to="lab_ehc_WorkersCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f36ade6-c2f5-487a-a58e-eccd2c948be8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53319786-8d5a-4d1e-9e6e-d6b30f8f9dd8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1d25f32-8f5a-43af-8914-e2f2bf4083e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_32c11a81-200b-46db-ba40-b3ab5c309ea1_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_3b11d441-bf83-438e-8511-c3f1657037bc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amounts and estimated fair values of financial instruments</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_67bba741-0818-4c51-a4fd-dfdbd03a8cdb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a308950-eefa-47c7-a9b0-00c01840af49_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_70d3ab2b-9d73-4847-9868-988c37a3c83d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_cba9f08d-010f-4ebb-b732-2eb5bd8fa7e4_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal or impairment of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncontrollingInterestExchangeTransaction_03316d46-de4f-48bd-9369-943d31aa3852_negatedTerseLabel_en-US" xlink:label="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange transaction</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestExchangeTransaction_label_en-US" xlink:label="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Exchange Transaction</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestExchangeTransaction_documentation_en-US" xlink:label="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Exchange Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExchangeTransaction" xlink:href="ehc-20200930.xsd#ehc_NoncontrollingInterestExchangeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncontrollingInterestExchangeTransaction" xlink:to="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_3a6999e5-28ab-4a9f-9293-b40f7b6131b8_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments to redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_2abfbd23-df6a-4ecf-9a31-b82a76177d0a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_label_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Change in Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:to="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_289642bb-4387-44a5-a06d-d55d6cb97811_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_fcfe4372-ca47-4c78-92c1-73251bcdf802_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_af26583e-b22a-4218-9685-fccb05e6a877_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Actual and Pro Forma Results of Operations for Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_92ab16c8-817d-43c1-b4ec-bbf64d04e8ff_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bf1d6f23-4670-4078-9595-e9b4f8fa5010_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Condition</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_e96ead8c-7c2e-443a-858c-0144b22514d9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ddc21ed6-e964-44ca-b0d7-35908252e038_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2a8efe5c-38f2-4ef3-bc41-4969d32223b9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesGainLoss_9ed012ae-aa9f-4795-9a20-ebf38f0db61d_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair market value of equity securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_a92ccea6-8de1-41c2-8e8f-6812a753b7c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_e51ae432-12b9-456a-a1ed-1583b63a47a5_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d193c7b5-35b0-4f66-9224-e34bfc08c2a7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_748af38c-4757-492f-8cba-3e32d2231643_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, pro forma revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_58f59643-3d00-4087-8995-5db3ea7e4a04_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_fc3279f0-6f1b-4c85-843c-76e63c3d5301_totalLabel_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_label_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss from Continuing Operations Attributable to Common Shareholders Basic</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_documentation_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations attributable to HealthSouth common shareholders basic.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:href="ehc-20200930.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:to="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_60fd97ed-bb93-4668-9b89-04ee5f4082e2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PortercareAdventistMember_7d8e0da4-7599-42dc-ad3c-d2cfce9591ce_terseLabel_en-US" xlink:label="lab_ehc_PortercareAdventistMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist</link:label>
    <link:label id="lab_ehc_PortercareAdventistMember_label_en-US" xlink:label="lab_ehc_PortercareAdventistMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist [Member]</link:label>
    <link:label id="lab_ehc_PortercareAdventistMember_documentation_en-US" xlink:label="lab_ehc_PortercareAdventistMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistMember" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PortercareAdventistMember" xlink:to="lab_ehc_PortercareAdventistMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_4e737ac7-5b5e-4229-900e-e10c348c05c2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0b6d7093-b980-4d1d-9c2b-002f7483ca15_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7a8e1d9d-b5fb-4a57-a052-d3c3aa2bb933_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_ebfa3758-adc4-43e8-941d-c19ca72a219f_terseLabel_en-US" xlink:label="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares to management investors exchange agreements percentages</link:label>
    <link:label id="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_label_en-US" xlink:label="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares to Management Investors Exchange Agreements Percentages</link:label>
    <link:label id="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_documentation_en-US" xlink:label="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares to Management Investors Exchange Agreements Percentages</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:href="ehc-20200930.xsd#ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:to="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_4c71a076-f28e-4391-bcab-64c12fa706cf_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_922fa07b-16cf-423a-b17b-1c31acec1892_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3270cfdf-f40c-4566-8be3-9c1842950abe_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_dfc24bcf-9088-4c32-815f-fe2df809ee04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_c2b9c620-6620-42e6-bbb4-76ebc3328b5a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equity interests in consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Distributions to Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:to="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92e1ad8d-4929-46a9-a0f7-43c2bdd36103_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8c0e8c03-1a07-4cd5-9826-03327d2f99c9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8715e12e-8eec-4236-9d48-ef7839c014c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicareMember_dee4e2a6-55b5-4560-8cb4-c9ab18a029ad_terseLabel_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ehc_MedicareMember_label_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ehc_MedicareMember_documentation_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember" xlink:href="ehc-20200930.xsd#ehc_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicareMember" xlink:to="lab_ehc_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_093fdefe-72cc-4b05-ad5f-cc22ac013248_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6dd4cf75-fc23-4976-9ce3-01e1a891ad14_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d6fd22cc-300a-4546-bfa5-2438ae3463ee_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_74a11846-070d-41ec-821b-93ff737bcef3_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_6938c75e-4f2e-4315-b12d-83b214f98710_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod_87201ccc-880e-437f-b169-56472394758b_terseLabel_en-US" xlink:label="lab_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospitals or agencies operated as a joint venture</link:label>
    <link:label id="lab_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod_label_en-US" xlink:label="lab_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Joint Ventures Accounted for Using the Equity Method</link:label>
    <link:label id="lab_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod_documentation_en-US" xlink:label="lab_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Joint Ventures Accounted for Using the Equity Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod" xlink:href="ehc-20200930.xsd#ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod" xlink:to="lab_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ecbd5586-9ac6-409d-a664-27a3403fbd7d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_ab60446d-e071-4a94-a2c1-44ae2685cd31_negatedTerseLabel_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of noncontrolling interest owned by joint venture partner</link:label>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Noncontrolling Interest, Fair Value</link:label>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:href="ehc-20200930.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:to="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d282f8b-7650-4b81-9669-ec94f8e3d4da_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_f9993491-f90d-4b73-b723-564e97af51c3_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_0bfa69d9-d1d9-4cd5-a407-2f873f157d33_periodStartLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_83cce79b-c449-4298-bdb0-036d9d420798_periodEndLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_fd3a38ca-d47e-4671-bcfa-8026b1bc7d84_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8c82337e-ed13-4eab-81d8-a830920dafeb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Jointventureownershippercentage_3adf924d-71b9-481e-a6ec-b34b2c9a68d0_terseLabel_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:label id="lab_ehc_Jointventureownershippercentage_label_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:label id="lab_ehc_Jointventureownershippercentage_documentation_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage" xlink:href="ehc-20200930.xsd#ehc_Jointventureownershippercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Jointventureownershippercentage" xlink:to="lab_ehc_Jointventureownershippercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_52879606-c246-4c70-ae33-2d35f5479b3e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d6d0a352-0433-4f65-9c04-dc4702d524c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_56b3f4a1-ac81-4d81-ac36-c4510fb8a18b_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a965d57d-dfdb-4771-9d23-ca8ef65c2a70_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e95c056a-52c4-4150-b9ef-1dc4e56d97c6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_a5983210-f414-4076-be77-0db1f86ad006_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_b326b760-b8af-4658-aabb-4845d6d89dda_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ehc-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e0fc9ecd-686a-431a-a15f-a624ec9cb1a0,g:253d3480-dc2c-4d92-b5eb-51ca56c502e3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CoverPage" xlink:type="simple" xlink:href="ehc-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8f5e98e9-e4a2-4505-8b15-62f021c14dab" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_DocumentType_8f5e98e9-e4a2-4505-8b15-62f021c14dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1d8cdaa4-119a-4359-b428-23c12adb40ee" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_DocumentQuarterlyReport_1d8cdaa4-119a-4359-b428-23c12adb40ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0ffaccb2-d5d2-4fac-9f2b-ca06b6c52e59" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_DocumentPeriodEndDate_0ffaccb2-d5d2-4fac-9f2b-ca06b6c52e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_96d2747f-868f-45a7-b3a9-0dc6fd2566bc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_DocumentTransitionReport_96d2747f-868f-45a7-b3a9-0dc6fd2566bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6fb4b321-2844-40c1-b133-cefc210fcea8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityFileNumber_6fb4b321-2844-40c1-b133-cefc210fcea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4b7a1fe5-4433-4958-9ed0-ed49dbe6dc27" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityRegistrantName_4b7a1fe5-4433-4958-9ed0-ed49dbe6dc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a50f39f2-89a0-4085-b824-5fa2ab45c86b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a50f39f2-89a0-4085-b824-5fa2ab45c86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_147927d7-3045-4b7e-b375-478e942fd1e0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityTaxIdentificationNumber_147927d7-3045-4b7e-b375-478e942fd1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5e377eae-1f25-40f1-8d3e-89a7be53a463" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityAddressAddressLine1_5e377eae-1f25-40f1-8d3e-89a7be53a463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_87b1d1b3-6b77-4899-93a3-250242fa7878" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityAddressCityOrTown_87b1d1b3-6b77-4899-93a3-250242fa7878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b5dd3447-b359-40dc-b382-14d1d2797453" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityAddressStateOrProvince_b5dd3447-b359-40dc-b382-14d1d2797453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5ca35b7c-f062-4d68-986a-388d42e12b76" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityAddressPostalZipCode_5ca35b7c-f062-4d68-986a-388d42e12b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fb42bd7b-7147-46c6-94c2-a7cc6e5b76a3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_CityAreaCode_fb42bd7b-7147-46c6-94c2-a7cc6e5b76a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5fb6c6d1-c79f-4755-9f20-ae8118bde049" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_LocalPhoneNumber_5fb6c6d1-c79f-4755-9f20-ae8118bde049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f6e0c364-adfd-405f-85af-221483d51444" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_Security12bTitle_f6e0c364-adfd-405f-85af-221483d51444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_68887490-afd2-488e-9213-d699d5f74509" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_TradingSymbol_68887490-afd2-488e-9213-d699d5f74509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c0b93817-5f86-4ea2-a40e-f41290fecefe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_SecurityExchangeName_c0b93817-5f86-4ea2-a40e-f41290fecefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b9a66748-223e-4397-b530-3fb121684f3c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityCurrentReportingStatus_b9a66748-223e-4397-b530-3fb121684f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2e195478-ddce-4105-9a26-844343ea8933" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityInteractiveDataCurrent_2e195478-ddce-4105-9a26-844343ea8933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_30e65b56-9ca5-461c-900e-d254c034a86c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityFilerCategory_30e65b56-9ca5-461c-900e-d254c034a86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7b7ac413-f390-4678-b2a3-c20882abbac4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntitySmallBusiness_7b7ac413-f390-4678-b2a3-c20882abbac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b7fbcf03-e295-4c6e-be63-c0d694e8ff30" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityEmergingGrowthCompany_b7fbcf03-e295-4c6e-be63-c0d694e8ff30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ccd26820-49a4-42a9-ac04-64d5c930508a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityShellCompany_ccd26820-49a4-42a9-ac04-64d5c930508a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ca1a434b-787c-4104-a4b4-e8ceba1b349b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ca1a434b-787c-4104-a4b4-e8ceba1b349b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fdb4eea9-810d-40e5-a307-3105e67bc8f2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_EntityCentralIndexKey_fdb4eea9-810d-40e5-a307-3105e67bc8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_06f582df-de60-431c-8217-418177547cbb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_CurrentFiscalYearEndDate_06f582df-de60-431c-8217-418177547cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9615584e-2891-4d1d-a07b-99e073d5b1fc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_DocumentFiscalYearFocus_9615584e-2891-4d1d-a07b-99e073d5b1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_348a3878-f920-4224-89d9-fbf33fd1e951" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_348a3878-f920-4224-89d9-fbf33fd1e951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cd16b952-919f-4493-8c86-6f57c950dc61" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_45b473ae-c321-42b3-afb9-f382b7a196d3" xlink:to="loc_dei_AmendmentFlag_cd16b952-919f-4493-8c86-6f57c950dc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:href="ehc-20200930.xsd#ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06dc70a0-31bd-41c8-83c8-4ca83bfb916a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06dc70a0-31bd-41c8-83c8-4ca83bfb916a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1b44ddc9-83f3-4471-9099-72fc42e5b614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1b44ddc9-83f3-4471-9099-72fc42e5b614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_550211aa-97dc-479e-bc21-bb1887c8b9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b44ddc9-83f3-4471-9099-72fc42e5b614" xlink:to="loc_us-gaap_LaborAndRelatedExpense_550211aa-97dc-479e-bc21-bb1887c8b9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_b482dd7f-fbb4-4de7-9d66-a2aaedad443b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b44ddc9-83f3-4471-9099-72fc42e5b614" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_b482dd7f-fbb4-4de7-9d66-a2aaedad443b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_7f6faa39-a02a-4574-a2ca-6d44f1ef58b9" xlink:href="ehc-20200930.xsd#ehc_OccupancyCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b44ddc9-83f3-4471-9099-72fc42e5b614" xlink:to="loc_ehc_OccupancyCost_7f6faa39-a02a-4574-a2ca-6d44f1ef58b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_3a9449e4-9b0e-4b41-85d1-ad7d47c09a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b44ddc9-83f3-4471-9099-72fc42e5b614" xlink:to="loc_us-gaap_SuppliesExpense_3a9449e4-9b0e-4b41-85d1-ad7d47c09a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_11e55f0f-a461-45fb-ab3e-844baf974ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b44ddc9-83f3-4471-9099-72fc42e5b614" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_11e55f0f-a461-45fb-ab3e-844baf974ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6fb42f05-dfe2-44a2-8f0e-f30d883b5a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b44ddc9-83f3-4471-9099-72fc42e5b614" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6fb42f05-dfe2-44a2-8f0e-f30d883b5a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_12a3ec1b-6cd8-491d-91c7-8972add02243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b44ddc9-83f3-4471-9099-72fc42e5b614" xlink:to="loc_us-gaap_LitigationSettlementExpense_12a3ec1b-6cd8-491d-91c7-8972add02243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e9d124b6-1366-4e86-9405-d92fc2361200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b44ddc9-83f3-4471-9099-72fc42e5b614" xlink:to="loc_us-gaap_CostsAndExpenses_e9d124b6-1366-4e86-9405-d92fc2361200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_86f86856-09e4-49ae-937c-2895383c82e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_86f86856-09e4-49ae-937c-2895383c82e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c263c265-367a-4b7a-adca-08bda010adc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_InterestExpense_c263c265-367a-4b7a-adca-08bda010adc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a22a3da0-69eb-4321-96bf-0d20880d5dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a22a3da0-69eb-4321-96bf-0d20880d5dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_027329cc-8124-462d-9fe3-a82680cef1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_027329cc-8124-462d-9fe3-a82680cef1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_16ba35c7-1f26-4acc-805a-821b486c37c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_16ba35c7-1f26-4acc-805a-821b486c37c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1bb6d6aa-e4ea-4254-87a7-b400d056c52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1bb6d6aa-e4ea-4254-87a7-b400d056c52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_10c92656-aaa8-4038-90e6-b9b197f8a1db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_10c92656-aaa8-4038-90e6-b9b197f8a1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_086bf792-313a-4bb8-ba86-6c0f5a4735a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_086bf792-313a-4bb8-ba86-6c0f5a4735a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a5cbd679-2187-46ba-aa08-4fdc59be8a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_ProfitLoss_a5cbd679-2187-46ba-aa08-4fdc59be8a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_27593be6-fc0e-4f64-97ca-f3535961806b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_27593be6-fc0e-4f64-97ca-f3535961806b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_066d4ac6-41ec-480b-ad13-64d4e5aa8564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_066d4ac6-41ec-480b-ad13-64d4e5aa8564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7909301a-5c35-476b-9429-17562f02590f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7909301a-5c35-476b-9429-17562f02590f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_94e0dadd-efa3-45d1-adae-e34acaa18663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_NetIncomeLoss_94e0dadd-efa3-45d1-adae-e34acaa18663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_81c5cc5f-279f-490f-9e65-d2d41e22dc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_81c5cc5f-279f-490f-9e65-d2d41e22dc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_64431710-2c36-4d50-90ed-c2811a7f7162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_64431710-2c36-4d50-90ed-c2811a7f7162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b40612f0-6155-4ccb-92c4-21f833a5db1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_64431710-2c36-4d50-90ed-c2811a7f7162" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b40612f0-6155-4ccb-92c4-21f833a5db1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0691c60a-b6cd-4c20-a6a7-011007713233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_64431710-2c36-4d50-90ed-c2811a7f7162" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0691c60a-b6cd-4c20-a6a7-011007713233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_973ccbad-76c7-4475-a04b-f37a4cb090e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_973ccbad-76c7-4475-a04b-f37a4cb090e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_efa70f15-ab88-4e30-9513-8f4ec4bb13f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_973ccbad-76c7-4475-a04b-f37a4cb090e6" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_efa70f15-ab88-4e30-9513-8f4ec4bb13f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1502e343-64af-4178-8a2d-84de5b874d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_efa70f15-ab88-4e30-9513-8f4ec4bb13f4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1502e343-64af-4178-8a2d-84de5b874d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_320034c5-cc67-412f-a59c-ecbbf5e51a77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_efa70f15-ab88-4e30-9513-8f4ec4bb13f4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_320034c5-cc67-412f-a59c-ecbbf5e51a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_628ac917-7260-4e2d-a5e6-ff4e42f7af48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_efa70f15-ab88-4e30-9513-8f4ec4bb13f4" xlink:to="loc_us-gaap_EarningsPerShareBasic_628ac917-7260-4e2d-a5e6-ff4e42f7af48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_0a9c48cc-0784-4a51-af31-620d26f07cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_973ccbad-76c7-4475-a04b-f37a4cb090e6" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_0a9c48cc-0784-4a51-af31-620d26f07cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_60d6f273-1ff0-4264-ab83-c55cf698d0fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_0a9c48cc-0784-4a51-af31-620d26f07cb5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_60d6f273-1ff0-4264-ab83-c55cf698d0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_07c75184-126f-449f-bd6b-534052aebf0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_0a9c48cc-0784-4a51-af31-620d26f07cb5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_07c75184-126f-449f-bd6b-534052aebf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ba1f2d8b-be42-47c7-aec9-bd4126cb3c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_0a9c48cc-0784-4a51-af31-620d26f07cb5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ba1f2d8b-be42-47c7-aec9-bd4126cb3c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_b206edac-375c-432a-a36e-103d3274c993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_b5c7d9d0-a646-4863-a010-f56172c8f243" xlink:to="loc_us-gaap_NetIncomeLossAbstract_b206edac-375c-432a-a36e-103d3274c993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_e6d33f55-e760-4b8d-9802-bd22b1396642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b206edac-375c-432a-a36e-103d3274c993" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_e6d33f55-e760-4b8d-9802-bd22b1396642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1b6eaef2-cdca-45b0-b62a-f078c4c5e3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b206edac-375c-432a-a36e-103d3274c993" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1b6eaef2-cdca-45b0-b62a-f078c4c5e3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9717cd1b-31e9-4a7d-b38a-a9b1f4bb6885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b206edac-375c-432a-a36e-103d3274c993" xlink:to="loc_us-gaap_NetIncomeLoss_9717cd1b-31e9-4a7d-b38a-a9b1f4bb6885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5599f55f-57fe-4556-b541-57c4f9a9d895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_184b02c1-62f1-4cb8-b0bd-dce4a02da662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5599f55f-57fe-4556-b541-57c4f9a9d895" xlink:to="loc_us-gaap_AssetsAbstract_184b02c1-62f1-4cb8-b0bd-dce4a02da662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f5d0d36f-a864-412b-af29-ab1a331b4486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_184b02c1-62f1-4cb8-b0bd-dce4a02da662" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f5d0d36f-a864-412b-af29-ab1a331b4486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e434137a-8dcc-47be-913b-5d6b7b853654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5d0d36f-a864-412b-af29-ab1a331b4486" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e434137a-8dcc-47be-913b-5d6b7b853654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_07d01c21-d57b-49fd-9363-1302541e3705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5d0d36f-a864-412b-af29-ab1a331b4486" xlink:to="loc_us-gaap_RestrictedCashCurrent_07d01c21-d57b-49fd-9363-1302541e3705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_58c89ca8-11c9-4ddd-ab84-afd1302d33e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5d0d36f-a864-412b-af29-ab1a331b4486" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_58c89ca8-11c9-4ddd-ab84-afd1302d33e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c7aec147-32af-4663-9391-60f21f1e97f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5d0d36f-a864-412b-af29-ab1a331b4486" xlink:to="loc_us-gaap_OtherAssetsCurrent_c7aec147-32af-4663-9391-60f21f1e97f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_54ca61d3-09df-410c-9925-312ac74cdffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5d0d36f-a864-412b-af29-ab1a331b4486" xlink:to="loc_us-gaap_AssetsCurrent_54ca61d3-09df-410c-9925-312ac74cdffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5315cc33-ad40-48e2-a7c9-f35f1c5ba85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_184b02c1-62f1-4cb8-b0bd-dce4a02da662" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5315cc33-ad40-48e2-a7c9-f35f1c5ba85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f85cef30-4d4b-4fe5-9218-5fdaf11fb45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_184b02c1-62f1-4cb8-b0bd-dce4a02da662" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f85cef30-4d4b-4fe5-9218-5fdaf11fb45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0d3405a3-e820-4238-999a-6c0f00f34ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_184b02c1-62f1-4cb8-b0bd-dce4a02da662" xlink:to="loc_us-gaap_Goodwill_0d3405a3-e820-4238-999a-6c0f00f34ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8a34e12b-ee01-4f1a-aeee-00f09635add9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_184b02c1-62f1-4cb8-b0bd-dce4a02da662" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8a34e12b-ee01-4f1a-aeee-00f09635add9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_15cccdaf-66e3-4cf8-9bc0-d039664250c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_184b02c1-62f1-4cb8-b0bd-dce4a02da662" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_15cccdaf-66e3-4cf8-9bc0-d039664250c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cff4ccd2-9ba9-4bb9-a067-a537921efd52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_184b02c1-62f1-4cb8-b0bd-dce4a02da662" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cff4ccd2-9ba9-4bb9-a067-a537921efd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4f822c82-e4ca-472d-b323-5ee5628a5b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_184b02c1-62f1-4cb8-b0bd-dce4a02da662" xlink:to="loc_us-gaap_Assets_4f822c82-e4ca-472d-b323-5ee5628a5b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5599f55f-57fe-4556-b541-57c4f9a9d895" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_04459b81-bba7-4123-acd3-88a995cc0e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_04459b81-bba7-4123-acd3-88a995cc0e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_544b6049-457f-4cdd-9ae2-f11f87c956ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_04459b81-bba7-4123-acd3-88a995cc0e6d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_544b6049-457f-4cdd-9ae2-f11f87c956ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c2544ceb-1d1d-4bde-9bf7-a861c9a4b850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_04459b81-bba7-4123-acd3-88a995cc0e6d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c2544ceb-1d1d-4bde-9bf7-a861c9a4b850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_de483e07-1fb8-4544-b5cc-5f973b89b7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_04459b81-bba7-4123-acd3-88a995cc0e6d" xlink:to="loc_us-gaap_AccountsPayableCurrent_de483e07-1fb8-4544-b5cc-5f973b89b7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_050be0e8-004f-460d-ad52-a4c43b05e5dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_04459b81-bba7-4123-acd3-88a995cc0e6d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_050be0e8-004f-460d-ad52-a4c43b05e5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_72fd0513-f7c1-4e1e-ab4c-fe5bd7394db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_04459b81-bba7-4123-acd3-88a995cc0e6d" xlink:to="loc_us-gaap_LiabilitiesCurrent_72fd0513-f7c1-4e1e-ab4c-fe5bd7394db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_7226988c-a87b-415b-9736-01850ec7ac40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_7226988c-a87b-415b-9736-01850ec7ac40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d852bc48-1e76-4ee7-869b-a49df8e16ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d852bc48-1e76-4ee7-869b-a49df8e16ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d724490e-b017-4a50-ac76-fbb42f0020ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d724490e-b017-4a50-ac76-fbb42f0020ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_14ae9406-f630-410c-a04c-fb28449b36d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:to="loc_us-gaap_Liabilities_14ae9406-f630-410c-a04c-fb28449b36d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cc4c2ec4-7bd8-4f87-b69d-2f198af74499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cc4c2ec4-7bd8-4f87-b69d-2f198af74499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_07565a83-8520-472e-9e57-24789f97d511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_07565a83-8520-472e-9e57-24789f97d511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_96d38263-77d3-434c-a430-435d1c9fedbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_96d38263-77d3-434c-a430-435d1c9fedbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e81a903c-1f4b-40ca-b2ca-9b34e5a8e4be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_96d38263-77d3-434c-a430-435d1c9fedbc" xlink:to="loc_us-gaap_StockholdersEquity_e81a903c-1f4b-40ca-b2ca-9b34e5a8e4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a8ca7bab-06c2-42c0-a9e4-4b7967ffef28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_96d38263-77d3-434c-a430-435d1c9fedbc" xlink:to="loc_us-gaap_MinorityInterest_a8ca7bab-06c2-42c0-a9e4-4b7967ffef28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7ede462-7495-4271-866b-97b7dab344e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_96d38263-77d3-434c-a430-435d1c9fedbc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7ede462-7495-4271-866b-97b7dab344e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec56f0b2-a1da-4926-8644-8cb8f1717e4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a19c432-1664-456b-9f5c-2211b239d124" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec56f0b2-a1da-4926-8644-8cb8f1717e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_da7bbb17-10c5-47ec-9f5f-2a5df10444d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aa9f5fdf-2945-4516-95fb-e8221369760e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_da7bbb17-10c5-47ec-9f5f-2a5df10444d9" xlink:to="loc_us-gaap_StatementTable_aa9f5fdf-2945-4516-95fb-e8221369760e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_149b6637-c875-4136-92db-5143ded0171b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aa9f5fdf-2945-4516-95fb-e8221369760e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_149b6637-c875-4136-92db-5143ded0171b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3d7bfc08-3721-4be4-964b-51400c1b3eab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_149b6637-c875-4136-92db-5143ded0171b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3d7bfc08-3721-4be4-964b-51400c1b3eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4dcf892e-afda-4335-82a3-b3e17fe7217f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3d7bfc08-3721-4be4-964b-51400c1b3eab" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4dcf892e-afda-4335-82a3-b3e17fe7217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_262299cb-3894-40df-8b7e-f270e11bf7d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aa9f5fdf-2945-4516-95fb-e8221369760e" xlink:to="loc_us-gaap_StatementLineItems_262299cb-3894-40df-8b7e-f270e11bf7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_099c43ac-43fa-4ec1-94c0-5d032568c631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262299cb-3894-40df-8b7e-f270e11bf7d0" xlink:to="loc_us-gaap_Assets_099c43ac-43fa-4ec1-94c0-5d032568c631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d2b0e41b-ed03-4724-88fd-2a80d24235ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_262299cb-3894-40df-8b7e-f270e11bf7d0" xlink:to="loc_us-gaap_Liabilities_d2b0e41b-ed03-4724-88fd-2a80d24235ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4042fa48-6197-4a17-9025-5bf370d5fc2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_04a58509-4a1d-4780-96aa-dfa2fa57d3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4042fa48-6197-4a17-9025-5bf370d5fc2c" xlink:to="loc_us-gaap_StatementTable_04a58509-4a1d-4780-96aa-dfa2fa57d3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b4b62133-9bbb-42b6-b575-d737255749c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_04a58509-4a1d-4780-96aa-dfa2fa57d3a6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b4b62133-9bbb-42b6-b575-d737255749c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b4b62133-9bbb-42b6-b575-d737255749c0" xlink:to="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f375e4fc-ed0a-40e9-b6ee-f0f3b3cd4826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:to="loc_us-gaap_CommonStockMember_f375e4fc-ed0a-40e9-b6ee-f0f3b3cd4826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_49ac9e21-a1eb-4375-b890-4c6220a692eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_49ac9e21-a1eb-4375-b890-4c6220a692eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5ec61244-96eb-4965-85b6-97f1c8b5ffbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:to="loc_us-gaap_RetainedEarningsMember_5ec61244-96eb-4965-85b6-97f1c8b5ffbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_68eb5276-927f-4fab-89fb-a59d40b3c6fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:to="loc_us-gaap_TreasuryStockMember_68eb5276-927f-4fab-89fb-a59d40b3c6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_af522481-b530-4403-b880-b136534d9c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62eeb55d-5286-494a-988d-a28f8e0829b6" xlink:to="loc_us-gaap_NoncontrollingInterestMember_af522481-b530-4403-b880-b136534d9c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_18171275-cf2b-4515-98bc-1ded30e311b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_04a58509-4a1d-4780-96aa-dfa2fa57d3a6" xlink:to="loc_us-gaap_StatementLineItems_18171275-cf2b-4515-98bc-1ded30e311b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18171275-cf2b-4515-98bc-1ded30e311b1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f561b18-faaf-477c-bf0b-45fd34990aff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f561b18-faaf-477c-bf0b-45fd34990aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_43388e37-12b4-4d44-b5bd-2a8fa27c4fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_43388e37-12b4-4d44-b5bd-2a8fa27c4fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_13d7c076-4ea6-432c-9951-c7610eafba22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_13d7c076-4ea6-432c-9951-c7610eafba22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_188bdec7-7eff-49c1-b129-82233575dd9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_188bdec7-7eff-49c1-b129-82233575dd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_50efee61-b5f0-4a46-bec0-54ec786f63fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_50efee61-b5f0-4a46-bec0-54ec786f63fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_a1eb63c7-74bf-4bed-80c0-fd934acd127b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_DividendsCommonStockCash_a1eb63c7-74bf-4bed-80c0-fd934acd127b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_faf4253c-5582-482d-8738-ed30020378a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_faf4253c-5582-482d-8738-ed30020378a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1b3e477d-e09c-4ffe-8c05-edbed682c852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1b3e477d-e09c-4ffe-8c05-edbed682c852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96416370-7885-45f2-9139-a3e09508f7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96416370-7885-45f2-9139-a3e09508f7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_bd6c29fc-5665-49e9-a5d1-7f4684acd335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_bd6c29fc-5665-49e9-a5d1-7f4684acd335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions_f76f9e1e-4f16-444f-8fe1-5bee95c577e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_PartnersCapitalAccountContributions_f76f9e1e-4f16-444f-8fe1-5bee95c577e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_6b058357-1cf2-4167-887b-80862677b4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_6b058357-1cf2-4167-887b-80862677b4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_b37ef4f3-08d4-4176-ac3d-c14bc7dc5fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_b37ef4f3-08d4-4176-ac3d-c14bc7dc5fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_21f926f2-3b72-4d08-9181-7a22447037ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_21f926f2-3b72-4d08-9181-7a22447037ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_c0267848-48eb-4338-86ef-8ab18201c93b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_c0267848-48eb-4338-86ef-8ab18201c93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_9391b389-a4cc-42d8-9e98-d3049c7632ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockholdersEquityOther_9391b389-a4cc-42d8-9e98-d3049c7632ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_2740f5d6-443a-43b5-b7fd-15d6af55cd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_2740f5d6-443a-43b5-b7fd-15d6af55cd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f1d3dd2-710c-4371-a73e-8fdc95ae1c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f1d3dd2-710c-4371-a73e-8fdc95ae1c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7e65c0fd-8264-48c3-bd3f-2568c8d5bb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dfac5b0b-b52b-4b0b-84d9-377dbd8a115b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7e65c0fd-8264-48c3-bd3f-2568c8d5bb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_39aae76c-3678-47fe-a7d6-19e216acaf8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_ddae4b83-8d55-4c5f-9606-7405f412581b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_39aae76c-3678-47fe-a7d6-19e216acaf8a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_ddae4b83-8d55-4c5f-9606-7405f412581b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="ehc-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_812eae78-69b1-4f60-82a6-b73b6a548a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc33753f-a066-4acb-992f-ddd3344b5789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_812eae78-69b1-4f60-82a6-b73b6a548a81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc33753f-a066-4acb-992f-ddd3344b5789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2c1c4aea-c980-417f-90f4-219463d4a564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc33753f-a066-4acb-992f-ddd3344b5789" xlink:to="loc_us-gaap_ProfitLoss_2c1c4aea-c980-417f-90f4-219463d4a564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_11f33a4c-5cfa-4026-ad35-9b20e15109cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc33753f-a066-4acb-992f-ddd3344b5789" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_11f33a4c-5cfa-4026-ad35-9b20e15109cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc33753f-a066-4acb-992f-ddd3344b5789" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_50fe2bed-fc18-428b-ad24-9a1df4d81b35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_50fe2bed-fc18-428b-ad24-9a1df4d81b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0145082a-5654-4d7c-a0d0-d8122fb03b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0145082a-5654-4d7c-a0d0-d8122fb03b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bb7718cb-39cc-4383-93f5-48a5ccd1f121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:to="loc_us-gaap_ShareBasedCompensation_bb7718cb-39cc-4383-93f5-48a5ccd1f121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_898e3dd3-cd50-4fe4-9d5d-8cd625efebef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_898e3dd3-cd50-4fe4-9d5d-8cd625efebef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_26a61929-e253-49f5-b696-ae26f0f7accc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_26a61929-e253-49f5-b696-ae26f0f7accc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_2fb4836e-4bd3-4851-ba72-a9368aeb082d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_2fb4836e-4bd3-4851-ba72-a9368aeb082d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_b809aa14-05b4-4c37-afa3-a76705bde358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_b809aa14-05b4-4c37-afa3-a76705bde358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7a47c476-2ac4-4308-9e6d-923711f4e0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_b809aa14-05b4-4c37-afa3-a76705bde358" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7a47c476-2ac4-4308-9e6d-923711f4e0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_55e9011f-da55-4b82-a802-eb7910389b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_b809aa14-05b4-4c37-afa3-a76705bde358" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_55e9011f-da55-4b82-a802-eb7910389b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0412166a-c5ba-4bd9-852f-570ad499b83b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_b809aa14-05b4-4c37-afa3-a76705bde358" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0412166a-c5ba-4bd9-852f-570ad499b83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_9e7a44da-0fca-4c56-807d-6f4aac3aec89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_b809aa14-05b4-4c37-afa3-a76705bde358" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_9e7a44da-0fca-4c56-807d-6f4aac3aec89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_62839d31-1de9-4d67-aa37-49ae974b7de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_b809aa14-05b4-4c37-afa3-a76705bde358" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_62839d31-1de9-4d67-aa37-49ae974b7de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d3e70a5c-f7b6-49b5-80a7-2d8d0fec829e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_b809aa14-05b4-4c37-afa3-a76705bde358" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d3e70a5c-f7b6-49b5-80a7-2d8d0fec829e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_d80d764f-7218-4f05-96cd-d38328d694e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_d80d764f-7218-4f05-96cd-d38328d694e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fe16f55d-ad9d-4c35-86c2-4c99a4837fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4972594-9c6c-484e-8a0c-e68ac799a7f1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fe16f55d-ad9d-4c35-86c2-4c99a4837fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_082367dc-96f2-4c48-99f7-bf57a57b03be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc33753f-a066-4acb-992f-ddd3344b5789" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_082367dc-96f2-4c48-99f7-bf57a57b03be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e38740d-42e5-4dfb-bdcf-f3888bc6aa21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_812eae78-69b1-4f60-82a6-b73b6a548a81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e38740d-42e5-4dfb-bdcf-f3888bc6aa21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a7c2dd17-00ca-49f1-9b80-022b172bb6a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e38740d-42e5-4dfb-bdcf-f3888bc6aa21" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a7c2dd17-00ca-49f1-9b80-022b172bb6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d42d49a-ab7d-4be9-90aa-83138ec0db4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e38740d-42e5-4dfb-bdcf-f3888bc6aa21" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d42d49a-ab7d-4be9-90aa-83138ec0db4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_80c1321b-b06c-48f4-b74b-c4ab48f12f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e38740d-42e5-4dfb-bdcf-f3888bc6aa21" xlink:to="loc_us-gaap_PaymentsForSoftware_80c1321b-b06c-48f4-b74b-c4ab48f12f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_69bf4e11-cb58-4f69-a598-b15a81ad1846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e38740d-42e5-4dfb-bdcf-f3888bc6aa21" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_69bf4e11-cb58-4f69-a598-b15a81ad1846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b69d0c81-6970-4956-b0a7-c9ee018cd79d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e38740d-42e5-4dfb-bdcf-f3888bc6aa21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b69d0c81-6970-4956-b0a7-c9ee018cd79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_812eae78-69b1-4f60-82a6-b73b6a548a81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_10c324eb-0981-4204-bbdc-9a533931ccd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_10c324eb-0981-4204-bbdc-9a533931ccd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_c82bb9a4-2836-48cc-84f2-dcb2b8ec2c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_c82bb9a4-2836-48cc-84f2-dcb2b8ec2c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_e4570bf0-0881-4f84-9783-231e191fb5ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_e4570bf0-0881-4f84-9783-231e191fb5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_5d293dac-51fd-4c06-81c2-5c578209704b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_5d293dac-51fd-4c06-81c2-5c578209704b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_becc58cc-953d-4237-ba6f-b955d57d1033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_becc58cc-953d-4237-ba6f-b955d57d1033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_77209ce8-9d26-4420-944d-4830de7cf81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_77209ce8-9d26-4420-944d-4830de7cf81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_22f5e482-9bc6-4a8f-861f-0070359ed1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_22f5e482-9bc6-4a8f-861f-0070359ed1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_48f7a2ae-26fd-42ac-9b4f-94d90b6cb22f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_48f7a2ae-26fd-42ac-9b4f-94d90b6cb22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_059c910a-6d12-498f-9863-3efea46f7b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_059c910a-6d12-498f-9863-3efea46f7b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5d8d7bc0-c618-4658-bf59-cac6614e65cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5d8d7bc0-c618-4658-bf59-cac6614e65cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_68b0773b-abc8-4380-8d5c-b543070d6631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_68b0773b-abc8-4380-8d5c-b543070d6631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_98ea437b-33a8-427c-bc9c-8eafcaab41c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_98ea437b-33a8-427c-bc9c-8eafcaab41c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b72e7a91-b9b8-4b97-a9a5-4414d73c8596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a712ece-b477-4300-81c4-ba56f2185ba1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b72e7a91-b9b8-4b97-a9a5-4414d73c8596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12d2fcaf-4605-4a6a-b163-6c78405037b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_812eae78-69b1-4f60-82a6-b73b6a548a81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12d2fcaf-4605-4a6a-b163-6c78405037b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42a779a3-e11d-4d0b-b32a-06a29a7b708a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_812eae78-69b1-4f60-82a6-b73b6a548a81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42a779a3-e11d-4d0b-b32a-06a29a7b708a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f41c7bfd-4853-4fb7-96ed-f88efa1c5ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_812eae78-69b1-4f60-82a6-b73b6a548a81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f41c7bfd-4853-4fb7-96ed-f88efa1c5ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a12ed1ab-7fd3-4950-849e-5ce716dd551b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_812eae78-69b1-4f60-82a6-b73b6a548a81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a12ed1ab-7fd3-4950-849e-5ce716dd551b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b3f95e8-529a-446f-96d1-59c8b27a8228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a12ed1ab-7fd3-4950-849e-5ce716dd551b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b3f95e8-529a-446f-96d1-59c8b27a8228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_394d51b0-8408-4a1f-b97d-6cd1221b6036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a12ed1ab-7fd3-4950-849e-5ce716dd551b" xlink:to="loc_us-gaap_RestrictedCashCurrent_394d51b0-8408-4a1f-b97d-6cd1221b6036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_63fc375c-6182-4e47-90f5-86f9fd112a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a12ed1ab-7fd3-4950-849e-5ce716dd551b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_63fc375c-6182-4e47-90f5-86f9fd112a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3a12a6e2-f826-41b2-ad35-0fcace1b8ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a12ed1ab-7fd3-4950-849e-5ce716dd551b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3a12a6e2-f826-41b2-ad35-0fcace1b8ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fdf180b4-503c-4242-977d-6371cc83c634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a12ed1ab-7fd3-4950-849e-5ce716dd551b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fdf180b4-503c-4242-977d-6371cc83c634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_67378364-69a1-4e40-80cd-e2ccb530959f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a12ed1ab-7fd3-4950-849e-5ce716dd551b" xlink:to="loc_us-gaap_RestrictedCashCurrent_67378364-69a1-4e40-80cd-e2ccb530959f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_eb519dde-4e73-4fbb-b9f5-542268bc9a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a12ed1ab-7fd3-4950-849e-5ce716dd551b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_eb519dde-4e73-4fbb-b9f5-542268bc9a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92e12bee-496b-4201-9035-6b53b1ff3d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a12ed1ab-7fd3-4950-849e-5ce716dd551b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92e12bee-496b-4201-9035-6b53b1ff3d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c0dab61e-ea2b-457f-87f7-a471652442c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_812eae78-69b1-4f60-82a6-b73b6a548a81" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c0dab61e-ea2b-457f-87f7-a471652442c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate_a6bd6948-8a2a-4945-8680-523d9a60ac5c" xlink:href="ehc-20200930.xsd#ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c0dab61e-ea2b-457f-87f7-a471652442c4" xlink:to="loc_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate_a6bd6948-8a2a-4945-8680-523d9a60ac5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentation" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a5a4913-c504-412a-b1b4-f82b0b041724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d76d7abf-f872-4089-893c-0662b2e47715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a5a4913-c504-412a-b1b4-f82b0b041724" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d76d7abf-f872-4089-893c-0662b2e47715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_679bc9c6-adbf-41aa-907e-d1ed6572ac4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_df769e9d-9160-47cc-b0fc-f6cb67252e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_679bc9c6-adbf-41aa-907e-d1ed6572ac4f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_df769e9d-9160-47cc-b0fc-f6cb67252e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1da49e05-e5f1-4843-91de-ae058874ae2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_dae541e2-93f1-46de-b200-9268477a2032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1da49e05-e5f1-4843-91de-ae058874ae2c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_dae541e2-93f1-46de-b200-9268477a2032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d29b023-c67f-4b57-8217-a6a161f288c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_7373c26e-3ad0-44c3-8b7f-81278a370c21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d29b023-c67f-4b57-8217-a6a161f288c2" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_7373c26e-3ad0-44c3-8b7f-81278a370c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_840c7af9-cc9c-462e-9876-c8d9793a16ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d29b023-c67f-4b57-8217-a6a161f288c2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_840c7af9-cc9c-462e-9876-c8d9793a16ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_5ffd45a0-bf14-4759-984a-2cf37c4c0f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d29b023-c67f-4b57-8217-a6a161f288c2" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_5ffd45a0-bf14-4759-984a-2cf37c4c0f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_3728f03b-40bc-4218-b244-f2c6a4eb5e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d29b023-c67f-4b57-8217-a6a161f288c2" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_3728f03b-40bc-4218-b244-f2c6a4eb5e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings_bc911417-3ecb-436a-aea8-275fd30894e0" xlink:href="ehc-20200930.xsd#ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d29b023-c67f-4b57-8217-a6a161f288c2" xlink:to="loc_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings_bc911417-3ecb-436a-aea8-275fd30894e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BasisofPresentationNetOperatingRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6469a6a2-4f0a-4c30-b99a-b7ce139ccddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_be1575bb-d6fc-4bc9-b7e9-4ef02945c710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6469a6a2-4f0a-4c30-b99a-b7ce139ccddc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_be1575bb-d6fc-4bc9-b7e9-4ef02945c710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41c7f8e4-8d66-4c71-ad5f-30aa96ded7cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_be1575bb-d6fc-4bc9-b7e9-4ef02945c710" xlink:to="loc_srt_ProductOrServiceAxis_41c7f8e4-8d66-4c71-ad5f-30aa96ded7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_41c7f8e4-8d66-4c71-ad5f-30aa96ded7cb" xlink:to="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_e0250a88-2b9f-4f91-baba-68695c5f2612" xlink:href="ehc-20200930.xsd#ehc_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_MedicareMember_e0250a88-2b9f-4f91-baba-68695c5f2612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember_b0084a86-5c03-48d8-acca-98399f180f1b" xlink:href="ehc-20200930.xsd#ehc_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_MedicareAdvantageMember_b0084a86-5c03-48d8-acca-98399f180f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember_6e13e6c0-97cb-4c35-9f0d-a13b4cffe3b7" xlink:href="ehc-20200930.xsd#ehc_ManagedCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_ManagedCareMember_6e13e6c0-97cb-4c35-9f0d-a13b4cffe3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember_d9ba4ef6-6d48-4f28-9bd3-039441415e05" xlink:href="ehc-20200930.xsd#ehc_MedicaidMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_MedicaidMember_d9ba4ef6-6d48-4f28-9bd3-039441415e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember_6fa2f6ac-95db-4ca8-b30f-62c7fb266235" xlink:href="ehc-20200930.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_OtherThirdpartyPayorsMember_6fa2f6ac-95db-4ca8-b30f-62c7fb266235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember_2cd71378-d32a-46dc-835f-f0b79693a13c" xlink:href="ehc-20200930.xsd#ehc_WorkersCompensationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_WorkersCompensationMember_2cd71378-d32a-46dc-835f-f0b79693a13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember_f53a0741-55b0-456d-8463-cad633f7e4ca" xlink:href="ehc-20200930.xsd#ehc_PatientsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_PatientsMember_f53a0741-55b0-456d-8463-cad633f7e4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember_ad5b0efb-d3f8-4960-8422-f5156e52c93f" xlink:href="ehc-20200930.xsd#ehc_OtherIncomeSourceMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2b34b63-d895-4ce3-9cb3-2ec4df1454ea" xlink:to="loc_ehc_OtherIncomeSourceMember_ad5b0efb-d3f8-4960-8422-f5156e52c93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_38e5a243-ff73-4d39-92af-4e14c906d32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_be1575bb-d6fc-4bc9-b7e9-4ef02945c710" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_38e5a243-ff73-4d39-92af-4e14c906d32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_75304931-c9ce-49ab-8bec-2d180466abd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_38e5a243-ff73-4d39-92af-4e14c906d32c" xlink:to="loc_us-gaap_SegmentDomain_75304931-c9ce-49ab-8bec-2d180466abd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_9eebb710-f488-4363-af55-02cccf9b70af" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_75304931-c9ce-49ab-8bec-2d180466abd7" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_9eebb710-f488-4363-af55-02cccf9b70af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_b158a808-0dbc-44dd-8bb5-d16b50c1f893" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_75304931-c9ce-49ab-8bec-2d180466abd7" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_b158a808-0dbc-44dd-8bb5-d16b50c1f893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ddd0ffbc-fbed-48b2-869a-6466b371a8fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_be1575bb-d6fc-4bc9-b7e9-4ef02945c710" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ddd0ffbc-fbed-48b2-869a-6466b371a8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07b24ced-9c5b-400a-8210-faffe4acaf46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ddd0ffbc-fbed-48b2-869a-6466b371a8fb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_07b24ced-9c5b-400a-8210-faffe4acaf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6d7efef2-42a3-41ef-8a74-39f44a3ed9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_93760a06-fa90-4919-8487-3514c204503c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6d7efef2-42a3-41ef-8a74-39f44a3ed9d5" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_93760a06-fa90-4919-8487-3514c204503c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_855f9c88-3856-427c-bd6f-520dc59cf441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_f14d6d3e-b26e-4a20-aeb2-675155e44252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_855f9c88-3856-427c-bd6f-520dc59cf441" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_f14d6d3e-b26e-4a20-aeb2-675155e44252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_40291a8d-8055-4b5d-b7e0-14c6fba78e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_855f9c88-3856-427c-bd6f-520dc59cf441" xlink:to="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_40291a8d-8055-4b5d-b7e0-14c6fba78e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_ea63b8af-0e46-49ed-97d8-075d4251e4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_855f9c88-3856-427c-bd6f-520dc59cf441" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_ea63b8af-0e46-49ed-97d8-075d4251e4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_800c8ed9-e806-4c8d-a7c0-713198ade1af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_800c8ed9-e806-4c8d-a7c0-713198ade1af" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ce1f4fd-cb5f-4862-9d71-98e5dada8c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ce1f4fd-cb5f-4862-9d71-98e5dada8c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_12eae7ed-64e8-4e09-b71f-15f02ae29e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ce1f4fd-cb5f-4862-9d71-98e5dada8c6b" xlink:to="loc_us-gaap_RelatedPartyDomain_12eae7ed-64e8-4e09-b71f-15f02ae29e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_1acd7a16-d00f-4961-aa9c-94208a39774b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_12eae7ed-64e8-4e09-b71f-15f02ae29e5c" xlink:to="loc_us-gaap_CorporateJointVentureMember_1acd7a16-d00f-4961-aa9c-94208a39774b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6bd0cfc2-8772-4888-8001-981c5787e3c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6bd0cfc2-8772-4888-8001-981c5787e3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb602bf8-7e37-4ba1-a998-0f038cb1dcf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6bd0cfc2-8772-4888-8001-981c5787e3c5" xlink:to="loc_us-gaap_SegmentDomain_bb602bf8-7e37-4ba1-a998-0f038cb1dcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_c944baa4-0427-4928-9185-b67e13cd3e9a" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bb602bf8-7e37-4ba1-a998-0f038cb1dcf1" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_c944baa4-0427-4928-9185-b67e13cd3e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7c69516b-1979-487e-8784-03f59840b7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7c69516b-1979-487e-8784-03f59840b7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b20fa820-2d47-4000-905a-2bc1ab2ca8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7c69516b-1979-487e-8784-03f59840b7d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b20fa820-2d47-4000-905a-2bc1ab2ca8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistMember_5f5c1f36-7e87-4486-ba70-807400d2233a" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b20fa820-2d47-4000-905a-2bc1ab2ca8eb" xlink:to="loc_ehc_PortercareAdventistMember_5f5c1f36-7e87-4486-ba70-807400d2233a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PremierHealthPartnersMember_6ccaabf7-b915-4d7c-9520-fd9086745ec7" xlink:href="ehc-20200930.xsd#ehc_PremierHealthPartnersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b20fa820-2d47-4000-905a-2bc1ab2ca8eb" xlink:to="loc_ehc_PremierHealthPartnersMember_6ccaabf7-b915-4d7c-9520-fd9086745ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_65c9f67e-56a3-4dcd-9372-093b24941915" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistandPremierHealthPartnersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b20fa820-2d47-4000-905a-2bc1ab2ca8eb" xlink:to="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_65c9f67e-56a3-4dcd-9372-093b24941915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59957da9-31ba-4ac2-a806-6be24648447f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c89212ee-5bbf-4d06-aa4b-be438a7c2c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c89212ee-5bbf-4d06-aa4b-be438a7c2c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsAcquired_ddd26e8a-c426-4d13-b95b-672f167ecc1f" xlink:href="ehc-20200930.xsd#ehc_NumberofBedsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_ehc_NumberofBedsAcquired_ddd26e8a-c426-4d13-b95b-672f167ecc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsContributed_3ecff0b9-aaff-4584-b0c0-16c704aecf70" xlink:href="ehc-20200930.xsd#ehc_NumberofBedsContributed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_ehc_NumberofBedsContributed_3ecff0b9-aaff-4584-b0c0-16c704aecf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsExpanded_5d355b7f-5346-47c9-9009-a66da2f8bfc0" xlink:href="ehc-20200930.xsd#ehc_NumberofBedsExpanded"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_ehc_NumberofBedsExpanded_5d355b7f-5346-47c9-9009-a66da2f8bfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofDeNovoBeds_3c1010f6-2d84-4ac1-a95e-f12c04c0a4e9" xlink:href="ehc-20200930.xsd#ehc_NumberofDeNovoBeds"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_ehc_NumberofDeNovoBeds_3c1010f6-2d84-4ac1-a95e-f12c04c0a4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d1b32cc9-9b16-4f0a-ba15-b2964ca219e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e0388fd-4dc0-48dc-8ad1-d6c6654f67a4" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d1b32cc9-9b16-4f0a-ba15-b2964ca219e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_735e2581-2b7b-437e-825e-1a4e9c2e7021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_735e2581-2b7b-437e-825e-1a4e9c2e7021" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ea507f48-9506-4246-b8e9-51388e3ddbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ea507f48-9506-4246-b8e9-51388e3ddbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1b362c48-9854-4220-aa41-b34730987ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ea507f48-9506-4246-b8e9-51388e3ddbd6" xlink:to="loc_us-gaap_SegmentDomain_1b362c48-9854-4220-aa41-b34730987ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_6810fa4e-62ac-46c8-a934-b3a5310af22a" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1b362c48-9854-4220-aa41-b34730987ead" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_6810fa4e-62ac-46c8-a934-b3a5310af22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_9f64b009-bc99-4d90-98dc-9131b987ea28" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1b362c48-9854-4220-aa41-b34730987ead" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_9f64b009-bc99-4d90-98dc-9131b987ea28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5b5d6453-a48a-4ba7-b039-a6076537ac66" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:to="loc_srt_RangeAxis_5b5d6453-a48a-4ba7-b039-a6076537ac66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_59c7367c-bb29-41e5-a983-99cdb26dbe82" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5b5d6453-a48a-4ba7-b039-a6076537ac66" xlink:to="loc_srt_RangeMember_59c7367c-bb29-41e5-a983-99cdb26dbe82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d10f35eb-106c-4004-a4de-98bd9f1f6e33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_59c7367c-bb29-41e5-a983-99cdb26dbe82" xlink:to="loc_srt_MaximumMember_d10f35eb-106c-4004-a4de-98bd9f1f6e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d045acaa-5aff-4f73-ba5b-f46407c6c770" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_59c7367c-bb29-41e5-a983-99cdb26dbe82" xlink:to="loc_srt_MinimumMember_d045acaa-5aff-4f73-ba5b-f46407c6c770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_847c6dfb-66c8-4f0a-a246-3c4b3d3de20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_847c6dfb-66c8-4f0a-a246-3c4b3d3de20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4fb9ca-f96c-4acd-ab63-6f2e760c2d74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_847c6dfb-66c8-4f0a-a246-3c4b3d3de20b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4fb9ca-f96c-4acd-ab63-6f2e760c2d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_013d8faf-6e6e-4a49-85b0-8ae5c8c85348" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistandPremierHealthPartnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4fb9ca-f96c-4acd-ab63-6f2e760c2d74" xlink:to="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_013d8faf-6e6e-4a49-85b0-8ae5c8c85348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsofLynchburgMember_0f61377d-56f4-4c7d-8ce0-69cd3a15fc15" xlink:href="ehc-20200930.xsd#ehc_GenerationSolutionsofLynchburgMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b4fb9ca-f96c-4acd-ab63-6f2e760c2d74" xlink:to="loc_ehc_GenerationSolutionsofLynchburgMember_0f61377d-56f4-4c7d-8ce0-69cd3a15fc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1ee2e870-2c9a-4b03-a713-db04ed307aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1ee2e870-2c9a-4b03-a713-db04ed307aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7387cf8-6e60-4a29-8755-60d0eb7319d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1ee2e870-2c9a-4b03-a713-db04ed307aca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7387cf8-6e60-4a29-8755-60d0eb7319d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_ca6fa22b-aebb-484d-8b8c-0ebcb792a021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7387cf8-6e60-4a29-8755-60d0eb7319d2" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_ca6fa22b-aebb-484d-8b8c-0ebcb792a021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_35a6eebc-4062-48a5-8a3b-857dc9dac123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7387cf8-6e60-4a29-8755-60d0eb7319d2" xlink:to="loc_us-gaap_TradeNamesMember_35a6eebc-4062-48a5-8a3b-857dc9dac123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3a05595b-37d5-409f-bf26-b9b60943ca46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7387cf8-6e60-4a29-8755-60d0eb7319d2" xlink:to="loc_us-gaap_LicensingAgreementsMember_3a05595b-37d5-409f-bf26-b9b60943ca46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_380c6bef-f00a-4840-8b00-e2431c973e35" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ded8ef4f-d36b-4ff7-8680-cd25710e232f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ded8ef4f-d36b-4ff7-8680-cd25710e232f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8819833a-52d8-48a7-bb54-fc84e351bd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8819833a-52d8-48a7-bb54-fc84e351bd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a4ed5c23-6981-45f1-bdb0-9cbc1b4e02fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a4ed5c23-6981-45f1-bdb0-9cbc1b4e02fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_19b6633b-23c4-4dde-91ae-f41c15de9112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_Goodwill_19b6633b-23c4-4dde-91ae-f41c15de9112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f7a83d2c-5d02-486f-9855-22b0a4ca2165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dfd6d436-2391-4953-a042-7ae8a26397ae" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f7a83d2c-5d02-486f-9855-22b0a4ca2165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsNetCashPaidforAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0ab10102-bb7b-4c61-894f-5ed0239bbaf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ac242be-e309-4d3c-9f38-7ddace4c42ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0ab10102-bb7b-4c61-894f-5ed0239bbaf1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ac242be-e309-4d3c-9f38-7ddace4c42ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d045f562-e04c-4a0b-bbec-2305ab4d5ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ac242be-e309-4d3c-9f38-7ddace4c42ec" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d045f562-e04c-4a0b-bbec-2305ab4d5ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f697900b-ceda-4daf-aaed-905ee8a11ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d045f562-e04c-4a0b-bbec-2305ab4d5ff1" xlink:to="loc_us-gaap_SegmentDomain_f697900b-ceda-4daf-aaed-905ee8a11ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_437ec991-5fd5-4e42-a35f-53418e9152a2" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f697900b-ceda-4daf-aaed-905ee8a11ca7" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_437ec991-5fd5-4e42-a35f-53418e9152a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_24ec47b5-e1b4-4fcb-b9a2-d068ce9838c4" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f697900b-ceda-4daf-aaed-905ee8a11ca7" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_24ec47b5-e1b4-4fcb-b9a2-d068ce9838c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_98edc427-f5dd-4324-b86e-e1b98993ae09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ac242be-e309-4d3c-9f38-7ddace4c42ec" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_98edc427-f5dd-4324-b86e-e1b98993ae09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62e1eef4-d1b2-478e-9a09-f25d6cca129f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_98edc427-f5dd-4324-b86e-e1b98993ae09" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62e1eef4-d1b2-478e-9a09-f25d6cca129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_438d8318-9839-42c3-87f6-000c4a3306d5" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistandPremierHealthPartnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62e1eef4-d1b2-478e-9a09-f25d6cca129f" xlink:to="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_438d8318-9839-42c3-87f6-000c4a3306d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsofLynchburgMember_36aa4e6f-67ab-4947-a17a-b469c1334da3" xlink:href="ehc-20200930.xsd#ehc_GenerationSolutionsofLynchburgMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_62e1eef4-d1b2-478e-9a09-f25d6cca129f" xlink:to="loc_ehc_GenerationSolutionsofLynchburgMember_36aa4e6f-67ab-4947-a17a-b469c1334da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ac242be-e309-4d3c-9f38-7ddace4c42ec" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_0441e5bd-7efd-454f-bf07-ab21df643f19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_0441e5bd-7efd-454f-bf07-ab21df643f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8c38e1e4-52fc-40f5-9d62-e9716e4827d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8c38e1e4-52fc-40f5-9d62-e9716e4827d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_5606c6cb-85ca-40a4-80a2-08cddc740e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_5606c6cb-85ca-40a4-80a2-08cddc740e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_694e2c04-ddf2-4cbe-a9ec-8a657b427bc1" xlink:href="ehc-20200930.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_694e2c04-ddf2-4cbe-a9ec-8a657b427bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0d9e85d2-4b8a-43e9-bfd7-e6a4b6090c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11092682-5c8e-482c-9c6a-e388c4c25a5f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0d9e85d2-4b8a-43e9-bfd7-e6a4b6090c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#BusinessCombinationsProFormaResultsofOperationDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_511eea4f-4748-45f1-b298-5a0e886b8459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89aed0aa-13a2-4887-8207-4d9a78ad568f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_511eea4f-4748-45f1-b298-5a0e886b8459" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89aed0aa-13a2-4887-8207-4d9a78ad568f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_84da6771-b5d3-485c-9e59-4673799fc80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89aed0aa-13a2-4887-8207-4d9a78ad568f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_84da6771-b5d3-485c-9e59-4673799fc80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edc35ee9-cbd0-4e44-9d61-b5d58689ee85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84da6771-b5d3-485c-9e59-4673799fc80b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edc35ee9-cbd0-4e44-9d61-b5d58689ee85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_393b7a87-943e-4ca0-8aa6-76eaf29f8d5e" xlink:href="ehc-20200930.xsd#ehc_PortercareAdventistandPremierHealthPartnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edc35ee9-cbd0-4e44-9d61-b5d58689ee85" xlink:to="loc_ehc_PortercareAdventistandPremierHealthPartnersMember_393b7a87-943e-4ca0-8aa6-76eaf29f8d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_GenerationSolutionsofLynchburgMember_d0d3966e-512b-4282-995d-cae87f3dc65b" xlink:href="ehc-20200930.xsd#ehc_GenerationSolutionsofLynchburgMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edc35ee9-cbd0-4e44-9d61-b5d58689ee85" xlink:to="loc_ehc_GenerationSolutionsofLynchburgMember_d0d3966e-512b-4282-995d-cae87f3dc65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a69274e8-9674-495b-8769-d6f8026ef960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89aed0aa-13a2-4887-8207-4d9a78ad568f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a69274e8-9674-495b-8769-d6f8026ef960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0f7d768a-3238-4a30-9ff0-5c0fbdc470f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a69274e8-9674-495b-8769-d6f8026ef960" xlink:to="loc_us-gaap_SegmentDomain_0f7d768a-3238-4a30-9ff0-5c0fbdc470f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_65e548bb-2876-47d3-9403-bf4b33e45795" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0f7d768a-3238-4a30-9ff0-5c0fbdc470f5" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_65e548bb-2876-47d3-9403-bf4b33e45795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_5f611f07-63c8-47d2-845a-c2c8fefb13ec" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0f7d768a-3238-4a30-9ff0-5c0fbdc470f5" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_5f611f07-63c8-47d2-845a-c2c8fefb13ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89aed0aa-13a2-4887-8207-4d9a78ad568f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_2847b179-6c71-461f-a77e-1fdf767485d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_2847b179-6c71-461f-a77e-1fdf767485d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f7477ef0-4b96-4317-93eb-540620f4a9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f7477ef0-4b96-4317-93eb-540620f4a9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_59c9e609-c00f-4a5d-ba8e-4ce4e0f9923c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_59c9e609-c00f-4a5d-ba8e-4ce4e0f9923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4836b27e-b72b-46e5-b592-3c4530da21d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1fbbf049-9c25-44af-9985-31a95b4dc30e" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4836b27e-b72b-46e5-b592-3c4530da21d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_663478b9-5533-4a56-897c-5d3d62a57477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_8bb9dcf2-5547-4857-8e25-4b83653eded1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_663478b9-5533-4a56-897c-5d3d62a57477" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_8bb9dcf2-5547-4857-8e25-4b83653eded1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntitiesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85702d51-f6e8-4732-ae37-034ed65cece6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_3028ec63-8cf5-447d-94fc-00c0492471ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_85702d51-f6e8-4732-ae37-034ed65cece6" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_3028ec63-8cf5-447d-94fc-00c0492471ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntitiesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2128927-90e5-436b-9321-6028019032f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a2e28881-523a-48bf-9efd-bb1e4371dafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2128927-90e5-436b-9321-6028019032f5" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a2e28881-523a-48bf-9efd-bb1e4371dafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_da091fea-4a4c-4385-9180-b7cdbb1f50d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a2e28881-523a-48bf-9efd-bb1e4371dafc" xlink:to="loc_srt_ConsolidatedEntitiesAxis_da091fea-4a4c-4385-9180-b7cdbb1f50d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f242f677-356e-466b-83db-0122acb40fe9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_da091fea-4a4c-4385-9180-b7cdbb1f50d3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f242f677-356e-466b-83db-0122acb40fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_bf3bb01a-ce7e-4930-b4d6-cb8c8932b1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f242f677-356e-466b-83db-0122acb40fe9" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_bf3bb01a-ce7e-4930-b4d6-cb8c8932b1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2fa2ff92-9d57-42cc-9177-7586f53907bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a2e28881-523a-48bf-9efd-bb1e4371dafc" xlink:to="loc_srt_RangeAxis_2fa2ff92-9d57-42cc-9177-7586f53907bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c74bc3cf-0b24-4285-87ca-582e5115a8b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2fa2ff92-9d57-42cc-9177-7586f53907bd" xlink:to="loc_srt_RangeMember_c74bc3cf-0b24-4285-87ca-582e5115a8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3846984d-ecd1-4c67-9c99-2d189da93ecb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c74bc3cf-0b24-4285-87ca-582e5115a8b6" xlink:to="loc_srt_MinimumMember_3846984d-ecd1-4c67-9c99-2d189da93ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_81c7b608-5083-4e8b-8ce0-e2637e009671" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c74bc3cf-0b24-4285-87ca-582e5115a8b6" xlink:to="loc_srt_MaximumMember_81c7b608-5083-4e8b-8ce0-e2637e009671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_b765abac-20a3-4cab-9d45-2be06bbde656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_a2e28881-523a-48bf-9efd-bb1e4371dafc" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_b765abac-20a3-4cab-9d45-2be06bbde656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_76e340fb-912f-4eeb-9426-11cc2c7ddfcb" xlink:href="ehc-20200930.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b765abac-20a3-4cab-9d45-2be06bbde656" xlink:to="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_76e340fb-912f-4eeb-9426-11cc2c7ddfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_38d26ed7-9f31-4a11-96ef-17f2a36af01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b765abac-20a3-4cab-9d45-2be06bbde656" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_38d26ed7-9f31-4a11-96ef-17f2a36af01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0cea505-51e5-4b37-8ea7-3f0c44529c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ee67286d-b83b-4312-9825-f89e2047839a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0cea505-51e5-4b37-8ea7-3f0c44529c37" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ee67286d-b83b-4312-9825-f89e2047839a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_ce6cbd7e-d67f-4e54-9bf3-d32d70e39fef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ee67286d-b83b-4312-9825-f89e2047839a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_ce6cbd7e-d67f-4e54-9bf3-d32d70e39fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6cd7d31b-f36b-4a7a-a501-57b913e705b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ce6cbd7e-d67f-4e54-9bf3-d32d70e39fef" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6cd7d31b-f36b-4a7a-a501-57b913e705b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_aa5c18b0-1dd8-4d55-b6fd-8918536c1f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_6cd7d31b-f36b-4a7a-a501-57b913e705b3" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_aa5c18b0-1dd8-4d55-b6fd-8918536c1f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_bb16f702-3b02-49b7-915a-e29f1cf96d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ee67286d-b83b-4312-9825-f89e2047839a" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_bb16f702-3b02-49b7-915a-e29f1cf96d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb16f702-3b02-49b7-915a-e29f1cf96d30" xlink:to="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_174dd466-43d1-4ec3-9da6-d97a08106cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_174dd466-43d1-4ec3-9da6-d97a08106cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d90be11f-c46a-4945-b711-af0747dadb33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d90be11f-c46a-4945-b711-af0747dadb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_50a836ea-d6ff-40af-a6d5-28ecc1a8a142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:to="loc_us-gaap_OtherAssetsCurrent_50a836ea-d6ff-40af-a6d5-28ecc1a8a142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f7c40c6b-a84d-42ad-8ee8-ea282c145379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0821022b-e4e5-4ce3-9966-34bd7efd0208" xlink:to="loc_us-gaap_AssetsCurrent_f7c40c6b-a84d-42ad-8ee8-ea282c145379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e952f3a5-2008-4947-8d37-c46c4edd361c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e952f3a5-2008-4947-8d37-c46c4edd361c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_73b1483c-6e31-41a5-b44f-5177df38257d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_73b1483c-6e31-41a5-b44f-5177df38257d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_91b9422c-68b8-4dfa-9d0a-aee7379c41f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_Goodwill_91b9422c-68b8-4dfa-9d0a-aee7379c41f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_eb66b8b7-6d66-47f5-8f9e-28a37d0ff1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_eb66b8b7-6d66-47f5-8f9e-28a37d0ff1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b0c28be2-2a3e-4a96-ab72-2646c5497bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b0c28be2-2a3e-4a96-ab72-2646c5497bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8079f8ed-5696-4209-b546-53a816b2741d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d885fd5-aaea-4c7a-98d7-7a2520ec50da" xlink:to="loc_us-gaap_Assets_8079f8ed-5696-4209-b546-53a816b2741d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb16f702-3b02-49b7-915a-e29f1cf96d30" xlink:to="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ccbabf80-eb83-4bb6-9d3f-c5b281e90919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ccbabf80-eb83-4bb6-9d3f-c5b281e90919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_be230a79-c848-4d73-8d6b-27dab73d5c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_be230a79-c848-4d73-8d6b-27dab73d5c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ac201b89-5caf-4989-a567-2af6a8bc4e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:to="loc_us-gaap_AccountsPayableCurrent_ac201b89-5caf-4989-a567-2af6a8bc4e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ea0cb60c-acb3-4e74-8543-bca8a3e31fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ea0cb60c-acb3-4e74-8543-bca8a3e31fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3589251a-55e3-4f66-9e2f-7dee02b2cc76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_939085ac-3e70-4257-b66d-8f3fda09fe2b" xlink:to="loc_us-gaap_LiabilitiesCurrent_3589251a-55e3-4f66-9e2f-7dee02b2cc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6c38f6c3-e9b7-4762-83ff-31790069f262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6c38f6c3-e9b7-4762-83ff-31790069f262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_610b03a5-4699-4857-aa15-23e7446775cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_610b03a5-4699-4857-aa15-23e7446775cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_54b9b1b9-4a86-498e-8c51-dcb2374d8005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_54b9b1b9-4a86-498e-8c51-dcb2374d8005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_25c57880-1799-490a-bb04-8a35b0c74281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_36a8fc41-6d3a-4f5c-b475-e0af0181d919" xlink:to="loc_us-gaap_Liabilities_25c57880-1799-490a-bb04-8a35b0c74281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bd4a5073-478f-4bdc-9d32-389b9a3545d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_768c2e2c-aa0b-4ff9-bc7a-e7bcf83a96b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bd4a5073-478f-4bdc-9d32-389b9a3545d2" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_768c2e2c-aa0b-4ff9-bc7a-e7bcf83a96b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a7a4888c-4a46-4c59-bc25-9cbfb285cfef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2ce29ea5-bbe6-4a7f-9c20-bbb1a4876377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a7a4888c-4a46-4c59-bc25-9cbfb285cfef" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2ce29ea5-bbe6-4a7f-9c20-bbb1a4876377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock_3c8ef5e5-dbcf-4e03-bc66-a5e2298af7b6" xlink:href="ehc-20200930.xsd#ehc_ScheduleOfFinancialCovenantsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a7a4888c-4a46-4c59-bc25-9cbfb285cfef" xlink:to="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock_3c8ef5e5-dbcf-4e03-bc66-a5e2298af7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_55488741-31f7-4f91-b899-6979adc1406b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_55488741-31f7-4f91-b899-6979adc1406b" xlink:to="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_89453f0a-3039-4006-87d5-f725edfa497d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:to="loc_us-gaap_CreditFacilityAxis_89453f0a-3039-4006-87d5-f725edfa497d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3b39e3d3-dbfc-4cc3-9251-26f0c960be26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_89453f0a-3039-4006-87d5-f725edfa497d" xlink:to="loc_us-gaap_CreditFacilityDomain_3b39e3d3-dbfc-4cc3-9251-26f0c960be26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_788d7b02-69c3-47c1-be82-0de633211a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3b39e3d3-dbfc-4cc3-9251-26f0c960be26" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_788d7b02-69c3-47c1-be82-0de633211a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_03c59cf0-d7d2-4585-8c8a-121053acbe7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_03c59cf0-d7d2-4585-8c8a-121053acbe7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2f194eeb-8c7d-4c7a-bdb5-f8325cc3cf07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_03c59cf0-d7d2-4585-8c8a-121053acbe7f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2f194eeb-8c7d-4c7a-bdb5-f8325cc3cf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_5665741c-30ce-4eb1-a0d6-54437edcec23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2f194eeb-8c7d-4c7a-bdb5-f8325cc3cf07" xlink:to="loc_us-gaap_LoansPayableMember_5665741c-30ce-4eb1-a0d6-54437edcec23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_6e941262-4eb4-475c-939d-23b962f67cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2f194eeb-8c7d-4c7a-bdb5-f8325cc3cf07" xlink:to="loc_us-gaap_SeniorNotesMember_6e941262-4eb4-475c-939d-23b962f67cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_a7fb0186-9cbd-4acd-b6d7-7c4e09942afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2f194eeb-8c7d-4c7a-bdb5-f8325cc3cf07" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_a7fb0186-9cbd-4acd-b6d7-7c4e09942afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9d25a63f-09db-4564-a6c3-864d70f91a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:to="loc_us-gaap_DebtInstrumentAxis_9d25a63f-09db-4564-a6c3-864d70f91a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d25a63f-09db-4564-a6c3-864d70f91a6c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_8bac15b8-f1cb-4b60-911d-b478aa25935a" xlink:href="ehc-20200930.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_TermLoanFacilitiesMember_8bac15b8-f1cb-4b60-911d-b478aa25935a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_c3b47591-47b6-4cea-95b4-105ed27d61e1" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_c3b47591-47b6-4cea-95b4-105ed27d61e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_2aa6a4de-88c3-42ea-9e37-3397c27fe955" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_SeniorNotes0575Due2024Member_2aa6a4de-88c3-42ea-9e37-3397c27fe955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_daf8e6bb-b381-480a-bb23-d409a06c8abd" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_daf8e6bb-b381-480a-bb23-d409a06c8abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_07c67e95-dc6e-48cc-bdfc-607f1010015c" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_07c67e95-dc6e-48cc-bdfc-607f1010015c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_d4e42c3a-790e-497f-bb5c-ffad387aab64" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4251e8dd-3190-4a7a-9ade-2156a4965073" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_d4e42c3a-790e-497f-bb5c-ffad387aab64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0c506724-b645-47c7-afdd-d438befd5f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_49894deb-fdb8-48df-aca5-00f55318a788" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0c506724-b645-47c7-afdd-d438befd5f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0c506724-b645-47c7-afdd-d438befd5f22" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee222a91-44b5-437e-a5b8-fd5cf35d1d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee222a91-44b5-437e-a5b8-fd5cf35d1d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f4713d8a-5ebd-4955-a059-3031b7efd6fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_LongTermDebt_f4713d8a-5ebd-4955-a059-3031b7efd6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_fc4d83bb-9cc9-433c-b20e-cc26346ea54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_FinanceLeaseLiability_fc4d83bb-9cc9-433c-b20e-cc26346ea54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_f67e6928-f4fe-484f-a13a-07453daae0fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_f67e6928-f4fe-484f-a13a-07453daae0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_12df17ed-ec8e-43c6-b02d-71ce7e440b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_12df17ed-ec8e-43c6-b02d-71ce7e440b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_da969eb0-ad58-4157-90a3-73db4172b6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_65e9cb51-e76b-41ae-b4f6-c057983e6489" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_da969eb0-ad58-4157-90a3-73db4172b6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtFinancialCovenantsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e985b381-2cfe-4337-b4fd-de49ca6b3711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dee6e5c6-c7d6-4b13-a58a-06bfce43e446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e985b381-2cfe-4337-b4fd-de49ca6b3711" xlink:to="loc_us-gaap_DebtInstrumentTable_dee6e5c6-c7d6-4b13-a58a-06bfce43e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b6913ee2-424e-4f6e-954d-9095dedf3518" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dee6e5c6-c7d6-4b13-a58a-06bfce43e446" xlink:to="loc_srt_StatementScenarioAxis_b6913ee2-424e-4f6e-954d-9095dedf3518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_73c78227-ba22-4327-81a7-dc131e1212e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_b6913ee2-424e-4f6e-954d-9095dedf3518" xlink:to="loc_srt_ScenarioUnspecifiedDomain_73c78227-ba22-4327-81a7-dc131e1212e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_fb79dd8b-db46-483d-890e-df4f7a749bc7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_73c78227-ba22-4327-81a7-dc131e1212e6" xlink:to="loc_srt_ScenarioForecastMember_fb79dd8b-db46-483d-890e-df4f7a749bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bbc3f52a-08d4-47cf-8d59-2fc8d7add09f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dee6e5c6-c7d6-4b13-a58a-06bfce43e446" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bbc3f52a-08d4-47cf-8d59-2fc8d7add09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_ac2c2f44-c402-4a43-af9f-55d5f792a31d" xlink:href="ehc-20200930.xsd#ehc_DebtInstrumentCovenantInterestCoverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbc3f52a-08d4-47cf-8d59-2fc8d7add09f" xlink:to="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_ac2c2f44-c402-4a43-af9f-55d5f792a31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_4b5e9b6e-2288-4c49-9c6e-5a77265cb334" xlink:href="ehc-20200930.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bbc3f52a-08d4-47cf-8d59-2fc8d7add09f" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_4b5e9b6e-2288-4c49-9c6e-5a77265cb334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#LongtermDebtTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b4501d20-923f-4022-84ec-9e3f4d42e715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b4501d20-923f-4022-84ec-9e3f4d42e715" xlink:to="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f3fab0fe-3962-40cc-866b-2561b380b30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f3fab0fe-3962-40cc-866b-2561b380b30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2d8ebeff-af94-4254-bd20-9bc9bf9627bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f3fab0fe-3962-40cc-866b-2561b380b30d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2d8ebeff-af94-4254-bd20-9bc9bf9627bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_b25a71f8-e609-4289-94c0-be910079c20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d8ebeff-af94-4254-bd20-9bc9bf9627bf" xlink:to="loc_us-gaap_SeniorNotesMember_b25a71f8-e609-4289-94c0-be910079c20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1d92dd89-6c62-47bb-afa6-95555cf48e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:to="loc_us-gaap_DebtInstrumentAxis_1d92dd89-6c62-47bb-afa6-95555cf48e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d92dd89-6c62-47bb-afa6-95555cf48e81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_4de14439-8e18-478f-989c-7888b2164ee3" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_4de14439-8e18-478f-989c-7888b2164ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_298093c0-a799-4f30-bd24-b6dabf74e569" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_298093c0-a799-4f30-bd24-b6dabf74e569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_89e9abb5-c7ea-4545-9b51-7648e4443d63" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_89e9abb5-c7ea-4545-9b51-7648e4443d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_c87c8f35-39d1-466a-a822-f2f61b3a237c" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e44fa2c7-5312-43ec-95e7-a4d036052305" xlink:to="loc_ehc_SeniorNotes0575Due2024Member_c87c8f35-39d1-466a-a822-f2f61b3a237c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_80d7e159-b0e1-4736-a275-d07d8135fb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_80d7e159-b0e1-4736-a275-d07d8135fb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8560e88a-236e-4847-927f-8032a2e5d192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_80d7e159-b0e1-4736-a275-d07d8135fb4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8560e88a-236e-4847-927f-8032a2e5d192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4906da64-54e4-40a1-9b3f-ab92a687d846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8560e88a-236e-4847-927f-8032a2e5d192" xlink:to="loc_us-gaap_SubsequentEventMember_4906da64-54e4-40a1-9b3f-ab92a687d846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_db06079b-2c40-436b-9fc0-5107a0154c9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:to="loc_srt_StatementScenarioAxis_db06079b-2c40-436b-9fc0-5107a0154c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7d62e3b4-d81a-47ac-a652-02f363b57710" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_db06079b-2c40-436b-9fc0-5107a0154c9b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7d62e3b4-d81a-47ac-a652-02f363b57710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_66d99988-5c33-4c9a-a985-b14447613230" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7d62e3b4-d81a-47ac-a652-02f363b57710" xlink:to="loc_srt_ScenarioForecastMember_66d99988-5c33-4c9a-a985-b14447613230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4cf97d7b-6490-4348-8ad6-edfb5cc26bcd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_753dbef4-fddf-4a92-a148-29df25825bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_753dbef4-fddf-4a92-a148-29df25825bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7d4606dd-f416-4339-b470-4eb05550858e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7d4606dd-f416-4339-b470-4eb05550858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_ca98d399-2756-4ce8-b50f-7683bd639002" xlink:href="ehc-20200930.xsd#ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_ca98d399-2756-4ce8-b50f-7683bd639002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_f1a19a1c-34c8-4af4-8b70-36d757526b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_f1a19a1c-34c8-4af4-8b70-36d757526b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_489b615f-2e72-4bbc-aa06-234c2a2a2584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_LongTermDebt_489b615f-2e72-4bbc-aa06-234c2a2a2584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6bb3dec1-47d4-4733-b12e-e790621fcb66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_752e78ad-423a-4369-aefc-b5822e743d9a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6bb3dec1-47d4-4733-b12e-e790621fcb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterests"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_a4b81fe6-c0ab-40f4-80a8-753c5b28f12c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_748754fb-ca9d-4318-a4c9-c4e283b549f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_a4b81fe6-c0ab-40f4-80a8-753c5b28f12c" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_748754fb-ca9d-4318-a4c9-c4e283b549f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_5b22d095-3183-4bae-8652-3e1c0fef11b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_d5f50558-5420-4780-bfc7-1c4fce585f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5b22d095-3183-4bae-8652-3e1c0fef11b9" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_d5f50558-5420-4780-bfc7-1c4fce585f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock_372809b9-9968-4595-9028-e5d3af83f5dd" xlink:href="ehc-20200930.xsd#ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5b22d095-3183-4bae-8652-3e1c0fef11b9" xlink:to="loc_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock_372809b9-9968-4595-9028-e5d3af83f5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_9695a88f-53d9-4e2f-a8af-d1ced35a399c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_72775f99-dca3-4f3a-b7cc-ac85f1f22d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_9695a88f-53d9-4e2f-a8af-d1ced35a399c" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_72775f99-dca3-4f3a-b7cc-ac85f1f22d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_59b72316-8f78-45e1-84db-beb5dd7546d3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_72775f99-dca3-4f3a-b7cc-ac85f1f22d4f" xlink:to="loc_dei_LegalEntityAxis_59b72316-8f78-45e1-84db-beb5dd7546d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_76cdb3f6-1bf4-499f-8f1c-88506f17645a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_59b72316-8f78-45e1-84db-beb5dd7546d3" xlink:to="loc_dei_EntityDomain_76cdb3f6-1bf4-499f-8f1c-88506f17645a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember_4e504b42-1753-473b-865c-297b750f31bc" xlink:href="ehc-20200930.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_76cdb3f6-1bf4-499f-8f1c-88506f17645a" xlink:to="loc_ehc_RedeemableNoncontrollingInterestMember_4e504b42-1753-473b-865c-297b750f31bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_10bd0be3-709c-4091-a9f4-c06a5d7acd77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_72775f99-dca3-4f3a-b7cc-ac85f1f22d4f" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_10bd0be3-709c-4091-a9f4-c06a5d7acd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:href="ehc-20200930.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_10bd0be3-709c-4091-a9f4-c06a5d7acd77" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_4dcb0617-724b-4f21-80c0-e964e1462be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_4dcb0617-724b-4f21-80c0-e964e1462be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_6a35389f-d00c-4484-96ab-6593e195d261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_6a35389f-d00c-4484-96ab-6593e195d261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c5ec2873-d924-44b1-b14a-6dc80ae47bf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c5ec2873-d924-44b1-b14a-6dc80ae47bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Contributiontojointventure_8b55f7a6-79a3-4ed4-bf9c-edeba45ecf13" xlink:href="ehc-20200930.xsd#ehc_Contributiontojointventure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_ehc_Contributiontojointventure_8b55f7a6-79a3-4ed4-bf9c-edeba45ecf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Reclassificationtononcontrollinginterests_523b4304-d001-436c-9eb5-bf003ee6528e" xlink:href="ehc-20200930.xsd#ehc_Reclassificationtononcontrollinginterests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_ehc_Reclassificationtononcontrollinginterests_523b4304-d001-436c-9eb5-bf003ee6528e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_f999468b-633a-42c7-92ec-98921a96d423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_f999468b-633a-42c7-92ec-98921a96d423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExchangeTransaction_3717ffb1-6964-4808-828b-f96b221253d0" xlink:href="ehc-20200930.xsd#ehc_NoncontrollingInterestExchangeTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_ehc_NoncontrollingInterestExchangeTransaction_3717ffb1-6964-4808-828b-f96b221253d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_328b0b0e-1876-4cff-8b82-188edf1524c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_328b0b0e-1876-4cff-8b82-188edf1524c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_f213b8fa-78b9-468a-aac0-204bba0a4214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_138b204d-4344-40a3-bd69-d6e262ec3e1d" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_f213b8fa-78b9-468a-aac0-204bba0a4214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_95a0b3f0-b759-46df-ab45-3914f5cc45ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_5dc0b743-15fd-4e78-be64-3cf327e462b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_95a0b3f0-b759-46df-ab45-3914f5cc45ad" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_5dc0b743-15fd-4e78-be64-3cf327e462b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_5e693b74-9b34-4e1c-b13c-1fe2d90e1277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_95a0b3f0-b759-46df-ab45-3914f5cc45ad" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_5e693b74-9b34-4e1c-b13c-1fe2d90e1277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_af88e9d8-a15d-4203-8ff0-0e0947ee5599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_95a0b3f0-b759-46df-ab45-3914f5cc45ad" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_af88e9d8-a15d-4203-8ff0-0e0947ee5599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#RedeemableNoncontrollingInterestsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_60079fa3-ad02-42e4-b3b6-17778994992d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_60079fa3-ad02-42e4-b3b6-17778994992d" xlink:to="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_86d8ce68-7691-45f4-8b75-2e4accd41cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_86d8ce68-7691-45f4-8b75-2e4accd41cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3600f5a4-ec62-4766-a661-d72a08faa2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_86d8ce68-7691-45f4-8b75-2e4accd41cfe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3600f5a4-ec62-4766-a661-d72a08faa2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EHHIMember_3559e8bd-e412-459a-b3e9-e1ef5f90ff4b" xlink:href="ehc-20200930.xsd#ehc_EHHIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3600f5a4-ec62-4766-a661-d72a08faa2f5" xlink:to="loc_ehc_EHHIMember_3559e8bd-e412-459a-b3e9-e1ef5f90ff4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cb097b5d-12cb-4a33-8a00-28b832b656c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cb097b5d-12cb-4a33-8a00-28b832b656c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_17621247-878c-4250-b205-fc89a1bd27df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cb097b5d-12cb-4a33-8a00-28b832b656c5" xlink:to="loc_us-gaap_SegmentDomain_17621247-878c-4250-b205-fc89a1bd27df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_58ff2680-5446-4d49-a438-c02f2065492a" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_17621247-878c-4250-b205-fc89a1bd27df" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_58ff2680-5446-4d49-a438-c02f2065492a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4a7f531a-757c-4a62-b54a-fe03928d64e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:to="loc_srt_OwnershipAxis_4a7f531a-757c-4a62-b54a-fe03928d64e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_78316e48-b62c-4ccf-a816-a726c18b647e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_4a7f531a-757c-4a62-b54a-fe03928d64e4" xlink:to="loc_srt_OwnershipDomain_78316e48-b62c-4ccf-a816-a726c18b647e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HoldingsAndEHHIMember_ce6e24b2-c0b4-4c6f-bb69-5e04c910d713" xlink:href="ehc-20200930.xsd#ehc_HoldingsAndEHHIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_78316e48-b62c-4ccf-a816-a726c18b647e" xlink:to="loc_ehc_HoldingsAndEHHIMember_ce6e24b2-c0b4-4c6f-bb69-5e04c910d713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_42beb2b4-a37b-496d-8b5b-10d7c6bf0deb" xlink:to="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_8ed4990d-fa72-46c7-b1e4-1b3aeedcc623" xlink:href="ehc-20200930.xsd#ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_8ed4990d-fa72-46c7-b1e4-1b3aeedcc623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_4a3d5c83-04ed-4a0f-9f4e-3114d27a2e12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_4a3d5c83-04ed-4a0f-9f4e-3114d27a2e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_28b0f066-0897-427b-9111-1cdcf1a56d0b" xlink:href="ehc-20200930.xsd#ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent_28b0f066-0897-427b-9111-1cdcf1a56d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_1f54fd93-5522-40a2-8060-271d366228d7" xlink:href="ehc-20200930.xsd#ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_1f54fd93-5522-40a2-8060-271d366228d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4a6011a9-9ef9-4af0-a9f5-2dc88ff3af9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4a6011a9-9ef9-4af0-a9f5-2dc88ff3af9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_a7babdde-f874-4e11-ae73-9336a379967a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_a7babdde-f874-4e11-ae73-9336a379967a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_26b33714-adfb-4892-ada4-639d04cb29ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_26b33714-adfb-4892-ada4-639d04cb29ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_d6d59734-af3b-4dda-acab-92a82fd7b0b5" xlink:href="ehc-20200930.xsd#ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_d6d59734-af3b-4dda-acab-92a82fd7b0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_eb07514a-a128-489e-9120-9eb7af2e545e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b6ef0e6e-b047-4bb4-97ff-e0a0ff74ead2" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_eb07514a-a128-489e-9120-9eb7af2e545e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9dee49a3-a8cc-4d41-b009-2be054d5f26f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6b622aaa-7c57-401a-b3e2-ab2aa3d536d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9dee49a3-a8cc-4d41-b009-2be054d5f26f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6b622aaa-7c57-401a-b3e2-ab2aa3d536d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_87e0817f-5ba7-45b5-8f3b-197ed6b0d094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0e3e91a4-4d1a-41fd-bcbb-ecdc67cbba2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_87e0817f-5ba7-45b5-8f3b-197ed6b0d094" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0e3e91a4-4d1a-41fd-bcbb-ecdc67cbba2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_b6bc777c-1b1c-45af-af88-16b9bdd31d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_87e0817f-5ba7-45b5-8f3b-197ed6b0d094" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_b6bc777c-1b1c-45af-af88-16b9bdd31d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1b67b4d5-1c7a-4272-9952-1da6852962b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b67b4d5-1c7a-4272-9952-1da6852962b0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_eae54555-7076-4299-a1d7-70a433bddcdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:to="loc_us-gaap_ValuationTechniqueAxis_eae54555-7076-4299-a1d7-70a433bddcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_475b77b2-354b-49f3-8c16-cf7b870a2766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_eae54555-7076-4299-a1d7-70a433bddcdf" xlink:to="loc_us-gaap_ValuationTechniqueDomain_475b77b2-354b-49f3-8c16-cf7b870a2766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketApproachValuationTechniqueMember_9c09a11f-4c9a-4c35-bba3-602df5d14c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketApproachValuationTechniqueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_475b77b2-354b-49f3-8c16-cf7b870a2766" xlink:to="loc_us-gaap_MarketApproachValuationTechniqueMember_9c09a11f-4c9a-4c35-bba3-602df5d14c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_faa1ac11-766e-447a-8f59-5508e311d255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_475b77b2-354b-49f3-8c16-cf7b870a2766" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_faa1ac11-766e-447a-8f59-5508e311d255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3de8d7e-a0d2-419f-a238-399c3a5e935d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3de8d7e-a0d2-419f-a238-399c3a5e935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_842dc390-1a30-464c-a4ac-8a2760e605c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3de8d7e-a0d2-419f-a238-399c3a5e935d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_842dc390-1a30-464c-a4ac-8a2760e605c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_94637d39-90d5-450e-b8c8-d3cef289e755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_842dc390-1a30-464c-a4ac-8a2760e605c3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_94637d39-90d5-450e-b8c8-d3cef289e755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bd12fa3-644f-49d4-951a-9412c50c9fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bd12fa3-644f-49d4-951a-9412c50c9fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_81f7fde3-0482-4291-9baf-55a8ae17c369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bd12fa3-644f-49d4-951a-9412c50c9fd0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_81f7fde3-0482-4291-9baf-55a8ae17c369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_247185f5-e26f-4a03-a3c4-6b1204766d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_81f7fde3-0482-4291-9baf-55a8ae17c369" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_247185f5-e26f-4a03-a3c4-6b1204766d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b2b5392a-c14a-4988-9d2c-983d88cdf208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_81f7fde3-0482-4291-9baf-55a8ae17c369" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b2b5392a-c14a-4988-9d2c-983d88cdf208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_91efa496-5c58-4e6e-95cf-1903db14ed30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_81f7fde3-0482-4291-9baf-55a8ae17c369" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_91efa496-5c58-4e6e-95cf-1903db14ed30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266b8ed2-d066-43bf-a891-ece088802ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_91836257-14bc-416d-b6da-fe1ae795589d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266b8ed2-d066-43bf-a891-ece088802ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5792408e-7181-4c8c-b079-1ff021c67148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266b8ed2-d066-43bf-a891-ece088802ab5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5792408e-7181-4c8c-b079-1ff021c67148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_07d60dc0-0458-4fa9-af05-7b6e3a047184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5792408e-7181-4c8c-b079-1ff021c67148" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_07d60dc0-0458-4fa9-af05-7b6e3a047184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aa87cfd1-b137-48ad-9cd6-5b2025d2df8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5792408e-7181-4c8c-b079-1ff021c67148" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aa87cfd1-b137-48ad-9cd6-5b2025d2df8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_14c7afff-5eeb-4130-9606-cfb0380dbef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_5792408e-7181-4c8c-b079-1ff021c67148" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_14c7afff-5eeb-4130-9606-cfb0380dbef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_52c72fa5-d855-458b-aa8a-227ef653a45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44cadcec-18fb-44eb-824d-c8718e0d677a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52c72fa5-d855-458b-aa8a-227ef653a45a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44cadcec-18fb-44eb-824d-c8718e0d677a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a18a97e4-521b-4039-8091-f5e873e2bd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44cadcec-18fb-44eb-824d-c8718e0d677a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a18a97e4-521b-4039-8091-f5e873e2bd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6f944d1-5017-430e-9e36-6044e4d90d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a18a97e4-521b-4039-8091-f5e873e2bd8f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6f944d1-5017-430e-9e36-6044e4d90d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_5ff16a10-97b3-4141-a9e3-36602acdd3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6f944d1-5017-430e-9e36-6044e4d90d76" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_5ff16a10-97b3-4141-a9e3-36602acdd3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4223aa65-63f5-4f22-9f95-1acf2542d607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44cadcec-18fb-44eb-824d-c8718e0d677a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4223aa65-63f5-4f22-9f95-1acf2542d607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_716bbfdc-1789-4700-91d1-0fec0bf8afe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4223aa65-63f5-4f22-9f95-1acf2542d607" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_716bbfdc-1789-4700-91d1-0fec0bf8afe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_70a3b03d-37f7-4e31-89f1-3f9398aba2db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_70a3b03d-37f7-4e31-89f1-3f9398aba2db" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_59298166-1b76-4b95-88a2-ed1db3f229fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:to="loc_us-gaap_CreditFacilityAxis_59298166-1b76-4b95-88a2-ed1db3f229fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d0d59d57-6984-4a46-b26e-fe8be056077e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_59298166-1b76-4b95-88a2-ed1db3f229fc" xlink:to="loc_us-gaap_CreditFacilityDomain_d0d59d57-6984-4a46-b26e-fe8be056077e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_96f10b40-34cf-4350-9b09-8be2e3eea7d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d0d59d57-6984-4a46-b26e-fe8be056077e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_96f10b40-34cf-4350-9b09-8be2e3eea7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_af50418e-b78a-496f-b236-99078f7b9522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d0d59d57-6984-4a46-b26e-fe8be056077e" xlink:to="loc_us-gaap_LetterOfCreditMember_af50418e-b78a-496f-b236-99078f7b9522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe86f1b4-d541-48ee-ab5d-9334a201ddc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe86f1b4-d541-48ee-ab5d-9334a201ddc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fca978d6-bd39-47a0-8714-78e5bab8b6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe86f1b4-d541-48ee-ab5d-9334a201ddc0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fca978d6-bd39-47a0-8714-78e5bab8b6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_8e5555c5-49e9-4a52-9f9f-cb0cad5a0f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fca978d6-bd39-47a0-8714-78e5bab8b6a9" xlink:to="loc_us-gaap_LoansPayableMember_8e5555c5-49e9-4a52-9f9f-cb0cad5a0f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_28b9c7d4-3552-478d-bf1e-c20f8a869eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fca978d6-bd39-47a0-8714-78e5bab8b6a9" xlink:to="loc_us-gaap_SeniorNotesMember_28b9c7d4-3552-478d-bf1e-c20f8a869eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f3775fc2-ec66-42d7-99dc-08f61c776d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fca978d6-bd39-47a0-8714-78e5bab8b6a9" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f3775fc2-ec66-42d7-99dc-08f61c776d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea0b260a-b755-4f2d-8377-f462a786a80d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea0b260a-b755-4f2d-8377-f462a786a80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea0b260a-b755-4f2d-8377-f462a786a80d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_6e7b5047-1756-46ab-979a-37d792d950ea" xlink:href="ehc-20200930.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_TermLoanFacilitiesMember_6e7b5047-1756-46ab-979a-37d792d950ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_2fb7b1e9-578c-49b8-b7ac-33c1c335b2a5" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_2fb7b1e9-578c-49b8-b7ac-33c1c335b2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_7bb6de3a-beae-4e15-bc34-d559036e30a2" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_SeniorNotes0575Due2024Member_7bb6de3a-beae-4e15-bc34-d559036e30a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_3c825887-96d7-49f0-a7a5-e901dc26bbd7" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_3c825887-96d7-49f0-a7a5-e901dc26bbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_bbe2def3-c939-45c0-a244-225c254cddab" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_bbe2def3-c939-45c0-a244-225c254cddab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_e575f5e2-dab1-4432-8aea-9bc9f74b4bf0" xlink:href="ehc-20200930.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7640d793-6ec2-4343-b69d-65aa3ce4e5df" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_e575f5e2-dab1-4432-8aea-9bc9f74b4bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_8ad2a728-a6d5-432c-83c5-5d7ff28813fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_8ad2a728-a6d5-432c-83c5-5d7ff28813fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_20862fab-0f15-459e-8103-33ff0137d0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8ad2a728-a6d5-432c-83c5-5d7ff28813fe" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_20862fab-0f15-459e-8103-33ff0137d0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_be2dbbe9-1420-4c36-af96-de72d75bbb50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_20862fab-0f15-459e-8103-33ff0137d0ab" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_be2dbbe9-1420-4c36-af96-de72d75bbb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5481d560-cb37-467e-bc31-dae955b853dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_be2dbbe9-1420-4c36-af96-de72d75bbb50" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5481d560-cb37-467e-bc31-dae955b853dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0df9e0cc-ab17-45ca-b7ae-e0de37e30b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_be2dbbe9-1420-4c36-af96-de72d75bbb50" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0df9e0cc-ab17-45ca-b7ae-e0de37e30b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8c183487-8d54-43da-8443-d4d45a1a8596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_572cf62e-4b21-41a5-93f1-dce446c21c6b" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8c183487-8d54-43da-8443-d4d45a1a8596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_5019a17a-707e-4486-b0d8-dcefc26ff1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8c183487-8d54-43da-8443-d4d45a1a8596" xlink:to="loc_us-gaap_LongTermDebtFairValue_5019a17a-707e-4486-b0d8-dcefc26ff1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be94b395-4247-4fca-b7d0-e6a42e36cf91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8c183487-8d54-43da-8443-d4d45a1a8596" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be94b395-4247-4fca-b7d0-e6a42e36cf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="ehc-20200930.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e175e5fc-6d22-425f-b759-ec30bc120ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a3fee434-eb38-49f5-b10a-d6f51abedfc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e175e5fc-6d22-425f-b759-ec30bc120ff5" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a3fee434-eb38-49f5-b10a-d6f51abedfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#ShareBasedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_712c4855-921d-45ca-8850-ac9a970bee67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2172db05-5671-4655-9181-cf977cfc0ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_712c4855-921d-45ca-8850-ac9a970bee67" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2172db05-5671-4655-9181-cf977cfc0ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2fdb4727-a1ee-4e54-87b0-5c665493ae16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2172db05-5671-4655-9181-cf977cfc0ef8" xlink:to="loc_us-gaap_AwardTypeAxis_2fdb4727-a1ee-4e54-87b0-5c665493ae16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b6fa4c-8770-435f-9ea5-e67532716e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2fdb4727-a1ee-4e54-87b0-5c665493ae16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b6fa4c-8770-435f-9ea5-e67532716e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_879a7d66-f3e8-4c4f-b6fa-12300b3962a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b6fa4c-8770-435f-9ea5-e67532716e1b" xlink:to="loc_us-gaap_RestrictedStockMember_879a7d66-f3e8-4c4f-b6fa-12300b3962a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3a0c5ad6-b89f-48f0-b3d1-a03813f8ecc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b6fa4c-8770-435f-9ea5-e67532716e1b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3a0c5ad6-b89f-48f0-b3d1-a03813f8ecc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_345d23cd-1006-4d6b-a15d-873b7c57fdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b6fa4c-8770-435f-9ea5-e67532716e1b" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_345d23cd-1006-4d6b-a15d-873b7c57fdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_2fe26a12-bf99-4db3-bf37-a6b91a20c1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2172db05-5671-4655-9181-cf977cfc0ef8" xlink:to="loc_us-gaap_VestingAxis_2fe26a12-bf99-4db3-bf37-a6b91a20c1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a6f8437c-7d76-4f65-8151-d57e98237f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_2fe26a12-bf99-4db3-bf37-a6b91a20c1bf" xlink:to="loc_us-gaap_VestingDomain_a6f8437c-7d76-4f65-8151-d57e98237f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b038703b-c11c-4b38-abab-d0862e186027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a6f8437c-7d76-4f65-8151-d57e98237f43" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b038703b-c11c-4b38-abab-d0862e186027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_dc4f343c-6fac-4835-a5cf-ceffa480391b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a6f8437c-7d76-4f65-8151-d57e98237f43" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_dc4f343c-6fac-4835-a5cf-ceffa480391b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2172db05-5671-4655-9181-cf977cfc0ef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c0715fe-7e9f-44e5-b2d8-660cfeecc4e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0c0715fe-7e9f-44e5-b2d8-660cfeecc4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_39e9fa96-9e85-4a11-aaf3-37b3f115e47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_39e9fa96-9e85-4a11-aaf3-37b3f115e47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7ba8552a-1279-4826-844f-7e92943b6a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7ba8552a-1279-4826-844f-7e92943b6a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_480a7701-efd8-417e-aa44-5794f45f613f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_480a7701-efd8-417e-aa44-5794f45f613f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AllocatedSharebasedCompensationLiability_27181ece-4775-4b78-b0d1-421c265b3592" xlink:href="ehc-20200930.xsd#ehc_AllocatedSharebasedCompensationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_ehc_AllocatedSharebasedCompensationLiability_27181ece-4775-4b78-b0d1-421c265b3592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_8713da1c-aff9-4d1b-aecc-aafffb9b82f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f5fa955-6e97-47fe-ba8e-0f6b8a551505" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_8713da1c-aff9-4d1b-aecc-aafffb9b82f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ehc-20200930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1f513b1c-ec1b-460e-9926-ac373d791b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a06f1382-d4d3-41c6-bba5-20e512d667bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1f513b1c-ec1b-460e-9926-ac373d791b4b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a06f1382-d4d3-41c6-bba5-20e512d667bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f2070d1d-c95a-4a47-b30a-b66c6ba8483b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a45d5482-0995-4063-89bf-a867b92b6c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2070d1d-c95a-4a47-b30a-b66c6ba8483b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a45d5482-0995-4063-89bf-a867b92b6c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShare"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_535c464b-d294-4be1-8317-e8ace179e80c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_02624f9f-e154-40cf-ba7e-0e21d7e33fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_535c464b-d294-4be1-8317-e8ace179e80c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_02624f9f-e154-40cf-ba7e-0e21d7e33fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a4dc8456-1e52-46e7-b8d5-b29bf633aea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e5c30f86-9255-4a25-a0eb-943ce03c5a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a4dc8456-1e52-46e7-b8d5-b29bf633aea6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e5c30f86-9255-4a25-a0eb-943ce03c5a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_4f2de062-50a8-46aa-9dcb-ce089d257542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a4dc8456-1e52-46e7-b8d5-b29bf633aea6" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_4f2de062-50a8-46aa-9dcb-ce089d257542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9a94552e-a08a-48d1-8cba-684d4a5edd84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5c003397-9353-44b6-a0e4-5561205b62cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9a94552e-a08a-48d1-8cba-684d4a5edd84" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5c003397-9353-44b6-a0e4-5561205b62cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9809e216-11e2-4c66-aa93-4e21f355dbc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5c003397-9353-44b6-a0e4-5561205b62cd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9809e216-11e2-4c66-aa93-4e21f355dbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_2e0c16c1-cf62-475b-b319-95c31562e1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5c003397-9353-44b6-a0e4-5561205b62cd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_2e0c16c1-cf62-475b-b319-95c31562e1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_0a7a7f26-3fce-4697-871c-adc8f51a4ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5c003397-9353-44b6-a0e4-5561205b62cd" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_0a7a7f26-3fce-4697-871c-adc8f51a4ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_40f08765-30d2-4c2e-858c-e1a8860835e3" xlink:href="ehc-20200930.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5c003397-9353-44b6-a0e4-5561205b62cd" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_40f08765-30d2-4c2e-858c-e1a8860835e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_53fe5b5f-f9be-4c5e-9fd4-be0c55cf3e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5c003397-9353-44b6-a0e4-5561205b62cd" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_53fe5b5f-f9be-4c5e-9fd4-be0c55cf3e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_c22d397c-91eb-4708-beca-b58e9b872df4" xlink:href="ehc-20200930.xsd#ehc_NetIncomeLossAvailabletoCommonStockholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5c003397-9353-44b6-a0e4-5561205b62cd" xlink:to="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_c22d397c-91eb-4708-beca-b58e9b872df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_a6c68dff-d266-4c2c-829b-f2c0699b4d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9a94552e-a08a-48d1-8cba-684d4a5edd84" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_a6c68dff-d266-4c2c-829b-f2c0699b4d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6e93503-e76a-43dc-b047-c33ae40b59a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_a6c68dff-d266-4c2c-829b-f2c0699b4d38" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6e93503-e76a-43dc-b047-c33ae40b59a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_60d56909-7e82-4269-a0b9-285dcc0756ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9a94552e-a08a-48d1-8cba-684d4a5edd84" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_60d56909-7e82-4269-a0b9-285dcc0756ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_815bbbdb-2159-487f-880e-6a51ba39a0cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_60d56909-7e82-4269-a0b9-285dcc0756ba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_815bbbdb-2159-487f-880e-6a51ba39a0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3c517792-4e8e-4fcd-927c-e646b688bc34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_60d56909-7e82-4269-a0b9-285dcc0756ba" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3c517792-4e8e-4fcd-927c-e646b688bc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_255882d2-9233-4c90-9619-22466be3794e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_60d56909-7e82-4269-a0b9-285dcc0756ba" xlink:to="loc_us-gaap_EarningsPerShareBasic_255882d2-9233-4c90-9619-22466be3794e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8c42c101-d8fd-40ef-bd30-3debbea437ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9a94552e-a08a-48d1-8cba-684d4a5edd84" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8c42c101-d8fd-40ef-bd30-3debbea437ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0b6ac730-c059-4392-9e00-2321b125a469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8c42c101-d8fd-40ef-bd30-3debbea437ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0b6ac730-c059-4392-9e00-2321b125a469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_d79de156-b06f-48eb-af1c-6d9fbe348575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8c42c101-d8fd-40ef-bd30-3debbea437ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_d79de156-b06f-48eb-af1c-6d9fbe348575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_9aa9138d-cf47-4ccb-92b0-c9809b9dff38" xlink:href="ehc-20200930.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8c42c101-d8fd-40ef-bd30-3debbea437ff" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_9aa9138d-cf47-4ccb-92b0-c9809b9dff38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a2e1f4d7-9765-418f-8bc6-daa9e162be78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8c42c101-d8fd-40ef-bd30-3debbea437ff" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a2e1f4d7-9765-418f-8bc6-daa9e162be78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_92252e18-ad6e-4e83-83e6-791262bb779c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8c42c101-d8fd-40ef-bd30-3debbea437ff" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_92252e18-ad6e-4e83-83e6-791262bb779c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_053d833e-a58c-4728-9a4f-d77a2c2310ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9a94552e-a08a-48d1-8cba-684d4a5edd84" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_053d833e-a58c-4728-9a4f-d77a2c2310ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb4352d0-38a8-4a9b-90a7-17a174903f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_053d833e-a58c-4728-9a4f-d77a2c2310ac" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb4352d0-38a8-4a9b-90a7-17a174903f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_2b631f84-1ad8-4745-8e60-80b210c10871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9a94552e-a08a-48d1-8cba-684d4a5edd84" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_2b631f84-1ad8-4745-8e60-80b210c10871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3d360d41-6e21-495d-864c-8515f11c0fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2b631f84-1ad8-4745-8e60-80b210c10871" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3d360d41-6e21-495d-864c-8515f11c0fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_66c771f2-dfd2-460b-9703-20e358b62358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2b631f84-1ad8-4745-8e60-80b210c10871" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_66c771f2-dfd2-460b-9703-20e358b62358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_73a7d190-f872-4739-8da8-f0da84e4186f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2b631f84-1ad8-4745-8e60-80b210c10871" xlink:to="loc_us-gaap_EarningsPerShareDiluted_73a7d190-f872-4739-8da8-f0da84e4186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_900d20ff-3464-46ba-8d9f-2882e24c5662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4f6f26cd-d42e-421f-b05d-e753a398a15b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_900d20ff-3464-46ba-8d9f-2882e24c5662" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4f6f26cd-d42e-421f-b05d-e753a398a15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_22e565fd-80b7-42a6-9a0f-01c8d6b5c8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_900d20ff-3464-46ba-8d9f-2882e24c5662" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_22e565fd-80b7-42a6-9a0f-01c8d6b5c8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_48a50d68-fd4a-49f3-9145-b3fbd3d9ebfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_900d20ff-3464-46ba-8d9f-2882e24c5662" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_48a50d68-fd4a-49f3-9145-b3fbd3d9ebfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="simple" xlink:href="ehc-20200930.xsd#ContingenciesandOtherCommitments"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97ec0a27-5b8b-4b74-9247-66a2b722f950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_de122ec9-0a83-44ae-953d-d5ca1de3d080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97ec0a27-5b8b-4b74-9247-66a2b722f950" xlink:to="loc_us-gaap_LossContingencyDisclosures_de122ec9-0a83-44ae-953d-d5ca1de3d080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#ContingenciesandOtherCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd38bc45-38c2-4c18-a58c-17b4161c57b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd38bc45-38c2-4c18-a58c-17b4161c57b0" xlink:to="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fbd5543d-3983-4119-b5b0-3a3b3a923f3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:to="loc_srt_RangeAxis_fbd5543d-3983-4119-b5b0-3a3b3a923f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8dee720-6e84-49f7-94ab-6c0fa3ac2990" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fbd5543d-3983-4119-b5b0-3a3b3a923f3a" xlink:to="loc_srt_RangeMember_c8dee720-6e84-49f7-94ab-6c0fa3ac2990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_52b6002f-9379-4051-9747-85f06f24545f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c8dee720-6e84-49f7-94ab-6c0fa3ac2990" xlink:to="loc_srt_MaximumMember_52b6002f-9379-4051-9747-85f06f24545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_71c7095a-3159-4797-8b66-b7f8b1a9a5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:to="loc_us-gaap_LitigationStatusAxis_71c7095a-3159-4797-8b66-b7f8b1a9a5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_cd754d73-dce0-4514-b400-9896d662c0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_71c7095a-3159-4797-8b66-b7f8b1a9a5e7" xlink:to="loc_us-gaap_LitigationStatusDomain_cd754d73-dce0-4514-b400-9896d662c0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_5d2d8da0-4110-47a7-905f-3740637f81cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_cd754d73-dce0-4514-b400-9896d662c0b7" xlink:to="loc_us-gaap_SettledLitigationMember_5d2d8da0-4110-47a7-905f-3740637f81cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d323d2ca-dc1b-48b0-91e6-8e19acc0bd06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:to="loc_srt_LitigationCaseAxis_d323d2ca-dc1b-48b0-91e6-8e19acc0bd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8274e9fc-6049-44e5-b8e8-ab4b72dd6d3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d323d2ca-dc1b-48b0-91e6-8e19acc0bd06" xlink:to="loc_srt_LitigationCaseTypeDomain_8274e9fc-6049-44e5-b8e8-ab4b72dd6d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NicholsLitigationMember_03f6adb1-3406-4056-9d91-8ff6d17ce3df" xlink:href="ehc-20200930.xsd#ehc_NicholsLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8274e9fc-6049-44e5-b8e8-ab4b72dd6d3a" xlink:to="loc_ehc_NicholsLitigationMember_03f6adb1-3406-4056-9d91-8ff6d17ce3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_85142746-e7a2-4be1-b7da-a7c3a3863e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_92e3870b-b4ff-494f-bf50-7c6bb2cf339a" xlink:to="loc_us-gaap_LossContingenciesLineItems_85142746-e7a2-4be1-b7da-a7c3a3863e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_f03255cc-3d94-430a-a251-856e8995b1cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_85142746-e7a2-4be1-b7da-a7c3a3863e91" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_f03255cc-3d94-430a-a251-856e8995b1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d01e28e2-db86-4c7a-a34f-16818174b9f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_9e25a9a4-a925-46dc-a25f-5bb124253c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d01e28e2-db86-4c7a-a34f-16818174b9f2" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_9e25a9a4-a925-46dc-a25f-5bb124253c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f5507000-6b3f-46b3-b42c-87388cdb7612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8df2319e-c4ee-4b6f-a30f-55bdaaf9818a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f5507000-6b3f-46b3-b42c-87388cdb7612" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8df2319e-c4ee-4b6f-a30f-55bdaaf9818a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_0e5588cd-25dd-4f4b-8ceb-ce85091b05f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f5507000-6b3f-46b3-b42c-87388cdb7612" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_0e5588cd-25dd-4f4b-8ceb-ce85091b05f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock_6d488eaa-0ebd-481c-b115-6d8a07008727" xlink:href="ehc-20200930.xsd#ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f5507000-6b3f-46b3-b42c-87388cdb7612" xlink:to="loc_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock_6d488eaa-0ebd-481c-b115-6d8a07008727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_45672f13-43ad-43e4-b8c3-ccb50623343b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f5507000-6b3f-46b3-b42c-87388cdb7612" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_45672f13-43ad-43e4-b8c3-ccb50623343b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTextualDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_77d5773e-c718-48d2-a0ff-0e30bdb27d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_616cfcfd-d392-4844-ac0b-ac75ea981b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_77d5773e-c718-48d2-a0ff-0e30bdb27d58" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_616cfcfd-d392-4844-ac0b-ac75ea981b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_488401f1-88c3-4e05-bf4b-53245d4073fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_616cfcfd-d392-4844-ac0b-ac75ea981b00" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_488401f1-88c3-4e05-bf4b-53245d4073fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9d5a7d54-702f-4c74-96a9-5dbf2d30818b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_488401f1-88c3-4e05-bf4b-53245d4073fb" xlink:to="loc_us-gaap_SegmentDomain_9d5a7d54-702f-4c74-96a9-5dbf2d30818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_5899fee0-7a88-4a4b-a373-ac02a7bdea24" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9d5a7d54-702f-4c74-96a9-5dbf2d30818b" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_5899fee0-7a88-4a4b-a373-ac02a7bdea24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_24381002-5070-4243-a30d-3ee1182f0e09" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9d5a7d54-702f-4c74-96a9-5dbf2d30818b" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_24381002-5070-4243-a30d-3ee1182f0e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c409514c-6c89-4c9f-88a8-986e5b223f73" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_616cfcfd-d392-4844-ac0b-ac75ea981b00" xlink:to="loc_srt_RangeAxis_c409514c-6c89-4c9f-88a8-986e5b223f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c3cd29ef-172f-43a0-99f9-4d66eb138d6c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c409514c-6c89-4c9f-88a8-986e5b223f73" xlink:to="loc_srt_RangeMember_c3cd29ef-172f-43a0-99f9-4d66eb138d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a8f1bb0d-6604-4dfd-bb08-5252b5a075fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c3cd29ef-172f-43a0-99f9-4d66eb138d6c" xlink:to="loc_srt_MinimumMember_a8f1bb0d-6604-4dfd-bb08-5252b5a075fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_618f35a9-3112-4f16-ab10-e2b61d5a2ed0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c3cd29ef-172f-43a0-99f9-4d66eb138d6c" xlink:to="loc_srt_MaximumMember_618f35a9-3112-4f16-ab10-e2b61d5a2ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_616cfcfd-d392-4844-ac0b-ac75ea981b00" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ad89a3fb-cfda-4ef1-bc11-a434be8d54ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ad89a3fb-cfda-4ef1-bc11-a434be8d54ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_e439583e-1fb7-4d47-9945-e96c42e8da66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_e439583e-1fb7-4d47-9945-e96c42e8da66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals_df02533e-6cf6-492b-8e02-6dd97c943de2" xlink:href="ehc-20200930.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_NumberOfInpatientRehabilitationHospitals_df02533e-6cf6-492b-8e02-6dd97c943de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_c6e95405-86f1-4d8f-93ff-2204b6d5bb44" xlink:href="ehc-20200930.xsd#ehc_Numberofsolelyownedinpatientrehabilitationhospitals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_c6e95405-86f1-4d8f-93ff-2204b6d5bb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage_c83a53ad-b2af-42d3-9b96-e269a9289bfe" xlink:href="ehc-20200930.xsd#ehc_Jointventureownershippercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Jointventureownershippercentage_c83a53ad-b2af-42d3-9b96-e269a9289bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_3c8603c8-dcc8-476c-8921-0b5b2b4f83d8" xlink:href="ehc-20200930.xsd#ehc_Numberofjointlyownedinpatientrehabilitationhospitals"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_3c8603c8-dcc8-476c-8921-0b5b2b4f83d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_0aee8e23-98fb-4cf2-9bd4-eeecd7e01821" xlink:href="ehc-20200930.xsd#ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_0aee8e23-98fb-4cf2-9bd4-eeecd7e01821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhomehealthlocations_489f492b-78df-49ea-a356-af96d8f4c192" xlink:href="ehc-20200930.xsd#ehc_Numberofhomehealthlocations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofhomehealthlocations_489f492b-78df-49ea-a356-af96d8f4c192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhospicelocations_e6374747-44f5-4594-9ec5-b1e307dc57d9" xlink:href="ehc-20200930.xsd#ehc_Numberofhospicelocations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofhospicelocations_e6374747-44f5-4594-9ec5-b1e307dc57d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod_a296a9bc-bd16-48b7-a2c7-61d597a7876a" xlink:href="ehc-20200930.xsd#ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod_a296a9bc-bd16-48b7-a2c7-61d597a7876a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_a57028f5-ecde-4ab7-ac92-1cf40e5956ca" xlink:href="ehc-20200930.xsd#ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_a57028f5-ecde-4ab7-ac92-1cf40e5956ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_376870af-8c21-4481-9746-6d1d4c74beb9" xlink:href="ehc-20200930.xsd#ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e1b31e4b-2bef-43bc-9870-daf1055753c4" xlink:to="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_376870af-8c21-4481-9746-6d1d4c74beb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fd124b17-a3a4-4e77-9716-a97a14bfe528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b40f3784-184a-4a81-b17d-45f86233b73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fd124b17-a3a4-4e77-9716-a97a14bfe528" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b40f3784-184a-4a81-b17d-45f86233b73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c76a7938-5c48-4dcf-a669-edfe7c5c1585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b40f3784-184a-4a81-b17d-45f86233b73a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c76a7938-5c48-4dcf-a669-edfe7c5c1585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b74d870d-96ea-4b40-a9bb-d74590365791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c76a7938-5c48-4dcf-a669-edfe7c5c1585" xlink:to="loc_us-gaap_SegmentDomain_b74d870d-96ea-4b40-a9bb-d74590365791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_a3d724bb-6b7b-406b-abcf-0b8d095387c0" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b74d870d-96ea-4b40-a9bb-d74590365791" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_a3d724bb-6b7b-406b-abcf-0b8d095387c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_d775c655-e079-4750-a239-82b29f537751" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b74d870d-96ea-4b40-a9bb-d74590365791" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_d775c655-e079-4750-a239-82b29f537751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b40f3784-184a-4a81-b17d-45f86233b73a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6ed6bdc-e02a-481d-bbec-a8aed37c1fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6ed6bdc-e02a-481d-bbec-a8aed37c1fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_874bcee4-45b7-4912-8328-362ba64e1a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_us-gaap_LaborAndRelatedExpense_874bcee4-45b7-4912-8328-362ba64e1a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_73e7bbee-520a-46db-8962-ee3cbbf5e54a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_73e7bbee-520a-46db-8962-ee3cbbf5e54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_a8c5c93a-0995-4290-b926-d82ba985e7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_us-gaap_SuppliesExpense_a8c5c93a-0995-4290-b926-d82ba985e7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_e32471c9-3776-4df9-9f40-b16122de1af1" xlink:href="ehc-20200930.xsd#ehc_OccupancyCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_ehc_OccupancyCost_e32471c9-3776-4df9-9f40-b16122de1af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization_d62dfedd-d495-4965-b02d-a632e74a7241" xlink:href="ehc-20200930.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_ehc_CostofServicesExcludingDepreciationandAmortization_d62dfedd-d495-4965-b02d-a632e74a7241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_1b5cc2c8-e66b-4cc2-8b81-f40ce50ab007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_1b5cc2c8-e66b-4cc2-8b81-f40ce50ab007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fb180a3c-46a6-4c94-9a0d-67a04b06b6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ebda6529-2369-4939-98f2-8c5b015dbedc" xlink:to="loc_us-gaap_CostsAndExpenses_fb180a3c-46a6-4c94-9a0d-67a04b06b6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9a8e7e4a-8dcc-4970-97d0-cb076c3e8f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9a8e7e4a-8dcc-4970-97d0-cb076c3e8f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7f0a5592-80db-4428-b82c-12d5e17adc40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7f0a5592-80db-4428-b82c-12d5e17adc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_24d5c1d7-6822-443e-bf88-aaf9162f68b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_24d5c1d7-6822-443e-bf88-aaf9162f68b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_ffc22dd8-fc2e-4ddd-a459-dbd3eace1edb" xlink:href="ehc-20200930.xsd#ehc_AdjustedEBITDA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_ehc_AdjustedEBITDA_ffc22dd8-fc2e-4ddd-a459-dbd3eace1edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_de83be24-42dc-418d-8cdc-d270727dafd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7c6b8c38-87e4-4584-8f28-5ec464ecf993" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_de83be24-42dc-418d-8cdc-d270727dafd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_359ffa08-a4fc-4414-a862-30ada656397f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_1d6df45e-09d5-4cca-a5d1-dc350bb0510a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_359ffa08-a4fc-4414-a862-30ada656397f" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_1d6df45e-09d5-4cca-a5d1-dc350bb0510a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1932b8d0-ae89-4cad-9759-260171022bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_1d6df45e-09d5-4cca-a5d1-dc350bb0510a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1932b8d0-ae89-4cad-9759-260171022bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1f9936da-d239-4646-a56b-df14813f9f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1932b8d0-ae89-4cad-9759-260171022bf2" xlink:to="loc_us-gaap_SegmentDomain_1f9936da-d239-4646-a56b-df14813f9f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_5c0f5a53-cfc2-4770-846d-b56f5729ae5e" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1f9936da-d239-4646-a56b-df14813f9f26" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_5c0f5a53-cfc2-4770-846d-b56f5729ae5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_ffdd6597-9793-4240-923d-924c4237817c" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1f9936da-d239-4646-a56b-df14813f9f26" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_ffdd6597-9793-4240-923d-924c4237817c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_ae1bdd4c-e245-4b96-9486-9b27bc014896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_1d6df45e-09d5-4cca-a5d1-dc350bb0510a" xlink:to="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_ae1bdd4c-e245-4b96-9486-9b27bc014896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1a8c5826-e68e-4da2-bde9-cbe9f522160f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_ae1bdd4c-e245-4b96-9486-9b27bc014896" xlink:to="loc_us-gaap_Assets_1a8c5826-e68e-4da2-bde9-cbe9f522160f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_09597be4-9cab-43e0-86d7-1cbb3058e12b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_ae1bdd4c-e245-4b96-9486-9b27bc014896" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_09597be4-9cab-43e0-86d7-1cbb3058e12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e8b6aae6-fe84-4eba-8907-15b112e583b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f3536776-05ef-49d8-8430-28650825c5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8b6aae6-fe84-4eba-8907-15b112e583b0" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f3536776-05ef-49d8-8430-28650825c5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f4720c68-5500-4755-93f2-64f71a41a867" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f3536776-05ef-49d8-8430-28650825c5ca" xlink:to="loc_srt_ConsolidationItemsAxis_f4720c68-5500-4755-93f2-64f71a41a867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8096495e-6c93-4224-a9e5-01e53b358a47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_f4720c68-5500-4755-93f2-64f71a41a867" xlink:to="loc_srt_ConsolidationItemsDomain_8096495e-6c93-4224-a9e5-01e53b358a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2bd69e51-3a20-4502-a7c7-9c818c9f0bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8096495e-6c93-4224-a9e5-01e53b358a47" xlink:to="loc_us-gaap_OperatingSegmentsMember_2bd69e51-3a20-4502-a7c7-9c818c9f0bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_2ad2d9dd-dbad-43ae-9af9-16b75bb2782d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8096495e-6c93-4224-a9e5-01e53b358a47" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_2ad2d9dd-dbad-43ae-9af9-16b75bb2782d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f3536776-05ef-49d8-8430-28650825c5ca" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_8b6fc9c6-0b21-4074-b9d8-28c6ac48860e" xlink:href="ehc-20200930.xsd#ehc_AdjustedEBITDA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_ehc_AdjustedEBITDA_8b6fc9c6-0b21-4074-b9d8-28c6ac48860e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cdfc3575-d9c0-4dd1-8230-c7d0438d0ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cdfc3575-d9c0-4dd1-8230-c7d0438d0ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ce5fa81b-c098-4611-af78-48ee9cfe5529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ce5fa81b-c098-4611-af78-48ee9cfe5529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a540099c-b63c-4162-bf7b-2640ade73495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a540099c-b63c-4162-bf7b-2640ade73495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_8c705a2d-05ce-43b1-97ca-c75c66bd6d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_LitigationSettlementExpense_8c705a2d-05ce-43b1-97ca-c75c66bd6d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_212ab53e-6841-47dd-8599-408a381af97a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_212ab53e-6841-47dd-8599-408a381af97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3415e998-94c7-48b2-b083-12403326fac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_InterestExpenseDebt_3415e998-94c7-48b2-b083-12403326fac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f8cedf1a-0f82-4b90-a3e6-b37f8acb04e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f8cedf1a-0f82-4b90-a3e6-b37f8acb04e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests_52218c9d-582b-4407-95d9-234a07b73184" xlink:href="ehc-20200930.xsd#ehc_SARsmarktomarketimpactonnoncontrollinginterests"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_ehc_SARsmarktomarketimpactonnoncontrollinginterests_52218c9d-582b-4407-95d9-234a07b73184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss_d1168e1e-b40b-4ad3-98c0-75ce6b492853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_MarketableSecuritiesGainLoss_d1168e1e-b40b-4ad3-98c0-75ce6b492853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_8d4ea449-bf3d-454d-86af-8653546e56ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_8d4ea449-bf3d-454d-86af-8653546e56ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayrolltaxesonSARsexercise_dfb03baf-2d6b-443d-99f5-1654cb979268" xlink:href="ehc-20200930.xsd#ehc_PayrolltaxesonSARsexercise"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_ehc_PayrolltaxesonSARsexercise_dfb03baf-2d6b-443d-99f5-1654cb979268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c73d88db-b769-462a-a519-866fd4a8a686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_eb9ba16e-9d0c-4161-8d69-4cea54621818" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c73d88db-b769-462a-a519-866fd4a8a686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a3f906ee-f123-47a9-b34b-24498311097d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_e38260ee-4da7-4cc9-96e5-d24e206a023a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a3f906ee-f123-47a9-b34b-24498311097d" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_e38260ee-4da7-4cc9-96e5-d24e206a023a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a34c40df-f845-4bad-a881-a2e52635794b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_e38260ee-4da7-4cc9-96e5-d24e206a023a" xlink:to="loc_srt_ConsolidationItemsAxis_a34c40df-f845-4bad-a881-a2e52635794b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8d7f846a-06c8-42d4-9ce0-bdd7e8896c1e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_a34c40df-f845-4bad-a881-a2e52635794b" xlink:to="loc_srt_ConsolidationItemsDomain_8d7f846a-06c8-42d4-9ce0-bdd7e8896c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_96ac3ee9-2e0f-40ca-86ac-4b32fe65b1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8d7f846a-06c8-42d4-9ce0-bdd7e8896c1e" xlink:to="loc_us-gaap_OperatingSegmentsMember_96ac3ee9-2e0f-40ca-86ac-4b32fe65b1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_63c6e740-50c5-4479-b229-ef246f6c9ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8d7f846a-06c8-42d4-9ce0-bdd7e8896c1e" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_63c6e740-50c5-4479-b229-ef246f6c9ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_3f954e66-f934-4094-92b7-df44a952e3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_e38260ee-4da7-4cc9-96e5-d24e206a023a" xlink:to="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_3f954e66-f934-4094-92b7-df44a952e3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_33f38f79-bb1c-4355-bb19-2fdf2165ba1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_3f954e66-f934-4094-92b7-df44a952e3c4" xlink:to="loc_us-gaap_Assets_33f38f79-bb1c-4355-bb19-2fdf2165ba1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_aac9a080-6fb4-4e44-b640-d0a94b6c1156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_3f954e66-f934-4094-92b7-df44a952e3c4" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_aac9a080-6fb4-4e44-b640-d0a94b6c1156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ehc-20200930.xsd#SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e7970126-d9ab-4a06-8719-41d6334e8711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a4cd56cc-9317-45b4-b2f7-613a70027952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e7970126-d9ab-4a06-8719-41d6334e8711" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a4cd56cc-9317-45b4-b2f7-613a70027952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f25d1c92-ca5a-4af7-aa70-b42f612adb97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a4cd56cc-9317-45b4-b2f7-613a70027952" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f25d1c92-ca5a-4af7-aa70-b42f612adb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1d1162ab-de78-4240-94b8-a692ff71235e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f25d1c92-ca5a-4af7-aa70-b42f612adb97" xlink:to="loc_us-gaap_SegmentDomain_1d1162ab-de78-4240-94b8-a692ff71235e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_2f36d3fb-e4c4-46ee-82e1-d2f11206d3e4" xlink:href="ehc-20200930.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1d1162ab-de78-4240-94b8-a692ff71235e" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_2f36d3fb-e4c4-46ee-82e1-d2f11206d3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_2f54abae-ece4-42e3-aae3-cbc8051bbd98" xlink:href="ehc-20200930.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1d1162ab-de78-4240-94b8-a692ff71235e" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_2f54abae-ece4-42e3-aae3-cbc8051bbd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_d5a98a47-ba84-4f1a-b4d3-ab7862428c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a4cd56cc-9317-45b4-b2f7-613a70027952" xlink:to="loc_us-gaap_SubsegmentsAxis_d5a98a47-ba84-4f1a-b4d3-ab7862428c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_d5a98a47-ba84-4f1a-b4d3-ab7862428c24" xlink:to="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientMember_ca15149f-51fe-4b01-bd24-8186bfe07962" xlink:href="ehc-20200930.xsd#ehc_InpatientMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:to="loc_ehc_InpatientMember_ca15149f-51fe-4b01-bd24-8186bfe07962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OutpatientandotherMember_d5d0ff2d-c799-417b-aa7e-737e73b63ace" xlink:href="ehc-20200930.xsd#ehc_OutpatientandotherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:to="loc_ehc_OutpatientandotherMember_d5d0ff2d-c799-417b-aa7e-737e73b63ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember_cd6b023d-0554-4eb7-aeee-98be4acf8abb" xlink:href="ehc-20200930.xsd#ehc_HomehealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:to="loc_ehc_HomehealthMember_cd6b023d-0554-4eb7-aeee-98be4acf8abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember_fd75360c-f5c2-4dc7-8690-b783d897daf8" xlink:href="ehc-20200930.xsd#ehc_HospiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_dadd2778-fb5e-491a-82b6-160d942b985d" xlink:to="loc_ehc_HospiceMember_fd75360c-f5c2-4dc7-8690-b783d897daf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ea114d79-f17d-48cc-b938-8b06d08ee61e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a4cd56cc-9317-45b4-b2f7-613a70027952" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ea114d79-f17d-48cc-b938-8b06d08ee61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8eb27782-5673-4211-b1fa-b3e6a1db0991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ea114d79-f17d-48cc-b938-8b06d08ee61e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8eb27782-5673-4211-b1fa-b3e6a1db0991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>ehc-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:ehc="http://www.encompasshealth.com/20200930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ehc-20200930.xsd" xlink:type="simple"/>
    <context id="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic825b775519446e9be5f06a4c5e5d17b_I20201022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-10-22</instant>
        </period>
    </context>
    <context id="id8918b77e8b4434b8851a792780313ba_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i34499cd542a14592b5e93ad755870e76_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6cf41bad492345de99ed38cb8db55427_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if166fe2888ed4236b69cbd1304d9ed61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifee6c827439c4117821d833d1398c1e3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9dc50352d6c046e996455f484c4b8d2b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i16b97f17d8db408195ceeadc301ddfb1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie736b33e93524e6286ddda20f63fb392_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4d86622446d240caa39846454393bef9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i709bd3432796446cb8af88e1449a8b8a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id2dbc33472e04f73b22f6023e08ebc8e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0b16ec5f39fd426987fd267959afaf04_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i22e461c575464b3faf3390da4ec357b2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if0aa9d846293410c8246584aeefc69d8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i19f0ded8fb484018a4a1c01ca5701bcd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9db578648abe46bf8900fa6e9eeff904_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i77e27e7871034346bd94e7d93e7781a5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4a5ea56a23aa4f73aca3bbb27f91c6e9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i42639cc7412e46f29b28dfa5b1b7fedd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i814c90a316b4443c999528ec80e7ee11_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f2714c865b0433b81dee771e5553136_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i75303561f2ef48ad8ff4e6b1651fc33f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if2656c38caa24df2bc08d8781a5e56b2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6671d6f397794090a985d9d5d859cb64_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i2e92833c9f1f4896aba1d31655bf9668_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iba9d8fa1efdb4f6f928d5446c8898f66_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iec188c294f984c1aa5e6a6cf0c9e7af3_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if20836f1c7e2469e9f0c2603fbd54843_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i57b58b477c6b44f8aae21799d9a882d1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i59a276c6995d4d178488c77f6e17f1f0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3577cda3504a48d3bf46aed515f88491_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0b92ed8623634131a7a34a47abf7dfb8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i111ab5fcfcc24b20b042f933187dcebf_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i361753f0507443df95849a9f371e2888_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2023d91010c1475cbf531020218e9ace_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if66065e8c14946cd8962d13d307a0707_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib1b6506fde8448a2b39adf066ab41b4d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ica9a466d7fcb45179986a30bd2f10e97_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id973fd7c00f34ecdb68ed4e62bafd936_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2180fc581434643b14bf9f6f6ec6d6f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaeecdaf0a74142089add642599699c41_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e111b0b8f72431eaf24841ce8608010_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b7aa9d337504c10b18e5c482efd7679_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibfa62b0932f148c892a41d1e76032b17_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia54e68786692437494a7725e493da451_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb56e8b6eccf4d0f952421ad0f6412f9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6f7a8b690bbf4c35bee679ec147ea72d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i655f76689f4e487d80a6416983d67786_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8eeff91751e644a28a060a7ad7988b9b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i34acebad6a69473fad71f2a9f267509d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id46c52daa7f1470a96f7d883e6a8cfa5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia4343fa926414dfb8314bc855f63f5b7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id22de6a707d946778ca077c5a44462af_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic8102226c2854289a3f93691bcd2de7c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic2623f131c3949988d9bd1994b6eadcb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if3c6ede3de4b41f086db0871d013257f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i744c10f6ed7148d6b5050c2d1f9af046_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5873889771684c2cae78023b5cec4fc8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b66c244e6394649b16c65e6c1d17603_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9eac552610d74721a0767d8c2e8f4b7d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1cc0e8dca788458691540d426154ef62_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9fb9260dccfc4ad9a9987f170f8a116b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic4591d2e05d1482594d3f6804849a4e2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i88d947760b414ceface797d75918f6c3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i77665009ef8c4684bcb85139cafb06dc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i322a014d46954ce696d8d8480f860d21_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4550c4ea110e4f929a058f20551c7afb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i51235bf4750c4c599d6756b7879a4939_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id5f0a3577bda4c609eb02fe086530d48_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie5c5802675ee44e99fb4499efcd6b2c8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i345e73d6d939476ba32049426ba68d70_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibc0c26b5364d4089bd5ce943f4309664_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5524ac2905524e6d812a13eb8e579d18_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i992298aaa6ce4481ae6d6fa2fdebef80_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i17489ebe48064383942c0df2df3d5443_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8b6e3a1ee04d4f429b30592defb5a698_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia6370fbb51164f019e9009265116e84e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib894026d74674e5f96d404bb4cfc3b09_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i732c02fb17ea40ad9e61516625f6ebc5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id2d4e1ad64bc4d1daff8885a47a9ffa4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d73a08c42ae41178ddeba3a203ab25f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i43ec8761fcd64c49b38ddf4391322512_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idabd0dd54725446c9f81802c9a397c00_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3ac15f62994f4ba29f3f686482654b89_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibfd12a6455e04deeaa0f18ba31b44fad_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i69c117f071984988883a0aca1685756b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i97bbbbdd86244b42975499d324035936_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4ef53d5ff22046d0bb56bf2117a9ff75_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4541f86f6464425ca691fe14b5d7e823_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icd8e538bfc2e4ff8bd996ad27939cca6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifaefd1a522f844a7aff1af78d82fd07e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2279c50c6c004924ab551e8bdb047c89_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i77b51433b8594e0fb5df286fd380aac0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib6a7ea8ec1664d5583fcb48015255e0e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if3ed726963d947acb35515778bbe3f2d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if015466e48914fd08001b347cd2dc00b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id0f354ef81c74b3e906182037853d5ec_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i694c2f12494e432eac4cc3d84cfad62c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i46f9a922335944feb38605cd28479c87_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9d1805e49bad499d82a78e70a324756e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ea5b28aef1345628308b8cd50db8b8e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i040e0067c9094904af97de3099bebb5f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i53b94005181d46348addb4f79179e077_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ica170b9067d145f1a3adaa78a1913f4c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id9274fa4448545fa95f5a18d72345a7e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i786f1ca5dc7149449a23ecb8c8d45527_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i09b152c7501b43ae9e8f226b1846e828_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie6303df3106440f089bd9b6a43b82d6f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i110e86db8c9843af98b966b2ffda9577_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i573b526d23014691a9fbcc99b22c39fd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i476f0404ddd94cadb700f8b16900ee5a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8f9bdde56e16463b988f64934c46d7c7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac3ba654254a43e8aa2ac93fcdf11d2a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia3c3d4ee236a4d4cb2625cc617ee83e3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib4fa52ee1d974b97bae8afb7aa7d412e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0cb123f9a5b744a79f1bc96d6320a60f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1cf1c4c55ac84c38b5a62a045e25c279_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i413089dc6a054eca94c13747f4f64efc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i91952fdfd623406fae39f30682f9061b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i824f669848e64d61b82896e206f54278_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9db501b105224f719473dd493715a2a6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaab07423dc1c456ba919a6f038750cbc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b8e309cf85040a28f0109ed6a570c17_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4b3869c9910a4b0691c07e0cceb1ad09_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia66f0eef25f94b08b660e5e2ee7255f9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ica29f20acf9c41c69b1152541cad96dd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if6ed9c2b17fe42f6a52a5c962bde16a7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i35ad441b632046c092723ff744dbd45a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie258e26fd75b4ed780d94575a67a5b1a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3a268959462c498a9cb35520cf233b92_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2bbc1f21caa34ceb8709c3862095c706_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie7f10e410cd6492ea62746dcbe08ed80_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaabb8c23a4b647edae1f42bce9eadd72_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaa215d6614464fd0a8b6f316d94f43c2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2c160d712eb475cada54fe76f2c249a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if00c6bc809b1468f8c5e1fd14713e9de_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3594d867ccaa4a45baee188e9b52d0ef_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if75b0cdfb90148b7b50327f55b2b4c05_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0c565f1d2caf41e5ad304df1e404ec13_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if67c608503ce4f62b40fed8996b085cc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7aceeeed5320482e9848586c21bfec7a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic4f3d5a74c95403bb0c19dace55fa0e4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1f3913477cf4583aabab55a753c76e7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2fa310487b624ab3abfe31fac6c6eae8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id7e0c420dd3740c9b36010b9f1facfaa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4034d7e50f5c43f5960d10776b6b7bf4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie1118ce1a69f43f0aa8ff017adb7d860_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5d6897c3387c46f0b25a5ce68caf3780_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i97911a33afcc4eb1b3bb2cf52223db83_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4e799fccf1b749bdb9a2fe12fa808cee_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i64dcfb692db141e38d22fc8b004d9924_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i99a8ead0bbbc4ac8baa360ca8dd8f1d0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8fbcb67b95b64900b8e58638b2420b02_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id221678cc7294df9b33d60a008d67b3d_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i33d295cd3f3b47759d61f44e07e56fc6_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i164768e9d98945009ca4f1d1e36917a8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99a4b3491a24492fbd0635cfe176d18c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8d63a47f4d3e460a94d90e53d7bcbef6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f877b7c9b844d33baa6901b87f3b8fb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i186e76d3e4134732aa2cae42033322a2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistandPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1560645449b747a1ba2a0753d5016fc6_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i56f08b6a993948f2baf0abcbb8879961_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2c76d4a587d74d698b634d1f495b2c74_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8f63f58dc90642eea45a7aa1f02b8503_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e4e00603d8740a8bcf31cfc8d4f58e1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibd3b016833a9435ca260fd97a50d18c8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc22792722ba436c9181b2a61d9649df_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if0584508681949b19044b898bcaac766_D20200301-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:GenerationSolutionsofLynchburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1708048c2a42448693822a76f275381d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i66fdf46a359740a785ea525eb38ea7fd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8546b47816c54ef381660703138b5caf_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ac9f48cbdbe488cb20eed7e2f9ca1ee_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i608f28a8c9c64873904629df071b372b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if83e06ff810244088cb996c03064f330_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie8fb9a7dd06c4e609086c04b5dbfe4ca_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2f1023a8574449fd9b9332edaf46f3bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i638ab89eae9440c5b0f1929587a02914_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8f0377bd53564ffdae03ff64e660194b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia523dc03179846ddaf98c887899b7679_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3892c4bc03204316bb6e77be3f27b240_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib40a6e6dd68b4a8da5d30d7aaa484c51_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic41c4e44b7b64428b528add431c16513_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6f1805d3ddcd4b188bc766e18298a2d5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i730f2a918b744a0e94177fd42ad004a4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i62eb57fb87fc40e59f8f33f73b921693_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idd067c2ff27b4ab8a68e5471e7c59ef9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1dfc00f6eb92471998309b5c12c9388f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i23cf331b54114349857c76ca9d89e4e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i30dd8fb7ca9b4d95a01ed19cec48d797_D20191001-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i02f7fbac1cd84620acf7f199e68c69d2_D20200401-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31cb706cd3d34a8f8c5550eb13fdc482_D20220331-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2ba53aa991c7496c824228ff7f76db73_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ieaf492cdb0114d0caa049a3dc713ea52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide941e50cb94438c842272441f7f7a9d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i54ca9b66117a446d97db8f7751e15718_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i47e1840cf2284314b9ab50ccca85d8dc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3dd6a4fa2af14b42a85c77bc5fc6a804_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie70bf042dd674e718cc447fc2ec12ba6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iff0d4dd7c88b4aecaeb023492578edbc_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i8a6a2cb269044ff8ba6e3aa662224738_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i97fd8177ab534173b7dff83fda1b0e42_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i2d3d451adabf4a9e939a4aa764188f34_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i15ba9115048c4b0cb334ce276b07e19f_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i4e156b6c09f3459a802a8b8b9d61246b_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5048837d2a04accb50ef68638e25287_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5017d71cfec249b39dc7bf0b2f16e8a8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6b1bdb6d04224fe9be09f756f95b5ab0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i65a8f469e2a84522ae2e22f5234508db_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9e9516c1a9cb4fb3be4969e22995bee4_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i9544a214c9f44991a2f78bb7573102e1_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="ib07fdb10b5d540cb9aedb3134847444d_D20180221-20180221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2018-02-21</startDate>
            <endDate>2018-02-21</endDate>
        </period>
    </context>
    <context id="i37c985034d924ca98f2216ba8ca4af2e_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i7c4dd0ed5ae24830b44a38ea9717cb05_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if85c5fb8e5614004b32140f219b1306a_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i4c98c9ecdddb4aa885207bc289ebb66c_D20200218-20200218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-02-18</startDate>
            <endDate>2020-02-18</endDate>
        </period>
    </context>
    <context id="i5b8fa809e4a440c2bad66de860a5fd7d_I20200218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-18</instant>
        </period>
    </context>
    <context id="i7fa6591e1e63436d87c66c1d9ccc6214_I20200220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="ib293675829044729970b8ad7871b3312_I20200306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-03-06</instant>
        </period>
    </context>
    <context id="i3efb00ba5fd74b7fab554086f72556bc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ehc:HoldingsAndEHHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if0c3b00829fa4d4e999d2af5868388c4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2f108164baf04c0891eeec5eedea407c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i109455a6fc6a45b8ac46c18c730e447c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia45c6446a6c14cb7a9ddd0a2cd90040c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0aed46c41ce046eaad78b41f59a23787_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id2768fdf72bc4ee4a44e6c72c3433df2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib6bcf1050dcf44a2be092ce5a39ac1a3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib7afd9afee71467ba27c4ef94b734857_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3782aabb4f6a4c8892fbf91aadc0bbf6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4130c6d73c9d4e2886d9e5ad5721507f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4a29bb284f84291ac766be040a1b558_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i171f20bc121a4840b1b7a626e688e5c2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MarketApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i66a6b0c4ea294ae9831e406beeaa1b02_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9b0646390aa047889e3811abde11c7d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i98081f26b7b0413894e5100ec374ac7b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i104c1230c0b9400ea5b323e382d7bf2e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i90e31655e1c843588845e5d149d3d78f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2cb6a7700bc94455b1a76981062358af_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia8ae8d59fc12411b879d99d7434e8c7a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4ca40e094ccf47d19b41a7336db5ee77_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4a0e75c4e9e143ea8c9e88f3a1327641_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia509d100e6ab4e2a9c6a5b3bc3d344dc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie58dd346723c4144a958394c28b0c3d2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i186457b966e448f8b789ee4909b7ae8d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id8c5bfe222cb48208514b96445916886_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia715c07fe5d248e9b5940e457b3706eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0cb787bf3ff4d24aa0ab14e1e0c373c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0051b03acc3e4e2986db12da328b3bac_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic19a05f81373432ca6b36a5c0470017e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3dc3ff3814494e65a5977ad5528ad3b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i934987b44af7446c8218601c95502de9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id68ab94595124a1e97f267729e976e5d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id58191662ff7460988e18540fde456ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e8394e3bcc5451cacdda373dfbbc0b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic5999223d44049ab8c9ad683173bdc2d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ief3957a1e65a4a2b85016faf016e95db_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i42640997d4454f199cf25a948fc95738_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i71f49077e01a45f097881493f89e0508_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id9d26a6364364e1a9b54ab393f994255_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib91ca67dc3504530b8450421abc7fb8a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icf31d36bee454c13a050e3f343b6a3c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice01013cd7f94c859dbdc8f630c352a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7cd83dbae36b43d7b4a6162c02698684_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id954ef15e93c4d14ae05f3cd3b278851_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i90ef0119e13b4be5826ee406b88feacb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i728449144459420bb67f2d96b87cbb5e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib34fdd3cc9e945d8af9a195dca36f84b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i455ce14d267f4b87b426320cf9bbdc10_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib6a3de203d80490b878e5ccae2d26b36_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id2152173f71549049764873566ae5676_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i29cc50ab07e74bbe9b5f86334dca8053_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic1c210278132437cbd3fe2285375e3cf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i80e176382eb04cdab88c4972bf3f6d7a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecb21c9d51d840279240febc1301d0e7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4cb38ea719844f6cb5c7d56debf66f6e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6fbf64e203144762b1d2ada6b0352efa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8958165af77d4177a1e12b5aa53be055_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i49095c84bb0c46e1bb8ad5d5e2601b49_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifbcfb44cf32548af90099a6a944afa74_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i130a002122d84a44a7f2a2f80eb06cb9_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i2c9a6e8916a642608c3dec74c2e5242b_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ehc:NicholsLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i02d74de04d0a49489fef3090ad053d4f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if254742956e843fdbdef4b70418d1d95_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4e1097dbae78496f9253f83fa0d57473_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8e7323c2241b4a16b1b13a4e1f206647_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia4085dac83c04f60a84bda9c69ca0fd4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4e018bd04e884537bdbb55709b14d86e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0d7e9389f7bb49d1937b89476ce847a4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iab84c70e34994c9dbed01b25069a83d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6fb52c020c90481fb7260d98ee51f72b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ica342deee7024b149e3a4aafeeb27c0e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifce0d088460444de9f461fc5f954104e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac44cb5b0a604e55a2dd05a02d35a226_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4b556ace711f4b07a26951c1b12a6868_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i62367bba18c143edac791ed9c0e6b12d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id5e3006bff47459eb04bfde259d0b285_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16bc1b11f6474259b5d2a6c7a7ed7d3f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i060b61eae5e141f5a0ecfd1970befba2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8a8f9f90011a4999af002b1dd34ca597_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7fc6b9fc57a843aa950bd9f011875dea_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib4eba057206a47f6ad35e724ea946fcc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b675f52d0454ca895e68f1f2ec026c3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia00b712980524ce3863212d497722fb9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic72bcc5ef89644cc8431b9901f34f714_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic3f156c397a54a5e942b4169a6555c29_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if7e0deb3678448e38f17bc49a774bc9c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8d7b86bab34f4844a928bf4006774a56_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief533155274145c69d708e96345ddceb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if5f70ec669814c3ab99525a8689c1d52_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iadc1cfae314f4bd3add26a155e7e540f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i542fad3dce5840d59dc96ad7e51d6df1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2819d470f954f05969b485651250dea_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="state">
        <measure>ehc:state</measure>
    </unit>
    <unit id="segment">
        <measure>ehc:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="bed">
        <measure>ehc:bed</measure>
    </unit>
    <unit id="entity">
        <measure>ehc:entity</measure>
    </unit>
    <unit id="hospital">
        <measure>ehc:hospital</measure>
    </unit>
    <unit id="location">
        <measure>ehc:location</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80L2ZyYWc6NGRiMzEwZjk2MDEzNDdlM2ExNzdhN2YzODlhZTYyNDIvdGFibGU6NDQyODVlZTM4MjdjNDcxOTllZjc0ZDlmYWYwZDJkMzIvdGFibGVyYW5nZTo0NDI4NWVlMzgyN2M0NzE5OWVmNzRkOWZhZjBkMmQzMl8zLTEtMS0xLTA_252bf9c4-0e09-4923-ac11-20a7bcfb9802">0000785161</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80L2ZyYWc6NGRiMzEwZjk2MDEzNDdlM2ExNzdhN2YzODlhZTYyNDIvdGFibGU6NDQyODVlZTM4MjdjNDcxOTllZjc0ZDlmYWYwZDJkMzIvdGFibGVyYW5nZTo0NDI4NWVlMzgyN2M0NzE5OWVmNzRkOWZhZjBkMmQzMl80LTEtMS0xLTA_368bf6b7-9b9f-4e72-8e58-db8555ef80b3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80L2ZyYWc6NGRiMzEwZjk2MDEzNDdlM2ExNzdhN2YzODlhZTYyNDIvdGFibGU6NDQyODVlZTM4MjdjNDcxOTllZjc0ZDlmYWYwZDJkMzIvdGFibGVyYW5nZTo0NDI4NWVlMzgyN2M0NzE5OWVmNzRkOWZhZjBkMmQzMl81LTEtMS0xLTA_b04d30f5-a9b8-462d-bd0d-5212e1d886ca">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80L2ZyYWc6NGRiMzEwZjk2MDEzNDdlM2ExNzdhN2YzODlhZTYyNDIvdGFibGU6NDQyODVlZTM4MjdjNDcxOTllZjc0ZDlmYWYwZDJkMzIvdGFibGVyYW5nZTo0NDI4NWVlMzgyN2M0NzE5OWVmNzRkOWZhZjBkMmQzMl82LTEtMS0xLTA_17ee92a1-ee1b-40f3-ab43-1eb1cfd23724">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80L2ZyYWc6NGRiMzEwZjk2MDEzNDdlM2ExNzdhN2YzODlhZTYyNDIvdGFibGU6NDQyODVlZTM4MjdjNDcxOTllZjc0ZDlmYWYwZDJkMzIvdGFibGVyYW5nZTo0NDI4NWVlMzgyN2M0NzE5OWVmNzRkOWZhZjBkMmQzMl83LTEtMS0xLTA_172e7217-5d57-488d-9bfb-a62509b80822">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTg4_94332bf5-6eda-4480-a592-085381085fac">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6NTk5NTI5Nzc5ZTE3NDViMmEzNWUwZmRhMzU5ZWRkNzAvdGFibGVyYW5nZTo1OTk1Mjk3NzllMTc0NWIyYTM1ZTBmZGEzNTllZGQ3MF8wLTAtMS0xLTA_bc442f69-c350-4c1e-8617-33c2bf6e8f82">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xNTE_080c4a3a-3217-44db-bd8a-807db94538ec">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6M2VkYWQ1ZmRjYWQyNDU5ZjhjNTc0OWQxNGIxOGYwMjMvdGFibGVyYW5nZTozZWRhZDVmZGNhZDI0NTlmOGM1NzQ5ZDE0YjE4ZjAyM18wLTAtMS0xLTA_fe330ee2-2177-4bdf-b14a-145837fc517a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTgx_2b5620d9-66d8-47c4-a555-776a71df667c">001-10315</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTk0_a85c586e-c590-4290-80f5-4c2ba2fcd608">Encompass Health Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6MjRkYWQ3NmIwMDdlNDI5MDllNGE0OWIwNjhmNThkMzkvdGFibGVyYW5nZToyNGRhZDc2YjAwN2U0MjkwOWU0YTQ5YjA2OGY1OGQzOV8wLTAtMS0xLTA_22276d43-db2c-4967-9f6c-bb2dd1e5e752">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6MjRkYWQ3NmIwMDdlNDI5MDllNGE0OWIwNjhmNThkMzkvdGFibGVyYW5nZToyNGRhZDc2YjAwN2U0MjkwOWU0YTQ5YjA2OGY1OGQzOV8wLTEtMS0xLTA_71ae9f76-a5aa-4dfc-8fb4-89a5ebf5bd67">63-0860407</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTk1_95c441ce-9299-42f6-8c22-badbfdf01745">9001 Liberty Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTgy_d56152b4-66ee-400c-906a-2b8ab1b00853">Birmingham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTk5_febbc9f2-0cad-4aed-b64c-f83f6049b07e">AL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTk2_1c9fcb99-d07f-4990-84e7-3561f05f3183">35242</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTgz_577f6458-2928-4569-b0f7-6d8941e7b510">205</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTg5_3cf7b3f0-5846-4db1-9ea8-682707046766">967-7116</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6ZjYyYmY1NmE1YTY2NGUxYThjZjEwYWM3YzJjZGExMjAvdGFibGVyYW5nZTpmNjJiZjU2YTVhNjY0ZTFhOGNmMTBhYzdjMmNkYTEyMF8xLTAtMS0xLTA_bd805ae6-7983-4b99-b695-ed88e8f6aa52">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6ZjYyYmY1NmE1YTY2NGUxYThjZjEwYWM3YzJjZGExMjAvdGFibGVyYW5nZTpmNjJiZjU2YTVhNjY0ZTFhOGNmMTBhYzdjMmNkYTEyMF8xLTEtMS0xLTA_0e3fb15f-ffc4-4c82-819b-56bdeccb7950">EHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6ZjYyYmY1NmE1YTY2NGUxYThjZjEwYWM3YzJjZGExMjAvdGFibGVyYW5nZTpmNjJiZjU2YTVhNjY0ZTFhOGNmMTBhYzdjMmNkYTEyMF8xLTItMS0xLTA_7d339095-a1f8-472e-8341-6678d071c542">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8yMDAw_244366b2-b452-4b08-88d1-946108794ba1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTkw_df9c0846-9f08-4f0a-b2a1-44d856136d63">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6NWEwNzI3M2E0MzIwNDU1N2I1YzQ4NmQ2OGJkNDdiN2UvdGFibGVyYW5nZTo1YTA3MjczYTQzMjA0NTU3YjVjNDg2ZDY4YmQ0N2I3ZV8wLTAtMS0xLTA_6b130e59-0d25-4d0e-8d47-ff5a410cd5af">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6NWEwNzI3M2E0MzIwNDU1N2I1YzQ4NmQ2OGJkNDdiN2UvdGFibGVyYW5nZTo1YTA3MjczYTQzMjA0NTU3YjVjNDg2ZDY4YmQ0N2I3ZV8xLTEtMS0xLTA_e5c4bdfa-7a3a-4110-becf-968a9e1461e7">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGFibGU6NWEwNzI3M2E0MzIwNDU1N2I1YzQ4NmQ2OGJkNDdiN2UvdGFibGVyYW5nZTo1YTA3MjczYTQzMjA0NTU3YjVjNDg2ZDY4YmQ0N2I3ZV8xLTMtMS0xLTA_22381474-ba6c-4377-ae8a-993fe4d8967e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTg0_5a74d4b6-9f25-4ae9-a41c-b7b003f19cc9">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic825b775519446e9be5f06a4c5e5d17b_I20201022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xL2ZyYWc6ZDliZWNmMjAzNDRkNDEyNzg4NGMzOGU0NmRhOTAwZGIvdGV4dHJlZ2lvbjpkOWJlY2YyMDM0NGQ0MTI3ODg0YzM4ZTQ2ZGE5MDBkYl8xOTEw_020e78b7-137c-4ede-9927-33329e6304e7"
      unitRef="shares">99432464</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMy0xLTEtMS0w_dc8147fb-89db-416f-9112-866ccfc41675"
      unitRef="usd">1173900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMy0zLTEtMS0w_0b77741f-7af0-47ce-a0be-9fdc8205d36b"
      unitRef="usd">1161600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMy01LTEtMS0w_68804db1-093d-424d-b0ec-38395e40778b"
      unitRef="usd">3430000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMy03LTEtMS0w_732558ed-adb5-44b5-a620-e2ae0d410c35"
      unitRef="usd">3420600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNS0xLTEtMS0w_07ca9ba0-a327-4d2a-b37a-156915fef851"
      unitRef="usd">664900000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNS0zLTEtMS0w_35e77557-ad33-4005-a9d8-94cb86deae9b"
      unitRef="usd">660800000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNS01LTEtMS0w_71b94e6c-3b2c-4129-8944-aa2b05cb39dc"
      unitRef="usd">1995900000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNS03LTEtMS0w_1e0fbd13-89d0-48af-bcd1-27e3c6f0ccb1"
      unitRef="usd">1904500000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNi0xLTEtMS0w_6d9d774e-0c73-4bce-9d41-06cf8518f3dd"
      unitRef="usd">163400000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNi0zLTEtMS0w_6b1bfeed-b50c-4598-90bb-a8141915de2a"
      unitRef="usd">156600000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNi01LTEtMS0w_2cce331c-2623-4519-b358-93962e4361a5"
      unitRef="usd">471300000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNi03LTEtMS0w_37671576-b25c-4a72-a807-df3b536106e2"
      unitRef="usd">456500000</us-gaap:OtherCostAndExpenseOperating>
    <ehc:OccupancyCost
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNy0xLTEtMS0w_6b0b70c5-bc3d-4ec5-9e60-69efca014e35"
      unitRef="usd">20300000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNy0zLTEtMS0w_b4631814-c59d-4349-9729-283ecbc8ccdb"
      unitRef="usd">21800000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNy01LTEtMS0w_ee6512dd-36a3-474b-b514-ec2c7fbf4671"
      unitRef="usd">60800000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNy03LTEtMS0w_c5029c10-92e7-44d6-9a28-b9ad944f90e6"
      unitRef="usd">61700000</ehc:OccupancyCost>
    <us-gaap:SuppliesExpense
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOC0xLTEtMS0w_c33c968f-8bff-4c58-a97a-62bd48743ab2"
      unitRef="usd">52500000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOC0zLTEtMS0w_7fe47cda-3cfc-4193-bd85-58e4b54f3f70"
      unitRef="usd">42900000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOC01LTEtMS0w_b1fdd5d1-0a05-4e64-9635-c8ceaad29927"
      unitRef="usd">148800000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOC03LTEtMS0w_1ee6f2b6-7915-460a-ad59-265de5fb09a0"
      unitRef="usd">124700000</us-gaap:SuppliesExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOS0xLTEtMS0w_08ad314d-f4b3-4de9-bf9f-b144c27b9562"
      unitRef="usd">39100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOS0zLTEtMS0w_1b475738-58ff-494a-b714-6cb9f48669e8"
      unitRef="usd">52500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOS01LTEtMS0w_e27bd639-b5b0-4898-ab0d-b7f0d0b41c57"
      unitRef="usd">117700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfOS03LTEtMS0w_287ce8cb-539f-4b89-9085-07150a2e8cb7"
      unitRef="usd">183000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTAtMS0xLTEtMA_cc31b030-fbe8-4827-b7da-3c462bace905"
      unitRef="usd">61200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTAtMy0xLTEtMA_e972b9b8-9d87-4898-9c89-170d376cd6f9"
      unitRef="usd">55100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTAtNS0xLTEtMA_ad89a574-3d4d-41f5-ade6-9dfba0d28ff4"
      unitRef="usd">180700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTAtNy0xLTEtMA_fc7abc65-9534-46bb-8c5c-0f70b45f0dd3"
      unitRef="usd">160300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LitigationSettlementExpense
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTEtMS0xLTEtMA_3678628a-0e5b-4280-a2de-c576afe91d81"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTEtMy0xLTEtMA_dda60c68-3076-4264-80c2-11dafe112651"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTEtNS0xLTEtMA_c0689499-a515-421b-a090-e17b5cff2190"
      unitRef="usd">2800000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTEtNy0xLTEtMA_7fd05a33-0451-45d9-a28a-86acb6700d1d"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:CostsAndExpenses
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTMtMS0xLTEtMA_b586637e-74fb-4b88-8321-94f493dc8e50"
      unitRef="usd">1001400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTMtMy0xLTEtMA_f7aaa038-04fd-4525-ae54-b4bac15305d4"
      unitRef="usd">989700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTMtNS0xLTEtMA_76c2b8d6-0bfc-457d-afa6-317edd8e4e2d"
      unitRef="usd">2978000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTMtNy0xLTEtMA_d8334a19-7759-4831-b5c1-704e71fb0099"
      unitRef="usd">2890700000</us-gaap:CostsAndExpenses>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTQtMS0xLTEtMA_9b2259f7-8cb8-4226-8bfd-6547ff381371"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTQtMy0xLTEtMA_ee780a10-bb5b-479c-8b51-647b435bd9e0"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTQtNS0xLTEtMA_fc22641e-9f98-4ea5-9a90-960ec8840913"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTQtNy0xLTEtMA_e4348f53-1516-4bb0-8207-d7a44c21c7b4"
      unitRef="usd">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpense
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTUtMS0xLTEtMA_27aeb2ad-12d2-4e7b-a63d-4e55d65b2be7"
      unitRef="usd">49000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTUtMy0xLTEtMA_3117e5b8-8906-4b55-9b90-7a3da634354c"
      unitRef="usd">40300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTUtNS0xLTEtMA_e1707c12-f47e-4531-9f70-320b37969b1c"
      unitRef="usd">138000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTUtNy0xLTEtMA_f506e2f8-d0ca-42bf-82a2-cf9888195288"
      unitRef="usd">115200000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTYtMS0xLTEtMA_47f2016c-35b1-4d80-ba0f-7d921411c797"
      unitRef="usd">2500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTYtMy0xLTEtMA_c85de7b5-a5ae-4e70-b86f-6600daf8bded"
      unitRef="usd">21000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTYtNS0xLTEtMA_da24edf1-dae4-4dad-a20a-17361fb6b48e"
      unitRef="usd">6400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTYtNy0xLTEtMA_d69d95c1-93e0-4bdd-9f87-ba33af15aade"
      unitRef="usd">26900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTctMS0xLTEtMA_e83215b8-d538-4179-aa1d-0ad3bdd3325f"
      unitRef="usd">1000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTctMy0xLTEtMA_502a6bb9-14f4-4103-93e2-ec9c734fa3f3"
      unitRef="usd">1200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTctNS0xLTEtMA_67ad95f0-1f45-49c6-bb14-9f6280a2f31f"
      unitRef="usd">2500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTctNy0xLTEtMA_10b56a6a-555d-42db-b680-7adc35e9b6b0"
      unitRef="usd">5500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTgtMS0xLTEtMA_000a3f0c-d058-4971-a572-8ad33ed5ee99"
      unitRef="usd">127000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTgtMy0xLTEtMA_aa39a579-807f-4742-bfcd-415fd3aea9a2"
      unitRef="usd">153800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTgtNS0xLTEtMA_575937ce-1a3a-4d30-8d89-8ec13a9a7a74"
      unitRef="usd">322900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTgtNy0xLTEtMA_268f6716-5810-469c-af68-027de924a85a"
      unitRef="usd">444800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTktMS0xLTEtMA_196f1051-d7bd-4d3f-9819-be0a5d232e3d"
      unitRef="usd">26900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTktMy0xLTEtMA_933def5f-c4f8-404b-85fe-da66a166dc8d"
      unitRef="usd">34300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTktNS0xLTEtMA_2118f0ea-acf6-4999-8764-7d7502440021"
      unitRef="usd">65800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMTktNy0xLTEtMA_f2c23a6a-b06f-45d2-9568-8ce1c705c752"
      unitRef="usd">88600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjAtMS0xLTEtMA_97f1a968-b381-4c6c-ab80-3722dd382c64"
      unitRef="usd">100100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjAtMy0xLTEtMA_7c09ae60-a92d-4862-a10d-4270229ebb9b"
      unitRef="usd">119500000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjAtNS0xLTEtMA_0018f62a-e16b-479b-bc20-9d6957fdf82b"
      unitRef="usd">257100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjAtNy0xLTEtMA_9b97e47c-9390-4ba6-a397-d19514e0afe7"
      unitRef="usd">356200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjEtMS0xLTEtMA_61aec65e-01e3-450b-a715-cab1e168b800"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjEtMy0xLTEtMA_e72ee539-7b0e-4254-9047-070d1a494144"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjEtNS0xLTEtMA_f8845c17-28dd-41ce-8a84-abe7b7369b45"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjEtNy0xLTEtMA_50bd1f97-1c00-41ad-b643-0ff84a121408"
      unitRef="usd">-600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItMS0xLTEtMA_384e526c-55e9-456c-9af1-ab25928c8250"
      unitRef="usd">100100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItMS0xLTEtMA_7f066a1e-0b11-4f9f-9e06-d3d1f0717bec"
      unitRef="usd">100100000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItMy0xLTEtMA_1e0e01a0-bdbf-4915-b21e-90b7b874d814"
      unitRef="usd">119500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItMy0xLTEtMA_a9a02509-2da7-44bc-8335-df956b226754"
      unitRef="usd">119500000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItNS0xLTEtMA_453ab30b-5c08-489a-afa1-c22de810a246"
      unitRef="usd">257100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItNS0xLTEtMA_aa2c4d48-044a-4e1d-af65-c9e1f8ace91c"
      unitRef="usd">257100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItNy0xLTEtMA_03006664-d2ad-460f-894a-2a0445720a05"
      unitRef="usd">355600000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjItNy0xLTEtMA_23f85370-cd49-4c05-8b48-66b9421a95bb"
      unitRef="usd">355600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtMS0xLTEtMA_3296b99e-6b83-4c8f-aea7-99f9a7d22747"
      unitRef="usd">22400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtMS0xLTEtMA_f6b62a1b-2aec-4d54-8c5b-2a5155eb7efd"
      unitRef="usd">22400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtMy0xLTEtMA_c6fa8b6a-5468-4632-ab67-b78de4a99a34"
      unitRef="usd">21900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtMy0xLTEtMA_f1d0688b-cbe9-4731-9a6f-eb4a07115592"
      unitRef="usd">21900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtNS0xLTEtMA_1422b4ed-f7ac-41f2-bd1b-9409408fce71"
      unitRef="usd">58900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtNS0xLTEtMA_809a3bff-e15e-43c9-8125-03f1c660c1c2"
      unitRef="usd">58900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtNy0xLTEtMA_1d546123-3005-4962-9593-a00feeb63906"
      unitRef="usd">64500000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjMtNy0xLTEtMA_ded5825c-bfb4-4f04-b4b7-541446ead672"
      unitRef="usd">64500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtMS0xLTEtMA_7726f083-59de-450c-93e6-9aec09726271"
      unitRef="usd">77700000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtMS0xLTEtMA_97df1cb2-75dd-43c0-afff-2b5b1c9b2e45"
      unitRef="usd">77700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtMy0xLTEtMA_2bb8c8b9-bb04-4d4d-b1c9-5a4a461b291d"
      unitRef="usd">97600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtMy0xLTEtMA_b716344e-e3c4-4937-b190-cf49fb1b82b4"
      unitRef="usd">97600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtNS0xLTEtMA_526ab746-ade9-4421-bbc4-ee2704145353"
      unitRef="usd">198200000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtNS0xLTEtMA_edf18735-93f5-477a-b900-a06a57fe7bb9"
      unitRef="usd">198200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtNy0xLTEtMA_6ced7785-38c4-4efb-a384-b94774faddcb"
      unitRef="usd">291100000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjQtNy0xLTEtMA_72b1c3eb-2756-46f5-8bbd-39f838871fcd"
      unitRef="usd">291100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjktMS0xLTEtMA_75269bea-7387-4be9-ba7c-8374684db1c5"
      unitRef="shares">98700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjktMy0xLTEtMA_0cb287e6-0c9c-405c-8b6b-ab463bec4d7d"
      unitRef="shares">97800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjktNS0xLTEtMA_3bdf9500-f06e-491f-a129-fb824d54b338"
      unitRef="shares">98500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMjktNy0xLTEtMA_3f2bbfe8-0774-4f04-896e-c4c346d53987"
      unitRef="shares">98100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzAtMS0xLTEtMA_77535d64-66b0-4794-a494-c9f09e954615"
      unitRef="shares">99900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzAtMy0xLTEtMA_e1ee1b6e-3fdb-4309-8a7d-c851aba1e1d5"
      unitRef="shares">99400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzAtNS0xLTEtMA_06ca4ff6-65ec-4ccb-a9d1-ca2cb216c16b"
      unitRef="shares">99700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzAtNy0xLTEtMA_7ab77045-9514-4a3b-8897-04c252c68253"
      unitRef="shares">99500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzMtMS0xLTEtMA_94bdaa4d-9288-4559-9a5e-7d169ca766ed"
      unitRef="usdPerShare">0.78</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzMtMy0xLTEtMA_b3a016bc-364f-4964-bb03-b6495921cc38"
      unitRef="usdPerShare">0.99</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzMtNS0xLTEtMA_639a597d-00ef-494c-a052-f48698bb696c"
      unitRef="usdPerShare">2.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzMtNy0xLTEtMA_9defde56-2454-4e72-abb1-87232d9e1a88"
      unitRef="usdPerShare">2.97</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzQtMS0xLTEtMA_0ce995c1-e344-4070-a2ca-c4cecd3b1a9b"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzQtMy0xLTEtMA_533bbbb8-c9bc-448e-b378-e9e730ea5bb5"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzQtNS0xLTEtMA_93104b06-41ac-4724-9a38-78834535111e"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzQtNy0xLTEtMA_ab8c6984-de1c-440a-8e42-822aab66285e"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzUtMS0xLTEtMA_42f6491e-52a0-4158-a3a4-688ad6360ecb"
      unitRef="usdPerShare">0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzUtMy0xLTEtMA_51f354a5-7c5f-4650-9347-6edc7ddeffb0"
      unitRef="usdPerShare">0.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzUtNS0xLTEtMA_013e5db3-1649-4bd2-acc2-f44fce51df61"
      unitRef="usdPerShare">2.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzUtNy0xLTEtMA_b8a29392-a378-4acc-b3ed-88376cdcf5bb"
      unitRef="usdPerShare">2.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzctMS0xLTEtMA_f1cccac5-f369-4ad8-aada-24394b227a1d"
      unitRef="usdPerShare">0.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzctMy0xLTEtMA_e9052588-68a1-4b06-ac2d-b94d66518016"
      unitRef="usdPerShare">0.98</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzctNS0xLTEtMA_c630441e-ff7e-42f7-8dca-35c32db51502"
      unitRef="usdPerShare">1.99</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzctNy0xLTEtMA_79b34c25-f07b-4399-9349-96c0197a7803"
      unitRef="usdPerShare">2.94</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzgtMS0xLTEtMA_ab3d25c5-d0d9-4db5-beda-8c955c0f7f25"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzgtMy0xLTEtMA_a6c65e02-2661-4809-876d-d3dde9bf3cac"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzgtNS0xLTEtMA_25fe47f0-85ea-4144-92b2-ce49f89435da"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzgtNy0xLTEtMA_569149e6-fe92-4529-ac89-877b1b0b8057"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzktMS0xLTEtMA_9dd9a89b-5d50-4b40-a4cc-8a229bc9cab4"
      unitRef="usdPerShare">0.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzktMy0xLTEtMA_8ef0823a-623a-41b0-82e5-a0734fdfec06"
      unitRef="usdPerShare">0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzktNS0xLTEtMA_8c1dd15b-d94f-4716-82e6-69ed6c09992f"
      unitRef="usdPerShare">1.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfMzktNy0xLTEtMA_f5c68be6-79e9-47aa-8083-f00f5275a6c3"
      unitRef="usdPerShare">2.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDItMS0xLTEtMA_fe8328ef-0c85-4897-891c-fe5e0ee3fc10"
      unitRef="usd">77700000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDItMy0xLTEtMA_54854104-07f1-4204-ba02-db4c565fec76"
      unitRef="usd">97600000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDItNS0xLTEtMA_27407e11-b0ea-47e0-a3d2-89d745ee1a06"
      unitRef="usd">198200000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDItNy0xLTEtMA_136477f4-cef2-44ca-8bcc-680ebc98c2a7"
      unitRef="usd">291700000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDMtMS0xLTEtMA_1149eda8-9b3a-4513-962c-96c2b7d76e85"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDMtMy0xLTEtMA_dc9503fa-8e4a-40ec-b8a6-90ade4995ce7"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDMtNS0xLTEtMA_aa1c1da6-a8bd-4704-ab2f-4f78399b73e9"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDMtNy0xLTEtMA_2cb10cf9-1a87-4798-bb00-f7b806bdd01d"
      unitRef="usd">-600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDQtMS0xLTEtMA_45386b85-6a8f-4116-9558-f53e20d08583"
      unitRef="usd">77700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDQtMy0xLTEtMA_e9c623f8-2741-41e7-a469-9627f9f0636c"
      unitRef="usd">97600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDQtNS0xLTEtMA_6a52d9d4-4fc1-41fc-92d3-e0b3949f2684"
      unitRef="usd">198200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xOS9mcmFnOjk2ZmFmNzVhNDk2ZjQwMjM5ZTRiNDM0OWViOGRjZThlL3RhYmxlOmMxNjliNDA4YzNhYjRmMjJhODNjYzliOWJkYjI5MjQ4L3RhYmxlcmFuZ2U6YzE2OWI0MDhjM2FiNGYyMmE4M2NjOWI5YmRiMjkyNDhfNDQtNy0xLTEtMA_86ec85f8-57e1-47d4-9b7f-e8aa014ea5e1"
      unitRef="usd">291100000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNC0xLTEtMS0w_1adfa618-4e91-4f91-93be-4708df5b36f5"
      unitRef="usd">450000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNC0zLTEtMS0w_5cd47fc4-d1b8-4639-b44a-0d53c5ab0650"
      unitRef="usd">94800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNS0xLTEtMS0w_15d337ec-a445-40d5-bb5e-80ce0522bfa8"
      unitRef="usd">57200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNS0zLTEtMS0w_fde08422-4b5d-4959-a0f5-b39f77b1581e"
      unitRef="usd">57400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNi0xLTEtMS0w_6c174978-44eb-4cec-9224-6be54196b65e"
      unitRef="usd">593300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNi0zLTEtMS0w_79b8a881-6ea3-4bee-b110-2c2e5c543f1c"
      unitRef="usd">506100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNy0xLTEtMS0w_51e9403d-56bf-4575-9398-a26bd380c7fb"
      unitRef="usd">73900000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfNy0zLTEtMS0w_29301840-cb77-414b-9115-3dbf105a31b3"
      unitRef="usd">97500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfOC0xLTEtMS0w_8b7ac621-9e20-44c9-a52b-31f63cca3a72"
      unitRef="usd">1174400000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfOC0zLTEtMS0w_39b4598b-f195-4bd7-8ee2-cef3f8ef63f1"
      unitRef="usd">755800000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfOS0xLTEtMS0w_0e0ef16b-b9b9-4a4a-9674-bde92bcda219"
      unitRef="usd">2094900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfOS0zLTEtMS0w_ac8d7caa-edeb-4b8f-a70b-699c4c1691a6"
      unitRef="usd">1959300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTAtMS0xLTEtMA_b4fcf783-531c-469a-8524-481fce61809d"
      unitRef="usd">267200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTAtMy0xLTEtMA_45a374d7-ea86-4d44-a14b-7533f57b23ff"
      unitRef="usd">276500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTEtMS0xLTEtMA_d30e5ed6-87ab-4c9b-b18a-cbcce20a1362"
      unitRef="usd">2318700000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTEtMy0xLTEtMA_b1d6126d-8733-4700-8b1c-fdbd6ee226fc"
      unitRef="usd">2305200000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTItMS0xLTEtMA_cb715739-a975-4bfc-880e-34bebe8224a4"
      unitRef="usd">441900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTItMy0xLTEtMA_60279774-a296-472e-8005-f8b306433f92"
      unitRef="usd">476300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTMtMS0xLTEtMA_f9f305d7-6169-4125-9f68-b2e1ce58364e"
      unitRef="usd">7500000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTMtMy0xLTEtMA_3ff9c461-1148-4d82-a432-7c8c64e73911"
      unitRef="usd">2900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTQtMS0xLTEtMA_e5a8873c-48fe-44e9-a9f0-4c2d32a60350"
      unitRef="usd">305900000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTQtMy0xLTEtMA_4fc27f2c-c98e-4ecd-9f2a-2ae3f709853f"
      unitRef="usd">304700000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMS0xLTEtMA_ebb6140b-8134-4576-8117-101988e3ab55"
      unitRef="usd">6610500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMy0xLTEtMA_4c2edf44-6da2-4948-b82c-510be11a7456"
      unitRef="usd">6080700000</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTgtMS0xLTEtMA_54df403f-2ebc-4de4-8ce6-415c33b296c0"
      unitRef="usd">37000000.0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTgtMy0xLTEtMA_2281e3e8-a17f-4aad-9625-12d633f4b2e3"
      unitRef="usd">39300000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTktMS0xLTEtMA_ae5fc12c-b14d-4690-8e90-9f01fd542e31"
      unitRef="usd">47100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTktMy0xLTEtMA_c48b527d-77cc-409b-8d9d-acd47d078889"
      unitRef="usd">40400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjAtMS0xLTEtMA_ac65daea-8947-45d9-9a4a-e8929b166b3b"
      unitRef="usd">119600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjAtMy0xLTEtMA_20616852-5e1c-4630-8a1a-bc2261533882"
      unitRef="usd">94600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjEtMS0xLTEtMA_3b9c7143-d208-43ef-b6f0-3eebde2602c1"
      unitRef="usd">478800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjEtMy0xLTEtMA_9e445b69-abe7-489c-b5f5-4751f7d20b6b"
      unitRef="usd">546700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjItMS0xLTEtMA_07234169-996c-4697-95db-637c91302b30"
      unitRef="usd">682500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjItMy0xLTEtMA_ac682c06-c4ce-4e2f-9b45-bcf1c8bdff20"
      unitRef="usd">721000000.0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjMtMS0xLTEtMA_5430e1aa-ec9a-457b-96b4-0ea201307799"
      unitRef="usd">3539400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjMtMy0xLTEtMA_154e089b-7dcd-406a-b202-4bc6cf7056ee"
      unitRef="usd">3023300000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjQtMS0xLTEtMA_e7ba1d0c-254f-4198-ae06-88e414973fc9"
      unitRef="usd">228900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjQtMy0xLTEtMA_2cf7ffc3-cc42-4b32-b5d2-252e560f3f4b"
      unitRef="usd">243800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjUtMS0xLTEtMA_9b0f245a-b99a-4760-9ee3-911ce9f1cea1"
      unitRef="usd">230000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjUtMy0xLTEtMA_b5c4a49d-960a-4529-9b58-4e237c728165"
      unitRef="usd">159900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjYtMS0xLTEtMA_acffcfd8-1d08-4da9-82a4-9bee70f126c1"
      unitRef="usd">4680800000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjYtMy0xLTEtMA_652d1f4b-3273-406c-8694-e570be63978d"
      unitRef="usd">4148000000.0</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjctMS0xLTEtMA_e17ba41d-7124-44d9-9b7e-8e17b0d0bfc7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjctMy0xLTEtMA_098b521e-5c9b-49e3-9013-75b7c02eb208"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjktMS0xLTEtMA_c76a7694-93fa-4549-a9e4-731f550d110c"
      unitRef="usd">34000000.0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMjktMy0xLTEtMA_50abcbd5-53d4-4818-9466-06517875ea7d"
      unitRef="usd">239600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:StockholdersEquity
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzEtMS0xLTEtMA_e8a9912b-3f93-473d-8de4-022cfcb7b789"
      unitRef="usd">1520800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzEtMy0xLTEtMA_4ac481be-257d-4479-b7e4-7e4652763352"
      unitRef="usd">1352200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzItMS0xLTEtMA_376598f8-1e1c-44b3-b8fe-1912524aa72f"
      unitRef="usd">374900000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzItMy0xLTEtMA_630bfafb-9ef9-451c-99c9-24bb59781d05"
      unitRef="usd">340900000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzMtMS0xLTEtMA_844d362e-e45c-4633-8051-b3eea0a9feaa"
      unitRef="usd">1895700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzMtMy0xLTEtMA_6b27c476-7fcc-4676-aedf-73ea0c323e1b"
      unitRef="usd">1693100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMS0xLTEtMA_7fe2fe5d-8a17-4f0d-b904-5da3eff95fff"
      unitRef="usd">6610500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMy0xLTEtMA_96422c3d-18b4-4626-ad92-22d400d71628"
      unitRef="usd">6080700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMTAz_e343074b-febe-4345-abc1-5fb6600a1180"
      unitRef="usd">222000000.0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMTEw_e476c36c-635b-40e3-831a-9a790b504d0f"
      unitRef="usd">215000000.0</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzA4_f545c332-fd6e-4270-a763-c8b5cf5530ed"
      unitRef="usd">44600000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzE1_83653dd3-c3b1-4c5b-956d-4b176764a4b3"
      unitRef="usd">41100000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i16b97f17d8db408195ceeadc301ddfb1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC0xLTEtMS0w_998e690d-9b9f-444c-a63b-aa30dc4a255d"
      unitRef="shares">99400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16b97f17d8db408195ceeadc301ddfb1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC0zLTEtMS0w_67e70642-aa8a-41a3-a9e5-12d317ce209c"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie736b33e93524e6286ddda20f63fb392_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC01LTEtMS0w_5ba32c73-b656-4f67-b583-ddaee34a1824"
      unitRef="usd">2362400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d86622446d240caa39846454393bef9_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC03LTEtMS0w_9eb38af1-b6e1-4aac-b72a-08b418456b55"
      unitRef="usd">-406000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i709bd3432796446cb8af88e1449a8b8a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC0xMS0xLTEtMA_2e622945-c408-4041-880d-0d11f6c91305"
      unitRef="usd">-494700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2dbc33472e04f73b22f6023e08ebc8e_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC0xMy0xLTEtMA_2ff5dff0-409b-4e22-ad35-4d000780c36e"
      unitRef="usd">368600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b16ec5f39fd426987fd267959afaf04_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNC0xNS0xLTEtMA_d0e668f3-9396-464a-9757-7d3aeaa25019"
      unitRef="usd">1831400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i22e461c575464b3faf3390da4ec357b2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNS03LTEtMS0w_628e53a1-97fc-48f5-8ce6-7e92d30eb823"
      unitRef="usd">77700000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="if0aa9d846293410c8246584aeefc69d8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNS0xMy0xLTEtMA_9986ad45-0a35-4f7b-bad2-a5c74ed44b99"
      unitRef="usd">20200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfNS0xNS0xLTEtMA_d065686b-0cc0-4e08-812c-2b329fee197f"
      unitRef="usd">97900000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfOC0wLTEtMS0wL3RleHRyZWdpb246Y2NhNmQ1NGIxOTY3NDY4ZDllN2RmMzg4MjdjZDE0NTJfMTA5OTUxMTYyNzgxNQ_180f785a-8420-4208-ab8e-7fddcba55ddc"
      unitRef="usdPerShare">0.28</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i19f0ded8fb484018a4a1c01ca5701bcd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfOC01LTEtMS0w_a85ddbf8-cc27-4c3b-a6c9-4e361320c5dd"
      unitRef="usd">28000000.0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfOC0xNS0xLTEtMA_a3314b42-b660-4144-90ad-caaaa61be534"
      unitRef="usd">28000000.0</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i19f0ded8fb484018a4a1c01ca5701bcd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTAtNS0xLTEtMA_14230624-43f2-49a0-991c-2b79d25b1eec"
      unitRef="usd">8300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTAtMTUtMS0xLTA_44b40188-11e8-4ab7-819b-f3c06585ab9e"
      unitRef="usd">8300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if0aa9d846293410c8246584aeefc69d8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTMtMTMtMS0xLTA_6b7d3556-01e1-4057-a713-387da797398b"
      unitRef="usd">21800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTMtMTUtMS0xLTA_31df272a-11f4-484b-b13b-6be16c4cc5d3"
      unitRef="usd">21800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="if0aa9d846293410c8246584aeefc69d8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTQtMTMtMS0xLTA_9fa50fec-87a1-4320-9bf2-15c2b3d47892"
      unitRef="usd">7800000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTQtMTUtMS0xLTA_2f2623d4-b29a-442f-b176-2277e424e383"
      unitRef="usd">7800000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:StockholdersEquityOther
      contextRef="i19f0ded8fb484018a4a1c01ca5701bcd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTktNS0xLTEtMA_2b77f250-94b3-4d61-a946-93bfb7b66259"
      unitRef="usd">-400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i9db578648abe46bf8900fa6e9eeff904_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTktMTEtMS0xLTA_209e017c-99e0-4c46-9503-71646b2385dd"
      unitRef="usd">400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if0aa9d846293410c8246584aeefc69d8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTktMTMtMS0xLTA_41adfb48-f136-4463-aba1-71bcc73ee17a"
      unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMTktMTUtMS0xLTA_e6d1211e-5517-42e0-a5f5-356a33eb44d1"
      unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i77e27e7871034346bd94e7d93e7781a5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtMS0xLTEtMA_870207ae-fc29-43f2-aa29-9e1646d91e45"
      unitRef="shares">99400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i77e27e7871034346bd94e7d93e7781a5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtMy0xLTEtMA_3fd09a4e-5ce8-4781-82d6-28a8e6a5f5a8"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a5ea56a23aa4f73aca3bbb27f91c6e9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtNS0xLTEtMA_666a0614-68f3-4faa-8e9a-b2ba4a5cd39c"
      unitRef="usd">2343100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42639cc7412e46f29b28dfa5b1b7fedd_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtNy0xLTEtMA_e041573f-16da-4bdc-870b-b0bafc317a06"
      unitRef="usd">-328300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i814c90a316b4443c999528ec80e7ee11_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtMTEtMS0xLTA_15e394d5-3f4e-48dc-9498-4319ad908edb"
      unitRef="usd">-495100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f2714c865b0433b81dee771e5553136_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtMTMtMS0xLTA_d3e1d3d1-1dd0-4d80-9ea5-0fe227d07bd0"
      unitRef="usd">374900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOmUwOTI0MTExYmM0YTQ4YTg4N2M1Y2I5ODQ3M2E5YjAwL3RhYmxlcmFuZ2U6ZTA5MjQxMTFiYzRhNDhhODg3YzVjYjk4NDczYTliMDBfMjAtMTUtMS0xLTA_2e93009b-fc4e-4565-bf8f-8bb10239c1ab"
      unitRef="usd">1895700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i75303561f2ef48ad8ff4e6b1651fc33f_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC0xLTEtMS0w_7a6b2caf-719f-49fb-be2e-a9f7e66e21d0"
      unitRef="shares">98600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75303561f2ef48ad8ff4e6b1651fc33f_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC0zLTEtMS0w_4d4aea73-108a-4296-a468-1e1d6e648823"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2656c38caa24df2bc08d8781a5e56b2_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC01LTEtMS0w_2edd72d2-8b37-45ac-b26d-6f9fe3b77bb6"
      unitRef="usd">2455600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6671d6f397794090a985d9d5d859cb64_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC03LTEtMS0w_32233972-4622-400d-a1b6-d656dd0a6ff2"
      unitRef="usd">-691700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e92833c9f1f4896aba1d31655bf9668_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC0xMS0xLTEtMA_47684dc8-ccb7-4e97-a06f-b173ecec6a16"
      unitRef="usd">-489100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba9d8fa1efdb4f6f928d5446c8898f66_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC0xMy0xLTEtMA_2933ab84-a70b-4e5e-8fb3-caa089b229ee"
      unitRef="usd">307900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec188c294f984c1aa5e6a6cf0c9e7af3_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNC0xNS0xLTEtMA_59bd6259-433e-4683-b8a1-ac363613eaa2"
      unitRef="usd">1583800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="if20836f1c7e2469e9f0c2603fbd54843_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNS03LTEtMS0w_f93b4b34-39ba-413c-aae7-039994c442c9"
      unitRef="usd">97600000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNS0xMy0xLTEtMA_34d0f157-a9db-481b-9646-cd82f98c259e"
      unitRef="usd">18200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNS0xNS0xLTEtMA_9a018273-2327-4f13-bfc2-2c05ec1a988e"
      unitRef="usd">115800000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i57b58b477c6b44f8aae21799d9a882d1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNy0xMS0xLTEtMA_6816e66e-1c19-4db2-bcd1-4c7e6f27491e"
      unitRef="usd">100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfNy0xNS0xLTEtMA_ce875f90-30a5-48e8-b6fa-4b8ff092bbe3"
      unitRef="usd">100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfOC0wLTEtMS01ODgvdGV4dHJlZ2lvbjo5ODdiZWQ0YjAyYjA0NmFkYTM4M2E4MDc1NWVhZjY4Ml8xMDk5NTExNjI3ODIx_4697d6ae-e822-44cf-98e1-dba1cf228f8f"
      unitRef="usdPerShare">0.28</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i59a276c6995d4d178488c77f6e17f1f0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfOC01LTEtMS0w_4e00c5a1-fb36-4634-b291-857e3cccc3ea"
      unitRef="usd">27800000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfOC0xNS0xLTEtMA_2a1b0d79-7463-4c19-8ab3-f0be4340db6f"
      unitRef="usd">27800000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i59a276c6995d4d178488c77f6e17f1f0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTAtNS0xLTEtMA_4c0d424e-e8e7-483c-98d4-735f58f18157"
      unitRef="usd">7800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTAtMTUtMS0xLTA_5c59b912-22d7-4ba8-aace-c43c8292f698"
      unitRef="usd">7800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTMtMTMtMS0xLTA_183eeb86-b232-41c4-b745-d120a955dab2"
      unitRef="usd">20200000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTMtMTUtMS0xLTA_3154e6e5-8c5a-4f5d-b768-dda03bdaea5e"
      unitRef="usd">20200000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTQtMTMtMS0xLTA_72ace4bc-6805-40bb-bc21-ba6294bab4d5"
      unitRef="usd">7200000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTQtMTUtMS0xLTA_fd0ece87-daab-4e58-9af3-ac7873343b4a"
      unitRef="usd">7200000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i59a276c6995d4d178488c77f6e17f1f0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTUtNS0xLTEtMA_24947dc4-3383-42be-bedc-1e415cfc83f9"
      unitRef="usd">-18200000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTUtMTUtMS0xLTA_86fc1f3e-fe32-430f-bfbb-d524ea5544cd"
      unitRef="usd">-18200000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTYtMTMtMS0xLTA_18ec146c-d552-4702-ad8d-ab6adec59a71"
      unitRef="usd">25000000.0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTYtMTUtMS0xLTg0NA_1c79f10d-c48d-448f-9103-19fc84a8e1f7"
      unitRef="usd">25000000.0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i3577cda3504a48d3bf46aed515f88491_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTctMS0xLTEtMA_4830d90d-7d5a-4f08-99e5-001c7dba2ca0"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i57b58b477c6b44f8aae21799d9a882d1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTctMTEtMS0xLTA_ce20153a-92d2-449b-bc63-f509464fff1e"
      unitRef="usd">2100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTctMTUtMS0xLTA_0557327e-1878-4fdd-ba39-4d1b29db2ced"
      unitRef="usd">2100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i3577cda3504a48d3bf46aed515f88491_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTktMS0xLTEtMA_d98712b7-d6a4-4fc9-a243-d8cefd7f4e7a"
      unitRef="shares">100000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i59a276c6995d4d178488c77f6e17f1f0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTktNS0xLTEtMA_1066dd3e-edfe-411a-ad93-636e82785461"
      unitRef="usd">-400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i57b58b477c6b44f8aae21799d9a882d1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTktMTEtMS0xLTA_3280bf4e-1b40-4cb6-9996-d5d8258e6f31"
      unitRef="usd">400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2057fe7fe33a44d6b3a2a669e98b3b75_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTktMTMtMS0xLTA_5f6b581a-e7c5-40ec-bb7b-6668cf929a89"
      unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMTktMTUtMS0xLTA_ac59fede-3791-403b-9d3d-2ec109b84863"
      unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0b92ed8623634131a7a34a47abf7dfb8_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtMS0xLTEtMA_95c69d9a-1de0-4fe3-9098-3b3286d53478"
      unitRef="shares">98600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b92ed8623634131a7a34a47abf7dfb8_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtMy0xLTEtMA_31885931-ef80-4a79-8f2b-f7073bd5c905"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i111ab5fcfcc24b20b042f933187dcebf_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtNS0xLTEtMA_7e0969ae-c107-4d09-b1bf-9b648f004a45"
      unitRef="usd">2417800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i361753f0507443df95849a9f371e2888_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtNy0xLTEtMA_00bcfde6-f63c-4dff-a1ee-304736346898"
      unitRef="usd">-594100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2023d91010c1475cbf531020218e9ace_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtMTEtMS0xLTA_e07ba68f-ab4a-481f-9947-f89e09aed21f"
      unitRef="usd">-491700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if66065e8c14946cd8962d13d307a0707_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtMTMtMS0xLTA_6179ead4-4f28-419d-94f2-8bafbf10e254"
      unitRef="usd">338200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80MC9mcmFnOmNlMzE2ZDFhNDRmODRiZDZhMWU0MjJlOTUzMTBhY2FiL3RhYmxlOjA4MzAxYTVjZTY5ZDQ0MjhiOTM0YWM0ZjY4ODRjZjA1L3RhYmxlcmFuZ2U6MDgzMDFhNWNlNjlkNDQyOGI5MzRhYzRmNjg4NGNmMDVfMjAtMTUtMS0xLTA_2d3b4a7a-2329-4ab0-b413-525e089ea2a3"
      unitRef="usd">1671300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ica9a466d7fcb45179986a30bd2f10e97_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC0xLTEtMS0w_45c18746-50d8-4de5-9436-ca31dbf562bb"
      unitRef="shares">98600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica9a466d7fcb45179986a30bd2f10e97_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC0zLTEtMS0w_ac5a2234-977a-4e51-bd99-18e4cc693e46"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id973fd7c00f34ecdb68ed4e62bafd936_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC01LTEtMS0w_54ae5c89-e60d-4fdb-b116-c2bc7a83e9e1"
      unitRef="usd">2369900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2180fc581434643b14bf9f6f6ec6d6f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC03LTEtMS0w_591978e6-1ce3-4bda-a026-10642ad81856"
      unitRef="usd">-526500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaeecdaf0a74142089add642599699c41_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC0xMS0xLTEtMA_25ebc9f4-98c1-4ef1-88bc-39eafa7416c4"
      unitRef="usd">-492300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e111b0b8f72431eaf24841ce8608010_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC0xMy0xLTEtMA_73a3568a-5228-4f21-89b8-727b0a1d6e81"
      unitRef="usd">340900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNC0xNS0xLTEtMA_c3f75a06-5986-477c-aa82-b799ab4ecfa9"
      unitRef="usd">1693100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i0b7aa9d337504c10b18e5c482efd7679_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNS03LTEtMS0w_687b72e3-5e11-4e13-b99c-02d56cac20bd"
      unitRef="usd">198200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ibfa62b0932f148c892a41d1e76032b17_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNS0xMy0xLTEtMA_3ad684e8-f606-406b-956a-a4b2ab019dd4"
      unitRef="usd">53200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNS0xNS0xLTEtMA_6e329818-13c8-441a-93ed-bf5705948938"
      unitRef="usd">251400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ia54e68786692437494a7725e493da451_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNi0xLTEtMS0w_97efdf1f-3382-4dff-b682-c84444e57965"
      unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ieb56e8b6eccf4d0f952421ad0f6412f9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNi0xMS0xLTEtMA_c322387d-8730-483a-9ad0-d11fc0df916d"
      unitRef="usd">15700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNi0xNS0xLTEtMA_4481d57c-7c3b-4598-9a45-4a853857e388"
      unitRef="usd">15700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNy0wLTEtMS02MTAvdGV4dHJlZ2lvbjo3NmRkZGNhOGIxZDI0OGU2OGQwYzExYmUyZTY0NjkyZl8xMDk5NTExNjI3ODE1_0d254fc6-14c7-45d9-b43f-b7c9c974efc1"
      unitRef="usdPerShare">0.84</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6f7a8b690bbf4c35bee679ec147ea72d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNy01LTEtMS0w_6290df9d-0504-45a5-9afb-ed39f1c560a6"
      unitRef="usd">83900000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfNy0xNS0xLTEtMA_2e555138-4744-4696-8ced-89d43e5634fb"
      unitRef="usd">83900000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia54e68786692437494a7725e493da451_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOC0xLTEtMS0w_38b4140e-40fc-4e35-8284-fbbdf986c3e8"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6f7a8b690bbf4c35bee679ec147ea72d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOC01LTEtMS0w_f48b5750-69ca-478d-a84b-9ff497d20e67"
      unitRef="usd">27100000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ieb56e8b6eccf4d0f952421ad0f6412f9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOC0xMS0xLTEtMA_fed121c8-3485-4f9f-96a7-522992d23c15"
      unitRef="usd">19200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOC0xNS0xLTEtMA_657d9c73-268e-445a-a4e5-aba0a000413a"
      unitRef="usd">46300000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6f7a8b690bbf4c35bee679ec147ea72d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOS01LTEtMS0w_19c64e2b-f6af-4b79-9b69-a3cb9f689ec8"
      unitRef="usd">25300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfOS0xNS0xLTEtMA_d0788865-3d4f-43d2-b6b1-e2eea4572e2f"
      unitRef="usd">25300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibfa62b0932f148c892a41d1e76032b17_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTItMTMtMS0xLTA_73f90320-c291-433a-8bab-648fdd7bbfc0"
      unitRef="usd">50900000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTItMTUtMS0xLTA_08751c9d-81df-4007-8908-260da4d73b50"
      unitRef="usd">50900000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="ibfa62b0932f148c892a41d1e76032b17_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTMtMTMtMS0xLTA_5e8a197f-3735-4525-9e9c-d8ea1e8d45c6"
      unitRef="usd">32500000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTMtMTUtMS0xLTA_4b3079c6-276b-462b-af76-3b2f5df0c802"
      unitRef="usd">32500000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ia54e68786692437494a7725e493da451_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTYtMS0xLTEtMA_021dc325-3772-42ac-b42a-3f5edf90be1f"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ieb56e8b6eccf4d0f952421ad0f6412f9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTYtMTEtMS0xLTA_419caad7-f4b8-4d53-9155-4efb682f81cc"
      unitRef="usd">4900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTYtMTUtMS0xLTA_161bea8c-ef7a-454f-b577-7aae0438aa96"
      unitRef="usd">4900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ia54e68786692437494a7725e493da451_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTgtMS0xLTEtMA_ab3dce4b-f9d3-4aa3-8e2a-ce1f0d649347"
      unitRef="shares">500000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i6f7a8b690bbf4c35bee679ec147ea72d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTgtNS0xLTEtMA_57277e66-709b-4e29-b804-72858dd6324b"
      unitRef="usd">-4700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ieb56e8b6eccf4d0f952421ad0f6412f9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTgtMTEtMS0xLTA_30941e25-efef-4c00-8d0a-5248bd16ee6c"
      unitRef="usd">1400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ibfa62b0932f148c892a41d1e76032b17_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTgtMTMtMS0xLTA_698af4b4-9597-44c5-8230-0859d78ddc0a"
      unitRef="usd">800000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTgtMTUtMS0xLTA_49ec5853-0737-4d46-b5a1-c17b00cbab56"
      unitRef="usd">-2500000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i77e27e7871034346bd94e7d93e7781a5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktMS0xLTEtMA_a027a8a2-8319-4fce-8540-0c7ee7a466d9"
      unitRef="shares">99400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i77e27e7871034346bd94e7d93e7781a5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktMy0xLTEtMA_70acb1e1-80e6-4b5d-a15d-7b867ca2473f"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a5ea56a23aa4f73aca3bbb27f91c6e9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktNS0xLTEtMA_90080e58-f73a-49de-bf6d-792454079467"
      unitRef="usd">2343100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42639cc7412e46f29b28dfa5b1b7fedd_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktNy0xLTEtMA_286e19da-1304-4b35-81ab-a0395422358e"
      unitRef="usd">-328300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i814c90a316b4443c999528ec80e7ee11_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktMTEtMS0xLTA_c2a676dc-6e17-4522-a859-2f46bde0e17e"
      unitRef="usd">-495100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f2714c865b0433b81dee771e5553136_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktMTMtMS0xLTA_fecb96a7-5489-4630-a330-05a495e9c3ba"
      unitRef="usd">374900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOmQwMmQxYWM3MzI4YjQ4OTk4MDU4ZGI2OTY3ZDk4NWVmL3RhYmxlcmFuZ2U6ZDAyZDFhYzczMjhiNDg5OTgwNThkYjY5NjdkOTg1ZWZfMTktMTUtMS0xLTA_46be5b91-24ba-4651-aeaa-09919e78b06b"
      unitRef="usd">1895700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i655f76689f4e487d80a6416983d67786_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC0xLTEtMS0w_4deedacc-0e6c-4fac-8187-01b596afcf84"
      unitRef="shares">98900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i655f76689f4e487d80a6416983d67786_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC0zLTEtMS0w_97a72690-478a-42fa-a7ce-cd053251b1b5"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8eeff91751e644a28a060a7ad7988b9b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC01LTEtMS0w_1ace3232-6c64-4e41-8cd9-31c17228bf23"
      unitRef="usd">2588700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34acebad6a69473fad71f2a9f267509d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC03LTEtMS0w_86f96fcd-84b5-453a-a7f3-2f4a5699ce1b"
      unitRef="usd">-885200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id46c52daa7f1470a96f7d883e6a8cfa5_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC0xMS0xLTEtMA_2fc5f230-2982-4753-8fda-54a154affbb9"
      unitRef="usd">-427900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4343fa926414dfb8314bc855f63f5b7_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC0xMy0xLTEtMA_856d31be-5670-4959-a454-a934fe3146a7"
      unitRef="usd">280300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id22de6a707d946778ca077c5a44462af_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNC0xNS0xLTEtMA_9f6536a4-9ab1-47a6-8317-d3d56df5c64c"
      unitRef="usd">1557000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ic8102226c2854289a3f93691bcd2de7c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNS03LTEtMS0w_f92206e8-68e6-438f-bee4-8ddd097e87be"
      unitRef="usd">291100000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNS0xMy0xLTEtMA_5ee03d80-1303-4b49-89b6-6c5152dfb01c"
      unitRef="usd">54400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNS0xNS0xLTEtMA_377e36af-b7d3-441e-b356-505e7c0502de"
      unitRef="usd">345500000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ic2623f131c3949988d9bd1994b6eadcb_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNy0xLTEtMS0w_eb126328-c247-4e26-bfb2-c8ce1a4aeafe"
      unitRef="shares">300000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if3c6ede3de4b41f086db0871d013257f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNy0xMS0xLTEtMA_15e228f1-28c8-4d70-b2bc-9bb963efbd50"
      unitRef="usd">16200000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfNy0xNS0xLTEtMA_5ef1506d-634c-4df0-a683-10b041c7dbdf"
      unitRef="usd">16200000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfOC0wLTEtMS02MzEvdGV4dHJlZ2lvbjo4MDk2NGRmYWNmNGY0OTIzYjVkNzY1M2MwZDJiNGUyYl8xMDk5NTExNjI3ODIx_64e6c624-3097-48ca-8436-ac17908528ba"
      unitRef="usdPerShare">0.82</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i744c10f6ed7148d6b5050c2d1f9af046_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfOC01LTEtMS0w_cb8f3070-0069-4c5c-8a57-f99cc9274ba5"
      unitRef="usd">81500000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfOC0xNS0xLTEtMA_44a9c442-e4ad-4362-aa8f-b3014cbcafe3"
      unitRef="usd">81500000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i744c10f6ed7148d6b5050c2d1f9af046_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTAtNS0xLTEtMA_157fb2cd-2afa-4290-9f3d-5ebd3407c0d7"
      unitRef="usd">24100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTAtMTUtMS0xLTA_52b9b290-7d45-4793-989f-e58ef4e18d8a"
      unitRef="usd">24100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTMtMTMtMS0xLTA_7552b8f6-35bc-4566-b12d-72a8841a7940"
      unitRef="usd">52800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTMtMTUtMS0xLTA_51f1702c-2e36-443e-bb22-276cb88ab387"
      unitRef="usd">52800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTQtMTMtMS0xLTA_73929832-d372-48c0-bfcb-f2e4ea055662"
      unitRef="usd">20000000.0</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTQtMTUtMS0xLTA_b82e3202-3e8f-4aab-80c1-09d877ed4434"
      unitRef="usd">20000000.0</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i744c10f6ed7148d6b5050c2d1f9af046_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTUtNS0xLTEtMA_ab83b6c5-f152-4471-b1c0-a3af64b86ee0"
      unitRef="usd">-118900000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTUtMTUtMS0xLTA_ddbd3156-7a79-4069-8b38-3a5127ac9045"
      unitRef="usd">-118900000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTYtMTMtMS0xLTE3Mg_c58139c9-524d-4dc1-b69b-11e2e4c68f47"
      unitRef="usd">25000000.0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTYtMTUtMS0xLTI2MA_1b1b9a11-3960-4598-b55d-ee392ad23091"
      unitRef="usd">25000000.0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic2623f131c3949988d9bd1994b6eadcb_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTYtMS0xLTEtMA_c1b5469e-28b8-4d8f-ab0d-6f3d71d7fb75"
      unitRef="shares">800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if3c6ede3de4b41f086db0871d013257f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTYtMTEtMS0xLTA_c3024a14-6355-4d36-bd35-a184b34872fb"
      unitRef="usd">45900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTYtMTUtMS0xLTA_f6016412-cca1-48f0-8aa9-54a9b9383332"
      unitRef="usd">45900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ic2623f131c3949988d9bd1994b6eadcb_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTgtMS0xLTEtMA_a5c6cc11-01fa-4f61-92cf-8989cf3fff5c"
      unitRef="shares">800000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i744c10f6ed7148d6b5050c2d1f9af046_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTgtNS0xLTEtMA_610d8f62-cfe5-4ceb-939b-96e3b7471e62"
      unitRef="usd">-5400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if3c6ede3de4b41f086db0871d013257f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTgtMTEtMS0xLTA_c00ea004-5068-4df0-8942-b6c90c2fd54a"
      unitRef="usd">1700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ic80f3e96c8984d77af3b5f78c5d5d946_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTgtMTMtMS0xLTA_16a50749-0ddf-46d2-8e93-5cb2528ab8d4"
      unitRef="usd">-11300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTgtMTUtMS0xLTA_3d0ec777-87be-4ffb-be91-03757d6a1214"
      unitRef="usd">-15000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0b92ed8623634131a7a34a47abf7dfb8_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktMS0xLTEtMA_ea3dbb55-b70e-491b-8e60-e6f98eb0542d"
      unitRef="shares">98600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b92ed8623634131a7a34a47abf7dfb8_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktMy0xLTEtMA_4e06d4e3-d176-4d85-9a85-5163cc6d6bc9"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i111ab5fcfcc24b20b042f933187dcebf_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktNS0xLTEtMA_8bc6c625-7be5-4f8e-8d3f-22395bc901fe"
      unitRef="usd">2417800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i361753f0507443df95849a9f371e2888_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktNy0xLTEtMA_7efcf5ff-71cd-4931-ba91-58abbf015a02"
      unitRef="usd">-594100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2023d91010c1475cbf531020218e9ace_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktMTEtMS0xLTA_570d19e0-058e-4927-b026-f89da45dcd7d"
      unitRef="usd">-491700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if66065e8c14946cd8962d13d307a0707_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktMTMtMS0xLTA_9858882f-7403-4a8f-b123-bc3c2cf2ea0f"
      unitRef="usd">338200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80My9mcmFnOmJhYTMyZGEyNmJhMDQ0NGI5NTFmOGVkYjA2Nzk0NGU4L3RhYmxlOjAzYTY2NTVjNGVkZTQwN2U5OWFjZDQ4MTQ4YTdkMmYwL3RhYmxlcmFuZ2U6MDNhNjY1NWM0ZWRlNDA3ZTk5YWNkNDgxNDhhN2QyZjBfMTktMTUtMS0xLTA_d48a0d81-447a-44de-a1a2-6ccfd30f2499"
      unitRef="usd">1671300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNC0xLTEtMS0w_8218df13-c603-4b72-8c4d-1cfa14875b75"
      unitRef="usd">257100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNC0zLTEtMS0w_3cdd8b2c-7621-4035-a3cf-7f35ab31813a"
      unitRef="usd">355600000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNS0xLTEtMS0w_191d0e03-1374-441d-9a8b-808a4f55e631"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNS0zLTEtMS0w_f4b5def5-4f8f-458a-bed9-34bb9f1054c8"
      unitRef="usd">-600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfOC0xLTEtMS0w_d1f531ea-a547-4231-b101-02314f71eea7"
      unitRef="usd">180700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfOC0zLTEtMS0w_bff7aacc-9f0f-4839-8a5a-e443ba6073e7"
      unitRef="usd">160300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfOS0xLTEtMS0w_b38d9fb7-a519-4a75-a071-6e4dd4a2f43d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfOS0zLTEtMS0w_0a060d88-43f1-4c0f-b0e3-0e06c1401a18"
      unitRef="usd">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTItMS0xLTEtMA_46d41d11-67e3-48bd-9b6c-1d554a57d644"
      unitRef="usd">25300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTItMy0xLTEtMA_e61df81f-d941-412f-bd5e-36a3a66f34eb"
      unitRef="usd">87000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTMtMS0xLTEtMA_5c4357ec-1cbf-4884-944f-f3e7a73454b8"
      unitRef="usd">-5700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTMtMy0xLTEtMA_9a4e67a8-0137-4019-a6b2-c966cd0fd12f"
      unitRef="usd">20800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTQtMS0xLTEtMA_4125abf9-5402-4e0d-ab96-94887e78cf3d"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTQtMy0xLTEtMA_ef331605-b79c-40d2-9e79-537dbe78b851"
      unitRef="usd">19200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTUtMS0xLTEtMA_34e7a63d-8eda-4a79-b51d-eb616929faff"
      unitRef="usd">-15500000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTUtMy0xLTEtMA_5655f61e-1556-420b-a389-f1ac36bd7d02"
      unitRef="usd">-2300000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTctMS0xLTEtMA_57230ff7-d8fc-4e84-8f95-e429e217b1e7"
      unitRef="usd">71800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTctMy0xLTEtMA_b964f3a5-ccf5-49a9-9a19-d3eeaf7c2c7f"
      unitRef="usd">37800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTgtMS0xLTEtMA_4a4c3c03-17b5-42b2-9afb-b56caa017cb6"
      unitRef="usd">-17300000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTgtMy0xLTEtMA_9da06a48-258f-4f15-9a88-1f2773274fd2"
      unitRef="usd">11100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTktMS0xLTEtMA_66358c2f-4aa3-42c6-ab72-52a69d999c8e"
      unitRef="usd">10300000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMTktMy0xLTEtMA_2841b0d0-348f-48c9-96e6-6ece02d79caa"
      unitRef="usd">-4200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjAtMS0xLTEtMA_328b8b49-5b5e-4f8e-97dd-74e0be2163d5"
      unitRef="usd">86700000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjAtMy0xLTEtMA_e8b10877-16b7-4ca4-ba51-6b1e48817aa2"
      unitRef="usd">-21000000.0</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjEtMS0xLTEtMA_f49e4eb4-3484-40fe-adbd-ac63ee746118"
      unitRef="usd">-200000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjEtMy0xLTEtMA_17f9dd7d-22da-43f7-b283-e7c012449ff7"
      unitRef="usd">7400000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjItMS0xLTEtMA_20f8d714-49d6-41d5-9f14-2813b10eaa83"
      unitRef="usd">-90000000.0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjItMy0xLTEtMA_0d4dee5b-c459-4fc1-88a8-9b08619054cc"
      unitRef="usd">-118700000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjMtMS0xLTEtMA_ce2830a4-c7d2-41ba-902a-b500f9d87acd"
      unitRef="usd">-200000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjMtMy0xLTEtMA_c52fa26f-afb5-473f-be78-0a3fa22fcb74"
      unitRef="usd">-4600000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjQtMS0xLTEtMA_856f61b2-a6fc-4d2d-987e-2a32b301c9c6"
      unitRef="usd">167900000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjQtMy0xLTEtMA_815d1a5b-884b-4b25-87df-be0f8d55b565"
      unitRef="usd">63500000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjUtMS0xLTEtMA_b75d631e-7bd6-44ce-a2e2-339695e00afd"
      unitRef="usd">425000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjUtMy0xLTEtMA_ba17f5e8-d761-4b0f-9865-df8a287176e5"
      unitRef="usd">419700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjctMS0xLTEtNzUw_e050a843-c0f5-465b-b2cc-43d8636623fd"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjctMy0xLTEtNzUw_6b3d63e1-f636-40a5-80b1-0ab2d7df6836"
      unitRef="usd">231200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjctMS0xLTEtMA_54ff4188-0dae-4ef5-a379-f89f6b790559"
      unitRef="usd">256200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjctMy0xLTEtMA_c25fa59d-5663-4b75-9936-13073aa7146f"
      unitRef="usd">259900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForSoftware
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjgtMS0xLTEtMA_5ffcceac-0d77-44b9-843c-db837246a784"
      unitRef="usd">5700000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMjgtMy0xLTEtMA_54db3741-924b-4fa5-8386-759328894aad"
      unitRef="usd">9200000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMzItMS0xLTEtMA_bc40ef27-1909-443c-93ca-c71f705ff7a7"
      unitRef="usd">1800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMzItMy0xLTEtMA_c6770933-a778-46bd-9c7d-2f3f5abfb66e"
      unitRef="usd">11400000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMzMtMS0xLTEtMA_4aac6577-997a-4c86-86f9-b075975e8ad0"
      unitRef="usd">-264800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfMzMtMy0xLTEtMA_5ca958bc-5c26-44d0-a5be-34eca938b702"
      unitRef="usd">-511700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDAtMS0xLTEtMA_64654c65-814f-4873-9154-8491bfda0d5b"
      unitRef="usd">592500000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDAtMy0xLTEtMA_088603f4-e15e-4494-b7e2-0cb8fbe581d1"
      unitRef="usd">1000000000.0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDEtMS0xLTEtMA_5ae14f00-9d35-45ed-8fc9-f95cea753a27"
      unitRef="usd">14700000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDEtMy0xLTEtMA_59ed9b8d-36ff-4cd1-b867-895ebd004ed0"
      unitRef="usd">115800000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDItMS0xLTEtMA_5befcb7e-3e7a-485d-a9f1-73a2fe84a9de"
      unitRef="usd">330000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDItMy0xLTEtMA_eff71a82-d5e0-4502-bd65-7b136d29443e"
      unitRef="usd">525000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDMtMS0xLTEtMA_c8bdf97a-9109-4e39-96dc-2a57f60874ab"
      unitRef="usd">375000000.0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDMtMy0xLTEtMA_658f2f43-4c7c-49d9-8348-508720cc5d20"
      unitRef="usd">555000000.0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDQtMS0xLTEtMA_043ee06b-1533-4604-8163-f176caf40fbd"
      unitRef="usd">16700000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDQtMy0xLTEtMA_35f78269-8a6e-4e1d-b6d2-37e32d48a5b6"
      unitRef="usd">14200000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDUtMS0xLTEtMA_c3a98e7d-87c6-4106-b894-d4829fcae76c"
      unitRef="usd">13500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDUtMy0xLTEtMA_d4af1592-bdfa-48f5-a919-851fce84fe41"
      unitRef="usd">15200000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDYtMS0xLTEtODMz_c79b7ef2-a860-4300-a606-a0fcf665e70b"
      unitRef="usd">15700000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDYtMy0xLTEtODMz_460161cf-7807-4898-ad5e-214edbaddd29"
      unitRef="usd">16200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDctMS0xLTEtOTE1_98c57dbf-ee24-4b76-9c64-5df500709968"
      unitRef="usd">84300000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDctMy0xLTEtOTE1_47c84b89-4206-4468-919c-1ca07f99efbc"
      unitRef="usd">81300000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDgtMS0xLTEtOTIx_bed56001-72de-4dfe-8155-0fa29163ed7f"
      unitRef="usd">52900000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDgtMy0xLTEtOTIx_2b35a74f-82de-4925-864e-15205b9a643a"
      unitRef="usd">57600000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDYtMS0xLTEtMA_609f7b2b-6573-4374-976a-e842c8eca231"
      unitRef="usd">4900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDYtMy0xLTEtMA_0f791a2b-8bb9-4606-9001-17adae5d3093"
      unitRef="usd">45900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDgtMS0xLTEtMA_6d58592e-7923-4eef-b7b1-5d5214788a30"
      unitRef="usd">162300000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNDgtMy0xLTEtMA_a22230b0-30af-4a3b-8cf6-9ccad2def94c"
      unitRef="usd">162900000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTItMS0xLTEtMA_46f13e86-59dd-4e28-97ba-c77ee96eee02"
      unitRef="usd">25800000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTItMy0xLTEtMA_b1804bde-1666-470d-940b-a8132deca87d"
      unitRef="usd">11400000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTMtMS0xLTEtMA_51dd8cb3-b734-4f49-a3db-1522087fd97e"
      unitRef="usd">208300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTMtMy0xLTEtMA_6f10125d-3712-4770-8afe-28d83b935d97"
      unitRef="usd">472300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTQtMS0xLTEtMA_913883f8-3abd-45ed-8463-028772356866"
      unitRef="usd">368500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTQtMy0xLTEtMA_17a6d01c-c706-4555-a6ff-97bb4fb952f4"
      unitRef="usd">380300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTUtMS0xLTEtMA_d3e5ee73-e798-4561-a67f-e2f5889486f9"
      unitRef="usd">159600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id22de6a707d946778ca077c5a44462af_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTUtMy0xLTEtMA_68affd75-1e54-4634-8aa5-67d6c0e6a8e3"
      unitRef="usd">133500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTYtMS0xLTEtMA_34ef2ec9-88fc-45ee-8c45-4e6eaa2e88c9"
      unitRef="usd">528100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTYtMy0xLTEtMA_df0fd174-7719-4db0-8238-3dd19c2c65ac"
      unitRef="usd">513800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTktMS0xLTEtMA_72d9cb1e-ed47-4d53-89ee-7720a49c47b2"
      unitRef="usd">94800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id22de6a707d946778ca077c5a44462af_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNTktMy0xLTEtMA_51fe780e-7bd2-4017-970a-8ee79036df3a"
      unitRef="usd">69200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjAtMS0xLTEtMA_653fa73d-fe97-40c8-b47b-36113f209180"
      unitRef="usd">57400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="id22de6a707d946778ca077c5a44462af_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjAtMy0xLTEtMA_622da362-0de3-4f98-a870-854e19e334f8"
      unitRef="usd">59000000.0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjEtMS0xLTEtMA_e45176fb-8c9b-458d-8e50-89f7a266f5ab"
      unitRef="usd">7400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id22de6a707d946778ca077c5a44462af_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjEtMy0xLTEtMA_8af4c402-1733-4acc-a836-3b5985389ea2"
      unitRef="usd">5300000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjItMS0xLTEtMA_681f1bc0-ee33-4198-b1c1-623d4f81a60d"
      unitRef="usd">159600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id22de6a707d946778ca077c5a44462af_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjItMy0xLTEtMA_304b1166-5f27-4ae1-a10f-07b33ccca497"
      unitRef="usd">133500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjQtMS0xLTEtMA_e137c47d-a289-4455-bc6e-b885803888ff"
      unitRef="usd">450000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjQtMy0xLTEtMA_0e86d5e5-8dc2-4c95-afca-cc05450505b2"
      unitRef="usd">422000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjUtMS0xLTEtMA_1d3558a4-fe75-4b78-99cd-6215626de507"
      unitRef="usd">57200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjUtMy0xLTEtMA_768e9623-7fce-47e4-90c6-a38ba290ae34"
      unitRef="usd">66800000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjYtMS0xLTEtMA_03954c82-31aa-4db4-8142-44339fa370d3"
      unitRef="usd">20900000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjYtMy0xLTEtMA_87f8e1dc-aa07-40f1-9c2e-eac6e5137485"
      unitRef="usd">25000000.0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjctMS0xLTEtMA_a351d568-a9d3-4275-a9e5-6253b5f80e62"
      unitRef="usd">528100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib1b6506fde8448a2b39adf066ab41b4d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNjctMy0xLTEtMA_5bd0e676-0388-45ec-95bb-62182d1ded58"
      unitRef="usd">513800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ehc:NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNzAtMS0xLTEtMA_1a18e0e8-aa53-4cb4-8ba9-566f48269062"
      unitRef="usd">0</ehc:NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate>
    <ehc:NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF80Ni9mcmFnOjVhY2YyOTUzYTg3OTQzYjc5MzczYjlhNzFhYWI2ZjFjL3RhYmxlOjkzNjM0OWVmMTk2ZDQ3Mzc5NTMxMzBhYzU5Zjk2OGYyL3RhYmxlcmFuZ2U6OTM2MzQ5ZWYxOTZkNDczNzk1MzEzMGFjNTlmOTY4ZjJfNzAtMy0xLTEtMA_faa88752-b8d1-4714-9687-531581c974a1"
      unitRef="usd">349400000</ehc:NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81Mi9mcmFnOjc1YzFhYWY4YjI5ZTRhMjVhMTgxOGJmMDMwNDQyMDg0L3RleHRyZWdpb246NzVjMWFhZjhiMjllNGEyNWExODE4YmYwMzA0NDIwODRfMjA4NQ_ec9ccbff-937d-498b-a5c8-eb80309f37a2">Basis of Presentation&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is one of the nation&#x2019;s largest providers of post-acute healthcare services, offering both facility-based and home-based patient services in 39 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using two reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. See also Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Encompass Health Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes contained in Encompass Health&#x2019;s Annual Report on Form&#160;10-K filed with the United States Securities and Exchange Commission on February&#160;27, 2020 (the &#x201c;2019 Form 10&#x2011;K&#x201d;). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December&#160;31, 2019 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of an amendment to the joint venture agreement related to Yuma Rehabilitation Hospital, the accounting for this hospital changed from the equity method of accounting to a consolidated entity effective July 1, 2019. The amendment revised certain participatory rights held by our joint venture partner resulting in Encompass Health gaining control of this entity from an accounting perspective. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. The consolidation of Yuma Rehabilitation Hospital did not have a material impact on our financial position, results of operations, or cash flows. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; increased by $24.9&#160;million and we recorded a $19.2&#160;million gain as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the three and nine months ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Operating Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by payor source and segment are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,396.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,577.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,420.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Medicare Administrative Contractors, under programs known as &#x201c;widespread probes&#x201d;, have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute or &#x201c;appeal&#x201d; most of these denials, and for claims we choose to take to administrative law judge (&#x201c;ALJ&#x201d;) hearings, we have historically experienced a success rate of 70%. This historical success rate is a component of our estimate of transaction price utilized in determining &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#x201c;OMHA&#x201d;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. If current OHMA practices continue, an increased number of unfavorable ALJ decisions could have a negative effect on our long-term ALJ success rate. We are exploring various remedies to counter such negative effects. We believe it is too early to determine what impact, if any, these recent changes in the appeals process will have on our historical success rate or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;See Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to the consolidated financial statements accompanying the&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019 Form 10-K for our policy related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;novel coronavirus disease 2019 (&#x201c;COVID-19&#x201d;) pandemic&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has caused a disruption to our nation&#x2019;s healthcare system. Such disruption includes reductions in the availability of personal protective equipment (&#x201c;PPE&#x201d;) to prevent spread of the disease during patient treatment and increases in the cost of PPE. Elective procedures were postponed by physicians and acute-care hospitals and limited by governmental order to preserve capacity for the expected volume of COVID-19 patients and reduce the risk of the spread of COVID-19. Initially, these postponements and limitations were widespread. Now, they are more market or state specific and driven by the extent of the pandemic in those areas. Beginning in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; mid-March and continuing into the second and third quarters, we experienced decreased volumes in both segments which we believe resulted from a number of conditions related to the COVID-19 pandemic including: lower acute-care hospital censuses due to the deferral of elective surgeries and shelter-in-place orders, restrictive visitation policies in place at acute-care hospitals that severely limit access to patients and caregivers by our clinical rehabilitation liaisons and care transition coordinators, lock downs of assisted living facilities that prevent our home care and hospice clinicians and other care providers from visiting patients, and heightened anxiety among patients and their family members regarding the risk of exposure to COVID-19 during acute-care and post-acute care treatment. In the home health and hospice segment, we also experienced decreases in visits per episode and institutional referrals because of the COVID-19 pandemic, both of which negatively impacted pricing for home health.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March and April 2020, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;federal government began to undertake numerous legislative and regulatory initiatives designed to provide relief to the healthcare industry during the COVID-19 pandemic&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. A specific initiative impacting us is the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#x201c;CARES Act&#x201d;) which&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; temporaril&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;y suspends the automatic 2% reduction of Medicare program payments known as &#x201c;sequestration&#x201d; for the period of May 1 through December 31, 2020 and authorizes the cash distribution of relief funds from the United States Department of Health and Human Services (&#x201c;HHS&#x201d;) to healthcare providers in response to the COVID-19 pandemic. On April 10, 2020, HHS began distributing CARES Act relief funds, for which we did not apply, to various of our bank accounts. We refused the CARES Act relief funds, and our banks returned all the funds to HHS. We intend to refuse any additional CARES Act relief funds distributed in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, the CARES Act and a series of waivers and guidance issued by the Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;) suspend various Medicare patient coverage criteria and documentation and care requirements in an effort to provide regulatory relief until the public health emergency for the COVID-19 pandemic has ended. For inpatient rehabilitation, the regulatory relief includes the temporary suspension of the requirement that patients must be able to tolerate a minimum of three hours of therapy per day for five days per week, waiver of certain of the requirements that at least 60% of a facility&#x2019;s patients must have a diagnosis from at least 1 of 13 specified medical conditions, and waiver of the requirement for a physician to conduct and document a post-admission evaluation (as part of the Notice of Final Rulemaking for Fiscal Year 2021 for inpatient rehabilitation facilities under the inpatient rehabilitation facility prospective payment system, CMS removed the post-admission evaluation requirement from the inpatient rehabilitation coverage criteria effective October 1, 2020). In addition, the requirement of physician face-to-face visits at least three days a week may be fulfilled using telehealth. For home health, the relief includes the allowance of nurse practitioners and physician assistants under certain conditions to certify, establish and periodically review the plan of care, as well as supervise the provision of items and services for beneficiaries under the Medicare home health benefit and expands the use of telehealth. Additionally, CMS expanded the definition of &#x201c;homebound&#x201d; to include patients needing skilled services who are homebound due solely to their COVID-19 diagnosis or patients susceptible to contract COVID-19. For hospice, the relief includes the temporary waiver of the requirement to use volunteers and to conduct a nurse visit every two weeks to evaluate aides, as well as the expanded use of telehealth for routine services and patient recertification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in April 2020, we amended our credit agreement primarily to provide covenant relief due to business disruptions from the COVID-19 pandemic. The amendment included, among other things, the carve-out of the COVID-19 pandemic from the definition of material adverse effect for 364 days and modifications to the interest coverage and leverage ratios under the agreement. &lt;/span&gt;&lt;/div&gt;The foregoing and other disruptions to our business as a result of the COVID-19 pandemic have had and are likely to continue to have an adverse effect on our business and could have a material adverse effect on our business, results of operations, financial condition and cash flows.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In June 2016, the FASB issued ASU 2016-13, &#x201c;Financial Instruments &#x2013; Credit Losses (Topic 326),&#x201d; which provides guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new guidance was effective for us beginning January 1, 2020. The adoption of this guidance resulted in an immaterial change to our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-15, &#x201c;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&#x201d; The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The new guidance was effective for us beginning January 1, 2020. The adoption of this guidance did not have a material impact to our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Securities and Exchange Commission adopted final rules that amend the financial disclosure requirements in Rule 3-10 of Regulation S-X for guarantors of registered debt securities and subsidiary issuers. The new rules are effective January 4, 2021, but early adoption is permitted. The new rules permit alternative disclosures of summarized financial information, rather than our previous footnote presentation of condensed consolidating financial statements. The new rules also permit the summarized financial information and related disclosures to be presented outside of the condensed consolidated financial statements and accompanying notes. We elected to early adopt the new rules effective July 1, 2020. The summarized financial information and related disclosures are presented in Item 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of this report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In December 2019, the FASB issued ASU 2019-12, &#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#x201d; The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. Either prospective or retrospective transition of this standard is dependent upon the specific amendments. The new guidance is effective for us beginning January&#160;1, 2021, including interim periods within that reporting period. Early adoption is permitted. We continue to review the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81Mi9mcmFnOjc1YzFhYWY4YjI5ZTRhMjVhMTgxOGJmMDMwNDQyMDg0L3RleHRyZWdpb246NzVjMWFhZjhiMjllNGEyNWExODE4YmYwMzA0NDIwODRfMjYw_8810ac3b-14a8-4ef6-b3b9-e7cf6f1eb02d"
      unitRef="state">39</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81Mi9mcmFnOjc1YzFhYWY4YjI5ZTRhMjVhMTgxOGJmMDMwNDQyMDg0L3RleHRyZWdpb246NzVjMWFhZjhiMjllNGEyNWExODE4YmYwMzA0NDIwODRfNDU1_5a541ede-859a-4799-a6aa-ca6f33bcfb0c"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xODY5L2ZyYWc6YzYwYWY4OWRmZTMyNGMxYmE0ZTkxOWQ3YzM0ODFhN2EvdGV4dHJlZ2lvbjpjNjBhZjg5ZGZlMzI0YzFiYTRlOTE5ZDdjMzQ4MWE3YV8xNDg0MzQwNjk3NzA5Mw_4497d6ed-be6a-41dd-92d2-fb81c6ce9c82"
      unitRef="usd">24900000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xODY5L2ZyYWc6YzYwYWY4OWRmZTMyNGMxYmE0ZTkxOWQ3YzM0ODFhN2EvdGV4dHJlZ2lvbjpjNjBhZjg5ZGZlMzI0YzFiYTRlOTE5ZDdjMzQ4MWE3YV8xNDg0MzQwNjk3NzA5Mw_d837081a-f9d2-444f-919c-a36b4151f941"
      unitRef="usd">24900000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xODY5L2ZyYWc6YzYwYWY4OWRmZTMyNGMxYmE0ZTkxOWQ3YzM0ODFhN2EvdGV4dHJlZ2lvbjpjNjBhZjg5ZGZlMzI0YzFiYTRlOTE5ZDdjMzQ4MWE3YV8xNDg0MzQwNjk3NzEwOA_2ff56e7e-61e7-4156-a253-c151f2da6586"
      unitRef="usd">19200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xODY5L2ZyYWc6YzYwYWY4OWRmZTMyNGMxYmE0ZTkxOWQ3YzM0ODFhN2EvdGV4dHJlZ2lvbjpjNjBhZjg5ZGZlMzI0YzFiYTRlOTE5ZDdjMzQ4MWE3YV8xNDg0MzQwNjk3NzEwOA_b7215e26-6515-4020-881b-47b06c26c34f"
      unitRef="usd">19200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RleHRyZWdpb246NTFkMWQ4ZDEzMTVhNGFiOGJiMmY2MjdjZDllNzFlZmFfMjY4_2c75484c-a78d-4a3a-8ca4-c324451d8871">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by payor source and segment are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,396.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,577.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,420.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5873889771684c2cae78023b5cec4fc8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy0xLTEtMS0w_40c0b7a6-3197-4a0e-b56a-18f1e6f886aa"
      unitRef="usd">592400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b66c244e6394649b16c65e6c1d17603_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy0zLTEtMS0w_60007d2e-2214-4374-bb9c-89d98c10e00e"
      unitRef="usd">624500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9eac552610d74721a0767d8c2e8f4b7d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy01LTEtMS0w_61733802-3871-48ae-9ac4-b5bb2e6ff81a"
      unitRef="usd">228600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cc0e8dca788458691540d426154ef62_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy03LTEtMS0w_04f0228c-d576-4fa9-a9c5-6c98eb4494ee"
      unitRef="usd">248400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb9260dccfc4ad9a9987f170f8a116b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy05LTEtMS0w_33dccd16-f8ec-4003-9b0a-eb2b33520944"
      unitRef="usd">821000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4591d2e05d1482594d3f6804849a4e2_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMy0xMS0xLTEtMA_6207999e-2e7a-442d-994f-ad76282ce8b2"
      unitRef="usd">872900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88d947760b414ceface797d75918f6c3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC0xLTEtMS0w_fef55798-4857-46b4-a92b-734873a45f03"
      unitRef="usd">141100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77665009ef8c4684bcb85139cafb06dc_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC0zLTEtMS0w_af0bcda8-acda-4d37-979c-32e69e834f58"
      unitRef="usd">94700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i322a014d46954ce696d8d8480f860d21_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC01LTEtMS0w_69598ab5-28f0-444c-a2e9-98bca49e978f"
      unitRef="usd">29600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4550c4ea110e4f929a058f20551c7afb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC03LTEtMS0w_ce376e7f-e685-490a-8162-c61bbeacbea6"
      unitRef="usd">25200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51235bf4750c4c599d6756b7879a4939_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC05LTEtMS0w_8deea67a-f5a8-4b1a-bdb8-db58df6fd2cc"
      unitRef="usd">170700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5f0a3577bda4c609eb02fe086530d48_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNC0xMS0xLTEtMA_1f816cc3-4e8b-4ef5-bcdb-bf9a6fb3af9a"
      unitRef="usd">119900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5c5802675ee44e99fb4499efcd6b2c8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS0xLTEtMS0w_88a6f377-eca6-4c72-ad43-6aa18c8540dd"
      unitRef="usd">95900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i345e73d6d939476ba32049426ba68d70_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS0zLTEtMS0w_bbb7bd0b-8d77-47df-ac90-f0194cf30390"
      unitRef="usd">87300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc0c26b5364d4089bd5ce943f4309664_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS01LTEtMS0w_dcaa4849-9f02-45ec-8790-db81a956f2bc"
      unitRef="usd">12400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5524ac2905524e6d812a13eb8e579d18_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS03LTEtMS0w_706144d4-a393-4652-9916-3f78befb956b"
      unitRef="usd">10400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i992298aaa6ce4481ae6d6fa2fdebef80_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS05LTEtMS0w_6bcee4f1-d995-442b-b7d3-0fcaacbdf600"
      unitRef="usd">108300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17489ebe48064383942c0df2df3d5443_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNS0xMS0xLTEtMA_d1c5230a-7303-4747-a41a-09295fe12e6f"
      unitRef="usd">97700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b6e3a1ee04d4f429b30592defb5a698_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi0xLTEtMS0w_6469da22-cc5c-46c9-a6be-9b37b997d4a3"
      unitRef="usd">38400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6370fbb51164f019e9009265116e84e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi0zLTEtMS0w_c3a99d61-5bc9-4d28-a01a-f0349e5f7c0e"
      unitRef="usd">28000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib894026d74674e5f96d404bb4cfc3b09_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi01LTEtMS0w_1f3651bb-3a27-4644-9189-86dec72c6bbe"
      unitRef="usd">3300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i732c02fb17ea40ad9e61516625f6ebc5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi03LTEtMS0w_ee937224-5f3d-4696-b09e-1bd30374855c"
      unitRef="usd">4800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2d4e1ad64bc4d1daff8885a47a9ffa4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi05LTEtMS0w_200d7cfe-2f92-47f8-9142-5a107f0f716c"
      unitRef="usd">41700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d73a08c42ae41178ddeba3a203ab25f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNi0xMS0xLTEtMA_8acef972-20ab-4079-97b0-c244e016939b"
      unitRef="usd">32800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43ec8761fcd64c49b38ddf4391322512_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy0xLTEtMS0w_8caa09ac-045c-40c3-a107-8d365a833292"
      unitRef="usd">10800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idabd0dd54725446c9f81802c9a397c00_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy0zLTEtMS0w_3e233753-3618-41d3-9d45-6e6cf0b78d11"
      unitRef="usd">12100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ac15f62994f4ba29f3f686482654b89_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy01LTEtMS0w_77e71bb8-6d48-43cd-a92d-f56be5f7af4e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfd12a6455e04deeaa0f18ba31b44fad_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy03LTEtMS0w_40bdc72b-f561-49ca-9531-6309c1e571c1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69c117f071984988883a0aca1685756b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy05LTEtMS0w_4c98f6d0-e660-4a4a-b73c-2b85dd9bc063"
      unitRef="usd">10800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97bbbbdd86244b42975499d324035936_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfNy0xMS0xLTEtMA_912914c4-0559-4ffa-a1c6-4af43dff9617"
      unitRef="usd">12100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ef53d5ff22046d0bb56bf2117a9ff75_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC0xLTEtMS0w_ccbdc7fc-d8c1-4bd7-9d0c-a6dbe33fd429"
      unitRef="usd">4600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4541f86f6464425ca691fe14b5d7e823_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC0zLTEtMS0w_e568c969-692f-49d2-987d-4cacbb265afe"
      unitRef="usd">6900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd8e538bfc2e4ff8bd996ad27939cca6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC01LTEtMS0w_04f3344d-6101-41e1-be9d-9826ec28ad47"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaefd1a522f844a7aff1af78d82fd07e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC03LTEtMS0w_bd86fc7d-f35a-4407-93d3-a1794c5a4ba8"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2279c50c6c004924ab551e8bdb047c89_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC05LTEtMS0w_432d9cc3-9257-471a-b58d-7c544482933a"
      unitRef="usd">4900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77b51433b8594e0fb5df286fd380aac0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOC0xMS0xLTEtMA_6dc97ce0-6ec4-4cbe-a98e-8bc2f362e58e"
      unitRef="usd">7200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6a7ea8ec1664d5583fcb48015255e0e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS0xLTEtMS0w_f17b2966-2d15-4576-ac52-dc36b3af958d"
      unitRef="usd">5100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3ed726963d947acb35515778bbe3f2d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS0zLTEtMS0w_dec510e4-8f07-485d-a6f6-2725383dbf0d"
      unitRef="usd">6100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if015466e48914fd08001b347cd2dc00b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS01LTEtMS0w_a7bffaa4-8975-4b1d-bc1b-04c650f54011"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0f354ef81c74b3e906182037853d5ec_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS03LTEtMS0w_20c7b98e-12a3-4e24-b9ed-983573e1b1c5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i694c2f12494e432eac4cc3d84cfad62c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS05LTEtMS0w_2d810446-0310-455f-be31-b147195d8dc2"
      unitRef="usd">5300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46f9a922335944feb38605cd28479c87_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfOS0xMS0xLTEtMA_92d55125-2f89-413c-bbfb-33e84f601b0d"
      unitRef="usd">6100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d1805e49bad499d82a78e70a324756e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtMS0xLTEtMA_371b7d98-b746-4bba-bfc3-5644f83e1557"
      unitRef="usd">11100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ea5b28aef1345628308b8cd50db8b8e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtMy0xLTEtMA_4293853c-a7ba-4f17-8d29-1edc15a7d7e0"
      unitRef="usd">12700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i040e0067c9094904af97de3099bebb5f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtNS0xLTEtMA_30002dd5-8289-4651-a1f3-c4e2b5f7a615"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53b94005181d46348addb4f79179e077_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtNy0xLTEtMA_b41cbfbd-aafd-4397-a997-9e31d00022d1"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica170b9067d145f1a3adaa78a1913f4c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtOS0xLTEtMA_6073b293-ac40-4d11-9233-c280858371b6"
      unitRef="usd">11200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9274fa4448545fa95f5a18d72345a7e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTAtMTEtMS0xLTA_935e34e6-4260-4296-afcf-818d7360a854"
      unitRef="usd">12900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtMS0xLTEtMA_318253b1-e883-406f-b75b-d548bcf8ac26"
      unitRef="usd">899400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtMy0xLTEtMA_9e1c1dea-29a3-4624-a70c-5a98fd569d90"
      unitRef="usd">872300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtNS0xLTEtMA_1f70d1e2-deb8-420b-bbd3-dabe9f0f1de8"
      unitRef="usd">274500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtNy0xLTEtMA_031b4219-3e2b-4dff-9d22-ffaa0ee88d14"
      unitRef="usd">289300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtOS0xLTEtMA_64eb21cc-947d-4bf0-a0c2-6d7bbfdf34e0"
      unitRef="usd">1173900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOmZkZDdhMzA1N2UxZTRiZDI4YTY2NWRiOWYzNmMwM2Y3L3RhYmxlcmFuZ2U6ZmRkN2EzMDU3ZTFlNGJkMjhhNjY1ZGI5ZjM2YzAzZjdfMTEtMTEtMS0xLTA_6fdaa2fe-a8f2-4918-acd2-90ef2f5fd36a"
      unitRef="usd">1161600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i786f1ca5dc7149449a23ecb8c8d45527_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy0xLTEtMS0w_59061b40-f150-430a-a9c2-d688a6471414"
      unitRef="usd">1738100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09b152c7501b43ae9e8f226b1846e828_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy0zLTEtMS0w_35f7492b-e5d9-4fbf-99cb-176466306ea6"
      unitRef="usd">1892800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6303df3106440f089bd9b6a43b82d6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy01LTEtMS0w_fa8b87f8-f0e7-4bb3-a5c5-480584ef45f6"
      unitRef="usd">658800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i110e86db8c9843af98b966b2ffda9577_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy03LTEtMS0w_c3d8e96d-9fdb-4438-8074-46de2703ee81"
      unitRef="usd">684400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i573b526d23014691a9fbcc99b22c39fd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy05LTEtMS0w_0e949620-0e53-49f3-8059-7a9ee7f2f501"
      unitRef="usd">2396900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i476f0404ddd94cadb700f8b16900ee5a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMy0xMS0xLTEtMA_f4c4fba6-a83b-4b9b-b760-8e7debfbd0c9"
      unitRef="usd">2577200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f9bdde56e16463b988f64934c46d7c7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC0xLTEtMS0w_e2c7d696-355b-4c82-8307-36c02d987d9b"
      unitRef="usd">418200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac3ba654254a43e8aa2ac93fcdf11d2a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC0zLTEtMS0w_d85c1864-6682-4e0b-9688-6edf6bf7990b"
      unitRef="usd">276200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3c3d4ee236a4d4cb2625cc617ee83e3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC01LTEtMS0w_5c122c6d-68a0-4f77-a9b3-8523eefe80d5"
      unitRef="usd">88300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4fa52ee1d974b97bae8afb7aa7d412e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC03LTEtMS0w_4bc36e6b-ab8d-4e12-8596-f7971157eddd"
      unitRef="usd">77400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cb123f9a5b744a79f1bc96d6320a60f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC05LTEtMS0w_38370f4c-f2cc-4eda-ae9c-1f346b5421d8"
      unitRef="usd">506500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cf1c4c55ac84c38b5a62a045e25c279_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNC0xMS0xLTEtMA_f52c4915-e4fd-493c-bafb-11f60620918c"
      unitRef="usd">353600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i413089dc6a054eca94c13747f4f64efc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS0xLTEtMS0w_0aa168eb-c8b3-4300-8010-d12059ecf631"
      unitRef="usd">274300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91952fdfd623406fae39f30682f9061b_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS0zLTEtMS0w_c5d7a9de-1e60-43f1-81de-a549d3888f87"
      unitRef="usd">257500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i824f669848e64d61b82896e206f54278_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS01LTEtMS0w_b5870039-4016-47c5-871f-054f92d42ca6"
      unitRef="usd">35900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9db501b105224f719473dd493715a2a6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS03LTEtMS0w_91a25c27-7bdd-4c5c-87a5-e5a14666b0fc"
      unitRef="usd">26700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaab07423dc1c456ba919a6f038750cbc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS05LTEtMS0w_942c7e7b-8c83-4bee-9abe-10997799e391"
      unitRef="usd">310200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b8e309cf85040a28f0109ed6a570c17_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNS0xMS0xLTEtMA_0a030e9b-4f6f-467a-8aae-f57a41a0a3e1"
      unitRef="usd">284200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b3869c9910a4b0691c07e0cceb1ad09_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi0xLTEtMS0w_d6329d24-c594-4176-ab1a-e9a0140343d9"
      unitRef="usd">103700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia66f0eef25f94b08b660e5e2ee7255f9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi0zLTEtMS0w_70cea430-b87a-4823-8753-7ca09945e604"
      unitRef="usd">81400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica29f20acf9c41c69b1152541cad96dd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi01LTEtMS0w_ea8f2848-8ba1-4ddc-86a6-fcf718480570"
      unitRef="usd">11700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6ed9c2b17fe42f6a52a5c962bde16a7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi03LTEtMS0w_8f823911-3201-4f31-8a07-9adefc5e1c82"
      unitRef="usd">13800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35ad441b632046c092723ff744dbd45a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi05LTEtMS0w_2e0d4f93-c0ac-400b-9238-38d8b3c03618"
      unitRef="usd">115400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie258e26fd75b4ed780d94575a67a5b1a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNi0xMS0xLTEtMA_4c1121dd-04e5-48ba-9e1a-92c4f19b293b"
      unitRef="usd">95200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a268959462c498a9cb35520cf233b92_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy0xLTEtMS0w_c222d83e-1db8-4925-87a1-e48fe8c8a040"
      unitRef="usd">31100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bbc1f21caa34ceb8709c3862095c706_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy0zLTEtMS0w_1db66a69-0ae0-475f-b4e3-9d6346d5c42d"
      unitRef="usd">32600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7f10e410cd6492ea62746dcbe08ed80_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy01LTEtMS0w_d91a4d49-3922-47f5-90ca-7b2acceec982"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaabb8c23a4b647edae1f42bce9eadd72_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy03LTEtMS0w_6d5abb4b-0068-4b26-a1da-063db208c002"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa215d6614464fd0a8b6f316d94f43c2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy05LTEtMS0w_bb6302e7-8838-4482-8474-704b61d6a46a"
      unitRef="usd">31100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2c160d712eb475cada54fe76f2c249a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfNy0xMS0xLTEtMA_9cfc0b9c-bfa0-40e2-9dab-79ede366592f"
      unitRef="usd">32600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if00c6bc809b1468f8c5e1fd14713e9de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC0xLTEtMS0w_8f471cb3-8ecd-4a50-b4c5-891115625e65"
      unitRef="usd">15700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3594d867ccaa4a45baee188e9b52d0ef_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC0zLTEtMS0w_57d23f8d-f268-4abb-abcf-c774673168e2"
      unitRef="usd">21600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if75b0cdfb90148b7b50327f55b2b4c05_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC01LTEtMS0w_96e3bd4a-85c9-462a-810c-9d8ff21c5e63"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c565f1d2caf41e5ad304df1e404ec13_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC03LTEtMS0w_eab59852-d423-408d-9f05-d25f199d904f"
      unitRef="usd">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if67c608503ce4f62b40fed8996b085cc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC05LTEtMS0w_4cd8c6cb-7ed8-4c5f-b09a-2af9531891a0"
      unitRef="usd">16500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7aceeeed5320482e9848586c21bfec7a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOC0xMS0xLTEtMA_1685f40b-c7ef-4137-88db-f1ed8bae102f"
      unitRef="usd">22300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4f3d5a74c95403bb0c19dace55fa0e4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS0xLTEtMS0w_f4600ee4-34f8-408c-8c8e-adc9ebe95aa7"
      unitRef="usd">14800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1f3913477cf4583aabab55a753c76e7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS0zLTEtMS0w_cd3b75c9-5dae-44bd-870e-2e6381f64a4d"
      unitRef="usd">17800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fa310487b624ab3abfe31fac6c6eae8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS01LTEtMS0w_f8d35ab0-b241-4cd5-8924-c7f69dd25c8b"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7e0c420dd3740c9b36010b9f1facfaa_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS03LTEtMS0w_ebe1f89b-a8e7-4259-81b0-e1af92fb125b"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4034d7e50f5c43f5960d10776b6b7bf4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS05LTEtMS0w_848d68fd-d6ac-47e6-98c5-44f466d1e67b"
      unitRef="usd">15700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1118ce1a69f43f0aa8ff017adb7d860_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfOS0xMS0xLTEtMA_8f3628bc-91b4-4426-8c36-804838dffac9"
      unitRef="usd">18300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d6897c3387c46f0b25a5ce68caf3780_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtMS0xLTEtMA_1f3952fb-efb5-4989-9738-f5a7efdc602e"
      unitRef="usd">37200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97911a33afcc4eb1b3bb2cf52223db83_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtMy0xLTEtMA_3d182abe-5b41-4d5a-b1cc-d6c0a27510ab"
      unitRef="usd">36400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e799fccf1b749bdb9a2fe12fa808cee_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtNS0xLTEtMA_3c3f3782-e4f6-48a4-8f3f-4ff6a949a7b1"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64dcfb692db141e38d22fc8b004d9924_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtNy0xLTEtMA_42605935-cefa-41e3-9a18-a23027dc7ed5"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99a8ead0bbbc4ac8baa360ca8dd8f1d0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtOS0xLTEtMA_3e6977f6-a3d6-4ed3-a667-49fd6958a1f3"
      unitRef="usd">37700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fbcb67b95b64900b8e58638b2420b02_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTAtMTEtMS0xLTA_04569171-f33a-4d27-9d7e-59fe89451fa8"
      unitRef="usd">37200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtMS0xLTEtMA_e327f1bd-9b4d-4165-973a-2392e9051b89"
      unitRef="usd">2633100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtMy0xLTEtMA_02f1b632-3266-4f9a-a154-9fdb336d64b9"
      unitRef="usd">2616300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtNS0xLTEtMA_59e550e0-367b-4947-8abc-cf48760276d2"
      unitRef="usd">796900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtNy0xLTEtMA_b4642c8f-8c65-4a3d-b53b-2e6b950a66bc"
      unitRef="usd">804300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtOS0xLTEtMA_fb4135e2-32dd-40e5-96e6-40c9575f5114"
      unitRef="usd">3430000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RhYmxlOjU4ZDkwMWVmZWRhYTQ3NjFhMjEwYWNlZDljNzM0NjMyL3RhYmxlcmFuZ2U6NThkOTAxZWZlZGFhNDc2MWEyMTBhY2VkOWM3MzQ2MzJfMTEtMTEtMS0xLTA_dfe93935-7dfc-4ce8-b255-f0b4865c4bb0"
      unitRef="usd">3420600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ehc:MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF81NS9mcmFnOjUxZDFkOGQxMzE1YTRhYjhiYjJmNjI3Y2Q5ZTcxZWZhL3RleHRyZWdpb246NTFkMWQ4ZDEzMTVhNGFiOGJiMmY2MjdjZDllNzFlZmFfMTQ4NDM0MDY5NzgwNDM_d30b782f-e751-4e3d-9402-f0250a321569"
      unitRef="number">0.70</ehc:MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82NC9mcmFnOjlhZjQ1ZWEwYzdiNzRlYzRhNjNkMmZmODgyYjk4MmYxL3RleHRyZWdpb246OWFmNDVlYTBjN2I3NGVjNGE2M2QyZmY4ODJiOTgyZjFfMzMyMQ_f06b5d81-c47d-4e1e-a99a-04d46aa4a5a7">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In June 2016, the FASB issued ASU 2016-13, &#x201c;Financial Instruments &#x2013; Credit Losses (Topic 326),&#x201d; which provides guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new guidance was effective for us beginning January 1, 2020. The adoption of this guidance resulted in an immaterial change to our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-15, &#x201c;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&#x201d; The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The new guidance was effective for us beginning January 1, 2020. The adoption of this guidance did not have a material impact to our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Securities and Exchange Commission adopted final rules that amend the financial disclosure requirements in Rule 3-10 of Regulation S-X for guarantors of registered debt securities and subsidiary issuers. The new rules are effective January 4, 2021, but early adoption is permitted. The new rules permit alternative disclosures of summarized financial information, rather than our previous footnote presentation of condensed consolidating financial statements. The new rules also permit the summarized financial information and related disclosures to be presented outside of the condensed consolidated financial statements and accompanying notes. We elected to early adopt the new rules effective July 1, 2020. The summarized financial information and related disclosures are presented in Item 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of this report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In December 2019, the FASB issued ASU 2019-12, &#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#x201d; The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. Either prospective or retrospective transition of this standard is dependent upon the specific amendments. The new guidance is effective for us beginning January&#160;1, 2021, including interim periods within that reporting period. Early adoption is permitted. We continue to review the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNTIyOQ_8a43704f-685a-4c43-a8b6-523fbad22472">Business Combinations&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the nine months ended September&#160;30, 2020, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In January 2020, we acquired 68% of the operations of a 13-bed inpatient rehabilitation unit in Denver, Colorado through a joint venture with Portercare Adventist Health System. The acquisition was funded through a contribution of our existing 40-bed inpatient rehabilitation hospital in Littleton, Colorado and through contributions of funds which were utilized by the consolidated joint venture to build a 20-bed expansion to the Littleton hospital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In May 2020, we acquired 51% of the operations of a 45-bed inpatient rehabilitation unit in Dayton, Ohio through a joint venture with Premier Health Partners. The acquisition was funded through contributions of funds which were utilized by the consolidated joint venture to build a 60-bed de novo inpatient rehabilitation hospital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#x2019;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#x2019;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. None of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 2 to 3 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 20 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the inpatient rehabilitation acquisitions during each period presented is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, we acquired the assets of Generation Solutions of Lynchburg, LLC in Lynchburg, Virginia. This acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in Central Virginia. The acquisition was funded using cash on hand and was immaterial to our financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired location from the date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. The fair values of identifiable intangible assets were based on valuations using an income approach. The income approach is based on management&#x2019;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired location&#x2019;s mobile workforce and established relationships within the community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. All of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the home health and hospice acquisitions during each period presented is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pro Forma Results of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 07/01/2020-09/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 07/01/2019-09/30/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2020-09/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2019-09/30/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,436.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have been achieved if the acquisitions had occurred as of the beginning of our 2019 reporting period.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to the consolidated financial statements accompanying the 2019 Form 10&#x2011;K for information regarding acquisitions completed in 2019.&lt;/span&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="id221678cc7294df9b33d60a008d67b3d_I20200131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNDQz_a6461425-9bf1-452c-99ff-d32323c634c0"
      unitRef="number">0.68</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberofBedsAcquired
      contextRef="id221678cc7294df9b33d60a008d67b3d_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNDY5_c32c1daf-cc8a-45ec-b9f7-bb643955d897"
      unitRef="bed">13</ehc:NumberofBedsAcquired>
    <ehc:NumberofBedsContributed
      contextRef="id221678cc7294df9b33d60a008d67b3d_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNjU3_937245de-3375-45a1-8e3e-b6175974620b"
      unitRef="bed">40</ehc:NumberofBedsContributed>
    <ehc:NumberofBedsExpanded
      contextRef="id221678cc7294df9b33d60a008d67b3d_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfODEx_307481b8-905a-4bdd-81b0-1cb2f83437af"
      unitRef="bed">20</ehc:NumberofBedsExpanded>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i33d295cd3f3b47759d61f44e07e56fc6_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfODgw_d1a030e3-0d2e-4a68-b129-3efd9b222b94"
      unitRef="number">0.51</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberofBedsAcquired
      contextRef="i33d295cd3f3b47759d61f44e07e56fc6_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfOTA2_2bac5804-fd06-4908-839a-4577a2ae98dc"
      unitRef="bed">45</ehc:NumberofBedsAcquired>
    <ehc:NumberofDeNovoBeds
      contextRef="i33d295cd3f3b47759d61f44e07e56fc6_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfMTEzNg_291c1133-ea79-47c3-8ac1-9c20478f0a40"
      unitRef="bed">60</ehc:NumberofDeNovoBeds>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfMjM3MA_03278cab-635b-40d8-a8d0-b45fafffe6a7"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNTE4OQ_b7170c6f-ffbf-41ca-9178-bee5c4c3588b">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 2 to 3 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 20 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNC0xLTEtMS0w_7840ba62-dd90-4cb7-bdf9-a60a80400da5"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i164768e9d98945009ca4f1d1e36917a8_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNi0wLTEtMS0wL3RleHRyZWdpb246ZjY3Y2IyNDNiMGIxNDZjMGEzNWVhNzZhYmEwZTYyYjBfMTY0OTI2NzQ0MTcyMQ_bfce9496-ba9f-48d0-a457-6339ef28d4dd">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i99a4b3491a24492fbd0635cfe176d18c_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNi0wLTEtMS0wL3RleHRyZWdpb246ZjY3Y2IyNDNiMGIxNDZjMGEzNWVhNzZhYmEwZTYyYjBfMTY0OTI2NzQ0MTczMQ_09b9bd82-82f0-47db-9736-b8c45b98fd1d">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i8d63a47f4d3e460a94d90e53d7bcbef6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNi0xLTEtMS0w_9bdf6d62-0839-43c1-b319-1e5a27a298d5"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i5f877b7c9b844d33baa6901b87f3b8fb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNy0wLTEtMS0wL3RleHRyZWdpb246ODYzMTM5MmE1OTZiNGZjMTk3ZGE5MGQ0MmQwNDM2M2VfMTY0OTI2NzQ0MTcxMg_3b4bde82-5788-463a-ac20-d6aa5708ac85">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i186e76d3e4134732aa2cae42033322a2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfNy0xLTEtMS0w_8c05ed52-f15d-4186-905c-f9fb7872c8f6"
      unitRef="usd">900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfMTAtMS0xLTEtMA_ab60c06a-ec19-465c-80c1-2aff9d33203c"
      unitRef="usd">9200000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjNmODYxZTYyNTgzYzQ2ZjZiMGE0OGM0ZTllOTM0Y2MyL3RhYmxlcmFuZ2U6M2Y4NjFlNjI1ODNjNDZmNmIwYTQ4YzRlOWU5MzRjYzJfMTItMS0xLTEtMA_dcb968bf-4003-492a-8153-ead890516986"
      unitRef="usd">10900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNTE5Nw_ea6ea9a5-2469-4d21-8e80-3257ef4216d8">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the inpatient rehabilitation acquisitions during each period presented is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the home health and hospice acquisitions during each period presented is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMi0xLTEtMS0w_b4390b79-a752-438e-81f7-f2ab4ac1558b"
      unitRef="usd">0</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMi0zLTEtMS0w_dda146b6-2e83-41de-a3d3-cfa9b2fa58ec"
      unitRef="usd">500000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMi01LTEtMS0w_ecf6cb87-28f3-4074-8e24-55593208af17"
      unitRef="usd">1700000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMi03LTEtMS0w_c47df116-b213-4184-8423-134d97445e01"
      unitRef="usd">500000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMy0xLTEtMS0w_167c7f0b-6464-41ec-bc2e-103d23d5f7b2"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMy0zLTEtMS0w_d801164d-a366-4860-a085-a6d0951babae"
      unitRef="usd">4800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMy01LTEtMS0w_ed539a73-4e26-437b-8dcb-a635fc6e6651"
      unitRef="usd">9200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfMy03LTEtMS0w_023976b3-6a6f-436d-b9e7-8d4e6a0132ff"
      unitRef="usd">4800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNC0xLTEtMS0w_87e6c885-a716-4b23-8bbd-596cde97ea2e"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNC0zLTEtMS0w_accc51de-bb29-4e34-866c-45ed99c79f1e"
      unitRef="usd">200000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNC01LTEtMS0w_781e9745-b9b6-4bfc-8aeb-cd63a287b192"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNC03LTEtMS0w_b716c17c-f11e-47cc-8d43-ee26f56f87c3"
      unitRef="usd">200000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNS0xLTEtMS0w_a46ea15c-1560-4ddd-8236-1670d544eb3f"
      unitRef="usd">0</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNS0zLTEtMS0w_2862a599-e3d9-401a-a9bb-6f79b9c5e590"
      unitRef="usd">5100000</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNS01LTEtMS0w_c48a1536-bde0-438e-abc1-db412a6b73d3"
      unitRef="usd">10900000</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNS03LTEtMS0w_517b965e-3c5f-46f5-b07f-d655fc419a2d"
      unitRef="usd">5100000</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNy0xLTEtMS0w_99ed6e0b-66a9-4ce5-8227-adb8038c7a76"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if4924a346a6d4ad8bf942d8c416ddd35_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNy0zLTEtMS0w_d7357c6b-4090-4db8-b2ac-52edb7cdb8d5"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNy01LTEtMS0w_c3f0b690-dd02-489a-8fa8-4b278672455e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i91e7b884c07f467186f589b0f70d1d14_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmU3YjU0YzNiNDhhNTQyMzU4Mjk1ZjFhMDJmMTA1MzcxL3RhYmxlcmFuZ2U6ZTdiNTRjM2I0OGE1NDIzNTgyOTVmMWEwMmYxMDUzNzFfNy03LTEtMS0w_30946cd1-bad6-4c52-8d2d-a1b7d8c627ac"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1560645449b747a1ba2a0753d5016fc6_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZkODc3YjIyYTRjNTQxN2RiYTQzMjk3ZmY5MDllZDIwL3RhYmxlcmFuZ2U6NmQ4NzdiMjJhNGM1NDE3ZGJhNDMyOTdmZjkwOWVkMjBfNi0wLTEtMS0wL3RleHRyZWdpb246OGYzMDUwYTMxNDcxNDViMTlkYzk4MzQwMDA2MDMxMzNfMTY0OTI2NzQ0MTcxMQ_aca572ba-3eb1-490b-8783-ecc1ba5bd153">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i56f08b6a993948f2baf0abcbb8879961_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZkODc3YjIyYTRjNTQxN2RiYTQzMjk3ZmY5MDllZDIwL3RhYmxlcmFuZ2U6NmQ4NzdiMjJhNGM1NDE3ZGJhNDMyOTdmZjkwOWVkMjBfNi0xLTEtMS0w_3d535a3f-5a66-453b-8527-8035371fcc93"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i2c76d4a587d74d698b634d1f495b2c74_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZkODc3YjIyYTRjNTQxN2RiYTQzMjk3ZmY5MDllZDIwL3RhYmxlcmFuZ2U6NmQ4NzdiMjJhNGM1NDE3ZGJhNDMyOTdmZjkwOWVkMjBfNy0xLTEtMS0w_c4ee2b8f-fbb0-408d-8f76-4decc39d0c35"
      unitRef="usd">1000000.0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i2c76d4a587d74d698b634d1f495b2c74_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZkODc3YjIyYTRjNTQxN2RiYTQzMjk3ZmY5MDllZDIwL3RhYmxlcmFuZ2U6NmQ4NzdiMjJhNGM1NDE3ZGJhNDMyOTdmZjkwOWVkMjBfOS0xLTEtMS0w_67a687fc-9c81-44b8-b1d8-9c4ec8edf7c1"
      unitRef="usd">1100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i8f63f58dc90642eea45a7aa1f02b8503_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMi0xLTEtMS0w_055da522-9775-4237-9e74-ea44ed7c06f2"
      unitRef="usd">0</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i9e4e00603d8740a8bcf31cfc8d4f58e1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMi0zLTEtMS0w_7d943434-e2f1-47e3-a611-929902b8d4bc"
      unitRef="usd">68600000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="ibd3b016833a9435ca260fd97a50d18c8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMi01LTEtMS0w_4cff7aae-1c9c-4acb-b420-b2d030935264"
      unitRef="usd">100000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="ibc22792722ba436c9181b2a61d9649df_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMi03LTEtMS0w_da4e48bf-15a4-4183-8156-bd9433113408"
      unitRef="usd">71800000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8f63f58dc90642eea45a7aa1f02b8503_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMy0xLTEtMS0w_6335ffec-ef43-4646-88c9-926941281e40"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i9e4e00603d8740a8bcf31cfc8d4f58e1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMy0zLTEtMS0w_5b634419-8046-4d87-bb39-e923d19f8270"
      unitRef="usd">163900000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ibd3b016833a9435ca260fd97a50d18c8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMy01LTEtMS0w_aa817e9a-ca6d-4181-ad98-ff2befe969e8"
      unitRef="usd">1000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ibc22792722ba436c9181b2a61d9649df_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfMy03LTEtMS0w_fa832b85-5e91-4188-a935-d7734c920875"
      unitRef="usd">174700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i8f63f58dc90642eea45a7aa1f02b8503_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNC0xLTEtMS0w_82d99fd0-b6a7-4f1b-b9d1-561ecc5d7eac"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i9e4e00603d8740a8bcf31cfc8d4f58e1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNC0zLTEtMS0w_c0ce9bbc-0d01-455c-b654-fec8f06e2216"
      unitRef="usd">15000000.0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ibd3b016833a9435ca260fd97a50d18c8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNC01LTEtMS0w_d00d1852-6e3a-40df-b9a2-e801aa8403b0"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ibc22792722ba436c9181b2a61d9649df_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNC03LTEtMS0w_71d92b15-8e49-4917-9a5f-2aca6301c3e1"
      unitRef="usd">15300000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8f63f58dc90642eea45a7aa1f02b8503_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNy0xLTEtMS0w_5680d561-273b-44e6-a5c7-4a37bfd58f0f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9e4e00603d8740a8bcf31cfc8d4f58e1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNy0zLTEtMS0w_db6d6919-f7bc-4ebc-92f9-08a29b0686d1"
      unitRef="usd">217500000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibd3b016833a9435ca260fd97a50d18c8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNy01LTEtMS0w_d3f78794-c4e7-4307-8ae8-2b42a5c743cd"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibc22792722ba436c9181b2a61d9649df_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOmQ5N2FlZjQyYzBmNTQ0NjhiNjg0OGFiZDBiYjhhMDU2L3RhYmxlcmFuZ2U6ZDk3YWVmNDJjMGY1NDQ2OGI2ODQ4YWJkMGJiOGEwNTZfNy03LTEtMS0w_35176b48-7950-4074-9732-0d0c5b79fad1"
      unitRef="usd">231200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RleHRyZWdpb246Y2ZjOTI1Njg1MmJjNDE2NGFlNzE5MTFjNmFlZGRjZTVfNTIwOA_3a3bc067-ffa0-4509-abf4-6ab27daa677c">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 07/01/2020-09/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 07/01/2019-09/30/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2020-09/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2019-09/30/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,436.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfMi0xLTEtMS0w_e54a84a4-a558-4168-9730-75e7d0c18129"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="iba9ed1fb20354070856bfd79263fdeaa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfMi0zLTEtMS0w_ffc65b77-69f5-433e-b673-32f3a22737e3"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="if0584508681949b19044b898bcaac766_D20200301-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNC0xLTEtMS0w_ce054291-feaa-4e8f-b931-46537b06e711"
      unitRef="usd">1100000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="if0584508681949b19044b898bcaac766_D20200301-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNC0zLTEtMS0w_95496efb-8938-4778-9909-aa305d9f20c1"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNS0xLTEtMS0w_74f2bdd0-757b-4843-b667-788fe950241a"
      unitRef="usd">1173900000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNS0zLTEtMS0w_a742e80b-baa2-4f78-9df5-461857433702"
      unitRef="usd">77700000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNi0xLTEtMS0w_f06dde3b-46ef-4b13-929e-6c08f8837c2d"
      unitRef="usd">1166900000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNi0zLTEtMS0w_32378001-afc6-41ae-8dda-fd9cbfebacfb"
      unitRef="usd">98100000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNy0xLTEtMS0w_262ef348-510a-4d1c-b523-892325aa7711"
      unitRef="usd">3435900000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfNy0zLTEtMS0w_3ab1f3db-9d7d-4e9e-89e6-666ec2f44bdc"
      unitRef="usd">198800000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfOC0xLTEtMS0w_3a019b75-d837-448e-aba9-6a6641ee30d0"
      unitRef="usd">3436300000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF82Ny9mcmFnOmNmYzkyNTY4NTJiYzQxNjRhZTcxOTExYzZhZWRkY2U1L3RhYmxlOjZlZTBhNWYwNTVhMDQxODc5YzZmYjcxMTdhZDBjM2E4L3RhYmxlcmFuZ2U6NmVlMGE1ZjA1NWEwNDE4NzljNmZiNzExN2FkMGMzYThfOC0zLTEtMS0w_40fe021f-515a-4589-afd4-070b3f6afac3"
      unitRef="usd">292600000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfMTMyNw_9b5e352e-0aaf-4c7f-b7d5-6c0a3083e039">Variable Interest Entities&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, we consolidated nine and eight, respectively, limited partnership-like entities that are variable interest entities (&#x201c;VIEs&#x201d;) and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 75.0% as of September&#160;30, 2020. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The carrying amounts and classifications of the consolidated VIEs&#x2019; assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <ehc:VariableInterestEntityNumberofEntitiesConsolidated
      contextRef="i1708048c2a42448693822a76f275381d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfNjY_716d820a-e18d-4b03-9ffb-23e344e832e4"
      unitRef="entity">9</ehc:VariableInterestEntityNumberofEntitiesConsolidated>
    <ehc:VariableInterestEntityNumberofEntitiesConsolidated
      contextRef="i66fdf46a359740a785ea525eb38ea7fd_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfNzM_fdf16e0e-205a-4d73-a75e-9ec5aacd24bb"
      unitRef="entity">8</ehc:VariableInterestEntityNumberofEntitiesConsolidated>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i8546b47816c54ef381660703138b5caf_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfMjcw_59a8b077-2c34-4343-9042-61c71b548bd7"
      unitRef="number">0.500</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i5ac9f48cbdbe488cb20eed7e2f9ca1ee_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfMjc2_67b97989-57ab-4e04-a4ab-eb010484f461"
      unitRef="number">0.750</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RleHRyZWdpb246NTc2ZjI4MWQ3NDRiNGYwZjk0NDQ1ZGRjODYxYmQ1YzFfMTMzMw_ca1bf5c3-317a-4e9c-a5e3-2450ee104a9d">The carrying amounts and classifications of the consolidated VIEs&#x2019; assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMy0xLTEtMS0w_bd481e57-f2c6-459e-933e-648e31f7a146"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMy0zLTEtMS0w_546c6b83-586b-44a5-971e-c23cc87e3df5"
      unitRef="usd">200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNC0xLTEtMS0w_c42b20f9-3e1d-4143-a414-60f405d9a99b"
      unitRef="usd">33600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNC0zLTEtMS0w_bcf3f15d-3a5b-4a52-b2c6-6e3d03bacdfc"
      unitRef="usd">29300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNS0xLTEtMS0w_3d497fea-97a8-4240-8c77-36d23c74d2f2"
      unitRef="usd">7500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNS0zLTEtMS0w_a60fb9c4-419e-444e-86d1-99d2e91a9dbf"
      unitRef="usd">6400000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNi0xLTEtMS0w_3cb7dba5-c041-4bce-a3cc-8ab5380d6152"
      unitRef="usd">41100000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNi0zLTEtMS0w_1aef8ea1-0cf2-4905-8188-e95f2a4938c8"
      unitRef="usd">35900000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNy0xLTEtMS0w_5eb3c36b-8ff9-4620-9d77-3f38baf1c2e1"
      unitRef="usd">121900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfNy0zLTEtMS0w_0601d09a-f64f-4710-9290-b485b0dbd8ad"
      unitRef="usd">122600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfOC0xLTEtMS0w_985df4eb-6fb3-4d1e-b84b-ce576a38e5ee"
      unitRef="usd">5100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfOC0zLTEtMS0w_cf32b95c-3906-49e0-b563-c1251566768f"
      unitRef="usd">6000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfOS0xLTEtMS0w_b629424c-c15e-4483-a385-d86576475b2f"
      unitRef="usd">19200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfOS0zLTEtMS0w_2c9747fd-ee40-4749-97e8-049824fcac0e"
      unitRef="usd">15900000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTAtMS0xLTEtMA_30c7694f-487b-4695-a710-fa2244099713"
      unitRef="usd">3700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTAtMy0xLTEtMA_0ace90d6-8e91-42c2-ad4d-edb951c01bc0"
      unitRef="usd">3300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTEtMS0xLTEtMA_eff01161-1c77-4ca4-b577-769f08596f05"
      unitRef="usd">31000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTEtMy0xLTEtMA_2351a53d-eaba-4618-b5c1-388a1fc504d5"
      unitRef="usd">31300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTItMS0xLTEtMA_a93bbf1d-47f4-4495-80ed-fd8ed5de0f3a"
      unitRef="usd">222000000.0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTItMy0xLTEtMA_514afc40-4194-4d53-bdf0-cae6ed5c5527"
      unitRef="usd">215000000.0</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTUtMS0xLTEtMA_55334a9f-cb80-4f44-a424-45949f172938"
      unitRef="usd">900000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTUtMy0xLTEtMA_99b3daba-b370-4567-b95a-1d97b245f79b"
      unitRef="usd">800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTYtMS0xLTEtMA_8e03c326-48a8-4198-a3bc-385025f812a4"
      unitRef="usd">1500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTYtMy0xLTEtMA_18a65e65-a344-4df0-91a3-7036c7a7d22e"
      unitRef="usd">1400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTctMS0xLTEtMA_d2a306ff-cefb-4afd-8b40-d378ae29004b"
      unitRef="usd">7400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTctMy0xLTEtMA_3ad1f515-ef81-4f06-bdcf-de72d7f7d264"
      unitRef="usd">6700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTgtMS0xLTEtMA_6a54f846-04d0-435a-8c52-958a534c639e"
      unitRef="usd">18200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTgtMy0xLTEtMA_1f860b84-2923-4f6b-9174-2b3faba6e0a9"
      unitRef="usd">17000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTktMS0xLTEtMA_dde1e35d-cb85-4628-8a87-0fc4ae2c8cab"
      unitRef="usd">28000000.0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMTktMy0xLTEtMA_9385ed17-88f3-4f95-960f-24f73926ec04"
      unitRef="usd">25900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjAtMS0xLTEtMA_d633bed5-872a-4ff1-96eb-cbe1fdf30220"
      unitRef="usd">9800000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjAtMy0xLTEtMA_7aa7287a-8192-4c17-890d-a0d424c78950"
      unitRef="usd">10500000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjEtMS0xLTEtMA_e69bc623-1642-4047-9efd-5f782a0896da"
      unitRef="usd">3700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjEtMy0xLTEtMA_073ab3a5-2f4b-41a2-8b01-c1e5ff4c358f"
      unitRef="usd">4700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjItMS0xLTEtMA_26c2062e-1460-4377-96d4-70955a93af86"
      unitRef="usd">3100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjItMy0xLTEtMA_4ce87b10-5085-40d4-976c-5f149bb91e17"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ifee6c827439c4117821d833d1398c1e3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjMtMS0xLTEtMA_eeadee49-b0b9-404c-aafb-9e5a957a8971"
      unitRef="usd">44600000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9dc50352d6c046e996455f484c4b8d2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF83My9mcmFnOjU3NmYyODFkNzQ0YjRmMGY5NDQ0NWRkYzg2MWJkNWMxL3RhYmxlOmE0ZTEwYTUzYzYzYTRmMDM5ZjM2OTc1ZDA1NDVhYTg1L3RhYmxlcmFuZ2U6YTRlMTBhNTNjNjNhNGYwMzlmMzY5NzVkMDU0NWFhODVfMjMtMy0xLTEtMA_b5647966-0370-4b0a-9613-475ee76e6e60"
      unitRef="usd">41100000</us-gaap:Liabilities>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfODI0NjMzNzIxODM0Mg_da2040a4-0f0a-4352-9be6-016f542df4d9">Long-term Debt&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our long-term debt outstanding consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.081%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Agreement&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bonds payable&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,576.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,539.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,023.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, we amended our existing credit agreement. The following are the changes made to the material&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;provisions of the credit agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the financial covenants to update the applicable interest coverage ratio and leverage ratio included in that covenant. The revised applicable ratios are set forth below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the definition of &#x201c;Material Adverse Effect&#x201d; to carve out the direct and indirect impacts of COVID-19 and the related legislative, regulatory and executive actions on us from that definition for a period of 364 days; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the investment limitation covenant and the restricted payment limitation covenant, to add to each a leverage ratio condition (not in excess of 4.50x) to the provisions allowing unlimited investments and restricted payments in the event certain conditions are met including a senior secured leverage ratio (not in excess of 2:00x) and the existence of no events of default in addition to the new leverage ratio condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other material terms of the existing credit agreement remain the same and are described in Note&#160;10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the consolidated financial statements accompanying the 2019 Form 10&#x2011;K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we issued an additional $300 million of our existing 4.50% Senior Notes due 2028 at a price of 99.0% of the principal amount and an additional $300 million of our existing 4.75% Senior Notes due 2030 at a price of 98.5% of the principal amount, which resulted in approximately $583 million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In October 2020, we issued $400&#160;million aggregate principal amount of 4.625% Senior Notes due 2031 (the &#x201c;2031 Notes&#x201d;) at par. The 2031 Notes mature on April 1, 2031 and bear interest at a per annum rate of 4.625%. Interest is payable semiannually in arrears on April 1 and October 1 of each year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In October 2020, we issued notice for redemption of all $700&#160;million in outstanding principal amount of the 5.75% Senior Notes due 2024 (the &#x201c;2024 Notes&#x201d;). Pursuant to the terms of the 2024 Notes, this full redemption will settle on November 1, 2020 and will be made at a price of par. We plan to use the net proceeds from the 2031 Notes offering together with cash on hand to fund the redemption. We expect to record an approximate $2&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; in the fourth quarter of 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY5Mw_320c4375-9cab-4986-b1b1-c8d0b08b3106">Our long-term debt outstanding consists of the following (in&#160;millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.081%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Agreement&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bonds payable&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,576.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,539.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,023.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i608f28a8c9c64873904629df071b372b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMi0xLTEtMS0w_6296f1f5-9d5f-4c1d-9ff0-4dbcad6d89ce"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if83e06ff810244088cb996c03064f330_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMi0zLTEtMS0w_790b8ae6-7cfa-43e2-97a4-2d5093a2c2a3"
      unitRef="usd">45000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie8fb9a7dd06c4e609086c04b5dbfe4ca_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMy0xLTEtMS0w_c6777b1a-f136-4238-847a-58ebcce43191"
      unitRef="usd">254800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2f1023a8574449fd9b9332edaf46f3bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMy0zLTEtMS0w_1c86ba08-8de0-4604-9fe3-31a2002cfa1c"
      unitRef="usd">265200000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i638ab89eae9440c5b0f1929587a02914_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNS0wLTEtMS0wL3RleHRyZWdpb246OTg0YTUyOWM3ZjdhNDQ1Mzk1NDkzZjBiZmZkMmYyOTJfMTY0OTI2NzQ0MTcwMg_85682d3d-20a6-41ff-a115-8a75c924d67d"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i638ab89eae9440c5b0f1929587a02914_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNS0xLTEtMS0w_8f830b2f-9838-4e0c-9a60-8fb1c5dfedb1"
      unitRef="usd">297900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8f0377bd53564ffdae03ff64e660194b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNS0zLTEtMS0w_9eff51ea-476f-486e-8c90-3042111d4f56"
      unitRef="usd">297300000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia523dc03179846ddaf98c887899b7679_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNi0wLTEtMS0wL3RleHRyZWdpb246NTY1ZjQyNzE5MTkxNDIyMThhYzcxZWJjYTA2YTJjMDdfMTY0OTI2NzQ0MTcwMA_ca119628-1082-43d1-9b39-627aad83471f"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia523dc03179846ddaf98c887899b7679_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNi0xLTEtMS0w_e22986d2-23f3-4fb4-864e-3cbbfb4fb396"
      unitRef="usd">697700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3892c4bc03204316bb6e77be3f27b240_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNi0zLTEtMS0w_96451a09-a4a9-4bdd-9e30-404961c881eb"
      unitRef="usd">697300000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib40a6e6dd68b4a8da5d30d7aaa484c51_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNy0wLTEtMS0wL3RleHRyZWdpb246MTI0NzM1NjVhMWVlNGJkMWIyMzFlZmFiNzA2NmZlNmNfMTY0OTI2NzQ0MTcwMA_7e99b7db-9307-443d-81f2-30ac03666728"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib40a6e6dd68b4a8da5d30d7aaa484c51_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNy0xLTEtMS0w_592e96a3-e635-4e76-87a8-a65a761b316c"
      unitRef="usd">346100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic41c4e44b7b64428b528add431c16513_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfNy0zLTEtMS0w_5fc192da-a7d9-45a4-a04f-91bfe747df49"
      unitRef="usd">345600000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6f1805d3ddcd4b188bc766e18298a2d5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOC0wLTEtMS0wL3RleHRyZWdpb246MjMxZDZiNGMyNTdkNDA3MGFlYTlmOGI2YjAwNjg0ZWVfMTY0OTI2NzQ0MTcwMA_2d864912-4c58-4bda-b961-5efbfd0c017f"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6f1805d3ddcd4b188bc766e18298a2d5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOC0xLTEtMS0w_3abaed51-80e7-447d-bbf7-e91631d61bc6"
      unitRef="usd">784600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i730f2a918b744a0e94177fd42ad004a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOC0zLTEtMS0w_d8948248-5171-4d2e-abff-09df2c4171e1"
      unitRef="usd">491700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i62eb57fb87fc40e59f8f33f73b921693_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOS0wLTEtMS0wL3RleHRyZWdpb246M2I3OTI0ZTg2MTZiNDk1MmJkZTY2OGU4ZTc3ZDY3OWRfMTY0OTI2NzQ0MTcwMA_dc2250a5-81b6-49e7-8f41-7cf55d8d768b"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i62eb57fb87fc40e59f8f33f73b921693_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOS0xLTEtMS0w_f218e1fb-cc39-42b0-9ce1-89ce2d4ef5d6"
      unitRef="usd">782800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idd067c2ff27b4ab8a68e5471e7c59ef9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfOS0zLTEtMS0w_9c59e92e-376b-40da-9c79-4177727fcdc0"
      unitRef="usd">491700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1dfc00f6eb92471998309b5c12c9388f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTAtMS0xLTEtMA_e80a0a8c-b5ab-4deb-92b6-25b933d679d2"
      unitRef="usd">40200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i23cf331b54114349857c76ca9d89e4e9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTAtMy0xLTEtMA_9943fe01-de60-4b3d-8f6d-6c3ed0b7c129"
      unitRef="usd">44700000</us-gaap:LongTermDebt>
    <us-gaap:FinanceLeaseLiability
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTEtMS0xLTEtMA_a589c550-5737-49b7-9b4d-d5cfcf2754be"
      unitRef="usd">372300000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTEtMy0xLTEtMA_91411da4-d00b-41cb-a29b-e3e6c0fbef82"
      unitRef="usd">384100000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTItMS0xLTEtMA_f2f07e48-09b7-4bf7-9a23-4543bec8da63"
      unitRef="usd">3576400000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTItMy0xLTEtMA_2fde1667-b87b-458b-8813-97301770abba"
      unitRef="usd">3062600000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTMtMS0xLTEtMA_01d854c9-8e09-48e8-9a0f-9684ec0d1697"
      unitRef="usd">37000000.0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTMtMy0xLTEtMA_b3c23bbe-0095-4438-9d3d-4a02f90b7a6d"
      unitRef="usd">39300000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTQtMS0xLTEtMA_1def6491-e7bc-4c68-8b61-ede6d97cfedf"
      unitRef="usd">3539400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjM0YzFmOTM0YjNmYzQ0MDg4MWZjYWE1NmE2NDkzNGE4L3RhYmxlcmFuZ2U6MzRjMWY5MzRiM2ZjNDQwODgxZmNhYTU2YTY0OTM0YThfMTQtMy0xLTEtMA_1481b6bb-7a7b-490f-9f7a-9f24f8fa8227"
      unitRef="usd">3023300000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <ehc:ScheduleOfFinancialCovenantsTableTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY4NA_d3e9c4a5-aaa9-49a4-969c-56c614537867">&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ehc:ScheduleOfFinancialCovenantsTableTextBlock>
    <ehc:DebtInstrumentCovenantInterestCoverageRatio
      contextRef="i30dd8fb7ca9b4d95a01ed19cec48d797_D20191001-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOmJmMzU5MDAxMmI0ZDQxNTRhMTg5Mjg5MWUxMmEyYWE5L3RhYmxlcmFuZ2U6YmYzNTkwMDEyYjRkNDE1NGExODkyODkxZTEyYTJhYTlfMS0xLTEtMS05OTMvdGV4dHJlZ2lvbjpkNmY3YjQ4MWQyNWQ0MGYxOTk1ZjFmYmVjNjM1YTkxYV8xNjQ5MjY3NDQxNjg0_3a02f842-ddfe-4672-b97c-6014da4d0e5a"
      unitRef="number">3.00</ehc:DebtInstrumentCovenantInterestCoverageRatio>
    <ehc:DebtInstrumentCovenantInterestCoverageRatio
      contextRef="i02f7fbac1cd84620acf7f199e68c69d2_D20200401-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOmJmMzU5MDAxMmI0ZDQxNTRhMTg5Mjg5MWUxMmEyYWE5L3RhYmxlcmFuZ2U6YmYzNTkwMDEyYjRkNDE1NGExODkyODkxZTEyYTJhYTlfMi0xLTEtMS0xMDIzL3RleHRyZWdpb246YTJmOWZhMzFiYTc4NDg5ZWJhZTdhZTNiNWJhZjljOTdfMTY0OTI2NzQ0MTY4NA_2e5ce464-5669-4b9b-940f-3248db5e8724"
      unitRef="number">2.00</ehc:DebtInstrumentCovenantInterestCoverageRatio>
    <ehc:DebtInstrumentCovenantInterestCoverageRatio
      contextRef="i31cb706cd3d34a8f8c5550eb13fdc482_D20220331-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOmJmMzU5MDAxMmI0ZDQxNTRhMTg5Mjg5MWUxMmEyYWE5L3RhYmxlcmFuZ2U6YmYzNTkwMDEyYjRkNDE1NGExODkyODkxZTEyYTJhYTlfMy0xLTEtMS0xMDI2L3RleHRyZWdpb246NTIzNDExYzExMGQ0NDRmNzgxNmRjY2Y5NjFkZGRhZjNfMTY0OTI2NzQ0MTY4NA_a897a1c6-4c81-4e7a-8358-de02f1015f1d"
      unitRef="number">3.00</ehc:DebtInstrumentCovenantInterestCoverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i2ba53aa991c7496c824228ff7f76db73_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfMS0xLTEtMS0xMDI5L3RleHRyZWdpb246ZjdhNTA2MGRmZmNkNGU1ZGJhMzAwOGZhZDBiN2M1NTdfMTY0OTI2NzQ0MTY4NA_a944ec5d-8bf5-469a-b0cd-5ccbd34ab437"
      unitRef="number">4.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i0b16ec5f39fd426987fd267959afaf04_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfMi0xLTEtMS0xMDMyL3RleHRyZWdpb246NDBiMDY2YjFkMzIxNGFiOWI1MGE4ODgyYjlmYmRiOTdfMTY0OTI2NzQ0MTY4NA_49d89b9b-037b-4a39-83e0-10fd1fc78331"
      unitRef="number">4.75</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfMy0xLTEtMS0xMDM1L3RleHRyZWdpb246OGI1OGJlMjdlZWMwNDM2ODkxYmI4NGE0NTQwY2UxOTBfMTY0OTI2NzQ0MTY4NA_f9bd5b41-10fc-4663-bada-a066d40d4362"
      unitRef="number">5.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="ieaf492cdb0114d0caa049a3dc713ea52_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfNC0xLTEtMS0xMDQ1L3RleHRyZWdpb246ZmNhMGM5Y2MxNmFhNDczNDllMmQ0YmE4MTk0ZjRlZDhfMTY0OTI2NzQ0MTY4NA_927cbc38-e479-4246-8610-637a8784c2a6"
      unitRef="number">6.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="ide941e50cb94438c842272441f7f7a9d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfNS0xLTEtMS0xMDM4L3RleHRyZWdpb246YWMyYjY2NWNiOWE1NDlhMTlmNjk0NWI3ZTRiM2JkNTlfMTY0OTI2NzQ0MTY4OA_ca01e727-5f3a-4558-a556-f22ec8ffa5f4"
      unitRef="number">6.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i54ca9b66117a446d97db8f7751e15718_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfNi0xLTEtMS0xMDQ3L3RleHRyZWdpb246OWRjYWZhMjRjMDNjNGZiZWJhMDdiODgwMmRhNjliZTlfMTY0OTI2NzQ0MTY4NA_4a2d588d-db60-4653-a44a-e2b172cb9980"
      unitRef="number">6.00</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i47e1840cf2284314b9ab50ccca85d8dc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfNy0xLTEtMS0xMDUwL3RleHRyZWdpb246MDhmNmU3YjgwZDRjNGFmY2I2ZDUyNWJkZTQ4ZTI3NDJfMTY0OTI2NzQ0MTY4NA_bacfd5bf-02d2-4614-9572-2ac46ce13439"
      unitRef="number">5.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i3dd6a4fa2af14b42a85c77bc5fc6a804_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfOC0xLTEtMS0xMDUzL3RleHRyZWdpb246YzlkNmQ0NTA5OTQyNDE2MjhjMjIxNWQyYTMzMzdjMmZfMTY0OTI2NzQ0MTY4NA_d1976703-2040-4b9c-9d15-2f51abcc5496"
      unitRef="number">5.00</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="ie70bf042dd674e718cc447fc2ec12ba6_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RhYmxlOjk3OWIzMTkzYWZmZDQzN2Y4ZDM5NDc3MjIyMjU2ZDQxL3RhYmxlcmFuZ2U6OTc5YjMxOTNhZmZkNDM3ZjhkMzk0NzcyMjIyNTZkNDFfOS0xLTEtMS0xMDU2L3RleHRyZWdpb246ZDEzMzQyMTdkNmFkNDgzYjg1MzIxZmNlYWY0NmM2OTZfMTY0OTI2NzQ0MTY4NA_3019bff1-6f59-49b0-b419-c139071185ee"
      unitRef="number">4.25</ehc:DebtInstrumentCovenantLeverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iff0d4dd7c88b4aecaeb023492578edbc_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTI5OA_922fb778-4a13-4622-845a-73cefde53f26"
      unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iff0d4dd7c88b4aecaeb023492578edbc_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTMxNw_414a1d81-1d8e-46f5-b840-b3d356a63f7d"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue
      contextRef="iff0d4dd7c88b4aecaeb023492578edbc_I20200531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTM1Ng_ea3ad133-7ff2-414f-bd81-44ce6c6b46b8"
      unitRef="number">0.990</ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8a6a2cb269044ff8ba6e3aa662224738_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTQwMQ_797aa8ae-3c94-4b26-b20f-b15ef603bccd"
      unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8a6a2cb269044ff8ba6e3aa662224738_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTQyMA_ba3f5947-672d-48a1-9e5e-bf971e80dc56"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue
      contextRef="i8a6a2cb269044ff8ba6e3aa662224738_I20200531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTQ1OQ_b55f26dd-918c-4d79-b862-4a1d4e6614a6"
      unitRef="number">0.985</ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i97fd8177ab534173b7dff83fda1b0e42_D20200501-20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTUxOQ_c81bc745-520b-42f3-8967-e87983b72792"
      unitRef="usd">583000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2d3d451adabf4a9e939a4aa764188f34_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY0OTI2NzQ1MDA5NA_fd303415-4b18-4720-87cf-25c5364243fe"
      unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2d3d451adabf4a9e939a4aa764188f34_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY0OTI2NzQ1MDEwOA_7d247c24-885a-450f-be03-b4f24fe2bc4f"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2d3d451adabf4a9e939a4aa764188f34_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTQ4NDM0MDY5ODM0NTQ_ba9e2e95-4fa2-4aaf-8857-9abf95bd7e4a"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i15ba9115048c4b0cb334ce276b07e19f_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY0OTI2NzQ1MDExNg_7e6e88c7-255b-46e2-862b-a11375d3ebd2"
      unitRef="usd">700000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i15ba9115048c4b0cb334ce276b07e19f_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTQ4NDM0MDY5ODM0NjI_96ac6552-fce2-4666-bdde-05d83a530043"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4e156b6c09f3459a802a8b8b9d61246b_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF84OC9mcmFnOmRiNmU2NzQxYjE5MDRiZGRhMzM5MTZmZjFlNjYxYmJjL3RleHRyZWdpb246ZGI2ZTY3NDFiMTkwNGJkZGEzMzkxNmZmMWU2NjFiYmNfMTY0OTI2NzQ1MDEzMA_09319407-4466-441f-9b72-a4919e01d3ba"
      unitRef="usd">-2000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNDI3NQ_e27553c5-2c99-4eae-9f15-98df0f8a4f19">Redeemable Noncontrolling Interests&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity related to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the nine months ended September&#160;30, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributions declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution to joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase of redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the net income attributable to nonredeemable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the shareholders&#x2019; equity section of the condensed consolidated balance sheets, and the net income attributable to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net and comprehensive income attributable to noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; presented in the condensed consolidated statements of comprehensive income for the three and nine months ended September&#160;30, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to nonredeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2014, we acquired 83.3% of our home health and hospice business when we purchased EHHI Holdings, Inc. (&#x201c;EHHI&#x201d;). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#x201c;Holdings&#x201d;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $64 million on the acquisition date, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;value. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $65 million in cash. In July 2019, we received additional exercise notices, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. In September 2019, Encompass Health settled the acquisition of those shares upon payment of approximately $163 million in cash. In January 2020, we received additional exercise notices, representing approximately 4.3% of the outstanding shares of the common stock of Holdings. On February 18, 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $162 million in cash. Upon settlement of these exercises, approximately $46 million of the shares of Holdings held by two management investors remained outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#x201c;Exchange Agreement&#x201d;) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#x201c;EHC Shares&#x201d;). Each of the Exchange Agreements provided that the management investor must deliver a written exchange notice (an &#x201c;Exchange Notice&#x201d;) to Encompass Health in order to exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#x2019;s common stock on the New York Stock Exchange (the &#x201c;NYSE&#x201d;) on the date of delivery of the Exchange Notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors. Based on the last sales price of Encompass Health&#x2019;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate 560,957 EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than 0.6% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares. Encompass Health now owns 100% of Holdings and EHHI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See also Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestTableTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNDI5MQ_aa3095f4-3d44-4aeb-970f-dade0d230674">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity related to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the nine months ended September&#160;30, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributions declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution to joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase of redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RedeemableNoncontrollingInterestTableTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ib5048837d2a04accb50ef68638e25287_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMi0xLTEtMS0w_bdf40cc1-e6b1-45e6-a8f3-9fb4a471dadf"
      unitRef="usd">239600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i5017d71cfec249b39dc7bf0b2f16e8a8_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMi0zLTEtMS0w_002b3827-db4e-451a-aa6b-148a1b07b9a4"
      unitRef="usd">261700000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMy0xLTEtMS0w_742027a3-4ccc-4011-b3fd-0c71bda614d2"
      unitRef="usd">5700000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMy0zLTEtMS0w_6e5b0e3f-ed29-4ead-b4ef-6ec4c4844c05"
      unitRef="usd">10100000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNC0xLTEtMS0w_e61d5e9c-78f7-4184-a44b-e34f8fd106b4"
      unitRef="usd">5800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNC0zLTEtMS0w_779ba211-764a-4458-ac9f-16619457a362"
      unitRef="usd">7600000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <ehc:Contributiontojointventure
      contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNS0xLTEtMS0w_30e9c83c-5752-49e1-95e0-afe92827ff25"
      unitRef="usd">3100000</ehc:Contributiontojointventure>
    <ehc:Contributiontojointventure
      contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNS0zLTEtMS0w_2d680508-461b-4fad-86ce-c8aef2cc9682"
      unitRef="usd">1000000.0</ehc:Contributiontojointventure>
    <ehc:Reclassificationtononcontrollinginterests
      contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNi0xLTEtMS0w_a6c5cf02-3334-497c-bbd4-900077b4fbe6"
      unitRef="usd">0</ehc:Reclassificationtononcontrollinginterests>
    <ehc:Reclassificationtononcontrollinginterests
      contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNi0zLTEtMS0w_a545c0c2-dad8-4da3-ba94-81038a1068f4"
      unitRef="usd">11200000</ehc:Reclassificationtononcontrollinginterests>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNy0xLTEtMS0w_d01554a5-3e89-411e-a461-f35bedef5a4a"
      unitRef="usd">162300000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfNy0zLTEtMS0w_395084e9-1d7d-44c5-8964-59f9cee7769c"
      unitRef="usd">162900000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <ehc:NoncontrollingInterestExchangeTransaction
      contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfOC0xLTEtMS0w_e6c4406f-6e11-4cc4-b5af-7b7413d4cadb"
      unitRef="usd">46300000</ehc:NoncontrollingInterestExchangeTransaction>
    <ehc:NoncontrollingInterestExchangeTransaction
      contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfOC0zLTEtMS0w_626c982d-a365-4396-a0ce-ea2eed5525df"
      unitRef="usd">0</ehc:NoncontrollingInterestExchangeTransaction>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i7b4f60c5a9844a9ea7d53ee59c92db60_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfOS0xLTEtMS0w_c5057548-96ee-4aab-88c6-8ed276137847"
      unitRef="usd">0</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="ibb29c883e6cf44fb85a975438790cc71_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfOS0zLTEtMS0w_2da476ea-a190-443e-a1c9-1fe6c7870601"
      unitRef="usd">118900000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i6b1bdb6d04224fe9be09f756f95b5ab0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMTEtMS0xLTEtMA_aff62918-4975-492b-962c-5166add1e313"
      unitRef="usd">34000000.0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i65a8f469e2a84522ae2e22f5234508db_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjU1MTExMGRmYmQ5NTRiMTFhYjIwM2M5NjNlZGYwY2Q4L3RhYmxlcmFuZ2U6NTUxMTEwZGZiZDk1NGIxMWFiMjAzYzk2M2VkZjBjZDhfMTEtMy0xLTEtMA_c277bc81-8c0f-4283-b67d-834b7f2de75f"
      unitRef="usd">210000000.0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <ehc:ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNDI4MA_d599b509-3b33-4cfd-becf-a8d1517f0a61">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the net income attributable to nonredeemable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the shareholders&#x2019; equity section of the condensed consolidated balance sheets, and the net income attributable to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net and comprehensive income attributable to noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; presented in the condensed consolidated statements of comprehensive income for the three and nine months ended September&#160;30, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to nonredeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ehc:ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMi0xLTEtMS0w_13950f00-a595-456b-88bf-f399ab202fc7"
      unitRef="usd">20200000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMi0zLTEtMS0w_d0c23df7-6492-424e-9e31-7ae4eb9c9517"
      unitRef="usd">18200000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMi01LTEtMS0w_d6f25e1d-0577-4306-9f4b-b4e66a256b16"
      unitRef="usd">53200000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMi03LTEtMS0w_ed49fa9d-48c7-40ba-8119-87186fbcc554"
      unitRef="usd">54400000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMy0xLTEtMS0w_7f62c514-42b4-421c-ac6d-3afe1f145909"
      unitRef="usd">2200000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMy0zLTEtMS0w_2f20b06a-fe74-4af4-bd5d-23b5c8ce21bd"
      unitRef="usd">3700000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMy01LTEtMS0w_4ae2060a-49c4-41ca-91db-e66043dbb2ca"
      unitRef="usd">5700000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfMy03LTEtMS0w_7e2bf512-6fb7-4854-a750-a7faa49669d3"
      unitRef="usd">10100000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfNC0xLTEtMS0w_b6252baa-64bd-4811-bd9a-54936a0ada9a"
      unitRef="usd">22400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfNC0zLTEtMS0w_b6718266-b012-447f-90aa-805bf7f5fe8f"
      unitRef="usd">21900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfNC01LTEtMS0w_60024e93-03d2-49d1-8542-f67d01466b25"
      unitRef="usd">58900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RhYmxlOjM5MDY5M2YzZmIzMzQxYzdhYjZmMTUwODcxNmFjZjA5L3RhYmxlcmFuZ2U6MzkwNjkzZjNmYjMzNDFjN2FiNmYxNTA4NzE2YWNmMDlfNC03LTEtMS0w_a6365069-146b-4f85-a80b-4d52a9ce339c"
      unitRef="usd">64500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <ehc:RedeemableNoncontrollingInterestEquityAcquiredPercent
      contextRef="i9e9516c1a9cb4fb3be4969e22995bee4_I20141231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNzc4_24a37ec4-e215-4fb7-b778-5299cf605cbe"
      unitRef="number">0.833</ehc:RedeemableNoncontrollingInterestEquityAcquiredPercent>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i9e9516c1a9cb4fb3be4969e22995bee4_I20141231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMTM0MQ_29b80ec1-5d00-4820-a26a-207d664221e7"
      unitRef="usd">64000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <ehc:SubsidiaryscommonstockheldbysubsidiarysmanagementPercent
      contextRef="i9e9516c1a9cb4fb3be4969e22995bee4_I20141231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMTM5OQ_f54f02e8-6052-41a7-8119-d4e54eb4f540"
      unitRef="number">0.167</ehc:SubsidiaryscommonstockheldbysubsidiarysmanagementPercent>
    <ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent
      contextRef="i9544a214c9f44991a2f78bb7573102e1_D20180201-20180228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMTg2Mw_5712d272-d650-4923-bf47-258c64e29520"
      unitRef="number">0.056</ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ib07fdb10b5d540cb9aedb3134847444d_D20180221-20180221"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjAzNA_d894e7f1-1bfa-4bbd-ad4f-9814c797a013"
      unitRef="usd">65000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent
      contextRef="i37c985034d924ca98f2216ba8ca4af2e_D20190701-20190731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjEyOA_e744cb09-1e56-4707-99a6-1e9d7b96bad0"
      unitRef="number">0.056</ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i7c4dd0ed5ae24830b44a38ea9717cb05_D20190901-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjI5Ng_25c421db-c130-4429-aacc-503493ce2c0b"
      unitRef="usd">163000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent
      contextRef="if85c5fb8e5614004b32140f219b1306a_D20200101-20200131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjM5Mw_55e12e20-88c7-4ba2-85b8-b901e089c381"
      unitRef="number">0.043</ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i4c98c9ecdddb4aa885207bc289ebb66c_D20200218-20200218"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjU2NA_80b3c73e-e7a6-4e99-84ff-986e29b20b39"
      unitRef="usd">162000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue
      contextRef="i5b8fa809e4a440c2bad66de860a5fd7d_I20200218"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMjYyNg_bbf32301-4ff7-40f5-9ccf-8a35c93381d1"
      unitRef="usd">46000000</us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i7fa6591e1e63436d87c66c1d9ccc6214_I20200220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfMzkxMw_37873ca6-3698-4f02-bec9-7a8e474f872f"
      unitRef="shares">560957</us-gaap:TemporaryEquitySharesIssued>
    <ehc:TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages
      contextRef="ib293675829044729970b8ad7871b3312_I20200306"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNDA2OQ_af0eebfb-e858-4bc1-af54-5269cee626f9"
      unitRef="number">0.006</ehc:TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i3efb00ba5fd74b7fab554086f72556bc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85NC9mcmFnOjYyNTkwNGQwNTUyMjQxMjZhN2M1YzZiYTkwNzQwYjE0L3RleHRyZWdpb246NjI1OTA0ZDA1NTIyNDEyNmE3YzVjNmJhOTA3NDBiMTRfNDIyMw_6cfec342-f062-4398-88d2-c11ee1fa701c"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RleHRyZWdpb246OWNjY2Q2ODNlMDUwNGMwNGJjMjc1NzNkNjVmMzBhZjJfMjk3MQ_bd76225b-bcd3-4b6f-aa1e-f86f9a848976">Fair Value Measurements&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from December 31, 2019 to September 30, 2020 primarily resulted from the final purchase of equity interests in Holdings from management investors discussed in Note 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our financial assets and liabilities are determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Equity and Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The fair values of our equity and debt securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The fair value of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to our home health segment was determined using the product of a twelve-month adjusted EBITDA measure and a specified median market price multiple based on a basket of public home health companies and transactions, after adding cash and deducting indebtedness that included the outstanding principal balance under any intercompany notes. To determine the fair value of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our joint venture hospitals, we use the applicable hospitals&#x2019; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable facilities. The projected operating results use management&#x2019;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the three and nine months ended September 30, 2020, we did not record any material gains or losses&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to these assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our consolidation of Yuma Rehabilitation Hospital and the remeasurement of our previously held equity interest at fair value, we recorded a $19.2&#160;million gain as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the three and nine months ended September&#160;30, 2019. We determined the fair value of our previously held equity interest using the income approach valuation technique. The income approach included the use of the hospital's projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the hospital. The projected operating results use management's best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Fair Value Measurements,&#x201d; to the consolidated financial statements accompanying the 2019 Form 10&#x2011;K, the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial commitments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letters of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inputs within the fair value hierarchy. See Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Fair Value Measurements,&#x201d; to the consolidated financial statements accompanying the 2019 Form 10&#x2011;K.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RleHRyZWdpb246OWNjY2Q2ODNlMDUwNGMwNGJjMjc1NzNkNjVmMzBhZjJfMjk3Ng_f3d0cb39-60ea-478b-a623-f21761f83980">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if0c3b00829fa4d4e999d2af5868388c4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMy0xLTEtMS0w_550bd729-e4d8-485d-bb71-e2f309e72fa4"
      unitRef="usd">70900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2f108164baf04c0891eeec5eedea407c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMy0zLTEtMS0w_3f6c21b6-c584-43d5-87f1-ce8ab4d7b44c"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i109455a6fc6a45b8ac46c18c730e447c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMy01LTEtMS0w_eef42eb3-ade4-4a35-9bf0-fe4c432c5c8a"
      unitRef="usd">70900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia45c6446a6c14cb7a9ddd0a2cd90040c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMy03LTEtMS0w_7434fe73-4f7f-4d4c-ada3-e22f41522ff6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0c3b00829fa4d4e999d2af5868388c4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNC0xLTEtMS0w_ed6dae1d-94ba-459e-be6c-ed5aca612ca9"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f108164baf04c0891eeec5eedea407c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNC0zLTEtMS0w_1fd0c9d7-69a0-455f-a74e-a549e547b410"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i109455a6fc6a45b8ac46c18c730e447c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNC01LTEtMS0w_7fe65b44-46b7-4feb-b464-70d2bf4dde09"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia45c6446a6c14cb7a9ddd0a2cd90040c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNC03LTEtMS0w_bd4c24b2-fe1e-49fa-8b5c-6cc53785d890"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i0aed46c41ce046eaad78b41f59a23787_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNS0xLTEtMS0w_f8679b92-5e78-4eb9-bc87-508be729bbc5"
      unitRef="usd">34000000.0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="id2768fdf72bc4ee4a44e6c72c3433df2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNS0zLTEtMS0w_77a7c856-f325-462e-9707-54c17b219000"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ib6bcf1050dcf44a2be092ce5a39ac1a3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNS01LTEtMS0w_4b3394ed-3bed-4961-9dc6-3c7368a6eac9"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ib7afd9afee71467ba27c4ef94b734857_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfNS03LTEtMS0w_8eba3233-b36a-4def-bbd1-aca58bb4f9b9"
      unitRef="usd">34000000.0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3782aabb4f6a4c8892fbf91aadc0bbf6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOC0xLTEtMS0w_ab5478a8-83bb-46fb-b627-5eb571f22f2d"
      unitRef="usd">63500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4130c6d73c9d4e2886d9e5ad5721507f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOC0zLTEtMS0w_878fbb8d-5357-4162-9c1c-b76c6818dc53"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie4a29bb284f84291ac766be040a1b558_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOC01LTEtMS0w_faea23ec-596e-48b3-8bbd-e24f40c924a8"
      unitRef="usd">63500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i171f20bc121a4840b1b7a626e688e5c2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOC03LTEtMS0w_23108c77-8e74-4a0d-80ff-5a2f6dde1ea4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3782aabb4f6a4c8892fbf91aadc0bbf6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOS0xLTEtMS0w_05e44bf3-9f64-429b-9a50-a38b5d5d6d98"
      unitRef="usd">12600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4130c6d73c9d4e2886d9e5ad5721507f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOS0zLTEtMS0w_63f95bfe-0585-4236-8e91-25ec196b7698"
      unitRef="usd">12600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4a29bb284f84291ac766be040a1b558_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOS01LTEtMS0w_424c0aad-79ed-4f86-8c44-5be7c264ee3e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i171f20bc121a4840b1b7a626e688e5c2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfOS03LTEtMS0w_058ad2bc-1e5a-45fc-8c38-98a09f03a00f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i66a6b0c4ea294ae9831e406beeaa1b02_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMTAtMS0xLTEtMA_54021a48-cfcf-44f0-abcd-bec1c7adb6e5"
      unitRef="usd">239600000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i9b0646390aa047889e3811abde11c7d7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMTAtMy0xLTEtMA_3a0d1013-996f-4cdc-93e8-89fa699db689"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i98081f26b7b0413894e5100ec374ac7b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMTAtNS0xLTEtMA_31584090-fa3c-48a1-bc03-d5f5ab859493"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i104c1230c0b9400ea5b323e382d7bf2e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOjdkYzQwOTljZDg4NDQ0YTZhZWM1YTQ1NmRlMmQ2ZTY5L3RhYmxlcmFuZ2U6N2RjNDA5OWNkODg0NDRhNmFlYzVhNDU2ZGUyZDZlNjlfMTAtNy0xLTEtMA_4ece07ea-8c2e-4e85-9072-d1be32fcae08"
      unitRef="usd">239600000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="i90e31655e1c843588845e5d149d3d78f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RleHRyZWdpb246OWNjY2Q2ODNlMDUwNGMwNGJjMjc1NzNkNjVmMzBhZjJfODI0NjMzNzIxMjQ0Mw_2705d942-b1c6-4deb-96bc-0721ebc019b6"
      unitRef="usd">19200000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="i2cb6a7700bc94455b1a76981062358af_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RleHRyZWdpb246OWNjY2Q2ODNlMDUwNGMwNGJjMjc1NzNkNjVmMzBhZjJfODI0NjMzNzIxMjQ0Mw_68a0eb00-f4a3-4411-a92c-92f6efea0552"
      unitRef="usd">19200000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RleHRyZWdpb246OWNjY2Q2ODNlMDUwNGMwNGJjMjc1NzNkNjVmMzBhZjJfMjk3OQ_28726565-8f8f-44a2-8019-7ae2ebfbe056">The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial commitments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letters of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia8ae8d59fc12411b879d99d7434e8c7a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMy0xLTEtMS0w_a0a2bbe0-ddee-4310-ab65-9944f6198d72"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i4ca40e094ccf47d19b41a7336db5ee77_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMy0zLTEtMS0w_80a7e16e-3282-4a8d-863a-cf09424cf43c"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i4a0e75c4e9e143ea8c9e88f3a1327641_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMy01LTEtMS0w_12ad4d1d-f4d1-4102-8dde-06c2b2a0b95e"
      unitRef="usd">45000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia509d100e6ab4e2a9c6a5b3bc3d344dc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMy03LTEtMS0w_c9fc4fbc-2ee6-49ed-a2ae-0507a13aa979"
      unitRef="usd">45000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ie58dd346723c4144a958394c28b0c3d2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNC0xLTEtMS0w_8dcf3078-936c-4dc0-bb37-116a7d77661d"
      unitRef="usd">254800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i186457b966e448f8b789ee4909b7ae8d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNC0zLTEtMS0w_812af1f0-daf9-437e-b5c1-ba43ab071afc"
      unitRef="usd">256500000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id8c5bfe222cb48208514b96445916886_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNC01LTEtMS0w_53c4fe71-0310-4434-a275-54871f0395b9"
      unitRef="usd">265200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia715c07fe5d248e9b5940e457b3706eb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNC03LTEtMS0w_09188599-386a-4f29-95e8-fcd9ff4e7aa0"
      unitRef="usd">266600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8f0377bd53564ffdae03ff64e660194b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS0wLTEtMS0wL3RleHRyZWdpb246ZWZlYzY3ODU1NzkwNDBlYzljMmQxN2VlNTRlYmM1ZDVfMTA5OTUxMTYyNzgxNA_1812e13c-49d0-4d37-a050-d37f8593cec9"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i638ab89eae9440c5b0f1929587a02914_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS0wLTEtMS0wL3RleHRyZWdpb246ZWZlYzY3ODU1NzkwNDBlYzljMmQxN2VlNTRlYmM1ZDVfMTA5OTUxMTYyNzgxNA_2780cf40-90b2-4af1-afd8-2bc66c96e519"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="ie0cb787bf3ff4d24aa0ab14e1e0c373c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS0xLTEtMS0w_37cd65a9-b186-4585-a857-95eb98defbf5"
      unitRef="usd">297900000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0051b03acc3e4e2986db12da328b3bac_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS0zLTEtMS0w_df812a17-bb9c-4feb-a6f0-f1275f1799a6"
      unitRef="usd">302600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic19a05f81373432ca6b36a5c0470017e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS01LTEtMS0w_3c133b45-d7ec-442d-bf98-8700fe11e3e5"
      unitRef="usd">297300000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i3dc3ff3814494e65a5977ad5528ad3b0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNS03LTEtMS0w_e5166d26-7a59-4cce-a30d-aadb288f2a72"
      unitRef="usd">306600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia523dc03179846ddaf98c887899b7679_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi0wLTEtMS0wL3RleHRyZWdpb246ODM4ZDBmZDliMDhmNGRmMWI5OTU1OGJjNjJmZmRkOGNfMTA5OTUxMTYyNzgxMg_1f0ecb5f-54e1-49c8-a3d7-e8ef7c8f27d7"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3892c4bc03204316bb6e77be3f27b240_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi0wLTEtMS0wL3RleHRyZWdpb246ODM4ZDBmZDliMDhmNGRmMWI5OTU1OGJjNjJmZmRkOGNfMTA5OTUxMTYyNzgxMg_8617eaa9-dd12-42bd-9e91-a7f317c226f6"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i934987b44af7446c8218601c95502de9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi0xLTEtMS0w_d8f658d6-3a6a-47fe-bcfe-74002a03d92f"
      unitRef="usd">697700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id68ab94595124a1e97f267729e976e5d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi0zLTEtMS0w_5218b252-e8a8-4eea-962e-b3f5bcff453a"
      unitRef="usd">701500000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id58191662ff7460988e18540fde456ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi01LTEtMS0w_0b01c51b-8459-4655-994c-8624328dd040"
      unitRef="usd">697300000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i6e8394e3bcc5451cacdda373dfbbc0b3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNi03LTEtMS0w_960b4416-1131-4d24-9f03-e8635dffc708"
      unitRef="usd">708800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib40a6e6dd68b4a8da5d30d7aaa484c51_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy0wLTEtMS0wL3RleHRyZWdpb246YmZkMWEyYTkxNTYzNDFiZWFmZTA3Yzg3ODRlZTk1Y2ZfMTA5OTUxMTYyNzgxMg_1e1ce535-b4a4-4809-a01f-25ff69117894"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic41c4e44b7b64428b528add431c16513_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy0wLTEtMS0wL3RleHRyZWdpb246YmZkMWEyYTkxNTYzNDFiZWFmZTA3Yzg3ODRlZTk1Y2ZfMTA5OTUxMTYyNzgxMg_206fb410-c746-439a-a015-f52e7b1cce05"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic5999223d44049ab8c9ad683173bdc2d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy0xLTEtMS0w_b97bd8f3-13a5-425d-b6da-14d8add38247"
      unitRef="usd">346100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ief3957a1e65a4a2b85016faf016e95db_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy0zLTEtMS0w_1148cf5b-fca3-496f-964f-becb9ef5f23b"
      unitRef="usd">361400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i42640997d4454f199cf25a948fc95738_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy01LTEtMS0w_87feb3b2-1d62-45bd-a87b-65707ca26181"
      unitRef="usd">345600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i71f49077e01a45f097881493f89e0508_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfNy03LTEtMS0w_449dcfdf-7bb5-48d9-8d21-ab45e1526ac0"
      unitRef="usd">369700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i730f2a918b744a0e94177fd42ad004a4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC0wLTEtMS0wL3RleHRyZWdpb246NDk1OTBmYzk5OTdkNDM5MDhjNTZlYTIwMDRkNzc1YTlfMTA5OTUxMTYyNzgxMg_3e4a53b0-f392-4aac-a93f-d3668352d54c"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6f1805d3ddcd4b188bc766e18298a2d5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC0wLTEtMS0wL3RleHRyZWdpb246NDk1OTBmYzk5OTdkNDM5MDhjNTZlYTIwMDRkNzc1YTlfMTA5OTUxMTYyNzgxMg_b4f3d06d-eb07-4c4f-8159-a5f676b8a009"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="id9d26a6364364e1a9b54ab393f994255_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC0xLTEtMS0w_1b7cbb5c-cb6f-41b3-aaa7-b9ea9a4aaec2"
      unitRef="usd">784600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib91ca67dc3504530b8450421abc7fb8a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC0zLTEtMS0w_675efaa2-5a9d-49c2-a4c2-c37607571fd1"
      unitRef="usd">804000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="icf31d36bee454c13a050e3f343b6a3c8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC01LTEtMS0w_a896d479-02f6-4c23-a0a1-53b9892bc95c"
      unitRef="usd">491700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ice01013cd7f94c859dbdc8f630c352a2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOC03LTEtMS0w_3d20e155-344b-4463-b4a9-8a5726b892f0"
      unitRef="usd">519400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i62eb57fb87fc40e59f8f33f73b921693_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS0wLTEtMS0wL3RleHRyZWdpb246M2MyM2I3M2FjODhmNDk2Yzk5MDY5NTM3Y2VjMGUxNWFfMTA5OTUxMTYyNzgxMg_1836756b-4f35-4a06-be96-796d8c8dfe82"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idd067c2ff27b4ab8a68e5471e7c59ef9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS0wLTEtMS0wL3RleHRyZWdpb246M2MyM2I3M2FjODhmNDk2Yzk5MDY5NTM3Y2VjMGUxNWFfMTA5OTUxMTYyNzgxMg_b5df9640-78e5-46fe-957d-da9a96f7c979"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7cd83dbae36b43d7b4a6162c02698684_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS0xLTEtMS0w_e55979f4-429b-4375-869c-5fbc1a4b9c1c"
      unitRef="usd">782800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id954ef15e93c4d14ae05f3cd3b278851_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS0zLTEtMS0w_69650335-e3e9-4437-a822-7015e3de5211"
      unitRef="usd">814000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i90ef0119e13b4be5826ee406b88feacb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS01LTEtMS0w_fe7b57d9-8aef-44ad-9233-ee534491259a"
      unitRef="usd">491700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i728449144459420bb67f2d96b87cbb5e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfOS03LTEtMS0w_8f9a82e7-9a90-4806-b240-58204231fcc1"
      unitRef="usd">520000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib34fdd3cc9e945d8af9a195dca36f84b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTAtMS0xLTEtMA_a2afb8db-5613-4089-ba3d-8e6546f16257"
      unitRef="usd">40200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i455ce14d267f4b87b426320cf9bbdc10_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTAtMy0xLTEtMA_dbf9bb42-6e2a-42c4-bc68-30b8cc3f4543"
      unitRef="usd">40200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib6a3de203d80490b878e5ccae2d26b36_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTAtNS0xLTEtMA_4e07dd74-fcc0-45eb-9b8f-4868622b3cde"
      unitRef="usd">44700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id2152173f71549049764873566ae5676_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTAtNy0xLTEtMA_7ba46e3d-1d25-45a4-9575-672f9f4a33c1"
      unitRef="usd">44700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i29cc50ab07e74bbe9b5f86334dca8053_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTItMS0xLTEtMA_81f4ea23-f9e8-4012-afbc-acfabf2c21ed"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic1c210278132437cbd3fe2285375e3cf_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTItMy0xLTEtMA_00b17b52-cd86-43df-bf35-cfe3d730abf2"
      unitRef="usd">36400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i80e176382eb04cdab88c4972bf3f6d7a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTItNS0xLTEtMA_6992d7cb-b676-4c06-8ef3-ee9e548f646c"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="iecb21c9d51d840279240febc1301d0e7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF85Ny9mcmFnOjljY2NkNjgzZTA1MDRjMDRiYzI3NTczZDY1ZjMwYWYyL3RhYmxlOmJiOGJhYjk1MDNmODQxMDI4NjBkNWExM2MwNmU2ZGIzL3RhYmxlcmFuZ2U6YmI4YmFiOTUwM2Y4NDEwMjg2MGQ1YTEzYzA2ZTZkYjNfMTItNy0xLTEtMA_ec21b373-5fa3-4c13-96e1-1d1c199527d4"
      unitRef="usd">38900000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzE3MzM_b4b67271-dbaf-4096-900e-f8e23b280b34">Share-Based Payments&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020, we issued a total of 0.4 million restricted stock awards to members of our management team and our board of directors. Approximately 0.2 million of these awards contain only a service condition, while the remainder contain both a service and a performance condition. For the awards that include a performance condition, the number of shares that will ultimately be granted to employees may vary based on the Company&#x2019;s performance during the applicable two year performance measurement period. Additionally, we granted 0.1 million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Note&#160;14, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to the consolidated financial statements accompanying the 2019 Form 10&#x2011;K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the EHHI acquisition discussed in Note 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we granted stock appreciation rights (&#x201c;SARs&#x201d;) based on Holdings common stock to certain members of EHHI management at closing. Half of the SARs vested on December&#160;31, 2018 and the remainder vested on December 31, 2019. Upon exercise, each SAR must be settled for cash in the amount by which the per share fair value of Holdings&#x2019; common stock on the exercise date exceeds the per share fair value on the grant date. As of December 31, 2019, the fair value of the remaining 115,545 SARs was approximately $101 million, all of which was included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the condensed consolidated balance sheet. In January 2020, members of the management team exercised the remaining SARs, and in February 2020, we settled those awards upon payment of approximately $101 million in cash.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see Note&#160;14, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;, to the consolidated financial statements accompanying the 2019 Form 10&#x2011;K.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4cb38ea719844f6cb5c7d56debf66f6e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzcz_171a6280-80c0-4ea6-a3ca-94ecf598f093"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6fbf64e203144762b1d2ada6b0352efa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzE3Ng_d9fdbe50-1ef6-40bf-9235-3ab7ce19da16"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8958165af77d4177a1e12b5aa53be055_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzE0ODQzNDA2OTc2NzUx_66df67cd-9ced-4df5-96cd-337260292c9c">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i49095c84bb0c46e1bb8ad5d5e2601b49_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzU0Ng_8c8ed690-41cf-435c-8bed-d6b68a923fc4"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="ifbcfb44cf32548af90099a6a944afa74_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzEzMDg_230fa3ed-016b-46db-9a12-65ee1bfc3c88"
      unitRef="shares">115545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ehc:AllocatedSharebasedCompensationLiability
      contextRef="ifbcfb44cf32548af90099a6a944afa74_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzEzMzQ_f12bb5a3-c62d-44cf-a2db-e17272389a87"
      unitRef="usd">101000000</ehc:AllocatedSharebasedCompensationLiability>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="i130a002122d84a44a7f2a2f80eb06cb9_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDMvZnJhZzo4N2QwMmM4YWE1M2Y0YWQwOWE4OTFhNWU0OTgxN2ZiZS90ZXh0cmVnaW9uOjg3ZDAyYzhhYTUzZjRhZDA5YTg5MWE1ZTQ5ODE3ZmJlXzE2MTM_e226093b-9135-4ca8-a393-2b20a46770c8"
      unitRef="usd">101000000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDkvZnJhZzo4YTc4MTQ5ODkwYzE0M2E5OGY4OWE4NzhkMWFjMzFjYi90ZXh0cmVnaW9uOjhhNzgxNDk4OTBjMTQzYTk4Zjg5YTg3OGQxYWMzMWNiXzc0Nw_e2f76399-e9bb-4dd1-9443-b3f32b615292">Income Taxes&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $26.9 million and $34.3 million for the three months ended September&#160;30, 2020 and 2019, respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rate. Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $65.8 million for the nine months ended September&#160;30, 2020 primarily resulted from the application of our estimated effective blended federal and state income tax rate offset by tax benefits resulting from share-based compensation windfalls. Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $88.6 million for the nine months ended September 30, 2019 primarily resulted from the application of our estimated effective blended federal and state income tax rate, tax benefits resulting from share-based compensation windfalls and the deductibility of the June 2019 settlement discussed in Note 18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies and Other Commitments, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the consolidated financial statements accompanying the 2019 Form 10&#x2011;K.&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDkvZnJhZzo4YTc4MTQ5ODkwYzE0M2E5OGY4OWE4NzhkMWFjMzFjYi90ZXh0cmVnaW9uOjhhNzgxNDk4OTBjMTQzYTk4Zjg5YTg3OGQxYWMzMWNiXzU5_196f1051-d7bd-4d3f-9819-be0a5d232e3d"
      unitRef="usd">26900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDkvZnJhZzo4YTc4MTQ5ODkwYzE0M2E5OGY4OWE4NzhkMWFjMzFjYi90ZXh0cmVnaW9uOjhhNzgxNDk4OTBjMTQzYTk4Zjg5YTg3OGQxYWMzMWNiXzIxOTkwMjMyNTYzNDM_933def5f-c4f8-404b-85fe-da66a166dc8d"
      unitRef="usd">34300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDkvZnJhZzo4YTc4MTQ5ODkwYzE0M2E5OGY4OWE4NzhkMWFjMzFjYi90ZXh0cmVnaW9uOjhhNzgxNDk4OTBjMTQzYTk4Zjg5YTg3OGQxYWMzMWNiXzIxOTkwMjMyNTY2MDk_2118f0ea-acf6-4999-8764-7d7502440021"
      unitRef="usd">65800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMDkvZnJhZzo4YTc4MTQ5ODkwYzE0M2E5OGY4OWE4NzhkMWFjMzFjYi90ZXh0cmVnaW9uOjhhNzgxNDk4OTBjMTQzYTk4Zjg5YTg3OGQxYWMzMWNiXzM0MQ_f2c23a6a-b06f-45d2-9568-8ce1c705c752"
      unitRef="usd">88600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90ZXh0cmVnaW9uOjY3ZGUyNzMwNTQ5ODQ1MGVhZWI1NDlmOTExNzk5ZmU1XzQ3Ng_9ac99d67-cb02-481d-88f4-dfc5e762f0fe">Earnings per Common Share&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income allocated to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards, dilutive stock options, and restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;17, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Common Share&lt;/span&gt;, to the consolidated financial statements accompanying the 2019 Form 10&#x2011;K for additional information related to our common stock.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90ZXh0cmVnaW9uOjY3ZGUyNzMwNTQ5ODQ1MGVhZWI1NDlmOTExNzk5ZmU1XzQ5Ng_9a2f0d73-923b-4b75-817f-77910bb8c043">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income allocated to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzQtMS0xLTEtMA_5e300d85-b1be-4728-a1e5-e4544ab15748"
      unitRef="usd">100100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzQtMy0xLTEtMA_5371794d-43c6-4f3c-aacf-62758c0612f8"
      unitRef="usd">119500000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzQtNS0xLTEtMA_70943f3f-d240-445b-aae7-1431a00fc868"
      unitRef="usd">257100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzQtNy0xLTEtMA_a13921ee-ec25-4af3-bbad-039969ca3d26"
      unitRef="usd">356200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzUtMS0xLTEtMA_b893fe7c-c6f6-4942-b513-31dd29a579dc"
      unitRef="usd">22400000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzUtMy0xLTEtMA_06da9724-684d-4b80-ac85-c519ed431088"
      unitRef="usd">21900000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzUtNS0xLTEtMA_1e36c8d3-e66d-42de-a57a-aeea35fef6ea"
      unitRef="usd">58900000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzUtNy0xLTEtMA_cff75778-915c-4143-8b94-b9dcf42dcb7d"
      unitRef="usd">64500000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzYtMS0xLTEtMA_a408fbd7-57dc-4cfc-8821-fd4315b682e2"
      unitRef="usd">300000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzYtMy0xLTEtMA_988b5e63-c10d-4bf3-9fee-ae5fc6d9da60"
      unitRef="usd">400000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzYtNS0xLTEtMA_424f5038-4f39-4eef-af83-35e2b4008484"
      unitRef="usd">700000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzYtNy0xLTEtMA_a632ebee-fc17-4ade-9ae8-5b3c2c3cbdeb"
      unitRef="usd">1100000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzgtMS0xLTEtMA_3c66e069-f2f6-468e-a015-53c335769956"
      unitRef="usd">77400000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzgtMy0xLTEtMA_bd57bfd5-e84f-450b-a542-da35968f9caa"
      unitRef="usd">97200000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzgtNS0xLTEtMA_de88c586-5c6c-47ee-813b-3ab22d51f194"
      unitRef="usd">197500000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzgtNy0xLTEtMA_171a2160-a3df-4bcd-8949-de674cb58f8b"
      unitRef="usd">290600000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzktMS0xLTEtMA_1149eda8-9b3a-4513-962c-96c2b7d76e85"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzktMy0xLTEtMA_dc9503fa-8e4a-40ec-b8a6-90ade4995ce7"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzktNS0xLTEtMA_aa1c1da6-a8bd-4704-ab2f-4f78399b73e9"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzktNy0xLTEtMA_2cb10cf9-1a87-4798-bb00-f7b806bdd01d"
      unitRef="usd">-600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <ehc:NetIncomeLossAvailabletoCommonStockholders
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzExLTEtMS0xLTA_d0b2c501-28fb-403a-b07e-a22a92a4fc2c"
      unitRef="usd">77400000</ehc:NetIncomeLossAvailabletoCommonStockholders>
    <ehc:NetIncomeLossAvailabletoCommonStockholders
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzExLTMtMS0xLTA_90c74420-9e04-4421-93c9-1450566b0467"
      unitRef="usd">97200000</ehc:NetIncomeLossAvailabletoCommonStockholders>
    <ehc:NetIncomeLossAvailabletoCommonStockholders
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzExLTUtMS0xLTA_dec8459e-ccf2-4cef-b079-709b43fada89"
      unitRef="usd">197500000</ehc:NetIncomeLossAvailabletoCommonStockholders>
    <ehc:NetIncomeLossAvailabletoCommonStockholders
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzExLTctMS0xLTA_b1b99990-3c99-4d87-9873-1df99cfeec6c"
      unitRef="usd">290000000.0</ehc:NetIncomeLossAvailabletoCommonStockholders>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzEzLTEtMS0xLTA_75269bea-7387-4be9-ba7c-8374684db1c5"
      unitRef="shares">98700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzEzLTMtMS0xLTA_0cb287e6-0c9c-405c-8b6b-ab463bec4d7d"
      unitRef="shares">97800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzEzLTUtMS0xLTA_3bdf9500-f06e-491f-a129-fb824d54b338"
      unitRef="shares">98500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzEzLTctMS0xLTA_3f2bbfe8-0774-4f04-896e-c4c346d53987"
      unitRef="shares">98100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE1LTEtMS0xLTA_94bdaa4d-9288-4559-9a5e-7d169ca766ed"
      unitRef="usdPerShare">0.78</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE1LTMtMS0xLTA_b3a016bc-364f-4964-bb03-b6495921cc38"
      unitRef="usdPerShare">0.99</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE1LTUtMS0xLTA_639a597d-00ef-494c-a052-f48698bb696c"
      unitRef="usdPerShare">2.01</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE1LTctMS0xLTA_9defde56-2454-4e72-abb1-87232d9e1a88"
      unitRef="usdPerShare">2.97</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE2LTEtMS0xLTA_0ce995c1-e344-4070-a2ca-c4cecd3b1a9b"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE2LTMtMS0xLTA_533bbbb8-c9bc-448e-b378-e9e730ea5bb5"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE2LTUtMS0xLTA_93104b06-41ac-4724-9a38-78834535111e"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE2LTctMS0xLTA_ab8c6984-de1c-440a-8e42-822aab66285e"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE3LTEtMS0xLTA_e30cceec-a234-4bf6-9dc3-0c08d2a1dcbf"
      unitRef="usdPerShare">0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE3LTMtMS0xLTA_31616761-ccfe-4af9-bdbb-536e9f4a3625"
      unitRef="usdPerShare">0.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE3LTUtMS0xLTA_3f7c0000-b0cd-46b2-bca6-5da246667bc9"
      unitRef="usdPerShare">2.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzE3LTctMS0xLTA_9153188f-e30b-4a05-b965-b33abe6a6960"
      unitRef="usdPerShare">2.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIxLTEtMS0xLTA_5e300d85-b1be-4728-a1e5-e4544ab15748"
      unitRef="usd">100100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIxLTMtMS0xLTA_5371794d-43c6-4f3c-aacf-62758c0612f8"
      unitRef="usd">119500000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIxLTUtMS0xLTA_70943f3f-d240-445b-aae7-1431a00fc868"
      unitRef="usd">257100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIxLTctMS0xLTA_a13921ee-ec25-4af3-bbad-039969ca3d26"
      unitRef="usd">356200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIyLTEtMS0xLTA_b893fe7c-c6f6-4942-b513-31dd29a579dc"
      unitRef="usd">22400000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIyLTMtMS0xLTA_06da9724-684d-4b80-ac85-c519ed431088"
      unitRef="usd">21900000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIyLTUtMS0xLTA_1e36c8d3-e66d-42de-a57a-aeea35fef6ea"
      unitRef="usd">58900000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzIyLTctMS0xLTA_bfe29c85-4e10-4b25-a309-63523d3aa5d7"
      unitRef="usd">64500000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI1LTEtMS0xLTA_a008ae4d-7304-4ac8-a7aa-92903542b833"
      unitRef="usd">77700000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI1LTMtMS0xLTA_2033c223-ddcb-487f-9b96-a81ff24eca0d"
      unitRef="usd">97600000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI1LTUtMS0xLTA_5b8c0c85-194a-4148-87ca-4c57cf81bf87"
      unitRef="usd">198200000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI1LTctMS0xLTA_496cf6b0-3c97-4d32-afba-54560e93114b"
      unitRef="usd">291700000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI2LTEtMS0xLTA_1149eda8-9b3a-4513-962c-96c2b7d76e85"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI2LTMtMS0xLTA_dc9503fa-8e4a-40ec-b8a6-90ade4995ce7"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI2LTUtMS0xLTA_aa1c1da6-a8bd-4704-ab2f-4f78399b73e9"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI2LTctMS0xLTA_2cb10cf9-1a87-4798-bb00-f7b806bdd01d"
      unitRef="usd">-600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI3LTEtMS0xLTA_a9a63d86-8b1f-4d06-af31-5b391817f38f"
      unitRef="usd">77700000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI3LTMtMS0xLTA_57ebe882-a61f-44df-a4be-34ec5c4633b8"
      unitRef="usd">97600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI3LTUtMS0xLTA_baadb65e-fa79-4330-a42c-3a9355ef2c9a"
      unitRef="usd">198200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI3LTctMS0xLTA_c4daa7bb-179c-43a0-8c24-1315c024a39f"
      unitRef="usd">291100000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI5LTEtMS0xLTA_77535d64-66b0-4794-a494-c9f09e954615"
      unitRef="shares">99900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI5LTMtMS0xLTA_e1ee1b6e-3fdb-4309-8a7d-c851aba1e1d5"
      unitRef="shares">99400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI5LTUtMS0xLTA_06ca4ff6-65ec-4ccb-a9d1-ca2cb216c16b"
      unitRef="shares">99700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzI5LTctMS0xLTA_7ab77045-9514-4a3b-8897-04c252c68253"
      unitRef="shares">99500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMxLTEtMS0xLTA_f1cccac5-f369-4ad8-aada-24394b227a1d"
      unitRef="usdPerShare">0.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMxLTMtMS0xLTA_e9052588-68a1-4b06-ac2d-b94d66518016"
      unitRef="usdPerShare">0.98</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMxLTUtMS0xLTA_c630441e-ff7e-42f7-8dca-35c32db51502"
      unitRef="usdPerShare">1.99</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMxLTctMS0xLTA_79b34c25-f07b-4399-9349-96c0197a7803"
      unitRef="usdPerShare">2.94</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMyLTEtMS0xLTA_ab3d25c5-d0d9-4db5-beda-8c955c0f7f25"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMyLTMtMS0xLTA_a6c65e02-2661-4809-876d-d3dde9bf3cac"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMyLTUtMS0xLTA_25fe47f0-85ea-4144-92b2-ce49f89435da"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMyLTctMS0xLTA_569149e6-fe92-4529-ac89-877b1b0b8057"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMzLTEtMS0xLTA_b7bc1feb-c705-462e-81f9-04f8032b3eef"
      unitRef="usdPerShare">0.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMzLTMtMS0xLTA_08c67e3e-d633-4a64-88f1-ee95725337be"
      unitRef="usdPerShare">0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMzLTUtMS0xLTA_161f2f1b-c290-45e7-9891-b350bb7da665"
      unitRef="usdPerShare">1.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZToxNzQyODEzZTgxMDQ0NDVmODliMDAzNThjMjJiNWNlYy90YWJsZXJhbmdlOjE3NDI4MTNlODEwNDQ0NWY4OWIwMDM1OGMyMmI1Y2VjXzMzLTctMS0xLTA_c6390220-3968-4e73-9766-c80173ad88b1"
      unitRef="usdPerShare">2.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90ZXh0cmVnaW9uOjY3ZGUyNzMwNTQ5ODQ1MGVhZWI1NDlmOTExNzk5ZmU1XzQ3Nw_d5dc68fe-28c3-4037-88a5-b6686636bec8">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards, dilutive stock options, and restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzItMS0xLTEtMA_75269bea-7387-4be9-ba7c-8374684db1c5"
      unitRef="shares">98700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzItMy0xLTEtMA_0cb287e6-0c9c-405c-8b6b-ab463bec4d7d"
      unitRef="shares">97800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzItNS0xLTEtMA_3bdf9500-f06e-491f-a129-fb824d54b338"
      unitRef="shares">98500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzItNy0xLTEtMA_3f2bbfe8-0774-4f04-896e-c4c346d53987"
      unitRef="shares">98100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzUtMS0xLTEtMA_b8cf1bd0-a236-4688-a2a8-ef746c862ed9"
      unitRef="shares">1200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzUtMy0xLTEtMA_6fc09b4b-5c59-42cf-9798-9ec0273cde29"
      unitRef="shares">1600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzUtNS0xLTEtMA_71c92a0d-4123-40bc-b5fa-002882d19542"
      unitRef="shares">1200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzUtNy0xLTEtMA_c5bc39ab-a5c1-4ec5-97ca-6a708c20502e"
      unitRef="shares">1400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzYtMS0xLTEtMA_bd749b64-6585-4a4f-a027-ba21923095a8"
      unitRef="shares">99900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzYtMy0xLTEtMA_87ab2cb6-d9dd-411e-bcff-1e2774ae3867"
      unitRef="shares">99400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzYtNS0xLTEtMA_2936b8e5-b8c1-4389-a881-6c5778008652"
      unitRef="shares">99700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTUvZnJhZzo2N2RlMjczMDU0OTg0NTBlYWViNTQ5ZjkxMTc5OWZlNS90YWJsZTo3OTMyM2NiZGJmNTA0M2I0YmU0MWQ5NmViZGJkM2MxZi90YWJsZXJhbmdlOjc5MzIzY2JkYmY1MDQzYjRiZTQxZDk2ZWJkYmQzYzFmXzYtNy0xLTEtMA_3b0da5f0-7d45-4c27-8522-8abca6996ca1"
      unitRef="shares">99500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:LossContingencyDisclosures
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTgvZnJhZzoyZDI1ZTYyNzA3ZDQ0NDVlYjVlODUwOTlmMjkxMmFlYi90ZXh0cmVnaW9uOjJkMjVlNjI3MDdkNDQ0NWViNWU4NTA5OWYyOTEyYWViXzUwNzM_7641af86-f27e-441c-bdbd-c928679d0769">Contingencies and Other Commitments&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nichols Litigation&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We were named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nichols v. HealthSouth Corp&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In July 2019, we entered into settlement agreements with all but one plaintiff and paid those settling plaintiffs an aggregate amount of cash less than $0.1 million. The remaining plaintiff alleges that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiff is seeking compensatory and punitive damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This case was stayed in the circuit court on August&#160;8, 2005. However, the complaint has been amended from time to time, including to request certification as a class action. Additionally, one of the former officers named as a defendant has repeatedly attempted to remove the case to federal district court. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. On December&#160;10, 2014, we filed a motion to dismiss on the grounds the plaintiffs lacked standing because their claims were derivative in nature, and the claims were time-barred by the statute of limitations. On May&#160;26, 2016, the trial court granted our motion to dismiss. On appeal, the Supreme Court of Alabama reversed the trial court&#x2019;s dismissal on March 23, 2018. On April 6, 2018, we filed an application for rehearing with the Alabama Supreme Court. On March 22, 2019, the Alabama Supreme Court denied our application for rehearing and remanded the case to the trial court for further proceedings. The court has not yet set a date for the trial to begin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to vigorously defend ourselves in this case against the sole remaining plaintiff. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate an amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The False Claims Act allows private citizens, called &#x201c;relators,&#x201d; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#x201c;whistleblower&#x201d; or &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; actions, can involve significant monetary damages, fines, attorneys&#x2019; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cases brought pursuant to the False Claims Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the United States Department of Health and Human Services Office of Inspector General and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.&lt;/span&gt;&lt;/div&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i2c9a6e8916a642608c3dec74c2e5242b_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMTgvZnJhZzoyZDI1ZTYyNzA3ZDQ0NDVlYjVlODUwOTlmMjkxMmFlYi90ZXh0cmVnaW9uOjJkMjVlNjI3MDdkNDQ0NWViNWU4NTA5OWYyOTEyYWViXzg1OQ_581de864-9eaa-453f-a48b-628ab8dc8a40"
      unitRef="usd">100000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzMyODQ_68b0790c-543e-4308-b1a5-54d295942139">Segment Reporting&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our national network of inpatient rehabilitation hospitals stretches across 36 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of September&#160;30, 2020, we operate 136 inpatient rehabilitation hospitals. We are the sole owner of 87 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 49 jointly owned hospitals. In addition, we manage three inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Home Health and Hospice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- As of September&#160;30, 2020, we provide home health services in 242 locations and hospice services in 83 locations across 31 states with concentrations in the Southeast and Texas. In addition, one of these home health agencies operates as a joint venture which we account for using the equity method of accounting. We are the sole owner of 317 of these locations. We retain 50.0% to 81.0% ownership in the remaining eight jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Our hospice services include in-home services to terminally ill patients and their families to address patients&#x2019; physical needs, including pain control and symptom management, and to provide emotional and spiritual support. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The accounting policies of our reportable segments are the same as those described in Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to the consolidated financial statements accompanying the 2019 Form 10&#x2011;K. All revenues for our services are generated through external customers. See Note 1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Net Operating Revenues,&#x201d; for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (&#x201c;Segment Adjusted EBITDA&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selected financial information for our reportable segments is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Occupancy costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of services sold (excluding depreciation and amortization)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Support and overhead costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net income of nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Encompass Health Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,058.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,610.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,080.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Segment reconciliations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on disposal or impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government, class action, and related settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SARs mark-to-market impact on noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair market value of equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on consolidation of joint venture formerly accounted for under the equity method of accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll taxes on SARs exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income from continuing operations before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets for reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,670.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of deferred income tax liabilities to net deferred income tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consolidated assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,610.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,080.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional detail regarding the revenues of our operating segments by service line follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,581.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outpatient and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inpatient rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total home health and hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,420.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE4NQ_0d63303b-ad5c-43bd-83e4-4b32eef6652a"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzY3Mg_9fd604c5-2095-4608-b639-4fc706e084e0"
      unitRef="state">36</us-gaap:NumberOfStatesInWhichEntityOperates>
    <ehc:NumberOfInpatientRehabilitationHospitals
      contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzgwNg_c0d10855-6ead-452b-97c6-55e8390ca2cd"
      unitRef="hospital">136</ehc:NumberOfInpatientRehabilitationHospitals>
    <ehc:Numberofsolelyownedinpatientrehabilitationhospitals
      contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzg3MA_3cd5b793-61a6-434c-86c9-8461238c4204"
      unitRef="hospital">87</ehc:Numberofsolelyownedinpatientrehabilitationhospitals>
    <ehc:Jointventureownershippercentage
      contextRef="if254742956e843fdbdef4b70418d1d95_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzkwMw_2b309e6a-0277-4a64-b933-90f2b9665d3e"
      unitRef="number">0.500</ehc:Jointventureownershippercentage>
    <ehc:Jointventureownershippercentage
      contextRef="i4e1097dbae78496f9253f83fa0d57473_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzkwOQ_990a83b7-be37-41b9-bada-2c2f718fc26d"
      unitRef="number">0.975</ehc:Jointventureownershippercentage>
    <ehc:Numberofjointlyownedinpatientrehabilitationhospitals
      contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzkzOQ_9273c42e-df23-44ca-9deb-fc9c1a744166"
      unitRef="hospital">49</ehc:Numberofjointlyownedinpatientrehabilitationhospitals>
    <ehc:NumberOfInpatientRehabilitationUnitsUnderManagementContracts
      contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzk5MA_2287dab9-84a8-466d-8458-b5e6d97ae846"
      unitRef="hospital">3</ehc:NumberOfInpatientRehabilitationUnitsUnderManagementContracts>
    <ehc:Numberofhomehealthlocations
      contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE1MTE_55250826-aac7-41c1-9e0a-a9391e131ca5"
      unitRef="location">242</ehc:Numberofhomehealthlocations>
    <ehc:Numberofhospicelocations
      contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE1NDg_2c2bf4a9-f594-44fd-bda2-459aa1797f11"
      unitRef="location">83</ehc:Numberofhospicelocations>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE1Njg_50b3efa6-bfff-4137-a8cf-13be2bc2976a"
      unitRef="state">31</us-gaap:NumberOfStatesInWhichEntityOperates>
    <ehc:NumberofJointVenturesAccountedforUsingtheEquityMethod
      contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE2Mzk_079603e3-90c9-4d56-9f49-ef2588cad1fe"
      unitRef="hospital">1</ehc:NumberofJointVenturesAccountedforUsingtheEquityMethod>
    <ehc:Numberofsolelyownedhospitalbasedhomehealthandhospicelocations
      contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE3ODU_38562a40-3e79-474f-8a70-2a61905a3eff"
      unitRef="location">317</ehc:Numberofsolelyownedhospitalbasedhomehealthandhospicelocations>
    <ehc:Jointventureownershippercentage
      contextRef="ia4085dac83c04f60a84bda9c69ca0fd4_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE4MTg_d587d329-3db9-47d1-bba0-7929e9e67510"
      unitRef="number">0.500</ehc:Jointventureownershippercentage>
    <ehc:Jointventureownershippercentage
      contextRef="i4e018bd04e884537bdbb55709b14d86e_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE4MjQ_c144f378-1863-4543-be8f-6985f1c906f5"
      unitRef="number">0.810</ehc:Jointventureownershippercentage>
    <ehc:Numberofjointlyownedhospitalbasedhomehealthandhospicelocations
      contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzE4NTQ_531c2edc-937a-4312-9dab-83d6fdbb771d"
      unitRef="location">8</ehc:Numberofjointlyownedhospitalbasedhomehealthandhospicelocations>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzMyNzA_56756a27-896e-410e-a350-63e12605da8f">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selected financial information for our reportable segments is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Occupancy costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of services sold (excluding depreciation and amortization)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Support and overhead costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net income of nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtMS0xLTEtMA_9e30fce8-030a-4106-b116-a53b18b258ac"
      unitRef="usd">899400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtMy0xLTEtMA_d27c7943-feed-44ff-bb54-289be277f8ac"
      unitRef="usd">872300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtNS0xLTEtMA_9ad1a8b2-ccd0-4042-8fee-e7bbfb70c4ef"
      unitRef="usd">2633100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtNy0xLTEtMA_e4c2e7e6-355b-491e-b91a-a2fe49b35dcf"
      unitRef="usd">2616300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtOS0xLTEtMA_c8695f2b-a50b-4a59-bc50-7d4a4ec1903d"
      unitRef="usd">274500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtMTEtMS0xLTA_a12750b7-bf8d-4396-b119-e4b450470cae"
      unitRef="usd">289300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtMTMtMS0xLTA_243efc96-744a-43c3-baef-68fb1af0646e"
      unitRef="usd">796900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzMtMTUtMS0xLTA_e8d97153-dfe5-4a9d-b9cd-8fc7f8b81602"
      unitRef="usd">804300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzYtMS0xLTEtMA_08c966e1-3f8f-4a37-891b-114b269d5ad5"
      unitRef="usd">475000000.0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzYtMy0xLTEtMA_d600e354-7656-4efa-8df1-b7333e91f7cf"
      unitRef="usd">459100000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzYtNS0xLTEtMA_990f7111-8cb1-48a1-921d-9118ead39245"
      unitRef="usd">1408700000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzYtNy0xLTEtMA_237fd61a-711f-4182-9e2a-6ccca11a4348"
      unitRef="usd">1347700000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzctMS0xLTEtMA_9f78f334-e101-4144-bbd5-1921498ff5f7"
      unitRef="usd">135500000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzctMy0xLTEtMA_b48251d9-43ae-4351-88f7-e234fc177473"
      unitRef="usd">131300000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzctNS0xLTEtMA_1569c84a-504e-4918-83a2-a410e9c7884e"
      unitRef="usd">394500000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzctNy0xLTEtMA_bf6aaf77-2581-4d64-9548-a4d7cca93f54"
      unitRef="usd">386100000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:SuppliesExpense
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzgtMS0xLTEtMA_b841100c-ed77-491c-9b52-0c5193291d27"
      unitRef="usd">45300000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzgtMy0xLTEtMA_ba062b39-1862-4d42-a05b-9b0aaddff92e"
      unitRef="usd">37000000.0</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzgtNS0xLTEtMA_0d25e7cd-b328-4736-b200-6b5bb6599e05"
      unitRef="usd">126900000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzgtNy0xLTEtMA_d50ce9dd-82cc-4317-9f44-1663e83c0851"
      unitRef="usd">109300000</us-gaap:SuppliesExpense>
    <ehc:OccupancyCost
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzktMS0xLTEtMA_d78c2536-3168-4a79-b831-617929cb60ce"
      unitRef="usd">15300000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzktMy0xLTEtMA_de65e5ab-550b-47fc-ae80-fa97695e744a"
      unitRef="usd">17000000.0</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzktNS0xLTEtMA_526d6679-6839-41dc-b675-b81533cf13ee"
      unitRef="usd">46000000.0</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzktNy0xLTEtMA_656ca6a4-f342-4f95-b9db-a6fce0f3b1d3"
      unitRef="usd">49100000</ehc:OccupancyCost>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzExLTktMS0xLTA_81cc3d5f-15fa-411f-856c-84c2f5d0729d"
      unitRef="usd">121800000</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzExLTExLTEtMS0w_624e61a7-56e2-447b-bf98-a80523daf7bc"
      unitRef="usd">136400000</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzExLTEzLTEtMS0w_522bc100-7491-4262-91a6-d55ee9884c5d"
      unitRef="usd">389400000</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzExLTE1LTEtMS0w_0868700f-51cd-466f-87ae-7d3ca1e552aa"
      unitRef="usd">372800000</ehc:CostofServicesExcludingDepreciationandAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEyLTktMS0xLTA_a3cc21f9-4ad5-4eb4-99ff-08909a7605f2"
      unitRef="usd">100700000</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEyLTExLTEtMS0w_4ae8aef9-ed6e-42e1-a381-0166892808e9"
      unitRef="usd">99600000</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEyLTEzLTEtMS0w_129763da-4ddf-4552-bc5b-bf4f2ae337e1"
      unitRef="usd">299200000</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEyLTE1LTEtMS0w_ab1095de-59d5-4588-aedb-73a2307ab367"
      unitRef="usd">278100000</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostsAndExpenses
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTEtMS0xLTA_9ccb6038-41ba-4b69-bd9c-dde24321158b"
      unitRef="usd">671100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTMtMS0xLTA_d993ddcf-833f-469a-b2a7-419d474b7e2f"
      unitRef="usd">644400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTUtMS0xLTA_d7de8c88-3f52-493e-80b0-75bf90de9c68"
      unitRef="usd">1976100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTctMS0xLTA_af964d06-d77c-403a-a75a-2fca256107cc"
      unitRef="usd">1892200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTktMS0xLTA_89096b6f-a880-4e2a-8305-ab82773f7cf7"
      unitRef="usd">222500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTExLTEtMS0w_87acccc6-9027-42f6-823c-cdf1651a4b3e"
      unitRef="usd">236000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTEzLTEtMS0w_1aa4cc1f-66a4-4815-8196-a989c6e33512"
      unitRef="usd">688600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzEzLTE1LTEtMS0w_a0dcbea0-f1ac-41e1-86b0-e9fb5ef397c5"
      unitRef="usd">650900000</us-gaap:CostsAndExpenses>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTEtMS0xLTA_fd4db32c-1989-4ba5-aa34-edcd5f558461"
      unitRef="usd">2100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTMtMS0xLTA_e81772b9-7d81-4e11-a2c7-175bc8883f62"
      unitRef="usd">1800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTUtMS0xLTA_2c5ac9eb-087f-4dc0-8ac7-e4429174c365"
      unitRef="usd">3900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTctMS0xLTA_e31d09ea-bdf1-4254-8239-f496ceb640cb"
      unitRef="usd">6500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTktMS0xLTA_c9068d97-086e-4284-8891-5ab8f7ee276e"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTExLTEtMS0w_aa155a93-f171-44e6-a149-2ba75092f772"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTEzLTEtMS0w_bbbc968f-b83d-4e98-b5ed-234b3f81f60d"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE0LTE1LTEtMS0w_72fccbb4-087e-4a98-8c4d-b140d679f074"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTEtMS0xLTA_930a7e50-4018-4d65-b7b7-b46daaa4a35e"
      unitRef="usd">900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTMtMS0xLTA_dcc2d5aa-033a-4809-9c32-58729cd49504"
      unitRef="usd">1000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTUtMS0xLTA_ff58567a-21ee-438c-8c2f-d7a88df14ae1"
      unitRef="usd">2100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTctMS0xLTA_f8a5d37e-edea-4edf-858c-d4551cf4ae98"
      unitRef="usd">4500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTktMS0xLTA_160bc2b1-9192-4315-852d-95b17fbe7eb2"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTExLTEtMS0w_7f103a7f-43a7-4c23-b04d-81f838513522"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTEzLTEtMS0w_46e398ed-4707-463c-828b-544b38932e7e"
      unitRef="usd">400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE1LTE1LTEtMS0w_a6a11505-caa9-45ea-ae63-9609673ea348"
      unitRef="usd">1000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTEtMS0xLTA_dfbe7551-569d-40d7-8e48-87a2bf015733"
      unitRef="usd">22100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTMtMS0xLTA_eabd59ad-2154-4269-9b2f-1fbfe38a7725"
      unitRef="usd">20100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTUtMS0xLTA_805f797d-ff8a-490f-9359-1f2530b1518d"
      unitRef="usd">58000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTctMS0xLTA_d33208f6-14ba-4cc4-9cab-aa97aa20a9a9"
      unitRef="usd">60600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTktMS0xLTA_44765c66-b037-4081-9f06-25581aefd478"
      unitRef="usd">300000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTExLTEtMS0w_cad28427-73f8-44ed-8337-77bff95551b5"
      unitRef="usd">2700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTEzLTEtMS0w_a3f3bde1-1d82-48b1-af1c-d37e2d9e32f3"
      unitRef="usd">900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE2LTE1LTEtMS0w_64469014-1b78-458f-afd1-5c7b1640cf19"
      unitRef="usd">8200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <ehc:AdjustedEBITDA
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTEtMS0xLTA_481ad2e0-ea67-4e75-b5eb-c6c46bcff1e6"
      unitRef="usd">209200000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTMtMS0xLTA_eb901b4c-48c8-41a7-bb2d-3bd5e4cb980d"
      unitRef="usd">210600000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTUtMS0xLTA_44cfbea1-73d4-40db-9fb1-23d9f9462f74"
      unitRef="usd">605000000.0</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTctMS0xLTA_2c705315-7bc7-497c-b656-8439f6627408"
      unitRef="usd">674500000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTktMS0xLTA_2d1faa15-e117-464b-a69c-eb12fa974962"
      unitRef="usd">51800000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTExLTEtMS0w_a38ab46d-2320-4a6e-a809-3297cdb712cb"
      unitRef="usd">50800000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTEzLTEtMS0w_875f4ce8-901d-45ff-9705-95389d2f2638"
      unitRef="usd">107800000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE3LTE1LTEtMS0w_5f71ef41-e3ea-4d97-9a96-2e3f82c51f47"
      unitRef="usd">146200000</ehc:AdjustedEBITDA>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTEtMS0xLTA_ece6c86b-93c0-4cb4-bc83-8d9efa5f0ddd"
      unitRef="usd">90400000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTMtMS0xLTA_14a2615c-284b-4a1e-9db9-bc0542bec1c0"
      unitRef="usd">103600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTUtMS0xLTA_49f4a773-ceb3-4b0e-8840-b741b591ef9d"
      unitRef="usd">262600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTctMS0xLTA_d25afe5c-51f0-481a-a0ab-758a4920127f"
      unitRef="usd">266000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTktMS0xLTA_1540a906-ebc9-4162-ae21-f4c317ce2a7f"
      unitRef="usd">500000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTExLTEtMS0w_45311005-0f60-4062-88d2-16dec6dcff0c"
      unitRef="usd">3100000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTEzLTEtMS0w_15d7fa69-6534-440a-8403-0f4301d071af"
      unitRef="usd">2600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo4NDJiYjIxNmRmZjc0NzUyYjA2MTgyYWY3N2I1YWVkNC90YWJsZXJhbmdlOjg0MmJiMjE2ZGZmNzQ3NTJiMDYxODJhZjc3YjVhZWQ0XzE5LTE1LTEtMS0w_ab3183f5-6f9d-4109-827f-5f5b57d192b5"
      unitRef="usd">11100000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzMyNDY_1b527b2a-bad2-44d9-848e-585b5badca24">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Encompass Health Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,058.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,610.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,080.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets for reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,670.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of deferred income tax liabilities to net deferred income tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consolidated assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,610.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,080.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzItMS0xLTEtMA_d8105eab-68f6-42c4-b5c3-d55b17bc5710"
      unitRef="usd">5058900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzItMy0xLTEtMA_b2f3c111-e367-4180-953a-5a5d3f9572b4"
      unitRef="usd">1611900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzItNS0xLTEtMA_b5a0dfb1-0417-4030-a122-5cbabe8135d0"
      unitRef="usd">6610500000</us-gaap:Assets>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i02d74de04d0a49489fef3090ad053d4f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzMtMS0xLTEtMA_4bbac530-e284-42d6-98af-043eea679959"
      unitRef="usd">1700000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i8e7323c2241b4a16b1b13a4e1f206647_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzMtMy0xLTEtMA_48299d52-9766-4fea-97ea-39264d96fcd3"
      unitRef="usd">3900000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzMtNS0xLTEtMA_f07e2d82-7e46-4757-8d11-0f77cb38dc48"
      unitRef="usd">5600000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets
      contextRef="i0d7e9389f7bb49d1937b89476ce847a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzUtMS0xLTEtMA_c5122fdd-0f37-48e5-96a1-6d46c1aa20cf"
      unitRef="usd">4501400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iab84c70e34994c9dbed01b25069a83d2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzUtMy0xLTEtMA_24f884a0-638a-4102-9417-aecbb76d5a95"
      unitRef="usd">1612800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzUtNS0xLTEtMA_7557ac5a-d4ec-441a-b921-7f31519b8342"
      unitRef="usd">6080700000</us-gaap:Assets>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i0d7e9389f7bb49d1937b89476ce847a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzYtMS0xLTEtMA_08fdc672-4ec5-42ab-bd87-e677511c1268"
      unitRef="usd">2000000.0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="iab84c70e34994c9dbed01b25069a83d2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzYtMy0xLTEtMA_324f77c4-82d7-4d3e-b2ed-d7f505754818"
      unitRef="usd">5400000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTo5OGQxZTUzZWFiZmM0OGUxODkwZDZiNGIxNmQzMGUwOS90YWJsZXJhbmdlOjk4ZDFlNTNlYWJmYzQ4ZTE4OTBkNmI0YjE2ZDMwZTA5XzYtNS0xLTEtMA_0ff9e665-2ad0-4fe4-aa1d-f6bd1090de54"
      unitRef="usd">7400000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <ehc:ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzMyNDg_df3d91aa-afb6-4057-9f8b-2f1b60343ae4">Segment reconciliations (in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on disposal or impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government, class action, and related settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SARs mark-to-market impact on noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair market value of equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on consolidation of joint venture formerly accounted for under the equity method of accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll taxes on SARs exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income from continuing operations before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ehc:ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock>
    <ehc:AdjustedEBITDA
      contextRef="i6fb52c020c90481fb7260d98ee51f72b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzItMS0xLTEtMA_cc87c286-59a0-49cc-b898-041053e23603"
      unitRef="usd">261000000.0</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="ica342deee7024b149e3a4aafeeb27c0e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzItMy0xLTEtMA_09c1486b-63bc-49b1-a512-d75448b98370"
      unitRef="usd">261400000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="ifce0d088460444de9f461fc5f954104e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzItNS0xLTEtMA_b60a3f7e-da4c-48a9-9f62-13ec11f5d3fa"
      unitRef="usd">712800000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="iac44cb5b0a604e55a2dd05a02d35a226_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzItNy0xLTEtMA_e2bdf565-f97c-43b9-8151-addece857526"
      unitRef="usd">820700000</ehc:AdjustedEBITDA>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzMtMS0xLTEtMA_c224acc3-20bc-47d7-be31-1b75ddaa1cae"
      unitRef="usd">39100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzMtMy0xLTEtMA_16720e50-e755-4c5f-84ad-40e9a3ea8919"
      unitRef="usd">52500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzMtNS0xLTEtMA_ad1de6cb-238e-447e-92e9-4f5ed5e506ff"
      unitRef="usd">117700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzMtNy0xLTEtMA_e8172337-b57a-4198-8add-21e05efeb3b7"
      unitRef="usd">183000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzQtMS0xLTEtMA_66ed8564-3dda-4226-a69c-e059e286fd44"
      unitRef="usd">61200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzQtMy0xLTEtMA_47a05297-d8ea-43a9-9c02-9720bca89f16"
      unitRef="usd">55100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzQtNS0xLTEtMA_2c813fc9-ac18-4af7-9ea1-88120c57221c"
      unitRef="usd">180700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzQtNy0xLTEtMA_6bab88d2-9c84-412c-a95f-ab13f4161964"
      unitRef="usd">160300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzUtMS0xLTEtMA_5f4ad9ef-5fbd-40f8-8699-5c6edadbacb1"
      unitRef="usd">-7500000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzUtMy0xLTEtMA_06907429-156f-492d-9433-f04630e0308f"
      unitRef="usd">-900000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzUtNS0xLTEtMA_6eec2226-6a57-40b8-b719-b1dda9c2c0d4"
      unitRef="usd">-10600000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzUtNy0xLTEtMA_4f0c0898-1f8c-48d5-b672-66fb8ddaa428"
      unitRef="usd">-3300000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzYtMS0xLTEtMA_22784cd8-497e-47e1-8734-a0490b5632d6"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzYtMy0xLTEtMA_8f199c22-7c4c-4980-bd6b-5bd0731ebcde"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzYtNS0xLTEtMA_1fca3d26-bf03-4f1c-9495-a01e01005d40"
      unitRef="usd">2800000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzYtNy0xLTEtMA_43810cb2-fce9-4672-b83d-011f2b8c5be4"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzgtMS0xLTEtMA_feedbaf2-07fe-433c-9f85-c4ebe4d0fd6b"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzgtMy0xLTEtMA_3f07ed5f-93eb-49d0-84c3-dbbc75f068a2"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzgtNS0xLTEtMA_21f08d91-ddfe-4a2e-8b60-cc7e8816550d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzgtNy0xLTEtMA_08974bac-b0db-42de-afa2-8fe4af62b060"
      unitRef="usd">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzktMS0xLTEtMA_6e8d5a9c-b5f9-40ca-a511-b80c5d28ab33"
      unitRef="usd">49000000.0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzktMy0xLTEtMA_7fef5756-a4c9-4656-9cc0-1d350eecc3a0"
      unitRef="usd">40300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzktNS0xLTEtMA_73142257-ca9d-4136-994a-c63436cda9cc"
      unitRef="usd">138000000.0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzktNy0xLTEtMA_4dc1ed7f-2632-4d0f-9afa-e6f783416e9e"
      unitRef="usd">115200000</us-gaap:InterestExpenseDebt>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzExLTEtMS0xLTA_c818d7f0-7f5b-493a-9d85-f27895c1272e"
      unitRef="usd">22400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzExLTMtMS0xLTA_25e5aab8-fcd1-4a26-9a5a-bd50848a39f3"
      unitRef="usd">21900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzExLTUtMS0xLTA_b49e4394-9b58-46a8-9b76-c2753c48fd8d"
      unitRef="usd">58900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzExLTctMS0xLTA_f5e81721-0820-4088-94a8-05830737e82e"
      unitRef="usd">64500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <ehc:SARsmarktomarketimpactonnoncontrollinginterests
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEyLTEtMS0xLTA_75a64a1b-1a2c-4962-a7c2-4989347fb117"
      unitRef="usd">0</ehc:SARsmarktomarketimpactonnoncontrollinginterests>
    <ehc:SARsmarktomarketimpactonnoncontrollinginterests
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEyLTMtMS0xLTA_09a59f43-eb9a-452e-b186-df4097095e7f"
      unitRef="usd">900000</ehc:SARsmarktomarketimpactonnoncontrollinginterests>
    <ehc:SARsmarktomarketimpactonnoncontrollinginterests
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEyLTUtMS0xLTA_3b339b0a-c0cf-45a3-9c4f-57334bdf072a"
      unitRef="usd">0</ehc:SARsmarktomarketimpactonnoncontrollinginterests>
    <ehc:SARsmarktomarketimpactonnoncontrollinginterests
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEyLTctMS0xLTA_a4357a3a-21f7-42e7-8669-644d1a7632b0"
      unitRef="usd">4300000</ehc:SARsmarktomarketimpactonnoncontrollinginterests>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEzLTEtMS0xLTA_e285d342-be77-4cd0-8181-d9fc9708177c"
      unitRef="usd">400000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEzLTMtMS0xLTA_b948e103-6683-4745-930a-b7410e3ba432"
      unitRef="usd">0</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEzLTUtMS0xLTA_aa1964a8-122a-4323-b079-79eda1e0acdb"
      unitRef="usd">300000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzEzLTctMS0xLTA_a7952046-bc87-423d-a746-f473c0fd4d30"
      unitRef="usd">1200000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE0LTEtMS0xLTA_0e38a666-13b8-4312-86be-bd18d4989e93"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE0LTMtMS0xLTA_b1dcded5-483c-42dd-ade3-4aa28559ba07"
      unitRef="usd">19200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE0LTUtMS0xLTA_e525e728-827e-481b-88d9-2ca8351dfbf4"
      unitRef="usd">2200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE0LTctMS0xLTA_02b26a3e-e999-4e3d-905c-95759ffd8131"
      unitRef="usd">19200000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <ehc:PayrolltaxesonSARsexercise
      contextRef="i0cf66936c09a4529997e2eb1da196f4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE1LTEtMS0xLTA_a9991747-3006-4539-8996-777c987434f1"
      unitRef="usd">0</ehc:PayrolltaxesonSARsexercise>
    <ehc:PayrolltaxesonSARsexercise
      contextRef="idc1b2df6a1c04c2eaf82f14655101b1d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE1LTMtMS0xLTA_47ef0688-c400-4b76-97b9-814f983a2006"
      unitRef="usd">800000</ehc:PayrolltaxesonSARsexercise>
    <ehc:PayrolltaxesonSARsexercise
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE1LTUtMS0xLTA_7d76f7b0-77d0-4eb8-8799-eff2b737f0fb"
      unitRef="usd">1500000</ehc:PayrolltaxesonSARsexercise>
    <ehc:PayrolltaxesonSARsexercise
      contextRef="i44cd2be6ee944aeaba7ae0aff1234878_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE1LTctMS0xLTA_d07ecb16-fd5b-4531-a76d-eb299b66a8f3"
      unitRef="usd">1000000.0</ehc:PayrolltaxesonSARsexercise>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE3LTEtMS0xLTA_8e3339e5-04e3-4a19-abf8-19748fb2757d"
      unitRef="usd">127000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE3LTMtMS0xLTA_dee456db-8db3-400b-bb41-6feabd6a43f7"
      unitRef="usd">153800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE3LTUtMS0xLTA_d5d633eb-783c-4845-ab6a-1698dd10da87"
      unitRef="usd">322900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTpiZTk4ZTBlZjAwMTk0OWU0YjhkZTA5MjAzMGUyNTg0NS90YWJsZXJhbmdlOmJlOThlMGVmMDAxOTQ5ZTRiOGRlMDkyMDMwZTI1ODQ1XzE3LTctMS0xLTA_d36105f7-cf1a-47cc-b7f9-07861a4b5c11"
      unitRef="usd">444800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="i4b556ace711f4b07a26951c1b12a6868_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzEtMS0xLTEtMA_1efdc3f8-bd26-4660-bd97-178a6b9fbe6e"
      unitRef="usd">6670800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i62367bba18c143edac791ed9c0e6b12d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzEtMy0xLTEtMA_0a641613-4ff2-46da-957f-15bd03d4674c"
      unitRef="usd">6114200000</us-gaap:Assets>
    <us-gaap:PriorPeriodReclassificationAdjustment
      contextRef="iccdbae000e944181891b3777a7fbbaf7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzItMS0xLTEtMA_826b6a09-c153-4e5e-8dc8-c0be21a04d66"
      unitRef="usd">-60300000</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:PriorPeriodReclassificationAdjustment
      contextRef="id5e3006bff47459eb04bfde259d0b285_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzItMy0xLTEtMA_87b33a92-a686-41c6-955c-50b1cb423731"
      unitRef="usd">-33500000</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:Assets
      contextRef="i6cf41bad492345de99ed38cb8db55427_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzMtMS0xLTEtMA_6dcccf62-516b-4e12-a850-5d5d60aa112c"
      unitRef="usd">6610500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if166fe2888ed4236b69cbd1304d9ed61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZTplM2UwYTUzOTZlMzY0M2NhOWNjMDVkZjliOTI3NzExOC90YWJsZXJhbmdlOmUzZTBhNTM5NmUzNjQzY2E5Y2MwNWRmOWI5Mjc3MTE4XzMtMy0xLTEtMA_39b677d3-285d-40a3-ad7b-c552dfd0bff0"
      unitRef="usd">6080700000</us-gaap:Assets>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90ZXh0cmVnaW9uOjhkMWY0OTIxNjk2YTQ4NTA4YWUxNmVhZWFiZGIyNGNkXzMyNTM_ded251c3-635c-4752-b267-31d7ed8e12c7">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional detail regarding the revenues of our operating segments by service line follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,581.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outpatient and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inpatient rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total home health and hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,420.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16bc1b11f6474259b5d2a6c7a7ed7d3f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzMtMS0xLTEtMA_c2fb8849-3b7f-4f4e-aea3-92f4cf69a995"
      unitRef="usd">883200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i060b61eae5e141f5a0ecfd1970befba2_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzMtMy0xLTEtMA_63d1a9cb-3e04-4b91-b4da-3f7891c42b78"
      unitRef="usd">850600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a8f9f90011a4999af002b1dd34ca597_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzMtNS0xLTEtMA_e1d72946-7356-41a7-a76c-c0c69ea20b96"
      unitRef="usd">2581200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fc6b9fc57a843aa950bd9f011875dea_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzMtNy0xLTEtMA_50dccc94-498f-465c-9dde-01f5537429d9"
      unitRef="usd">2550000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4eba057206a47f6ad35e724ea946fcc_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzQtMS0xLTEtMA_25918e99-ea3d-4942-aad5-cc58ddad78c7"
      unitRef="usd">16200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b675f52d0454ca895e68f1f2ec026c3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzQtMy0xLTEtMA_68e4fbec-29c4-4361-ac67-8d5d47be5705"
      unitRef="usd">21700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia00b712980524ce3863212d497722fb9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzQtNS0xLTEtMA_37784ee0-b959-4933-9d2d-896c67b22e93"
      unitRef="usd">51900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic72bcc5ef89644cc8431b9901f34f714_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzQtNy0xLTEtMA_4f439520-3fc5-44f6-b9ad-8223136465e5"
      unitRef="usd">66300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzUtMS0xLTEtMA_30e87871-704f-4be8-ba53-a808ce6af283"
      unitRef="usd">899400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i955a06a4d6d0446faaf738849fa7fd36_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzUtMy0xLTEtMA_47dd3233-fea6-49f7-b2c1-db9a6faeb71b"
      unitRef="usd">872300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10b0c887a0904f01b1476a66a6f7331d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzUtNS0xLTEtMA_75b3cf05-34fd-42c4-b783-d517e11d08be"
      unitRef="usd">2633100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2394e9be2d4249e8a1f28d39525d0635_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzUtNy0xLTEtMA_0e8b77ad-6c69-4433-9c54-4b54efad6503"
      unitRef="usd">2616300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3f156c397a54a5e942b4169a6555c29_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzctMS0xLTEtMA_2cec2806-0068-430a-8bb2-dd45c61dcf63"
      unitRef="usd">223300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7e0deb3678448e38f17bc49a774bc9c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzctMy0xLTEtMA_db7c3407-eec0-4f41-b7cb-2c8ce6be70a8"
      unitRef="usd">238900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d7b86bab34f4844a928bf4006774a56_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzctNS0xLTEtMA_ecf4f5fc-ceaf-4b89-b18c-8cec7f652d55"
      unitRef="usd">649900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief533155274145c69d708e96345ddceb_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzctNy0xLTEtMA_f737688e-cf5c-444e-b8e7-9ec566e90a1d"
      unitRef="usd">681100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5f70ec669814c3ab99525a8689c1d52_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzgtMS0xLTEtMA_97bf2ca2-c207-4bf4-9dd8-77b08a236f69"
      unitRef="usd">51200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadc1cfae314f4bd3add26a155e7e540f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzgtMy0xLTEtMA_08edc223-f922-4ac8-a8c0-f5d6dc9d5706"
      unitRef="usd">50400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i542fad3dce5840d59dc96ad7e51d6df1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzgtNS0xLTEtMA_660f719d-31fe-4fb9-a771-46e41798061c"
      unitRef="usd">147000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2819d470f954f05969b485651250dea_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzgtNy0xLTEtMA_b0e88b4c-85da-429f-b8de-ccea18b2c0d0"
      unitRef="usd">123200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida71cacfc9bd44868f11c57b3eb51b19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzktMS0xLTEtMA_2dacb7bb-a322-49bf-9afc-e24f6ee07d86"
      unitRef="usd">274500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf93d004d0d94341a177a46b580dfd69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzktMy0xLTEtMA_eedba53f-b0a2-4e52-99ad-ff0617329424"
      unitRef="usd">289300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a47cb9fde7e45fa92854242423635b1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzktNS0xLTEtMA_3ae8c3d5-a11d-468f-a87f-31442c6ac087"
      unitRef="usd">796900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icef2a96ac65c4c4da6249c9d92041e7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzktNy0xLTEtMA_e996fa01-f92c-4800-9d2d-671a10e841aa"
      unitRef="usd">804300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8918b77e8b4434b8851a792780313ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzEwLTEtMS0xLTA_b137b368-286c-488c-8249-77ce550c6b45"
      unitRef="usd">1173900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i017841de5d9446e992d9623cdc40d80b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzEwLTMtMS0xLTA_87d5e1ec-bbd6-4979-9580-ed662c39d021"
      unitRef="usd">1161600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzEwLTUtMS0xLTA_06cf4528-5d76-4718-87b3-3ed1b1748c4d"
      unitRef="usd">3430000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34499cd542a14592b5e93ad755870e76_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8xMjEvZnJhZzo4ZDFmNDkyMTY5NmE0ODUwOGFlMTZlYWVhYmRiMjRjZC90YWJsZToxN2JiMGRhOGM0Yjg0MTU0ODczZDc0NGU1N2Y1MmNhMi90YWJsZXJhbmdlOjE3YmIwZGE4YzRiODQxNTQ4NzNkNzQ0ZTU3ZjUyY2EyXzEwLTctMS0xLTA_f39725d4-f6fd-43e3-bea2-b6a55ef17c13"
      unitRef="usd">3420600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMy0xLTEtMA_4c2edf44-6da2-4948-b82c-510be11a7456"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMy0xLTEtMA_4c2edf44-6da2-4948-b82c-510be11a7456"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMS0xLTEtMA_ebb6140b-8134-4576-8117-101988e3ab55"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMS0xLTEtMA_ebb6140b-8134-4576-8117-101988e3ab55"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMy0xLTEtMA_96422c3d-18b4-4626-ad92-22d400d71628"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMy0xLTEtMA_96422c3d-18b4-4626-ad92-22d400d71628"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMS0xLTEtMA_7fe2fe5d-8a17-4f0d-b904-5da3eff95fff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMS0xLTEtMA_7fe2fe5d-8a17-4f0d-b904-5da3eff95fff"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzUz_7165f141-3da2-4f42-969a-a86f3d941f6a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzUz_7165f141-3da2-4f42-969a-a86f3d941f6a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of September&#160;30, 2020 and December&#160;31, 2019 include total assets of variable interest entities of $222.0 million and $215.0 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September&#160;30, 2020 and December&#160;31, 2019 include total liabilities of the variable interest entities of $44.6 million and $41.1 million, respectively. See Note 3, </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMy0xLTEtMA_4c2edf44-6da2-4948-b82c-510be11a7456"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzUz_7165f141-3da2-4f42-969a-a86f3d941f6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMTUtMS0xLTEtMA_ebb6140b-8134-4576-8117-101988e3ab55"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzUz_7165f141-3da2-4f42-969a-a86f3d941f6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMy0xLTEtMA_96422c3d-18b4-4626-ad92-22d400d71628"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzUz_7165f141-3da2-4f42-969a-a86f3d941f6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RhYmxlOmZjYzdjY2UyMDIxOTRkY2I4M2RkNDIyYmFhNjVlNGUzL3RhYmxlcmFuZ2U6ZmNjN2NjZTIwMjE5NGRjYjgzZGQ0MjJiYWE2NWU0ZTNfMzQtMS0xLTEtMA_7fe2fe5d-8a17-4f0d-b904-5da3eff95fff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjVlYzJkMWY5MDNkMzQwYzE5ZWU3NDk4MzcwMGRjMjhkL3NlYzo1ZWMyZDFmOTAzZDM0MGMxOWVlNzQ5ODM3MDBkYzI4ZF8zMS9mcmFnOmIwZjkyMWZmYzYwNzRkY2RiNGY4YjgzODJlOTZkNTg5L3RleHRyZWdpb246YjBmOTIxZmZjNjA3NGRjZGI0ZjhiODM4MmU5NmQ1ODlfMzUz_7165f141-3da2-4f42-969a-a86f3d941f6a"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219211321880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-10315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Encompass Health Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">63-0860407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9001 Liberty Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Birmingham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">35242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-7116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,432,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000785161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219211941672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract', window );"><strong>Statement Of Comprehensive Income And Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 1,173.9<span></span>
</td>
<td class="nump">$ 1,161.6<span></span>
</td>
<td class="nump">$ 3,430.0<span></span>
</td>
<td class="nump">$ 3,420.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">664.9<span></span>
</td>
<td class="nump">660.8<span></span>
</td>
<td class="nump">1,995.9<span></span>
</td>
<td class="nump">1,904.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">163.4<span></span>
</td>
<td class="nump">156.6<span></span>
</td>
<td class="nump">471.3<span></span>
</td>
<td class="nump">456.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
<td class="nump">61.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">52.5<span></span>
</td>
<td class="nump">42.9<span></span>
</td>
<td class="nump">148.8<span></span>
</td>
<td class="nump">124.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">39.1<span></span>
</td>
<td class="nump">52.5<span></span>
</td>
<td class="nump">117.7<span></span>
</td>
<td class="nump">183.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">61.2<span></span>
</td>
<td class="nump">55.1<span></span>
</td>
<td class="nump">180.7<span></span>
</td>
<td class="nump">160.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Government, class action, and related settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,001.4<span></span>
</td>
<td class="nump">989.7<span></span>
</td>
<td class="nump">2,978.0<span></span>
</td>
<td class="nump">2,890.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense and amortization of debt discounts and fees</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">40.3<span></span>
</td>
<td class="nump">138.0<span></span>
</td>
<td class="nump">115.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
<td class="num">(26.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income tax expense</a></td>
<td class="nump">127.0<span></span>
</td>
<td class="nump">153.8<span></span>
</td>
<td class="nump">322.9<span></span>
</td>
<td class="nump">444.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
<td class="nump">88.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">100.1<span></span>
</td>
<td class="nump">119.5<span></span>
</td>
<td class="nump">257.1<span></span>
</td>
<td class="nump">356.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">100.1<span></span>
</td>
<td class="nump">119.5<span></span>
</td>
<td class="nump">257.1<span></span>
</td>
<td class="nump">355.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">100.1<span></span>
</td>
<td class="nump">119.5<span></span>
</td>
<td class="nump">257.1<span></span>
</td>
<td class="nump">355.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="num">(22.4)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(58.9)<span></span>
</td>
<td class="num">(64.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(22.4)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(58.9)<span></span>
</td>
<td class="num">(64.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Encompass Health</a></td>
<td class="nump">77.7<span></span>
</td>
<td class="nump">97.6<span></span>
</td>
<td class="nump">198.2<span></span>
</td>
<td class="nump">291.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Encompass Health</a></td>
<td class="nump">$ 77.7<span></span>
</td>
<td class="nump">$ 97.6<span></span>
</td>
<td class="nump">$ 198.2<span></span>
</td>
<td class="nump">$ 291.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">98.7<span></span>
</td>
<td class="nump">97.8<span></span>
</td>
<td class="nump">98.5<span></span>
</td>
<td class="nump">98.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">99.9<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
<td class="nump">99.7<span></span>
</td>
<td class="nump">99.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (in dollars per share)</a></td>
<td class="nump">0.78<span></span>
</td>
<td class="nump">0.99<span></span>
</td>
<td class="nump">2.01<span></span>
</td>
<td class="nump">2.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">0.78<span></span>
</td>
<td class="nump">0.98<span></span>
</td>
<td class="nump">1.99<span></span>
</td>
<td class="nump">2.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Amounts attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations</a></td>
<td class="nump">$ 77.7<span></span>
</td>
<td class="nump">$ 97.6<span></span>
</td>
<td class="nump">$ 198.2<span></span>
</td>
<td class="nump">$ 291.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Encompass Health</a></td>
<td class="nump">$ 77.7<span></span>
</td>
<td class="nump">$ 97.6<span></span>
</td>
<td class="nump">$ 198.2<span></span>
</td>
<td class="nump">$ 291.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_OccupancyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_OccupancyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statement Of Comprehensive Income And Income Statement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219214253800">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 94.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57.2<span></span>
</td>
<td class="nump">57.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">593.3<span></span>
</td>
<td class="nump">506.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73.9<span></span>
</td>
<td class="nump">97.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,174.4<span></span>
</td>
<td class="nump">755.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,094.9<span></span>
</td>
<td class="nump">1,959.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">267.2<span></span>
</td>
<td class="nump">276.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,318.7<span></span>
</td>
<td class="nump">2,305.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">441.9<span></span>
</td>
<td class="nump">476.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">305.9<span></span>
</td>
<td class="nump">304.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,610.5<span></span>
</td>
<td class="nump">6,080.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">39.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47.1<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">119.6<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">478.8<span></span>
</td>
<td class="nump">546.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">682.5<span></span>
</td>
<td class="nump">721.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,539.4<span></span>
</td>
<td class="nump">3,023.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228.9<span></span>
</td>
<td class="nump">243.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">230.0<span></span>
</td>
<td class="nump">159.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,680.8<span></span>
</td>
<td class="nump">4,148.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34.0<span></span>
</td>
<td class="nump">239.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Encompass Health shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,520.8<span></span>
</td>
<td class="nump">1,352.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">374.9<span></span>
</td>
<td class="nump">340.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,895.7<span></span>
</td>
<td class="nump">1,693.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,610.5<span></span>
</td>
<td class="nump">$ 6,080.7<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of September&#160;30, 2020 and December&#160;31, 2019 include total assets of variable interest entities of $222.0 million and $215.0 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September&#160;30, 2020 and December&#160;31, 2019 include total liabilities of the variable interest entities of $44.6 million and $41.1 million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219222933352">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,610.5<span></span>
</td>
<td class="nump">$ 6,080.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,680.8<span></span>
</td>
<td class="nump">4,148.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">VIE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222.0<span></span>
</td>
<td class="nump">215.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 44.6<span></span>
</td>
<td class="nump">$ 41.1<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of September&#160;30, 2020 and December&#160;31, 2019 include total assets of variable interest entities of $222.0 million and $215.0 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September&#160;30, 2020 and December&#160;31, 2019 include total liabilities of the variable interest entities of $44.6 million and $41.1 million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219214619768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2018</a></td>
<td class="nump">$ 1,557.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 2,588.7<span></span>
</td>
<td class="num">$ (885.2)<span></span>
</td>
<td class="num">$ (427.9)<span></span>
</td>
<td class="nump">$ 280.3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">345.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(16.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(81.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(52.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value adjustments to redeemable noncontrolling interests</a></td>
<td class="num">(118.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Consolidation of Yuma Rehabilitation Hospital</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock in open market</a></td>
<td class="num">(45.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of common stock in open market (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2019</a></td>
<td class="nump">1,671.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,417.8<span></span>
</td>
<td class="num">(594.1)<span></span>
</td>
<td class="num">(491.7)<span></span>
</td>
<td class="nump">338.2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2019</a></td>
<td class="nump">1,583.8<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,455.6<span></span>
</td>
<td class="num">(691.7)<span></span>
</td>
<td class="num">(489.1)<span></span>
</td>
<td class="nump">307.9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">115.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(27.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(20.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value adjustments to redeemable noncontrolling interests</a></td>
<td class="num">(18.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Consolidation of Yuma Rehabilitation Hospital</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock in open market</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of common stock in open market (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2019</a></td>
<td class="nump">1,671.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,417.8<span></span>
</td>
<td class="num">(594.1)<span></span>
</td>
<td class="num">(491.7)<span></span>
</td>
<td class="nump">338.2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">1,693.1<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,369.9<span></span>
</td>
<td class="num">(526.5)<span></span>
</td>
<td class="num">(492.3)<span></span>
</td>
<td class="nump">340.9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">251.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(15.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(83.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange of Holdings shares</a></td>
<td class="nump">46.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange of Holdings shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(50.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">32.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock in open market</a></td>
<td class="num">(4.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of common stock in open market (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2020</a></td>
<td class="nump">1,895.7<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,343.1<span></span>
</td>
<td class="num">(328.3)<span></span>
</td>
<td class="num">(495.1)<span></span>
</td>
<td class="nump">374.9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2020</a></td>
<td class="nump">1,831.4<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,362.4<span></span>
</td>
<td class="num">(406.0)<span></span>
</td>
<td class="num">(494.7)<span></span>
</td>
<td class="nump">368.6<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">97.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(28.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(21.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2020</a></td>
<td class="nump">$ 1,895.7<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 2,343.1<span></span>
</td>
<td class="num">$ (328.3)<span></span>
</td>
<td class="num">$ (495.1)<span></span>
</td>
<td class="nump">$ 374.9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total contributions made by each class of partners (i.e., general, limited and preferred partners).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219218905672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared on common stock (in dollars per share)</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219209034120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 257.1<span></span>
</td>
<td class="nump">$ 355.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities&#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">180.7<span></span>
</td>
<td class="nump">160.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax (benefit) expense</a></td>
<td class="num">(5.7)<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of Yuma Rehabilitation Hospital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(19.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Change in assets and liabilities, net of acquisitions&#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(71.8)<span></span>
</td>
<td class="num">(37.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">17.3<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="num">(4.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">Accrued payroll</a></td>
<td class="nump">86.7<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(90.0)<span></span>
</td>
<td class="num">(118.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities of discontinued operations</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">167.9<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">425.0<span></span>
</td>
<td class="nump">419.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(231.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(256.2)<span></span>
</td>
<td class="num">(259.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Additions to capitalized software costs</a></td>
<td class="num">(5.7)<span></span>
</td>
<td class="num">(9.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(264.8)<span></span>
</td>
<td class="num">(511.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from bond issuance</a></td>
<td class="nump">592.5<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Principal payments on debt, including pre-payments</a></td>
<td class="num">(14.7)<span></span>
</td>
<td class="num">(115.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings on revolving credit facility</a></td>
<td class="nump">330.0<span></span>
</td>
<td class="nump">525.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Payments on revolving credit facility</a></td>
<td class="num">(375.0)<span></span>
</td>
<td class="num">(555.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments under finance lease obligations</a></td>
<td class="num">(16.7)<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(13.5)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid on behalf of employees for shares withheld</a></td>
<td class="num">(15.7)<span></span>
</td>
<td class="num">(16.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid on common stock</a></td>
<td class="num">(84.3)<span></span>
</td>
<td class="num">(81.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions paid to noncontrolling interests of consolidated affiliates</a></td>
<td class="num">(52.9)<span></span>
</td>
<td class="num">(57.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock, including fees and expenses</a></td>
<td class="num">(4.9)<span></span>
</td>
<td class="num">(45.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Purchase of equity interests in consolidated affiliates</a></td>
<td class="num">(162.3)<span></span>
</td>
<td class="num">(162.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">25.8<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">208.3<span></span>
</td>
<td class="nump">472.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">368.5<span></span>
</td>
<td class="nump">380.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">159.6<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">528.1<span></span>
</td>
<td class="nump">513.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of Cash, Cash Equivalents, and Restricted Cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">94.8<span></span>
</td>
<td class="nump">69.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash at beginning of period</a></td>
<td class="nump">57.4<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other long-term assets at beginning of period</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">159.6<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">450.0<span></span>
</td>
<td class="nump">422.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash at end of period</a></td>
<td class="nump">57.2<span></span>
</td>
<td class="nump">66.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other long-term assets at end of period</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">528.1<span></span>
</td>
<td class="nump">513.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental schedule of noncash financing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate', window );">Adoption of ASC 842</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 349.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Financing Activities, Adoption Of Accounting Standard Update</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDistributionsToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDistributionsToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219207144568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is one of the nation&#8217;s largest providers of post-acute healthcare services, offering both facility-based and home-based patient services in 39 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using two reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. See also Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Encompass Health Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes contained in Encompass Health&#8217;s Annual Report on Form&#160;10-K filed with the United States Securities and Exchange Commission on February&#160;27, 2020 (the &#8220;2019 Form 10&#8209;K&#8221;). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December&#160;31, 2019 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of an amendment to the joint venture agreement related to Yuma Rehabilitation Hospital, the accounting for this hospital changed from the equity method of accounting to a consolidated entity effective July 1, 2019. The amendment revised certain participatory rights held by our joint venture partner resulting in Encompass Health gaining control of this entity from an accounting perspective. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. The consolidation of Yuma Rehabilitation Hospital did not have a material impact on our financial position, results of operations, or cash flows. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased by $24.9&#160;million and we recorded a $19.2&#160;million gain as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three and nine months ended September 30, 2019.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source and segment are as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,396.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare Administrative Contractors, under programs known as &#8220;widespread probes&#8221;, have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute or &#8220;appeal&#8221; most of these denials, and for claims we choose to take to administrative law judge (&#8220;ALJ&#8221;) hearings, we have historically experienced a success rate of 70%. This historical success rate is a component of our estimate of transaction price utilized in determining </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. If current OHMA practices continue, an increased number of unfavorable ALJ decisions could have a negative effect on our long-term ALJ success rate. We are exploring various remedies to counter such negative effects. We believe it is too early to determine what impact, if any, these recent changes in the appeals process will have on our historical success rate or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 Form 10-K for our policy related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">novel coronavirus disease 2019 (&#8220;COVID-19&#8221;) pandemic</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has caused a disruption to our nation&#8217;s healthcare system. Such disruption includes reductions in the availability of personal protective equipment (&#8220;PPE&#8221;) to prevent spread of the disease during patient treatment and increases in the cost of PPE. Elective procedures were postponed by physicians and acute-care hospitals and limited by governmental order to preserve capacity for the expected volume of COVID-19 patients and reduce the risk of the spread of COVID-19. Initially, these postponements and limitations were widespread. Now, they are more market or state specific and driven by the extent of the pandemic in those areas. Beginning in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mid-March and continuing into the second and third quarters, we experienced decreased volumes in both segments which we believe resulted from a number of conditions related to the COVID-19 pandemic including: lower acute-care hospital censuses due to the deferral of elective surgeries and shelter-in-place orders, restrictive visitation policies in place at acute-care hospitals that severely limit access to patients and caregivers by our clinical rehabilitation liaisons and care transition coordinators, lock downs of assisted living facilities that prevent our home care and hospice clinicians and other care providers from visiting patients, and heightened anxiety among patients and their family members regarding the risk of exposure to COVID-19 during acute-care and post-acute care treatment. In the home health and hospice segment, we also experienced decreases in visits per episode and institutional referrals because of the COVID-19 pandemic, both of which negatively impacted pricing for home health.</span></div><div style="text-indent:36pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2020, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">federal government began to undertake numerous legislative and regulatory initiatives designed to provide relief to the healthcare industry during the COVID-19 pandemic</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. A specific initiative impacting us is the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;) which</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> temporaril</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">y suspends the automatic 2% reduction of Medicare program payments known as &#8220;sequestration&#8221; for the period of May 1 through December 31, 2020 and authorizes the cash distribution of relief funds from the United States Department of Health and Human Services (&#8220;HHS&#8221;) to healthcare providers in response to the COVID-19 pandemic. On April 10, 2020, HHS began distributing CARES Act relief funds, for which we did not apply, to various of our bank accounts. We refused the CARES Act relief funds, and our banks returned all the funds to HHS. We intend to refuse any additional CARES Act relief funds distributed in the future.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the CARES Act and a series of waivers and guidance issued by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) suspend various Medicare patient coverage criteria and documentation and care requirements in an effort to provide regulatory relief until the public health emergency for the COVID-19 pandemic has ended. For inpatient rehabilitation, the regulatory relief includes the temporary suspension of the requirement that patients must be able to tolerate a minimum of three hours of therapy per day for five days per week, waiver of certain of the requirements that at least 60% of a facility&#8217;s patients must have a diagnosis from at least 1 of 13 specified medical conditions, and waiver of the requirement for a physician to conduct and document a post-admission evaluation (as part of the Notice of Final Rulemaking for Fiscal Year 2021 for inpatient rehabilitation facilities under the inpatient rehabilitation facility prospective payment system, CMS removed the post-admission evaluation requirement from the inpatient rehabilitation coverage criteria effective October 1, 2020). In addition, the requirement of physician face-to-face visits at least three days a week may be fulfilled using telehealth. For home health, the relief includes the allowance of nurse practitioners and physician assistants under certain conditions to certify, establish and periodically review the plan of care, as well as supervise the provision of items and services for beneficiaries under the Medicare home health benefit and expands the use of telehealth. Additionally, CMS expanded the definition of &#8220;homebound&#8221; to include patients needing skilled services who are homebound due solely to their COVID-19 diagnosis or patients susceptible to contract COVID-19. For hospice, the relief includes the temporary waiver of the requirement to use volunteers and to conduct a nurse visit every two weeks to evaluate aides, as well as the expanded use of telehealth for routine services and patient recertification.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in April 2020, we amended our credit agreement primarily to provide covenant relief due to business disruptions from the COVID-19 pandemic. The amendment included, among other things, the carve-out of the COVID-19 pandemic from the definition of material adverse effect for 364 days and modifications to the interest coverage and leverage ratios under the agreement. </span></div>The foregoing and other disruptions to our business as a result of the COVID-19 pandemic have had and are likely to continue to have an adverse effect on our business and could have a material adverse effect on our business, results of operations, financial condition and cash flows.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326),&#8221; which provides guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new guidance was effective for us beginning January 1, 2020. The adoption of this guidance resulted in an immaterial change to our condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, &#8220;Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&#8221; The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The new guidance was effective for us beginning January 1, 2020. The adoption of this guidance did not have a material impact to our condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Securities and Exchange Commission adopted final rules that amend the financial disclosure requirements in Rule 3-10 of Regulation S-X for guarantors of registered debt securities and subsidiary issuers. The new rules are effective January 4, 2021, but early adoption is permitted. The new rules permit alternative disclosures of summarized financial information, rather than our previous footnote presentation of condensed consolidating financial statements. The new rules also permit the summarized financial information and related disclosures to be presented outside of the condensed consolidated financial statements and accompanying notes. We elected to early adopt the new rules effective July 1, 2020. The summarized financial information and related disclosures are presented in Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In December 2019, the FASB issued ASU 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. Either prospective or retrospective transition of this standard is dependent upon the specific amendments. The new guidance is effective for us beginning January&#160;1, 2021, including interim periods within that reporting period. Early adoption is permitted. We continue to review the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements.</span></div>We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219243054776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the nine months ended September&#160;30, 2020, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2020, we acquired 68% of the operations of a 13-bed inpatient rehabilitation unit in Denver, Colorado through a joint venture with Portercare Adventist Health System. The acquisition was funded through a contribution of our existing 40-bed inpatient rehabilitation hospital in Littleton, Colorado and through contributions of funds which were utilized by the consolidated joint venture to build a 20-bed expansion to the Littleton hospital.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2020, we acquired 51% of the operations of a 45-bed inpatient rehabilitation unit in Dayton, Ohio through a joint venture with Premier Health Partners. The acquisition was funded through contributions of funds which were utilized by the consolidated joint venture to build a 60-bed de novo inpatient rehabilitation hospital.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#8217;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. None of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 2 to 3 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 20 years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the inpatient rehabilitation acquisitions during each period presented is as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:56.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we acquired the assets of Generation Solutions of Lynchburg, LLC in Lynchburg, Virginia. This acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in Central Virginia. The acquisition was funded using cash on hand and was immaterial to our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired location from the date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. The fair values of identifiable intangible assets were based on valuations using an income approach. The income approach is based on management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired location&#8217;s mobile workforce and established relationships within the community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. All of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of 10 years)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the home health and hospice acquisitions during each period presented is as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions): </span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 07/01/2020-09/30/2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 07/01/2019-09/30/2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-09/30/2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,435.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2019-09/30/2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,436.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been achieved if the acquisitions had occurred as of the beginning of our 2019 reporting period.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K for information regarding acquisitions completed in 2019.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133724232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities</a></td>
<td class="text">Variable Interest Entities<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, we consolidated nine and eight, respectively, limited partnership-like entities that are variable interest entities (&#8220;VIEs&#8221;) and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 75.0% as of September&#160;30, 2020. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133787528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our long-term debt outstanding consists of the following (in&#160;millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.081%"><tr><td style="width:1.0%"/><td style="width:59.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,539.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we amended our existing credit agreement. The following are the changes made to the material</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provisions of the credit agreement:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the financial covenants to update the applicable interest coverage ratio and leverage ratio included in that covenant. The revised applicable ratios are set forth below. </span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Coverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr></table></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25 to 1.00</span></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the definition of &#8220;Material Adverse Effect&#8221; to carve out the direct and indirect impacts of COVID-19 and the related legislative, regulatory and executive actions on us from that definition for a period of 364 days; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the investment limitation covenant and the restricted payment limitation covenant, to add to each a leverage ratio condition (not in excess of 4.50x) to the provisions allowing unlimited investments and restricted payments in the event certain conditions are met including a senior secured leverage ratio (not in excess of 2:00x) and the existence of no events of default in addition to the new leverage ratio condition.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other material terms of the existing credit agreement remain the same and are described in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued an additional $300 million of our existing 4.50% Senior Notes due 2028 at a price of 99.0% of the principal amount and an additional $300 million of our existing 4.75% Senior Notes due 2030 at a price of 98.5% of the principal amount, which resulted in approximately $583 million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In October 2020, we issued $400&#160;million aggregate principal amount of 4.625% Senior Notes due 2031 (the &#8220;2031 Notes&#8221;) at par. The 2031 Notes mature on April 1, 2031 and bear interest at a per annum rate of 4.625%. Interest is payable semiannually in arrears on April 1 and October 1 of each year. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In October 2020, we issued notice for redemption of all $700&#160;million in outstanding principal amount of the 5.75% Senior Notes due 2024 (the &#8220;2024 Notes&#8221;). Pursuant to the terms of the 2024 Notes, this full redemption will settle on November 1, 2020 and will be made at a price of par. We plan to use the net proceeds from the 2031 Notes offering together with cash on hand to fund the redemption. We expect to record an approximate $2&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> in the fourth quarter of 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133738392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Redeemable Noncontrolling Interests</a></td>
<td class="text">Redeemable Noncontrolling Interests<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the nine months ended September&#160;30, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange transaction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the condensed consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net and comprehensive income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the condensed consolidated statements of comprehensive income for the three and nine months ended September&#160;30, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2014, we acquired 83.3% of our home health and hospice business when we purchased EHHI Holdings, Inc. (&#8220;EHHI&#8221;). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#8220;Holdings&#8221;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $64 million on the acquisition date, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $65 million in cash. In July 2019, we received additional exercise notices, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. In September 2019, Encompass Health settled the acquisition of those shares upon payment of approximately $163 million in cash. In January 2020, we received additional exercise notices, representing approximately 4.3% of the outstanding shares of the common stock of Holdings. On February 18, 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $162 million in cash. Upon settlement of these exercises, approximately $46 million of the shares of Holdings held by two management investors remained outstanding. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#8220;Exchange Agreement&#8221;) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#8220;EHC Shares&#8221;). Each of the Exchange Agreements provided that the management investor must deliver a written exchange notice (an &#8220;Exchange Notice&#8221;) to Encompass Health in order to exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#8217;s common stock on the New York Stock Exchange (the &#8220;NYSE&#8221;) on the date of delivery of the Exchange Notice.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors. Based on the last sales price of Encompass Health&#8217;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate 560,957 EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than 0.6% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares. Encompass Health now owns 100% of Holdings and EHHI.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219222604328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): </span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from December 31, 2019 to September 30, 2020 primarily resulted from the final purchase of equity interests in Holdings from management investors discussed in Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our financial assets and liabilities are determined as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity and Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The fair values of our equity and debt securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active. </span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to our home health segment was determined using the product of a twelve-month adjusted EBITDA measure and a specified median market price multiple based on a basket of public home health companies and transactions, after adding cash and deducting indebtedness that included the outstanding principal balance under any intercompany notes. To determine the fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our joint venture hospitals, we use the applicable hospitals&#8217; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable facilities. The projected operating results use management&#8217;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the three and nine months ended September 30, 2020, we did not record any material gains or losses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to these assets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our consolidation of Yuma Rehabilitation Hospital and the remeasurement of our previously held equity interest at fair value, we recorded a $19.2&#160;million gain as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three and nine months ended September&#160;30, 2019. We determined the fair value of our previously held equity interest using the income approach valuation technique. The income approach included the use of the hospital's projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the hospital. The projected operating results use management's best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; to the consolidated financial statements accompanying the 2019 Form 10&#8209;K, the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs within the fair value hierarchy. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133749128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we issued a total of 0.4 million restricted stock awards to members of our management team and our board of directors. Approximately 0.2 million of these awards contain only a service condition, while the remainder contain both a service and a performance condition. For the awards that include a performance condition, the number of shares that will ultimately be granted to employees may vary based on the Company&#8217;s performance during the applicable two year performance measurement period. Additionally, we granted 0.1 million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the EHHI acquisition discussed in Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we granted stock appreciation rights (&#8220;SARs&#8221;) based on Holdings common stock to certain members of EHHI management at closing. Half of the SARs vested on December&#160;31, 2018 and the remainder vested on December 31, 2019. Upon exercise, each SAR must be settled for cash in the amount by which the per share fair value of Holdings&#8217; common stock on the exercise date exceeds the per share fair value on the grant date. As of December 31, 2019, the fair value of the remaining 115,545 SARs was approximately $101 million, all of which was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated balance sheet. In January 2020, members of the management team exercised the remaining SARs, and in February 2020, we settled those awards upon payment of approximately $101 million in cash.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Note&#160;14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span>, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219222604328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $26.9 million and $34.3 million for the three months ended September&#160;30, 2020 and 2019, respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rate. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $65.8 million for the nine months ended September&#160;30, 2020 primarily resulted from the application of our estimated effective blended federal and state income tax rate offset by tax benefits resulting from share-based compensation windfalls. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $88.6 million for the nine months ended September 30, 2019 primarily resulted from the application of our estimated effective blended federal and state income tax rate, tax benefits resulting from share-based compensation windfalls and the deductibility of the June 2019 settlement discussed in Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the consolidated financial statements accompanying the 2019 Form 10&#8209;K.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133732856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Common Share</a></td>
<td class="text">Earnings per Common Share<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.294%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income allocated to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Common Share</span>, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K for additional information related to our common stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133679032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Other Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies and Other Commitments</a></td>
<td class="text">Contingencies and Other Commitments<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nichols Litigation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nichols v. HealthSouth Corp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In July 2019, we entered into settlement agreements with all but one plaintiff and paid those settling plaintiffs an aggregate amount of cash less than $0.1 million. The remaining plaintiff alleges that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiff is seeking compensatory and punitive damages. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This case was stayed in the circuit court on August&#160;8, 2005. However, the complaint has been amended from time to time, including to request certification as a class action. Additionally, one of the former officers named as a defendant has repeatedly attempted to remove the case to federal district court. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. On December&#160;10, 2014, we filed a motion to dismiss on the grounds the plaintiffs lacked standing because their claims were derivative in nature, and the claims were time-barred by the statute of limitations. On May&#160;26, 2016, the trial court granted our motion to dismiss. On appeal, the Supreme Court of Alabama reversed the trial court&#8217;s dismissal on March 23, 2018. On April 6, 2018, we filed an application for rehearing with the Alabama Supreme Court. On March 22, 2019, the Alabama Supreme Court denied our application for rehearing and remanded the case to the trial court for further proceedings. The court has not yet set a date for the trial to begin. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in this case against the sole remaining plaintiff. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate an amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the False Claims Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the United States Department of Health and Human Services Office of Inspector General and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2127197<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2127163<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133799336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inpatient Rehabilitation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our national network of inpatient rehabilitation hospitals stretches across 36 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of September&#160;30, 2020, we operate 136 inpatient rehabilitation hospitals. We are the sole owner of 87 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 49 jointly owned hospitals. In addition, we manage three inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Home Health and Hospice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- As of September&#160;30, 2020, we provide home health services in 242 locations and hospice services in 83 locations across 31 states with concentrations in the Southeast and Texas. In addition, one of these home health agencies operates as a joint venture which we account for using the equity method of accounting. We are the sole owner of 317 of these locations. We retain 50.0% to 81.0% ownership in the remaining eight jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Our hospice services include in-home services to terminally ill patients and their families to address patients&#8217; physical needs, including pain control and symptom management, and to provide emotional and spiritual support. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The accounting policies of our reportable segments are the same as those described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2019 Form 10&#8209;K. All revenues for our services are generated through external customers. See Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (&#8220;Segment Adjusted EBITDA&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information for our reportable segments is as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.787%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services sold (excluding depreciation and amortization)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:51.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,058.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,610.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Segment reconciliations (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARs mark-to-market impact on noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll taxes on SARs exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets for reportable segments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,670.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of deferred income tax liabilities to net deferred income tax assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consolidated assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,610.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional detail regarding the revenues of our operating segments by service line follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,581.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inpatient rehabilitation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total home health and hospice</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net operating revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133728376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326),&#8221; which provides guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new guidance was effective for us beginning January 1, 2020. The adoption of this guidance resulted in an immaterial change to our condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, &#8220;Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&#8221; The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The new guidance was effective for us beginning January 1, 2020. The adoption of this guidance did not have a material impact to our condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Securities and Exchange Commission adopted final rules that amend the financial disclosure requirements in Rule 3-10 of Regulation S-X for guarantors of registered debt securities and subsidiary issuers. The new rules are effective January 4, 2021, but early adoption is permitted. The new rules permit alternative disclosures of summarized financial information, rather than our previous footnote presentation of condensed consolidating financial statements. The new rules also permit the summarized financial information and related disclosures to be presented outside of the condensed consolidated financial statements and accompanying notes. We elected to early adopt the new rules effective July 1, 2020. The summarized financial information and related disclosures are presented in Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In December 2019, the FASB issued ASU 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; The standard removes certain exceptions to the general principles of ASC 740 and simplifies other areas such as accounting for outside basis differences of equity method investments. Either prospective or retrospective transition of this standard is dependent upon the specific amendments. The new guidance is effective for us beginning January&#160;1, 2021, including interim periods within that reporting period. Early adoption is permitted. We continue to review the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements.</span></div>We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133684056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Concentration of Net Operating Revenues by Payor</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source and segment are as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,396.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133748568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 2 to 3 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 20 years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of 10 years)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock', window );">Schedule of Noncash or Part Noncash Acquisitions</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the inpatient rehabilitation acquisitions during each period presented is as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:56.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the home health and hospice acquisitions during each period presented is as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Summary of Actual and Pro Forma Results of Operations for Acquisitions</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2019 (in millions): </span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient Rehabilitation</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 07/01/2020-09/30/2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 07/01/2019-09/30/2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-09/30/2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,435.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2019-09/30/2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,436.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of acquisition of assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure may include the equity interest acquired, value of assets acquired, value of liabilities acquired, net monetary assets acquired, number of shares, warrants or options issued as consideration for a business or asset acquired and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219244734936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities</a></td>
<td class="text">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133714984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Outstanding Long-term Debt</a></td>
<td class="text">Our long-term debt outstanding consists of the following (in&#160;millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.081%"><tr><td style="width:1.0%"/><td style="width:59.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,539.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_ScheduleOfFinancialCovenantsTableTextBlock', window );">Schedule of Financial Covenants</a></td>
<td class="text"><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Coverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr></table></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25 to 1.00</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ScheduleOfFinancialCovenantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Financial Covenants [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ScheduleOfFinancialCovenantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133582392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock', window );">Redeemable Noncontrolling Interests Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the nine months ended September&#160;30, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange transaction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock', window );">Reconciliation of Noncontrolling Interests</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the condensed consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net and comprehensive income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the condensed consolidated statements of comprehensive income for the three and nine months ended September&#160;30, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of Net Income Attributable to Noncontrolling Interests [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133830520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): </span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments</a></td>
<td class="text">The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133688344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earnings Per Common Share</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.294%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income allocated to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Weighted Average Number of Shares Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219210643016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information for our reportable segments is as follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.787%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services sold (excluding depreciation and amortization)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Reconciliation of Assets from Segment to Consolidated</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:51.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,058.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,610.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets for reportable segments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,670.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of deferred income tax liabilities to net deferred income tax assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consolidated assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,610.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock', window );">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense</a></td>
<td class="text">Segment reconciliations (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARs mark-to-market impact on noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll taxes on SARs exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Revenue from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional detail regarding the revenues of our operating segments by service line follows (in millions):</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,581.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inpatient rehabilitation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total home health and hospice</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net operating revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation segment adjusted EBITDA to income from continuing operations before income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219211317336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation - Textual (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>state</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Goodwill increase</a></td>
<td class="nump">$ 24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings', window );">Collection success rate of denied payments (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare Denials, Percentage Collected After Appeal, Including Administrative Law Judge Hearings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219208626008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation - Net Operating Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 1,173.9<span></span>
</td>
<td class="nump">$ 1,161.6<span></span>
</td>
<td class="nump">$ 3,430.0<span></span>
</td>
<td class="nump">$ 3,420.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">899.4<span></span>
</td>
<td class="nump">872.3<span></span>
</td>
<td class="nump">2,633.1<span></span>
</td>
<td class="nump">2,616.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">274.5<span></span>
</td>
<td class="nump">289.3<span></span>
</td>
<td class="nump">796.9<span></span>
</td>
<td class="nump">804.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">821.0<span></span>
</td>
<td class="nump">872.9<span></span>
</td>
<td class="nump">2,396.9<span></span>
</td>
<td class="nump">2,577.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareMember', window );">Medicare | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">592.4<span></span>
</td>
<td class="nump">624.5<span></span>
</td>
<td class="nump">1,738.1<span></span>
</td>
<td class="nump">1,892.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareMember', window );">Medicare | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">228.6<span></span>
</td>
<td class="nump">248.4<span></span>
</td>
<td class="nump">658.8<span></span>
</td>
<td class="nump">684.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareAdvantageMember', window );">Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">170.7<span></span>
</td>
<td class="nump">119.9<span></span>
</td>
<td class="nump">506.5<span></span>
</td>
<td class="nump">353.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareAdvantageMember', window );">Medicare Advantage | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">141.1<span></span>
</td>
<td class="nump">94.7<span></span>
</td>
<td class="nump">418.2<span></span>
</td>
<td class="nump">276.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareAdvantageMember', window );">Medicare Advantage | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">29.6<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">88.3<span></span>
</td>
<td class="nump">77.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_ManagedCareMember', window );">Managed care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">108.3<span></span>
</td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">310.2<span></span>
</td>
<td class="nump">284.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_ManagedCareMember', window );">Managed care | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">95.9<span></span>
</td>
<td class="nump">87.3<span></span>
</td>
<td class="nump">274.3<span></span>
</td>
<td class="nump">257.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_ManagedCareMember', window );">Managed care | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">32.8<span></span>
</td>
<td class="nump">115.4<span></span>
</td>
<td class="nump">95.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicaidMember', window );">Medicaid | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">103.7<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicaidMember', window );">Medicaid | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherThirdpartyPayorsMember', window );">Other third-party payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">31.1<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherThirdpartyPayorsMember', window );">Other third-party payors | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">31.1<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherThirdpartyPayorsMember', window );">Other third-party payors | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_WorkersCompensationMember', window );">Workers&#8217; compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_WorkersCompensationMember', window );">Workers&#8217; compensation | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_WorkersCompensationMember', window );">Workers&#8217; compensation | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_PatientsMember', window );">Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_PatientsMember', window );">Patients | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_PatientsMember', window );">Patients | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherIncomeSourceMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherIncomeSourceMember', window );">Other income | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
<td class="nump">36.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherIncomeSourceMember', window );">Other income | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_ManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_ManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_OtherThirdpartyPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_OtherThirdpartyPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_WorkersCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_WorkersCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_PatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_PatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_OtherIncomeSourceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_OtherIncomeSourceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219211327576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Textual (Details) - Inpatient Rehabilitation<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>bed</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>bed</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be tax-deductible amount | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Portercare Adventist</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsAcquired', window );">Number of beds acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsContributed', window );">Number of beds contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsExpanded', window );">Number of beds expanded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofBedsAcquired', window );">Number of beds acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofDeNovoBeds', window );">Number of de novo beds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofBedsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Beds Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofBedsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofBedsContributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Beds Contributed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofBedsContributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofBedsExpanded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Beds Expanded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofBedsExpanded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofDeNovoBeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of DeNovo Beds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofDeNovoBeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistandPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistandPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219210520280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Fair Value of Assets and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,318.7<span></span>
</td>
<td class="nump">$ 2,305.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Portercare Adventist and Premier Health Partners | Noncompete Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Portercare Adventist and Premier Health Partners | Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Maximum | Portercare Adventist and Premier Health Partners | Noncompete Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Minimum | Portercare Adventist and Premier Health Partners | Noncompete Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Generation Solutions of Lynchburg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Generation Solutions of Lynchburg | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistandPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistandPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsofLynchburgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsofLynchburgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219214290856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Net Cash Paid for Acquisitions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 231.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationNoncontrollingInterestFairValue', window );">Fair value of noncontrolling interest owned by joint venture partner</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Generation Solutions of Lynchburg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">68.6<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">163.9<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">174.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(15.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 217.5<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 231.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Noncontrolling Interest, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistandPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistandPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsofLynchburgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsofLynchburgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219211728280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Pro Forma Results of Operation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business acquisition, pro forma revenue</a></td>
<td class="nump">$ 1,173.9<span></span>
</td>
<td class="nump">$ 1,166.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,435.9<span></span>
</td>
<td class="nump">$ 3,436.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business acquisition, pro forma net income</a></td>
<td class="nump">$ 77.7<span></span>
</td>
<td class="nump">$ 98.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198.8<span></span>
</td>
<td class="nump">$ 292.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistandPremierHealthPartnersMember', window );">Portercare Adventist and Premier Health Partners | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsofLynchburgMember', window );">Generation Solutions of Lynchburg | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistandPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistandPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsofLynchburgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_GenerationSolutionsofLynchburgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219210448856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities - Textual (Details) - VIE - entity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_VariableInterestEntityNumberofEntitiesConsolidated', window );">Number of consolidated limited partnership-like entities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Ownership interest in consolidated entities (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Ownership interest in consolidated entities (percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_VariableInterestEntityNumberofEntitiesConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of facilities consolidated as variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_VariableInterestEntityNumberofEntitiesConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219209071064">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 94.8<span></span>
</td>
<td class="nump">$ 422.0<span></span>
</td>
<td class="nump">$ 69.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">593.3<span></span>
</td>
<td class="nump">506.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73.9<span></span>
</td>
<td class="nump">97.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,174.4<span></span>
</td>
<td class="nump">755.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,094.9<span></span>
</td>
<td class="nump">1,959.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">267.2<span></span>
</td>
<td class="nump">276.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,318.7<span></span>
</td>
<td class="nump">2,305.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">441.9<span></span>
</td>
<td class="nump">476.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">305.9<span></span>
</td>
<td class="nump">304.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,610.5<span></span>
</td>
<td class="nump">6,080.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">39.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47.1<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">119.6<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">478.8<span></span>
</td>
<td class="nump">546.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">682.5<span></span>
</td>
<td class="nump">721.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,539.4<span></span>
</td>
<td class="nump">3,023.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228.9<span></span>
</td>
<td class="nump">243.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">230.0<span></span>
</td>
<td class="nump">159.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,680.8<span></span>
</td>
<td class="nump">4,148.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">VIE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33.6<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41.1<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">121.9<span></span>
</td>
<td class="nump">122.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31.0<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222.0<span></span>
</td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">25.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 44.6<span></span>
</td>
<td class="nump">$ 41.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of September&#160;30, 2020 and December&#160;31, 2019 include total assets of variable interest entities of $222.0 million and $215.0 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September&#160;30, 2020 and December&#160;31, 2019 include total liabilities of the variable interest entities of $44.6 million and $41.1 million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219208648920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Long-term Debt Outstanding (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations</a></td>
<td class="nump">$ 372.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt and finance lease obligations</a></td>
<td class="nump">3,576.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,062.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: Current portion</a></td>
<td class="num">(37.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="nump">3,539.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,023.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan facilities | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 254.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 297.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 697.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 784.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 782.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219212009032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Financial Covenants (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantInterestCoverageRatio', window );">Interest Coverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Leverage Ratio</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">4.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantInterestCoverageRatio', window );">Interest Coverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">4.25<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">6.00<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219210243320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Textual (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt issuance costs</a></td>
<td class="nump">$ 583,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue', window );">Issuance of face value (percent)</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue', window );">Issuance of face value (percent)</a></td>
<td class="nump">98.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 782,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 782,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% Senior Notes due 2031 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2024 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2024 | Subsequent Event | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Discount Rate at Issuance of Face Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219209597112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward', window );"><strong>Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(21.8)<span></span>
</td>
<td class="num">(20.2)<span></span>
</td>
<td class="num">(50.9)<span></span>
</td>
<td class="num">(52.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at end of period</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember', window );">Redeemable Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward', window );"><strong>Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239.6<span></span>
</td>
<td class="nump">261.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Contributiontojointventure', window );">Contribution to joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Reclassificationtononcontrollinginterests', window );">Reclassification to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162.3)<span></span>
</td>
<td class="num">(162.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NoncontrollingInterestExchangeTransaction', window );">Exchange transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">118.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at end of period</a></td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Contributiontojointventure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contribution of primarily intangible assets relating to a joint venture agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Contributiontojointventure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncontrollingInterestExchangeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Exchange Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncontrollingInterestExchangeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Reclassificationtononcontrollinginterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of redeemable noncontrolling interests reclassified to noncontrolling interests during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Reclassificationtononcontrollinginterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219211800456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest', window );">Net income attributable to nonredeemable noncontrolling interests</a></td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="nump">$ 18.2<span></span>
</td>
<td class="nump">$ 53.2<span></span>
</td>
<td class="nump">$ 54.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to redeemable noncontrolling interests</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
<td class="nump">$ 58.9<span></span>
</td>
<td class="nump">$ 64.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of net income (loss) attributable to nonredeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219208617064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 18, 2020</div></th>
<th class="th"><div>Feb. 21, 2018</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 06, 2020</div></th>
<th class="th"><div>Feb. 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent', window );">Percentage of shares exercised by investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of redeemable noncontrolling interests</a></td>
<td class="nump">$ 162.0<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages', window );">Temporary equity, shares to management investors exchange agreements percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ehc_HoldingsAndEHHIMember', window );">Holdings And EHHI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_EHHIMember', window );">EHHI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue', window );">Outstanding common stock of Holdings, fair value</a></td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_EHHIMember', window );">EHHI | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent', window );">Redeemable noncontrolling interest, equity, acquired percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent', window );">Subsidiary's common stock held by subsidiary 's management, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests), percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Equity, Acquired Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subsidiary's common stock held by subsidiary 's management, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares to Management Investors Exchange Agreements Percentages</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of noncontrolling interests which are redeemable by the parent entity and classified as other equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ehc_HoldingsAndEHHIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ehc_HoldingsAndEHHIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_EHHIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_EHHIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219214352984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details) - Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember', window );">Market Approach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 70.9<span></span>
</td>
<td class="nump">$ 63.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember', window );">Market Approach | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember', window );">Market Approach | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">70.9<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember', window );">Market Approach | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember', window );">Income Approach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="nump">239.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember', window );">Income Approach | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember', window );">Income Approach | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember', window );">Income Approach | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219207213736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Gains or losses related to non-financial assets and liabilities</a></td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219218836184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan facilities | Term loan facilities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 254.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan facilities | Term loan facilities | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 256.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 297.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 302.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2024 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 697.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2024 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 701.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 361.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 784.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 804.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 782.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">814.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letters of credit | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letters of credit | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 36.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219211383512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Service Condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Service and Performance Condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Performance measurement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">SARs outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AllocatedSharebasedCompensationLiability', window );">Fair value of SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash used to settle award</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AllocatedSharebasedCompensationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocated Share-based Compensation Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AllocatedSharebasedCompensationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219244231384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="nump">$ 26.9<span></span>
</td>
<td class="nump">$ 34.3<span></span>
</td>
<td class="nump">$ 65.8<span></span>
</td>
<td class="nump">$ 88.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219208728680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Basic Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 100.1<span></span>
</td>
<td class="nump">$ 119.5<span></span>
</td>
<td class="nump">$ 257.1<span></span>
</td>
<td class="nump">$ 356.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests included in continuing operations</a></td>
<td class="num">(22.4)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(58.9)<span></span>
</td>
<td class="num">(64.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Income allocated to participating securities</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic', window );">Income from continuing operations attributable to Encompass Health common shareholders</a></td>
<td class="nump">77.4<span></span>
</td>
<td class="nump">97.2<span></span>
</td>
<td class="nump">197.5<span></span>
</td>
<td class="nump">290.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NetIncomeLossAvailabletoCommonStockholders', window );">Net income attributable to Encompass Health common shareholders</a></td>
<td class="nump">$ 77.4<span></span>
</td>
<td class="nump">$ 97.2<span></span>
</td>
<td class="nump">$ 197.5<span></span>
</td>
<td class="nump">$ 290.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Basic Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (shares)</a></td>
<td class="nump">98.7<span></span>
</td>
<td class="nump">97.8<span></span>
</td>
<td class="nump">98.5<span></span>
</td>
<td class="nump">98.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Diluted Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 100.1<span></span>
</td>
<td class="nump">$ 119.5<span></span>
</td>
<td class="nump">$ 257.1<span></span>
</td>
<td class="nump">$ 356.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests included in continuing operations</a></td>
<td class="num">(22.4)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(58.9)<span></span>
</td>
<td class="num">(64.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted', window );">Income from continuing operations attributable to Encompass Health common shareholders</a></td>
<td class="nump">77.7<span></span>
</td>
<td class="nump">97.6<span></span>
</td>
<td class="nump">198.2<span></span>
</td>
<td class="nump">291.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Encompass Health common shareholders</a></td>
<td class="nump">$ 77.7<span></span>
</td>
<td class="nump">$ 97.6<span></span>
</td>
<td class="nump">$ 198.2<span></span>
</td>
<td class="nump">$ 291.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Diluted Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (shares)</a></td>
<td class="nump">99.9<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
<td class="nump">99.7<span></span>
</td>
<td class="nump">99.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (loss) from continuing operations attributable to HealthSouth common shareholders basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income loss from continuing operations attributable to common shareholders diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NetIncomeLossAvailabletoCommonStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period), cumulative preferred stock (accumulated for the period), and/or income allocated to participating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NetIncomeLossAvailabletoCommonStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133553192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (shares)</a></td>
<td class="nump">98.7<span></span>
</td>
<td class="nump">97.8<span></span>
</td>
<td class="nump">98.5<span></span>
</td>
<td class="nump">98.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Restricted stock awards, dilutive stock options, and restricted stock units (shares)</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (shares)</a></td>
<td class="nump">99.9<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
<td class="nump">99.7<span></span>
</td>
<td class="nump">99.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219133818360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Other Commitments (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Settled Litigation | Nichols Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Cash payment for litigation settlement</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ehc_NicholsLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ehc_NicholsLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219210852008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Textual (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>hospital </div>
<div>location </div>
<div>state </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberOfInpatientRehabilitationHospitals', window );">Number of inpatient rehabilitation hospitals operated</a></td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofsolelyownedinpatientrehabilitationhospitals', window );">Number of solely owned inpatient rehabilitation hospitals</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofjointlyownedinpatientrehabilitationhospitals', window );">Number of jointly owned inpatient rehabilitation hospitals</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts', window );">Number of inpatient rehabilitation units under management contracts</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">97.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofhomehealthlocations', window );">Number of home health locations | location</a></td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofhospicelocations', window );">Number of hospice locations | location</a></td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod', window );">Number of hospitals or agencies operated as a joint venture</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations', window );">Number of solely owned hospital based home health and hospice locations | location</a></td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations', window );">Number of jointly owned hospital based home health and hospice locations | location</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">81.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Jointventureownershippercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture ownership percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Jointventureownershippercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfInpatientRehabilitationHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfInpatientRehabilitationHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of inpatient rehabilitation units under management contracts with the Company as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Joint Ventures Accounted for Using the Equity Method</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofhomehealthlocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of home health locations the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofhomehealthlocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofhospicelocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of hospice locations the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofhospicelocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of jointly owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofjointlyownedinpatientrehabilitationhospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofjointlyownedinpatientrehabilitationhospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of solely owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofsolelyownedinpatientrehabilitationhospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of solely owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofsolelyownedinpatientrehabilitationhospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219209141624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 1,173.9<span></span>
</td>
<td class="nump">$ 1,161.6<span></span>
</td>
<td class="nump">$ 3,430.0<span></span>
</td>
<td class="nump">$ 3,420.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">664.9<span></span>
</td>
<td class="nump">660.8<span></span>
</td>
<td class="nump">1,995.9<span></span>
</td>
<td class="nump">1,904.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">163.4<span></span>
</td>
<td class="nump">156.6<span></span>
</td>
<td class="nump">471.3<span></span>
</td>
<td class="nump">456.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">52.5<span></span>
</td>
<td class="nump">42.9<span></span>
</td>
<td class="nump">148.8<span></span>
</td>
<td class="nump">124.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
<td class="nump">61.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,001.4<span></span>
</td>
<td class="nump">989.7<span></span>
</td>
<td class="nump">2,978.0<span></span>
</td>
<td class="nump">2,890.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
<td class="num">(26.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="nump">58.9<span></span>
</td>
<td class="nump">64.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">899.4<span></span>
</td>
<td class="nump">872.3<span></span>
</td>
<td class="nump">2,633.1<span></span>
</td>
<td class="nump">2,616.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">475.0<span></span>
</td>
<td class="nump">459.1<span></span>
</td>
<td class="nump">1,408.7<span></span>
</td>
<td class="nump">1,347.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">135.5<span></span>
</td>
<td class="nump">131.3<span></span>
</td>
<td class="nump">394.5<span></span>
</td>
<td class="nump">386.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">45.3<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">126.9<span></span>
</td>
<td class="nump">109.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
<td class="nump">49.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">671.1<span></span>
</td>
<td class="nump">644.4<span></span>
</td>
<td class="nump">1,976.1<span></span>
</td>
<td class="nump">1,892.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests</a></td>
<td class="nump">22.1<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="nump">60.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AdjustedEBITDA', window );">Segment Adjusted EBITDA</a></td>
<td class="nump">209.2<span></span>
</td>
<td class="nump">210.6<span></span>
</td>
<td class="nump">605.0<span></span>
</td>
<td class="nump">674.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="nump">90.4<span></span>
</td>
<td class="nump">103.6<span></span>
</td>
<td class="nump">262.6<span></span>
</td>
<td class="nump">266.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">274.5<span></span>
</td>
<td class="nump">289.3<span></span>
</td>
<td class="nump">796.9<span></span>
</td>
<td class="nump">804.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_CostofServicesExcludingDepreciationandAmortization', window );">Cost of services sold (excluding depreciation and amortization)</a></td>
<td class="nump">121.8<span></span>
</td>
<td class="nump">136.4<span></span>
</td>
<td class="nump">389.4<span></span>
</td>
<td class="nump">372.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldOverhead', window );">Support and overhead costs</a></td>
<td class="nump">100.7<span></span>
</td>
<td class="nump">99.6<span></span>
</td>
<td class="nump">299.2<span></span>
</td>
<td class="nump">278.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">222.5<span></span>
</td>
<td class="nump">236.0<span></span>
</td>
<td class="nump">688.6<span></span>
</td>
<td class="nump">650.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AdjustedEBITDA', window );">Segment Adjusted EBITDA</a></td>
<td class="nump">51.8<span></span>
</td>
<td class="nump">50.8<span></span>
</td>
<td class="nump">107.8<span></span>
</td>
<td class="nump">146.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AdjustedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AdjustedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_CostofServicesExcludingDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of services rendered during the reporting period, excluding depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_CostofServicesExcludingDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_OccupancyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_OccupancyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldOverhead">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indirect cost incurred related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldOverhead</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219214428344">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Segment Reporting Information, Total Assets and Investments In and Advances to Nonconsolidated Affiliates (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,610.5<span></span>
</td>
<td class="nump">$ 6,080.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to nonconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,058.9<span></span>
</td>
<td class="nump">4,501.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to nonconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,611.9<span></span>
</td>
<td class="nump">1,612.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to nonconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of September&#160;30, 2020 and December&#160;31, 2019 include total assets of variable interest entities of $222.0 million and $215.0 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September&#160;30, 2020 and December&#160;31, 2019 include total liabilities of the variable interest entities of $44.6 million and $41.1 million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAssetReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219208639128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">$ (39.1)<span></span>
</td>
<td class="num">$ (52.5)<span></span>
</td>
<td class="num">$ (117.7)<span></span>
</td>
<td class="num">$ (183.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(61.2)<span></span>
</td>
<td class="num">(55.1)<span></span>
</td>
<td class="num">(180.7)<span></span>
</td>
<td class="num">(160.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Government, class action, and related settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="nump">58.9<span></span>
</td>
<td class="nump">64.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income tax expense</a></td>
<td class="nump">127.0<span></span>
</td>
<td class="nump">153.8<span></span>
</td>
<td class="nump">322.9<span></span>
</td>
<td class="nump">444.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AdjustedEBITDA', window );">Total Segment Adjusted EBITDA</a></td>
<td class="nump">261.0<span></span>
</td>
<td class="nump">261.4<span></span>
</td>
<td class="nump">712.8<span></span>
</td>
<td class="nump">820.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(39.1)<span></span>
</td>
<td class="num">(52.5)<span></span>
</td>
<td class="num">(117.7)<span></span>
</td>
<td class="num">(183.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(61.2)<span></span>
</td>
<td class="num">(55.1)<span></span>
</td>
<td class="num">(180.7)<span></span>
</td>
<td class="num">(160.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Loss on disposal or impairment of assets</a></td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Government, class action, and related settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense and amortization of debt discounts and fees</a></td>
<td class="num">(49.0)<span></span>
</td>
<td class="num">(40.3)<span></span>
</td>
<td class="num">(138.0)<span></span>
</td>
<td class="num">(115.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="nump">58.9<span></span>
</td>
<td class="nump">64.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_SARsmarktomarketimpactonnoncontrollinginterests', window );">SARs mark-to-market impact on noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Change in fair market value of equity securities</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on consolidation of joint venture formerly accounted for under the equity method of accounting</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_PayrolltaxesonSARsexercise', window );">Payroll taxes on SARs exercise</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.8)<span></span>
</td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AdjustedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AdjustedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_PayrolltaxesonSARsexercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll taxes on SARs exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_PayrolltaxesonSARsexercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SARsmarktomarketimpactonnoncontrollinginterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of SARs mark-to-market adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SARsmarktomarketimpactonnoncontrollinginterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219210644696">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Assets from Segment to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,610.5<span></span>
</td>
<td class="nump">$ 6,080.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,670.8<span></span>
</td>
<td class="nump">6,114.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Reclassification of deferred income tax liabilities to net deferred income tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (60.3)<span></span>
</td>
<td class="num">$ (33.5)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of September&#160;30, 2020 and December&#160;31, 2019 include total assets of variable interest entities of $222.0 million and $215.0 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September&#160;30, 2020 and December&#160;31, 2019 include total liabilities of the variable interest entities of $44.6 million and $41.1 million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAssetReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140219212001384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 1,173.9<span></span>
</td>
<td class="nump">$ 1,161.6<span></span>
</td>
<td class="nump">$ 3,430.0<span></span>
</td>
<td class="nump">$ 3,420.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">899.4<span></span>
</td>
<td class="nump">872.3<span></span>
</td>
<td class="nump">2,633.1<span></span>
</td>
<td class="nump">2,616.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Inpatient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">883.2<span></span>
</td>
<td class="nump">850.6<span></span>
</td>
<td class="nump">2,581.2<span></span>
</td>
<td class="nump">2,550.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Outpatient and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
<td class="nump">66.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">274.5<span></span>
</td>
<td class="nump">289.3<span></span>
</td>
<td class="nump">796.9<span></span>
</td>
<td class="nump">804.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Home health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">223.3<span></span>
</td>
<td class="nump">238.9<span></span>
</td>
<td class="nump">649.9<span></span>
</td>
<td class="nump">681.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="nump">$ 50.4<span></span>
</td>
<td class="nump">$ 147.0<span></span>
</td>
<td class="nump">$ 123.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_InpatientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_InpatientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_OutpatientandotherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_OutpatientandotherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_HomehealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_HomehealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>69
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ;:Y2L'(95 "#F41;,HAR $&?JMR>=1)1Y^/\X94Q<,9S%=#6;!38ZY IH^
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MF:?/N[L$5X+.S,@+27=19@W.4@EZ9YAX8?<BT + C1GVNE>@;R <#7&W3)<
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M)D4 ,XL R^-]@.7TC6)[ 33Q?7WU@;O=O1Z"23W S'I@F(=H.E$*&7?OBUA
MZM.(DO4],^N?HV(]G=K%L>L:DC\_JXDZ!2D-/+,T&*YO/>AB-=(>;+/"U$ E
MQWMFCG\;?>OI.D"[,+FT@-0)2+'@O?"ZMS?DNC<(ZE[W!D# =6_+>.KT)&-[
M+V3L(5JHZ5MA-D@+03@]53H(U$( #M1"$ [20@#.H(4\J3"\%U[9/TL+>3I#
MV]AOVOJ^3/6%JU^C7%!PX21\(_IP)[[H,C]^A^GXILSV]5=H[K.RS';URRV/
M!.E5 /'_39:5SV^J;^6<ODEV]2]02P,$%     @ ^(5B48X%#V*7 @  Z@8
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MCQ%H9X#G*Z7L?N$$NN<M_P-02P,$%     @ ^(5B45ITZYLR"0  +2D  !@
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M^E(7G)0YM1-BY:_Y4@O7]#LV?5CYA"I'SA*CF1M79-LW]1XZIA:Q:1BQO]:
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M$/YT.L(=F5E]D,6X]%A]A!YU)A93[7BKJS2T3^O(:CATY?ROX#.XZ%EQO7M
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MO&NB/H!QB?*89:%35?I"S+ 0 T9!=O1991)-^R>DG'<I#GY G*\ZQ/;HW._
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MI2=  ?Q7(*NUZG3RM=].C:>'4@FS3W,HHON>E4=[<9HI)YG.8RB'R95B',4
M!'J'ZHF\+2FRI?NZP=?6THS;,R.^(ZD^CZ=%##>/O'4]'NS[<'[4LJ&%PX-I
MA?K0%:;4GV)"_=XZTOAOU.,,0U.Y>>^IH0&>\CU&O]_^\-L[VG+<;4Q]0%\4
MCA3<B\V$^CJ$HOLYVY-4C.?W+G[7$_L-VW=96S.GA)3R1*!$#%.C.VIA_9ET
M J;,45L?\6]$0\D(O-F*46HQ290^.UK[JBM6MN"1H+ ;"J >8<SW^[@FKG_7
MX>0$B00U4%3!-4QH$I'L&/AZ2CT8UC1@KZSH$X.JA!:&NW:%X(K<#*>TSF=
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MX,CZ%;S'Y,A.L(7X\T_N4N:O8</>M)KH33 !#FTXH_[X*/YOPD/4@+$K='M
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MWRK:'U95[I/W3%FK"G>+\RS*(2W ^[F"!<T/VJ#['\C5_P!02P,$%     @
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M\]4V,V-<'Z%-<KGFF>Y8V# D;N'QZ:_]?8B#_,19UTUD<M-VMPI\L+KRDK8
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M5*Z.CL0DI("#8<MWC(,?.:9%<KP^OW7A,SW^Z;&]KHPJR"Q3JZJ&4A,8.=I
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MJ2:S-ZM)9'2_\*8.+S6ZU>C=%SY+>FBC90$ZWQB*OENP@^'I?O8/4$L#!!0
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MH)S-=JVIS!;J!G)0G5 6<[73T88^*:?WJ;<YS57MM.WPERQU9JT=_RJF!)B
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M$C,OIXBS 6Y(;Z0L]D(GC@0F,Q[M.)AQ8E_QGK=:S0N5?E4:^'M;@/CZCM(
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M983NX;/'Y#7V?4/ '&)O+UQ-I888&3#R6B$I44[Q:'2T4=*#0-Q@*<I&/A_
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M2!V4J08M1G#5?EM/A:.BO0F-$=65U-@#+?:YQGZ7Y#BQX<<GE_*>;/5U+ZG
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M/VWAY28,*L#^5FMW7*"#Z2VX^@]02P,$%     @ ^(5B4>"EA=9>!0  ;P\
M !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULW5=M<]LV#/XK."^WJ^\R
MZ\7QZQ+?)5G;9-=VN23;/NSV@;9@BZM$JB05-_OU RA9MAM'77JW+_MBDQ0
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MG=CGU$A]071# DU]NSOOD3Y9UR]YN0!F/*IVUYM"[6!-03>J4")';7R\+]\
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M+:%VUOY+GG^PS<9]/9LWUC9KMZ1&3VK:@/\736/[![I@^)QZ_E]02P,$%
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MOKS338=$6>\AW>;5_]Y+@_4GWL-37J2[IK$Y@UV<U'^COYJ!:#4P=? &M&E
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M\7=:#B@O<,7C+/\+CD5LI()7ATSRI 2K"A*6%O_)]Y*(&@#Z P!4 E ;@ <
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M?1B#P'G!/_9=(7TJTDUK_:M*WS^A'Z-'2L22HVN206;A1\U\\AX_;N;]3H.
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M%;+AT,.E;,Z!*0/Y?DZIV$V4 ]/N#W\!4$L#!!0    ( /B%8E$W\)V Z@0
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MIR^(.+\A;&.[:3IF]!B"<Q-\;(9/(55P>R?\MC7<\9IR^;'>OWRL]SLS_(]
M&E/GM\[\V]ZWZH#4VX84?&0GG]HL?B(DSY3R2_3/5Q6 ? FQ^-= WZWINP5]
M=^>N% (I*P#*HQ>D=F28++-0K(J^V$*I^4PVU4_)ZA:LN<T]C52NGC9+9&_$
M9&_$E_<1F-CYOSIN:]*]>M(]XZ2GD(2,H]^9!&'(8;^FZY]BB=R:WC6.]H&S
M & NT(*SN%@0% J1T20 %# A19-:NN\RUQN4J=N1NT$]FD'KW*'_4/>\9_^*
MMAKG&>1[9V"8NE=WYITBLXZM/<DVSN9JN>2PI!)0RL,D"%/E1S1F6=)4]-<5
MV696JYSNRJJSX8Z.<23%5$,]U3!17@E"(IZ/[BP%'JCF9F<T,Q=+U+2'C\1-
MCL3YA^.V<XEU+K&1R7_='DK %E3]/M$HVY=$,Z7GG=OFT6E!=XB1ZA'F$*?E
M'^"[2FU<<6R6FCOH]K=+K5J.UJ%^0VC7<UQ3 6LC<<Q.\DX8W%ZC,!#;E$4M
MX4[O)-*@1=WI_TQIZ!\L#5K_';,!?$0:S,S%(C66WW&XR9$X_W#<=BZU>SEF
M^SI*&LR4WF"?<&F[<[R?( U>PW['@T9I:!WJ-X3ND0:L71:;7?:=-/3Q#FUP
MU.-I-A/P(\LK_?8)WN9@>PC:7K%S"KG VG.PV2 .DHN[BFPKVV:YP-I?L-E?
MCI>+NSW,Y<*9TJ7= A_D%KU=;H&[INZT6^"3N 76;H'-;G%\TL=[F'N[M/9(
MG'\X;CLGVK>P6;5;J1E^_Z;2]URW2<W:A_K-H:9W1ZPM!!_T!F0HW0/%3-L$
M/LEK$=&"3<R"_0$)V<.\K[J(5G1B?EUH4UUW%<>6 9IUEFC%)V;%_U =J*8)
MXQ!082H)LG%*=))C(J(%FYSDH.B&-)SA-.;?VCA:CH$OB^\2 @7YTI;'975K
M_>WCJCCQ?]-^XUS<.@WM$^?B2_EE0].7'UKN*5^J:D<1+%17MEK(#N+EMXOR
M1K*T.-B>,2E97%RN@,Z!YP'J^8*I]:YN\@[J+TBC_P%02P,$%     @ ^(5B
M41":]GA$!   /!$  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULQ5A-
M;]LX$/TKA-!#"Z22*/DSL W$EA?;0XK 07</BSW0$FUS*Y$N2=O)OR\IR?JD
M5*=;[%YBB7HS\V8TG!=J=F'\JSA@+,%+$E,QMPY2'N\=1X0'G"!ALR.FZLF.
M\01)=<OWCCARC*+4*(D=SW5'3H((M1:S=.V)+V;L)&-"\1,'XI0DB+\N<<PN
M<PM:UX4-V1^D7G 6LR/:XV<LOQR?N+IS"B\123 5A%' \6YN/<#[-9QJ@Q3Q
M!\$74;D&.I4M8U_US:=H;KF:$8YQ*+4+I'[.>(7C6'M2/+[E3JTBIC:L7E^]
M_Y8FKY+9(H%7+/Z31/(PMR86B/ .G6*Y89??<9[04/L+62S2O^"28UT+A"<A
M69(;*P8)H=DO>LD+43%0?LP&7F[@-0T&'09^;N#?&F&0&PQNC3#,#=+4G2SW
MM' !DF@QX^P"N$8K;_HBK7YJK>I%J&Z49\G54Z+LY&*#(ZQ:;QMC\)G1D%')
M6:Q >_")2LRQD )\!+>@'O0K)_(5O ^P1"06'Y3AE^< O'_W ;P#A()'HFP8
M%3-'*N8ZOA/F+)<92Z^#I0\>5<R# &L:X<A@'_3;3WOL'56QHFS>M6Q+K]?A
M,S[:P'?O@.=ZKH'/ZF9S.#6E\^^BKW\Z>JT8?M%#?NK/_^D>N@/K;R?5&W=@
MA3A_U8\>$G:B$ORU45"@]OP%\>CO'C*#@LP@)3/H(+-$,:(A!DB"+=X32G4P
MM@-'S DSMD[F;Y3ZTW/UO/#\J3V:.6<#C6%!8]A+X[.:\435(M%,)"?;DTP+
M)!F@]1J1ZPXR;8MAFYOM%<RR5FMC?'M<QP099E+!#)N8==L/=&UH+L.H*,.H
MMPP!$5GR>M^K 1[&B!LW\'+48OC1@_:DD:L)Y38K$AA00]>>-O(UH;Q*Q%K"
MXR+A<6_"JP.B>ZRGW0X1#LXH/F'3?!BW@\-),Y&U":5@4S/'2<%Q<NL6P33J
MW1S+S-.PVER#1K5[(36"TX+@M)?@CP=*SZ" ;BE][O\_MV!%B>$OGERYPTGG
MZ,JZR 0;P<K^KQ/V2L+>?S#C@CQ*_W R@+JG$RR5"_J_9CX%N:/ZN&C.I[4)
M->[2$EAJ&NP7M96N94Y3E_<?IBH*SIC*$S>-ER#W-ZF) FR2';1V;E=!2]F#
M_;JWT244@NQ(B*YLW]0,PQ8GMTF[+69J*E9F9YUZ*56P7ZN>3CP\J#.'WG.\
M' UO8F_0%#CR;+^90@>N8[##4GU@O_RL7\),@"1'5*#T,&8D:E"6P:C-<]SS
M-NH42_&!_>ISHT(&L*TKK4Z8M(="MSS"4GY@O_Z\12!S5^,>A5P9,!YL)!/<
MX&C] T=9ND[E-)A@OD^/X0*$6K>R?^J+U>*H_Y ><!OK2WB_@H;U0'\:2$^?
MI?OLN\(CXDJX!(CQ3H5R[;%Z>SP[JF<WDAW3L^B6276R32\/&$68:X!ZOF-,
M7F]T@.*#R>([4$L#!!0    ( /B%8E$4NW\HU0(  !0)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;*5676_:,!3]*U;4AU;:\IV45H!4/J;UH5,%
MZO8P[<$D%[#JV,PVI?OWLYV0TB0@U+Z0V#[GGNOCBV_Z.RZ>Y1I H=>",CEP
MUDIM;CU/9FLHL'3Y!IA>67)18*6'8N7)C0"<6U)!O=#W4Z_ A#G#OIU[%,,^
MWRI*&#P*)+=%@<6_$5"^&SB!LY^8D=5:F0EOV-_@%<Q!/6T>A1YY=92<%, D
MX0P)6 Z<N^!VFAJ\!?PDL),'[\CL9,'YLQG<YP/'-PD!A4R9"%@_7F ,E)I
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M5[IEV=>U_FP!80!Z?<FYV@^,0/TA-/P/4$L#!!0    ( /B%8E&6\\B.200
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MRE+;^VU)@QFU<Z#[A5)V8[@ _:C/_@!02P,$%     @ ^(5B45H4X-1>!@
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MT=7(:"^;)KP9:%&YMG0MM&ERW6UN/EQ0V@7F^48(_3*P!KI/H=D_4$L#!!0
M   ( /B%8E']@UIM<P(  )X&   9    >&PO=V]R:W-H965T<R]S:&5E=#0V
M+GAM;*5576_:,!3]*U;4AU;:2$@"I15$*H1I?4!"9=T>ICV8Y$*L.G9FFX_]
M^UT[(:,M9=7& [%O[CG']]H^&>ZD>M(%@"'[D@L]\@ICJEO?UUD!)=4=68'
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M)P=;@=7R![]2_X"<^A>='2 8<'@ 8-#I 8!9C@^X%C%X0,7\W@,$!H0%<((
M8=TC! 0#SA 0K/\0@6L]@^V"YO>IYW(@+?G<V7&[*"-;X%VR9+!K@O7.2MH,
M=F$DP$[/NDYJM4.\_Z.&+D=EVPR&(>$P)"HAE^EH4JLY8E=S_X&2+GN<V3,,
M0 UE&& "91@ ,QG6LVN26M41NZH[[1L-16W[2:^69L0NS4Y^?Y&D+GL[*]W
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MJUP]\OTM.2QH8OPE/)?V+]@?YD8!2"JI>'$PU@@*RNI?_'(@XL1@C'H,T,'
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M&VDS07_?<JZ. Q.@N7%;_PM02P,$%     @ ^(5B47.7T#1S!P  H"0  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULM5I=;]LV%/TK@K&'%FALD=1G
MD 1(+ T)L*Y%TFX/PQX4BXZURI(JT4FZ7S_J(Y;$>T4[6Y:'Q%8.+W4N+WD.
M*9T]Y>6W:L.Y,)ZW:5:=SS9"%*>+1;7:\&U4S?."9_(_Z[S<1D)^+1\655'R
M*&X:;=,%-4UGL8V2;'9QUES[7%Z<Y3N1)AG_7!K5;KN-RA]7/,V?SF=D]G+A
M-GG8B/K"XN*LB![X'1=?B\^E_+;81XF3+<^J),^,DJ_/9Y?D-&1^W:!!_);P
MIVKPV:BIW.?YM_K+37P^,^L[XBE?B3I$)/\\\B5/TSJ2O(_O7=#9OL^ZX?#S
M2_2?&_*2S'U4\66>_I[$8G,^\V9&S-?1+A6W^=,U[PC9=;Q5GE;-;^.IPYHS
M8[6K1+[M&LL[V"99^S=Z[A(Q:"#CX UHUX"J#:R)!JQKP([MP>H:6,?V8'<-
M&NJ+EGN3N" 2T<59F3\998V6T>H/3?:;UC)?2587RITHY7\3V4Y<W/$'.>S"
MN.5%7HHD>S!.#'CM)FM+4@[M!WEYE6>K)$V:[T:^-GZ5!?VIX&74@&_Y(\]V
MO#)$O@]U&?\EN?#8"*]NO@27QKN BRA)J_>RNZ]W@?'NI_?&3T:2&1^3-)51
MJ[.%D.SJ>URL.B97+1,ZP809'_-,;"HCS&(>(^T#?7M?TWXAL[I/+7U)[175
M!KSCQ=Q@Y@>#FM1$[F=Y='/B8W3^6^_AO^Y]E RVKS/6Q&-'U]F@IHP_?I%P
MXT;P;?6GIC-KWYG5=&9-=%;78[ZOQ[*K1ZRDVCA.$Z=>4Q\O"''97#)^'(X4
M!G/(W!G#@A;F#F#,8N88%,)8S*+F(-:(LKVG;&OSVT\__BQ%I.+5J2:1SCZJ
MHTWD791&92*G<I3%QCW/^#H1:![;,-Z E.-8((T8RIQ[2A8ABOB^K08+,9AI
MS6T\C^Z>L:ME_$EL>#DHGI=L8J1=> <.FUL*:01E.Z!T(,IRR9PIG!&4C#5!
MV=M3]O2#O"N*-,$I>J!#FP[Z:QE"D$75X0H@B%B>.O8A@J+6W,4)^GN"OGY,
M5ZM=$66K'\8JK_#Z]4&_<DHJV5\B( *J%X)@B8<(B$RQ)&8OY::6YY=<1.F1
MM=N%&F7:- FH7@3G>_[@7CMI;6'V,#>^J])&@E'/-R>9#TP,.6+6)MDJWW*4
M+0$=G\ Z[E#V"$54ID@H1TU;B';H#";%F"CMB5(MT?#[+A$_:J.428UK"=<.
M+)..3+JF/$WBJ+99T7K=&+2)P:>0*%&302$#,J=J-A 42&R(H>RI98OTEH(P
MO<PWI$692\LHRSW)!"_YQ 3O0HU*C\)J1U $+&4(RO: /B$H9U*>2&]MB-[;
MW&2%G-VME=I$]W*41>.A-&I/>A-!]"[B35P:Z=T%T=N+XWT:@6KO^3X</P3F
M4G4A#Q 8=1B;$W4(,1QQ!O'&Q'N30=PW=&ND5W)R0,J/]6M=G.$*8+E@/42$
MW?;5+ 4(C%BFIVI$B.&8Y4ZN_KV\DP/Z_@K/1J#T$F9#*<!@P(\%"(SY%ES_
M$)CG#!(YWE_V@D_U@J]S;A1JK64#2T.A;C-5VY%(9*1EW7X2<Q3^U%RAO;;3
M ]I^V+U1J+8$X0KEG0"N$&,Y*E'8F^5/#F8O[50O[:]Q;Q0*JB.W"ZJ&8S#+
M4E?- ($1WW7 <HCA/)\.3,&8>B_D5"_DA^P;A5(J709@BZ"@/\=08,,?8JC)
MC1;MQ9OJQ?MM[%O7R>CF3+#9[E ZDQ=@D4!B0PPUZ61H;S:H_6;VK0NEV#=0
M 0C*!'K5H8:)L=6="A+)F3RCH;WAH0?.4_#C4)0QXCWD<DI5R@B,F.!XH8/9
M(SZJ3"&Q''=ZH'NW0_5G*LNH2.JUK5G1XD3LRHFZAL<;<G-HF8,?,.+(Z8K)
M('T(HPY586$'&^UBG:E![TT9U9NRZWJ27_,H%9O&EUWG59&LN.Z$N;<^U/__
M#3OK#0?3&X[C#3M#MOHN<$9+#.;YP&<A,->'%@2!>:8U94%8;T$8>4.[SGK)
M9WK)7TI#4R__%2\?9454AE2 V'C'GU?I+JZ[BWE1\E7WH*6NG6A;#_/?S87W
M:-X1C8:G5$L,QL Q1H# F >V72$&D]LN;R+O@V<&>E]0^UO)MV&>/_)RPZ-X
MV@4RJ-G$--5MR!*!R9VD[0]_U#0@QP(^6(M##.9Z4\Z0]:Z!Z5W#:YPA@UI-
M*3SJ8M <4*:NFD@LQ_/ JHG!;'/JK(OU_H#I_<$A5\B@CILJS8.0X# DU$+&
MY'HGP/1.X&V<((.*?0(,SQ)'J4=Y. I,=6@D3J8*O#<(3&\07N,$&91R>%*/
M@"@XLT8C 4F!(#FC?7RU&-/O#0([<&ISO"MDR ,99'5'4/ Y&X(BI@N>56 P
MRYG:]+'>NC#]J<VQKK +XXR&":QG$ 2.\P($!#T@ B($K.&+P1L76UX^-*^Z
M5%*;=IEH'XKOK^Y?I[EL7B)1KE^1TR5!K@?D-&Q?ENG#M^_N?(S*AR2KC)2O
M95=2W^1<+-O78=HO(B^:]SWN<R'R;?.Q%DY>U@#Y_W6>BY<O=0?[EY(N_@%0
M2P,$%     @ ^(5B46 U9_G] P  40T  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3(N>&ULO5??;^(X$/Y7K*@/NQ*7Q F_6@%2"W=JI=N[JKW=>UCM@PD#
ML=:)<[:![7]_8R>$T*2T4J6^@#.>;V:^SX,S3/92_=0I@"&_,I'KJ9<:4UP%
M@4Y2R)CV90$Y[JRERIC!1[4)=*& K1PH$T$4AL,@8SSW9A-GNU>SB=P:P7.X
M5T1OLXRIIQL0<C_UJ'<P//!-:JPAF$T*MH%',%^+>X5/01UEQ3/(-9<Y4;">
M>M?T:D'[%N \OG'8Z\::6"I+*7_:A[O5U MM12 @,38$PZ\=S$$(&PGK^*\*
MZM4Y+;"Y/D3_PY%',DNF82[%OWQETJDW]L@*UFPKS(/<WT)%:&#C)5)H]TGV
ME6_HD62KC<PJ,%:0\;S\9K\J(=X"B"I ] R RG0#X@H0OQ70KP!.ZJ"DXG18
M,,-F$R7W1%EOC&873DR'1OH\M^?^:!3N<L29V2-L\!0->8!"*L/S#?F-M&UW
M>=EA>%(]\H\T3)!KK<%HPO(5[NY &PO1N':FZ]6.Y0EH8B3Y2^:)S+44?,4,
MX-YZS07'I2:?%F 8%_HS9OWZN""?+CZ3"\)S\H4+@<GT)#!(TI8:)!6A>4DH
M>I%0X9,X[)$HC,(.^.(\? $)PJF%T\M3>(#2UOI&M;Z1BQ>_5=]>J1P:4)0$
MA;#R&LC(]S\1ZI;ZQYG$<9TX=HG[+R0N3XFY4^J0X>8\^CO]T25]"1HZD+U1
M=K/AD(;^8!+LFA)WN(7CT!_5;B>,^C6C_MF:FFW&RS9CC3;+G[49J]NLBTF9
M:MPH<> /G]%H^XS\?C>'0<UA\ J' G]%94.D;(D%&O>K.G/@PSKT\&,[;50G
M'KVGT^:CMM3A8.Q?/E.[[=8?A/0EP<=U<>./:YIQJT3::.J21NDS:/A$W0PN
M:P:79QG<R@S(+3!A4E?^K=0%3^#,P='P>/F'']LSM/'>H>_JF@I^(O:0TE;;
M=/M%_KA;=7J\N&GT<9U3Y6I>B7&;2MMI\%+_4_L>.+4<[U%Z_B+MOMQO7D']
MO57DE'$U 6@BUS@S%-@;2U#UN]<IAJ_3REJ]4E'*1&Q7@!(>S]\&V#'%V5(
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M<L<HI)P&P.\;(=3Q1@]0O.J[^AM02P,$%     @ ^(5B48]-X]?# P  H@L
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MN-V-G+>A"^R]2CP[@'@O[3[2^39IK^XM-=<'+?-OZW347KNK49!*T6_N%#O
MU"8<T(JP$-\11I>*VEDIX92M'3RQ0"R95$B;4S5B?(N4SR[L.\\>>,O#J9"J
MJ>TJN-]EF[X3V'A6(&6L$SC!#HB"@F@-2MP;ITENP!<AU-J+=6$49HJL_<D,
M]Q.:P1192I6 ZLKX> -% 8/4RE$TR^VH9>'9H-:2&R.A))."-!HV,UK#T,;
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( /B%8E$%BRA/[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( /B%8E&97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ^(5B
M49W]9+LS!0  :Q4  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( /B%8E'X+RB2=P@  ,LJ   8
M      " @78-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" #XA6)1@LUY,*@&  "%&@  &               @($C%@  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ^(5B4;FUQMU1 P  5PD  !@
M             ("! 1T  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( /B%8E&AU[0L60D  %4V   8              " @8@@  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #XA6)1C@4/8I<"  #J
M!@  &               @($7*@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ ^(5B45ITZYLR"0  +2D  !@              ("!Y"P
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( /B%8E%FR+_!
M 1<  ! ]   8              " @4PV  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " #XA6)1!-+D8KX)   /'P  &
M@(&#30  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ^(5B
M458=9M;"!0  ' T  !D              ("!=U<  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " #XA6)1%N*.PF\'  #P$@  &0
M        @(%P70  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( /B%8E$\*LTO_P<   \9   9              " @19E  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ^(5B41F3:O_)"   J1@
M !D              ("!3&T  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " #XA6)1)1.ZH@H%  #&"P  &0              @(%,=@
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( /B%8E'$2'3/
M&@,  "@(   9              " @8U[  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ ^(5B415]NTE!!   /PX  !D
M ("!WGX  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #X
MA6)1 ZW][U8*  "&&   &0              @(%6@P  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( /B%8E&YF^'1\ L  !X?   9
M          " @>.-  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#
M%     @ ^(5B46<LQ\'9!@  )!$  !D              ("!"IH  'AL+W=O
M<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #XA6)14$$#_UD$   7
M"@  &0              @($:H0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
M;%!+ 0(4 Q0    ( /B%8E'@I8767@4  &\/   9              " @:JE
M  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ^(5B4056
M;DGF P  J @  !D              ("!/ZL  'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6Q02P$"% ,4    " #XA6)1^:.ZS>H#  #;"0  &0
M    @(%<KP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M /B%8E$(-NO#!P0  %4+   9              " @7VS  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ ^(5B4>W[,8'+!   MPL  !D
M             ("!N[<  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " #XA6)1S/,VD($$   '#P  &0              @(&]O   >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( /B%8E&HU399[ <
M %H5   9              " @77!  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ ^(5B45 +;AE  P  [ @  !D              ("!
MF,D  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #XA6)1
M9NI(LOT'  "3-   &0              @($/S0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( /B%8E&_80 &2P,  /D*   9
M      " @4/5  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ ^(5B46S60JAA!   B!,  !D              ("!Q=@  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #XA6)18;-#K5<$  #S$
M&0              @(%=W0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( /B%8E'?HOH9KP,  'X-   9              " @>OA  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ^(5B42&]$!&I
M @  )@@  !D              ("!T>4  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " #XA6)1)%L=8F4'   :(P  &0
M@(&QZ   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( /B%
M8E%WV&-(KP0  $P7   9              " @4WP  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ ^(5B41&#9ID/ P  ^@L  !D
M         ("!,_4  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    " #XA6)1-_"=@.H$  !-&@  &0              @(%Y^   >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( /B%8E$0FO9X1 0  #P1
M   9              " @9K]  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ ^(5B412[?RC5 @  % D  !D              ("!%0(!
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #XA6)1EO/(
MCDD$  ! $0  &0              @($A!0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( /B%8E$? 24+" 0  +H3   9
M  " @:$) 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M^(5B413^W;)V @  ]@4  !D              ("!X T! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " #XA6)16A3@U%X&  #%+P  &0
M            @(&-$ $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( /B%8E$2YZ4B=@,  !8-   9              " @2(7 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ^(5B4?V#6FUS @
MG@8  !D              ("!SQH! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " #XA6)12=(K"=L%  !#'0  &0              @(%Y
M'0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( /B%8E&!
M6"B#"0,  %H)   9              " @8LC 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ ^(5B40]*JIU& @  [@0  !D
M     ("!RR8! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /B%8E&/3>/7PP,  *(+   9              "
M@2U  0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ ^(5B
M4:%6UW,4!   [Q$  !D              ("!)T0! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " #XA6)1V@;SK4("  !:"P  #0
M        @ %R2 $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /B%8E&7BKL<
MP    !,"   +              "  =]* 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( /B%8E&D.R:%5@0  -0D   /              "  <A+ 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #XA6)1O '6P> !  #L(   &@
M    @ %+4 $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #XA6)1%-1QY- !  "M(   $P              @ %C4@$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     /P _ # 1  !D5 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>335</ContextCount>
  <ElementCount>323</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106102 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntities</Role>
      <ShortName>Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Redeemable Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests</Role>
      <ShortName>Redeemable Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2131107 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Earnings per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShare</Role>
      <ShortName>Earnings per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Contingencies and Other Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ContingenciesandOtherCommitments</Role>
      <ShortName>Contingencies and Other Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2141111 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Basis of Presentation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BasisofPresentationTables</Role>
      <ShortName>Basis of Presentation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/BasisofPresentation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/BusinessCombinations</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Variable Interest Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesTables</Role>
      <ShortName>Variable Interest Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/VariableInterestEntities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/LongtermDebt</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Redeemable Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables</Role>
      <ShortName>Redeemable Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Earnings per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShareTables</Role>
      <ShortName>Earnings per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/EarningsperCommonShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2342308 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SegmentReporting</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BasisofPresentationTextualDetails</Role>
      <ShortName>Basis of Presentation - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation - Net Operating Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails</Role>
      <ShortName>Basis of Presentation - Net Operating Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Business Combinations - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails</Role>
      <ShortName>Business Combinations - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Business Combinations - Net Cash Paid for Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails</Role>
      <ShortName>Business Combinations - Net Cash Paid for Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails</Role>
      <ShortName>Business Combinations - Pro Forma Results of Operation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Variable Interest Entities - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails</Role>
      <ShortName>Variable Interest Entities - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails</Role>
      <ShortName>Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails</Role>
      <ShortName>Long-term Debt - Long-term Debt Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Long-term Debt - Financial Covenants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails</Role>
      <ShortName>Long-term Debt - Financial Covenants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Long-term Debt - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtTextualDetails</Role>
      <ShortName>Long-term Debt - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Redeemable Noncontrolling Interests - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Fair Value Measurements - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails</Role>
      <ShortName>Fair Value Measurements - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/ShareBasedPayments</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails</Role>
      <ShortName>Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails</Role>
      <ShortName>Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Contingencies and Other Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails</Role>
      <ShortName>Contingencies and Other Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/ContingenciesandOtherCommitments</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Segment Reporting - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingTextualDetails</Role>
      <ShortName>Segment Reporting - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails</Role>
      <ShortName>Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Segment Reporting - Segment Reporting Information, Total Assets and Investments In and Advances to Nonconsolidated Affiliates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails</Role>
      <ShortName>Segment Reporting - Segment Reporting Information, Total Assets and Investments In and Advances to Nonconsolidated Affiliates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Segment Reporting - Reconciliation of Assets from Segment to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Assets from Segment to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ehc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ehc-20200930.htm">ehc-20200930.htm</File>
    <File>ehc-20200930.xsd</File>
    <File>ehc-20200930_cal.xml</File>
    <File>ehc-20200930_def.xml</File>
    <File>ehc-20200930_lab.xml</File>
    <File>ehc-20200930_pre.xml</File>
    <File>ehc10q93020ex101.htm</File>
    <File>ehc10q93020ex22.htm</File>
    <File>ehc10q93020ex311.htm</File>
    <File>ehc10q93020ex312.htm</File>
    <File>ehc10q93020ex321.htm</File>
    <File>ehc10q93020ex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ehc-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "contextCount": 335,
   "dts": {
    "calculationLink": {
     "local": [
      "ehc-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ehc-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ehc-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ehc-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ehc-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ehc-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 445,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 5
   },
   "keyCustom": 40,
   "keyStandard": 283,
   "memberCustom": 29,
   "memberStandard": 36,
   "nsprefix": "ehc",
   "nsuri": "http://www.encompasshealth.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.encompasshealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Variable Interest Entities",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntities",
     "shortName": "Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Long-term Debt",
     "role": "http://www.encompasshealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Redeemable Noncontrolling Interests",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests",
     "shortName": "Redeemable Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Fair Value Measurements",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131107 - Disclosure - Share-Based Payments",
     "role": "http://www.encompasshealth.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133108 - Disclosure - Income Taxes",
     "role": "http://www.encompasshealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Earnings per Common Share",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShare",
     "shortName": "Earnings per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Contingencies and Other Commitments",
     "role": "http://www.encompasshealth.com/role/ContingenciesandOtherCommitments",
     "shortName": "Contingencies and Other Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141111 - Disclosure - Segment Reporting",
     "role": "http://www.encompasshealth.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.encompasshealth.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Basis of Presentation (Tables)",
     "role": "http://www.encompasshealth.com/role/BasisofPresentationTables",
     "shortName": "Basis of Presentation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Business Combinations (Tables)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Variable Interest Entities (Tables)",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesTables",
     "shortName": "Variable Interest Entities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Long-term Debt (Tables)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Redeemable Noncontrolling Interests (Tables)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables",
     "shortName": "Redeemable Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Earnings per Common Share (Tables)",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShareTables",
     "shortName": "Earnings per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342308 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/BasisofPresentationTextualDetails",
     "shortName": "Basis of Presentation - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i017841de5d9446e992d9623cdc40d80b_D20190701-20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation - Net Operating Revenues (Details)",
     "role": "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
     "shortName": "Basis of Presentation - Net Operating Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i9fb9260dccfc4ad9a9987f170f8a116b_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Business Combinations - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
     "shortName": "Business Combinations - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
     "shortName": "Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i3b957ceedc5b4a6aa068c6f89d8d5111_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Business Combinations - Net Cash Paid for Acquisitions (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
     "shortName": "Business Combinations - Net Cash Paid for Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "idc62d78790764e1b9c56dbbeaca2d7a3_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueOfAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
     "shortName": "Business Combinations - Pro Forma Results of Operation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i1708048c2a42448693822a76f275381d_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:VariableInterestEntityNumberofEntitiesConsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "entity",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Variable Interest Entities - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails",
     "shortName": "Variable Interest Entities - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i1708048c2a42448693822a76f275381d_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:VariableInterestEntityNumberofEntitiesConsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "entity",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details)",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
     "shortName": "Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "ifee6c827439c4117821d833d1398c1e3_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
     "shortName": "Long-term Debt - Long-term Debt Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ScheduleOfFinancialCovenantsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i30dd8fb7ca9b4d95a01ed19cec48d797_D20191001-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:DebtInstrumentCovenantInterestCoverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Long-term Debt - Financial Covenants (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
     "shortName": "Long-term Debt - Financial Covenants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ScheduleOfFinancialCovenantsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i30dd8fb7ca9b4d95a01ed19cec48d797_D20191001-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:DebtInstrumentCovenantInterestCoverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Long-term Debt - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
     "shortName": "Long-term Debt - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i97fd8177ab534173b7dff83fda1b0e42_D20200501-20200531",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "if166fe2888ed4236b69cbd1304d9ed61_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails",
     "shortName": "Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "ib5048837d2a04accb50ef68638e25287_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
     "shortName": "Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Redeemable Noncontrolling Interests - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails",
     "shortName": "Redeemable Noncontrolling Interests - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "if85c5fb8e5614004b32140f219b1306a_D20200101-20200131",
      "decimals": "3",
      "lang": "en-US",
      "name": "ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "if0c3b00829fa4d4e999d2af5868388c4_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "if0c3b00829fa4d4e999d2af5868388c4_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i90e31655e1c843588845e5d149d3d78f_D20190701-20190930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Fair Value Measurements - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails",
     "shortName": "Fair Value Measurements - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i90e31655e1c843588845e5d149d3d78f_D20190701-20190930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "ie58dd346723c4144a958394c28b0c3d2_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "ie58dd346723c4144a958394c28b0c3d2_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i4cb38ea719844f6cb5c7d56debf66f6e_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i4cb38ea719844f6cb5c7d56debf66f6e_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Income Taxes (Details)",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details)",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails",
     "shortName": "Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details)",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails",
     "shortName": "Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2c9a6e8916a642608c3dec74c2e5242b_D20190701-20190731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Contingencies and Other Commitments (Details)",
     "role": "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails",
     "shortName": "Contingencies and Other Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2c9a6e8916a642608c3dec74c2e5242b_D20190701-20190731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id22de6a707d946778ca077c5a44462af_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id22de6a707d946778ca077c5a44462af_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Segment Reporting - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingTextualDetails",
     "shortName": "Segment Reporting - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i02d74de04d0a49489fef3090ad053d4f_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
     "shortName": "Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i4b68311393c1424ab3638c7acd5c6320_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Segment Reporting - Segment Reporting Information, Total Assets and Investments In and Advances to Nonconsolidated Affiliates (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails",
     "shortName": "Segment Reporting - Segment Reporting Information, Total Assets and Investments In and Advances to Nonconsolidated Affiliates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails",
     "shortName": "Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6fb52c020c90481fb7260d98ee51f72b_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ehc:AdjustedEBITDA",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i6cf41bad492345de99ed38cb8db55427_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Segment Reporting - Reconciliation of Assets from Segment to Consolidated (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails",
     "shortName": "Segment Reporting - Reconciliation of Assets from Segment to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i4b556ace711f4b07a26951c1b12a6868_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
     "shortName": "Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i16bc1b11f6474259b5d2a6c7a7ed7d3f_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "id8918b77e8b4434b8851a792780313ba_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation",
     "role": "http://www.encompasshealth.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106102 - Disclosure - Business Combinations",
     "role": "http://www.encompasshealth.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20200930.htm",
      "contextRef": "i2a83f6360d4c4fa49ca852d0ff54f610_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ehc_AdjustedEBITDA": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.",
        "label": "Adjusted EBITDA",
        "totalLabel": "Segment Adjusted EBITDA",
        "verboseLabel": "Total Segment Adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEBITDA",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_AllocatedSharebasedCompensationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allocated Share-based Compensation Liability",
        "label": "Allocated Share-based Compensation Liability",
        "terseLabel": "Fair value of SARs"
       }
      }
     },
     "localname": "AllocatedSharebasedCompensationLiability",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_BusinessCombinationNoncontrollingInterestFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Noncontrolling Interest, Fair Value",
        "label": "Business Combination, Noncontrolling Interest, Fair Value",
        "negatedTerseLabel": "Fair value of noncontrolling interest owned by joint venture partner"
       }
      }
     },
     "localname": "BusinessCombinationNoncontrollingInterestFairValue",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Contributiontojointventure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contribution of primarily intangible assets relating to a joint venture agreement.",
        "label": "Contribution to joint venture",
        "terseLabel": "Contribution to joint venture"
       }
      }
     },
     "localname": "Contributiontojointventure",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_CostofServicesExcludingDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of services rendered during the reporting period, excluding depreciation and amortization.",
        "label": "Cost of Services, Excluding Depreciation and Amortization",
        "terseLabel": "Cost of services sold (excluding depreciation and amortization)"
       }
      }
     },
     "localname": "CostofServicesExcludingDepreciationandAmortization",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DebtInstrumentCovenantInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio",
        "terseLabel": "Interest Coverage Ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatio",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentCovenantLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio",
        "label": "Debt Instrument, Covenant, Leverage Ratio",
        "terseLabel": "Leverage Ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatio",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Discount Rate at Issuance of Face Value",
        "label": "Debt Instrument, Discount Rate At Issuance Of Face Value",
        "terseLabel": "Issuance of face value (percent)"
       }
      }
     },
     "localname": "DebtInstrumentDiscountRateAtIssuanceOfFaceValue",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_EHHIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "EHHI [Member]",
        "label": "EHHI [Member]",
        "terseLabel": "EHHI"
       }
      }
     },
     "localname": "EHHIMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_GenerationSolutionsofLynchburgMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generation Solutions of Lynchburg [Member]",
        "label": "Generation Solutions of Lynchburg [Member]",
        "terseLabel": "Generation Solutions of Lynchburg"
       }
      }
     },
     "localname": "GenerationSolutionsofLynchburgMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HoldingsAndEHHIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Holdings And EHHI [Member]",
        "label": "Holdings And EHHI [Member]",
        "terseLabel": "Holdings And EHHI"
       }
      }
     },
     "localname": "HoldingsAndEHHIMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HomeHealthandHospiceSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Home Health and Hospice Segment [Member]",
        "label": "Home Health and Hospice Segment [Member]",
        "terseLabel": "Home Health and Hospice"
       }
      }
     },
     "localname": "HomeHealthandHospiceSegmentMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HomehealthMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Home health [Member]",
        "label": "Home health [Member]",
        "terseLabel": "Home health"
       }
      }
     },
     "localname": "HomehealthMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "ehc_NetIncomeLossAvailabletoCommonStockholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income (loss) from continuing operations attributable to HealthSouth common shareholders basic.",
        "label": "Income Loss from Continuing Operations Attributable to Common Shareholders Basic",
        "totalLabel": "Income from continuing operations attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income loss from continuing operations attributable to common shareholders diluted.",
        "label": "Income Loss from Continuing Operations Attributable to Common Shareholders Diluted",
        "totalLabel": "Income from continuing operations attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_InpatientMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inpatient [Member]",
        "label": "Inpatient [Member]",
        "terseLabel": "Inpatient"
       }
      }
     },
     "localname": "InpatientMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_InpatientRehabilitationSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inpatient Rehabilitation Segment [Member]",
        "label": "Inpatient Rehabilitation Segment [Member]",
        "verboseLabel": "Inpatient Rehabilitation"
       }
      }
     },
     "localname": "InpatientRehabilitationSegmentMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_Jointventureownershippercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Joint venture ownership percentage",
        "label": "Joint venture ownership percentage",
        "terseLabel": "Joint venture ownership percentage"
       }
      }
     },
     "localname": "Jointventureownershippercentage",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_ManagedCareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Managed Care [Member]",
        "label": "Managed Care [Member]",
        "terseLabel": "Managed care"
       }
      }
     },
     "localname": "ManagedCareMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicaid [Member]",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare Advantage [Member]",
        "label": "Medicare Advantage [Member]",
        "terseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare Denials, Percentage Collected After Appeal, Including Administrative Law Judge Hearings",
        "label": "Medicare Denials, Percentage Collected After Appeal, Including Administrative Law Judge Hearings",
        "terseLabel": "Collection success rate of denied payments (percent)"
       }
      }
     },
     "localname": "MedicareDenialsPercentageCollectedAfterAppealIncludingAdministrativeLawJudgeHearings",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare [Member]",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NetIncomeLossAvailabletoCommonStockholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net income after adjustments for dividends on preferred stock (declared in the period), cumulative preferred stock (accumulated for the period), and/or income allocated to participating securities.",
        "label": "Net Income (Loss) Available to Common Stockholders",
        "totalLabel": "Net income attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailabletoCommonStockholders",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NicholsLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nichols Litigation",
        "label": "Nichols Litigation [Member]",
        "terseLabel": "Nichols Litigation"
       }
      }
     },
     "localname": "NicholsLitigationMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Financing Activities, Adoption Of Accounting Standard Update",
        "label": "Noncash Financing Activities, Adoption Of Accounting Standard Update",
        "terseLabel": "Adoption of ASC 842"
       }
      }
     },
     "localname": "NoncashFinancingActivitiesAdoptionOfAccountingStandardUpdate",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NoncontrollingInterestExchangeTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncontrolling Interest, Exchange Transaction",
        "label": "Noncontrolling Interest, Exchange Transaction",
        "negatedTerseLabel": "Exchange transaction"
       }
      }
     },
     "localname": "NoncontrollingInterestExchangeTransaction",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests), percent.",
        "label": "Noncontrolling Interests, Decrease from Redemptions or Purchase of Interests, Percent",
        "terseLabel": "Percentage of shares exercised by investor"
       }
      }
     },
     "localname": "NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_NumberOfInpatientRehabilitationHospitals": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of Inpatient Rehabilitation Hospitals",
        "terseLabel": "Number of inpatient rehabilitation hospitals operated"
       }
      }
     },
     "localname": "NumberOfInpatientRehabilitationHospitals",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of inpatient rehabilitation units under management contracts with the Company as of the balance sheet date.",
        "label": "Number of Inpatient Rehabilitation Units Under Management Contracts",
        "terseLabel": "Number of inpatient rehabilitation units under management contracts"
       }
      }
     },
     "localname": "NumberOfInpatientRehabilitationUnitsUnderManagementContracts",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofBedsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Beds Acquired",
        "label": "Number of Beds Acquired",
        "terseLabel": "Number of beds acquired"
       }
      }
     },
     "localname": "NumberofBedsAcquired",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofBedsContributed": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Beds Contributed",
        "label": "Number of Beds Contributed",
        "terseLabel": "Number of beds contributed"
       }
      }
     },
     "localname": "NumberofBedsContributed",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofBedsExpanded": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Beds Expanded",
        "label": "Number of Beds Expanded",
        "terseLabel": "Number of beds expanded"
       }
      }
     },
     "localname": "NumberofBedsExpanded",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofDeNovoBeds": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of DeNovo Beds",
        "label": "Number of DeNovo Beds",
        "terseLabel": "Number of de novo beds"
       }
      }
     },
     "localname": "NumberofDeNovoBeds",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofJointVenturesAccountedforUsingtheEquityMethod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Joint Ventures Accounted for Using the Equity Method",
        "label": "Number of Joint Ventures Accounted for Using the Equity Method",
        "terseLabel": "Number of hospitals or agencies operated as a joint venture"
       }
      }
     },
     "localname": "NumberofJointVenturesAccountedforUsingtheEquityMethod",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofhomehealthlocations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of home health locations the Company owns and operates as of the balance sheet date.",
        "label": "Number of home health locations",
        "terseLabel": "Number of home health locations"
       }
      }
     },
     "localname": "Numberofhomehealthlocations",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofhospicelocations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of hospice locations the Company owns and operates as of the balance sheet date.",
        "label": "Number of hospice locations",
        "terseLabel": "Number of hospice locations"
       }
      }
     },
     "localname": "Numberofhospicelocations",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of jointly owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.",
        "label": "Number of jointly owned hospital based home health and hospice locations",
        "terseLabel": "Number of jointly owned hospital based home health and hospice locations"
       }
      }
     },
     "localname": "Numberofjointlyownedhospitalbasedhomehealthandhospicelocations",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofjointlyownedinpatientrehabilitationhospitals": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of jointly owned inpatient rehabilitation hospitals",
        "terseLabel": "Number of jointly owned inpatient rehabilitation hospitals"
       }
      }
     },
     "localname": "Numberofjointlyownedinpatientrehabilitationhospitals",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of solely owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.",
        "label": "Number of solely owned hospital based home health and hospice locations",
        "terseLabel": "Number of solely owned hospital based home health and hospice locations"
       }
      }
     },
     "localname": "Numberofsolelyownedhospitalbasedhomehealthandhospicelocations",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofsolelyownedinpatientrehabilitationhospitals": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of solely owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of solely owned inpatient rehabilitation hospitals",
        "terseLabel": "Number of solely owned inpatient rehabilitation hospitals"
       }
      }
     },
     "localname": "Numberofsolelyownedinpatientrehabilitationhospitals",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_OccupancyCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.",
        "label": "Occupancy Cost",
        "terseLabel": "Occupancy costs"
       }
      }
     },
     "localname": "OccupancyCost",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_OtherIncomeSourceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Income Source [Member]",
        "label": "Other Income Source [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncomeSourceMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_OtherThirdpartyPayorsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Third-party Payors [Member]",
        "label": "Other Third-party Payors [Member]",
        "terseLabel": "Other third-party payors"
       }
      }
     },
     "localname": "OtherThirdpartyPayorsMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_OutpatientandotherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outpatient and other [Member]",
        "label": "Outpatient and other [Member]",
        "terseLabel": "Outpatient and other"
       }
      }
     },
     "localname": "OutpatientandotherMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patients [Member]",
        "label": "Patients [Member]",
        "terseLabel": "Patients"
       }
      }
     },
     "localname": "PatientsMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PayrolltaxesonSARsexercise": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payroll taxes on SARs exercise",
        "label": "Payroll taxes on SARs exercise",
        "negatedLabel": "Payroll taxes on SARs exercise"
       }
      }
     },
     "localname": "PayrolltaxesonSARsexercise",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_PortercareAdventistMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portercare Adventist [Member]",
        "label": "Portercare Adventist [Member]",
        "terseLabel": "Portercare Adventist"
       }
      }
     },
     "localname": "PortercareAdventistMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PortercareAdventistandPremierHealthPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portercare Adventist and Premier Health Partners [Member]",
        "label": "Portercare Adventist and Premier Health Partners [Member]",
        "terseLabel": "Portercare Adventist and Premier Health Partners"
       }
      }
     },
     "localname": "PortercareAdventistandPremierHealthPartnersMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PremierHealthPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Premier Health Partners [Member]",
        "label": "Premier Health Partners [Member]",
        "terseLabel": "Premier Health Partners"
       }
      }
     },
     "localname": "PremierHealthPartnersMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_Reclassificationtononcontrollinginterests": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of redeemable noncontrolling interests reclassified to noncontrolling interests during the period.",
        "label": "Reclassification to noncontrolling interests",
        "negatedTerseLabel": "Reclassification to noncontrolling interests"
       }
      }
     },
     "localname": "Reclassificationtononcontrollinginterests",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reconciliation of Net Income Attributable to Noncontrolling Interests [Table Text Block]",
        "label": "Reconciliation of Net Income Attributable to Noncontrolling Interests [Table Text Block]",
        "terseLabel": "Reconciliation of Noncontrolling Interests"
       }
      }
     },
     "localname": "ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation segment adjusted EBITDA to income from continuing operations before income tax expense.",
        "label": "Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table Text Block]",
        "terseLabel": "Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense"
       }
      }
     },
     "localname": "ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Equity, Acquired Percent",
        "label": "Redeemable Noncontrolling Interest, Equity, Acquired Percent",
        "terseLabel": "Redeemable noncontrolling interest, equity, acquired percent"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityAcquiredPercent",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]",
        "terseLabel": "Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmountRollForward",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_RedeemableNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Member]",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SARsmarktomarketimpactonnoncontrollinginterests": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in noncontrolling interest during the period as a result of SARs mark-to-market adjustment.",
        "label": "SARs mark-to-market impact on noncontrolling interests",
        "terseLabel": "SARs mark-to-market impact on noncontrolling interests"
       }
      }
     },
     "localname": "SARsmarktomarketimpactonnoncontrollinginterests",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_ScheduleOfFinancialCovenantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Financial Covenants [Table Text Block]",
        "label": "Schedule Of Financial Covenants [Table Text Block]",
        "terseLabel": "Schedule of Financial Covenants"
       }
      }
     },
     "localname": "ScheduleOfFinancialCovenantsTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_SeniorNotes04.750Due2030Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes, 04.750%, Due 2030 [Member]",
        "label": "Senior Notes, 04.750%, Due 2030 [Member]",
        "terseLabel": "4.75% Senior Notes due 2030"
       }
      }
     },
     "localname": "SeniorNotes04.750Due2030Member",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes04625Due2031Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes, 04.625%, Due 2031",
        "label": "Senior Notes, 04.625%, Due 2031 [Member]",
        "terseLabel": "4.625% Senior Notes due 2031"
       }
      }
     },
     "localname": "SeniorNotes04625Due2031Member",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes05.125Due2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes, 05.125%, Due 2023 [Member]",
        "label": "Senior Notes, 05.125%, Due 2023 [Member]",
        "terseLabel": "5.125% Senior Notes due 2023"
       }
      }
     },
     "localname": "SeniorNotes05.125Due2023Member",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes05.75Due2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes; 05.75%; Due 2025 [Member]",
        "label": "Senior Notes; 05.75%; Due 2025 [Member]",
        "terseLabel": "5.75% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotes05.75Due2025Member",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes0575Due2024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "5.75% Senior Notes Due 2024 [Member]",
        "label": "Senior Notes; 05.75%; Due 2024 [Member]",
        "terseLabel": "5.75% Senior Notes due 2024"
       }
      }
     },
     "localname": "SeniorNotes0575Due2024Member",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes4.50Due2028Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes, 4.50%, Due 2028 [Member]",
        "label": "Senior Notes, 4.50%, Due 2028 [Member]",
        "terseLabel": "4.50% Senior Notes due 2028"
       }
      }
     },
     "localname": "SeniorNotes4.50Due2028Member",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Statement Of Comprehensive Income And Income Statement [Abstract]",
        "label": "Statement Of Comprehensive Income And Income Statement [Abstract]",
        "terseLabel": "Statement Of Comprehensive Income And Income Statement [Abstract]"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAndIncomeStatementAbstract",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "xbrltype": "stringItemType"
    },
    "ehc_SubsidiaryscommonstockheldbysubsidiarysmanagementPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of subsidiary's common stock held by subsidiary 's management, Percent",
        "label": "Subsidiary's common stock held by subsidiary 's management, Percent",
        "terseLabel": "Subsidiary's common stock held by subsidiary 's management, percent"
       }
      }
     },
     "localname": "SubsidiaryscommonstockheldbysubsidiarysmanagementPercent",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Shares to Management Investors Exchange Agreements Percentages",
        "label": "Temporary Equity, Shares to Management Investors Exchange Agreements Percentages",
        "terseLabel": "Temporary equity, shares to management investors exchange agreements percentages"
       }
      }
     },
     "localname": "TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_TermLoanFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan Facilities [Member]",
        "label": "Term Loan Facilities [Member]",
        "terseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "TermLoanFacilitiesMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_VariableInterestEntityNumberofEntitiesConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of facilities consolidated as variable interest entities.",
        "label": "Variable Interest Entity, Number of Entities Consolidated",
        "terseLabel": "Number of consolidated limited partnership-like entities"
       }
      }
     },
     "localname": "VariableInterestEntityNumberofEntitiesConsolidated",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_WorkersCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Workers' Compensation [Member]",
        "label": "Workers' Compensation [Member]",
        "terseLabel": "Workers\u2019 compensation"
       }
      }
     },
     "localname": "WorkersCompensationMember",
     "nsuri": "http://www.encompasshealth.com/20200930",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r313",
      "r314",
      "r320",
      "r321",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r313",
      "r314",
      "r320",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r138",
      "r151",
      "r152",
      "r153",
      "r154",
      "r156",
      "r158",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r138",
      "r151",
      "r152",
      "r153",
      "r154",
      "r156",
      "r158",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r246",
      "r249",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r442",
      "r444"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r246",
      "r249",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r442",
      "r444"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r164",
      "r227",
      "r228",
      "r384",
      "r441",
      "r443"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r164",
      "r227",
      "r228",
      "r384",
      "r441",
      "r443"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r235",
      "r246",
      "r249",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r442",
      "r444"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r235",
      "r246",
      "r249",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r442",
      "r444"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r195",
      "r247",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r12",
      "r27",
      "r169",
      "r170"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "Accounts receivable",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Finite-lived intangible asset useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r263",
      "r264",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities\u2014"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Receipt of treasury stock"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r250",
      "r252",
      "r266",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r146",
      "r153",
      "r160",
      "r175",
      "r313",
      "r320",
      "r349",
      "r401",
      "r423"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r47",
      "r93",
      "r175",
      "r313",
      "r320",
      "r349"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r172",
      "r173",
      "r177",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r253",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r245",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r245",
      "r248",
      "r294",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Summary of Actual and Pro Forma Results of Operations for Acquisitions"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill expected to be tax-deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Business acquisition, pro forma net income"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Business acquisition, pro forma revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Business combination, pro forma information, earnings of acquiree since acquisition date, actual"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Business combination, pro forma information, revenue of acquiree since acquisition date, actual"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "negatedLabel": "Gain on consolidation of Yuma Rehabilitation Hospital",
        "terseLabel": "Gain on consolidation of joint venture formerly accounted for under the equity method of accounting"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationTextualDetails",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "verboseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r11",
      "r31",
      "r88"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r83",
      "r88",
      "r92"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r83",
      "r351"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r7",
      "r83"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash used in operating activities of discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r194",
      "r408",
      "r428"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends declared on common stock (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r26",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r61",
      "r416",
      "r437"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Encompass Health"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r51",
      "r60",
      "r309",
      "r310",
      "r330",
      "r415",
      "r436"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r51",
      "r59",
      "r308",
      "r330",
      "r414",
      "r435"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldOverhead": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indirect cost incurred related to good produced and service rendered.",
        "label": "Cost, Overhead",
        "terseLabel": "Support and overhead costs"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldOverhead",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 2.0,
       "parentTag": "ehc_AdjustedEBITDA",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r407",
      "r429"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Lease Obligation",
        "totalLabel": "Total debt and finance lease obligations"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r402",
      "r403",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r361",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r39",
      "r95",
      "r218",
      "r219",
      "r220",
      "r221",
      "r360",
      "r361",
      "r363",
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r94",
      "r275",
      "r280",
      "r281",
      "r282"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax (benefit) expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r86",
      "r141"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "negatedTerseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Concentration of Net Operating Revenues by Payor"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r62",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r110",
      "r112",
      "r120",
      "r123",
      "r124",
      "r129",
      "r130",
      "r417",
      "r438"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "verboseLabel": "Basic earnings per share attributable to Encompass Health common shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r62",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r112",
      "r120",
      "r123",
      "r124",
      "r129",
      "r130",
      "r417",
      "r438"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per share attributable to Encompass Health common shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r125",
      "r127",
      "r128",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.",
        "label": "Share-based Payment Arrangement, Cash Used to Settle Award",
        "terseLabel": "Cash used to settle award"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r132",
      "r176",
      "r217",
      "r223",
      "r263",
      "r264",
      "r265",
      "r276",
      "r277",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r333",
      "r347",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r334",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r333",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r333",
      "r334",
      "r337",
      "r338",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r236",
      "r237",
      "r242",
      "r244",
      "r334",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r236",
      "r237",
      "r242",
      "r244",
      "r334",
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r334",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r340",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "terseLabel": "Gains or losses related to non-financial assets and liabilities"
       }
      }
     },
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r365",
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "verboseLabel": "Finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments under finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r183",
      "r185",
      "r188",
      "r189",
      "r385",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r183",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "terseLabel": "Loss on disposal or impairment of assets"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r86",
      "r208",
      "r209"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on early extinguishment of debt",
        "negatedTerseLabel": "Loss on early extinguishment of debt",
        "terseLabel": "Loss on early extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedTerseLabel": "General and administrative expenses",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r178",
      "r179",
      "r400"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Goodwill increase"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeApproachValuationTechniqueMember": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation approach converting future amounts to single current discounted amount.",
        "label": "Valuation, Income Approach [Member]",
        "terseLabel": "Income Approach"
       }
      }
     },
     "localname": "IncomeApproachValuationTechniqueMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r66",
      "r87",
      "r102",
      "r103",
      "r104",
      "r105",
      "r117",
      "r124",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r305",
      "r308"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: Net income attributable to noncontrolling interests included in continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r55",
      "r146",
      "r152",
      "r156",
      "r159",
      "r162",
      "r399",
      "r411",
      "r420",
      "r439"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from continuing operations before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r93",
      "r100",
      "r146",
      "r152",
      "r156",
      "r159",
      "r162",
      "r175",
      "r308",
      "r349"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from continuing operations",
        "totalLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r53",
      "r62",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r112",
      "r120",
      "r123",
      "r409",
      "r412",
      "r417",
      "r431"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r53",
      "r62",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r112",
      "r120",
      "r123",
      "r124",
      "r417",
      "r431",
      "r434",
      "r438"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r8",
      "r9",
      "r285",
      "r432"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Loss from discontinued operations, net of tax",
        "verboseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r6",
      "r8",
      "r308"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders",
        "verboseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r57",
      "r62",
      "r116",
      "r120",
      "r123",
      "r417",
      "r432",
      "r434",
      "r438"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r116",
      "r120",
      "r123",
      "r331"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r56",
      "r86",
      "r143",
      "r174",
      "r410",
      "r430"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 4.0,
       "parentTag": "ehc_AdjustedEBITDA",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in net income of nonconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r278",
      "r283",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r108",
      "r109",
      "r144",
      "r271",
      "r279",
      "r284",
      "r440"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedSalaries": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in accrued salaries.",
        "label": "Increase (Decrease) in Accrued Salaries",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalaries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "verboseLabel": "Change in assets and liabilities, net of acquisitions\u2014"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r124"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Restricted stock awards, dilutive stock options, and restricted stock units (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r182",
      "r186"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r54",
      "r140",
      "r359",
      "r362",
      "r419"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense and amortization of debt discounts and fees"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r70",
      "r207"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedTerseLabel": "Interest expense and amortization of debt discounts and fees"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "verboseLabel": "Investments in and advances to nonconsolidated affiliates"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letters of credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r93",
      "r154",
      "r175",
      "r314",
      "r320",
      "r321",
      "r349"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r93",
      "r175",
      "r349",
      "r405",
      "r426"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r93",
      "r175",
      "r314",
      "r320",
      "r321",
      "r349"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "negatedLabel": "Government, class action, and related settlements",
        "terseLabel": "Government, class action, and related settlements"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r24",
      "r206",
      "r403",
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Total debt",
        "verboseLabel": "Redemption amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Debt and Lease Obligation [Abstract]",
        "verboseLabel": "Schedule of Outstanding Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "negatedTerseLabel": "Less: Current portion",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Carrying amounts and estimated fair values of financial instruments"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r39",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Cash payment for litigation settlement"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDisclosures": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.",
        "label": "Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies and Other Commitments"
       }
      }
     },
     "localname": "LossContingencyDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketApproachValuationTechniqueMember": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation approach using price and other relevant information generated by market transaction involving identical or comparable asset, liability, or group of assets and liabilities.",
        "label": "Valuation, Market Approach [Member]",
        "terseLabel": "Market Approach"
       }
      }
     },
     "localname": "MarketApproachValuationTechniqueMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Gain (Loss)",
        "terseLabel": "Change in fair market value of equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r45",
      "r93",
      "r175",
      "r349",
      "r404",
      "r425"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestChangeInRedemptionValue": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.",
        "label": "Noncontrolling Interest, Change in Redemption Value",
        "terseLabel": "Change in fair value",
        "verboseLabel": "Fair value adjustments to redeemable noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestChangeInRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions declared",
        "negatedTerseLabel": "Distributions declared"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r223",
      "r311",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of redeemable noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "Redeemable Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r45",
      "r67",
      "r306",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r83",
      "r84",
      "r87"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r9",
      "r48",
      "r50",
      "r58",
      "r87",
      "r93",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r117",
      "r146",
      "r152",
      "r156",
      "r159",
      "r162",
      "r175",
      "r349",
      "r413",
      "r433"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Encompass Health"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Amounts attributable to Encompass Health common shareholders:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r50",
      "r108",
      "r109",
      "r316",
      "r329"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 5.0,
       "parentTag": "ehc_AdjustedEBITDA",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: Net income attributable to noncontrolling interests",
        "terseLabel": "Net income attributable to noncontrolling interests",
        "totalLabel": "Net income attributable to noncontrolling interests",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to nonredeemable noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to redeemable noncontrolling interests",
        "verboseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Basic Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r111",
      "r119",
      "r124"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Diluted Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r213",
      "r316",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental schedule of noncash financing activity:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete Agreements"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r224",
      "r298",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Consolidation of Yuma Rehabilitation Hospital"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r223",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Other notes payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which entity operates"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r10",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r36"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 3.0,
       "parentTag": "ehc_AdjustedEBITDA",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountContributions": {
     "auth_ref": [
      "r222",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total contributions made by each class of partners (i.e., general, limited and preferred partners).",
        "label": "Partners' Capital Account, Contributions",
        "terseLabel": "Capital contributions from consolidated affiliates"
       }
      }
     },
     "localname": "PartnersCapitalAccountContributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r72",
      "r75",
      "r96"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchases of common stock, including fees and expenses"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForSoftware": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments for Software",
        "negatedLabel": "Additions to capitalized software costs"
       }
      }
     },
     "localname": "PaymentsForSoftware",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDistributionsToAffiliates": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Payments of Distributions to Affiliates",
        "negatedLabel": "Purchase of equity interests in consolidated affiliates"
       }
      }
     },
     "localname": "PaymentsOfDistributionsToAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedTerseLabel": "Dividends paid on common stock"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid on behalf of employees for shares withheld"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions of businesses, net of cash acquired",
        "verboseLabel": "Net cash paid for acquisitions"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "verboseLabel": "Purchase of redeemable noncontrolling interests"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedLabel": "Distributions paid to noncontrolling interests of consolidated affiliates"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts.",
        "label": "Prior Period Reclassification Adjustment",
        "terseLabel": "Reclassification of deferred income tax liabilities to net deferred income tax assets"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).",
        "label": "Proceeds from Issuance of Senior Long-term Debt",
        "terseLabel": "Proceeds from bond issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowings on revolving credit facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r77",
      "r81",
      "r96"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r9",
      "r48",
      "r50",
      "r82",
      "r93",
      "r100",
      "r108",
      "r109",
      "r146",
      "r152",
      "r156",
      "r159",
      "r162",
      "r175",
      "r308",
      "r315",
      "r317",
      "r329",
      "r330",
      "r349",
      "r420"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r19",
      "r20",
      "r190",
      "r427"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": {
     "auth_ref": [
      "r153",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table]",
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r153",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r152",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest, by Legal Entity [Table]",
        "terseLabel": "Redeemable Noncontrolling Interest, by Legal Entity [Table]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestByLegalEntityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r211",
      "r212",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {
     "auth_ref": [
      "r211",
      "r212",
      "r214",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Fair Value",
        "terseLabel": "Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue": {
     "auth_ref": [
      "r211",
      "r212",
      "r214",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of noncontrolling interests which are redeemable by the parent entity and classified as other equity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Other, Fair Value",
        "terseLabel": "Outstanding common stock of Holdings, fair value"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityOtherFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Redeemable Noncontrolling Interest [Line Items]",
        "terseLabel": "Redeemable Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Redeemable Noncontrolling Interests Activity"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r243",
      "r369",
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r243",
      "r369",
      "r371",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "negatedLabel": "Payments on revolving credit facility"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Principal payments on debt, including pre-payments"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r11",
      "r18",
      "r92"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "periodEndLabel": "Restricted cash at end of period",
        "periodStartLabel": "Restricted cash at beginning of period",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r15",
      "r21",
      "r92",
      "r448"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "periodEndLabel": "Restricted cash included in other long-term assets at end of period",
        "periodStartLabel": "Restricted cash included in other long-term assets at beginning of period"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r176",
      "r263",
      "r264",
      "r265",
      "r276",
      "r277",
      "r445",
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r137",
      "r138",
      "r151",
      "r157",
      "r158",
      "r164",
      "r165",
      "r167",
      "r226",
      "r227",
      "r384"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 1.0,
       "parentTag": "ehc_AdjustedEBITDA",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net operating revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "verboseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r39",
      "r95",
      "r218",
      "r219",
      "r220",
      "r221",
      "r360",
      "r361",
      "r363",
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Earnings Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of acquisition of assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure may include the equity interest acquired, value of assets acquired, value of liabilities acquired, net monetary assets acquired, number of shares, warrants or options issued as consideration for a business or asset acquired and other information necessary to a fair presentation.",
        "label": "Schedule of Noncash or Part Noncash Acquisitions [Table Text Block]",
        "terseLabel": "Schedule of Noncash or Part Noncash Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "verboseLabel": "Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r146",
      "r149",
      "r155",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r146",
      "r149",
      "r155",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r253",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r313",
      "r314",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r322",
      "r323",
      "r325",
      "r326",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Weighted Average Number of Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r133",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAssetReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Asset Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingAssetReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofAssetsfromSegmenttoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r133",
      "r135",
      "r136",
      "r146",
      "r150",
      "r156",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Performance measurement period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards issued (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "SARs outstanding (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Stock options granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r251",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Service Condition"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Service and Performance Condition"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedLabel": "Receipt of treasury stock (shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r5",
      "r133",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r181",
      "r191",
      "r192",
      "r193",
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationTotalAssetsandInvestmentsInandAdvancestoNonconsolidatedAffiliatesDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r132",
      "r176",
      "r217",
      "r223",
      "r263",
      "r264",
      "r265",
      "r276",
      "r277",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r132",
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "SARs"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r217",
      "r218",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Exchange of Holdings shares (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r217",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Exchange of Holdings shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r26",
      "r28",
      "r29",
      "r93",
      "r171",
      "r175",
      "r349"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "verboseLabel": "Encompass Health shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r93",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r175",
      "r176",
      "r223",
      "r263",
      "r264",
      "r265",
      "r276",
      "r277",
      "r305",
      "r306",
      "r328",
      "r349",
      "r352",
      "r353",
      "r357",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Other (shares)"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r358",
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r358",
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r358",
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued (shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r42",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r26",
      "r217",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Repurchases of common stock in open market (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r217",
      "r223",
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchases of common stock in open market"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r118",
      "r121",
      "r122"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 3.0,
       "parentTag": "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedTerseLabel": "Less: Income allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Ownership interest in consolidated entities (percent)"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r313",
      "r314",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "VIE"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r124"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Diluted weighted average common shares outstanding (shares)",
        "verboseLabel": "Diluted weighted average common shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails",
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Diluted Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r110",
      "r124"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Basic weighted average common shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails",
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "verboseLabel": "Basic Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "verboseLabel": "Weighted average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2793-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2814-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/subtopic&trid=2127163"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/subtopic&trid=2127197"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "16(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14172-108612"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r451": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r452": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r453": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r454": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r455": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0000785161-20-000070-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000785161-20-000070-xbrl.zip
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M,[H((QR SB48)D(,13LYF;^R-&:Z[9:E&=E'":5SD$**),&9%(O14O"OTE/
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MZR&IA.2\4!S\$R4HJ0GKK]5%HW\?#O)I&N\,G]'P33?1%&NU8K8I=Q,.Z0O
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M,;(C%L5^6ML4IGN$+KA/WI8F_$Y(O1@,7]-P5%>8X LFSUU&:@ #LGA;+%@
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M9F%T_B0ZR[$:&@(+40 L#J!N<RZ]%3(%8X3*%)8DRC=W@YYF4N@LFYFLQQC
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M,AJ<#A.-IE\/"?,D=N?NFP<_\U\7NIR2RK($H;,&D60@<A"\=FRSI'Q^.7G
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M:C.D>G@RHON7'_Z5NZ.3'I[=[_8GP)A<]*\W-!QW$_8NT,GWO(@N(=SE0M<
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MV!1E6SQ\D>W,(N@/K>YOSXH2\TFA6:EB/[+)8)R+]1O&Y;(.86$Q+MC?SL_
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M6B.Y\]HKDW *=V3!Z>/%Z7V&.0N$VX#P,I(ID%'4<PN(P190A!60D6V!UMA
M9@U1SJ;4BU*L*-O'#.+[#/T5$+<!XF5T#WD8C$,D%7Q 0*4.P%@7!24\L3Q
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M1MVZMB/>(EJ?6L+\T-II_%I[5G>[+JGR._>__;%]MECUQ#J%8FY",<WC7=Q
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M>.>DIQY'CPYO*R'7K[@NH']<H+_/(7@%].N"OI$ZD810C100@BE )4' ,(N
M@-0+%$RD9Y5 +U5[I59W"_J6BCDZ'7OX?3@>]R(@O1[USWKQ1N.-3ZOQ<8IM
M]H8A LM,2LW& ]=L_*:KP3A)RH\/!R]79'087D0)%=ZZ$6_]V8P\*(,Q4T$
M:8T$%&.>NA0ZP!D5(1")B"@IWZ< YGNJW"A@;AW,C4,:/E*O1A 8D\JPA+(1
MS P!3H6AA!FG/"Q@?@)@;CET4,!\7V!NA!&"C<J8(@]44%$S>\V T@H"Q:&W
M4E*H$"E@?@)@;B$D,([/&W\J^+US_#:4<72)9& $((8XH,9 ('&:PR=T:D2&
M;-3)J3:K2S.R6JH]Z+3/_RI":^3'DWFAP85F"W/'O^>JL8T/.QGGMP1?I@_<
M8Q^&N9A*B=EMF.AMT\?'0GN#M0,(.QPM"6& YGEP'V..,X.-%UN[5+66C=C0
MG,/C1FCK90(%H6LB=&DK$(2$9T8"J6"R%5BT]4VT]84F+D(U^N[41H1VZ[1G
M06CWO/:"T#81VO#&/1)06(1!H,(#R@B*?KF @&!HB%!<&101BDA[*?T"T0Y"
MM/5&"@6B:T*T46K'TFC[((&#5@.*38@.M\; !B6E1(IA*5-C4M:IUF)/(<U^
M.#GVHUXUL,,3_\32Z3\]I ^=U_U@.%@<KGB515"XYC9<\Z[I4E,1(K]S"P@S
M"-#H/P&C80#"*8PH0E8HD8)[%WN6_Z/$Y!\#5EOWI@M6V\7JTBZPDCDO# .:
M:9_"7Q&KD@? .81.!VF<3_6XZ!++O8#U48"U=<>Z@+55L#;\;*<Q]2X@X+2G
M4;%J!S2&&B!!. J&&RK]UBZ_Y!1<P>JCP&KK'G;!:KM8;=2\<^54*G)7Q$-
MC7- !2FB)4R(#HAI[2)6,;]D;NZ#@/4I9+=?_F=:3<ZBK]T;^,G,Y4X)[;CX
M$6;YB$!N2JA#J/I5_/&IY;0?U"&OJ2=5W/PZ&I[4LMKWD^.A>S7X[,>3W"2R
M4-*-*,DV_7*?CLVG1)IC1 **A ):(P>@=B3R$R&8A:W=]4S]$I_O,&3O(,M=
M('L'D%U:$0QBS8U1 -$0+7X$2;(G,/!664&BNT9":G5\2="^0/910/8.TMX%
MLNU#MN&D<Z&CX1\@0($R$ 7&@3&(1NN?8PDU#@2%=:/?!;(=ANP=I,$+9.\
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M(1F@UT#;P$%T[A20@E,@HD\',8U[ *.M7<[6M_,+4KN+U#MRZPM2UT9JHVD
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M1W[8*(@@ 1841:+T FC*4_MJ+((*D!-N6RU3*D19B+(0Y;T56!6B7(<H&S%
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M0BBUM4NV&5&=2JB6^$5G3(N"Y@=&\](208QZ*)4!PED'*.0:F$C"@!H;V5I
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M]>KK^XBG@X][)&'A_6^OX/N/QU7\/KI_\I8=G/R)#E_T(Q;>?OL[;G$6$$6
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M%%($I(0.I'%_@5N%2.H[3!6]I&_%HV73PGQ/@?EN0'P..V,)H0)[2(,@!N/
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M*RKJ?,BIRB;]?CBGJ"+@)-PZ8,<F2=E?4OW8;62#Q)&$;?SK;_=((&&#C8R
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M>C9;IYP;+Z@@"(*D  *Y!,.,@.1]7J 9%3B:XMY;5)GRND_7:K57K=02UGT
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M4+S6^?(PI5#T5B+N%44V<(:DM41[G5/]PL:6$?>VC;A&:1$=AI<%A$54+,@
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MEKCGR5F)K&9@#SKCD%,2(QU5B+E8//8F,R$8]O=V9?+7.<YU_U>]K1P?:9I
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M/G&AF;4./$, M6!>R=B=3U]##*]46 _,J1R#$\%&Q+D+2"L<$8V2:9(DMSP
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M&N)HX#_0]R\^=\5B]W8^+:X^]+N:GQ5\ E%F^AP7M#97#T^S:3R<]8MC,+T
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M &_[L0)/_P,6H-CIXS9D@SR6]_!+'S;W[$#BM7&DDZ*U3395#D>'=/!&HQ@
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M<1_F[A6' RZJI]]!A[HD/$.,J,PT83RR(C)$N0 ]"TAO3;@:#E D,<LE#22
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M(FZP0)IHC:(1B5INF/9ZX]TJ"$ ?2YQ7&6EX!BE,?_=S5<EPQ.>34U&.<XG
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M)@L^!TOALO'!L3V?ZWI0)B(]<+^#OT<37N+,77#&SYH#@5J&94K(QY1YU%-
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M[I(Z0Z2HF'7,"D03=X@32Y%VF"" 4I$2]TSDA@I\K23UE44;KA(IE@D03Y@
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MX85R:GJ*Y(FAP2*K IB>PG)D,4_($)>BXBHD;K)0BI718Y51SR<Z<4]$8U"
M(?C '=':>25E))H:;6D0I>GYQ'*Y]_XGIF>K>G:P?="L?:R>U^KAJ+:]Q:H?
M/[3WZ^W.WL==NM_:.JVU#O'!MW\7F9XT:,D!4Q%8/3H[F!8Y\"R1B,FE@#TF
MJN W%]?3HQ>;GKJ,>O[BP/U.TE9JN55*T]3T9-;9& 1!&L?L>JF G$L*14,D
M(P&,3R\WWBF] A+(,NJYOD*I&$[4&J*=XMSB:#A1*@5.;<"86UZ:G@\OE%/3
M,VC#->4:":((XH%&9%U*")N0*'@)BL1,S&K(6AU%E%'/.YB>-#JADM,J>8ZC
M,$DGQI)BSE BS0V,R*7I^7AR^9-DSRK=96!.XH/Z(85Q-N'[2+7SZ>B@OD_W
M/G[E!W7/#K;WV=ZW+XM,S^ I%=@*I(F3B!O0OSIQD@OUA @Z**E=T5KGEE%/
MALNHYR],SSM)6ZGE5BE-4],S4:(C20YYSPSBU&%D? 1+%'[2P&,2H3 ]:5DX
M]I*%,I=Q*D]3/E_GUFDK=10<3!SEA8G)E*;GPPOES(%[GG0#!B=3TN4&+A:$
M4H%X@C^@*.!F\'A%IN<SCGH^A4B-VKQU"X4_+A\KV[O=!"HD)(]QDA$T.V")
M,9IAXX0GU!NF=2HU_4-7H];G^L1'C2VVVB,G,HEIB X9"E8O%;E,.$AE @58
MP?<O1RVC3.LKE91YL+>)$YP0SKC10GDEO35!F\ACJ>H?12JG+2Z,X2Q%3%"(
MN<VBRWDW208D/8L!.P5P:8H&0*\YS/04,C5B_H_CON\]!R,JV(Y+4IB;?7N?
M.'$V<$,9%R$:$P/3WNG@A.!4W5;CCZ=^OI=T"3)+@<Q<KW<KP*$7 B.AF$+<
M.(6,XP$%X9,'IT]P%S?>,477JGJL=/-7S0I'I$R1:JUCX)1))XUW@3#, TBJ
M)+?5_:5\KD0^9XP  M98L!P%C'.'=^^0I<:AR*+T.+F8-)CF3/.U2CZ\K\=_
M'R/]?LW[GK44WUW+SO+*=D\ZH3<<O[_H)&NK&][;X^;0M@LYWYL:0*6D+R7I
M<UW5$TU81:X1SDJ8YS0/8RE#7'#FHM?!2@:2_D8HN<E79/&O34?/4OZ?5HN7
M\O]$\C_5]#2%".NGD-,*-+W0#FE-&#**8:(4ML[9+/]8TI5E>SU.S\H7'@[X
M*PX&;ROO3_K]V!U6CGO]O""O+!3PGR>(!<S&&6^&I/&ZE,BT%#+-=2+')&C!
MO4$Z8H.XCAHL$YR0D9I'CP.11N48P0*2ZO^6T8&7(+*K"@^4(ON@(CO3'IMY
MRIR+"'!4Y)I=$-G,7,@MILE@IZP,(+)F053O243V-:0(_#77PO%-I1N'N66C
M_[GA<$L3;@5]R5]H&X\53M!Z _IZ!8IN!_4EQB^%\9]GS3(28LK5<2@JYQ'W
M4B/M)/P9H@Q&^11#*@)& /,K#ABM0)C6O+]1":LEK*YC_*V$U8>!U:GI3'BN
M^' .*9OC<"8[NDE9^$%YTLEJ2E41AZ-L9;163P^KA0'^6]%1^UWQ4+-MO!>T
M!R_NWNP&L%S?,OD4]5PT"^=NM[)UW&^VB^[+;RJGL0+2 J,*E=Y)OQ+/FH/A
M3*--.^G,NUFISS5*M_U8M$[W#=L]A-%U;( 7>L5K()<P-MN^;:=T_&23<=SO
M_6@.LOQ/6L%??>ZWMWP(6-#)KAI5[0D^T5_C-4=$/]ESDLW)8SS^M\]/"\&;
M12WC5MYT>8(G$Y^*/ C8-: @?D3X?3C(^^GD.,!N*JZPQ\=MD,8LY,UQ/6!Q
M;=\>QDH_BUW%=D.E'>=>:G9]^R1O[V87[F*'E[<?[>A^A T [\[<O/C<H-CA
M W X0=$,&Q478>-O5N9WPPC):B<=F!=_)374:I8DDSAPSY/EQELM:, I"9XD
MP=^W"W^!8(*FCL-(<<6&?_N/;\1PTHY[Z<-D7MY/IJ6>1UF';_JCW?-'SU-=
MS=4='GS<I0?U?1C/AV:U?G2:V=8./NY<5"^.SFJ=@T[U&]RW]:&Y/V);X[6M
M[X%%X[D5R-K,HV@L1P9,!R2DEX0+IK14&Y4(.OTX0V__)&[\#(%R/[WQ2UEA
M7&FO-VH=#S<HP/Y2-8T4# A1VQX/XMO)+[^'YN"X;<_?-KN%*!0?NJI*X%M^
M/VV&8>.M4IO@4F:K:1S,&=]^]"[9+ RJ*UIQ])Z$3W)VX]MXD]SXWL]N2\VF
M%NI6M_U%#.HGH:;1E#Z1U:INR%'-%F#E\XGMP] &E9UN'OPM6AD]K\><E%)7
MWD^@\TO&N_NU&[]G"_;6"1@=Z7RMG)CMZ&,N<*\P\J:2G9!"N51MWS?&+U%\
MB\WQN.WJKYJ;5_!KK9S!A?P!#(>@DU/>YIQ:(RPF,1#CH^<Z**.RV@1_$$_4
M)IMW#&>(!+(6G2<1F"C0B01,!*#8_Y?^'WZ>"G7D_W4^=:H77^':K;-J9Q<?
M;'\^J]7A,_5#46W!_]^^PNL[Y^ +BJO^WSYXBS50OM5M>+_UY:BV#?[BQYVS
MO>VC<_C_[* .K]<_@2_83M5IV;, G_!'^/@O#W]^:A_0]@_7.CX"SY/MMSZ#
MW_GYO/8-?-"/^V=[]2,"8^[L=_YMU5I5LE\_.MO_5Y_56I]A;%GYPUA;A_@[
MRP<NFE,40HJ(2T61,\HCB0D/E@<<1<[JV,37STZSP4B*-Z[Q!CS <<DZHM:G
MDVZL,/QF[-W]$X^'8Q2[?.T*L.67YE -?L[>A2RX"RFP\.J-R"K:_KTZQ(/-
MKA),"_%!<TFQ]? W,29*[:4)=.PH\!'BD:NAL!+Q'@?QIIT5SJK;NQ=771BX
MKK/W[0#&"FY*W?/:]B',SZ?&03W _[5F+?_>:K?VZE=[E13N#(W"1RXY^"\R
MT\(;APS'"3'*\P%3U(KRC7?TH3'OUZEDZXAY<^A%"VC*I>71)MCU]S'17BTF
M,>*=PM('%ABW.FDOA,#1$98"&&(C3*+9^,J81$M,>AI,.I_#)'J]?]+N!7S^
M#.;EK/KQ,ZYM?^G4+@[/:ITOK7VZ+VJM#T?Y60Y:5TGL"TRRVBA+O$3<:Y))
MO"W23&@4(LZ]L8E()-S1#KN,FO\B,%R&9<JPS"L)R_P5RVA,&8U9,SN .BN8
MM<80K[B17E-.J4[@H"@9G)KPR]TE"#/9[R]([;>.V-ZWW8MJ_>AB_QM<L_WY
MHD;W.7RGJ&U[5FWMGE=;7VDV!ZZJ_;VZ%_LM&%>]UL@MM6O;N=UV Y[O"-<N
M_'G^;*V>7_\P&WS):E]<.TW);;KK6Q3FH7/0J1W5/GXE!Q\_P=BW3O<^'C0.
MMO]HUFB5U!:[(M9P'KT(2+LD$)?&(H=]0,)[EZU!QYFZ@4"\#+_,A5_*<,A=
MPB&.2-A^B9G,UBR-5BE0J8PP-MF$)^W+Y8T$LB7D/ #DS$4_JN?7/ V E.HV
M^!3@450O=L]J'S\T85RD^G&'[VT?@B?3[NS#\]T0_>"9+RG'/##+^4.6&? T
M(D8$IT"25SHKF,7$L67TXWJ(MPQYW(6X^D[YW27N/"SNS$4XJN0J[NQ]W"5[
M'S^UJZW0AF<_A7O1'"79[^SRVL<=7*O#G-&O\%U_+,*=9%P0CI,,-!Y,'<D0
M[ "++)8R<!PXDS2WZ2M-G5][9*6Y<R?8B38!XOC@,"$\8&\MYL:RX!5AT0HZ
M@IT[!5A+V+DK[-3>S\+.YVNPDU.BX1G%/JV>U3H?&O#=%[7M=KO:^8SW.SL<
MQH</6E_:!]N-1;!CJ/+.,XTBST3$<$.D)<%(,F6UTMQ3FQMS/S3L/$]S9_ZH
MNC1U[H Y(7?#B0)[9W*9J]><4D4Y)SFN8TTH,(>449W'Q9RYJ$Z57SM@AN?=
M;^W3VK<:N%8[!/"F4:VW.[46W.O;+CNHY[*-3T>U?#!T!7/VMK[[G$BEJ$+@
M65O$A=#("B%1HC1ZG9(5B3\"YCQ/4V<N':92VCEWP!S!<T:?E(0HRWDNM@Q.
M)Z4$B40HHL>84X9U'A5SYL(ZG]DU]^K;E]9^3FIIP3QLUUJUCP?-G-12W0[-
MO>W#TVKG2Z/6:C</%F!.#NOD[H=:!Q1<9F.6@B%8>XLB=411T#Y&XXPY95++
M;<(ZI:US%]SA*A+-L0<]ISDCW!GKP/+QN1HGZ.#'N%.&=1X5=^;".E^O]R';
M;G1@[&R_=7AZL/T%<.=#9Y_NPO=^/:]]R_W(/O.#^B[,UZ=%N -2D()P"6$:
M*. .X<@(11&UGDL?">/,E&&=6X9URJ3>.R70A2 M3Y;:!)C#*:"-5\IYD;RT
M>GR*=;=<WA)V[@H[>W-AG:_7<W@OVD>USF=<JV^)O?KG\]KV#H7Y@#G9/:M]
M^WR^7X>GN BM:N=@$>P$8I14F"&*>6X^83PR@0A$DR#6>2^XD1EV2G.GS.%]
MC,BRPBYA3@&)%(_@8GG/N4H>_'U"G94%!-$RRO.X$#07Y?EZ+67W8#M7/7\^
MK]8#0-$'^,SA!5A!)!^J'W1@3K[MXUJG2O?J"R&(86)<2@3))')5M,/(<6*0
M)\Q@18@6,>:#=+K\0?I\RNYO<Y7O/TOAI6O-BT#7GQ<AQ-0$0<\"#Z_\__^?
M!J']O3IFV*AL!1#%0:SLI!3]L'B7_)[7TMO^CUCIG0Q'-VGVX>T"5F'61W\T
M.\>P]@7QQ?N]?W>WT3BI<EBP(K1SD^5*.QXV!_!K\T=\ R\>GL#OO?YY<5T\
MB_XDOU,9;2&X$V#2H)+ZO<Z(:6%FZ*G7K]C*,0RZ%_(W,LDKP9X/?L^WNBU/
MR'KO);;^>ZG9_1$'P^*5=K/3'!94-9>$&#.K#XC?]'D#'-OSFRY_D[<9?&W^
M)UK0WO8J]0;HHS!:_O]T>\-,P!'/?!P46RXG$)[]=\(8,\/#8B<,,R?=XDL+
MYH[)L ?%&*^/;S!B]X@5& ",UH-2M\WN=  C-H].'([I0 H&F\I@U'-Z /NX
M'Z\1AUP?,WV+\Y@GTU1PY<3<U@K>Z_9&WUU<"!O?GK2+3^=U*:9@_*1=6.Z;
MIFGS"OA>XQ2:$8WQXG.ZJ7)9Q'%O4-SB;2&Y()3C,H:QY3#SP;$PX>E'K!OT
MVB?#FS]RDP'T[G^[_F_O;I3>-;";1N0W[,J\SOQL]*?E H<1.; XCU!A=+ZU
M[5, J(W?YA$)X.C*U"\[:X]865 \_D[7]P#J80O_&6U[V*B\[_6/>_V1,.>]
M_,^)&S1#T_:;<;!&B[GX:48-XD&8WO<RY&?J'OBMR-<O--8E74[E'\"K@L)I
ML&CYK\C6R'3E5":O&0M>"HYES)GO0AH+/R*8S^2G'#+TBBYZ0HZOK7:[TBO:
MZTZHN"J91?>2Y.I&EB^ UHX=0^D O(!B?V3H#''@^TTWHE'*:S!B;2/X3>6!
MM5YQQ[>9LJ_I;_'H4\K@[+N\>3J5O/%N OE^=G].::X&E_L3#*A"1+OG>4WR
M1XH*EP\]> J"LU&'S>__9_.V9A)>GXVXVZU4[?F4:JXY&)QDLJVI7H2)^%_+
M\$4F''@(RFOMN(W>1H<IXX8*I6-P?IRF*19XM4LU;)DZO1^LCUN=WLGS9U>_
M!^?6KMC+>4LT.:4TXI8PQ"6E2'-AD6(^IA %2U2"&;PHO@5;JSWV8.98!I<+
M:=QC\7^VPI-*Y"\@CX72"'_'?E9R8!%<KCFBKV[1JV>UT^^<P&H'31#\R&PL
M22"G.4:.!2:DE2RI<$,YT/]4_AD9V".='4XRKE%= <\07$$PX O#^3&V +LY
MIK7='/@LW'GQMX:[@$^Y&^->RF+_KVV?O.X=0&J'WZ-E-A#&D$J)(M@/";F\
M(3CW47KIN'1ZXYTQ"WJ9_,_$X(#5!J5W#&!O"R@=V15WU@+:2DN]H])@SE/2
MSLK(K)4 290KIDLM\"#;X?-I]?-W992UVD;$O.&(PR(@1S'L"2)BDI@Y[\.#
M:H%[+'ZI!>ZPZ.>Y.8IE21BND%0T(*XM028*\)>3421J'+R0-U1H+=0"#-]+
M"]QM"Y1:X(X[@.Q]_NZ$ /,N!&2(]H@'9< .D#3;@H%'*<%,@!U@].:B'7"#
M%@"7H-'TC1S/.VF/ GV9A[??.VMFO[5]OI12,"J!6E+*.L$X4<RI %N#I6")
MPY%/B+3$A#KPRNY <@GE\'>_YV,,@P_]7L$K7XO#O339-N][@^&SYY._QW[Y
M>@;[Q6OBO.(""9J[,-/$D#92H:B5T; V5)E<6Z6O\\%?J@G8#;GAS_%XKC<K
MWV+EI.!JGG3^F6RLV<LFYP_-0<7U^OTBEIQ#U8>Q"(B<-H>-BK>#1CZM:( 9
M4H2Q^_$8W-3+ZP>PSP)<G+54/_[HM7_,!$N2]46/[F?FCV,U\L?W_+"7\WNN
M^N3+B!H-+'!!;+ N<6NB8<9R:Y7D1.O$QD7:!)?VUVJ9KR?GO:2ZO25R 6-@
M&+!.@!E&P"U7%".M?$)4>,$DIYRE?-Z[P!8;A>\FDF8/#_OQ,/.L7S/4E];-
M]]@;I7EVOSVQ<[JW]5T%,($\Y4AKD2L]LFD>,4..YVX<D3K/4S;5Y((D@,6V
M&JG\)X/L^.BY>*%X?WS:_-]LRAW;_HA/?_IVCCV?]&/&V5'#B2*YAXVX0UVT
M_2F+_\@6!%"R7=A3^5CL#D9AN?$>URKDM3RF[?T\EEQI#4Z"B33FYHG)9L/0
MIKP'<T]V<!.$"RIR>^/.VZQ<$I.#Y@9M/.)TBYUFWA.V#<9@M@[[?=@X@YD]
M5>RFB4XC>=<49]'G,6_(EZ6AN[UA]I9R*@58(K%S/#&!8':64M]$P%(1(C#7
MGCOL'6/<1ZJDPRH2DQ9+RE(&\FS3I5)CC]#YK';X7449M?8*5+0 LUA&BL"+
M<L@2PI0(++H 9K'ZI<8&6>B=# =#6[#A+53;&;.70]"[[8L205>#H*W=[T9:
M+X6@*,&T9T(*B5P($6$1-+."8<Q93B&^;9B%\BNJ&UZ84]V;E;]/^MEK'4X.
M*^?.B:<?>#/RJ-()0,T,^)S"=LQ-<H;M0L_7>C]&Q0-C2H@"G(MK7!QUB)J/
M^A16 WAUQVU;),B =W>C/S=G6O12 GC-AZ4W^G7Y?NGD,J-I,N3B^^+9<<Z
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M/TEI[,*[E0Y\I#&HC/K-7E(<C RM"7UEX304"9#_ 2-B;'X-_GO;1JQ/V30
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M)I70U&#.%35&8:=M@+DACC%"QT+(L+PP+K!0QH:][=/I>#V9C0G.ITIV'!"
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M'+2'.1MA\/Q"]WD9L;YRC=6YQA.+%/T[#H>Q/ZAZJ?+]&-K#$B>Z2)52X[W
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M3QO\]U5DOX"_'?"?S<"/O:-:18FPSQVYL #<.^F0=5PR%ST/*E2-5F\=P53
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MSA^G@-(L)6["@G:JZAT5"P*CC.-DTJL$2Z"046Q$S"]=&#H@O>-.83T&0(K
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MH#C!>553Z91BISI<M;F'O2L/R:U.%=4Z12!@X*A!P%3?R K7YRZ\1T-[_A1
M \R6@"#K<ZTB[GZ&I\_6AHPP$+Y"=3#6T.O7^Z4&Y/1&U26]RNI8(7.S*2<\
MT^XJ&EA0&S.>8&'G@&[NEW\=>] %IU^JIB6?,7%FD<A?KB3'"A)A6&T8%WM=
MP%N%C5K[['P\#4?5H0^;9T&6A2F%D;BJ'/!TCON9S$?U:+K5)2 <UC>&\WW<
MS=?"4X&JN_U:0%@07GMP!9Q(E2I=*<U5.''^9/;=?$DMN_3S5FAFIC[8?CSB
M:BJ:G;#U&#7?VF*U5TWR^/$JO9FF?H>- >Q8'S\[<*K;7F6C.*E.JRSY3.".
MV8CAL\P:.OEU*?ZE,JP/03BM?B>_Y.TTL]? MSX#TR\"I"J_?6Q[:0J$-R R
MYFJL^8P>U_)PAMOG[K!7GV[3"R^.L*)7^,O<OE/M[4^#X9=*2&H&^ 5V&&PX
M!V^33_QZD+ /FX]72Z/^[VFW,[']A]2>IU-4RY;5>@^RIC'LY53M[M&@DD0'
M6;8;Q$F6U1IA?S,K#_D_ (?A:!#/QHU  '):8^'-RUBE?^<U=9EGNG4W@YI5
MZYW4^7(\S)8[(.IQ.LVF-]@_X^@KN6?4<:/&!Y0U\;SNT^\?93UGD(EE:\7L
M)*\>?E4KCJW-NV.0\+*P51^ZE?H!JP$2&,SK9F,;[D=X5@4EN/1H=F@M>M3R
MJ04']()N-%-T)F<GV6L-*P?D7LFIM3*QL,KG!?CYTLT/SJRB=D.M9E8"WN'T
MU)S;XE9KF5< O UJX=P_:R0I$&$RXF9+&+\"'4:0@BH;^70SS-<N2Z1G( "#
M]/KVN-N+%Y86%K22B:HO;E[ 72.%U<I1=MG,9:1:V,OF!Q@9;)UPFH\8 //0
MAL:.T<ARM:@4XZ>L1OA\[[-&43ZW_I4II):X[:BB$1=A[+$R@57;YLMQK#ZO
M#B0XH#_'09SMU>EP)O93_8J]:"L)<RI4-G[F6A];E.1[W32IWS!/07[*X.(T
M].&F(.?"97DPX\HA,;AR/%N=W73QV]4+Q%I=6+QV<Q$_U3S&7N.<690@3T#0
M/FW>J3%5STW1 ,E+!_ B;^[68N1,-,R270'919!-)8X%YU6CP,X\4E,BK:^;
M07&.G$KQJVQ^%2DOH+1R6M5T/,Z7 1%FFU!M!*C@FS<GC"%_>*$D2FF9U4[+
M+'-A7DO+K-(RZ^J66;>,'WB@#=[86W.$8GVXYK/V%%@?F 58)=01,--#L":C
M&3=5G%;9>_,AY.+Y, 'KX.K)64-VE2TZ6QLKCFONNW*.S%4X5&H!'02BTVQ(
MJ4[Q+.<T8O,EY?<1FAEJX2+;7(>N-Y/VLB^B$N%\]Z01[/=BZ%9Q*7,A;ZHI
MG ]:.1K9?@7M><C*3+8\#=W&]C>52AMYQWI_.K+^;.IE<]E'!]M[? :"<7^\
M\-"%T)!* NYFZV%C4QN?"X-I[CV.TX=5)KQ*/.C;T)@#O\"#SAO[0$[<G((M
MAYM-5_N\3>1YS/,SM9@UE)QO^*]36)/.:Q /N]FJ>5!Y>?(UNX-Q#J !X+T$
MP7'41+K\MO>Z%A\;]U)MZ:M,H>/3Z@N=!<\@"(7HI/$ SP3P\7S:-V<";:C?
M!FBTFEE0TZ=3"@.H9O)+=PRB[NO&M5G?9_&UJXFJ9[+2)ROQJ-9AJMG-?[ET
M*(UB.FW:LC4O H.8;9WIH[^W<[9N(CW=,/"3DL<?^$F>6N#GZUB9I?^,(-UD
M5,PC/U>F6V1^3AWRP/-WX)YG>X?OQ'[_!:Y"'5[^WML[?)]3,H[?]?_L[GW\
M\^/[WRZ&/!SG\>&#P]VO^Q\_T7>'KW*H W_W]LW7_7[N&OE[]_W+W;/]E_N?
M_OZV=W;P_-4'J1U6!GLD.(N(,ZR1(U; KX$:83@E[%($J!66NYPQ8TGDQ ;C
M7<0^*NT33B2JBQ&@S>QW9M/_$_&>/W[F^3%ZHJDG6&%J)4]46.(=93Q8F9@#
MH>VQQ'L>G(YJRT .=)\';8RF4]G86@:VKO\"PQO!J9@]4=W<&!-DO;E#K6\_
M9FWT["169^1X>IXT4:&5WGF1?1OQ;U"YXO*)/HMR!.4W/__ZU*MZU=M-WMS=
M__U<N!-,J\\A3U] Q(7C["+NIYE8!_6H!T?-5IR'.CUX&_-[Q_T+OO_J PZ2
M,<P<LD%X@+T+2+/($7>,QIBD%-1N;$^^#"^'.@VG<]EI5GC<F$ J02Y[9O(^
MJ3=HTZ.UONQ9YQ_DGW7H0G=P K>H+8G'M2(Q5SK_09NKCK,<<3P7@XZ'XQ/8
ML%-_T,(CKAA3'DW.-ZFLH),ZJF#1K%T! S9\E25RW(VI$[]FWT..UVC":#8K
M#T4CRM;7S!\TL_AEX6Y4I;CD@.5QE<13/2;+D%4P<0_.ERPMY;CETY&/C9EQ
MWLLVNVNSOP,>$( Z1]V3:7#S=5.YC%9P[L 5_*(@0O2#D5OE@I(KY9H[/UN$
MU^+)[FR__GENOSZH(HDZ^7 8V"8+:A !KJ-/>==<"Z\*03 1.=QM%"?^.+N*
M_"@[]Z_G\:R<7*SA08/B(6(>,% XUR;%Q+#!-F#! D\?=J\E[ZL)NM: =@=O
M,Y.\@(-\<E9S=GS*5 UO=_3!I" Q]P+.0R,0EUE"D\P@GKS",F+-(][89I=+
MB-;A<+6>^Y_3. *&^K/KAYM-!'1>T6RO:\Q]L&WFNZ/QGD0[SI)'YSMN?+@W
MB-"VUI+ADED(7TWAK(JYH[A2DZ>)*]=NM>D VMYM\=C/=MH,RN>1_*_INS_A
M[7;T9?_H@\>!8"T$DM$&Q 5UN0B>1$)$S4!1L-0'4"&OVF\_IIU*FLPG\RP,
M;/AE4,6M/N2F&*8\E-Y9'DN8O<3Y=S@N^^/;$<L)^#X(IPQ#DE@)DB/W2$MO
MD.:24*8]IYAO;.O+]3OF%J'SVP'.H>PSNW;]!]4:75A]T.BXXJ"ARJ@Y2\&%
MF+A3F!,=2##BZM5GBVO_QQ#TJL^PT* L5;MP?-P] 8;*G C:SFR=$7UR"_WI
MR]Z7#]0!G**T"%.E$ <U&H$"SI#!B3H#&D)@H-L+O(4O+?7_R=+P<@O*(\%&
M!6=!I>=&)D,%2Z J6AR$XHJ5!;W=@AZ\^F" '#5S"KG(8$&)R^U"@T74TZ2(
M3I[*NF/@Y=(9_Z<SF]"I;#"/WWU0YOZ8%[U0]P\WP+>\ 7+)>4XC"BF7K>;>
M(A.B0\D;3ZSBG$BYL<TO%W_L-+-<[8*PR-^[@UDAADK$:RQ%][@E?FP,NH'T
MEX7:\9OLR-R;F=)RGEP>_Y/>-B+7[*):!>OR$6\U*" RP$\"M! 193#*P@D,
MVV9R/(IQ"9FP:O0#3%+Y01<MF'XZ[Y5TT-@F.]EMU04-_EL,Y^Z4<Y9&T39>
MLT''#2MCT<)SZURZR?179\?=G -3V55_J"9/'U\GVL><3_XY]K(H<V$0E;\I
M1V75=ZR#6ZLD^UC%MF6BK)QKV6_9K0VHE9.]2CT;#3\M.D$'\70T[ V/<G!E
M]I]5_OLJ0G<4NM8W*7B]/NC]H[.%.VYVW"C+4E5DW4EW4"6NC+*C[>-I#N'8
MK-V;\6MG.)H<@SH6:E_+[.N5N:I_<CK--RIFIGLU,_TK&SP7_;ZUP?.N@RB^
M.WGH!HK]%"6+!MN9=^%[LGUE&(6_7#@.=%2,,D\I""G<$NF((\R"B)@HEI*K
MI22$/*AZ3-.G/65&?T'V#E]\$((*K*E$UOHL"GJ"3,066<,,B801;\7&-N67
M&UAT9I.X:))?I=6N!E26.B_U_O.C#R#=N\2M04D8#D)?"L@%2Q$7QEJBC$J$
M@+[.OKO2/V$BOO6J%A/Q#1?YX]$'@1V+R4KD4DJ 9]#OK/8)$>8B=9X:)>W&
M-KNB<$%C(ZY,PN<,PC,C<%7K(UN"%XV]Y^3^9:7]6VR-9:3]8:HL G_5%H'Q
MCO<Y>B@&N,>;[+J&MWKQWU/81GL1A*'PE#<1W?OVZ0-61F(6LX7'&\2#D,@D
M;E!,5&CM;2 I;FP/!U=(^0NFO067[;3F5V/W']<Q@)4NV6GL-(WK^$L5K5?E
MH^:\E--91&JL%JC3KU:HRF2I+X//?\:6?!\GT((M>;K_74YKGLLA@*-R3,TW
M'X/[?F!:2&HY1BPJV'R*)Z2MPHA:20P6%N@M90;[GEUY-IL_;U>&$6@1K-?,
M8YXDMIK#:6F\--[B%'@Q0]XN]&3O\.A#$%H%1@UBP>6E#@0Y9S%2AIIHHE2"
MX#8-RYAH%S"/6G/!E O.":&P<80'+6-9T5NNZ,=7'SP!N9(I#4J^9"!9<H9<
MU E)HT4BWF"90)W0Y,H5_1G+<OL\OIQ@L6AU+B1_LZ"SPU<?!"B6- :/#%,6
M<48H,L$ZI%F0"7"I% D;VY7UX4<VZ 6NSZ:\:RP/53Y=%>K0/\GU7@;C;*N;
ME;>8!I&CIO!29=N&&PU.1^,ZF*RY4P[N"CE ?6;>RR5]8@QU[;?1+";MXK,W
M<\QZ#I#/=KWQ9F?\J5L556B>L-DY.3X;9S/?9F?H_>E)$\RSV9CP8O15+9R1
M/3G;!"DH5!;!\;"* <W1/IN-%KX@=576TF88T\FYI*37$Y,SUO)7%]]S$D?]
M[J!.ZN[UYB_<I&MW1YW*S-2=SDH853%OS6732@#3UZHF:;Q8[NHD'\J5C7=8
M9RN,S_HGDV%_P03<Y(8/9W:E6!<Q:M(;X&5&W4E5;_'T)(?&K4@US1_8(+/5
M[/*_#X_C@DS;.1GVNK7,?&WLWUSF!5K*(G5=K+ .''1UFOY"L?-5JW7^^K3?
MSU;K;%)<*#*Q,Y^#_S1S\)!6S[9+EF]U=GJ]JJ#6X#2.*R4G+^\,>'E-CZH4
MGJJ$0N,5@8.M#OSVIV/8OU4RTK26?6?E5O;7[%G)Z_J?.K7HP2,D-Z>U7_;C
MI#,+ >_\V:S"K)+-M#A7Z(ZGM3W/A=_6EV_!M&=W2I4@&ZN\J>-<2Z"JM51'
M^%:D%;N5#^=Z ->D_/UXXD[\;'NGE=)<U<A8""EN;CRG@X40X_$\QKC9P/V.
MF];4LN$C;"/X>58(LJFD4.47Q#'P[L1^S5ZBD+/#8)_7YIW:*933#;[5$_./
M9EJG>1T[TQN_^'7W\/E.,ZW_O%'65<E97W974UQRUDO.^DURUG^8 W4A9XJX
MA)5.*B060(E3UJFH8F0*]&: M+O[-#U_'$',C@?I8L+>[CQSX]>SYL.GG+JW
M_VWG@Y!*2)L;(!D9$2<X(LL$1I)%0B46P>IT,17O<22]O:X*WIP3N!93=Z;2
MTU7"<;>R,M>I->/./T 6;DHSC_]YXZ293(/-GW)7)W&^^]F,+YHG3\^AJ@L4
MS%#/GHSCL^D/OX!0<=*S9\^Z@^H]JR]=[/<$3YGS[A:NN;=IZMW<O_EXJ_KH
M0N^J^C-*MX@VUWZ,M\BUGWWOMFI+J9^[Z_<_TT0_FK$*JLI8G_A8RWY]5&/5
M-[MKU5NO8=HKNG3^N!DGF7?C/-<H\(>M "\?*0_44?.28%H=/S_*>/Q.:].G
M.VG7Q.^=F[/;[CAS<>YNU'ARQ2?N, </=_;@NN-QYT55AWW>"X#AS1OLNAO-
MQM.:U7WXR^TF]6G.6]F-#[T;;TN22R[$XYC ;#6Y\ZVWIC.W4.CS%FRWII-3
MME795F5;K=#,E6U5MM7=;ZL?"%FYJ5K=! TU0_0^QI2^]]HYFVVE7CI[_N<^
M]JDK_^(&^M$;WW@7X,YJ3<HE]THU*?]S=^^_^-ZC_,B5>O$ENK)R)S4CA!GF
M":?<.B:9]LKZ(+QD=.K-5-?4*<Q=6<_[-INHD]]'P_XTL_QM=W+\6Q/9\^)K
M$R"W4Q61B^'0?EV=?JP_Z>%\]_:/\?O#(=]__D?WW<?=K_O]/_OO/WJ\_^W-
MV;N/.W3O\.CLW=MW;)_N$OCNI_WI=_[^X]CU0^_@XQ'>Z_\!]WM!W[]\WX>Q
ML?U#^/WYNZ\'SV$\'SU[]S%[1U_AO[_M3?9>XZ__/GPQV=OY8"+#R4>-,,,V
M.T<E<H1(9 5S1#LJM/4;V]J8+7XIU+2.G+LSD.1/EP3+]TZH']'TQ5.ND%TA
MNPMD9X2P6%H>9,"<RV1M4DQK;I)5*3!YL05U(;M5(+NS&=D%JKPRG*$48\@Y
MO@DY)SBBVKA(E4HUV2FZ=3G-MY!=(;LG178$.^RU5A8;S!,FCG EK83_ ^DQ
M$GY0@3J3W4*R4$X4"L-)\WGAP?OGP?T%H<\&8D&X0]X'C#CF%&F@1!25<\DI
M['E,H AO2L:V+N?"%R8L3/BDF) RPV.6$ )HN"9J2Q+5@1E!1<"2B4;L(]\1
M^PH3KA(3SB7"R#V-*DK$A'"(&Q*1,\0B2U/DQC$1?,V$1!:9L##A4V?"8!7Q
MUB=O7.!<2YT(\4(Y%IT  =$4:]\*TMW!7/#S6AJ1J$-68* [*PQR7F"D K<\
M>I+[>0'=*7Y%;=M"=H7LGA39N618P+G6;C"<<6*)4I9+)S0.*4A3K'TK2'9[
MF>@JPMOY8 E5P',*N:0#XLQ4O@V#(G=<8 YZKHW =MH4T:ZPW5-G.Z VY9U)
M =0A+I(U5 M0=^%_#%1<1VY@[BML=_]LMS=C.\I9!,%<(L5Y+AKD&7(V)@1"
MNB,V8<DEL)TR<NMRX?K"=H7MGA3;^9BH-=)Z*3SW.=6?<N--,!1S$E6Z@4FO
ML-W]L]V;&=M%'8PB@J&0H@!-U@3DC ]()Z^2=AKXC&YL:\P?CVRW=)QAJOY9
MT3C#JR$ZKRX4OY[D.AX++3J78?P+KWZ3"-5RCW*/<H\5OL=]QUDO%#8YUV7$
M/$0]EPO)Y.<;[5RHR-*F;%SN4>Y1[O'([G'?DN)U3/DPO:HJJGQM>U7ENJI^
MA(N#F+J7*KY=JJ>QW Q=J>T_:JVW]62-?UO0BG8&X<]<?C*&%[5,7Q3;I13;
M=XOY&%A[(V4DB"6=0*]EN6P=<8@0[J@T0=@@-K:Y$E?4B%]2K[V:%.[44'=3
M$?+)([7U3(."U':0NI!,(#&.3'"DI)"(QV21#HD@IQACT9"D<N@8%^;V(;2/
M JGK#<C[C(8O6&T%JXL![P8G10A!VCN"N+8$&4H",H3H: ,SE,.I2C8YUEN7
M.R=]%ZT%E$\C,+N LAU0S@]0RD"4D<0B0&9NQJ@I,I%:)+WWEA#+&=<9E(RK
M]0+E.LFT52,;^LLZ"C1EF1[%,JWI:MS=I)>Y?1!O_1UYJZBZT(\ /9S_ZJ#N
MZ'/)QW\+N^P5L_9(-N)#VF6KA?AM.)Z P-I(JK/(BR*R+B6R^G/5<I+2B3&.
M8M8I..$<.1<$(J!-<J-3$DF!R,I$:_DS*Q1&6?!Z9];9@M<V\3I7,1W75)!@
M$&<VPK\$05HGA2)E/'FB%%<LXY6T%B58\+J">&W!>%OP>F=X7;#3$B&-U]PB
M@7G,Z?@::68ILKEKE_$*.#9N;#/37GYJP>L*XK4%NV[!Z]WA=>%\33++/@I1
MH4$>#I(C([@&O ;EO34L"0YXU;*U,D(%KZMD2"G+5):I+%-9IK),;2U3">W=
M?GUZ<M*[U)3ZB3CJ'M)J/)WX$MOP,X+QT:*AV&E.8$$]B@&D8U!D/3).4(2]
M((910P)5.3CP]G:G1^&C?:((;=U.7!!Z2X0NJ*ZP,M0Q@XB6%%173I'%P@%,
ML85-F9*AV=2DGDB<_7H#L74#< 'B[8"X8//%@8JH?$".48VX8A(Y6 (DG7!.
M"F,BSK&Y=.FZ-05P:V3!+8"[)> 6$E<$]M&$@#3U'G%&%#*)<T2D9%$SC[4@
M #B\=%F\U0;<.LF@:QS.69;I42S3FJY&B;I=[;E=E:C;!S2/'GA_"H_U9S !
MXUO5/'B\9OJ'L)+&8_]L-O<YEJ#(H$O)H)\6[:-!:4\%J'J,2%#ZK#+(P3(A
M292AQCL)(BK(H"W81XL+;76QV9I]M&#SUMA<T ^C%%%8AT35)$(ECVS4&':+
M4=*(F.L+ S9;L(P6;*XN-ELSF19LWA:;"\920660$DY+$&H,XB1XY*02<'@2
MP9A/A$4X-[DLV%QG;+9F72W8O#4VY^>F%-);D&908IPBG@S T@2'@#%]Q(DY
M$AA@LX5Z0 6;*VC>*,M4EJDL4UFFLDSK%@O[< 45_C7LQ\YQM+W)<57H]G@X
M/NGZ>)MZX#=U]91[W.4]'N&0U^D>]WCIJGBL5JE.3-8T.\/4@:]_!CH;YV8Z
MH?./.&V2!+KJR0C4U:KY045\MC^$U_U6_>&?3]+E]>"G<1&:RC*592K+5):I
M+-//FZZ#5<1;G[QQ@7,M=2+$"^58=((X8I8*Q\ARQ#"];J2(68_%YPO2 P@/
M.PNR0[%O+V7??O'UWX>?9CT7-?&>!9$0$<DBGJOV:B$]TMS3) )6U(0<J4^V
M=+%PKR^$73(L8,P##H8S3BQ1RG+IA,8A!6F6BMHH$+X'"+^H752O\9</DO(H
MB55(R$@1Y\HA6$^-K,:"LF"3<CY71)-;O&!X?3'<6K?W@N'[PO"W&88%I<[#
MDB/%#4&<2HH,L1(%(6(T&HYC$7+5)5,PO,X8;JV'><'P?6&8S#",0?51&"<D
MB ^(2PFRM+(1J<"\)5$(:FU./Z<K)4NOBD=NE8S9.3,54%&9J8?P(L?1AENG
M9I2<MQ7,>2O+]"B6:4U7HTQZF?0U)J2'L"%/BTMDX?<@O1P.PWAG$*9"\.MA
M+QPT!WH1=I<3=L\6[<:6>4]),HC;(!"/CB-C4D)8@U)BE<0BT5QP B_;YNV1
M'E!/%+:MV8T+;.\0M@NV8FZCMA%P&X.,B--(D&6:($RDU(9JK*/9V#9F2SX)
MV*XW.ENS"!=TWB4ZYU9@0HV2+%C$0TB("T&1\R*[<WBB-C*F(MG8I@!/NBIE
MG K8VC;=%K#=)=CFYEKK"#8B1"1,%F&%ULC&X)!BEC*L<E41!6!3>MGDOE4H
MBG,;%XL;CD(<H<GPY%D>_GC8ZX;.%&OK#>+6ZV]G$(_G'6K&!;++079Z-E9*
MI_&YB@S3B!,'9Z23!KE@/ HA4LXH(4*[C6VI2&OIN#>&PB/RH#YA>+=>O+O
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M)87<K8)HG$O!6"2L""P9D>TC&]MD4X*,4\BGD,]C(1_I$]".#=Q0QD6(QL3
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M _51.<=-((8IIPU7TD?-E>7Y1"6&4$:*B>L^3\TWB[JB%X32% (<DTPAKJ-
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MT$)RQ$#M1IQ2B:PT'@'WF$BU3('SC6U)MN@MR*>D-Z\P9%M7Q MD[P*R"^7
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M.JX8X90*A;PU 7'" *&&6^0EXR#YY/2%7)J Z7*(KBM$6R]-4"#: D070AA
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MU+=G_44!AYOFMK7BMA\3;CN;VF-N<JN[6-C8-F<Z[\['LWZ7VY/)P!K.[?[
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MY$TKOG8BX!A6 6RF&+E)SW+U#X^!1@-G?76>RWAX;QVDAV@%I!-PP&G4,SX
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M0<;2"X@EP6:(83,OLULZ1QRI?P+3=L32XG \O__AY AK[ AS ;1?=)9GN1D
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MQX,..CQ!.0C1Q@$)AS\1K$'E3X+)C+:H\=?8XQK[E5WB,C1PX_CQ=^,W4,/
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M;YS4'!W@G<=;N&(!7_DN3A2RG3 *G$4L9@/8Z9R+PM,ML 'LAFU%B^=_Q2P
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MG(>NT6N2?J(=_*=$D!!W^UTPM2\)4_L@F5J5-R_QW$JSWU8!>%?V?\SX^DB
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ME)A!QU.10]&O7;H59>M!$EJ.Z%R4#P?J_)QGR,^97$)^SKYZ41$XT\CE>[R
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MG$T8.  S.+^:?G5D-&UN=.&"N_Y]S_C3P7G6<OS3D>GK<EI4Q]AO>/80"-3
ML7. P*;W&5B9(69^A'&(N85RI!I " >MR9FU^S/;>SB8+3LG.#.1#6>9*0"$
MG&<'/MZ(SXWR@Q\;.(-F!T*.M_2#M0+E+0N2$;6B,&8?6&+B"L+ABQP-<P!$
M"!UQR\RZ313\5<X6JW::8#)<>'^:8,\X2E9ZQEAA$ _[^2UF_]33PDK?FD_
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MU/?"&&<8R0M B@9?\@#K8N"%W$6B@#V%<7#+D^;%X8K#!@/ =1>4":!(,@I
MSL'6466@G]R!*).W9 -LSW+$X<4/0($YL)]0J#8A0 '.MP6E8^W@@Q8/27>1
MEU!L G]Y"R\*0KQL>$LMH 4T+78OJ>LP(=[5SX3X)$@"3&'S(.I!0X$#@)[Q
M#4R>>[H&#.Y2B$!VG3O$]))9N"@<1"10"*KC'CS!O.\.C[:8S@H/YO8),'5
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MV-)*#C4O<J@:SMC[N@HX-S["<ZO0>.^A:7'#-Q$GW6'8[Q1P;SUJ?3<5-G_
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MD?$.1+ECW,I9+*=#&1K==FL%)^I).V)?8?,)/ED5-,=#Z3G+DA4=*D:TB:+
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MI8=D(PP+-9[KL])DO<X+/:73-Z8[37:F\:'T*K5+),<\#8I4J>/^/.F/^2B
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MQKU1^]WA7W&D#TGO$N-0<BQ\+T51 #@)"072G] Q\61%::+DCB((QG,FFI5
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MLG>E',=0 FC]%#OHN$]$*">!![O?2X?D/=!'SJ#,)0VU0!IS&I?1JUL&U^]
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M5/)B_6CRI'/>,P>G*]-C-=J?57J67KG4*#Q0!/71$]X)@H[6_JR*5&TD%RH
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MXOG7RQLAXPD?U&O4P$_X"#%C&E=*/ZL'4%\#V?Q'Z)'-!"+'C6QZK+7PO1<
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M 5"CWP!^+<"?6*>D'A,_B1(<.41)+P!G)9]![$]1Q3J)S>*X >@3  4QR09
MX(,!DLR0#G^VVJ#CJ=LGF>K&7(H0=!A:Y^R>Y?WOTY9QT@&T^'/#"U#ML')%
MTSJ@*20 ^VP("3S</66S&ILN!"%(1Q&BA9^$J-XE\@\:'Q$W&EL8QT9&';QV
M)FTR4.B](/+'S%C8OD'&L:<L_9.>>EDT 3OR#'P1Z9 W :OR#U(6/NF?5KT8
M-&F ;*Q?;8-5,Z8-D0H:"3<T[H274%P#E,)WJ3I*(U$J0^+D?*6E<3TW L)&
MXQ4.,B-[4"DV%14A8X'#DTK0G%PP\%$@A8D-."'2A_/B-M&"<O&4-IIHL$7
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MUR?AD-E$"B^>@-V%<2,GB>)P;H),IH<#](XP_&:#H(ZD-I.&2>2BV=0",\'
M'PIC!LI@CFXO!NJ")#(\ AK75\*#LPQZ+397/.%.R9RZEYZ'_ZNV%(1S>B#
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M&\!%1F_H5Q3+:95OCX4S=7T<+,1E%GEE7S8H4@2*V!A)!]X#RU$(0EW0!3:
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ML]5;GA'8<%7#59MQU>]7OS5<5>:JW\50>@U#-0RU 4-]R4V<.SH +&,H''&
M9:8;*ZK+AJ_VX2:E]SRD?[P2Y3J W1A?<%!K=73P)+NB$%$A^J<F.N.,9[Z#
MT.6_(*4J(H)+^^@_-4P8A[D__WCW%1N._V_#^"A\ !?%6?'X"#),7\3;(I!&
M(@[".8]VA@]%&&+&(CZ\V\FW3[6P5_\=!LX<_F<23[U?_Q]02P,$%     @
M^(5B46$!)E$)$0  $[,  !    !E:&,M,C R,# Y,S N>'-D[5U;<]NV$G[O
MK^#12WMF(IN4*,?VU.DH=M*XX\0>VVG[UH%(2$)#$2H ^G)^_5F %U$F"5XD
MA3J'GNFD,HE=+/9;+!8+$/CYEZ>%9SQ@Q@GUSWK6@=DSL.]0E_BSL][7^X_]
MX]XO[W[XX>=_]?M_OK^],BZH$RRP+XQSAI' KO%(Q-SXP\7\FS%E=&'\0=DW
M\H#Z_7>*Z)PNGQF9S84Q, ?FR[?L%)M3YP0[;O_H^ CU[:&%^L@:3?OH:&!C
MY\296,A\,SL=C(;NT#XV^ZXS</JV>S+H3T9XTA]9#AH=.2-S@(>*Z1,_Y<X<
M+Y !#?/YZ1,_Z\V%6)X>'CX^/AX\#@\HFQT.3-,Z_//SU9TJVHO*>L3_ME;Z
M:<*\N/SP4+Z>(([CXGCNK)66>ELL$>=SC#PQ/X"_#F6CS9.A&=-(CD13!_&Y
M0+Z3U.%3WP\6^02N8(?B>8D/H5 ?2F%&G(2NG"@F0$(P,@D$_DC9X@)/4>")
MLU[@_Q,@CTP)=L$B/"PQ7RN0>BT0FV'Q!2TP7R('5U?*NQ\,0R)&%DO*A.%G
M.$P1GRBQ.1.*K&]:_:'5,T*,KZB#A#+<J+QJ9H;H$'N"R[_Z*Q8'3]SM'587
M(.#]&4++^D*D"4-!HB?UA4D9L'5R<G+X)"VR4(RL<:GR??FS;PWJ55MDI=7K
MAK_Z,=TV9%CUQGHRQ'0;RI#?^:J(DJ;\$A)*64ZD+-;19K(TDZ.I$(H5Q\[!
MC#X<NIB EJT37>?@143R1W]%O5X_\GTJ%!?Y)'JV7!)_2L,'\$BB>AI#>XNG
ML;O-N/2<_J/^=XJ8PZA7TMD.EXPN,1,$\_1PH!C,&9Z>]6!0Z,?^[2\'>0<@
M2%PBPW_=/.7K0R!Q D^U]FK5G)B#Q.NLQP$1#X<*VN/6NWA:M_5 0GSR_]!X
M#TWJ-AY(L/>_WNXEPW7;#20<HHLF-B_I[^&]0=RSWCF%./8&S4 \^?SK[65I
M)*+J7]'%S&/V*W-\9T+$"/\9_54$W#<4I2%)?SY\2?""5<"Q>^V_4[]?-C@B
MCHIH"%\XA\ITZ]TJERQZ&"M4JV;?Q3X0PP]./>+*:< =M$;%B)Q.ST'-#,^A
M#'G EU+K^*N/ I<(&2S6A&:3NC1P6@K. 6"8<%-X1M49Z?I61;A!I\9:E498
MI_%34NN_NVX*[Y$G8[R[.<:";Q7X LYZF*6?J09SQ-X(^;]"6J;X&\2@G7,L
M"$B^.WS7J]&#/31->U.PC9_6:NP\^&EW>S<'U<RIYV+&/_P3$/&\,\^NJTIO
M!+9ICIHX]G2-/QIAG:]>H#8Z6W<+C>K5F\C(-(]V82*OOD,3JB$^_^C1Q^W&
M!"4UZ,W@R#3?-@H!H2)#U=11__ ><0(*OTDUHB:8>1PT8 TLT[+"Z1?ACD=Y
MP##\H;A(1-)\NHW##=BL Y/US?%(..EP@8G_H"(NX!PCCAWO*O=HXFT#H(B/
M#IZA.1Q6AB?DUW5P\),(D'>!!2+>-D!:YZ<#RS9MNRI8?2-B;/P4L>XX;E^P
MN%YB!K_]V2U^P'Z ^=9 U#'7(SJR59:I$J)0BY%48\3U=!/@@!,?<WY.%Q/B
M*V%JPYC'0A]B'%DY8$5LC#2?CB/1;  K9J0?P=X.*Z+2R1$L3ZL;#6'E#/4>
M[]A6"=<*<'5\#,M1]$=$V._("S"=CCG'@B/?O2)H0CPB%^#@6;# [O: K5>?
M'O<36^5>*^$NZS54Q7(8#*LVH&XC5;D1U?YJ')'>(#R0B8<;1-PI96/GGX!P
M55_3.*=1'5HCL$Q;Y5XK&8$,=U0F1=9F0'5&NKY7V"--W3 J-]ZA6\P#3Z:Y
MHA"1^MN#O;P./>R6K?*IE6"'N@Q5F1'5)EU 4E\G8?\=,2(CETM?8&B(^. +
MY0)K(EO(1AOU6A#X9@;LF)41\S)B9J^P- M_2YAI0V!K.*P#41?CX$+U;A(+
M5V2J]XVVK189JF+7[:"X2.-RH[X;>%@N\C#V3/S9>$$#7P6LYQY 1Z8DW&D*
M@]?OEQ]X7CB[72/8JDAZ$QK!K*J6"<6RA8M5H71&))Z*LU\(*,N!B#_RHEB\
MB[9X1?T9J'9Q@2>BILVLD>I'WR,K.VV2Y'U);T@&'55YHU$VAX%^9'T[+%-_
M%T?3M!K3OZ\#(;_@D%^'-7.F-1CK7>*Q;9Z4X)9YD*JD\P[M(\S(?(<@3^YA
MAI^BX>A8C:<>RQ/;,DNQ3)@;"??.@[A1<*MAI(5K8,)\OQ2N+@>QM]C%>"$'
MC2\4M.\+> NE9G&D5A>I<G[:$ ."C&Q2;L736&>:Q)-=FNF7:KA1,%*5JS9"
M&0R&C=#K8MA2JO#2 F-'D <BGINYU.W7K_?$0]O*K(Q6,8UJI6)97GUX/I3P
MU('YL1*43@N*[<R0:M6N-R/;MC+9Q:IFE!9#9A&*W=&K$>4, )L$<'6YZXU@
M9%N9B7 U(^ARJ)<LH'_&2"I-;1&OB6,^#WU(=V1E%]Q2B^II3EU'HU'HIN.D
M#]?>#BLCT\40+5>QJU1Z\CHO61Z1N-1',/ $C($G4GLIF_G/G8JB=[;'MI6)
MZ8N,9#V;ORKUIBA7'\MFP(@L%]DC\:)MIZ]>.N[-FXR]53CJ3>#$MBK[B=<Q
M5M-/LZMO'[@@"_G95D+)D^SAI<\%4^<W[,9K;"R-UFJ&IFUE%I.K.8[<9<!$
MMA03_B:5:TT)V$G;4Q]\@N.4GY<^-PGN<AAH([NA966W"R@F?<7%B-ET&H1F
M7;>8C[[3R>6F*I!TLH>$!Z#<HZ?:,7::4M\GAE9V_T-T\(HB[Z:ZFW6"' 9Z
MZ[=M*[/2FE9^)ZW^ V(^#*9\B=DY72RHK_Q!32@*F.C[PLC*+GS'C S@9(2L
M0@?5>40:3?ZUK+2S_^'1,#MZ%Z+3Q?E_OF[EF5J!B'+9<I[J0'1Z0;P 0M.8
MXF:-HIGSVW;M>L_YUAYD]C44&T/?2,DA(W8EB0K3(UE6Q#<92WKUP1$T+U=&
M_L#R]&GLCA\P0S/\)5A,,(L.DN$;[V?:C0QZLSJV!YG]%SJSRB[2Q/(8D4!&
M*%%RP@WO_%:I<^K+C[ !=X+E)/Y:S$.$B6@R"RQEIQ_S3ZSL!JDUELI+**9&
MBNLK7HDJFO7NJERU_=4V[4%FE;X">IWL=W=X)AM_B^61TZ"@NC/\E^3:?F5;
M5G8G6\3"2'AT6/N-HN<")MJXV1X,LS/\#!)=C)<SVMQDU:*$F=Z-29#*(>KV
M4L5+!;_\^]*?RB]?96V9'3PY1\P(&C$8NW\'7,Y&WE_>7XRW _YN9=/;DFT/
M,IM-\FPI^RPEY9N\[4?Y1^@(FK"*Q35">5_-5&\*]U0@+UD!O_0? 'D5GESZ
M\/?8?9"GZ((QA/N#D@,3Q].I@J5IEK(-"?4F.[('F27[!B:KI$VOW*<$AM_J
M42RS--L74ALKL5\M5WFC=4^5ZY,$#?/5\GZJ,/ .@#0Y<H"_QP 03A+C'YZ6
M\@30[1CN=Q!0;[=']B"SSR#/;K.^M,AC@E5&^7]UX==*X-4I#MP(14XM%!B1
MU*]FFV,5H3^0ZHQ*"IH^?G8WIEBQ4KUYO;4'V>7J2N85^4!E0S$%F-;:L;NO
MMI*%+0IJ4KCQ[V$ME:O5V\NQ/:@PT<NSETB -8/A7;.8GP_7+[\*_UZ[($M>
MCQ5=V*?L"<^=O^*,\QR<<0B\%UW,!6:")EPPY(BSWA1Y\G(?>=/764]+XQ//
MDW/QLYY@@;P/2-YK> KNGU#W7EW8$][U)GH&#X _$8&D_)718'G6"TL3@1<]
M([S>)WKB"SS#[!)>2":K*\"*VO,>NQS&%0B:Y&GB)0U9+]QR"]8#@$+97Q8K
ME]H-PB$X?C<)+[HXZSD,NZ1>:Q;4A][$GLN;<P,=%S,',0S!*[P@7'S&4NWI
MEH4BAPW3$-1I8Z7&A)=HGKIT@8A? 1I/&3IVU5J(O(W*E2MS$+Q$_3S<:OM<
M#%IE!C6,\'NB&49M5Y3SCP41Z3BZ-%0*?T]32U_1Y0C1BF6ABK98P[YVB=\H
M. -IVC#(T4<?1)Z3)8CER(%&7E)6H)I2NFU[+MDW(O[EK2K[Z"B\$T,=Y ?*
MO0G9%K:U(;=6-1 /)Q!S8.]9(N02?PD&!H7 .L.^K>QM3OD2?GKE8VPM7BV/
M7)>Q@+=K D81F=[K5Z-M>P HLTI]&ZM2M]W*SV!K#B*NOC4O2[4M]:_8CT:(
M.^HISIQ.KYY]9SX)V$S?EFJT;;<PQR?$G5^%$JMX'")9]<;!U:/YAEQ;]CG)
M]3O7>3<^CF7:5_Y(BHTC)1190G-^6[>.\ FPERZB5!'G%&;=TSO,'@ ?F,TX
M7A!N'((V..%<62:]%W(>_9](C *+:,)J@UC+Q9.=A5JADU)3":2"I"H^+:?X
MOG1].5.-@YY*T]I5X98[ZJ?$C>@AR)9K6_<W86#"2Z:M+TJU+?4.EQ?47@NY
MF/\>QH%OFA#^NTFP*V6+N(I&>0YPDC<,+PAFGY1!WR FY*RM=OZCC%';MG8W
MON4+Q+X)*O_%@BR6T"S@L1;FDM4A5P464YO/GHXZ]Y@MKBCR/R(G^2I<!WEQ
M^;:1+9A\/SD0#,[P/4,^A];H@HD:'/84S7 XO9X63%$_59S+5V'0\A@M3^A;
M?=<;GZ9XA<.]X+=2VL)&5J+=3?N6 8P0E4.H"YA]/U 9&Y4&4.FB+4/39"#9
MYR'CVG&")?3=9SG9* 3B1:D]=1#QQ_37T^PYIQ5CI3HL]B#82<\P9-2F\O$5
M9R1KY5ON5=6RS.LG-]Q"D8^4/2+F-DWTE;)M.9=PAWU"V1<J,+</1N9%@ ?F
MX%CO;?0T;;L;.:O\%">Q/H5)K$IYZ0J$;;<MI7G3/G@;Z7YH5L8KEZKM5JW'
M$W)7B.HE2."QN.0\D&X=O"5RL#J;I&)<4H%/JTM(?U"8]S">7A36PZ@A:!O!
MU3:1FIGHO4LR)X%[Q36L?4%@K8\?#49A%[=J.(8L4=MM^D0]F8SF8]_]\.G3
M99GWSBW<=AMB0U<+^K^'"_I\["C/A.7U>E\Y2"WF. P4/F,QI^7!54UN;4]H
MT+.,BH0\*(3Z,O.#G\!+$E[LRG4D^SHU2'6F$8RR85@TJMX#<XC:MMY;[*S=
M$21HW3Q?#0Y[BNL]7BPI@Z)AGPJ_C1?T,_+13)4,/]Z@C,>9KO&,X?#XM9MD
MQTZQAK;&O]5H)EY.NP"#AM:M!#L'G+&COK4!I,?+)98GWD7KC&-W07PBU2+(
M [Y"C[\%[DP&X7+R4JRRW536KOX4W"Y,%,O6+;,%V_82<N:+^#Q*9X"BPS/C
MY=W!+EW*FJZGT2 EO^*2:QPP]?VZE)NUM<GDYDSW=3^@^L _VE=  [ -/=B%
MQ5N'/ I$_I:!R/8WJ#1EVWJ.*?/);+29)+6/-?X(,?\BD/IKK9M5L@<91F7D
M]W/"W"5BXAE"/UJ6[]:2M-TW-M_6K Y]VN&VZ8C_OCK)W,LVGV/?\"&ZX3+]
MQ4^AKIJPVE%&MOH^-^!)7 *JXHZ"#H(_Y]L<>^[DF:_>+9( L6R#=7.&K89$
M.7>4YSNUY$SE0@TT8;6GTY'K0$2I)Q@!J?2#):ZRL'S;?G)M[AM/?>T:\^4,
M3=LMBA8-RA)5:X7:EGD] V%%2<#!L$[>(DO5=JORMRC$O5S^W72;0P&/'0T:
MU?8[).NL*L'R=^K;(<W&WV*2?8T+DDA7QC[C!T2\,-2- APUJ(4!3O$$HP:+
M?55#>2Y\'Q/@Z2G=QI]*U6/6\JPPSE95VX^^-[@5728'M@TS<;F)5^Y]6*A4
M#*?L)F#.'%[0:5*V+"[=9A7;5U>MSP&) VZ#7\%L8E9A);>P>.N@Z[<O?O6)
MX%]]<(^K[+0:2*"%C?=$EC#];IU7G:+ G3E>H'<__!=02P,$%     @ ^(5B
M40:#">"7)@  ^)T! !0   !E:&,M,C R,# Y,S!?8V%L+GAM;.U]6W.;N;'M
M>WZ%S^S7TS'NEU2271[/S"Y736*7[23[C85+P^()12HDY;'SZT^#%&5)IB1>
M .KS3*JF-)), 0O="T!WH]'XXW]_.I\\^XCSQ7@V_=-W_/?LNV<X3;,\GG[X
MTW=_>_\3N._^^\^_^]T?_P_ _W[_]N=G/\S2Y3E.E\]>SC$L,3_[9;P\>_:/
MC(M_/BOSV?FS?\SF_QQ_# !_7OW1R]G%Y_GXP]GRF6""W?W7^1^0E>0Q93#.
M!%"2!PA<%PA&*$P^11[8__WP!Z%EELHQR$DD4-D+B!HC:)Z"-DDS@7+5Z&0\
M_><?ZI<8%OB,!C==K'[\TW=GR^7%'YX__^677W[_*<XGOY_-/SP7C,GGFT]_
M=_7Q3U]]_A>Y^C3WWC]?_>OU1Q?C;1^D9OGS__W+S^_2&9X'&$\7RS!-M8/%
M^ ^+U2]_GJ6P7,G\45S/[OU$_0DV'X/Z*^ ")/_]IT7^[L^_>_9L+8[Y;()O
ML3RK___;VU>WNJS*/K\(B\49ALGR[/?TT_/ZN><O9\2*-^%#1;UJ9?GY O_T
MW6)\?C&Y_MW9',N?OL.S!%6[S$M6N_ZO+W_[_ N*%";I<K(:],_T\U4+M:^C
M .&G)4XSYIM='3A@:F:ZP$S?+&:3<:[T?K>DKY7OBUEY27\WQS/ZS/@COJK-
MX-^FX3*/Z7,'">F8_IH*MMG KY51T6WP36;IUH<FE?JS^>8O)R'B9/7;T>4"
M/H1P,7HSGY7Q\N?98C'**@E:(1R@SI$F?L[@HE60+&(N3*),_+:@KX:\FBDE
M+.)JNERU_+QJX#E.EHO-;U8Z <:O9LU_?0UA+>K#![,66&WI)UH?2<;+\?22
MEM?7%SA?*6U!GYA<UA7WS6Q>?_%BN9R/X^4RQ F^G_UU1@U,EZ0JZN'#J^D2
MY[A8CI2DQ5($!.^=!&6,@1"B!E3"Q<BU\+;T$$R?X=P6\@U&OYBG9[-YQCEM
M3M\]^P7K5G*U3ZW'%N;I*ZK?7B6O/O%\<7E^OFH3B+CGF[^OFU83]BUG@]/[
MFJ(T_K8<_F&\2.OA8/XRFK_B\G5Y'SZ-M.<\)17 V5#W:I<A""&!4 JG0TFJ
MB/[,?!CD+GP3WS+?&NJH&8NH]R\@1Q&]=,J1T<<2 Q4" U>8 L6Y%S('089=
M#YK<0G'LD&[HC@F.(1M7E4434]!XO!06BD\IH3"<!G?*G>II%]'#=7V7UP>*
MN ]K=UJB2];(?$)P#CVH:!G$6!"BL;X4D[+/7;;FO9'NN0K"-\*8OAIK1JP?
MPWQ*(!9O</[N+,SQA_'DDBSJ4?9)<X?DX8IL014?(:)TH$OP@<N$,M@>]+D'
M3W_[ESJ\ZFO5[PAC)..&%*&]I<VI$ N\EAZ<-E9+%H51\6E,VSM(A[3@MF#3
M_B;L,:I[$NOT+F!AF/9%TE1W2(L-.><0$I> CF<N6% \ZZ<V5@]@W:ELU_ZL
MZZ?.;@OY]V$Q3B,RIWT03@ KGO:M&"P$)25D%HI%)C.3_A3+^ K-21;Q54]K
M/9B@4PZZ0)(B@TI>UR7 $1.XUD7DF$MZLB7\"\XA+^#[L^B@Y?M I3W5XGT#
MKC2%&2X+.(6:1&/(ARTY@ V6B\"=+5_"DT^X=._'MJ=:N%NSK9<BF_'NY6RQ
M7+R8YA\_7=3@-WD<0?*"BD/6T1#GA:)-1!A 8U)@3CH3NM#I+I!C!_9SB+,Y
MM?<6)S60?]7LR!03+=>!AA?JSLAJQ$>2>89:9IY5L*G+=K0=SI 6WJ.8<'<6
M-)!^,XJ_7I[AO([NR^"NIN+TPRB*8(N,"3 F6NP%64K1R A6,\ZDCLA]EW#5
M0Z"&M$ V944S31S-#3Q+H]<I75Z$:?I<$8V$]2YKZB_ZS&C7CQ9B*@**M>@Q
M%F[CG6C55T>97S6ZBR+EMZ3(X\36;$:_N[RXF(QQL5E6/(N)(VW0423:KYFR
MX%PPP) Y'LD#8ZK+4<L='+NH6WU+ZFXA[V9*_Q^<TE(QH3&]R.?CZ7BQK O'
M1]R <I'FH64&4I#D:]M"9KNDK4;S),F@8L7H+CO[([AV(87^%DG14A_-2/(#
M7LPQC5?"H.\GN)(T03RO9\O_7OU^)(O07 H/DCD:M; )O,D<>'$B):<=MUV\
M\EW [4(7\RW2I;EFFG'FY_%R_&'5_SM<+B>K=)\-B3'HG+*V8 H*4)@D!*<4
M2.>CT43ES%@/JCR :1>&V&^1(:WTT- W_BKAZSIS('LF.+<9,&D::$#: G,@
MMYW;0@QF)OLN)L<#F#H.]Z 4'1>8CCJJ&OR.)"(RZ#T7CNQ#@SQ8F:7M<J;0
M>!S#\M';,/+NU'M*U9]BNNX$FBDC"Z?EA5M!!HOT%@)* 8YK3"*;F$*7?(4C
M<0\J>^$)"-I<MYUB^LU2'R-*ED7T(+0FE]N'0M-,>M#921.%2ECDMYKRVD/(
MWV.9S:](0WRI;BRY*C0SQM,P__R*^+RX+\G4!T\&C8>H! ?E0@1?%/WHHC$2
M4[+Z!$<K3<<TI-UL /-C_[/"T["I\1I$0*\LZ>_):R_CY4@8R2TR!UX6VJ&3
M]1 \1T!O2F19H4P=3Z:_PC.H36RPO#Q.C2?<UPZ?)#*3A1!,#27722+1T1YM
M+)"#9ZW*#(/I<M'E9$ON_N)^BQ]Q>HD;7/.0EO\8+\]>7BZ6!&7^XZ<K+KY8
MD >^P%QM+9Y9XL9)X,Z1A94E0E!D:X7B>>8955:NAQ@/P/IM[4BG8?;=Z=^;
M IV6AA__=3E>?OX++L]F^=7T(TEA=95N)$.26'0"M(I$D<D3(*?00I12!*VU
MM^($5V/N03>DT]>A\K&]FML=$X7Q=%&1X>+UE(1!0[X<+\XJHM?E!XS+45',
M&^H:/$."5;*$F$V 4J1E6:M88A?V/8IL2,?%0V5>6_7V2Z-22F0O7*Q'%P:4
MCA9<$1Y09%N\1D]".'T:U:-GTD]M6#\-J8[27ML\)1K=;),2LQ;#Y@A$A.P0
M$X'@MKH/QI/1C]6;S$&F$@R-M%NFTKVPAG2\/51Z-51L0T-M/; -",:0Q60+
M&%EO#'#-UP=L%D.,RD7M>9?;5G=P['G\_=M<KH[1W1T"_?'Y74'_3#_W*"'R
M?9C4XB_OSA"7B^8%0^YIO7=YD%T&U:@82'7MEHN7E_,YF3HCSWVP9.6 -)E4
M+@PY=]S35F4C5T7Z>C^TQW2]A>)HHRDLSFC7K?^K+L3',*ENPXOERS"??Z;)
M\O<PN<11\#X*&P)X$VB =9)X= 5B3$B+)3.^=!GJ3NB&%+PXG"%?V4/-%=-L
MWWI+Z]Y\G&B6572;P:(V):AZLL=<O6=GR>97RH')4I@0B['8Y4AL*YHA!1#:
M<>)XP3?CP(N49I=$R+>8D,@9)_4L>(,H"Y6<#!D,[7OU%@WQLV@$SIWG&!G+
M?>X;/@1J2(Y].T8T4T-;#^K. *TJRD<$F4EGRDORY#!;$#II'[2)R7<YPOT:
MRI"RP]N1X$B1-TSB#'$\&2_'6!WY=\M9^N?9;$)"7:RCDR-M,&=, 81QKAK)
M&:(1-2^IABBERC%UR49[#%B#K*?S\3K@6K?LE9/R@:Q8ZF]D;61VM3DKC#0)
M'8TY1 /"J\)*$5+'+D[= YB&9# UY<R6C*4F>FEH.67$\]4RO=4E78]Y8^*]
M.*]K^\@:*05J#>@SUOV=YK+%!$I;S;1@B?=AT"%@AV1W=:56=TVVNZCUU< /
MRIS(J2 &S<&J4",F69"5&2,DSHTV+H;@0P\6MH$_).NO*R^?0-L][(=1$-I2
M7P&<\^34F"(AB&R@T!P1Y-0Z%%V\R1L8AF0L=N7,H7+OHGA#VS)3UI"74J^G
MFU4"NU#@-9)3:X+4K,O)\+V*/VHX&WL\>N^SXQGRRD?G48-/TH%W.:!7V6:.
MG4>UAPOT!,;?7GI_@,"'"+P=CV?3#^]Q?E[/P%>QNXOQ,DQ^QK# UW%R=;%J
M,<KDDT5O/11R^FBH3(!+$D%@++YP(SN5Y]P-WD!-N.,(TEXQ[0(FFQ/)%9S-
MB#_7C?F*R\Z8E'0JX*.N-WF"A\"\ILW8">4\MR5U*4_[*+*!6E5'4:6M.MJ&
MU6Z,\08>'YUB2G(:;3UZ-#7^2YLXD'?K4JZ"Z'-#XGY( [6<CN-%&P6T"\"O
MXGVCB#:0N<9(.62C*X4TI(0"DG-DKZ/Q:+LH?]U]@YK5--V6G]],PG15D(:,
MV8L:K_DKTA8>&"E'%^ H/8E52W#5)1'9N9B]+EEV&=I#H(9D/1W @"T%K=O(
MO]-N^+:*\77YVP)7@QV%K#D75@!3-:PM3"T3[^IE=-3)Q5JFN<]2]Q"J(1E,
M#3C13@/M\HEGL_S+>#(9)96SD;4JE<8,JBA-WVD%+&1+BS@:P[M80AL 0S)X
M&JCZ(+FV3'\+TP_C.%E3JU9DO+Y$<8V,&85D>QO(F=>XAJ^%ZEB!6 KCFJD4
M1!>-[P)N2&9. S8TUT?#BD(%R=3*UTE^UP!'OF2E:I4#CD6"TK7>LC(<BH\I
M:EJ>T';AQ_V0AI2-VX 5C63?([_@A@DN&4<=4@+GF ;:FB3X$+">Z\6BR5N+
MILO)\E8T0ZH?U<(@.%KBC9V>38S/>8,R>E;3G<A M9(,5,<1)#.1LZB<P"YQ
MM+U32DY5"JJ!L@^7<(_3@ T.QJ(F+YH,SE2_:)-J=DRJR=:,;!>KT?0^#6J4
M;[M;)'(S[F"YCE%XR#&27>:LA9I,#N282<LPU&=IGBY2/.P3A4.X<UC<^!!M
M]0X?7\]@F6E!SA)8(23*BGJQA19LK3E-[A@-*UT**CT,:T@N<V/*--1'\V3=
M-^%S/?7_,DQE>5 U<1A7 1X-P:<(W!5N?+'1JJYINK?A#,FW;LR)!O+O=I!P
MO7@I##FP %@O62I'0PL$ H(T$6EL1H4N6\T]>(;D6[=>(1IH8&C98<5:57Q!
MJ)?@0&5AP)?HR14LP:,LJF 7_ZM'=E@+(9)[Y$H*QH'U7M2Z"UCS#RQ)169K
MLX\\=+E[_EAR\].:9T_ ML<3Y/;25;.)]Y?Q=#9?">!J4+206!-R!JLX37\N
M<RTC52![+F@)T+11=+E;?A?(D&RS ?#E*#T-[*;OFU WFC-<C@G";8RMK_W>
M[NII[@ _,-SK"\'/>TC_W9*^KJX=S,KJ7:E;%&Y^\7K7[GIKX:!A#T(372;&
M07T/1$>#F#KUDNM/D]DO[4L5/-++*97PV" ;E2Y871B^?9?\]FWBU4-A-W]Q
MXY-O<#ZN9<72O,8T?L#U_Z^WXA\_I;,P_8!O:50_EH*)?!D18W3U973) RAK
M.&V2ELP/5IC5(@:.78R9TPZSP7ON%<*;^>SCF%3\_>>_+>I!VT_C*>UF]=I0
M6HX_KE/7M%?.5L.%&:UJ-21?ZXM(0,UB%@J9[.-/[ YQ2'[&@-F^Y87X'AQH
MYJ?<@V]=8_ V/I^4M,*;FAM40(E(+E36$1S3'+.)TO=)V-L=XI!\FV^?H\=R
MH#='KT/Q-_ 9(4(.0D.AR0(J<@>Q%FO6V0M.HE'!=(EY[PYQ2''P;Y^CQW*@
MW1E,_G^75T59W\_>8IK1ZKZJUO&EPMG[V:XC2#G(DGP 87.B$20'3F8+&(T7
MJ;[3J;ID/;4<Q$F>F2M1E\0Y!V&" .5C/6XK#"SSZ+#4XLQ=MJ16S\R=+)?\
MJ=AYT!-U^VBUW4G)U=ODU94[KT7_UEA"%KIH): 8AJ RB^"9-H"TEFBO:9WI
M\SK==CA#,G &PZD&FNN7RGKG,0G4FG9!9L$PL;K'S2!:G<#RY++![%,^33[K
M_F^#G"SQ?2B\:JG+YA6,$PG@=HU;$W(1,B,X9\@TSXZL<B421!F#DRX$[)/N
M<2^B0=7%'@RKVBBPY6L2=^SWKVO.C6B85B,C*,)BO17$P(ED@:0@2 Z>VSZ5
MUG<!MV<^_F^$9<W5VI%PJQGQ10#K)&?:GS-/01,KHJVOT7H(:!,$[52**A:4
M\324VP9O4#6T!TRZHU5[@G7N*FMOY!!+J?EY3&<#RM2WXQS-AB)\L=X&)?I4
M-7T4V:"N( R7:\?HLR_-YI>8WX5)F*^B4\$%4S"##;4Z85((/K "7& ,-B1#
MOSX9S6XBVX5F[C\T.T:?)]M$;U;%\(%K[@PMLIE&KFQ@4 .QD#)7LDCC51^_
M8 ^,NU#/_X=Z;73<[D&FW83PPWB1UN]Z8/[RK >)ICC:\0FR,B0:2:9 ,"E
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MF#AN:NMJMM4O,2SPS[_[_U!+ P04    " #XA6)1+M*()"MC  !G- 0 %
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M/^O]ML.@K\SW1]<C_!\@Z^-I@LHNEL0]4TX*IB-J%JR>H^,\D6N$T'3NM]2
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MV<4^FQA=$]%T#^<[.+>5:S#>\, TB,RT\YP%"\!HVL@"QF4%]JQS6P^)L3Y
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MT!ND/;R97>+DSI 'AH-7EM;&;$NI+9$* TOKI?28D@ /0C=I0GT?RCF0?Z"
M&Y2.N NFN*1YLI%!/070$C+SB)XA2"^3T$:Y)F69SX[H_<7:H-W/V\GX$TYF
M7]Y> 0UOE.N.]*E&2]#*,\!@9"%_CJCA?E&#T6?EZ@J4-.:LK&@2,/,0J&=M
M%O8F[18+_**NXNCB-<(4WPTO+F=ORC^FB\[& Z>BJ+UHF<4:XB4(9M2Z,".<
MRT5Y:5R7*ZK=U_J'4#UK7>A/W@V6_E7GS4$0,6@I"8>/I)2YT @S!P:(M3Y
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ME<RK4HBZVM#6AB)MD_OA;O#.P!'IGX;F]THWULRM8S K>.3UXDO;$&H)8L<
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MW=1(ZP"P98W)1Q&>IM9D+WQVT)'#R3B)UBC+>3%DF>.B!+ZU#*P5+#L)W!<
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M"M)GJ[%+5EJGJJ%WWOS\]^W#A-GC)?L=($O5[0*E[PK0:QB.7_?Y #8V<7J
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MHBRZ@>JD#(L1%+.<' ^3R394;3*O.L$[OA7?#YWK>3;]<]'@E&K1<.A1E 5
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MSQQ3$QZQ$X^F"#N(NHD"P&CZ%K[4]6ZY9=&+Z7_)T&Z%A C,//"JL!1Y@FR
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M[$J1W@M5FARQ/8+K;$]8^N2CQ_5@!>_M>#(7\]<@^9L//PVG-6Z4$*]N"SI
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M2JT-9EB4V3-K>2J(-"VQ2:V&8PWP^#O9D?7^7K3?4]2<%E&C^XYS_L\_D>R
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M\_T!]"CLN@%<S^;K_[C4I.X$H_S3\.IZAGGU%V_O_,7^:TC?"%I3VI-LUK1
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M/][^\<-9NR:.OOCZ]80<4*Z;]-"!&P,^8M&H"UJ?A+:(CKQNC*@>MICTA7J
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MD(94P#@6+*"^1"@P2L1LVN'<IOY.9K 56B^_6['-]]N,\+Z\R3DTBB.3PT4
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M3(U=N2L$F1N/M1)K(_OVRQU(4&#APUPS(@:NX$0XC^TNUFJ K1Z=E&8W8#L
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MSW1%[Z6XHX5LKQ$A%,?,2V" $8,("0H9B2,H8B1]SB+L>[%I[-U1ZW-CDD9
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M\D9?=1].^S -3,Q#3-=:@+ZO][$2GT 2XPC&?B+\-,!)!9,Y5SO -$4)-W>
M_)@FH523DA-)(4I)"%F !8S4"I<P7_W;LTP?; _1-'E_K_Z6S-8@>_5'7F<N
M?!S6*\2^@D.N DW+DS+]OC:';'[P6WN/]\]Y^93QUE.)1.3%<1!"+XQ3B&@8
M0\9$ F./>^K'$?<BHW.VHY;G1DB-<.9>W3Y.EQU<9^U'GFR-7 Y^[3X"YCZM
M,Q(3^;/&B%BYLB>U[G%C]Y^?S(4]*6;7?3W]@!W/E,5Z%Y'^A<L5+;*\RC4<
M4H*%I )2G""(0D]"DL8,"BS5FD\3Z85&-UO/]C WWFEEL\KB?!Z_?AX:!)6Q
M=^$- 3&>?!>5[C$(U+L=8T#]Z] 0.-_X)#/VHF[MS+W\H.OF4WTGK:DSHF,C
M%Q$67$U:'U)M.* X508ZDS[TI228>P(C(=L"0U]M-IV.NC+Z;/>K"WV=9+.I
MN?8J:U'KJZ*/^GSBO^N2.7E:!T^+K.2[,AZIM$V_=PI^TXTG-S2GVFEJ$&S$
MNZG"I(?<,SJK_;";1,?=3+PK=%;/XVV@\X_:>Q&?J^O<>LOO]'W7MW_?9.OG
MZDY'(45[HUYZ-" T4:M_@CR(!%.KOR<%]$.&(HG\@"=&,3S.$LS-.M@I<>Y^
M^ V0E2(W]5TRI4I[7=S<D'<;K,LNS^A#,#(+== _D[7B!KQMT&^UL,](X8:^
MN;LU^BA,Y):-,AI6+MQ52/:X>F[M3N827J5VUW6\KB''^J/YZE[9?-6MG=N5
MN*-/F3X$T*D6/K)E4R]O=WG#3WT9!Y&$41ACB%A,E?^92!@+G^- <D0]8K>Y
M;"? _#:ANU7+/F[6Y5I9JGK2?=@&G?::9D,,BIE%.Q[0(R\S^TA6GD E-=B)
M/<KM&3? !JVV:2?!M 4XG= YJLGIUHIC>.R&E57EYO7;;^J/KZJ5:E,H\C!+
M))?08\*'* D]2%,J8(+3@$N4^,(L8^N%?N9F/._$!)6<0 OJ5"WM'+!FQ#0
M7&/ON;D@91_LVH_#H &N9[J:-JBU7]^C0-8+C[O>H/OR2)?+-HO"PH^BR..Z
M^*[4-==]IL/C20IC% A/8!ZFU*CF^IGVY\8!S06P2D;0"FE[2VX?P?Y)/P N
M(T]V.T@<;L*=5/SJ"W#[K4Y\[^VD2L?7W4X_YK:8_U4Y1#J<O4Y/+-2\#9@@
M$ =I#!&A 4P\Q* ?J F;2L0"9+6$[[4^MTG;".>8UWD?.+,EVAF.D>>J,1+6
MB_%)C8=<@O<[F'3A/:G;X7)[^J%!3L$6(HF2.(A22'DLE,$=<$A]&4*!D(Y<
MHR*A1E$S9]J?VWQ]L?,NM[.N&<WOPW.NT4ZX)CC=>M&3+<-3K6L=['7.?VN2
M#=>;E=4MUP7S(^59(VU*A[KL@IKJE-$$1CZE/&*I#(EH3[P-7>S3/3D<>(\\
M]RNQ;/.AGD;1T)N^ IFILJ#N)/R7[9%$/U .Z4][81@V\^GIKB9.>MJK[W&^
MT_[''6Z"2I'I:Y"WXANMB@HT<8^8X-2/DP RBM7<Y\R'2<P2R*- IS6-0Q]Y
MQO=!3_<QM_6^%1-LY;2X#'D&QO[)/Q X(T_\8UQ<;HN> <CBSNCU0$UU<]0!
M,+O[H_U0]-TB/?/F='=)^T7?NU%ZX5$W8^>-?"HDSZI/0/U]*?5?;E?BMF/8
M+U(:\@2S$$8L#""*?019R)7/$R=^2CB6"!O=AK?I=&YTV)7YR/6Q,XV,,&?(
MDU%(4GU]%T'DIQ(R1AC$?N)[L1\%C".'^,K!H)\^X'+J$3"S5(?^ED=>O;KB
MZGC+1N *SUL3/*UM6!N AC1HC?J=U+JU0>+0U+5ZU_40Z5VVE,6=FL_W>?&\
MX$C7%Q0ZO1+1B;"1/E F'/H!\^,HB3'S+ ^1]MJ?&\$W)R:5C* 5TO80:1]!
MTT,D9URF.40RA,3A$.FDXE<?(NVW.O$ATDF5C@^13C_F[K"^D:N,+MNB0<HZ
MO,N72\G5TGR;JMES^_0DZ?+]BB\W.J[K5CQFJTR'HZRS;VIB_?Y_;\2]_+.D
MA?IEN?!U;C7!F')TI9K^DC*8! F"(?*HG\1>%$BC[&IC"3@WZFA4T>MHN>%<
MUZ50@LMZ0WR5Z6AM^ER7[GS5Q&V?+T@QS1";>^(O-7!3N?&-?MLJ@]H_W:H(
M*AU!K>0-V*H)]O4$2E%0:0I:55]X?.TW$EYJG*?>A9AZO)VV,L88#(-]D$&[
MG7P390S03NW C-*/_=+_?O6DFE02-'N'#$LI. X@Y52MVE%,8$)(#$,1,DR)
MKW>M35?M@[;GMN!NQ3-GV4.T+B^ 5V P^H%R(YG#SO,A#N8+Q15X3,3Q%KA8
ML?(9S7L(]?"-R;CPC*A=&COWB'UVAT]%+C9\_;'X(HMO&:_#I1-"0X(5#24)
MT_7_.(()0LI3XYQAGQ&:),;)'4YU,#<N:F2L=M :,:W3/)P$LI^AAH!G9)IR
M0,8JWT.?^M>F>SC9]F39'OHTZR9[Z'W.\2I=1EFVK,J[+&CL*;>?(9@2(2'B
M$8)4YX7R(A0% 6:)H*E-,K].VU:S>+*,?LN=@)9WW3JHA3*1DGH$1CCU(,*4
M0H((@J'DB%,L4<J,"/!:U";@O@]#X&5VSN*(PL@49P* _96]8U4'O8_7:7[:
MRW;'>AW=I#OQB.MIQJT0:JC+.QT65'S-?U?6K9<**7$" QF'RC21512/!Z-
M^4U$$$Y2HV)Z/7W,;88V6_B-G#= 2ZIP!%I6V\.-8T!-#SBN@FF:0PX[A!S.
M.LYB</5YQW'+$Y]YG%7M^-SC_*..%VCH<E-YE5\E?UAE?]_4MK//D4]\+B!1
M7@A$@?H;BT,!PR2A,:720\BJ"/GI;N8VV;=2Z@W,(J?\H;*]MS([78L]@[#9
MJGT];B//_FLAL[^2TXO(H'=S3O<T[26=7FV/;NOT/VV_1:HOY+]?E>NBVGVZ
MR[_)%5VM/\AOLJ#W\K/N:\%]C%-=6C*A%"FJP PJXSV%RMM!OL=C#W'CY+<&
M_<V-,UKA0"6=^3ZB";27]U@'!FQDLJ@R=^S$5;9"(_ -&!-&\RW:@>&<:-OV
M>EBM=G,M0.K9X35I9;)=7PN5NCO!-J^YF6>7DD%]U;_:%9P3OD^)'T>0!"*"
M2*(4$DHI%"ST/:'^FJ965RKMNI\;-5_.A5:VM;<- ]4<A\7,UAL/[)%I_3+.
MX-=*>#!*>4 WW(:T%"TEF-2"=$/GT+)T;,6-].[RQ\=L7<5[Z6Q05:V=>[GB
MF2QW=0NW><]8[*7$XQ(&4IF>B'E(<5Z"H"]X*B45C#&KLEU6O<^-\CK"5W[8
MGOA[E3HOITH;8&S,B&\TQ$?FO2'!MF8])]"&)#T[ 2;E/"=L#BG/K1$WQGM'
MLT([[_+]ZFFS+K4%N?2; ),8I5$HL(1>2#!$7NQ#YOL$BL17-ET8!%)8E6SO
MZ6MN;/:_-[F.*?Q49%Q-J&Q56VL2_$R+WZ2:=&E>@/="C5#&Z;(I8 Y>51H!
MWS!"V&0(S&AL(&!')BTM):C$U.&96M#:2U2(#1CU8X')D)S4U]VD#&2@]R'?
MF+QR);O4,T2Q6>>8\&=)-9&)CZO/4M>?UQ&7*Z&LO*+]YVM:9F5EX"V"T,,D
M"A4#Q:P*D0PA89Z W(_") GT+7XK_W(PR>;&7-U9MI6^,A*Z\C=ND:4)-MQP
M6O+:E(,T(0M>,3[N?#@4EJ.PY]7"O0S7#H7I668>K ,W'O]EHQ>#CVE5HJA\
MO_K/AXP_U,?"=1E:62X8(Q$)B ^5V>A!) ,"DP@+B$6:!(A[,O"LO&&#/N?&
MO;7(^O)860FM#<??M=A UJ$*>2.X'>V:H&]&J -C.C)5[N#\<@!G$_GQ\1*<
MUBQI ="0_&?2[:3,9H'#(6?9O&H?(/:F.=AZIQQANOPO28MWZB?E@O,$"Q$Q
M*+A.NH$3#HD,,8RC*/ 1#45L=O[0T\?<V*85$]1R BTHJ"0U#P\[!V<_G0P$
MTMAGOO;X6 6'74#@BN"P<RU/%AQV0;5N<-BE1UTSMO)"%V%X(^O_OE_=\CHS
MZ2?Z7'D05 :1CX2:ZYZGS(TTI3#Q0ZDF/ XI\Q*.<6J7P_5"CW.;_JUX^H:Z
MEL\V4^LE@,TLBD%A&YD06EG!JU;:'^JMO0;(3Q> =$CR:@C.L&E?+W4Z<2)8
M0PR.4\.:ONB:/ZT;0E%%1G+!HB2F 12AIS-W(0Q)E##ET? @CF(9I6;U#<]W
M,3<2.0C@<0HS/0&D&7=<!\_8UH,=,@[)M<XI/VPJK:->)DZ<=4[+XS199Y]T
MF]^W0F0Z^HTN/]%,O%\UM9V:@Q5$@R"@RDN0,4Z4OZ!<!1H(Y300CPJBC ?!
MK0HV]/8VMUG?"*<7O[??JZ0WRL?^1)M]2;O9WP^S&1$,!M[(G+"3$VA!H<*O
MA7+X RPC4(;DBOX.)Z4-(]T/&<3L)3<RJ7<NLM7]%WE?'<PWWS<)J!=[H7+@
M,.(Z!$C Q*,48M_3)=89HM+J6.I,/W,CD*V8H)73CC3.P6E&%P. -#)1'.,S
M D%<@&%(:CC7U:2D<$'?0SJX]+BCUY"5]/Z^D'5ER(_I9_E-KC;R0[:2[]?R
ML5Q$6 @I0@91PBE$7J!\"$J4-X%B27D:)0GA5C[$A0[G1@W[\FK#HI$8_*IE
M!I70MA[&)= -_8T!H1S;^[@.17MOQ!":07V32WU.ZZD8(G#DMYB^Y\8W7XOJ
ME/>Y*IA1'P4W];?O\G+]LUP_Y&(1>8G H:\0CF6@.(?HQ#V4P3!*PY!+/\",
M.F0<-^G;:,Y,GW'\LWQ233W04E:^#<\?'W6*3ZV(]GKR)[D"CU4LGQT3&0V'
M&1L-ANXTC-2*"RIY;]H0EE9F??6K7(-:[.%XR0:D(;G)J-])^<D&B4..LGK7
M^< F?Y0?\K)\IT2O8Y8WROAJK+!\I9,NZG@4_N6!%G(1<>ZE/ D@3XFBK,A#
MD"(IH QB7WJ<<1Y9I=JQ[']N5M-.X"9&1$L,7BFJ$OER28L2J)^"4HMN&5UL
M.S#&QSYCP3W^(9"2'+S2LO\ ]#P#'?!W\E=99D&E JAT&/18R 6\@0^)K$28
M^LC(!9\3!TA.S=AG4_R0K;/:_KM3%D=U L(\RD,9$XB85'\D*(0D55YAG C!
M4$R0;Y;&Y'3S<Z.OG81 BVB=1?$$@/T\=#TL(].,)2)6V1//*WYM[L03+4^6
M.?&\5MV\B3U/N1DN/V>KO,C6S^U]TO:X67.&OGOZ^%11Q8*P.$BB,(8\":6:
MU0F#A,<<IMA+):)8UQ=U\+$,NY^IF_6I<;*TCU7L[F*O]N]B9^V==SO+Q71D
MS"R6(8&>*/SU](UV7?NIB6.IK)>.\#KY67=(WE\$WMIVL81Q2)O%M.M);15+
M/ YM%-O7W:^UYZO*^ZM,G?+C9EVNZ4HGN5]@GR6$80GCE B(L(]@DI (TB",
M(B1BR0.Q4"93EHLO:UJLS7BMKTN;.7;8\7C3[355_^02T#5@\CY;K2IG+ 6U
M!.!5Y7R5EMY7+_*!E^(H31 43.H01NS!1"AK42:Q<H4E33DG#?)O5X:%J8?%
MO>UV$M3E2HR+M]E",12"(Z\.M9CM;EPMZ0WHR#KLA?]+B Q]O_]L?Y-?Y[^D
M^:G;^Q??N6:3[2O]?B+A12+3*$%1"OTD4C0>4 ]2/PH@CJAB=R]!R&5#[61?
M<_,^FRT=)>L0>4;Z0+;9'+L:NFDVPNQ1<]SOZL5C^+VMT]V]P#Y6K]ZG]ZSZ
M7[%/IOEGU>:#I,OU0Q-GP['R9GT_AAC36-E\4:)M/@H#/_)CQ1<,4>."0X>-
MSXT=M'R@%M \N>,18OTS_UH<1I[J'0@<Z@X=86&>U?(:3"9*86F%C56VRG/*
M]Z2F/'IELCR4YX3M)IT\^XSCSEMU_MXF;S[.(-Q\;2%)(JHO9=" 8XC\,(4)
M5JR?!$@J/\D+,+&Z5V[6[=Q8K)8:M&);[J29(6VXD38X?B.SWU;$&W" X@A!
MF7;H#+H]9M;SM+MC5F@<;8[9O>V:Y_9;OORF?+.[0HIL_8YRG5[CN9D2/@U"
M%GL>)$I[B"BB,)$^A9BF*)82AWZ4++[)@N7FB6U[^K.9-=U>QYL\6W%!+2]H
M!;9-6]N'LAGQ#(;<R'QS%K(1Z,8(DV$3SO9U.'%^60/=C]/)FKSD6M&DR/3Y
M5[N97R>]V'ERN[3,,9$!IPSIV^K*IHEH"AE+!!2!%U%&_# 25C:-<<]S,VM:
MP7?YFBO1K:N2F4-OQC6C #JZG7,2R^>][9U1\F!;HS5LL133SB>NGV*)R7%)
M%=L&QHK<?"W3O)#;K2E9OOV^+JCJ(UO1XKF*<C^=FWM!(AI@/^205)=A4"(A
M\;T8,APRZ5&/$139E*$<458K9IR@K&6S/5L=\?.3T:&L4A5D]8-K^AW([T]R
M5=IG AEM_&WVRU]\5*?9;[\8>-J.ZVY_7A_LG0D&F3(H]>I!F#: U5W<F06[
M7HV[?6#L]5VZYFSXVZ:L,Y_K]FGY4/7U-?\L-9S94OXBUSOQO^9WZI%/1?XM
M$U*\?OY+*<7[U?;B9U-A11F3VP.\-&11& 821DB?DDI?%SM/$(PBXB<>P\HJ
MM_3GQQ9Y?EL"'8W!.@=%JR=8R?5V-<JK?VDXP%.C+&!M LPJX^U6TW_^QR3P
M@W^U33LQ\I=BMG3-:?1'7K\ZJM;+D1[;2ML;/=Q;A8'2&.PO=NK76F_PJ?,E
MO-*ZJ\_E![!5'^ST'^4<>JK!&C8IQ\@R3YS78YH1.$X-,E&_;LO>EPTKY=\W
M2KRWW]0?[3$K0C%B80!#AI7S1%,"J<=3&'IA&B=^$@;(:I/H9"]SVQ#:"0DJ
M*>U6A=- FE'YU?",S+^'R(RPF]P+P9"L=KJC2:FH5]=#_NA_V&W2?Z+/%2%]
MS9O+N*\W9;:292E+148?4TU![37=!:7$2PDG4*:H2F\<0(9X"%%"]7U9F4HN
MVMLG9FQ@T[W1+-B_?3*V#:HE*[/FUD,*V%;XF\KPU'?^M<5!&PWL:,1J:"1C
M@H7J&\<D32&*$@Y9ZL<0>4@Y%5$:)C2P<RD&'YI)W8-?MG8_S415*(EV!FO$
M@3"C^;' '9G]6[&U+=V(!UYW/OI?ZH^^,K-O+WWTU@N#"VA#KA=6_4^ZC+@@
M<[BZ.+7AMNBT+7?X\Y-4G^AJ3>_EQ_2O^;JSF5-NIY8?\I2&E$*::H[S/ Z)
MP!Q2AAF1?HI9C&Q,43<QYF:KMEIT"4Y?7VGTT//Q6Z7)[@:DXX+D.&QFC#C^
M8(S,C=MQZ&A0I6_H#$2MQ5[YY:%)\CH<AZ1+1TDF)<[KT#JDT"M;NZ)(016B
MO&PN_53W?6[7ZR)CFW55F#BO?O::EE(T-'];%.KCK=XK%\3SDH 2#B,>1Q 1
MAF 28@&]B*(X2I&R[:U\_.M%FAO)?E8#5F1<5^.LTW?1WVDAE,4CLN6FJLE9
M_SA_:M*VZ%)JQ>%+FU6F"W0ZW2D<8)B-ST$G'+SQCSM;94![5[%2!W3UT>;L
MFW8@WZ;*C:W,V.I)R+26H%$3=/4<N$3#()@/7L/A.JFF+_(P"(HGJT ,T[(;
MR7_(5_=?9?&H\]/K:LQU4ND/^I+^1[9L<I&4=YNB4)TML,=C-:8A9*D70!0C
M]14'/H.8R@ GL2<M*TA8]3XWZF[$ D]YT68Q72I]H.K[$0BED1T/VXU$@$4:
M$)% 0O6.&1$"TL1':J:%@GM1F! _=,C7,OR 3)^UY8,RE/X(#D9GS+$P6_Y&
M^]9'7ND^;+_IJF:(MC\JH<%.ZIL6[>$6+B>TAERC[ 28=#ERPN9PY7%KQ/$
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M2]T8<EH9*3?_S^2B'#_6CU0L/^UJ?OIJ;E'7$Z@<9JF$TBQX4@2@YH9+DDP
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MYO&) <X)PHJB7/HUH!WW@9E@*3W#!\9MQ3PJ\B,O?RWHQ^**IY*))\]'XT/
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M[U+;G%%FT#SS6  B!08P2PE@D,: ,H&X9M+\NU<3!,_QY\84M9W13U7?&,\
MK"_X6.(<TYB!3,09@)JDP!AH?HH-^4LN-<;(KX9V1/BGJ:YM)N"/VI&(59X<
M5=,6T>;@PT1S);)<Y P;QM%2 )B:?0U+1&X(2)C_LA1S&W#;[-CJU6?J8,7_
M#^?)[84\(OHCOZL;RZ/:].AP6%R9';7LMN5+I4?AWN0]D0OYDO<U8=+W?T]\
M3I<&?6_CWW7RXW*W?"B/+MZR0GTU-ZB7M@Q1G!)JR"YGY@^.8L")UL"\E"!B
M2J4I<LIIZAID;N__@YU69U=Y[A0ZX>PFIE @C<P^WOAX=9Z\!<#0WI-7[S]9
M]\E;'K;[3]Z\MM\.X:/:[2R55)N/NEA&"ZH@3!(0VVXZ,)/*=NP29F$JE(IY
M)E3N55A]:9#9/>NEC656E"C-]%N87,31;?4Q%)VQ'_+2O+)98Q48"%]BU(5
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M(9YF1&,ORKTXRMR8]&!D&7GUC39<PI&;+0JA&!G@K+9OBB!@4B,K,L:)V;=
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M^OBFDTE/7_2E+3=]^8)^2R@;S:PBF0]J+<QB[:N-72ZPBF,BLARDPLH>,JP
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MM?G!_>;4_9&<?>7Z<SFWYH$^.;NS+,BNFE@[>L#^S&['K*]BS,#$.[,=+^A
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MX&-#SV_? !_T3W_Y4_,O^@]S(/F7/_T_4$L#!!0    ( /B%8E$5%"$B#)(
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MKYL)B8K%!%G$&+1D7OLF]7J'NYG-TD?C8^]X%76)M2N^2PZ:^Y0RL6$WN;!
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M9;%(?TQGL[NOG4YT*4EI9! *5Q2!:4_<* 01B[11159,$^ ]3-:X9<3CHV]
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M"$Z2SUM8L-[4DTJYRQ6N>U\PSL7_-F 81HHC0^$]T5WS*1>4%RV16<5!Z\!
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M@JFW):/*S'LEL#1I7/D(72-79@T/I"'UT &LKGN FXW<)Z'1R +,IT ;N5&
MM8K1&94L*_[_;^_-FMLZDOW!]_DNV5/[\C(1LMMN:\*V')+ZWD=&+5D2;E.
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MUG@.2J_;+VD@"864LN*I-.GF]P0]XX)H $W/AA=[I^BIW\YQVS5>T@HK.BC
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MXE/9LVR;5"O\)=+=CL+#">ENQRBG4[PM[B_5[5B>4K@)G!Q?&R6YP(I#(+Y
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MBDCOI:TP&TT)*A'GEM6&!@4\UIPT8[44EAOD3:[)6S S+L+/P-:NU1Q;T1V
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M<?9FN9Q/XLUR-5AB1LLKU:/ZV?7U2J"T^Q*?5T)EG7BV8)P0Q*)$B,4YJ%.
MN!'%T+[? H1'4_H*ZK'/ 61;S8V>D/ P8?:JE$01<'9 _X\4&E,L$Y3VD&.6
M&!)RS#O]H_<&CP^?^@IJJT]!R)GBZ\#EVHYH_3A[D\C2SO&/^2S?I.7D&ZZG
M05UE=#*B4+79 .WPW&7R1>F[+"RSPN90<I/^;2]2]@J*IL^Q.L-JYJ]39O&Q
M8G\M@3"][Q*\71W&Y&]AFFHYP-HTWP[%>5/*JH  %Q<IMAB,RI%*+MI(N77A
MA=2^E,!HHU6%5H3B"H(S B0+-:HVTMLF$6*KPHMC!_2MTIEX-KDHC<!\UO6
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M\V'!Q+V'CMR7:$ MGRJI'CR\1]<D*Y_XR3LY#)RK;#T4;C,H1VYQ]'4N>*0
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M83"#;^C;",<:9RJX S4N4/EM6A8YZ8#X^GE9W*:)"B;PXCQ.HRRH5-R4:;W
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MG>PE5,8$CQ\]P;^/C0!R#6.V3(PH":5$"TLVV)D6MAV-/:5SY8K<A*ZGLCV
M5L5CNI!TU0&5O!5W.6S&-*6:+Y"Q'/LQ>KP_-JVO]^$E>W6)_HFCDV3_!.^[
M69/=,/*"J01P-TIVCRYY(]9/2*R7P:PH2?RK5,Z7],9\OVAJ,!79R829#CSG
M=LH1I\'.QG2YR"KGQ9UJNWF-G.Z,W=T:(A[Q1-+E!"8MNF@R6PZ8*>W0%P6B
MP+2$+==J5RBU25/JRQ0.."TH4MW,Z:J\@WDO]B=%4P9[QT]&=%-JHP3.LIZ2
MITK'()&DBT",[[&"#=,DQQ58/#J. 8?4Z&)C403J DQSI")C)N7JSIX0#ETY
MIR?*B(362_DZ+TRZ)C)T^]>453,MLD1U0O#!'48',))V*Y6<5KD!??GWHA0_
M"#Z3+(GC$X7"6]*,+.J"S#;:%*!JI=G$/GW?5IEU6:(MVVO<>??^(._>AEC7
M'/T=V2?J-BT:C$]5A2%7X$N%J<[D:M#,977R+OV*^KOU,F^M6#Q:MEGZ+RQ1
MK3G?+TFKB@T(RMTNYAA<-->Z_JT.6=*/&_SG]N_HZDC43)4W[*5",BPRLTLM
M29MRYB Y5:.<=4/6_K1:H$>:M+_WGO5R,;53-\I8:&<<E@&%"[2%.B45 #\D
MW;2J5">(&.PYMBY5>-I5X)6 R?ZCH#/E,/"B_#5B8[%CV*D48E5O[W2DM9 X
MJO3=LF33G('"P+FS'&6'_#*E J%0*4K;+G(53$&/PWQ-HZRAB#0Z<+^^]9E:
M4P=PH:^:@NXS=U?V;)*K70J=I_AJ\ 'G*T9[0? !J4?%6(&Y*=?8OA&JQ#+K
M3,(;YE\KI.0WV:NJ*6]!7<+AF*+AH<X6N1LI\!OMGZ G9.]5#ST9!B :#[G:
MEYZ<@ Z"P4>R$$C'69.L_N@]NI^><)$[]\M W"]%,J"<29-T>XZ:*+IW+]$%
MV @L"%#8T<L7ST+*!6((HP/X!;(&X5,X99\DZ1?&L^""BSC>472',_P!NA(4
MQU%Q8%/\!00;*] 12NO5KPPAZ]$I_3+WP338('=_MB/YH9"\]60,C/3_'P)T
MP@V)0<:&Y#/.5*I,)K[*A$1'Y-6YCMO040ASA-4<K$^)\4Z><&<G=M0Y&.JT
M57FO==+$P.A4DU=WHIZ1NJ.I8="4K>D:&!V!73Y=5+I62TK(#(:=F!14I8WY
M[WQ72^XO7/:)BMB>C&&HL?)^E5$\D_)X,+\[S9L"R[J-BY32FB3?*$=7:7:K
MP-HZ'HEGE,0KO[]$1:.L>M*&XVC.P$(3'>?6,4="QYN0!Q"'L FTN!@..21N
M>0<'RT%2ZQH"TO 5T'YJLS-9SXAK+!@!I5NE\]I&#^K*X!Q)<;H SSD%?>P$
M 54&+*UXT0*_6YZ:[<4]=#H!/('?"?2@S2P5R][9J)T4&(84H%+:@0D "ECI
M$-RE+?T\1PQ3DR2[H!19TOZ?/W&U?Y,VBUF[S+.N#NX&R&J#6K>CQX'0HQ.H
M'"!9.MF>[DR9#$^^)1GN8C\[@* !\.?;*"V#GZ/RHZJ#7]$>'0*3<OD&9O5%
ME4ZOO &V &T0^(OS/N*LJ#@[%@.XH*ZP$D8.W/Y\!@KPUF6$O(P>[A051-=C
M6_%/.+N1(PQD>R<"*X1CYX@(AK NG'6NOY*7+QUKI)_'G?H?U!MY3D;HN._"
M2 GEUB7IA-Q>-2\9EIJCMI4Y)2DE(L 6,Q([_VH*+CX)JD55JYF=&'MDZ8V@
MU?$>4#P&LPY@OXHF2U;9>^0+YDE$ D3A[S\6SZ"B7ZI]1=C1*>C!":)JBJ]"
M>\=EUQ:5LXDF790R1?"']K ?AD^S$Q3?3%#\ PL!+RFU?@@BPM[CF$ ,Q$)E
M8E)(K7W%XA_V4E;%Y*D]F$"G9D32G"M3*(E9:)BEBD$:CN$@PFR*5E-0Q* ^
M4)H8EMLU/EBM9P:V;"_1)7)W,$G?I@0>#?$$CW6'S:D20 .E+.6/QQ6W7EX/
M554P85UY% 5:\S%&*GV*9C[6?D3Y1[;VIRHSN^[!9.DHE429]=A\(I$N.ZYT
M@:RDX4<)0:L'L<ED;9^+R8%CF<^A-IYJ:++X2RKSQV1FLM;E,PK%!3H;2I(:
MYO,BY9 QY2A1\CO2(5P)\1)8/ K;T?>8_<5WDXA>GK>+&&'CD=<I[-P1?D5_
M'7O[1:E1^.IE+^QVE$#T,5,84^C"F)9GNT/6F" C^=\(3[QDC$@*QR5'P7&(
M@S*NX8S[\R17ETU]";>L[N[RN/AP!2-:;H!-;F)=";^4$>J"/7UNSP1.+8[J
M=4BYIQ?$/;7THU!G)'??O<0"K)H9^=<L$&6HBQ 9)1*KW,NZR=%#H4U ]S/R
M5L8*Z=1;JK 9%<9@ B[C\:4>ILM!<%'42,@F7U8>43<%Y3Q'SE9CS3_=$%Y4
MDP "Z!XJI::&J;]@+/R&Q>;>J1PK56GROA*"(/?/P(IJ)T<&Y%^*9[U\(U!6
M\8*<3T-,=W#3R\F).8\66!KM(6]&,YZ8&84_@ %>._.T2V>9C/M#!,0+J/1F
MSMA\X7":GRAA$EELN6S%<&L$=+]8XLUDW?A-[USDI3W$3>+)- (1KR_F ::P
M$2C)G3=H'RO'I*L>)KHG46TGK^[-('1H/5W6#@#KI1O!'9%[T*.#GAM1WY,G
MWJ<,O,^CT=%*H1H.G%'*C2X^L#RZ1OL;U V="YSD+;]$=$_)#2?[D ,?-E>Y
M2C\%>\],M,,(U[[W4-V6R*!V3KF.EE">4\_#.V+]XN1,AU:QB1!6;7 M#E7K
M[3T]A%-(,ROSLB+V,C>M;P D.J-3N9"+DQXSXK,TR.4.S0<D:*\^TIUG="NR
MXGM5M<0T%0A!E<E-)H$VP$%>QF4Z7E'>"SS$Y;VBR#GI]*+Z.9X*K?,A,%+T
M4>6V-/0@.#7EQ=@OZP^<3!OMK>6BP,F:$NZ6VV!91;<&/C#AXB50 >Q7ZW,J
M[(G+46K/<3CMC[#Q;YK6TEF$[-&0;R,/A\&$Y!'EMNWM:PTDOPYMJ;>!"]'[
M@-T0,6^*@^@TB#^WBA!U>\=E^(S6X,M/2PY65V^H3ZG..4 W#JN$#R$4\0/#
MU0P**A#"WK/#;^)/>W[P8@TV[1&P=3'_8?_) 3(Y)G1CWH;($[21V!E83S?I
M ^33M$1$]R&:IIJ!Q1P2E$8&,3#%6<M@%#[FQ5VFDAO#+6'0Y)0]TF$6)#]F
M)8\Y^WG.3XMFG_9;[G:%USQ[))?U&&L9/JW%]=!=((VU'*$TYC8+B2$]T1][
MP.+<?E[PZV$VIKF*IV",@50YWR01DAJ/TMOLI*<MV5/:92(,(X#!S1F&$+L0
M=#II_Z ;.GQ>_P;JT]F4H)Q7R@]W$A(P*AG<YY7C=&(MVH_I/N:+\6$MVW:4
M^NWZ&5N1/ 1R]7I#6"R%=LG@M. &O>302G;7QUK71\CH2L"KE9Z6I/'KK*.>
MGJ:Z(N7XX/!HQ[,#X=GA-7(A@WMEG_A[FL&[V6\AJJ+48-SM!<*AREF1\&7"
M.BK>*.A*PO_V4*])*-Z1[D!(MZ">K5'6I8?A4/2*F)=X+=B+WNF_X/AUK,5H
MFCY7;A\'/>*N^\$B(']HI0$ 7$1#KBG.JV8V,QYHSC*[HS0R6[K1-<4_)W;P
MZ/=[O0T7C]+7@-BJ_IP86_-F#*(0Z_'SO&AR2IG);4=JNI.BCPR.7!A$0?S,
M30&CZ9 KU! YWGE,VRYVRY^2E <(*/<GI78?46X73-ON8-HW0 S$R#*VF-H[
M>KH=4(%O_CQ0@:M!GAAQSZ!BP8$)^I4?X0]TM[#E^C]%.ARU^ M@YY?8;!O:
M0AW]0]RF.VS%%O)NY,7*[6C;(G/)F)ET8MT2O]'9.Y+B4SIUSQ1>#;(BO^%,
M(#D4:CB"B:S2?22MO-;S59SFTJ9>0R!C.<MX(5YE3I$F32C 7DM<7J$U(DH&
M:>7_.MF3'#;:H28/Q3 OB_V2$P<QH7P8P0NOL']2:L0P(![!]VQF"-/-E$L5
M4XV&_Y8T,E ^YI7Q%K7!-0E6M*B#A:JY*X.J&2J-NJ(@4T@R@5^.3OE3435U
M^NU*6^Y2<EPE%-^?X50[7>2)A?HBQ$Y"E>:AM(R;&=Y@:&UXX5C3XQC17L8J
M*^X8S87XC+<*V(&!0NUF<59I9\MTEG7/-M@;WMF053NQ)(G:S<PAW<(_K#L&
M3&4$)?,]U:*8NKM[MI7S%;5$I)_(JH^>[5(@'L:-;(B0::'^U9!?!G,BZ##A
M&J/#V8GQ88AQ5I%/YUCPR!U @TM\< C2W%K<CV8W3R^'L''],7S*K?:JS3X[
MJ*]K2K!Q+]\Y\##<#:+"Z])@:K9N>P5WRKD%<1+-MH[5UDU=49]4&:>5\9C#
M9G-I+_Z#%JGK?<WWNP+=H3#&V>LA,$:KO,IO -<'MT%5YM0)<W=A#822O*Z5
M R2J5EM-!FLY\</5.]"@1TR &H]U8+07.4BQ>*$O S"7VW'<5#!JA5&#N;2N
MHHK$7FSS'>T-@_:N'9/U#<B'89%@>%_UB&V1K!=!NIU-^!3/A;O,"TY83\"R
MO:7Z^;X"$1_,_YZTM&,F\VXVQGVO]2 "> RW?>*RW'VMOQ)8Y(Z3AL=)?-9#
MXR7=3PAL&H)=ZFL4NQ>-6C9=BQ/(D\9X'_B-=LHOAT5PW(@8-W!JCM;AJKWQ
MJ&TJM@O(OG1&W%\2_G!015?/[&2'<[?#N1NV,.K4]@]+&#&^E,O%B4)L(K)0
MTETN_9JE6/T@#KL<^^WAX>,=#_\Y>/AXQ\/;RL,G.Q[^<_#PR>9X>+@<:QIA
M@T7W;8[K<$WB[T\A'":)4[.P.=!7M.E,J(/@W/8@,R 141!G*J($O[J,RH53
M>!#-Y_!-%9(OH>;&(4FE ^_(-&D>:E'D?%I,](<8OG"^H&W1WQ'<K<&PPV R
M\=_=M,@4/8C95.(EF!,W-MB,Y!3_0I^:Z9YF>CXV8V MZH(6DKNA Z@KS^(C
M\G0H 7%R,72_#@0+@Q*@XIY-X,PB@K25G']JS8(2 (A!NPM,PK/WE))G1C('
M,Q8[2Q%\,$MG::VA0B2)6%HDXGHX<6O.X7@#2\W8-*J<'037\)A>%4[,+HL
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M/ZO'.:>=QV+>"19NC=.A4C;ML!TK_;HIT+ZJ9,IXZ&)*VE_@&/*#4>@CX*(
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MH@$/X:X(@&5Y-]L %JO>$^H;Q&054 J"[18AY1KH3@PF:0G* O=N_+(&P(]
M )[L!."Z I"<M7T"1Z21[4;M24/CZ!4Z_W924<27G4=GIF8N+"-[1>1J\:*1
MB.2Q%7)AE1SHE7,T?U,^&V.\,<O8W6(V@).DJ->K[A%(;5;$XV\;!NZ=.ON
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M@4'5DU*AD%<TK_68\VCPS#E \^>M3=WI9<R!,V5_GM$0F-."[&- 0X(@;H,
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M53I\FM*??![1%+S(P5RL&=&4GV#*AVT -@67/R=J6V2 Q25-P<4>TP50O#\
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M,S$Q+FAT;>U;;7,:.1+^?K]"B^NR3A5OPXM?L.,J!Y,*=XF=<\AE]].5&&E
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M \5BX$?D2+QFPH12F0SZ(7-J)3U64JU"SN"V(;L #<8!:S[^G>MP2),!)Z=
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M<\)"J-VC]%BJ86?64:ACK=)FENW=#5 9Q\):SK^1$OH*Z@EL9P+L<TIV <[
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MAN[\^5?^Z7^,YGX6=_(_4$L#!!0    ( /B%8E%+H9^;N @  (XW   4
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MDJ2"19F@9/]0U G5,[?S3.4:SA.SA"XAN)Y6NG<R86.FH.Q9[GF-KT)S.8X
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MM;V.Y:[MNVK6<MVJUNY^6L]J-!IWKVS5JC4V[WQ:U[/J[OJAJ]/:AK6,.?0
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M\6VGXIB_>V7> MOY%U!+ 0(4 Q0    ( /B%8E&?9D+I^>D" #@I)@ 0
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M2P$"% ,4    " #XA6)1D<^F^6[3  !UF0@ %               @ &$A0,
M96AC+3(P,C P.3,P7VQA8BYX;6Q02P$"% ,4    " #XA6)1%10A(@R2   &
MF08 %               @ $D600 96AC+3(P,C P.3,P7W!R92YX;6Q02P$"
M% ,4    " #XA6)1C4/0(2)K  #3(@, %               @ %BZP0 96AC
M,3!Q.3,P,C!E>#$P,2YH=&U02P$"% ,4    " #XA6)1*I0E*$D,   M  $
M$P              @ &V5@4 96AC,3!Q.3,P,C!E>#(R+FAT;5!+ 0(4 Q0
M   ( /B%8E$3.6JSI0@  '$W   4              "  3!C!0!E:&,Q,'$Y
M,S R,&5X,S$Q+FAT;5!+ 0(4 Q0    ( /B%8E%+H9^;N @  (XW   4
M          "  0=L!0!E:&,Q,'$Y,S R,&5X,S$R+FAT;5!+ 0(4 Q0    (
M /B%8E$18X%"2P8  , F   4              "  ?%T!0!E:&,Q,'$Y,S R
M,&5X,S(Q+FAT;5!+ 0(4 Q0    ( /B%8E'@1(\Q7@8  & F   4
M      "  6Y[!0!E:&,Q,'$Y,S R,&5X,S(R+FAT;5!+!08     #  ,  \#
(  #^@04    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
